0001471242-15-000066.txt : 20150810 0001471242-15-000066.hdr.sgml : 20150810 20150810170722 ACCESSION NUMBER: 0001471242-15-000066 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150531 FILED AS OF DATE: 20150810 DATE AS OF CHANGE: 20150810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncologix Tech Inc. CENTRAL INDEX KEY: 0000799694 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 861006416 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-15482 FILM NUMBER: 151041627 BUSINESS ADDRESS: STREET 1: P.O. BOX 8832 CITY: KENTWOOD STATE: MI ZIP: 49518-8832 BUSINESS PHONE: 616-977-9933 MAIL ADDRESS: STREET 1: P.O. BOX 8832 CITY: KENTWOOD STATE: MI ZIP: 49518-8832 FORMER COMPANY: FORMER CONFORMED NAME: BESTNET COMMUNICATIONS CORP DATE OF NAME CHANGE: 20001219 FORMER COMPANY: FORMER CONFORMED NAME: WAVETECH INTERNATIONAL INC DATE OF NAME CHANGE: 19980225 FORMER COMPANY: FORMER CONFORMED NAME: WAVETECH INC DATE OF NAME CHANGE: 19920703 10-Q/A 1 oclg10qa05312015.htm OCLG10QA05312015
 

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q/A

(Mark One)

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

ACT OF 1934.

For the quarterly period ended May 31, 2015

[_] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

ACT OF 1934.

For the transition period from ____________________ to ___________________.

Commission File Number 0-15482

ONCOLOGIX TECH, INC.

(Name of Small Business Issuer as Specified in Its Charter)

Nevada   86-1006416
(State or other jurisdiction of incorporation or organization   (I.R.S. Employer Identification No.)
     
1604 W. Pinhook Drive #200, Lafayette, LA   70508
(Address of principal executive offices)   Zip Code
     
     
Registrant’s Telephone Number, Including Area Code:  (616) 977-9933
 

 

Check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [_]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [_]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated Filer [_] Accelerated Filer [_]

Non-accelerated Filer [_] Smaller Reporting Company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes [_] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class   Outstanding at July 3, 2015
Common Stock, $0.001 par value   340,126,946

 

-1-
 

EXPLANATORY NOTE

 

This amendment to the Current Report on Form 10-Q filed by Oncologix Tech, Inc. (the “Company”) with the Security and Exchange Commission on July 20, 2015 is filed solely to correct the following error: 1) The reclassification of a $100,000 convertible note from accounts payable and accrued expenses.

 

 

 

 

TABLE OF CONTENTS  
   
PART I. FINANCIAL INFORMATION  
   
ITEM 1. Financial Statements  
   
Condensed Consolidated Balance Sheets as of May 31, 2015 (Unaudited) and August 31, 2014 4
   
Condensed Consolidated Statements of Operations (Unaudited) for the three  and nine month periods  
     ended May 31, 2015 and 2014 5
   
Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine month period  
     ended May 31, 2015 6
   
Notes to Condensed Consolidated Financial Statements (Unaudited) 7
   
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 46
   
ITEM 3. Quantitative and Qualitative Disclosure about Market Risk 50
   
ITEM 4. Controls and Procedures 50
   
PART II. OTHER INFORMATION  
   
ITEM 1. Legal Proceedings 51
   
ITEM 1A. Risk Factors 51
   
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 55
   
ITEM 3. Defaults Upon Senior Securities 60
   
ITEM 4. Mine Safety Disclosures 60
   
ITEM 5. Other Information 60
   
ITEM 6. Exhibits 60
   
Signatures 61

 

 

 

-2-
 

 

FORWARD LOOKING STATEMENTS

 

There are certain statements within this Report that are not historical facts. These statements contained herein are based on current expectations that involve a number of known and unknown risks and uncertainties. These statements can be identified by the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” or “anticipates,” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved. The risk factors disclosed in Item 1A “Risk Factors” of Part II of this Quarterly Report on Form 10-Q and in Part I – Item 1A of our Annual Report on Form 10-K for the year ended August 31, 2014, include all known risks our management believes could materially affect the results described by forward-looking statements contained in this Report. However, those risks may not be the only risks we face. Our business, operations, and financial performance could also be affected by additional factors that are not presently known to us or that we currently consider to be immaterial to our operations. In addition, new risks may emerge from time to time that may cause actual results to differ materially from those contained in any forward-looking statements. We believe that the forward-looking statements contained in this Report are reasonable. However, given these risks and uncertainties, we cannot provide you with any guarantee that the anticipated results will be achieved. We disclaim any obligation to update or revise information contained in any forward-looking statement to reflect development or information after the date this Report is filed with the Securities Exchange Commission.

 

Throughout this report, unless otherwise indicated by the context, references herein to the “Company”, “Oncologix”, “OCLG”, “we”, our” or “us” means Oncologix Tech, Inc.., a Nevada corporation and its corporate subsidiaries and predecessors. September 1, 2014 to August 31, 2015 means “fiscal 2015 and September 1, 2013 to August 31, 2014 means “fiscal 2014”.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


-3-
 

PART I: FINANCIAL INFORMATION

ITEM 1. Financial Statements

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

         
     May 31,  August 31,
     2015  2014
     (Unaudited)   
ASSETS                  
Current Assets:            
Cash and cash equivalents    $120,485   $17,504 
Accounts receivable (net of allowance of $71,000 and $9,000)     1,037,009       213,399  
Inventory     137,436    31,271 
Prepaid expenses and other current assets     15,911       9,307  
Prepaid commissions and finders' fees     3,974       3,152  
             
Total current assets     1,314,815    274,633 
             
Property and equipment (net of accumulated depreciation       
of $38,026 and $28,264)     35,246    39,967 
Deposits and other assets     77,678    14,582 
Goodwill     2,404,389    1,781,779 
Patents, registrations (net of amortization of $102,576 and $97,983)     19,903       24,497  
             
Total assets    $3,852,031   $2,135,458 
             
LIABILITIES AND STOCKHOLDERS' DEFICIT               
Current liabilities:            
Convertible notes payable (net of discount of $405,429 and $99,491)    $477,596    $ 436,308  
Notes payable (net of discount of $2,091 and $18,596)     2,377,667       946,104  
Notes payable - related parties     —        51,600  
Inventory finance agreements     417,000        —    
Accounts payable and other accrued expenses     1,087,319       732,934  
Accrued interest payable     208,736    148,681 
Accrued interest payable - related parties     —        6,342  
Current portion of long term debt     96,644       82,532  
             
Total current liabilities     4,664,962       2,404,501  
             
Long-term liabilities:            
Notes payable (net of current portion)     376,037       395,675  
Convertible notes payable     —         —   
             
Total long-term liabilities     376,037       395,675  
             
Total liabilities     5,040,999    2,800,176 
             
Stockholders' Deficit:            
Series A Preferred stock, par value $.001 per share; 10,000,000 shares              
authorized; 129,062 and 129,062 shares issued and outstanding at              
May 31, 2015 and August 31, 2014, respectively     129       129  
Series D Preferred stock, par value $.001 per share; 10,000,000 shares               
authorized; 78,564 and 78,564 shares issued and outstanding at               
May 31, 2015 and August 31, 2014, respectively     79       79  
Common stock, par value $.001 per share; 750,000,000 shares authorized;               
276,746,130 and 134,600,152 shares issued and outstanding at               
May 31, 2015 and August 31, 2014, respectively    276,746      134,600  
Additional paid-in capital     48,398,569    47,565,869 
Accumulated deficit     (49,864,491)   (48,370,395)
Common stock subscribed (0 and 1,058,201 shares issuable, respectability at May 31, 2015 and August 31, 2014)     —          5,000  
             
Total stockholders' deficit   (1,188,968)      (664,718 )
             
Total liabilities and stockholders' deficit    $3,852,031      2,135,458  
             
             

 

See accompanying notes to unaudited condensed consolidated financial statements.

-4-
 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

   For the Three Months Ended  For the Nine Months Ended
   May 31,  May 31,  May 31,  May 31,
   2015  2014  2015  2014
             
Revenues  $1,235,656   $988,385   $3,625,407   $2,696,776 
                     
Cost of revenues   885,596    788,757    2,628,797    2,066,800 
                     
Gross profit   350,060    199,628    996,610    629,976 
                     
Operating expenses:                    
General and administrative   443,889    276,950    1,379,769    999,910 
Research and development expense   —      —      10,000    —   
Depreciation and amortization   5,022    5,664    14,356    17,156 
                     
Total operating expenses   448,911    282,614    1,404,125    1,017,066 
                     
Loss from operations   (98,851)   (82,986)   (407,515)   (387,090)
                     
Other income (expense):                    
Acquisition costs             —      —   
Interest and finance charges   (437,908)   (167,474)   (1,090,013)   (634,833)
Interest and finance charges - related parties   —      (791)   (1,051)   (18,056)
Loss on conversion of notes payable - related parties   —      (62,151)   —      (155,728)
Loss on disposal of assets   —      —      —      (28,748)
Other income (expenses)   11,321    74,450    4,483    72,062 
                     
Total other income (expense)   (426,587)   (155,966)   (1,086,581)   (765,303)
                     
Loss from continuing operations   (525,438)   (238,952)   (1,494,096)   (1,152,393)
                     
Discontinued operations                    
Operating loss from discontinued operations   —      —      —      (36)
Gain on disposal of discontinued operations   —      —      —      95,564 
                     
                     
Gain from discontinued operations   —      —      —      95,528 
                     
Less loss attributable to noncontrolling interest   —      —      —      —   
                     
Net gain from discontinued operations   —      —      —      95,528 
                     
Net loss before income taxes   (525,438)   (238,952)   (1,494,096)   (1,056,865)
                     
Income taxes   —      —      —      —   
                     
Net loss attributable to common shareholders  $(525,438)  $(238,952)  $(1,494,096)  $(1,056,865)
                     
Gain (loss) per common share, basic and diluted:                    
Continuing operations  $(0.00)  $(0.00)  $(0.01)  $(0.01)
Discontinued operations   —      —      —      0.00 
                     
   $(0.00)  $(0.00)  $(0.01)  $(0.01)
                     
Weighted average number of shares                    
outstanding - basic and diluted   242,589,170    112,247,396    187,353,653    93,925,094 

 

See accompanying notes to unaudited condensed consolidated financial statements.

-5-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   For the Nine Months Ended
   May 31,  May 31,
   2015  2014
Operating activities:          
Net loss  $(1,494,097)  $(1,056,865)
           
Net gain from discontinued operations   —      (95,528)
           
Net loss from continuing operations   (1,494,097)   (1,152,393)
           
Adjustments to reconcile net loss to net cash used          
  in operating activities:          
Depreciation and amortization   14,356    17,156 
Loss on disposal of property and equipment   —      28,748 
Stock based compensation   —      91,163 
Amortization of discount on notes payable and warrants   334,437    18,021 
Beneficial conversion feature notes payable   —      139,823 
Loss on conversion of notes payable - related parties   —      155,729 
Induced conversion expense notes payable   66,520    —   
Non-cash interest charges   218,415    —   
Issuance of stock and warrants for fees   78,100    302,658 
         —   
Changes in operating assets and liabilities:          
Accounts receivable   (250,480)   (125,813)
Prepaid expenses and other current assets   (5,829)   (2,686)
Prepaid commissions and finders' fees   (737)   —   
Deposits and other assets   (52,545)   (43,700)
Accounts payable and other accrued expenses   626,654    6,691 
Accrued interest payable - related parties   (6,342)   (60,192)
Accrued interest payable   80,578    83,424 
           
Net operating cash flows - continuing operations   (390,970)   (546,190)
           
Net operating cash flows - discontinued operations   —      95,528 
           
Net cash used in operating activities   (390,970)   (450,662)
           
Investing activities:          
Purchase of property and equipment   (2,033)   (878)
Cash acquired from Amian Health Services   —      8,646 
Acquisition of Amian Health Services   —      (75,000)
Acquisition of Esteemcare and Affordable   (560,984)   —   
           
Net cash used in investing activities   (563,017)   (67,232)
           
Financing activities:          
 Proceeds from issuance of convertible notes   596,250    719,933 
 Proceeds from issuance of notes payable   1,933,000    655,128 
 Proceeds from the issuance of common stock   —      10,000 
 Repayment of notes payable   (918,975)   (490,798)
 Repayment of notes payable - related parties   (51,600)   (4,600)
 Repayment of inventory financing agreements   (335,608)   —   
 Repayment of convertible notes payable   (166,099)   (224,845)
           
Net cash provided by financing activities   1,056,968    664,818 
           
Net increase (decrease) in cash and cash equivalents   102,981    146,924 
           
Cash and cash equivalents, beginning of period   17,504    39,456 
           
Cash and cash equivalents, end of period  $120,485   $186,380 

 

See accompanying notes to unaudited condensed consolidated financial statements.

-6-
 

 ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 - ORGANIZATION AND DESCRIPTION OF THE COMPANY

 

Oncologix Tech, Inc. is a diversified medical holding company with operating segments in medical device, healthcare services and medical products and technologies. We operate and manufacture Class II medical device products, deliver Personal Healthcare Services and provide Home Medical Equipment (HME) and Durable Medical Equipment (DME) sales in licensed markets. For its clients, Oncologix provides FDA approved medical devices, State licensed healthcare services and medical product sales. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company’s corporate mission is to be the best small cap medical device and healthcare services holding company in North America.

 

We were originally formed in 1995 and in 2000 we changed our name to "BestNet Communications Corp." At that time we provided worldwide long distance telephone communication and teleconferencing services to commercial and residential consumers through the internet, which we disposed of in 2007 due to lack of profitability. In July 2006 we changed our business model to medical device products.  In July 2006 we acquired JDA Medical Technologies, Inc. ("JDA") and merged this business into Oncologix Corporation, our wholly owned subsidiary.  On January 22, 2007, we changed our name to Oncologix Tech, Inc., to reflect this new business model. Our business at this time was the development of a medical device for brachytherapy (radiation therapy), called the “Oncosphere” (or “Oncosphere System”), for the advanced medical treatment of soft tissue cancers. Due to a lack of funding, we suspended these development activities on December 31, 2007. On November 1, 2013, due to the development of the brachytherapy device being several years away, indication that the product could not be marketed and no guarantee of FDA approvals, it was determined that continued financial support of this product by Oncologix Corporation would cost the Company substantial capital beyond its means and the Company’s management and Board of Directors disposed of Oncologix Corporation and its Brachytherapy medical device subsidiary. Furthermore, as part of the disposal, the Company was relieved of over $90,000 in debt.   

 

On March 22, 2013, we acquired all the outstanding stock of Dotolo Research Corporation (“Dotolo”), a FDA Registered, Class II, medical device manufacturer with 25 years of product sales in the hydro-colonic irrigation, bowel preparation market. Dotolo Research Corporation began operations in 1989 and sells hardware and disposable products to a customer base of over 900+ customers both domestically and internationally.  The Company currently operates in a limited, but competitive environment in hydro-colonic irrigation, of which there are only four (4) companies approved by the FDA to manufacture a Class II medical device for colonic-hydro therapy.  Since the acquisition, we have not had significant revenues from sales of our products, including sales to medical facilities due to a lack of operating capital needed to procure raw material inventory to currently fill customers’ orders. We are currently in the final phase of new product hardware redesign which we believe will allow Dotolo Research the ability to successfully enter into the medical markets to become the dominate market leader.

 

On August 1, 2013, we acquired the outstanding stock of Angels of Mercy, Inc. (“AOM”). Angels provides non-medical, Personal Care Attendant (PCA) services, Supervised Independent Living (SIL), Long-Term Senior Care, and other approved health service programs performed by a trained caregiver that will meet the health service needs of beneficiaries whose disabilities preclude the performance of certain independent living skills related to the activities of daily living (ADL). We changed the name to Amian Angels Inc. (“Amian”) in August 2014.

 

On December 10, 2013, Angels of Mercy, Inc. acquired the assets of Amian Health Services LLC and Amian Health Services of Alex LLC, herein after referred to as “Amian”.  Amian delivers health-care care-services who provide routine health and personal care support with Activities of Daily Living (ADL) to clients with physical impairments or disabilities in private homes, nursing care facilities, hospice care settings, and other residential settings. Amian holds both PCA-Medicaid Waiver Provider and Residential Rehabilitation/Supervised Independent Living (SIL), and personal care services for Veterans with licenses issued by the Division of Licensing and Certification of the Department of Social Services, Veterans Administration Social Services and the Louisiana Department of Health and Hospitals.  All administrative personnel of Amian have been merged to gain operating synergies.

 

On July 21, 2014 we formed Advanced Medical Products and Technologies Inc. (“AMPT”) to enter into the Durable Medical and Home Medical Equipment markets. We anticipate acquiring active companies in this area to develop our Medical Products and Technologies Segment.

-7-
 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

On September 25, 2014, we acquired the outstanding stock of Esteemcare, Inc. and its wholly owned subsidiary Affordable Medical Equipment Solutions, Inc. Esteemcare, Inc is a Durable and Home Medical equipment and supply distributor for respiratory therapy and is accredited by the “Joint Commission on Healthcare Organizations”. Esteemcare targets patients with sleep obstructive disorders or related chronic illnesses who are insured by Medicare, Medicaid, third-party insurers, or have the ability to pay for our products from their own private resources. Sleep apnea is a serious sleep disorder that occurs when a person's breathing is interrupted during sleep. People with untreated sleep apnea stop breathing repeatedly during their sleep, sometimes hundreds of times. This means the brain -- and the rest of the body -- may not get enough oxygen.

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

BASIS OF PRESENTATION

 

In the opinion of management, the accompanying balance sheets and related interim statements of income, cash flows, and stockholders' equity include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management's estimates and assumptions. Interim results are not necessarily indicative of results for a full year.

 

PRINCIPLES OF CONSOLIDATION

 

The unaudited consolidated financial statements for the three and nine months ended May 31, 2015 and 2014 include the accounts of Oncologix Tech, Inc. and its wholly owned subsidiaries, Dotolo Research Corporation (“Dotolo”), Amian Angels, Inc. (“Amian”), Advanced Medical Products & Technologies Inc. (“AMPT”), Esteemcare Inc. and Affordable Medical Equipment Solutions Inc. (collectively “Esteemcare”) Dotolo and Amian are Louisiana Corporations. AMPT is a Nevada corporation. Esteem & Affordable are South Carolina corporations. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

USE OF ESTIMATES

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reportable amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

SEGMENT INFORMATION

 

ASC 280-10 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the Company’s Chief Executive Officer and Chief Financial Officer in deciding how to allocate resources and in assessing performance. The Company currently has three business segments; medical device manufacturing (Dotolo), personal care services (Amian) and medical products and technologies (AMPT and Esteem & Affordable.

 

REVENUE RECOGNITION

 

Revenue is recognized by the Company in accordance with Accounting Standards Codification Topic (“ASC”) 605. Accordingly, revenue is recognized when all the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the seller’s price to the buyer is fixed and determinable; and collectability is reasonably assured. Currently, the primary revenue for the Company is derived from its sales in its Personal Care Services and Medical Products and Technologies Segments’.

 

 

-8-
 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Amian is reimbursed for each approved “Unit of Service” provided, as determined by the Health Care Financing Administration (HCFA), the Department of Health & Hospitals and the Department of Social Services and based upon a detailed Case Management, Plan of Care for each beneficiary. A unit of service for PCA services will be one-half hour. At least fifteen (15) minutes of service must be provided to the individual in order for Amian Angels to bill for a unit of service. A maximum of 1,825 hours (3,650 half-hour units) per beneficiary, per year can be billed under the Medicaid waiver program. Our primary payer sources is the State of Louisiana, the Department of Veterans Administration and Private Pay individuals who reimburse us for the services we provide. We currently experience a two percent claims rejection rate. With the acquisition of Amian, Amian Angels now has private pay clients as well as Veterans Administration Social Services clients.

 

Esteemcare recognizes revenue related to product sales upon delivery to customers provided that we have received and verified any written documentation required to bill Medicare, other government agencies, third-party payers, and patients. For product shipments for which we have not yet received the required written documentation, revenue recognition is delayed until the period in which those documents are collected and verified. We record revenue at the amounts expected to be collected from government agencies, other third-party payers, and from patients directly. Government and insurance payers’ generally require patient compliance with product usage. Accordingly, most pay for the product purchases over a multi-month plan, generally 10 to 13 months. We record these revenues as received since the transfer of ownership is not guaranteed until the full purchase price is paid to us. We record, if necessary, contractual adjustments equal to the difference between the reimbursement amounts defined in the fee schedule and the revenue recorded per the billing system. These adjustments are recorded as a reduction of both gross revenues and accounts receivable. We analyze various factors in determining revenue recognition, including a review of specific transactions, current Medicare regulations and reimbursement rates, historical experience and the credit-worthiness of patients. Medicare reimburses at 80% of the government-determined prices for reimbursable supplies, and we bill the remaining balance to either third-party payers or directly to patients.

 

CASH AND CASH EQUIVALENTS

 

The Company considers all highly liquid instruments, with an initial maturity of three (3) months or less to be cash equivalents.

 

ACCOUNTS RECEIVABLE

 

The Company’s receivables in its medical device segment are subject to credit risk, and the Company typically does not require collateral on its accounts receivable. Receivables are generally due within 30 days. The Company maintains an allowance for uncollectable receivables that reduces the receivables to amounts that are expected to be collected. .

 

The lead time for account receivables in our Personal Care service divisions ranges from 14 to 90 days. The majority of the Company’s receivables, approximately 90%, are collected within 14 days. We bill the State of Louisiana on a weekly basis and are reimbursed two weeks later via electronic funds transfer. We are able to resubmit any rejected claims an additional two times to Molina Healthcare, the EDI payment provider for payments within the next twelve months. Currently we maintain an allowance for uncollectible receivables at a rejection rate of 2% of outstanding receivables. We analyze our claim rejection rate on a quarterly basis and make quality improvements to reduce the number of rejected claims. Private pay customers are billed semi-monthly. Generally collections occur within 30 days. Veterans Administration (VA) customers are billed monthly. Generally collections occur within 45 to 60 days. Due to the recent governmental shutdown, the current lead time for payments is approximately 90 days. Upon final rejection of any resubmitted claims, the claims are resubmitted and after twelve months the receivables are written off to bad debt expense.

 

 

 

 

 

 

 

 

-9-
 

 ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Our medical products and technologies accounts receivable are generally due from Medicare, Medicaid, private insurance companies, and our private patients. Accounts receivable are reported net of allowances for contractual adjustments and uncollectible accounts. The collection process is time consuming, complex and typically involves the submission of claims to multiple layers of payers whose payment of claims may be contingent upon the payment of another payer. As a result, our collection efforts may be active for up to 18 to 24 months from the initial billing date. In accordance with regulatory requirements, we make reasonable and appropriate efforts to collect our accounts receivable, including deductible and co-payment amounts, in a manner consistent for all classes of payers.

 

INVENTORY

 

Inventories are stated at cost and are held on a first-in, first-out basis. Our inventory in our medical device segment consists primarily of miscellaneous hardware parts. Our inventory in our medical products and technologies segment consists of masks, CPAP machines, BiPAP machines and other necessary breathing equipment and supplies.

 

PROPERTY AND EQUIPMENT

 

Property and equipment is recorded at cost. Depreciation is provided for on the straight-line method over the estimated useful lives of the related assets as follows:

 

Furniture and fixtures 5 to 10 years
Computer equipment 5 years
Equipment 5 to 10 years
Software 3 to 5 years

 

The cost of maintenance and repairs is charged to expense in the period incurred. Expenditures that increase the useful lives of assets are capitalized and depreciated over the remaining useful lives of the assets. When items are retired or disposed of, the cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.

 

LONG-LIVED ASSETS

     ASC 360 – Property, Plant and Equipment addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment or whether the remaining balance of property and equipment, or other long-lived assets, should be evaluated for possible impairment. Instances that may lead to an impairment include: (i) a significant decrease in the market price of a long-lived asset group; (ii) a significant adverse change in the extent or manner in which a long-lived asset or asset group is being used or in its physical condition; (iii) a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset or asset group, including an adverse action or assessment by a regulatory agency; (iv) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset or asset group; (v) a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset or asset group; or (vi) a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

An estimate of the related undiscounted cash flows, excluding interest, over the remaining life of the property and equipment and long-lived assets is used in assessing recoverability. Impairment loss is measured by the amount which the carrying amount of the asset(s) exceeds the fair value of the asset(s). The Company primarily employs two methodologies for determining the fair value of a long-lived asset: (i) the amount at which the asset could be bought or sold in a current transaction between willing parties or (ii) the present value of estimated expected future cash flows grouped at the lowest level for which there are identifiable independent cash flows.

 

 

 

-10-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

GOODWILL AND OTHER INTANGIBLE ASSETS

The Company adopted Accounting Standards Update 2011-08 “Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment (“ASU 2011-08”) in the fourth quarter of fiscal 2014 due to its recent acquisition of Dotolo Research Corporation and Angels of Mercy, Inc. ASU 2011-08 permits an entity to first assess qualitative factors to determine whether it is more likely that not that the fair value of a reporting unit is less than its carrying amount. Goodwill represents the excess of the cost of a business combination over the fair value of the net assets acquired and these costs are subject to annual impairment tests.

We accounted for the acquisition of Dotolo, Amian and Esteemcare using the acquisition method of accounting under ASC 805 and ASC 810-10-65. The purchase price was allocated first to identifiable current then fixed assets as well as liabilities assumed. We then earmarked identifiable intangibles, with the remainder to goodwill. We identified patents as our identifiable asset for Dotolo Research Corporation. Amounts allocated to Goodwill for the acquisition of Dotolo are based on expanding our product into the medical market and the potential upside of the sale with a FDA medical device product with a reimbursement code. Dotolo is one of four companies worldwide with an FDA approved, Class II medical device product. Amounts allocated to goodwill for Amian and Esteemcare are based on increased clients and future revenues.

The Company evaluates the recoverability of its indefinite lived intangible assets, which consist of Dotolo, Amian and Esteemcare, based on estimates of future royalty payments that are avoided through its ownership of the intangibles and patents, discounted to their present value. In determining the estimated fair value of the intangibles and patents, management considers current and projected future levels of revenue based on its plans for Dotolo, business trends, prospects and market and economic conditions. See Note 4 – Acquisitions for further information on the acquisition of Dotolo.

We follow the two step process in ASC 350-20-35 for impairment testing. In the first step we compare the fair value of the reporting unit as a whole to its carrying value, including goodwill. For both reporting units, we have determined that the reporting units’ fair value exceeds its carrying value. We also compare the carrying value of goodwill by itself for both reporting units.

The following explains the results of our impairment testing. We have allocated $564,075 of goodwill to the Amian Angels, Inc. reporting unit. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 39%. We have allocated $1,217,704 of goodwill to the reporting unit Dotolo Research Corporation. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 18%. We have allocated $622,610 of goodwill the Esteemcare reporting unit. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 47%. In calculating the valuation, we used a discounted cash flow method based on the future 5 years cash flows of each reporting unit. We used a discount rate of 8% which is currently higher that the current long term interest rate. An increase in the overall national interest rate could have a negative impact on our valuation. An additional risk is the possibility of cash flow projections falling short of our 5 year estimate amount.

 

 

ADVERTISING COSTS

 

Advertising costs included with selling, general and administrative expenses in the accompanying consolidated statements of operations were minimal for the three and nine months ended May 31, 2015 and 2014. Such costs are expensed as incurred.

 

 

 

 

 

 

 

 

-11-
 

 ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

INCOME TAXES

 

The Company adopted the provisions of FASB ASC 740 - Income Taxes provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Income taxes are determined using the asset and liability method. This method gives consideration to the future tax consequences associated with temporary differences between the carrying amounts of assets and liabilities for financial statement purposes and the amounts used for income tax purposes.

 

FAIR VALUE OF FINANCIAL INSTRUMENTS

 

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable, accrued expenses, and notes payable approximate fair value.

 

STOCK-BASED COMPENSATION

 

The Company has a stock-based compensation plan, which is described more fully in Note 12. The Company accounts for stock-based compensation in accordance with ASC 718. Under the fair value recognition provisions of this statement, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation model. The fair value of all awards is amortized on a straight-line basis over the vesting periods. The expected term of awards granted represent the period of time they are expected to be outstanding. The Company determines the expected term based on historical experience with similar awards, giving consideration to the contractual terms and vesting schedules. The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of its common stock. The risk-free interest rate is based on the U.S. treasury security rate estimated for the expected life of the options at the date of grant. If actual results differ significantly from estimates, stock-based compensation could be impacted.

 

INVENTORY FINANCING AGREEMENTS

 

Our inventory finance agreements consist of qualified for-sale equipment purchases. Qualifying inventory purchases are grouped into a 12 month finance agreements allowing the company to spread the payments for this inventory over a twelve month period. All inventory finance agreements are interest free and consist of only minor fees for setup.

 

CONVERTIBLE DEBT

 

Interest on convertible debt is calculated using the simple interest method. The company recognizes a beneficial conversion feature to the extent the conversion price is less than the closing stock price on the issuance of the convertible notes. The Company also follows ASC 470-50 and ASC 470-20 regarding changes in the terms of the convertible notes and the induced conversion of its convertible debt.

 

RECLASSIFICATIONS

 

Certain prior year amounts have been reclassified to conform to the current year presentation.

 

STOCK INCENTIVE PLANS

 

Share based payment compensation costs for equity-based awards are measured on the grant date based on the fair value of the award on that date and is recognized over the required service period. The fair-value of stock option awards is estimated using the Black-Scholes model. Fair value of restricted stock awards is based upon the quoted market price of the common stock on the date of grant.

 

 

-12-
 

 ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NET LOSS PER COMMON SHARE

 

Basic earnings (loss) per share is calculated under the provisions of ASC 260 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is calculated by dividing income (loss) available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is calculated based on the weighted average number of common shares outstanding during the period plus the dilutive effect of common stock purchase warrants and stock options using the treasury stock method and the dilutive effects of convertible notes payable and convertible preferred stock using the if-converted method. On Basic and diluted earnings per share for the three and nine months ended May 31, 2015 and 2014 are as follows:

 

   For the Three Months Ended  For the Nine Months Ended
   May 31,  May 31,  May 31,  May 31,
   2015  2014  2015  2014
             
             
Net gain (loss) attributable to common shareholders                    
Continuing operations  $(525,438)  $(238,952)  $(1,494,096)  $(1,152,393)
Discontinued operations   —      —      —      95,528 
                     
                     
   $(525,438)  $(238,952)  $(1,494,096)  $(1,056,865)
                     
Weighted average shares outstanding   242,589,170    112,247,396    187,353,653    93,925,094 
                     
Loss per common shares, basis and diluted                    
Continuing operations  $(0.00)  $(0.00)  $(0.01)  $(0.01)
Discontinued operations   —      —      —      0.00 
                     
                     
   $(0.00)  $(0.00)  $(0.01)  $(0.01)

 

Due to the net losses during the three and nine months ended May 31, 2015 and 2014, basic and diluted loss per share was the same, as the effect of potentially dilutive securities would have been anti-dilutive. Shares attributable to convertible notes, stock options, preferred stock and warrants not included the diluted loss per share calculation. Below lists securities dilutive within 90 days of May 31, 2015 and 2014:

            As of
            May 31,   May 31,
            2015 2014
           Underlying     Underlying 
Description  Common Shares     Common Shares 
Convertible preferred stock            78,564,000              22,500,000
Convertible notes payable          210,272,886              81,383,460
Options              6,173,750                6,186,250
Warrants            21,000,000              26,583,333
                 
Total potentially dilutive securities          316,010,636            136,653,043

 

 

 

 

 

-13-
 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


SEGMENT INFORMATION

 

ASC 280-10 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the Company’s Chief Executive Officer and Chief Financial Officer in deciding how to allocate resources and in assessing performance. The Company currently has three business segments; medical device manufacturing, personal care services and medical products and technologies.

 

RECENT ACCOUNTING PRONOUNCEMENTS

 

We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact.

 

New Accounting Standard

 

In July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2012-02 “Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment” (“ASU 2012-02”). ASU 2012-02 permits entities to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. Under the amendments in ASU 2012-02, an entity is not required to calculate the fair value of an indefinite-lived intangible asset unless it determines that it is more likely than not that the fair value of the asset is less than its carrying amount. An entity also will have the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. ASU 2012-02 is effective for interim and annual indefinite-lived intangible asset impairment tests performed for fiscal years beginning on or after September 15, 2012, with early adoption permitted. The Company’s adoption of ASU 2012-02 is not expected to have an impact on its consolidated financial statements.

 

 

NOTE 3 - GOING CONCERN

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses from operations over the past several years and anticipates additional losses in fiscal 2015 and prior to achieving breakeven.

 

During the year ended August 31, 2013 we acquired Dotolo Research Corporation and Angels of Mercy, Inc. In December 2013, through Amian Angels, we also acquired the assets of Amian Health Services and changed the company’s name to Amian Angels Inc. In September 2014 we acquired Esteemcare Inc. and Affordable Medical Equipment Solutions Inc. While these acquisitions greatly increase the value of our Company, the combined operations of OCLG are not cash flow positive at this time. Amian and Esteemcare are currently cash flow positive but alone is unable to support all the corporate overhead or needs of our other subsidiary, Dotolo. We anticipate that we will require approximately $1,000,000 to operate through December 31, 2015. Approximately $500,000 will be required to fund corporate overhead including debt servicing with the balance to invest into raw material inventory, manufacturing and new product development at Dotolo Research as well as beginning business with AMPT. Additional funding will allow us to meet our current sales demands and expenses of Dotolo, Amian Angels and Oncologix, while keeping our public filings current.

 

Our Company is not profitable and we have to rely on debt and equity financings to fund operations. There is no assurance that the business activities of Dotolo will achieve breakeven status by the end of 2015. Significant delays in achieving break-even status could affect the ability to obtain future debt and equity funding. These factors raise substantial doubt about the Company’s ability to continue as a going concern. After auditing our financial statements, our independent auditor issued a going concern opinion and our ability to continue is dependent on our ability to raise additional capital. Currently there is a substantial doubt in the Company’s ability to continue as a going concern.

 

 

-14-
 

 ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 4 – ACQUISITIONS

 

Amian Health Services

 

On December 10, 2013, our subsidiary Angels of Mercy acquired the assets of Amian Health Services. Pursuant to the Agreement, the Owners sold all the assets for $100,000 represented by a down payment of $75,000 at closing and a one year Secured Promissory Note for $25,000.

 

The acquisition was accounted for using the acquisition method of accounting and the purchase price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values at the date of acquisition. Identifiable intangible assets include patents and purchased goodwill.

 

The purchase price was allocated to assets acquired and liabilities assumed as follows:

 

               
Cash and cash equivalents    $               8,646
Property and equipment                     6,000
Purchased goodwill                     85,354
               
  Total assets acquired    $           100,000

 

On September 25, 2014, we acquired all the outstanding shares of Esteemcare Inc. and its wholly owned subsidiary, Affordable Medical Equipment Solutions Inc. in exchange for a $400,000 down payment, $100,000 note and payoff of $173,433 in operating leases.

 

The acquisition was accounted for using the acquisition method of accounting and the purchase price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values at the date of acquisition. Identifiable intangible assets include patents and purchased goodwill.

 

The purchase price was allocated to assets acquired and liabilities assumed as follows:

 

Cash and cash equivalents    $             12,449
Accounts receivable (net)                 573,130
Inventory                       106,165
Prepaid expenses and other current assets                      860
Property and equipment                     3,008
Deposits and other assets                   10,551
Purchased goodwill                   622,610
               
  Total assets acquired    $        1,328,773
               
Accounts payable and other accrued expenses  $           454,877
Inventory financing agreements               125,463
Notes payable                       75,000
               
  Total liabilities assumed  $           655,340

 

 

 

 


-15-
 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 5 – DISCONTINUED OPERATIONS

 

During October 2013 the Company’s management and Board of Directors determined to dispose of Oncologix Corporation its Brachytherapy medical device subsidiary. On November 1, 2013, the company entered into a settlement agreement with Firetag, Stoss & Dowdell, PC., our former attorneys. Per the terms of the settlement agreement, we exchanged our 90% ownership and executed a $50,000 promissory note payable to Firetag in exchange for the forgiveness by Firetag of $145,522 in prior legal billings. The promissory note bears interest at 4% and requires 12 monthly payments of $4,257.49 beginning on December 1, 2013. Detailed below are the income and expenses related to these discontinued operations:

 

   For the Three Months Ended  For the Nine Months Ended
   May 31,  May 31,  May 31,  May 31,
   2015  2014  2015  2014
Operating expenses:                    
General and administrative  $—     $—     $—     $36 
Depreciation and amortization   —      —      —      —   
                     
Total operating expenses   —      —      —      36 
                     
Loss from operations   —      —      —      (36)
                     
Other income (expense):                    
                     
Total other income (expense)   —      —      —      —   
                     
Loss from discontinued operations   —      —      —      (36)
Gain on disposal of discontinued operations   —      —      —      95,564 
                     
Loss from discontinued operations   —      —      —      95,528 
                     
Less loss attributable to noncontrolling interest   —      —      —      —   
                     
Net loss from discontinued operations  $—     $—     $—     $95,528 

 

NOTE 6 – INVENTORY

 

We have inventory, on hand in the amounts of $137,436 and $31,271 as of May 31, 2015 and 2014, respectively. Our inventory as of May 31, 2015 relates to our medical device manufacturing segment. Inventories at May 31, 2015 also included $106,165 related to our medical products and technologies division. Our inventory in our medical device segment consists primarily of miscellaneous parts. Our inventory in our medical products and technologies segment consists primarily of disposable products such as masks, oxygen tubing, and other breathing equipment supplies. We also hold minor amounts of CPAP machines and BiPAP machines. Our machine purchases are generally set up on a Just-in-time order system. We do not maintain any inventory for our personal service care segment or our medical products division. We are currently in the redesign and final bench testing phase of our Toxygen hardware system and disposable products. The new hardware design will position Dotolo Research with a unique technological advantage in the medical markets.. Currently, inventory on hand is made up of miscellaneous Toxygen hardware parts, custom tooling and molds.

 

 

 

 

 

-16-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 7 - PROPERTY AND EQUIPMENT

 

Property and equipment is composed of the following at May 31, 2015 and August 31, 2014

 

   May 31,  August 31,
   2015  2014
Furniture  $14,118   $12,688 
Office Equipment   13,625    12,962 
Computers   24,409    22,321 
Software   3,497    3,497 
Leasehold improvements   —      —   
Equipment   17,623    16,763 
           
Total property and equipment at cost   73,272    68,231 
           
Less: accumulated depreciation and amortization   (38,026)   (28,264)
           
   $35,246   $39,967 

 

NOTE 8 – OFFICE LEASES

 

The Company leases office space in Alexandria and Lafayette Louisiana and in West Columbia and Charleston SC. Alexandria is on a three year lease; Lafayette a five year lease; West Columbia has one year remaining on its lease; and Charleston is on a three year lease. On March 28, 2014, Dotolo Research moved from its current manufacturing location in Phoenix AZ into E&R Engineer manufacturing facilities located in Tempe, AZ. Rent expense for the three months ended May 31, 2015 and 2014 were $36,527 and $19,178, respectively. Rent expense for the nine months ended May 31, 2015 and 2014 were $112,055 and $64,680, respectively. Following are the minimum lease payments:

   
2015  $             33,495
2016               126,424
2017               114,808
2018                 42,448
   
   
Totals  $           317,175

 

NOTE 9 – GOODWILL, PATENTS AND OTHER INTANGIBLE ASSETS

 

We currently carry our patents and registrations net of amortization. As of May 31, 2015 and 2014, the Company has a capitalized cost of patents and registrations in the amount of $122,479 and accumulated amortization of 102,576. Our patents and registrations are amortized over a 20 year period. Amortization for each of the next 4 fiscal years, assuming no impairment, will be $6,124 per year.

 

 

 

 

 

 

 

-17-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 10 – INVENTORY FINANCE AGREEMENTS

 

Our inventory finance agreements consist of qualified for-sale inventory purchases. These finance agreements are held solely by Esteemcare. Qualifying inventory purchases are grouped into a 12 month finance agreements allowing the company to spread the payments for this inventory over a twelve month period. This allows the company to collect payments for the purchases of that inventory over that time period as most insurance plans spread the purchase payments over a multi-month period, generally 10 to 13 months. All inventory finance agreements are interest free and consist of only minor fees for setup. Below is a listing of our outstanding inventory finance agreements as of May 31, 2015 and 2014 as well as the monthly payment on each agreement.

 

   As of May 31,   
   2015  2014  Monthly Payment
Wells Fargo (017)  $8,331   $—     $4,165 
VGM (322)   23,787    —      5,947 
Wells Fargo (018)   24,694    —      6,174 
VGM (323)   32,106    —      5,351 
DLL (61942)   90,781    —      11,348 
DLL (67910)   31,389    —      3,488 
VGM (324)   32,512    —      3,612 
DLL (68936)   11,263    —      1,126 
Wells Fargo (019)   76,459    —      6,951 
VGM (325)   85,680    —      7,140 
DLL (61649)   —           1,126 
                
                
Outstanding leases  $417,001   $—     $56,428 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-18-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 11 — NOTES PAYABLE

 

CONVERTIBLE NOTES PAYABLE:

 

Convertible notes payable consist of the following as of May 31, 2015 and 2014:

 

The following is a summary of future minimum payments on convertible notes payable as of May 31, 2015:

 

Ref.     May 31,  May 31,
Numb.  Description  2015  2014
 2210   Conv. Note Payable (net of discount)  $64,025   $235,025 
 2218   Conv. Note Payable (net of discount)  $—     $100,000 
 2232   Conv. Note Payable (net of discount)  $—     $(567)
 2238   Conv. Note Payable (net of discount)  $—     $5,300 
 2239   Conv. Note Payable (net of discount)  $—     $7,260 
 2247   Conv. Note Payable (net of discount)  $—     $4,918 
 2250   Conv. Note Payable (net of discount)  $—     $68,429 
 2261   Conv. Note Payable (net of discount)  $8,100   $—   
 2265   Conv. Note Payable (net of discount)  $12,370   $—   
 2267   Conv. Note Payable (net of discount)  $24,897   $—   
 2271   Conv. Note Payable (net of discount)  $16,911   $—   
 2274   Conv. Note Payable (net of discount)  $11,123   $—   
 2276   Conv. Note Payable (net of discount)  $17,161   $—   
 2278   Conv. Note Payable (net of discount)  $56,910   $—   
 2281   Conv. Note Payable (net of discount)  $13,095   $—   
 2290   Conv. Note Payable (net of discount)  $31,918   $—   
 2292   Conv. Note Payable (net of discount)  $18,885   $—   
 2294   Conv. Note Payable (net of discount)  $15,579   $—   
 2297   Conv. Note Payable (net of discount)  $17,680   $—   
 2310   Conv. Note Payable (net of discount)  $15,650   $—   
 2312   Conv. Note Payable (net of discount)  $1,813   $—   
 2314   Conv. Note Payable (net of discount)  $20,592   $—   
 2316   Conv. Note Payable (net of discount)  $30,887   $—   
 2322   Conv. Note Payable (net of discount)  $100,000   $—   
                
                
     Subtotal   477,596    420,365 
                
 Less:  Long-Term portion    —    (235,025 )
                
 Current portion $477,596 $ 185,340  

 

The following is a summary of future minimum payments on convertible notes payable as of May 31, 2015:

 

      Convertible 
 Fiscal Year Ending August 31,    Notes Payable 
 2015   $0 
 2016   $477,596 

 

 

 

-19-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

2210 - On April 1, 2009, we issued to Ms. Lindstrom, our former Chief Executive Officer, a convertible promissory note in lieu of payment of $235,025 in accrued salary owed to Ms. Lindstrom. This note accrues interest at a rate of 6% per annum and was originally due on March 31, 2012. On March 16, 2012, Ms. Lindstrom agreed to extend the due date of the note to September 30, 2013. There was no beneficial conversion feature recognized upon the issuance of this note. An outside party has entered into an assignment and settlement agreement with Ms. Lindstrom to purchase the note. The note assignment is currently in default. During fiscal 2014, the Assignee has converted $46,000 of principal into 8,788,171 shares of stock reducing the current balance of the note to $189,025. During fiscal 2015, the Holder assigned $125,000 of principal to another accredited investor. As of May 31, 2015, the Company has an outstanding principal balance of $64,025 and an accrued interest in the amount of $82,833.

 

2218 - During May and June 2007, we issued nine Convertible Promissory Notes in an aggregate principal amount of $700,000. Eight of these notes we-+re converted into common stock in fiscal 2009. The remaining Convertible Promissory Note, in the principal amount of $125,000, was extended on January 28, 2010 initially to March 31, 2012, where the conversion rate was reduced to $.60, and then extended to September 30, 2013. In October 2013 and November 2014, the investor sold two $25,000 positions of principal in the note to another accredited investor. In May 2015, the investor sold the remaining $75,000 of principal in the note to another accredited investor. The note has been extended to December 31, 2015 and we are negotiating the final payment of accrued interest. As of May 31, 2015, the Company has accrued interest in the amount of $65,469.

 

2232 - On October 2, 2013 we issued a convertible promissory note in the principal amount of $25,000. This promissory note bore interest at a rate of 8% per annum and is due on October 2, 2013. The note was convertible at a 45% discount of the average of the three lowest closing bid prices in the twenty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $25,000. On April 6, 2014 the holder elected to convert $17,074 in principal plus $690 in accrued interest into 5,383,007 shares of common stock at a conversion price of $.0033. In August 1, 2014 the remaining principal of $7,926 plus accrued interest of $530 was converted into 3,416,764 shares of common stock at a conversion rate of $.002475.

 

2238 - On March 19, 2014 we issued a convertible promissory note in the principal amount of $26,500 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on March 19, 2015. The note was convertible at a 38% discount of the lowest closing bid prices in the thirty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $26,500. During fiscal 2015, the investor converted $26,500 of principal plus accrued interest of $1,384 into 16,801,705 shares of common stock.

 

2239 - On April 8, 2014 we issued a convertible promissory note in the principal amount of $50,000 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on April 8, 2015. The note is convertible at a 35% discount of the average 4 lowest closing bid prices in the twenty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $50,000. This note was paid in full on October 2, 2014.

 

2247 - On April 25, 2014 we issued a convertible promissory note in the principal amount of $25,000 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on October 25, 2015. The note is convertible at a 35% discount of the average 4 lowest closing bid prices in the thirty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $25,000. During October and November 2014, the entire principal amount of $25,000 was converted into 8,284,469 shares of common stock.

 

 

 

-20-
 

 ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

2250 -On May 21, 2014 we issued a convertible promissory note in the principal amount of $115,000 to an unrelated accredited investor. This promissory note bore interest at a rate of 10% per annum. This principal includes a 10% OID in the amount of $10,000, which is being amortized over the term of the note. The note is due in 4 equal installments beginning on the 180th day after the execution of the note. The company may make the payments in common stock. The note is convertible at a $.009 per share. As additional consideration, the Company issued 9,583,333 5 year warrants with an exercise price of $.009. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $38,322 related to the issuance of the warrants. This note was paid in full on February 23, 2015.

 

2253 - On July 16, 2014 we issued a convertible promissory note in the principal amount of $26,500 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on July 26, 2015. The note is convertible at a 38% discount of the lowest closing bid prices in the thirty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $26,500. During the second quarter of fiscal 2015, the company converted $26,500 in principal plus $1,134 of accrued interest into 18,571,550 shares of common stock.

 

2259 -On November 17, 2014, the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $25,000 of the current convertible note holder note. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 30% discount into shares of the Company’s common stock using a five-day average of the lowest closing stock prices immediately preceding the conversion date. The Company recorded a beneficial conversion feature of $10,545. During fiscal 2015, the investor converted the $25,000 in principal plus $85 in accrued interest into 9,641,872 shares of common stock.

 

2261 -On November 17, 2014 we issued a convertible promissory note in the principal amount of $25,000. This promissory note bears interest at a rate of 8% per annum and is due on October 2, 2013. The note is convertible at a 30% discount of the average of the five closing stock prices immediately preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $10,545. During fiscal 2015 the investor converted $11,989 of principal and $1,011 of interest into 6,211,180 shares of common stock. As of May 31, 2015 the company has accrued interest of $7.

 

2265 -On January 22, 2015 we issued a convertible promissory note in the principal amount of $35,000. This promissory note bears interest at a rate of 8% per annum and is due on January 22, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $35,000. As of May 31, 2015 the company has accrued interest of $1,003.

 

2267 - On January 30, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 12% per annum and is due on September 30, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $50,000. As of May 31, 2015 the company has accrued interest of $1,989.

 

2269 - On February 5, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $50,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. The Company recorded a beneficial conversion feature of $50,000. During the second and third quarters of fiscal 2015, the investor converted the $50,198 in principal and interest into 16,669,092 shares of common stock.

 

 

-21-
 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

2274 - On February 4, 2015 we issued a convertible promissory note in the principal amount of $35,000. This promissory note bears interest at a rate of 8% per annum and is due on February 4, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $35,000. As of May 31, 2015 the company has accrued interest of $1,128.

 

2271 - On February 12, 2015 we issued a convertible promissory note in the principal amount of $75,000. This promissory note bears interest at a rate of 10% per annum and is due on February 12, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $75,000. As of May 31, 2015 the company has accrued interest of $2,250.

 

2281 - On February 25, 2015 we issued a convertible promissory note in the principal amount of $30,000. This promissory note bears interest at a rate of 12% per annum and is due on October 25, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $30,000. As of May 31, 2015 the company has accrued interest of $937.

.

2276 - On March 5, 2015 we issued a convertible promissory note in the principal amount of $36,750. This promissory note bears interest at a rate of 8% per annum and is due on March 5, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $711.

 

2283 - On March 9, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $30,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. During the third quarter of fiscal 2015, the investor converted $30,096 of principal and interest into 9,180,298 shares of common stock.

 

2278 - On March 11, 2015 we issued a convertible promissory note in the principal amount of $88,000. This promissory note bears interest at a rate of 12% per annum and is due on September 11, 2015. The note is convertible at a 38% discount of the lowest closing price immediately during the 20 days preceding the date of conversion. The Company also paid an OID in the amount of $6,000. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $2,376.

 

2290 - On March 25, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 10% per annum and is due on September 25, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $931.

 

2292 - On March 30, 2015 we issued a convertible promissory note in the principal amount of $32,000. This promissory note bears interest at a rate of 8% per annum and is due on March 30, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $441.

 

-22-
 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

2294 - On April 7, 2015 we issued a convertible promissory note in the principal amount of $27,500. This promissory note bears interest at a rate of 12% per annum and is due on April 7, 2017. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. The Company also paid an OID in the amount of $6,000. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $330.

 

2297 - On April 8, 2015 we issued a convertible promissory note in the principal amount of $58,000. The company received net proceeds of $50,000 with the balance of the note going for finders fees and processing fees. This promissory note bears interest at a rate of 8% per annum and is due on April 8, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $683.

 

2310 - On May 7, 2015 we issued a convertible promissory note in the principal amount of $35,000. This promissory note bears interest at a rate of 12% per annum and is due on October 25, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $21,452. As of May 31, 2015 the company has accrued interest of $280.

 

2312 - On May 8, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $45,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $29,715. During the third quarter of fiscal 2015, the investor converted $16,261 of principal into 9,400,000 shares of common stock.

 

2314 - On May 22, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 8% per annum and is due on December 31, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $30,645. As of May 31, 2015 the company has accrued interest of $100.

 

2316 - On May 22, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $75,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $45,968.

 

2322 - On January 2, 2015, The Company issued a $100,000 convertible promissory note in full payment of an outstanding invoice of an accredited investor. The Company issued to the accredited investor a convertible promissory note bearing interest at 4% and convertible at a 35% discount of the average of the last en closing stock prices immediately preceding the date of the conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares.

  

 

 

 

 

-23-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

CONVERTIBLE RELATED PARTY NOTES PAYABLE:

 

As of May 31, 2015, there are currently no related party convertible notes payable outstanding. The note related to our former CEO is now classified as non-related convertible debt for all comparable periods.

 

 

RELATED PARTY NOTES PAYABLE:

 

   May 31,  May 31,
   2015  2014
6.0% line of credit (2)  $—     $51,600 
         —   
           
Outstanding unsecured related party notes payable  $—     $51,600 
           
(1)  Note payable to current CEO.          

 

During the last two years, Wayne Erwin, our President and CEO, has advanced a total of $51,600 directly to Dotolo in an open advance account. Interest is being accrued at a rate of 6% per annum. As of May 31, 2015 the Company has repaid $51,600 of principal and $7,393 of accrued interest.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-24-
 

 ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

 

OTHER NOTES PAYABLE:

Ref.     May 31,  May 31,
Numb.  Description  2015  2014
 Dot 1   Note Payable (net of discount)  $1,500   $60,600 
 Dot 2   Note Payable (net of discount)   30,000    30,000 
 Dot 3   Note Payable (net of discount)   20,000    20,000 
 AA 1   Line of Credit   43,149    44,469 
 AA 2   Line of Credit   37,467    —   
 AA 3   Merchant Loan   —      130,400 
 AA 4   Merchant Loan   —      142,109 
 AA 5   Merchant Loan   68,409    —   
 AA 6   Merchant Loan   42,080    —   
 AA 7   Merchant Loan   228,215    —   
 AA 8   Merchant Loan   67,400    —   
 AA 9   Note Payable (net of discount)   —      14,765 
 EST 1   Note Payable (net of discount)   73,552    —   
 2226   Note Payable (net of discount)   —      10,833 
 2227   Note Payable (net of discount)   —      6,689 
 2228   Note Payable (net of discount)   —      6,844 
 2229   Note Payable (net of discount)   —      21,076 
 2230   Note Payable (net of discount)   68,510    70,659 
 2231   Note Payable (net of discount)   12,000    7,692 
 2236   Note Payable (net of discount)   1,533,584    275,155 
 2237   Note Payable (net of discount)   —      11,444 
 2255   Note Payable (net of discount)   22,909    —   
 2257   Note Payable (net of discount)   68,920    —   
 2258   Note Payable (net of discount)   22,973    —   
 2263   Note Payable (net of discount)   56,215    —   
 2264   Note Payable (net of discount)   11,500    —   
 2300   Note Payable (net of discount)   416,466    498,179 
 2432   Note Payable (net of discount)   25,499    78,915 
                
     Subtotal   2,850,348    1,429,829 
                
 Less:  Long-Term portion (376,037 )  (416,466 )
                
 Current portion $2,474,311 $ 1,013,363  

 

 

Notes held by Dotolo

 

DOT 1 - During April 2012, our subsidiary Dotolo, entered into a financing agreement to provide up to $150,000 in funding for the subsidiary. The financing agreement was due in January 2013. We entered into a settlement agreement whereby we paid $45,000 from amounts held in reserve by our senior lender and are required to make 10 monthly payments of $1,500. As of May 31, 2015, the current balance is $1,500.

 

DOT 2 - On February 27, 2013 our subsidiary Dotolo, entered into a note payable agreement to provide funding to its subsidiary in the principal amount of $30,000. The note bears interest at 18% payable monthly on the 15th and is due in full in January 2016. For the three months ended May 31, 2015, we made interest payments in the amount of $1,350. As of May 31, 2015, we have accrued interest of $1,965.

 

-25-
 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

DOT 3 - On March 17, 2013 our subsidiary Dotolo, entered into a note payable agreement to provide funding to its subsidiary in the principal amount of $20,000. The note bears interest at 18% payable monthly on the 15th and is due in full in January 2016. For the year ended May 31, 2015, we made interest payments in the amount of $900. As of May 31, 2015, we have accrued interest of $1,090.

 

Notes held by Amian Angels

 

AA 1 – During fiscal 2014 we borrowed $45,000 from our $50,000 line of open line of credit with our bank. As of May 31, 2015 the outstanding balance of the line of credit loan was $43,149.

 

AA 2 – During fiscal 2015 we borrowed $80,000 from our line of open line of credit with another lender. During the third quarter of fiscal 2015 we have repaid $42,533 of principal plus additional interest. As of May 31, 2015 the outstanding balance of the line of credit loan was $37,467.

 

AA 3 – On April 18, 2014, the Company obtained a merchant loan for additional working capital in the amount of $120,000. This loan requires 189 daily payments in the amount of $800 for a total repayment amount of $151,200. We netted gross proceeds of $119,301 after paying loan fees. This note was paid in full in December 2014.

 

AA 4 – On March 11, 2014, the Company obtained a merchant loan for additional working capital in the amount of $150,000. This loan requires 209 daily payments in the amount of $940 for a total repayment amount of $196,500. We netted gross proceeds of $146,750 after paying loan fees. This note was paid in full in December 2014.

 

AA 5 – On May 22, 2015, the Company obtained a merchant loan for additional working capital in the amount of $50,000. This loan requires 132 daily payments in the amount of $530 for a total repayment amount of $70,000. The balance of this loan on May 31, 2015 was $68,409.

 

AA 6 – On May 7, 2015, the Company obtained a merchant loan for additional working capital in the amount of $35,000. This loan requires 85 daily payments in the amount of $599 for a total repayment amount of $51,065. The balance of this loan on May 31, 2015 was $42,080.

 

AA 7 – On December 15, 2014, the Company obtained a merchant loan for additional working capital in the amount of $300,000. This loan requires 252 daily payments in the amount of $1,607 for a total repayment amount of $405,000. We netted gross proceeds of $163,713 after paying loan fees and paying off our other 4 merchant loans. The balance of this loan on May 31, 2015 was $228,215.

 

AA 8 – On April 30, 2015, the Company obtained a merchant loan for additional working capital in the amount of $60,000. This loan requires 87 daily payments in the amount of $999 for a total repayment amount of $87,450. The balance of this loan on May 31, 2015 was $67,400.

 

AA 9 – In connection with the acquisition of Amian Health Services, the Company entered into a twelve month promissory note in the total principal amount of $25,000. The note bears interest at $6% and requires monthly payments of $2,152. This note was paid in full in December 2014.

 

Notes held by Esteemcare

 

EST 1 - On September 25, 2014, as part of the terms and conditions of the acquisition of Esteemcare Inc. and Affordable Medical Inventory Solutions Inc., the company issued an 18 month note to Imad Siddiqui in the principal amount of $75,000. This note was executed on May 1, 2015 and requires monthly payments of $4,524. As a result of the delay in execution of the note, the Company accrued $2,688 of interested and added it to the balance of the note.

 

-26-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Notes held by Oncologix Tech

 

2216 - On August 1, 2013, in connection with our acquisition of Angels of Mercy, Inc. we entered into a promissory note to pay $65,000 of broker’s fees incurred in the acquisition. Monthly payments of $5,417 are due and payable beginning on August 15, 2013. This note bears no interest. This was paid in full in July 2014.

 

2227 & 2228 - On November 5, 2013 and November 8, 2013, the Company entered into two, one-year promissory notes with accredited investors to borrow a total principal amount of $20,000. Each promissory note is $10,000 in principal balance, bore interest at 18% and requires monthly interest payments of $150 each. The company also issued 3,000,000 in cashless warrants as finder’s fees for these funds. The Company recorded a discount of $14,805 for the issuance of the warrants. These notes were paid in full in November 2014.

 

2229 - On November 1, 2013, the Company entered into a Settlement Agreement with its former legal counsel. The current balance owed to prior counsel is $145,523. Pursuant to the settlement agreement, the Company agreed to pay $50,000 in the form of a one year promissory note and transfer its 90% ownership interest and all marketing rights of Oncologix Corporation, one of its subsidiaries as full settlement of the current balance owed. The promissory note bears interest of 4% and requires monthly payment of $4,257 beginning on December 1, 2013. This note was paid in full during November 2014.

 

2230 - On December 3, 2013, The Company entered into a twelve month promissory note with an accredited investor to borrow a total principal amount of $75,000. The note bears interest of 18% per annum and calls for monthly payments of principal and interest of $1,375 beginning on January 15, 2014 with a balloon payment due December 15, 2014. The Company also issued as additional finders’ fees to the investor, 3,500,000 shares of common stock and 1,000,000 cashless warrants with an exercise price of $.025. As of May 31, 2015, the balance was $68,510. The Company recorded a discount of $5,992 for the issuance of the warrants.

 

2231 - On December 20, 2013, the Company issued a 1-year promissory note to a non-related accredited investor in the principal amount of $12,000. This note bears interest at 10% per annum and matures in December 2014. This note was extended to June 2015. As additional consideration for the operating capital loan, the company issued 3,000,000 cashless two-year warrants with an exercise price of $0.02. The Company recorded a discount of $7,746 for the issuance of the warrants. As of May 31, 2015 the Company has accrued interest of $1,437.

 

2236 - On January 3, 2014, the Company closed on a 4 million dollar line of credit facility, with an initial draw of $500,000. The Company must meet specific monthly reporting and collateral requirements to further draw on the revolving credit facility. The $500,000 initial draw is secured by a 14.5% promissory note, which is convertible ONLY upon default by the Company. In July 2014, we borrowed an additional $75,000 from the principal we repaid. This note is due in nine months with an automatic option to renew after nine months. On September 25, 2014, the Company took down a second draw from its $4 million dollar line of credit facility in the amount of $1,200,000. The Company must meet specific monthly reporting and collateral requirements to further draw on the revolving credit facility. The outstanding balance at the time of the draw was $1,533,584 which is secured by twelve month 14.5% promissory note, which is convertible ONLY upon default by the Company. This note is automatically renewable for an additional twelve months. The company is required to pay interest and fees only for the initial 3 months. The balance of this note on May 31, 2015 is $1,533,584.

 

2237 - On February 7, 2014, the Company issued a 1-year promissory note in the principal amount of $15,000 to a non-related accredited investor. This note bears interest at 6% per annum and matures in February 2015. As additional consideration for the operating capital loan, the company issued 1,500,000 two-year warrants with an exercise price of $0.15 and 1,000,000 shares of common stock. The Company recorded an expense of $9,000 for the issuance of the common stock. The Company recorded a discount of $5,151 for the issuance of the warrants. On August 1, 2014 this investor used $10,000 to purchase 1,200,000 shares of common stock. This note was paid in February 2015.

 

 

 

-27-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

2255 - On August 15, 2014 the Company issued a 1-year promissory note to a non-related accredited investor in the principal amount of $25,000. This note bears interest at 10% per annum and matures in August 2015. As additional consideration for the operating capital loan, the company issued 4,000,000 cashless two-year warrants with an exercise price of $0.065. The Company recorded a discount of $10,177 for the issuance of the warrants. As of May 31, 2015 the Company has accrued interest of $1,993.

 

2257 & 2258 - On September 25, 2014, the Company issued a $75,000 and $25,000 1-year promissory notes bearing interest at 6% in connection with the acquisition of Esteemcare Inc. and Affordable Medical Inventory Solutions Inc. As of May 31, 2015, the outstanding balances of these notes were $68,920 and $22,973, respectively.

 

2263 - On November 16, 2014, the Company borrowed $60,000 in principal from an unrelated investor. This note bears interest at a rate of 12% and calls for 60 monthly payments of $1,334.67 beginning on January 19, 2015. The note matures on January 19, 2019. As of May 31, 2015, the outstanding balance of this note was 56,217.

 

2264 - On December 16, 2014, the Company borrowed $48,000 in principal from an unrelated investor. This note bears calls for two interest payments, each in the amount of $8,500 in January and February 2015. The note matures on March 16, 2015. As of May 31, 2015, the outstanding balance of this note was 11,500.

 

2300 - On August 1, 2013, in connection with our acquisition of Angels of Mercy, Inc. we entered into a promissory note to pay $550,000 for the purchase of Angels of Mercy, Inc. Monthly payments of $9,115 are due and payable beginning on November 1, 2013 with a final balloon payment of $205,705 due on October 1, 2017. This note bears interest at a rate of 6%. As of May 31, 2015, the outstanding balance of the note is $416,466.

 

2432 - On July 26, 2013 the Company issued an 18 month promissory note in the principal amount of $100,000. These funds were used for the cash down payment for the Angels acquisition. The note bears interest at 18% and requires monthly interest payments of $1,200 beginning on September 26, 2013. In December 2013, we modified the loan agreement to make monthly payments of $6,200. As of May 31, 2015 the outstanding balance was $25,499.

 

The following is a summary of future minimum payments on r notes payable as of May 31, 2015:

    Related Conv.
Fiscal Year Ending August 31,   Notes Payable
2015      2,394,130
2016           97,813
2017         326,226
2018           14,580
2019           17,599

 

 

 

 

 

 

 

 

 

 

 

 

 

-28-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 12 — STOCKHOLDERS EQUITY

PREFERRED STOCK:

 

Series A Convertible Preferred Stock.

 

The Company is authorized to issue up to 10,000,000 shares of preferred stock, in one or more series, and to determine the price, rights, preferences and privileges of the shares of each such series without any further vote or action by the stockholders. The rights of the holders of common stock will be subject to, and may be adversely affected by, the rights of the holders of any shares of preferred stock that may be issued in the future.  

 

In January 2003, our Board of Directors authorized up to 4,500,000 shares of Series A Convertible Preferred Stock.  Each share of Series A Convertible Preferred stock has a par value of $0.001 and is convertible into one-half share of common stock in upon a cash payment by the holder to the Company of $0.40 per common share.  The Series A Convertible Preferred Stock is entitled to receive, in preference to the common stock, of noncumulative dividends, if declared by the Board of Directors, and a claim on the Company's assets upon any liquidation of the Company senior to the common stock.  These preferred shares are not entitled to voting rights. There are presently outstanding 129,062 shares of Series A Preferred Stock.

 

On March 30, 2003, the Company completed the private placement of Units pursuant to the terms of a Unit Purchase Agreement (the “Units”) with accredited investors. Each Unit consists of the following underlying securities: (i) three shares of the Company’s common stock; (ii) one share of Series A Convertible Preferred Stock, par value $.001 per share; and (iii) one three-year warrant to purchase one share of common stock at a per share price of $0.30. The warrants expired on March 31, 2006. Each share of Series A Convertible Preferred Stock is convertible into one half share of the Company’s common stock in exchange for $0.40 per common share ($.20 for each Series A Convertible Preferred share converted). The securities underlying the Units are not to be separately tradable or transferable apart from the Units until such time as determined by the Company’s Board of Directors. A total of 4,032,743 Units were issued. As of August 31, 2014 and August 31, 2013, there were 129,062 and 129,062 Units outstanding that had not been separated, respectively. These units are presented as their underlying securities on our balance sheet and consist of 64,531 shares of Series A Preferred Stock and 96,797 shares of common stock which is included in the issued and outstanding shares.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-29-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Below is a table detailing the outstanding Series A Convertible Preferred Stock shares outstanding during the last two fiscal years:

 

      Preferred    Number of          Weighted Avg. 
      Shares    Common Shares    Proceeds if    Per Common Sh. 
      Outstanding    Convertible    Converted    Exercise Price 
 Outstanding, August 31, 2013    129,062    64,531   $25,812   $0.40 
                       
 Expired/Retired    —      —      —     $—   
 Converted    —      —      —     $0.40 
 Issued    —      —      —     $—   
 Outstanding, August 31, 2014    129,062    64,531   $25,812   $0.40 
                       
 Expired/Retired    —      —      —     $0.40 
 Converted    —      —      —     $—   
 Issued    —      —      —     $—   
 Outstanding, May 31, 2015    129,062    64,531   $25,812   $0.40 

 

Series D Convertible Preferred Stock

 

In March 2013, our Board of Directors authorized up to 60,000 shares of Series D Convertible Preferred Stock. Each share of Series D Convertible stock has a par value of $0.001 and is convertible into 1,000 shares of common stock beginning after March 1, 2014. Each share of Series D Convertible Preferred Stock has a stated liquidation value of $80.25. Each shares of Series D Convertible Preferred Stock shall have voting rights as stated below:

 

March 1, 2013 to May 31, 2014, 400 votes per share;

March 1, 2014 to May 31, 2015, 800 votes per share;

March 1, 2015 to May 31, 2016, 1,200 votes per share;

March 1, 2016 to May 31, 2017, 1,600 votes per share;

March 1, 2017 and after, 2,000 votes per share;

 

On March 22, 2013, the Company issued 58,564 shares of Series D Convertible Preferred Stock to acquire 100% of the outstanding common stock of Dotolo. On March 22, 2013 the issued shares had a fair market value of $585,640 based on the fair market value of the underlying common stock shares.

 

On January 3, 2014, as payment for $150,000 of banking fees associated with our $4 million line of credit, we issued 20,000 shares of Series D Convertible Preferred Stock.

 

 

 

 

 

 

 

 

 

 

 

 

 

-30-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Below is a table detailing the outstanding Series D Convertible Preferred Stock shares outstanding during the last two fiscal years:

 

      Preferred    Number of          Weighted Avg. 
      Shares    Common Shares    Proceeds if    Per Common Sh. 
      Outstanding    Convertible    Converted    Exercise Price 
 Outstanding, August 31, 2013    58,564    58,564,000   $—     $80.25 
                       
 Expired/Retired    —      —      —     $—   
 Converted    —      —      —     $—   
 Issued    20,000    20,000,000    —     $80.25 
 Outstanding, August 31, 2014    78,564    78,564,000   $—     $—   
                       
 Expired/Retired    —      —      —     $—   
 Converted    —      —      —     $—   
 Issued    —      —      —     $—   
 Outstanding, May 31, 2015    78,564    78,564,000   $—     $80.25 

 

SUBSCRIBED COMMON STOCK:

 

Below is a table detailing the Common Stock Subscribed during the last two fiscal years:

 

For the period Ended May 31, 2015
              Shares   Amount  
Shares issuable upon conversion of convertible notes payable                        -       $                    -     
                     
Total subscribed stock                          -       $                    -     
                     
For the period Ended August 31, 2014
              Shares   Amount  
Shares issuable upon conversion of convertible notes payable            1,058,201    $               5,000  
                     
Total subscribed stock              1,058,201    $               5,000  

 

COMMON STOCK:

 

On March 7, 2014, the Company increased its authorized shares of common stock to 750,000,000. The increase was approved by a majority of the Company’s shareholders on January 27, 2014. As of May 31, 2015, the Company has 276,746,130 shares outstanding. Please see Part II, Item II – Sale of Unregistered Securities for information on recent sales of unregistered securities.

 

NON-CONTROLLING INTEREST

 

On February 27, 2009, in connection with the Technology Agreement we entered into with Institut für Umwelttechnologien GmbH, a German Company (“IUT”) whereunder the parties have agreed that the Company’s marketing rights have been transferred to its subsidiary, Oncologix Corporation and have issued IUTM 10% of the equity ownership of that subsidiary. As of February 27, 2009, the value of the non-controlling interest was $212. It was determined at August 31, 2010 the value of the investment in IUTM was impaired. Accordingly, we recorded an impairment loss in the amount of $3,186 for the year ended August 31, 2010. As of May 31, 2015, as a result of the disposition of Oncologix Corporation, we do not have to recognize a non-controlling interest.

 

 

-31-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

 

WARRANTS:

 

The following table summarizes warrant activity in fiscal 2015 and 2014:

 

        Weighted Avg.
    Number Exercise Price
Outstanding, August 31, 2013              7,000,000                       0.012
Expired/Retired                          -                               -    
Exercised                          -                               -    
Issued            23,583,333                       0.011
Outstanding, August 31, 2014            30,583,333                            -    
         
Expired/Retired                          -                               -    
Exercised            (9,583,333)                       0.009
Issued                          -                               -    
Outstanding, May 31, 2015            21,000,000                       0.012

 

The fair value of warrants granted is estimated using the Black-Scholes option pricing model. This model utilizes the following factors to calculate the fair value of options granted: (i) annual dividend yield, (ii) weighted-average expected life, (iii) risk-free interest rate and (iv) expected volatility. The warrants were expensed and accounted for under ASC 718.

 

The fair value for these warrants was estimated as of the date of grant using a Black-Scholes option-pricing model with the following assumptions:

 

        For the Nine Months Ended May 31,
        2015   2014
Volatility                                     -       124% - 702% 
Risk free rate     0.00%   0.25%
Expected dividends      None     None 
Expected term (in years)                                   -    2 to 5 years 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-32-
 

 ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Details relative to the 21,000,000 immediately exercisable outstanding warrants at May 31, 2015 are as follows:

 

        Weighted          
        Average          
Date of   Number   Exercise    Remaining    Expiration  
Grant   of Shares   Price    Exercise Life    Date  
                   
Outstanding, August 31, 2013              7,000,000              
                   
First quarter of fiscal 2014              4,500,000    $     0.012    3 years    November 2017  
Second quarter of fiscal 2014              5,500,000    $     0.017    2 to 3 years    Dec 2015 to Dec 2016
Third quarter of fiscal 2014              9,583,333    $     0.012    5 years    May 2019  
Fourth quarter of fiscal 2014              4,000,000    $     0.007    2 years    August 2016  
                   
Outstanding, August 31, 2014            30,583,333              
                   
First quarter of fiscal 2015                          -       $         -                              -         
Second quarter of fiscal 2015                          -                 
Third quarter of fiscal 2015            (9,583,333)    $     0.009          
                   
                   
Outstanding, May 31, 2015            21,000,000              

 

On August 1, 2013, the company issued 1,000,000 four-year cashless warrants as additional consideration for the acquisition of Amian Angels. These warrants expire four years after the date of issuance and have an exercise price of $.015.

 

On August 5, 2013, the company issued 6,000,000 three-year cashless warrants, to a related party, as finder’s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.012.

 

On September 11, 2013, the company issued 1,500,000 three-year cashless warrants, to a related party, as finder’s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.015.

 

On November 8, 2013, the company issued 3,000,000 three-year cashless warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.01.

 

On December 3, 2014, the company issued 1,000,000 three-year cashless warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.025.

 

On December 20, 2014, the company issued 3,000,000 two-year cashless warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire two years after the date of issuance and have an exercise price of $.016.

 

On February 7, 2014, the company issued 1,000,000 two-year cashless warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire two years after the date of issuance and have an exercise price of $.015.

 

On May 21, 2014, the company issued 9,583,333 five-year cashless warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire five years after the date of issuance and have an exercise price of $.009.

  

-33-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

On August 15, 2014, the company issued 4,000,000 two-year warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire two years after the date of issuance and have an exercise price of $.0065.

During the third quarter of fiscal 2015, 9,583,333 warrants were exercised in a cashless transaction. 33,382,960 shares of Common stock were issued for the warrants’ exercise.

 

The remaining contractual life of warrants outstanding as of May 31, 2015 was 1.17 years. Warrants for the purchase of 21,000,000 and 26,586,333 shares were immediately exercisable on May 31, 2015 and 2014, respectively with a weighted-average price of $0.012 and $0.011 per share, respectively.

 

STOCK OPTIONS:

 

ASC 718 requires the estimation of forfeitures when recognizing compensation expense and that this estimate of forfeitures be adjusted over the requisite service period should actual forfeitures differ from such estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment, which is recognized in the period of change and which impacts the amount of unamortized compensation expense to be recognized in future periods.

 

ASC 718 requires that modification of the terms or conditions of an equity award is to be treated as an exchange of the original award for a new award. This event is accounted for as if the entity repurchases the original instrument by issuing a new instrument of equal or greater value, incurring additional compensation cost for any incremental value.

 

2000 Stock Incentive Plan

 

The Company is authorized to issue up to 7,500,000 shares of common stock under its 2000 Stock Incentive Plan. Shares may be issued as incentive stock options, non-statutory stock options, deferred shares or restricted shares. Options are granted at the fair market value of the common stock on the date of the grant and have terms of up to ten years. The 2000 Stock Incentive Plan also provides for an annual grant of options to members of our Board of Directors. For fiscal years ended August 31, 2008 through 2012, our Board of Directors elected to waive the grant of these annual options.

 

On December 13, 2013, the Board of directors authorized the granting of 6,100,000 options to its three officers; 2,400,000 options to Wayne Erwin, our CEO; 2,100,000 options to Michael Kramarz, our CFO; and 1,600,000 options to Vickie Hart, President of Amian Angels. These options vest immediately and have an exercise price $.015, the closing stock price on December 13, 2013.

 

On December 20, 2014, the Company issued 20,000 options as part of its annual grant program to its two directors. These options vest in 1 year and have an exercise price of $.016, the closing stock price on December 20, 2013.

 

We have 473,253 shares of common stock available for future issuance under our 2000 Stock Incentive Plan as of May 31, 2015. This plan has been approved by our shareholders.

 

During the three and nine months years ended May 31, 2015 and 2014, we granted 6,120,000 and nil options from the stock incentive plan described above, respectively. During the three and nine months ended May 31, 2015 and 2014, nil and nil options were exercised, respectively. During the three months ended May 31, 2015 and 2014, nil and nil options expired, respectively. During the nine months ended May 31, 2015 and 2014, nil and 150,835 options expired, respectively. During the three and nine months ended May 31, 2015 and 2014, $0 and $91,163 was expensed as stock based compensation, respectively.

 

 

 

 

-34-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

                Weighted Average 
      Number of    Option Price    Exercise Price 
      Options Granted    Per Share    Per Share 
 Outstanding, August 31, 2013    217,085    $0.12 - $2.00   $1.120 
 Granted    6,120,000     $0.015 - $0.016    $0.020 
 Exercised    —      —     $—   
 Cancelled    (163,335)   $1.04 - $2.00   $1.380 
 Outstanding, August 31, 2014    6,173,750    $0.12 - $2.00   $0.016 
 Granted    —     $—     $—   
 Exercised    —      —     $—   
 Cancelled    —     $0.00   $—   
 Outstanding, May 31, 2015    6,173,750    $0.12 - $2.00   $0.016 

 

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between our closing stock price on the last trading day of the third quarter of fiscal 2015 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on May 31, 2015.

 

Expected volatility is based primarily on historical volatility. Historical volatility is computed using weekly average pricing observations for an applicable historic period. We believe this method produces an estimate that is representative of our expectations of the future volatility over the expected term of our options. We currently have no reason to believe future volatility over the expected life of these options is likely to differ materially from historical volatility. The weighted-average expected life is based upon share option exercises, pre and post vesting terminations and share option term expirations. The risk-free interest rate is based on the U.S. treasury security rate estimated for the expected life of the options at the date of grant.

 

The remaining contractual life of options outstanding as of May 31, 2015 was 8.49 years. Options for the purchase of 6,173,750 exercisable on May 31, 2015 with a weighted-average price of $0.016 and $0.016 per share, respectively.

 

          Options   Options
          Outstanding   Exercisable
Number of options                      6,173,750                  6,173,750
Aggregate intrinsic value of options    $                           -    $                           -
Weighted average remaining contractual term (years)                         8.74                           8.74
Weighted average exercise price      $                   0.016   $                   0.016

 

2013 Omnibus Incentive Plan

 

The Company is authorized to issue up to 10,000,000 shares of common stock under its 2013 Omnibus Incentive Plan to employees, officers, directors and consultants. The issuance adoption of this plan has been approved by the Company’s Board of Directors on May 20, 2013 and was approved by our shareholders on January 27, 2014. Any options are granted at the fair market value of the common stock on the date of the grant and have terms of up to ten years. Under the 2013 Omnibus Incentive Plan the price of the granted common stock options are equal to the fair market value of such shares on the date of grant.

 

On September 11, 2013, we issued 1,000,000 S-8 shares to a consultant in payment for investor relations work for the Company. On January 3, 2014, we issued 1,000,000 S-8 shares to a consultant in payment for services to be provided for the Company. On November 15, 2014 we issued 1,000,000 S-8 shares to a consultant in payment for investor relations work for the Company. We have 7,000,000 shares of common stock available for future issuance under our 2013 Omnibus Incentive Plan as of May 31, 2015.

 

 

-35-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

   Number of Securities     Number of Securities
   To Be Issued Upon  Weighted Average  Remaining Available
   Exercise of Outstanding  Exercise Price of  For Future
   Options  Outstanding Options  Issuance Under Plans
                
Equity compensation plans               
approved by stockholders   —     $0.00    7,000,000 
                
Equity compensation plans               
not approved by stockholders   —     $0.00    —   
                
TOTAL   —     $0.00    7,000,000 

 

NOTE 13 - RELATED PARTY TRANSACTIONS AND CONTINGENCIES:

 

FINANCING WITH RELATED PARTIES:

 

During the three and nine months ended May 31, 2015 and 2014, the Company entered into financing agreements with related parties of the Company. Please see Note 11 – Notes Payable for further descriptions of these transactions.

 

NOTE 14 – BUSINESS SEGMENTS

 

We identify our reportable segments based on our management structure, financial data and market. We have identified three business segments: Personal Care Services and Medical Device Products and Medical Products & Technologies

 

Our Personal Care Service segment consists of the services of Angels of Mercy, Inc. This segment provides non-medical, Personal Care Attendant (PCA) services, Supervised Independent Living (SIL), Long-Term Senior Care, and other approved programs performed by a trained caregiver that will meet the health service needs of beneficiaries whose disabilities preclude the performance of certain independent living skills related to the activities of daily living (ADL).

 

Our Medical Device Manufacturing segment consists of the products of Dotolo Research Corporation. This segment designs, develops, manufactures and distributes the Toxygen hardware system with disposable speculums and medical grade tubing.

 

Our Medical Products and Technologies segment will consist of Advanced Medical Products and Technologies, Esteemcare Inc. and Affordable Medical Inventory Solutions Inc. and future acquisitions.

 

The accounting policies of the segments are the same as those described, or referred to, in Note 2 - Summary of Significant Accounting Policies. Assets and related depreciation expense in the column labeled “Corporate Overhead” pertain to capital assets maintained at the corporate level. Segment loss from operations in the “Corporate Overhead” column contains corporate related expenses not allocable to the operating segments. Intercompany transactions between operating segments were immaterial in all periods presented.

 

 

 

 

 

 

 

 

-36-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Below are the segment assets as of May 31, 2015.

 

As of May 31, 2015
   Personal Care  Medical Device  Med. Products  Corporate   
   Segment  Segment  Segment  Overhead  Totals
   (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited)   
ASSETS                 
Current Assets:                         
Cash and cash equivalents  $76,633   $120   $21,008   $22,724   $120,485 
Accounts receivable (net)   233,710    —     $803,299    —      1,037,009 
Inventory   —      31,271   $106,165    —      137,436 
Prepaid expenses and other current assets   —      —     $2,946    12,965    15,911 
Prepaid commissions and finders' fees   —      —      85    3,889    3,974 
                          
Total current assets   310,343    31,391    933,503    39,578    1,314,815 
                          
Property and equipment (net)   16,211    15,217    3,283    535    35,246 
Deposits and other assets   2,307    32,303    9,866    33,202    77,678 
Goodwill   564,075    1,217,704    622,610    —      2,404,389 
Patents, registrations (net of amortization)   —      19,903    —      —      19,903 
                          
Total assets  $892,936   $1,316,518   $1,569,262   $73,315   $3,852,031 

 

Below are the segment assets as of August 31, 2014.

 

As of August 31, 2014
   Personal Care  Medical Device  Med. Products  Corporate   
   Segment  Segment  Segment  Overhead  Totals
                
ASSETS                 
Current Assets:                         
Cash and cash equivalents  $9,336   $(110)  $1,000   $7,278   $17,504 
Accounts receivable (net)   213,399    —      —      —      213,399 
Inventory   —      31,271    —      —      31,271 
Prepaid expenses and other current assets   —      —      —      9,307    9,307 
Prepaid commissions   —      —      —      3,152    3,152 
                          
Total current assets   222,735    31,161    1,000    19,737    274,633 
                          
Property and equipment (net)   21,287    17,893    —      787    39,967 
Deposits and other assets   2,082    12,500    —      —      14,582 
Goodwill   564,075    1,217,704    —      —      1,781,779 
Patents, registrations (net of amortization)   —      24,497    —      —      24,497 
                          
Total assets  $810,179   $1,303,755   $1,000   $20,524   $2,135,458 

 

 

 

-37-
 

 ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Below are the statements of operations for the reporting periods presented.

 

   For the Three Months Ended May 31, 2015
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $812,626   $—     $423,030   $—     $1,235,656 
                          
Cost of revenues   698,215    —      187,381    —      885,596 
                          
Gross profit   114,411    —      235,649    —      350,060 
                          
Operating expenses:                         
General and administrative   81,451    14,739    159,793    187,906    443,889 
Research and development Expense   —      —      —      —      —   
Depreciation and amortization   2,262    2,423    253    84    5,022 
                          
Total operating expenses   83,713    17,162    160,046    187,990    448,911 
                          
Loss from operations   30,698    (17,162)   75,603    (187,990)   (98,851)
                          
Other income (expense):                         
Interest and finance charges   (81,952)   (1,500)   (3,076)   (351,380)   (437,908)
Interest and finance charges - related parties   —      —      —      —      —   
Other income (expenses)   11,307    14    —      —      11,321 
                          
Total other income (expense)   (70,645)   (1,486)   (3,076)   (351,380)   (426,587)
                          
Loss from continuing operations  $(39,947)  $(18,648)  $72,527   $(539,370)  $(525,438)

 

   For the Three Months Ended May 31, 2014
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $988,385   $—     $—     $—     $988,385 
                          
Cost of revenues   776,406    12,351    —      —      788,757 
                          
Gross profit   211,979    (12,351)   —      —      199,628 
                          
Operating expenses:                         
General and administrative   166,867    4,979    —      105,104    276,950 
Depreciation and amortization   3,157    2,423    —      84    5,664 
                          
Total operating expenses   170,024    7,402    —      105,188    282,614 
                          
Loss from operations   41,955    (19,753)   —      (105,188)   (82,986)
                          
Other income (expense):                         
Interest and finance charges   (80,786)   (2,250)   —      (84,438)   (167,474)
Interest and finance charges - related parties   —      (791)   —      —      (791)
Loss on conversion of notes payable - related parties   —      —      —      (62,151)   (62,151)
Loss on disposal of assets   —      —      —      —      —   
Other income (expenses)   74,667    (217)   —      —      74,450 
                          
Total other income (expense)   (6,119)   (3,258)   —      (146,589)   (155,966)
                          
Loss from continuing operations  $35,836   $(23,011)  $—     $(251,777)  $(238,952)

 


-38-
 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Below are the statements of operations for the reporting periods presented.

 

   For the Nine Months Ended May 31, 2015
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $2,573,547   $—     $1,051,860   $—     $3,625,407 
                          
Cost of revenues   2,129,572    —      499,225    —      2,628,797 
                          
Gross profit   443,975    —      552,635    —      996,610 
                          
Operating expenses:                         
General and administrative   317,165    58,489    424,693    579,422    1,379,769 
Research and development expense   —      10,000    —      —      10,000 
Depreciation and amortization   6,289    7,269    546    252    14,356 
                          
Total operating expenses   323,454    75,758    425,239    579,674    1,404,125 
                          
Loss from operations   120,521    (75,758)   127,396    (579,674)   (407,515)
                          
Other income (expense):                         
Interest and finance charges   (244,613)   (5,500)   (3,848)   (836,052)   (1,090,013)
Interest and finance charges - related parties   —      (1,051)   —      —      (1,051)
Other income (expenses)   8,541    (3,854)   —      (204)   4,483 
                          
Total other income (expense)   (236,072)   (10,405)   (3,848)   (836,256)   (1,086,581)
                          
Loss from operations  $(115,551)  $(86,163)  $123,548   $(1,415,930)  $(1,494,096)

 

   For the Nine Months Ended May 31, 2014
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $2,696,776   $—     $—     $—     $2,696,776 
                          
Cost of revenues   2,030,450    36,350    —      —      2,066,800 
                          
Gross profit   666,326    (36,350)   —      —      629,976 
                          
Operating expenses:                         
General and administrative   506,387    28,222    —      465,301    999,910 
Depreciation and amortization   9,636    7,268    —      252    17,156 
                          
Total operating expenses   516,023    35,490    —      465,553    1,017,066 
                          
Loss from operations   150,303    (71,840)   —      (465,553)   (387,090)
                          
Other income (expense):                         
Interest and finance charges   (171,837)   (8,560)   —      (454,436)   (634,833)
Interest and finance charges - related parties   —      (2,348)   —      (15,708)   (18,056)
Loss on conversion of notes payable - related parties   —      —      —      (155,728)   (155,728)
Loss on disposal of assets   (28,748)   —      —      —      (28,748)
Other income (expenses)   72,775    (713)   —      —      72,062 
                          
Total other income (expense)   (127,810)   (11,621)   —      (625,872)   (765,303)
                          
Loss from operations  $22,493   $(83,461)  $—     $(1,091,425)  $(1,152,393)

 

-39-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 15 - JOINT VENTURE

 

Institut für Umwelttechnologien GmbH (IUT)

 

In February 2009, we entered into a Technology Agreement with Institut für Umwelttechnologien GmbH, a German Company (“IUT”). On September 23, 2010, the Company signed a Memorandum of Understanding with Institut für Umwelttechnologien GmbH and IUT Medical GMBH confirming certain understandings among the parties with respect to their future relationships and business activities as originally contemplated in their Technology Agreement of February 27, 2009, which was reaffirmed. On November 1, 2013, with the disposal of the Company’s subsidiary Oncologix Corporation, the company also ended its relationship with IUT and IUTM.

 

NOTE 16 - RETIREMENT PLAN

 

Currently, the Company does not have a retirement plan in place.

 

NOTE 17 - RECENT ACCOUNTING PRONOUNCEMENTS

 

 

We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact on our financial condition or results of operations.

 

NEW ACCOUNTING STANDARD

 

In July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2012-02 “Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment” (“ASU 2012-02”). ASU 2012-02 permits entities to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. Under the amendments in ASU 2012-02, an entity is not required to calculate the fair value of an indefinite-lived intangible asset unless it determines that it is more likely than not that the fair value of the asset is less than its carrying amount. An entity also will have the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. ASU 2012-02 is effective for interim and annual indefinite-lived intangible asset impairment tests performed for fiscal years beginning on or after September 15, 2012, with early adoption permitted. The Company’s adoption of ASU 2012-02 is not expected to have an impact on its consolidated financial statements.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-40-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 18 – STATEMENT OF CASH FLOWS

 

For the nine months ended May 31, 2015, these supplemental non-cash investing and financing activities are summarized as follows:

Amount

On November 15, 2014, the Company issued 1,000,000 S-8 shares of common stock in payment for a investor relations consulting contract.   

 

4,000

   
On November 15, 2014, the Company issued 5,000,000 shares of common stock in payment for  investor relations consulting contract.   

 

20,000

   
On November 17, 2014, the Company issued a $25,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $10,545 related to that transaction.

 

 

10,545

   
On November 17, 2014, the Company issued a $25,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $10,545 related to that transaction.

 

 

10,545

   
On January 22, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $35,000 related to that transaction.

 

 

35,000

   
On January 30, 2015, the Company issued 5,000,000 shares of common stock in payment for  investor relations consulting contract.   

 

38,500

   
On January 30, 2015, the Company issued a $50,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $50,000 related to that transaction.

 

 

50,000

   
On February 5 2015, the Company issued a $50,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $50,000 related to that transaction.

 

 

50,000

   
On February 4, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $35,000 related to that transaction.

 

 

35,000

   
On February 12, 2015, the Company issued a $75,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $75,000 related to that transaction.

 

 

75,000

   
On February 25, 2015, the Company issued a $30,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $30,000 related to that transaction.

 

 

30,000

   
       On March 5, 2015, the Company issued a $36,750 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $25,698 related to that transaction.

 

 

25,698

   
       On March 11, 2015, the Company issued a $88,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $49,539 related to that transaction.

 

 

49,539

   

 

 

-41-
 

 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 18 – STATEMENT OF CASH FLOWS

 

For the nine months ended May 31, 2015, these supplemental non-cash investing and financing activities are summarized as follows:

Amount

       On March 11, 2015, the Company issued a $30,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $20,100 related to that transaction.

 

 

20,100

   
On March 25, 2015, the Company issued a $50,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $29,404 related to that transaction.

 

 

29,404

   
On March 30, 2015, the Company issued a $32,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $15,790 related to that transaction.

 

 

15,790

   
On April 7, 2015, the Company issued a $27,500 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $10,372 related to that transaction.

 

 

10,372

   
On April 8, 2015, the Company issued a $58,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $39,146 related to that transaction.

 

 

39,146

   
On May 7, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $21,452 related to that transaction.

 

 

21,452

   
On May 8, 2015, the Company issued a $45,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $29,715 related to that transaction.

 

 

29,715

   
On May 22, 2015, the Company issued a $50,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $30,645 related to that transaction.

 

 

30,645

   
On May 22, 2015, the Company issued a $75,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $45,968 related to that transaction.

 

 

45,968

   
Total non-cash transactions from investing and financing activities.  $      676,419

 

 

 

 

 

 

 

 

 

 

 

 

 

-42-
 

 ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

For the nine months ended May 31, 2014, these supplemental non-cash investing and financing activities are summarized as follows:

 

On September 11, 2013, the Company issued 1,500,000 warrants to an affiliated party for additional compensation related to an operating capital investment.  The value of these warrants was expensed as interest and finance charges.

 

 

$ 15,656

   
On September 11, 2013, the Company issued 1,000,000 S-8 shares of common stock in payment for a investor relations consulting contract.   

 

11,500

   
On October 2, 2013, the Company issued a $25,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $25,000 related to that transaction.

 

 

25,000

   
On October 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $15,620.

 

15,620

   
On November 5, 2013 and November 8, 2013, the Company issued a total of 3,000,000 warrants to a non-related party as additional compensation for an operating capital investment.

 

 

14,805

   
On December 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $12,069.

 

12,069

   
On December 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $9,720.

 

9,720

   
On December 3, 2013, the Company issued a total of 1,000,000 warrants as additional compensation.

 

5,992

   
On December 20, 2013, the Company issued a total of 3,000,000 warrants as additional compensation.

 

7,746

   
On January 3, 2014, the Company issued 2,000,000 shares of common stock in payment for a services contract.

 

22,000

   
On January 13, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $26,154.

 

26,154

   
On January 14, 2014, the Company issued 1,000,000 shares of common stock as partial compensation for a investor relations contract.

 

19,000

   
On January 21, 2014, the Company issued 3,500,000 shares of common stock as additional compensation for finder’s fees.

 

45,500

   
On January 21, 2014, the Company issued 1,500,000 shares of common stock as additional compensation for finder’s fees.

 

30,000

   
On January 31, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $16,667.

 

16,667

   
On February 7, 2014, the Company issued 1,000,000 shares of common stock as additional compensation for finder’s fees.

 

9,000

 

-43-
 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

For the nine months ended May 31, 2014, these supplemental non-cash investing and financing activities are summarized as follows (continued):

 

On February 7, 2014, the Company issued 3,000,000 shares of common stock as additional compensation for finder’s fees.

 

5,151

   
On February 24, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $2,308.

 

2,308

   
On March 19, 2014, the Company recorded a beneficial conversion feature on the issuance of a convertible note.

 

26,500

   
On March 31, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $30,000.

 

30,000

   
On April 6, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $1,468.

 

1,468

   
On April 6, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $30,683

 

30,683

   
On April 8, 2014, the Company recorded a beneficial conversion feature on the issuance of a convertible note.

 

50,000

   
On April 25, 2014, the Company recorded a beneficial conversion feature on the issuance of a convertible note.

 

25,000

   
On May 21, the Company recorded a discount for the issuance of 9,583,333 warrants in connection with the issuance of a convertible note.

 

38,322

   
       Total non-cash transactions from investing and financing activities.  $      495,861

 

 

NOTE 19 - EMPLOYMENT AGREEMENTS

 

On March 22, 2013, Wayne Erwin, the Company’s Chief Executive Officer, signed a three year employment agreement. The agreement provides for an annual salary of $120,000 along with a monthly auto allowance and health insurance allowance totaling $1,250. The annual salary was increased to $150,000 per year beginning March 2015. Annual increases are to be approved by the Company’s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $97,500 and $101,250 was expensed as salary, respectively.

 

On October 1, 2013, Michael Kramarz, the Company’s Chief Financial Officer, signed a three year employment agreement. The agreement provides for an annual salary of $80,000 along with a monthly auto allowance and health insurance allowance totaling $500. The annual salary was increased to $120,000 beginning on March 1, 2015. Annual increases are to be approved by the Company’s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $76,333 and 62,669 was expensed as salary, respectively.

 

On August 1, 2013, Vickie Hart, the President of Amian Angels Inc., signed a three year employment agreement. The agreement provides for an annual salary of $52,000 along with a monthly health insurance allowance totaling $400. The annual salary was increased to $85,000 beginning on March 1, 2015. Annual increases are to be approved by the Company’s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $49,900 and $46,214 was expensed as salary, respectively.

 

-44-
 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

On July 16, 2014, Harold Halman, the President of our Medical Products Segment, signed a three year employment agreement. The agreement provides for an annual salary of $85,000, along with a monthly auto allowance and health insurance allowance totaling $1,300 plus bonus allowances. Annual increases are to be approved by the Company’s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $63,750 and $0 was expensed as salary, respectively.

 

NOTE 20 – COMMITMENTS AND CONTINGENCIES

 

On June 6, 2014, the Company and its subsidiary Dotolo entered into a services agreement with E & R Industries to provide the Company with retooling and redesign of Dotolo’s disposable products. The contract calls for periodic cash payments totaling $60,000 along with the issuance of 5,000,000 common stock shares upon meeting certain milestones.

 

On June 6, 2014, the Company and its subsidiary Dotolo entered into a services agreement with Schmitt Engineering to provide the Company with engineering redesign services of its Toxygen hardware system. The contract calls for periodic cash payments totaling $30,000 along with the issuance of 3,000,000 common stock shares upon meeting certain milestones.

 

NOTE 21 - SUBSEQUENT EVENTS

 

On June 3 2015, the Company entered into a 1 year consulting agreement. The Company agrees to pay consultant 4% of any monies raised by the efforts of the consultant. In addition, the Company issued 2,500,000 shares of its Common Stock as additional compensation.

 

On June 15, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 8% per annum and is due on December 31, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares.

 

On June 5, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $45,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-45-
 

 

ITEM 2. Management’s Discussion And Analysis of Financial Condition and Results of Operation

THIS QUARTERLY REPORT ON FORM 10-QSB CONTAINS CERTAIN STATEMENTS WHICH ARE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE SAFE HARBOR PROVISIONS OF SECTION 27A OF THE SECURITIES ACT OF 1993, AS AMENDED, AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THESE STATEMENTS RELATE TO FUTURE EVENTS, INCLUDING THE FUTURE FINANCIAL PERFORMANCE OF ONCOLOGIX. IN SOME CASES, YOU CAN IDENTIFY FORWARD-LOOKING STATEMENTS BY TERMINOLOGY SUCH AS “MAY,” “WILL,” “SHOULD,” “EXPECTS,” “PLANS,” “ANTICIPATES,” “BELIEVES,” “ESTIMATES,” “PREDICTS,” “POTENTIAL,” OR “CONTINUE” OR THE NEGATIVE OF SUCH TERMS AND OTHER COMPARABLE TERMINOLOGY. THESE STATEMENTS ONLY REFLECT MANAGEMENT’S EXPECTATIONS AND ESTIMATES AS OF THE DATE OF THIS REPORT. ACTUAL EVENTS OR RESULTS MAY DIFFER MATERIALLY FROM THESE EXPECTATIONS. IN EVALUATING THOSE STATEMENTS, YOU SHOULD SPECIFICALLY CONSIDER VARIOUS FACTORS, INCLUDING THE RISKS INCLUDED IN THE REPORTS FILED BY ONCOLOGIX WITH THE SEC. THESE FACTORS MAY CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FORWARD-LOOKING STATEMENTS. ONCOLOGIX IS NOT UNDERTAKING ANY OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS CONTAINED IN THIS REPORT.

This report should be read in conjunction with our Annual report on Form 10-K for the fiscal year ended August 31, 2014.

OVERVIEW

 

Oncologix Tech, Inc. is a diversified medical holding company with operating segments in medical device, healthcare services and medical products and technologies. We operate and manufacture Class II medical device products, provides Personal Healthcare Services and provides Home Medical Inventory (HME) and Durable Medical Inventory (DME) sales in licensed markets. For its clients, Oncologix provides FDA approved medical devices, State licensed healthcare services and medical product sales. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company’s corporate mission is to be the best small cap medical device and healthcare services holding company in North America.

 

We were originally formed in 1995 and in 2000 we changed our name to "BestNet Communications Corp." At that time we provided worldwide long distance telephone communication and teleconferencing services to commercial and residential consumers through the internet, which we disposed of in 2007 due to lack of profitability. In July 2006 we changed our business model to medical device products.  In July 2006 we acquired JDA Medical Technologies, Inc. ("JDA") and merged this business into Oncologix Corporation, our wholly owned subsidiary.  On January 22, 2007, we changed our name to Oncologix Tech, Inc., to reflect this new business model. Our business at this time was the development of a medical device for brachytherapy (radiation therapy), called the “Oncosphere” (or “Oncosphere System”), for the advanced medical treatment of soft tissue cancers. Due to a lack of funding, we suspended these development activities on December 31, 2007. On November 1, 2013, due to the development of the brachytherapy device being several years away, indication that the product could not be marketed and no guarantee of FDA approvals, it was determined that continued financial support of this product by Oncologix Corporation would cost the Company substantial capital beyond its means and the Company’s management and Board of Directors disposed of Oncologix Corporation and its Brachytherapy medical device subsidiary. Furthermore, as part of the disposal, the Company was relieved of over $90,000 in debt.   

 

On March 22, 2013, we acquired all the outstanding stock of Dotolo Research Corporation (“Dotolo”), a FDA Registered, Class II, medical device manufacturer with 25 years of product sales in the hydro-colonic irrigation, bowel preparation market. Dotolo Research Corporation began operations in 1989 and sells hardware and disposable products to a customer base of over 900+ customers both domestically and internationally.  The Company currently operates in a limited, but competitive environment in hydro-colonic irrigation, of which there are only four (4) companies approved by the FDA to manufacture a Class II medical device for colonic-hydro therapy.  Since the acquisition, we have not had significant revenues from sales of our products, including sales to medical facilities due to a lack of operating capital needed to procure raw material inventory to currently fill customers’ orders.

 

 

 

-46-
 

On August 1, 2013, we acquired the outstanding stock of Angels of Mercy, Inc. (“AOM”). Angels provides non-medical, Personal Care Attendant (PCA) services, Supervised Independent Living (SIL), Long-Term Senior Care, and other approved health service programs performed by a trained caregiver that will meet the health service needs of beneficiaries whose disabilities preclude the performance of certain independent living skills related to the activities of daily living (ADL).

 

On December 10, 2013, Angels of Mercy, Inc. acquired the assets of Amian Health Services LLC and Amian Health Services of Alex LLC, herein after referred to as “Amian”.  Amian delivers health-care care-services who provide routine health and personal care support with Activities of Daily Living (ADL) to clients with physical impairments or disabilities in private homes, nursing care facilities, hospice care settings, and other residential settings. Amian holds both PCA-Medicaid Waiver Provider and Residential Rehabilitation/Supervised Independent Living (SIL), and personal care services for Veterans with licenses issued by the Division of Licensing and Certification of the Department of Social Services, Veterans Administration Social Services and the Louisiana Department of Health and Hospitals.  All administrative personnel of Amian have been merged into to gain operating synergies. This company changed its name to Amian Angels, Inc. (“Amian Angels”) in August 2014.

 

On July 21, 2014 we formed Advanced Medical Products and Technologies Inc. to enter into the Durable Medical and Home Medical Inventory markets. We anticipate acquiring active companies in this area to develop our Medical Products and Technologies Segment.

 

On September 25, 2014, we acquired the outstanding stock of Esteemcare, Inc. and its wholly owned subsidiary Affordable Medical Inventory Solutions, Inc. Esteemcare, Inc is a Durable and Home Medical inventory and supply distributor for respiratory therapy and is Accredited by the “Joint Commission on Healthcare Organizations”.

 

Esteemcare targets patients with sleep obstructive disorders or related chronic illnesses who are insured by Medicare, Medicaid, third-party insurers, or have the ability to pay for our products from their own private resources. Sleep apnea is a serious sleep disorder that occurs when a person's breathing is interrupted during sleep. People with untreated sleep apnea stop breathing repeatedly during their sleep, sometimes hundreds of times. This means the brain -- and the rest of the body -- may not get enough oxygen.

 

RECENT ACQUISITIONS AND DIVESTURES

 

In furthering our strategy to be the best small cap medical device and healthcare holding company, we acquired Dotolo Research Corporation (“DOTOLO”) on March 22, 2013, Angels of Mercy, Inc. (“AOM”) on August 1, 2013, Amian Health Services on December 10, 2013, and Esteemcare Inc. on September 25, 2014. These acquisitions are further described in Note 4 – Acquisition Activities, in the Notes to Unaudited Condensed Consolidated Financial Statements.

 

RESULTS OF OPERATIONS

 

Comparison of the three and nine months ended May 31, 2015 (‘fiscal 2015”) and 2014 (‘fiscal 2014”)

 

Revenue

 

Revenues increased to $1,235,656 for the three months ended May 31, 2015, from $988,385 from the comparable period in fiscal 2014. The increases were primarily due to the acquisitions of Amian Health Services in December 2013 and Esteemcare in September 2014.

 

Revenues increased to $3,625,407 for the nine months ended May 31, 2015, from $2,696,776 from the comparable period in fiscal 2014. The increases were primarily due to the acquisitions of Amian Health Services in December 2013 and Esteemcare in September 2014.

 

Cost of Revenues

 

Cost of revenues increased to $885,596 for the three months ended May 31, 2015, from $788,757 during the comparable period in fiscal 2014. Cost of revenues for Dotolo were $0 for the three months ended May 31, 2015. Cost of revenues for Amian Angels were $698,215 for the three months ended May 31, 2015 and consist primarily of wages paid to personal care service employees who directly provide the PCA and SIL services. Cost of revenues for Esteemcare were $187,371 for the three months ended May 31, 2015 and consist primarily of purchases of leased and sold inventory.

 

 

-47-
 

 

Cost of revenues increased to $2,628,797 for the nine months ended May 31, 2015, from $2,066,800 during the comparable period in fiscal 2014. Cost of revenues for Dotolo were $0 for the nine months ended May 31, 2015. Cost of revenues for Amian Angels were $2,129,572 for the nine months ended May 31, 2015 and consist primarily of wages paid to personal care service employees who directly provide the PCA and SIL services. Cost of revenues for Esteemcare were $499,225 for the nine months ended May 31, 2015 and consist primarily of purchases of leased and sold inventory.

 

Research and Development Expense

 

Research and development expense increased to $10,000 for the three and nine months ended May 31, 2015, from $0 during the comparable period in fiscal 2014. Research and development expenses consisted of costs for the development of dies and molds for Dotolo’s Toxygen product.

 

General and Administrative Expense

 

General and administrative expenses primarily include officer and administrative salaries, office rent, utilities, legal and accounting services, insurance, public filing costs as well as other incidental overhead costs.

General and administrative expense increased to $443,889for the three months ended May 31, 2015, from $276,950 from the comparable period in fiscal 2014. The primary reason for the increase was the additional general and administrative expenses associated with the acquisition of Esteemcare in September 2014.

General and administrative expense increased to $1,379,769 for the nine months ended May 31, 2015, from $999,910 from the comparable period in fiscal 2014. The primary reason for the increase was the additional general and administrative expenses associated with the acquisition of Esteemcare Inc.

Depreciation and Amortization

 

Depreciation and amortization decreased to $5,022 for the three months ended May 31, 2015, from $5,664 during fiscal 2014. The decrease in depreciation and amortization was the result of assets becoming fully depreciated.

 

Depreciation and amortization decreased to $14,356 for the nine months ended May 31, 2015, from $17,156 during fiscal 2014. The decrease in depreciation and amortization was the result of the disposal of assets as a result of moving our Amian Angels office.

 

Interest Income

 

We had no interest income in fiscal 2015 or fiscal 2014.

 

Interest and Finance Charges

 

Interest and finance charges increased to $437,908 for the three months ended May 31, 2015 from $167,474, from fiscal 2014. The increase is primarily attributable to additional merchant loans and additional convertible notes and the amortization of beneficial conversion features from new convertible notes.

 

Interest and finance charges increased to $1,090,013 for the nine months ended May 31, 2015 from $634,833, from fiscal 2014. The increase is primarily attributable to the second tranche taken from TCA, additional merchant loan, and the amortization of beneficial conversion features from new convertible notes.

 

Interest and finance charges – related parties decreased to $0 for the three months ended May 31, 2015, from $791, from the comparable period in fiscal 2014. The decrease is primarily attributable to the repayment of a related party loan during fiscal 2015.

 

Interest and finance charges – related parties decreased to $1,051 for the nine months ended May 31, 2015, from $18,056, from the comparable period in fiscal 2014. The decrease is primarily attributable to the repayment of a related party loan during fiscal 2015.

 

 

-48-
 

A summary of interest and finance charges is as follows:

 

   For the Three Months Ended  For the Nine Months Ended
   May 31,  May 31,  May 31,  May 31,
   2015  2014  2015  2014
Interest expense on non-convertible notes  $174,930   $92,607   $510,491   $188,817 
Interest expense on non-convertible notes - related parties   —      2,349    1,051    2,400 
Interest expense on convertible notes payable   19,715    31,721    44,123    54,845 
Interest expense on convertible notes payable - related parties   —      —      —      —   
Amortization of note payable discounts   156,599    33,661    334,437    51,682 
Amortization of note payable discounts - related parties   —      —      —      —   
Other interest and finance charges   86,664    7,927    200,962    355,145 
                     
Total interest and finance charges  $437,908   $168,265   $1,091,064   $652,889 

 

Loss on Conversion of Notes Payable

 

Loss on conversion of notes payable decreased to $0 for the three months ended May 31, 2015, from $57,197, for the comparable period in fiscal 2014. The decrease was due to conversions of only substansive convertible notes in fiscal 2015.

 

Loss on conversion of notes payable decreased to $0 for the nine months ended May 31, 2015, from $93,577, for the comparable period in fiscal 2014. The decrease was due to conversions of only substansive convertible notes in fiscal 2015.

LIQUIDITY AND CAPITAL RESOURCES

Since March 2013, we have acquired five companies. While these acquisitions greatly increased the value of our Company, we are not fully cash flow positive. Cash flows from the issuances of promissory notes and common stock for cash are not sufficient to meet our working capital requirements for the foreseeable future or provide for expansion opportunities. We incurred $1,494,097 and $1,152,393 in net losses, and we used $390,970 and $450,662 in cash for operations for the nine months ended May 31, 2015 and 2014, respectively. Investing activities used $563,017 and $67,232 for the nine months ended May 31, 2015 and 2014, respectively, due primarily to our acquisition of Esteemcare. Net cash generated from financing activities for the nine months ended May 31, 2015 and 2014 was $1,059,126 and $664,818, respectively. As of May 31, 2015, we had a cash balance of $120,485. These conditions raise substantial doubt about our ability to continue as a going concern.

 

We anticipate that we will require approximately $1,000,000 to operate through August 31, 2015. Approximately $500,000 will be required to fund corporate overhead including debt servicing with the balance to invest into raw material inventory, manufacturing and new product development at Dotolo, as well as begin sales activities with AMPT. Additional funding will allow us to meet our current sales demands and expenses of Dotolo, Amian Angels and Oncologix, while keeping our public filings current.

 

As of May 31, 2015, we had total outstanding short-term and long-term debt and liabilities totaling $4,901,157 net of discounts. Please see Note 11 for further information.

 

CRITICAL ACCOUNTING POLICIES

 

“The preparation of financial statements in accordance with accounting standards generally accepted in the United States requires management to make estimates and assumptions that affect both the recorded values of assets and liabilities at the date of the financial statements and the revenues recognized and expenses incurred during the reporting period. Our estimates and assumptions affect our recognition of income taxes, the carrying value of our long-lived assets and our provision for certain contingencies. We evaluate the reasonableness of these estimates and assumptions continually based on a combination of historical information and other information that comes to our attention that may vary our outlook for the future. Actual results may differ from these estimates under different assumptions.

 

-49-
 

We suggest that the Summary of Significant Accounting Policies, as described in Note 2 of our Unaudited Condensed Consolidated Financial Statements, be read in conjunction with this Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

CODE OF ETHICS

Our Board of Directors has adopted a code of ethics that applies to our principal executive officer, principal financial officer and to other persons performing similar functions. The code of ethics is designed to deter wrongdoing and to promote honest and ethical conduct, full, fair, accurate, timely and understandable disclosure, compliance with applicable laws, rules and regulations, prompt internal reporting of violations of the code and accountability for adherence to the code. We will provide a copy of our code of ethics, without charge, to any person upon receipt of written request for such delivered to our corporate headquarters. All such requests should be send to Oncologix Tech, Inc., P.O. Box 8832, Grand Rapids, MI 49518-8832.

OFF-BALANCE SHEET ARRANGEMENTS

 

We do not maintain off-balance sheet arrangements nor do we participate in any non-exchange traded contracts requiring fair value accounting treatment. The Company has no off-balance sheet arrangements as of May 31, 2015 and 2014.

NEW ACCOUNTING STANDARDS

We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact. For details of new accounting standards, please refer to Note 17 of our Consolidated Financial Statements.

 

ITEM 3. Quantitative and Qualitative Disclosure about Market Risk

 

We are a smaller reporting company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934, and accordingly, we are not required to provide the information required by this Item.

 

ITEM 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, due to the material weaknesses disclosed in its Annual Report on Form 10-K for the year ended August 31, 2014 that remain open, the Company’s disclosure controls and procedures were not effective as of May 31, 2015. As a result of this conclusion, the financial statements for the periods covered by this report were prepared with particular attention to the material weaknesses previously disclosed. Accordingly, management believes that the condensed consolidated financial statements included in the Quarterly Report present fairly, in all material respects, the Company’s financial condition, results of operations and cash flows as of and for the periods presented.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal controls over financial reporting that occurred during the three months ended May 31, 2015 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

 

 

 

 

 

 

  

 

-50-
 

 

PART II – OTHER INFORMATION

ITEM 1. Legal Proceedings

None

 

ITEM 1A. Risk Factors

RISK FACTORS

 

Those interested in investing in the Company should carefully consider the following Risk Factors pertaining to Oncologix Tech as well as the risks and uncertainties that are described in the Company's most recent Annual and Quarterly Reports under the Securities Exchange Act of 1934. These Risk Factors are not all inclusive.

 

Going Concern Qualification.

 

Our Independent Accountants have expressed doubt about our ability to continue as a going concern. The ability to continue as a going concern is an issue raised as a result of the material operating losses incurred since inception, and its stockholders' deficit. We expect to continue to experience net operating losses. Our ability to continue as a going concern is subject to our ability to obtain necessary funding from outside sources, including obtaining additional funding from the sale of our securities or obtaining loans from various financial institutions where possible. The going concern increases the difficulty in meeting such goals.

 

Risk of Issued Series D Convertible Preferred Stock to Common Shareholders

 

In March 2013, our Board of Directors authorized up to 60,000 shares of Series D Convertible Preferred Stock. Each share of Series D Convertible stock has a par value of $0.001 and is convertible into 1,000 shares of common stock beginning after March 1, 2014. Each share of Series D Convertible Preferred Stock has a stated value of $80.25. Each shares of Series D Convertible Preferred Stock shall have voting rights as stated next: March 1, 2013 to May 31, 2014, 400 votes per share; March 1, 2014 to May 31, 2015, 800 votes per share; March 1, 2015 to May 31, 2016, 1,200 votes per share; March 1, 2016 to May 31, 2017, 1,600 votes per share; March 1, 2017 and after, 2,000 votes per share.

 

In the event of any liquidation, dissolution or winding-up of the Corporation, the Series D Preferred Stock then issued and outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its shareholders in a position senior to the Corporation’s Common Stock shareholders. The effect of these senior securities could affect the value of our common stock.

 

Our internal control over financial reporting is not considered effective, our business and stock price could be adversely affected.

 

Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate the effectiveness of our internal control over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of our internal control over financial reporting in our annual report on Form 10-K for that fiscal year. Our management, including our chief executive officer and chief financial officer, does not expect that our internal control over financial reporting will prevent all error and all fraud. As of August 31, 2013, the Company identified two material weaknesses: a) Oncologix lacks the necessary corporate accounting resources to maintain adequate segregation of duties; b) In addition, we have a lack of a functioning Audit Committee as we only have one independent director is not considered a Financial Expert within the meaning of Section 407 of the Sarbanes-Oxley Act. We may experience a loss of public confidence, which could have an adverse effect on our business and on the market price of our common stock due to our internal control being ineffective.

 

Financial Condition of Dotolo Research Corporation (“DRC”)

 

DRC has limited working capital with little cash on hand at May 31, 2015. Since January 31, 2013, DRC has incurred indebtedness of $50,000 to meet its working capital needs. These two notes bear interest at 18% per annum and require minimum, monthly interest payments of $750. Additional financing will be required to get DRC to cash flow break even.

 

-51-
 

Need for Additional Capital

 

We will need substantial funds for raw material inventory, complete the development of new product introductions, manufacturing, and the sales and marketing of our products at DRC. Consequently, we will seek to raise further capital through not only possible public and private offerings of equity and debt securities, but also collaborative arrangements, strategic alliances, and equity and debt financings from other sources. AOM operates with positive cash flow sufficient to service the business operations and debt payment requirements of the acquisition but will need additional funds to complete the audit of Angels as well as costs for other required SEC and other regulatory filings. We now estimate the need to raise at least $500,000 of additional funding for working capital and inventory procurement for DRC. Additionally, we estimate the need to raise at least $500,000 for overhead of Oncologix Tech, Inc and debt servicing. We may be unable to raise additional capital on commercially acceptable terms, if at all, and if we raise capital through additional equity financing, existing shareholders may have their ownership interests diluted. Our failure to be able to generate adequate funds from operations or from additional sources would harm our business.

 

Uncertainties Regarding Healthcare Reimbursement and Reform

 

Our ability to execute our strategy in the medical markets depends in part on the extent to which healthcare services and products are paid by governmental agencies, private health insurers and other organizations, such as health maintenance organizations, for the cost of such products and related treatments. Our business could be harmed if healthcare payers and providers implement cost-containment measures and governmental agencies implement measures that reduce payment to our customers for their use of our products.

 

Industry Intensely Competitive.

 

The medical device and health services industry is intensely competitive. While we maintain a market share in hardware and disposable products sales , there is no guarantee we can maintain that market share. We will compete with both public and private medical device and pharmaceutical companies that have a greater number of products on the market, have greater financial resources and have other competitive advantages. We cannot be certain that one or more of our competitors will not receive patent protection that dominates, blocks or adversely affects our product development or business; will benefit from significantly greater sales and marketing capabilities or will not develop products that are accepted more widely than ours.

 

Healthcare Service Industry Intensely Competitive.

 

The healthcare service industry is very competitive. We will compete with both public and private healthcare service companies that hold licenses within the State of Louisiana and directly compete with companies that may have greater financial resources and have other competitive advantages.

 

Intellectual Property Risk.

 

Our ability to obtain and maintain patent and other protection for our products will affect our success. The patent positions of medical device companies can be highly uncertain and involve complex legal and factual questions. Future patent rights, if granted, may not be upheld in a court of law if challenged. Our patent rights may not provide competitive advantages for our products and may be challenged, infringed upon or circumvented by our competitors. We cannot patent our products in all countries or afford to litigate every potential violation worldwide. Because of the large number of patent filings in medical device, our competitors may have filed applications or been issued patents and may obtain additional patents and proprietary rights relating to products or processes competitive with or similar to ours. We cannot be certain that U.S. or foreign patents do not exist or will not issue that would harm our ability to commercialize our products and product candidates.

 

Possible Failure to Comply with Government Regulations.

 

We, and any prospective contract manufacturers and suppliers are subject to extensive, complex, costly, and evolving governmental rules, regulations and restrictions administered by the FDA, by other federal and state agencies, and by governmental authorities in other countries. In the United States, our products are registered as a Class II device and cannot be marketed until they are approved for market by the FDA. Obtaining FDA market approval involves the submission, among other information, may require clinical studies on the product, and requires substantial time, effort and financial

 

 

-52-
 

resources. The FDA, and other federal and state agencies, as well as equivalent agencies of other countries with whom we will export our products, will also perform pre-licensing inspections of our facility, if any, and our contract manufacturers' and suppliers' facilities. Our failure or the failure of our contract manufacturers or suppliers to meet FDA or other agencies' requirements would delay or preclude our ability to sell our products potentially having an adverse material effect on our business. Even with FDA market approval, we, as well as our partners, contract manufacturers and suppliers, are subject to numerous FDA requirements covering, among other things, testing, manufacturing, quality control, labeling and continuing review of medical products, and to permit government inspection at all times. Failure to meet or comply with any rules, regulations, or restrictions of the FDA or other agencies could result in fines, unanticipated expenditures, product delays, non-approval or recall, interruption of production, and criminal prosecution.

 

Exposure to Product Liability Claims.

 

Our design, testing, development, manufacture, and marketing of products involve an inherent risk of exposure to product liability claims and related adverse publicity. Although we believe that our product liability insurance is adequate, additional insurance coverage is expensive and in the future we may be unable to obtain additional liability coverage on acceptable terms. If we are unable to obtain sufficient insurance at an acceptable cost or if a successful product liability claim is made against us, whether fully covered by insurance or not, our business could be harmed.

 

Reliance on Key Personnel

 

Our success will depend, to a great extent, upon the experience, abilities and continued services of our executive officers and key management personnel. If we lose the services of any of these officers or key personnel, our business could be harmed. Our success also will depend upon our ability to attract and retain other highly qualified Regulatory, Marketing, Sales, and manufacturing personnel and our ability to develop and maintain relationships with key individuals in the industry. Competition to attract qualified personnel and relationships is intense and we compete with other companies in our industry. We may not be able to continue to attract and retain qualified personnel.

 

Uncertainty as to our Ability to Initiate Operations and Manage Growth.

 

Our efforts to market our products will result in new and increased responsibilities for management personnel and will place a strain upon our management, financial systems, and resources. We may be required to continue to implement and to improve our management, operating and financial systems, procedures and controls on a timely basis and to expand, train, motivate and manage our employees. There can be no assurance that our personnel, systems, procedures, and controls will be adequate to support our future operations.

 

Healthcare Service Industry Intensely Competitive.

 

The healthcare service industry is very competitive. . We compete with both public and private healthcare service companies that hold licenses within the State of Louisiana and directly compete with companies that may have greater financial resources and have other competitive advantages.

 

Compliance with Government Regulations.

 

We, and all healthcare service companies are subject to extensive, and evolving governmental rules, regulations and restrictions administered by the Department of Health & Hospitals, the Bureau of Health Services Financing, by other federal and state agencies, and by governmental authorities.

 

Integration of Newly Acquired Businesses.

 

The Company may make strategic acquisitions in the future and cannot assure that it will be able to successfully integrate the operations of newly-acquired businesses into the Company's current operations. It is Management intent to consolidate various business functions to include Information Technology, Accounting, legal under a central core operation. The failure to integrate newly acquired businesses or the inability to make suitable strategic acquisitions in the future could have an adverse effect on the Company's business, results of operations and financial condition.

 

-53-
 

 

Attraction and Retention of Qualified Personnel

 

The Company is dependent on the efforts and abilities of its senior executive officers. While the Company believes that its senior management team has significant experience and depth, appropriate senior management succession plans are in place. The Company's future success also depends on its ability to identify, attract and retain additional qualified personnel.

 

Broker-Dealer Requirements May Affect Trading and Liquidity of Our Common Stock

 

Section 15(g) of the Securities Exchange Act of 1934, as amended, and Rule 15g-2 promulgated thereunder by the SEC require broker-dealers dealing in penny stocks to provide potential investors with a document disclosing the risks of penny stocks and to obtain a manually signed and dated written receipt of the document before effecting any transaction in a penny stock for the investor's account.

 

Potential investors in the Registrant's common stock are urged to obtain and read such disclosure carefully before purchasing any shares that are deemed to be "penny stock." Moreover, Rule 15g-9 requires broker-dealers in penny stocks to approve the account of any investor for transactions in such stocks before selling any penny stock to that investor. This procedure requires the broker-dealer to (i) obtain from the investor information concerning his or her financial situation, investment experience and investment objectives; (ii) reasonably determine, based on that information, that transactions in penny stocks are suitable for the investor and that the investor has sufficient knowledge and experience as to be reasonably capable of evaluating the risks of penny stock transactions; (iii) provide the investor with a written statement setting forth the basis on which the broker-dealer made the determination in (ii) above; and (iv) receive a signed and dated copy of such statement from the investor, confirming that it accurately reflects the investor's financial situation, investment experience and investment objectives. Compliance with these requirements may make it more difficult for holders of our common stock to resell their shares to third parties or to otherwise dispose of them in the market or otherwise.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-54-
 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

Date Securities   Underwriters/  
Sold Sold Consideration Purchasers * Notes
         
9/12/2013       1,000,000  $                     - Vendor The Company issued 1,000,000 S-8 shares to a vendor for consulting work.  The Company recorded an expense of $11,500 upon the issuance of those shares.
9/12/2013       1,500,000  $             10,000 Accredited Investor The Company sold 1,500,000 shares of common stock to an affiliated accredited investor at $0.00667 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act
10/3/2013       4,000,000  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $15,620 in principal and interest into 4,000,000 shares of common stock at $0.00391 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
12/3/2013       1,891,123  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $9,380 in principal and interest into 1,891,123 shares of common stock at $0.00496 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
1/3/2014       2,000,000  $                     - Vendor The company issued 2,000,000 shares of common stock as consideration for services.  The company recorded an expense of $22,000 in connection with this issuance.  These shares were exempt from registration under Section 4(2) of the Securities Act.
1/13/2014       3,076,923  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $20,000 in principal and interest into 3,076,923 shares of common stock at $0.0065 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
1/14/2014       1,000,000  $                     - Vendor The company issued 1,000,000 shares of common stock as consideration for services.  The company recorded an expense of $19,000 in connection with this issuance.  These shares were exempt from registration under Section 4(2) of the Securities Act.
1/15/2014         117,436  $                     - Accredited Investor Additional reset shares were issued to a non-affiliated accredited investor in connection with the prior conversion of $9,380 in principal and interest into 117,436 shares of common stock.  These shares were exempt from registration under Section 4(2) of the Securities Act.
1/21/2014       3,500,000  $                     - Accredited Investor The company issued 3,500,000 shares of common stock as consideration for  fees.  The company recorded an expense of $45,500 in connection with this issuance.  These shares were exempt from registration under Section 4(2) of the Securities Act.
1/21/2014       1,500,000  $                     - Accredited Investor The company issued 1,500,000 shares of common stock as consideration for  fees.  The company recorded an expense of $30,000 in connection with this issuance.  These shares were exempt from registration under Section 4(2) of the Securities Act.
1/31/2014       3,472,222  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $25,000 in principal and interest into 3,472,222 shares of common stock at $0.0072 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
2/7/2014       1,000,000  $                     - Accredited Investor The company issued 1,000,000 shares of common stock as consideration for  fees.  The company recorded an expense of $9,000 in connection with this issuance.  These shares were exempt from registration under Section 4(2) of the Securities Act.
2/24/2014       4,615,385  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $30,000 in principal and interest into 4,615,385 shares of common stock at $0.0065 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.

 

 

 

-55-
 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds (Continued)

Date Securities   Underwriters/  
Sold Sold Consideration Purchasers * Notes
         
3/12/2014       4,615,385  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $30,000 in principal and interest into 4,615,385 shares of common stock at $0.0065 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
4/7/2014       2,936,314  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $19,086 in principal and interest into 2,936,314 shares of common stock at $0.0065 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
4/7/2014       5,383,007  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $17,764 in principal and interest into 5,383,007 shares of common stock at $0.0033 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
6/2/2014       5,000,000  $                     - Accredited Investor The company issued 5,000,000 shares of common stock as consideration for services.  The company recorded an expense of $30,000 in connection with this issuance.  These shares were exempt from registration under Section 4(2) of the Securities Act.
6/25/2014       5,138,746  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $25,000 in principal and interest into 5,138,746 shares of common stock at $0.004865 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
7/14/2014       2,500,000   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $11,000 in principal and interest into 2,500,000 shares of common stock at $0.0044 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
7/24/2014       1,149,425   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $5,000 in principal and interest into 1,149,425 shares of common stock at $0.00435 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
8/1/2014       3,416,764   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $8,456 in principal and interest into 3,416,764 shares of common stock at $0.002475 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
8/26/2014       1,200,000  $                     - Accredited Investor The Company sold 1,200,000 shares of common stock to an affiliated accredited investor at $0.00833 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act
9/10/2014       1,058,201  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $5,000 in principal and interest into 1,058,201 shares of common stock at $0.004725 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
10/28/2014       1,473,622  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $5,000 in principal and interest into 1,473,622 shares of common stock at $0.003383 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
11/3/2014       1,508,296  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $5,000 in principal and interest into 1,508,296 shares of common stock at $0.003315 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.

 

 

-56-
 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds (Continued)

Date Securities   Underwriters/  
Sold Sold Consideration Purchasers * Notes
         
11/10/2014       1,724,733  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $5,000 in principal and interest into 1,724,733 shares of common stock at $0.002899 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
11/12/2014       6,000,000   Vendor The company issued 6,000,000 shares of common stock as consideration for services.  The company recorded an expense of $24,000 in connection with this issuance.  These shares were exempt from registration under Section 4(2) of the Securities Act.
11/24/2014       2,380,952  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $7,000 in principal and interest into 2,380,952 shares of common stock at $0.00294 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
11/28/2014       3,577,818  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $10,000 in principal and interest into 3,577,818 shares of common stock at $0.002795 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
11/28/2014       2,126,602  $                     - Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $4,219 in principal and interest into 2,126,602 shares of common stock at $0.001984 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
12/9/2014       6,384,676   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $16,000 in principal and interest into 6,384,676 shares of common stock at $0.002506 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
12/9/2014       3,026,555   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $5,317 in principal and interest into 3,026,555 shares of common stock at $0.001922 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
12/18/2014       3,286,650   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $5,298 in principal and interest into 3,286,650 shares of common stock at $0.001612 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
12/24/2014       2,632,040   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $4,243 in principal and interest into 2,632,040 shares of common stock at $0.001612 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
1/12/2015          (55,349)     Share adjustment by transfer agent
1/13/2015       2,863,750   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $4,261 in principal and interest into 2,863,750 shares of common stock at $0.001488 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
1/16/2015         876,244   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $2,084 in principal and interest into 876,244 shares of common stock at $0.00238 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
1/20/2015       2,866,108   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $4,265 in principal and interest into 2,866,108 shares of common stock at $0.001488 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
1/23/2015       8,398,588   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $12,497 in principal and interest into 8,398,588 shares of common stock at $0.001488 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.

 

-57-
 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds (Continued)

Date Securities   Underwriters/  
Sold Sold Consideration Purchasers * Notes
         
1/30/2015       5,000,000   Accredited Investor The company issued 5,000,000 shares of common stock as consideration for services.  The company recorded an expense of $38,500 in connection with this issuance.  These shares were exempt from registration under Section 4(2) of the Securities Act.
2/3/2015       7,365,772   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $10,960 in principal and interest into 7,365,772 shares of common stock at $0.001488 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
2/5/2015       2,807,190   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $4,177 in principal and interest into 2,807,190 shares of common stock at $0.001488 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
2/10/2015       9,697,060   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $18,699 in principal and interest into 9,697,060 shares of common stock at $0.0019283 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
3/1/2015       4,500,000   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $20,572 in principal and interest into 4,500,000 shares of common stock at $0.004572 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
3/11/2015       2,000,000   Accredited Investor The company issued 2,000,000 shares of common stock as consideration for services.  The company recorded an expense of $15,600 in connection with this issuance.  These shares were exempt from registration under Section 4(2) of the Securities Act.
3/13/2015       2,472,032   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $10,926 in principal and interest into 2,472,032 shares of common stock at $0.004572 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
3/19/2015       4,500,000   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $16,554 in principal and interest into 4,500,000 shares of common stock at $0.004572 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
3/21/2015     10,000,000   Accredited Investor A non-affiliated accredited investor exercised cashless warrants in the into 10,000,000 shares of common stock at $0.004572 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
4/3/2015       4,680,298   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $13,541 in principal and interest into 4,680,298 shares of common stock at $0.0028933 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
4/10/2015       6,756,079   Accredited Investor A non-affiliated accredited investor exercised cashless warrants in the into 6,756,079 shares of common stock at $0.0002093 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
4/30/2015       9,096,774   Accredited Investor A non-affiliated accredited investor exercised cashless warrants in the into 9,096,774 shares of common stock at $0.001488 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
5/13/2015       4,000,000   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $7,109 in principal and interest into 4,680,298 shares of common stock at $0.0017773 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
5/15/2015       7,530,107   Accredited Investor A non-affiliated accredited investor exercised cashless warrants in the into 7,530,107 shares of common stock at $0.00001488 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.

 

58
 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds (Continued)

Date Securities   Underwriters/  
Sold Sold Consideration Purchasers * Notes
         
5/18/2015       6,211,180   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $13,000 in principal and interest into 6,211,180 shares of common stock at $0.002093 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
5/21/2015       5,400,000   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $9,151 in principal and interest into 5,400,000 shares of common stock at $0.0016947 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
6/2/2015       6,500,000   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $10,615 in principal and interest into 6,500,000 shares of common stock at $0.001633 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
6/2/2015       6,783,571   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $13,052 in principal and interest into 6,783,571 shares of common stock at $0.001924 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
6/3/2015       7,021,230   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $11,318 in principal and interest into 7,021,230 shares of common stock at $0.001612 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
6/3/2015       2,500,000   Accredited Investor The company issued 2,500,000 shares of common stock as consideration for a consulting contract.  The company recorded an expense of $11,000 in connection with this issuance.  These shares were exempt from registration under Section 4(2) of the Securities Act.
6/5/2015     11,189,002   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $18,272 in principal and interest into 11,189,002 shares of common stock at $0.001633 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
6/10/2015     14,818,011   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $23,887 in principal and interest into 14,818,011 shares of common stock at $0.001612 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
6/17/2015       3,101,737   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $5,000 in principal and interest into 3,101,737 shares of common stock at $0.001612 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
6/24/2015       3,402,749   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $5,000 in principal and interest into 3,402,749 shares of common stock at $0.0014694 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
6/30/2015       8,064,516   Accredited Investor A non-affiliated accredited investor converted a promissory note in the amount of $10,000 in principal and interest into 8,084,516 shares of common stock at $0.00124 per share.  These shares were exempt from registration under Section 4(2) of the Securities Act.
         
    265,539,524  $                     -    
         
*  There were no underwriters associated with any of our Sales of Unregistered Securities.

 

 

 

-59-
 

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

Not applicable.

 

ITEM 5. Other Information

None.

 

ITEM 6. Exhibits

  Exhibits.   Description  
       31.1      Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.      
  31.2   Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.  
  32.1   Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.  
  32.2   Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-60-
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Dated: August 10, 2015 ONCOLOGIX TECH, INC.
   
   
  By: /s/ Roy Wayne Erwin
  Roy Wayne Erwin, President and Chief Executive Officer, Principal Executive Officer
   
  By: /s/ Michael A. Kramarz
  Michael A. Kramarz, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer

 

 

 

 

 

 

 

 

 

 EX-31.1 2 oclg10qa05312015ex31_1.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Roy Wayne Erwin certify that:

(1)I have reviewed this Quarterly Report on Form 10-Q of Oncologix Tech, Inc.;
(2)Based on my knowledge, the Report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the Report;
(3)Based on my knowledge, the financial statements, and other financial information included in the Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods represented in this report;
(4)The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others with these entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and
(d)Disclosed in this Report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
(5)The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record , process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 10, 2015

 

By: /s/ Roy Wayne Erwin

Roy Wayne Erwin

Principal Executive Officer, Chief Executive Officer and President

 EX-31.2 3 oclg10qa05312015ex31_2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael A. Kramarz, certify that:

(1)I have reviewed this Quarterly Report on Form 10-Q of Oncologix Tech, Inc.;
(2)Based on my knowledge, the Report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the Report;
(3)Based on my knowledge, the financial statements, and other financial information included in the Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods represented in this report;
(4)The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others with these entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and
(d)Disclosed in this Report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
(5)The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: August 10, 2015

 

By: /s/ Michael A. Kramarz

Michael A. Kramarz

Principal Financial Officer, Principal Accounting Officer and Chief Financial Officer

 

 

 EX-32.1 4 oclg10qa05312015ex32_1.htm ONCOLOGIX TECH, INC. AND SUBSIDIARIES

Exhibit 32.1

 

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

 

 

CERTIFICATION OF PRINCIPAL

EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual Report of Oncologix Tech, Inc. (the “Company”) on Form 10-Q for the three months ended May 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Roy Wayne Erwin, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 

 

/s/ Roy Wayne Erwin

Roy Wayne Erwin

Chief Executive Officer and President

August 10, 2015

 EX-32.2 5 oclg10qa05312015ex32_2.htm ONCOLOGIX TECH, INC. AND SUBSIDIARIES

Exhibit 32.2

 

ONCOLOGIX TECH, INC. AND SUBSIDIARIES

 

 

CERTIFICATION OF PRINCIPAL

FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Annual Report of Oncologix Tech, Inc. (the “Company”) on Form 10-Q for the three months ended May 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I Michael A. Kramarz, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

 

(3)The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(4)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 

/s/ Michael A. Kramarz

Michael A. Kramarz

Chief Financial Officer

August 10, 2015

 EX-101.SCH 6 oclg-20150531.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Organization and Description of the Company link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Goodwill, Patents and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Inventory Financing Agreement link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Business Segments link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Joint Ventures link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Retirement Plan link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Recent Accounting Prouncements link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Employment Agreements link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Inventory Financing Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Business Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Statement of Cash Flows (Tables) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Description of Company (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) (USD$) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share -Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share - Dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Acquisitions - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Acquisitions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Discountinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Discountinued Operations (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Inventory (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Goodwill, Patents and Other Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Inventory Financing Agreement - Financing Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Convertible Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Convertible Notes Payable (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Convertible Notes Payable (Details Narrative 1) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Notes Payable - Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Other Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Notes Payable - Other (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Notes Payable - Other(Details Narrative 1) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Stockholders Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Stockholders Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Stockholders Equity Additional (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Stockholders Equity (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - Stockholders Equity (Details Narrative 1) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - Stockholders Equity - Stock Subscribed (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000069 - Disclosure - Stockholders Equity (Details Narrative 2) link:presentationLink link:calculationLink link:definitionLink 00000070 - Disclosure - Stockholders Equity - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000071 - Disclosure - Stockholders Equity- Warrants (Details Narrative 1) link:presentationLink link:calculationLink link:definitionLink 00000072 - Disclosure - Stockholders Equity - 2000 Stock Incentatvie Plan (Details) link:presentationLink link:calculationLink link:definitionLink 00000073 - Disclosure - Stockholders Equity - 2000 Stock Incentatvie Plan (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000074 - Disclosure - Stockholders Equity - 2013 Omnibus (Details) link:presentationLink link:calculationLink link:definitionLink 00000075 - Disclosure - Business Segments - Balance Sheet(Details) link:presentationLink link:calculationLink link:definitionLink 00000076 - Disclosure - Business Segments - Business Segments (Details) (USD $) link:presentationLink link:calculationLink link:definitionLink 00000077 - Disclosure - Joint Ventures (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000078 - Disclosure - Income Taxes - Uncertain Tax Positions (Details) link:presentationLink link:calculationLink link:definitionLink 00000079 - Disclosure - Income Taxes - Income Tax Benefit (Details) link:presentationLink link:calculationLink link:definitionLink 00000080 - Disclosure - Income Taxes - Statutory Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 00000081 - Disclosure - Income Taxes - Deferred Tax Assets (Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 00000082 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000083 - Disclosure - Statement of Cash Flows (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000084 - Disclosure - Statement of Cash Flows (Details 1) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000085 - Disclosure - Employment Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000086 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000087 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.INS 7 oclg-20150531.xml XBRL INSTANCE FILE 0000799694 2013-08-31 0000799694 us-gaap:FurnitureAndFixturesMember 2014-09-01 2015-05-31 0000799694 us-gaap:ComputerEquipmentMember 2014-09-01 2015-05-31 0000799694 us-gaap:EquipmentMember 2014-09-01 2015-05-31 0000799694 us-gaap:ComputerSoftwareIntangibleAssetMember 2014-09-01 2015-05-31 0000799694 us-gaap:StockOptionMember 2015-05-31 0000799694 us-gaap:OptionMember 2015-05-31 0000799694 2003-01-01 2003-01-31 0000799694 2010-08-31 0000799694 2009-02-27 0000799694 us-gaap:SeriesDPreferredStockMember 2013-03-22 0000799694 us-gaap:ConvertibleNotesPayableMember 2015-05-31 0000799694 us-gaap:ConvertibleNotesPayableMember 2014-05-31 0000799694 OCLG:ConvertibleDebtRelatedPartyMember 2014-05-31 0000799694 OCLG:ConvertibleDebtRelatedPartyMember 2015-05-31 0000799694 OCLG:Dot2Member 2014-05-31 0000799694 OCLG:NotesPayableOtherPayablesDetailsMember 2014-05-31 0000799694 OCLG:NotesPayableOtherPayablesDetailsMember 2015-05-31 0000799694 OCLG:Dot2Member 2015-05-31 0000799694 us-gaap:RedeemablePreferredStockMember 2013-03-01 2014-05-31 0000799694 us-gaap:RedeemablePreferredStockMember 2014-03-01 2015-05-31 0000799694 us-gaap:RedeemablePreferredStockMember 2015-03-01 2016-05-31 0000799694 us-gaap:RedeemablePreferredStockMember 2016-03-01 2017-05-31 0000799694 us-gaap:RedeemablePreferredStockMember 2017-03-01 2018-05-31 0000799694 us-gaap:ChiefExecutiveOfficerMember 2013-03-21 2013-03-22 0000799694 us-gaap:ChiefFinancialOfficerMember 2013-05-01 2013-05-31 0000799694 us-gaap:SeriesAPreferredStockMember 2015-05-31 0000799694 us-gaap:SeriesAPreferredStockMember 2014-08-31 0000799694 us-gaap:SeriesDPreferredStockMember 2015-05-31 0000799694 us-gaap:SeriesDPreferredStockMember 2014-08-31 0000799694 OCLG:EsteemcareIncMember 2015-05-31 0000799694 2013-09-01 2014-08-31 0000799694 2014-09-01 2015-08-31 0000799694 2015-09-01 2016-08-31 0000799694 2016-09-01 2017-08-31 0000799694 us-gaap:SeriesAPreferredStockMember 2014-09-01 2015-05-31 0000799694 us-gaap:SeriesDPreferredStockMember 2014-09-01 2015-05-31 0000799694 us-gaap:MinimumMember 2013-09-01 2014-05-31 0000799694 us-gaap:MaximumMember 2013-09-01 2014-05-31 0000799694 2013-09-01 2014-05-31 0000799694 2014-08-31 0000799694 us-gaap:ChiefExecutiveOfficerMember 2014-09-01 2015-05-31 0000799694 us-gaap:ChiefExecutiveOfficerMember 2013-09-01 2014-05-31 0000799694 us-gaap:ChiefFinancialOfficerMember 2014-09-01 2015-05-31 0000799694 us-gaap:ChiefFinancialOfficerMember 2013-09-01 2014-05-31 0000799694 OCLG:ConvertibleNote1Member 2015-05-31 0000799694 OCLG:ConvertibleNote1Member 2014-09-01 2015-05-31 0000799694 OCLG:LineOfCreditAA1Member 2014-05-31 0000799694 2013-11-01 0000799694 us-gaap:SeriesAPreferredStockMember 2013-08-31 0000799694 OCLG:AmianHealthServicesMember 2015-05-31 0000799694 2013-12-01 2013-12-10 0000799694 us-gaap:SeriesAPreferredStockMember 2013-09-01 2014-08-31 0000799694 us-gaap:SeriesDPreferredStockMember 2013-09-01 2014-08-31 0000799694 us-gaap:CorporateMember 2014-03-01 2014-05-31 0000799694 OCLG:PersonalCareServicesMember 2014-09-01 2015-05-31 0000799694 OCLG:PersonalCareServicesMember 2013-09-01 2014-05-31 0000799694 OCLG:MedicalDeviceManufacturingMember 2014-09-01 2015-05-31 0000799694 OCLG:MedicalDeviceManufacturingMember 2013-09-01 2014-05-31 0000799694 us-gaap:CorporateMember 2014-09-01 2015-05-31 0000799694 us-gaap:CorporateMember 2013-09-01 2014-05-31 0000799694 OCLG:PersonalCareServicesMember 2014-08-31 0000799694 OCLG:PersonalCareServicesMember 2015-05-31 0000799694 OCLG:MedicalDeviceManufacturingMember 2014-08-31 0000799694 OCLG:MedicalDeviceManufacturingMember 2015-05-31 0000799694 us-gaap:CorporateMember 2014-08-31 0000799694 us-gaap:CorporateMember 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote1Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote2Member 2014-09-01 2015-05-31 0000799694 OCLG:WarrntsForAdditionalCompensation1Member 2013-09-01 2014-05-31 0000799694 OCLG:WarrntsForAdditionalCompensation2Member 2013-09-01 2014-05-31 0000799694 OCLG:WarrntsForAdditionalCompensation3Member 2013-09-01 2014-05-31 0000799694 OCLG:CommonStockInvestorContract1Member 2014-09-01 2015-05-31 0000799694 OCLG:CommonStockInvestorContract2Member 2014-09-01 2015-05-31 0000799694 OCLG:AngelOfMercyIncMember 2014-09-01 2015-05-31 0000799694 2014-05-31 0000799694 2014-02-27 0000799694 OCLG:OminbusMember 2013-08-31 0000799694 OCLG:OminbusMember 2015-05-31 0000799694 OCLG:StockIncentativePlanMember 2000-02-28 0000799694 OCLG:StockIncentativePlanMember 2013-12-13 0000799694 OCLG:StockIncentativePlanMember 2014-12-20 0000799694 OCLG:StockIncentativePlanMember 2014-08-31 0000799694 OCLG:StockIncentativePlanMember 2015-05-31 0000799694 OCLG:StockIncentativePlanMember 2013-08-31 0000799694 OCLG:StockIncentativePlanMember 2013-09-01 2014-08-31 0000799694 us-gaap:ConvertibleNotesPayableMember 2014-08-31 0000799694 us-gaap:NotesPayableOtherPayablesMember 2014-08-31 0000799694 us-gaap:NotesPayableOtherPayablesMember 2015-05-31 0000799694 2014-03-01 2014-05-31 0000799694 OCLG:ConvertibleNote2247Member 2015-05-31 0000799694 OCLG:ConvertibleNote2247Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNote2250Member 2015-05-31 0000799694 OCLG:ConvertibleNote2250Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNote2253Member 2015-05-31 0000799694 OCLG:ConvertibleNote2253Member 2014-09-01 2015-05-31 0000799694 2015-08-31 0000799694 2014-05-30 0000799694 OCLG:AngelOfMercyIncMember 2015-05-31 0000799694 OCLG:DotoloResearchCorporationMember 2015-05-31 0000799694 us-gaap:MinimumMember 2014-09-01 2015-05-31 0000799694 us-gaap:MaximumMember 2014-09-01 2015-05-31 0000799694 2014-08-30 0000799694 OCLG:MedicalProductsSegmentMember 2014-09-01 2015-05-31 0000799694 OCLG:MedicalProductsSegmentMember 2013-09-01 2014-05-31 0000799694 OCLG:MedicalProductsSegmentMember 2014-08-31 0000799694 OCLG:MedicalProductsSegmentMember 2015-05-31 0000799694 us-gaap:ServiceAgreementsMember 2014-08-31 0000799694 us-gaap:ServiceAgreementsMember 2013-09-01 2014-08-31 0000799694 OCLG:ServiceAgreements2Member 2014-08-31 0000799694 OCLG:ServiceAgreements2Member 2013-09-01 2014-08-31 0000799694 2014-09-01 2015-05-31 0000799694 2015-05-31 0000799694 2015-07-03 0000799694 2013-09-01 2014-02-28 0000799694 2014-09-25 0000799694 2014-09-24 2014-09-25 0000799694 us-gaap:ProductMember 2015-05-31 0000799694 OCLG:WellsFargo17Member 2014-09-01 2015-05-31 0000799694 OCLG:WellsFargo17Member 2015-05-31 0000799694 OCLG:VGM322Member 2014-09-01 2015-05-31 0000799694 OCLG:VGM322Member 2015-05-31 0000799694 OCLG:WellsFargo18Member 2014-09-01 2015-05-31 0000799694 OCLG:WellsFargo18Member 2015-05-31 0000799694 OCLG:ConvertibleNote2259Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNote2259Member 2015-05-31 0000799694 OCLG:ConvertibleNote2261Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNote2261Member 2015-05-31 0000799694 us-gaap:SeriesDPreferredStockMember 2013-08-31 0000799694 OCLG:LineOfCreditAA1Member 2015-05-31 0000799694 OCLG:Dot3Member 2015-05-31 0000799694 OCLG:Dot3Member 2014-05-31 0000799694 OCLG:EsteemcareReportingUnitMember 2015-05-31 0000799694 OCLG:VGM323Member 2014-09-01 2015-05-31 0000799694 OCLG:VGM323Member 2015-05-31 0000799694 OCLG:VGM324Member 2014-09-01 2015-05-31 0000799694 OCLG:VGM324Member 2015-05-31 0000799694 OCLG:DLL61924Member 2014-09-01 2015-05-31 0000799694 OCLG:DLL61924Member 2015-05-31 0000799694 OCLG:DLL679104Member 2014-09-01 2015-05-31 0000799694 OCLG:DLL679104Member 2015-05-31 0000799694 OCLG:DLL61649Member 2014-09-01 2015-05-31 0000799694 OCLG:DLL61649Member 2015-05-31 0000799694 OCLG:ConvertibleNote2265Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNote2265Member 2015-05-31 0000799694 OCLG:ConvertibleNote2267Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNote2267Member 2015-05-31 0000799694 OCLG:ConvertibleNote2269Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNote2269Member 2015-05-31 0000799694 OCLG:ConvertibleNote2274Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNote2274Member 2015-05-31 0000799694 OCLG:ConvertibleNote2271Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNote2271Member 2015-05-31 0000799694 OCLG:ConvertibleNote2281Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNote2281Member 2015-05-31 0000799694 2017-09-01 2018-08-31 0000799694 2018-09-01 2019-08-31 0000799694 us-gaap:ChiefExecutiveOfficerMember 2015-03-01 2015-03-30 0000799694 OCLG:AngelOfMercyIncMember 2013-09-01 2014-05-31 0000799694 OCLG:PersonalCareServicesMember 2015-03-01 2015-05-31 0000799694 OCLG:PersonalCareServicesMember 2014-03-01 2014-05-31 0000799694 OCLG:MedicalDeviceManufacturingMember 2015-03-01 2015-05-31 0000799694 OCLG:MedicalDeviceManufacturingMember 2014-03-01 2014-05-31 0000799694 OCLG:MedicalProductsSegmentMember 2015-03-01 2015-05-31 0000799694 OCLG:MedicalProductsSegmentMember 2014-03-01 2014-05-31 0000799694 us-gaap:CorporateMember 2015-03-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote1Member 2013-09-01 2014-05-31 0000799694 OCLG:ConversionOfPromissoryNote2Member 2013-09-01 2014-05-31 0000799694 OCLG:ConversionOfPromissoryNote3Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote3Member 2013-09-01 2014-05-31 0000799694 OCLG:ConversionOfPromissoryNote4Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote4Member 2013-09-01 2014-05-31 0000799694 OCLG:ConversionOfPromissoryNote5Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote5Member 2013-09-01 2014-05-31 0000799694 OCLG:ConversionOfPromissoryNote6Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote6Member 2013-09-01 2014-05-31 0000799694 OCLG:ConversionOfPromissoryNote7Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote7Member 2013-09-01 2014-05-31 0000799694 OCLG:ConversionOfPromissoryNote8Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote8Member 2013-09-01 2014-05-31 0000799694 OCLG:CommonStockInvestorContract3Member 2014-09-01 2015-05-31 0000799694 OCLG:CommonStockInvestorContract1Member 2013-09-01 2014-05-31 0000799694 OCLG:CommonStockInvestorContract2Member 2013-09-01 2014-05-31 0000799694 OCLG:AdditionalCompensation1Member 2013-09-01 2014-05-31 0000799694 OCLG:AdditionalCompensation2Member 2013-09-01 2014-05-31 0000799694 OCLG:FindersFee1Member 2013-09-01 2014-05-31 0000799694 OCLG:FindersFee2Member 2013-09-01 2014-05-31 0000799694 OCLG:FindersFee3Member 2013-09-01 2014-05-31 0000799694 OCLG:FindersFee4Member 2013-09-01 2014-05-31 0000799694 2015-03-01 2015-05-31 0000799694 OCLG:DLL68936Member 2014-09-01 2015-05-31 0000799694 OCLG:WellsFargo019Member 2014-09-01 2015-05-31 0000799694 OCLG:VGM325Member 2014-09-01 2015-05-31 0000799694 OCLG:WellsFargo019Member 2015-05-31 0000799694 OCLG:DLL68936Member 2015-05-31 0000799694 OCLG:VGM325Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2210Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2210Member 2014-05-31 0000799694 OCLG:ConvertibleNotesPayable2218Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2218Member 2014-05-31 0000799694 OCLG:ConvertibleNotesPayable2232Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2232Member 2014-05-31 0000799694 OCLG:ConvertibleNotesPayable2238Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2238Member 2014-05-31 0000799694 OCLG:ConvertibleNotesPayable2239Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2239Member 2014-05-31 0000799694 OCLG:ConvertibleNotesPayable2247Member 2014-05-31 0000799694 OCLG:ConvertibleNotesPayable2250Member 2014-05-31 0000799694 OCLG:ConvertibleNotesPayable2261Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2265Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2267Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2271Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2274Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2276Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2278Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2281Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2290Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2292Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2294Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2297Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2310Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2312Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2314Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2316Member 2015-05-31 0000799694 2016-08-31 0000799694 OCLG:ConvertibleNotesPayable2218Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2232Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2232AdditionalMember 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2238Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayableAdditional2238Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayableAdditional2238Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2276Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2278Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2283Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2283Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2294Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2310Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2312Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2314Member 2014-09-01 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2316Member 2014-09-01 2015-05-31 0000799694 OCLG:Dot1Member 2015-05-31 0000799694 OCLG:Dot1Member 2014-05-31 0000799694 OCLG:Dot1Member 2014-09-01 2015-05-31 0000799694 OCLG:Dot2Member 2014-09-01 2015-05-31 0000799694 OCLG:Dot3Member 2014-09-01 2015-05-31 0000799694 OCLG:LineOfCreditAA2Member 2015-05-31 0000799694 OCLG:LineOfCreditAA2Member 2014-05-31 0000799694 OCLG:LineOfCreditAA2Member 2014-09-01 2015-05-31 0000799694 OCLG:MerchantLoanAA3Member 2015-05-31 0000799694 OCLG:MerchantLoanAA3Member 2014-05-31 0000799694 OCLG:MerchantLoanAA3Member 2014-09-01 2015-05-31 0000799694 OCLG:MerchantLoanAA4Member 2015-05-31 0000799694 OCLG:MerchantLoanAA4Member 2014-05-31 0000799694 OCLG:MerchantLoanAA5Member 2015-05-31 0000799694 OCLG:MerchantLoanAA6Member 2015-05-31 0000799694 OCLG:MerchantLoanAA7Member 2015-05-31 0000799694 OCLG:MerchantLoanAA8Member 2015-05-31 0000799694 OCLG:NotePayableAA9Member 2015-05-31 0000799694 OCLG:NotePayableAA9Member 2014-05-31 0000799694 OCLG:NotePayableEST1Member 2015-05-31 0000799694 OCLG:NotePayable2226Member 2015-05-31 0000799694 OCLG:NotePayable2226Member 2014-05-31 0000799694 OCLG:NotePayable2227Member 2015-05-31 0000799694 OCLG:NotePayable2227Member 2014-05-31 0000799694 OCLG:NotePayable2228Member 2015-05-31 0000799694 OCLG:NotePayable2228Member 2014-05-31 0000799694 OCLG:NotePayable2229Member 2015-05-31 0000799694 OCLG:NotePayable2229Member 2014-05-31 0000799694 OCLG:NotePayable2230Member 2015-05-31 0000799694 OCLG:NotePayable2230Member 2014-05-31 0000799694 OCLG:NotePayable2231Member 2015-05-31 0000799694 OCLG:NotePayable2231Member 2014-05-31 0000799694 OCLG:NotePayable2236Member 2015-05-31 0000799694 OCLG:NotePayable2236Member 2014-05-31 0000799694 OCLG:NotePayable2237Member 2015-05-31 0000799694 OCLG:NotePayable2237Member 2014-05-31 0000799694 OCLG:NotePayable2255Member 2015-05-31 0000799694 OCLG:NotePayable2255Member 2014-05-31 0000799694 OCLG:NotePayable2257Member 2015-05-31 0000799694 OCLG:NotePayable2257Member 2014-05-31 0000799694 OCLG:NotePayable2258Member 2015-05-31 0000799694 OCLG:NotePayable2258Member 2014-05-31 0000799694 OCLG:NotePayable2263Member 2015-05-31 0000799694 OCLG:NotePayable2263Member 2014-05-31 0000799694 OCLG:NotePayable2264Member 2015-05-31 0000799694 OCLG:NotePayable2264Member 2014-05-31 0000799694 OCLG:NotePayable2300Member 2015-05-31 0000799694 OCLG:NotePayable2300Member 2014-05-31 0000799694 OCLG:NotePayable2432Member 2015-05-31 0000799694 OCLG:NotePayable2432Member 2014-05-31 0000799694 OCLG:MerchantLoanAA4Member 2014-09-01 2015-05-31 0000799694 OCLG:MerchantLoanAA5Member 2014-09-01 2015-05-31 0000799694 OCLG:MerchantLoanAA6Member 2014-09-01 2015-05-31 0000799694 OCLG:MerchantLoanAA7Member 2014-09-01 2015-05-31 0000799694 OCLG:MerchantLoanAA8Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayableAA9Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayableEST1Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2226Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2227Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2228Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2229Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2230Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2231Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2236Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2237Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2255Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2263Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2264Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2300Member 2014-09-01 2015-05-31 0000799694 OCLG:NotePayable2432Member 2014-09-01 2015-05-31 0000799694 OCLG:ConsultantMember 2014-09-01 2015-05-31 0000799694 OCLG:PromissoryNoteMember 2014-09-01 2015-05-31 0000799694 us-gaap:InvestorMember 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote9Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote10Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote11Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote12Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote13Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote14Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote15Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote16Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote17Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote18Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote19Member 2014-09-01 2015-05-31 0000799694 OCLG:ConversionOfPromissoryNote9Member 2013-09-01 2014-05-31 0000799694 2015-05-30 0000799694 OCLG:ConvertibleNotesPayable2322Member 2015-05-31 0000799694 OCLG:ConvertibleNotesPayable2322Member 2014-09-01 2015-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:Y xbrli:pure OCLG:Number 340126946 9307 9307 12965 2946 15911 274633 222735 310343 31161 31391 19737 39578 1000 933503 1314815 39967 21287 16211 17893 15217 787 535 3283 35246 2135458 810179 892936 1303755 1316518 20524 73315 1000 1569262 3852031 436308 477596 235025 25000 115000 26500 25000 25000 35000 50000 50000 35000 75000 30000 700000 25000 26500 36750 88000 50000 32000 27500 58000 35000 50000 50000 732934 1087319 148681 208736 6342 2404501 4664962 395675 376037 2800176 5040999 129 129 79 79 134600 276746 47565869 48398569 -48370395 -49864491 -664718 -1188968 2135458 3852031 28264 38026 129062 129062 78564 78564 129062 58564 0.001 0.001 750000000 750000000 134600152 276746130 134600152 276746130 10.0 5.0 10.0 5.0 5.0 5.0 5.0 5.0 64531 78564000 64531 78564000 25812 25812 1058201 0 6173750 6173750 6173750 6173750 217085 1.17 1.17 4500000 0.001 129062 3 1 0.001 64531 129062 96797 129062 212 3186 3701 3734 7000000 30583333 4500000 5500000 9583333 4000000 21000000 -9583333 14582 2082 2307 12500 32303 33202 9866 77678 24497 24497 19903 19903 9000 71000 0.40 80.25 0.40 80.25 0.40 0.40 80.25 400 800 1200 1600 2000 97500 101250 76333 62669 49900 63750 46214 1250 500 400 1300 80.25 0.20 0.009 7393 82833 1134 85 567 1003 1989 1128 250 937 65469 711 2376 931 441 330 683 280 100 100 0.06 0.06 0.12 0.10 0.12 0.08 0.08 0.08 0.08 0.08 0.08 0.10 0.12 0.08 0.12 0.08 0.12 0.10 0.08 0.12 0.08 0.08 0.08 0.08 0.08 0.12 0.08 0.04 60000 0.001 58564 50000 80000 120000 150000 50000 35000 300000 60000 75000 65000 20000 10000 145523 75000 12000 4000000 15000 25000 75000 25000 60000 48000 550000 100000 1500 800 940 530 599 1607 999 2152 4524 5417 150 150 4257 1375 1334 8500 9115 6200 10 189 209 132 85 252 87 0.001 0.001 0.001 0.001 10000000 10000000 10000000 10000000 129062 129062 78564 78564 39456 17504 9336 76633 -110 120 7278 22724 186380 1000 21008 120485 213399 213399 233710 803299 1037009 31271 31271 31271 31271 106165 137436 106165 1781779 564075 564075 1217704 1217704 564075 1217704 622610 2404389 622610 51600 946104 2377667 395675 376037 12449 8646 3008 6000 1328773 100000 622610 85354 75000 100000 25000 1965 1090 2688 1437 1993 2394130 97813 326226 14580 17599 25812 25812 20000 20000000 7000000 30583333 17000000 21000000 .016 0.016 0.015 .016 1.24 7.02 0.0025 0 0 P2Y P5Y 405429 99491 18596 2091 2696776 2573547 2696776 988385 1051860 3625407 812626 423030 1235656 2066800 2129572 2030450 36350 788757 499225 2628797 698215 776406 12351 187381 885596 629976 443975 666326 -36350 199628 552635 996610 114411 211979 -12351 235649 350060 999910 105104 317165 506387 58489 28222 579422 465301 276950 424693 1379769 81451 166867 14739 4979 159793 187906 443889 17156 84 6289 9636 7269 7268 252 252 5664 546 14356 2262 3157 2423 2423 253 84 5022 -634833 -84438 -244613 -171837 -5500 -8560 -836052 -454436 -167474 -3848 -1090013 -81952 -80786 -1500 -2250 -3076 -351380 -437908 -1152393 -238952 -1494096 -525438 64680 19178 112055 36527 120000 85000 125000 17074 7926 690 530 1384 3000000 3500000 3000000 1500000 4000000 1350 900 1200 30000 43265 20000 150000 37467 228215 67400 25000 1500 68920 68510 1533584 68920 22973 56217 11500 416466 25499 45000 42533 151200 196500 70000 51065 405000 87450 50000 205705 0.40 0.40 97983 102576 4257 0.35 0.38 0.30 0.38 0.38 0.38 0.38 0.38 0.38 0.60 0.45 0.38 0.35 0.38 0.38 0.38 0.38 0.38 0.38 0.38 0.38 0.35 8788171 8284469 18571550 9641872 6211180 16669092 5383007 3416764 16801705 9180298 9400000 51600 0 477596 45000 80000 119301 146750 68409 42080 163713 500000 14805 5992 7746 5151 10177 5992 7746 1500000 1000000 3000000 1000000 5000000 0.012 0.012 0.012 0.017 0.012 .007 0.009 10000000 7500000 6100000 20000 473253 7000000 -163335 82532 96644 3152 3152 3889 85 3974 90000 10545 10545 38322 26500 10545 10545 35000 50000 50000 35000 75000 30000 12069 9720 35000 26154 50000 16667 50000 9000 35000 2308 75000 26500 30000 50000 25000 26500 50000 6000 21452 29715 30645 45968 25698 49539 20100 29404 15790 10372 39146 21452 29715 30645 45968 25000 0.0033 0.002475 477596 420365 64025 235025 100000 -567 5300 7260 4918 68429 8100 12370 24897 16911 11123 17161 56910 13095 31918 18885 15579 17680 15650 1813 20592 30887 100000 30000 1429829 2850348 30000 44469 43149 20000 20000 1500 60600 37467 130400 142109 68409 42080 228215 67400 14765 73552 10833 6689 6844 21076 68510 70659 12000 7692 1533584 275155 11444 22909 68920 22973 56215 11500 416466 498179 25499 78915 -416466 -376037 23583333 6120000 Oncologix Tech Inc. 0000799694 10-Q 2015-05-31 true --08-31 No No Yes Smaller Reporting Company Q3 2015 5000 10000 10000 210272886 81383460 6173750 6186250 21000000 26583333 316010636 136653043 22500000 78564000 0.39 0.18 0.47 36 95528 68231 73272 12688 14118 16763 17623 12962 13625 3497 3497 22321 24409 6124 122479 46000 25000 25000 11989 50198 30096 16261 120000 80000 52000 85000 150000 60000 30000 5000000 3000000 2500000 417000 -18056 -1051 -2348 -15708 -791 -1051 -791 155728 62151 28748 28748 -765303 -155966 -1086581 -426587 1000000 500000 573130 106165 860 10551 -454877 -75000 655340 -125463 100000 400000 173433 50000 145522 417001 8331 23787 24694 32106 32512 90781 31389 11263 76459 85680 56428 4165 5947 6174 5351 3612 11348 3488 1126 1126 6951 7140 64025 10545 51600 4032743 78564000 58564000 80.25 1017066 105188 323454 516023 75758 35490 579674 465553 282614 425239 1404125 83713 170024 17162 7402 160046 187990 448911 -387090 -105188 120521 150303 -75758 -71840 -579674 -465553 -82986 127396 -407515 30698 41955 -17162 -19753 75603 -187990 -98851 72062 8541 72775 -3854 -713 -204 74450 4483 -70645 74667 -1486 -217 -3076 -351380 -426587 -765303 -146589 -236072 -127810 -10405 -11621 -836256 -625872 -155966 -3848 -1086581 -6119 -3258 4000 20000 38500 11500 19000 495861 676419 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>NOTE 1 - ORGANIZATION AND DESCRIPTION OF THE COMPANY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Oncologix Tech, Inc. is a diversified medical holding company with operating segments in medical device, healthcare services and medical products and technologies. We operate and manufacture Class II medical device products, deliver Personal Healthcare Services and provide Home Medical Equipment (HME) and Durable Medical Equipment (DME) sales in licensed markets. For its clients, Oncologix provides FDA approved medical devices, State licensed healthcare services and medical product sales. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company&#146;s corporate mission is to be the best small cap medical device and healthcare services holding company in North America.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We were originally formed in 1995 and in 2000 we changed our name to &#34;BestNet Communications Corp.&#34; At that time we provided worldwide long distance telephone communication and teleconferencing services to commercial and residential consumers through the internet, which we disposed of in 2007 due to lack of profitability. In July 2006 we changed our business model to medical device products.&#160; In July 2006 we acquired JDA Medical Technologies, Inc. (&#34;JDA&#34;) and merged this business into Oncologix Corporation, our wholly owned subsidiary.&#160; On January 22, 2007, we changed our name to Oncologix Tech, Inc., to reflect this new business model. Our business at this time was the development of a medical device for brachytherapy (radiation therapy), called the &#147;Oncosphere&#148; (or &#147;Oncosphere System&#148;), for the advanced medical treatment of soft tissue cancers. Due to a lack of funding, we suspended these development activities on December 31, 2007. On November 1, 2013, due to the development of the brachytherapy device being several years away, indication that the product could not be marketed and no guarantee of FDA approvals, it was determined that continued financial support of this product by Oncologix Corporation would cost the Company substantial&#160;capital beyond its means and the&#160;Company&#146;s management and Board of Directors disposed of Oncologix Corporation and its Brachytherapy medical device subsidiary. Furthermore, as part of the disposal, the Company was relieved of over $90,000 in debt. &#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 22, 2013, we acquired all the outstanding stock of Dotolo Research Corporation (&#147;Dotolo&#148;), a FDA Registered, Class II, medical device manufacturer with 25 years of product sales in the hydro-colonic irrigation, bowel preparation market. Dotolo Research Corporation began operations in 1989 and sells hardware and disposable products to a customer base of over 900+ customers both domestically and internationally.&#160; The Company currently operates in a limited, but competitive environment in hydro-colonic irrigation, of which there are only four (4) companies approved by the FDA to manufacture a Class II medical device for colonic-hydro therapy.&#160; Since the acquisition, we have not had significant revenues from sales of our products, including sales to medical facilities due to a lack of operating capital needed to procure raw material inventory to currently fill customers&#146; orders. We are currently in the final phase of new product hardware redesign which we believe will allow Dotolo Research the ability to successfully enter into the medical markets to become the dominate market leader.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 1, 2013, we acquired the outstanding stock of Angels of Mercy, Inc. (&#147;AOM&#148;). Angels provides non-medical, Personal Care Attendant (PCA) services, Supervised Independent Living (SIL), Long-Term Senior Care, and other approved health service programs performed by a trained caregiver that will meet the health service needs of beneficiaries whose disabilities preclude the performance of certain independent living skills related to the activities of daily living (ADL). We changed the name to Amian Angels Inc. (&#147;Amian&#148;) in August 2014.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 10, 2013, Angels of Mercy, Inc. acquired the assets of Amian Health Services LLC and Amian Health Services of Alex LLC, herein after referred to as &#147;Amian&#148;.&#160; Amian delivers health-care care-services&#160;who provide routine health and personal care support with Activities of Daily Living (ADL) to clients with physical impairments or disabilities in private homes, nursing care facilities, hospice care settings, and other residential settings. Amian holds both PCA-Medicaid Waiver Provider and Residential Rehabilitation/Supervised Independent Living (SIL), and personal care services for Veterans with licenses issued by the Division of Licensing and Certification of the Department of Social Services, Veterans Administration Social Services and the Louisiana Department of Health and Hospitals. &#160;All administrative personnel of Amian have been merged to gain operating synergies. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 21, 2014 we formed Advanced Medical Products and Technologies Inc.. (&#147;AMPT&#148;) to enter into the Durable Medical and Home Medical Equipment markets. We anticipate acquiring active companies in this area to develop our Medical Products and Technologies Segment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">On September 25, 2014, we acquired the outstanding stock of Esteemcare, Inc. and its wholly owned subsidiary Affordable Medical Equipment Solutions, Inc. Esteemcare, Inc is a Durable and Home Medical equipment and supply distributor for respiratory therapy and is accredited by the &#147;Joint Commission on Healthcare Organizations&#148;. Esteemcare targets patients with sleep obstructive disorders or related chronic illnesses who are insured by Medicare, Medicaid, third-party insurers, or have the ability to pay for our products from their own private resources. Sleep apnea is a serious sleep disorder that occurs when a person's breathing is interrupted during sleep. People with untreated sleep apnea stop breathing repeatedly during their sleep, sometimes hundreds of times. This means the brain -- and the rest of the body -- may not get enough oxygen.</font></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">NOTE 2 &#151; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BASIS OF PRESENTATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the opinion of management, the accompanying balance sheets and related interim statements of income, cash flows, and stockholders' equity include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (&#34;U.S. GAAP&#34;). Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management's estimates and assumptions. Interim results are not necessarily indicative of results for a full year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PRINCIPLES OF CONSOLIDATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited consolidated financial statements for the three and nine months ended May 31, 2015 and 2014 include the accounts of Oncologix Tech, Inc. and its wholly owned subsidiaries, Dotolo Research Corporation (&#147;Dotolo&#148;), Amian Angels, Inc. (&#147;Amian&#148;), Advanced Medical Products &#38; Technologies Inc. (&#147;AMPT&#148;), Esteemcare Inc. and Affordable Medical Equipment Solutions Inc. (collectively &#147;Esteemcare&#148;) Dotolo and Amian are Louisiana Corporations. AMPT is a Nevada corporation. Esteem &#38; Affordable are South Carolina corporations. All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">USE OF ESTIMATES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reportable amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">SEGMENT INFORMATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC 280-10 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the Company&#146;s Chief Executive Officer and Chief Financial Officer in deciding how to allocate resources and in assessing performance. The Company currently has three business segments; medical device manufacturing (Dotolo), personal care services (Amian) and medical products and technologies (AMPT and Esteem &#38; Affordable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">REVENUE RECOGNITION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Revenue is recognized by the Company in accordance with Accounting Standards Codification Topic (&#147;ASC&#148;) 605. Accordingly, revenue is recognized when all the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the seller&#146;s price to the buyer is fixed and determinable; and collectability is reasonably assured. Currently, the primary revenue for the Company is derived from its sales in its Personal Care Services and Medical Products and Technologies Segments&#146;.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Amian is reimbursed for each approved &#147;Unit of Service&#148; provided, as determined by the Health Care Financing Administration (HCFA), the Department of Health &#38; Hospitals and the Department of Social Services and based upon a detailed Case Management, Plan of Care for each beneficiary. A unit of service for PCA services will be one-half hour. At least fifteen (15) minutes of service must be provided to the individual in order for Amian Angels to bill for a unit of service. A maximum of 1,825 hours (3,650 half-hour units) per beneficiary, per year can be billed under the Medicaid waiver program. Our primary payer sources is the State of Louisiana, the Department of Veterans Administration and Private Pay individuals who reimburse us for the services we provide. We currently experience a two percent claims rejection rate. With the acquisition of Amian, Amian Angels now has private pay clients as well as Veterans Administration Social Services clients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Esteemcare recognizes revenue related to product sales upon delivery to customers provided that we have received and verified any written documentation required to bill Medicare, other government agencies, third-party payers, and patients. For product shipments for which we have not yet received the required written documentation, revenue recognition is delayed until the period in which those documents are collected and verified. We record revenue at the amounts expected to be collected from government agencies, other third-party payers, and from patients directly. Government and insurance payers&#146; generally require patient compliance with product usage. Accordingly, most pay for the product purchases over a multi-month plan, generally 10 to 13 months. We record these revenues as received since the transfer of ownership is not guaranteed until the full purchase price is paid to us. We record, if necessary, contractual adjustments equal to the difference between the reimbursement amounts defined in the fee schedule and the revenue recorded per the billing system. These adjustments are recorded as a reduction of both gross revenues and accounts receivable. We analyze various factors in determining revenue recognition, including a review of specific transactions, current Medicare regulations and reimbursement rates, historical experience and the credit-worthiness of patients. Medicare reimburses at 80% of the government-determined prices for reimbursable supplies, and we bill the remaining balance to either third-party payers or directly to patients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CASH AND CASH EQUIVALENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company considers all highly liquid instruments, with an initial maturity of three (3) months or less to be cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ACCOUNTS RECEIVABLE</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#146;s receivables in its medical device segment are subject to credit risk, and the Company typically does not require collateral on its accounts receivable. Receivables are generally due within 30 days. The Company maintains an allowance for uncollectable receivables that reduces the receivables to amounts that are expected to be collected. .</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The lead time for account receivables in our Personal Care service divisions ranges from 14 to 90 days. The majority of the Company&#146;s receivables, approximately 90%, are collected within 14 days. We bill the State of Louisiana on a weekly basis and are reimbursed two weeks later via electronic funds transfer. We are able to resubmit any rejected claims an additional two times to Molina Healthcare, the EDI payment provider for payments within the next twelve months. Currently we maintain an allowance for uncollectible receivables at a rejection rate of 2% of outstanding receivables. We analyze our claim rejection rate on a quarterly basis and make quality improvements to reduce the number of rejected claims. Private pay customers are billed semi-monthly. Generally collections occur within 30 days. Veterans Administration (VA) customers are billed monthly. Generally collections occur within 45 to 60 days. Due to the recent governmental shutdown, the current lead time for payments is approximately 90 days. Upon final rejection of any resubmitted claims, the claims are resubmitted and after twelve months the receivables are written off to bad debt expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our medical products and technologies accounts receivable are generally due from Medicare, Medicaid, private insurance companies, and our private patients. Accounts receivable are reported net of allowances for contractual adjustments and uncollectible accounts. The collection process is time consuming, complex and typically involves the submission of claims to multiple layers of payers whose payment of claims may be contingent upon the payment of another payer. As a result, our collection efforts may be active for up to 18 to 24 months from the initial billing date. In accordance with regulatory requirements, we make reasonable and appropriate efforts to collect our accounts receivable, including deductible and co-payment amounts, in a manner consistent for all classes of payers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">INVENTORY</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Inventories are stated at cost and are held on a first-in, first-out basis. Our inventory in our medical device segment consists primarily of miscellaneous hardware parts. Our inventory in our medical products and technologies segment consists of masks, CPAP machines, BiPAP machines and other necessary breathing equipment and supplies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PROPERTY AND EQUIPMENT</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Property and equipment is recorded at cost. Depreciation is provided for on the straight-line method over the estimated useful lives of the related assets as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 72%; padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Furniture and fixtures</font></td> <td style="width: 28%; padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">5 to 10 years</font></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Computer equipment</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">5 years</font></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Equipment</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">5 to 10 years</font></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Software</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">3 to 5 years</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The cost of maintenance and repairs is charged to expense in the period incurred. Expenditures that increase the useful lives of assets are capitalized and depreciated over the remaining useful lives of the assets. When items are retired or disposed of, the cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">LONG-LIVED ASSETS<i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0">&#160;&#160;&#160;&#160;&#160;ASC 360 &#150; Property, Plant and Equipment addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment or whether the remaining balance of property and equipment, or other long-lived assets, should be evaluated for possible impairment. Instances that may lead to an impairment include: (i)&#160;a significant decrease in the market price of a long-lived asset group; (ii)&#160;a significant adverse change in the extent or manner in which a long-lived asset or asset group is being used or in its physical condition; (iii)&#160;a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset or asset group, including an adverse action or assessment by a regulatory agency; (iv)&#160;an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset or asset group; (v)&#160;a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset or asset group; or (vi)&#160;a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An estimate of the related undiscounted cash flows, excluding interest, over the remaining life of the property and equipment and long-lived assets is used in assessing recoverability. Impairment loss is measured by the amount which the carrying amount of the asset(s) exceeds the fair value of the asset(s). The Company primarily employs two methodologies for determining the fair value of a long-lived asset: (i)&#160;the amount at which the asset could be bought or sold in a current transaction between willing parties or (ii)&#160;the present value of estimated expected future cash flows grouped at the lowest level for which there are identifiable independent cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">GOODWILL AND OTHER INTANGIBLE ASSETS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0">The Company adopted Accounting Standards Update 2011-08 &#147;Intangibles &#150; Goodwill and Other (Topic 350): Testing Goodwill for Impairment (&#147;ASU 2011-08&#148;) in the fourth quarter of fiscal 2014 due to its recent acquisition of Dotolo Research Corporation and Angels of Mercy, Inc. ASU 2011-08 permits an entity to first assess qualitative factors to determine whether it is more likely that not that the fair value of a reporting unit is less than its carrying amount. Goodwill represents the excess of the cost of a business combination over the fair value of the net assets acquired and these costs are subject to annual impairment tests.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0">&#160;We accounted for the acquisition of Dotolo, Amian and Esteemcare using the acquisition method of accounting under ASC 805 and ASC 810-10-65. The purchase price was allocated first to identifiable current then fixed assets as well as liabilities assumed. We then earmarked identifiable intangibles, with the remainder to goodwill. We identified patents as our identifiable asset for Dotolo Research Corporation. Amounts allocated to Goodwill for the acquisition of Dotolo are based on expanding our product into the medical market and the potential upside of the sale with a FDA medical device product with a reimbursement code. Dotolo is one of four companies worldwide with an FDA approved, Class II medical device product. Amounts allocated to goodwill for Amian and Esteemcare are based on increased clients and future revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0">The Company evaluates the recoverability of its indefinite lived intangible assets, which consist of Dotolo, Amian and Esteemcare, based on estimates of future royalty payments that are avoided through its ownership of the intangibles and patents, discounted to their present value. In determining the estimated fair value of the intangibles and patents, management considers current and projected future levels of revenue based on its plans for Dotolo, business trends, prospects and market and economic conditions. See Note 4 &#150; Acquisitions for further information on the acquisition of Dotolo.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0">We follow the two step process in ASC 350-20-35 for impairment testing. In the first step we compare the fair value of the reporting unit as a whole to its carrying value, including goodwill. For both reporting units, we have determined that the reporting units&#146; fair value exceeds its carrying value. We also compare the carrying value of goodwill by itself for both reporting units.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following explains the results of our impairment testing. We have allocated $564,075 of goodwill to the Amian Angels, Inc. reporting unit. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 39%. We have allocated $1,217,704 of goodwill to the reporting unit Dotolo Research Corporation. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 18%. We have allocated $622,610 of goodwill the Esteemcare reporting unit. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 47%. In calculating the valuation, we used a discounted cash flow method based on the future 5 years cash flows of each reporting unit. We used a discount rate of 8% which is currently higher that the current long term interest rate. An increase in the overall national interest rate could have a negative impact on our valuation. An additional risk is the possibility of cash flow projections falling short of our 5 year estimate amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ADVERTISING COSTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Advertising costs included with selling, general and administrative expenses in the accompanying consolidated statements of operations were minimal for the three and nine months ended May 31, 2015 and 2014. Such costs are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">INCOME TAXES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company adopted the provisions of FASB ASC 740 - Income Taxes provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Income taxes are determined using the asset and liability method. This method gives consideration to the future tax consequences associated with temporary differences between the carrying amounts of assets and liabilities for financial statement purposes and the amounts used for income tax purposes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">FAIR VALUE OF FINANCIAL INSTRUMENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable, accrued expenses, and notes payable approximate fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">STOCK-BASED COMPENSATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">The Company has a stock-based compensation plan, which is described more fully in Note 12. The Company accounts for stock-based compensation in accordance with ASC 718. Under the fair value recognition provisions of this statement, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation model. The fair value of all awards is amortized on a straight-line basis over the vesting periods. The expected term of awards granted represent the period of time they are expected to be outstanding. The Company determines the expected term based on historical experience with similar awards, giving consideration to the contractual terms and vesting schedules. The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of its common stock. The risk-free interest rate is based on the U.S. treasury security rate estimated for the expected life of the options at the date of grant. If actual results differ significantly from estimates, stock-based compensation could be impacted.</font></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">INVENTORY FINANCING AGREEMENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our inventory finance agreements consist of qualified for-sale equipment purchases. Qualifying inventory purchases are grouped into a 12 month finance agreements allowing the company to spread the payments for this inventory over a twelve month period. All inventory finance agreements are interest free and consist of only minor fees for setup.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CONVERTIBLE DEBT</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest on convertible debt is calculated using the simple interest method. The company recognizes a beneficial conversion feature to the extent the conversion price is less than the closing stock price on the issuance of the convertible notes. The Company also follows ASC 470-50 and ASC 470-20 regarding changes in the terms of the convertible notes and the induced conversion of its convertible debt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">RECLASSIFICATIONS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain prior year amounts have been reclassified to conform to the current year presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">STOCK INCENTIVE PLANS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Share based payment compensation costs for equity-based awards are measured on the grant date based on the fair value of the award on that date and is recognized over the required service period. The fair-value of stock option awards is estimated using the Black-Scholes model. Fair value of restricted stock awards is based upon the quoted market price of the common stock on the date of grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NET LOSS PER COMMON SHARE</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Basic earnings (loss)&#160;per share is calculated under the provisions of ASC 260 which provides for calculation of &#147;basic&#148; and &#147;diluted&#148; earnings per share. Basic earnings per share includes no dilution and is calculated by dividing income (loss)&#160;available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings (loss)&#160;per share is calculated based on the weighted average number of common shares outstanding during the period plus the dilutive effect of common stock purchase warrants and stock options using the treasury stock method and the dilutive effects of convertible notes payable and convertible preferred stock using the if-converted method. On Basic and diluted earnings per share for the three and nine months ended May 31, 2015 and 2014 are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">For the Nine Months Ended</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net gain (loss) attributable to common shareholders</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Continuing operations</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(525,438</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(238,952</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,494,096</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,152,393</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Discontinued operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">95,528</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(525,438</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(238,952</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,494,096</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,056,865</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">242,589,170</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">112,247,396</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">187,353,653</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">93,925,094</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss per common shares, basis and diluted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Continuing operations</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Discontinued operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.00</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.00</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the net losses during the three and nine months ended May 31, 2015 and 2014, basic and diluted loss per share was the same, as the effect of potentially dilutive securities would have been anti-dilutive. Shares attributable to convertible notes, stock options, preferred stock and warrants not included the diluted loss per share calculation. Below lists all dilutive securities as of May 31, 2015 and 2014:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">As of</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr> <td style="text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;Underlying&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;Underlying&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-decoration: underline; text-align: center; padding-bottom: 1pt">Description</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;Common Shares&#160;</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;Common Shares&#160;</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Convertible preferred stock</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right">78,564,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right">22,500,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible notes payable</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">123,452,480</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,433,965</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Options</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,173,750</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,186,250</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,583,333</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">238,773,563</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">52,120,215</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">SEGMENT INFORMATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC 280-10 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the Company&#146;s Chief Executive Officer and Chief Financial Officer in deciding how to allocate resources and in assessing performance. The Company currently has three business segments; medical device manufacturing, personal care services and medical products and technologies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<br /> RECENT ACCOUNTING PRONOUNCEMENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">New Accounting Standard</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2012, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update 2012-02 &#147;Intangibles &#150; Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment&#148; (&#147;ASU 2012-02&#148;). ASU 2012-02 permits entities to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. Under the amendments in ASU 2012-02, an entity is not required to calculate the fair value of an indefinite-lived intangible asset unless it determines that it is more likely than not that the fair value of the asset is less than its carrying amount. An entity also will have the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. ASU 2012-02 is effective for interim and annual indefinite-lived intangible asset impairment tests performed for fiscal years beginning on or after September 15, 2012, with early adoption permitted. The Company&#146;s adoption of ASU 2012-02 is not expected to have an impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BASIS OF PRESENTATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In the opinion of management, the accompanying balance sheets and related interim statements of income, cash flows, and stockholders' equity include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America (&#34;U.S. GAAP&#34;). Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management's estimates and assumptions. Interim results are not necessarily indicative of results for a full year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PRINCIPLES OF CONSOLIDATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The unaudited consolidated financial statements for the three and nine months ended May 31, 2015 and 2014 include the accounts of Oncologix Tech, Inc. and its wholly owned subsidiaries, Dotolo Research Corporation (&#147;Dotolo&#148;), Amian Angels, Inc. (&#147;Amian&#148;), Advanced Medical Products &#38; Technologies Inc. (&#147;AMPT&#148;), Esteemcare Inc. and Affordable Medical Equipment Solutions Inc. (collectively &#147;Esteemcare&#148;) Dotolo and Amian are Louisiana Corporations. AMPT is a Nevada corporation. Esteem &#38; Affordable are South Carolina corporations. All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">USE OF ESTIMATES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reportable amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">SEGMENT INFORMATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC 280-10 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the Company&#146;s Chief Executive Officer and Chief Financial Officer in deciding how to allocate resources and in assessing performance. The Company currently has three business segments; medical device manufacturing (Dotolo), personal care services (Amian) and medical products and technologies (AMPT and Esteem &#38; Affordable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">REVENUE RECOGNITION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Revenue is recognized by the Company in accordance with Accounting Standards Codification Topic (&#147;ASC&#148;) 605. Accordingly, revenue is recognized when all the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the seller&#146;s price to the buyer is fixed and determinable; and collectability is reasonably assured. Currently, the primary revenue for the Company is derived from its sales in its Personal Care Services and Medical Products and Technologies Segments&#146;.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Amian is reimbursed for each approved &#147;Unit of Service&#148; provided, as determined by the Health Care Financing Administration (HCFA), the Department of Health &#38; Hospitals and the Department of Social Services and based upon a detailed Case Management, Plan of Care for each beneficiary. A unit of service for PCA services will be one-half hour. At least fifteen (15) minutes of service must be provided to the individual in order for Amian Angels to bill for a unit of service. A maximum of 1,825 hours (3,650 half-hour units) per beneficiary, per year can be billed under the Medicaid waiver program. Our primary payer sources is the State of Louisiana, the Department of Veterans Administration and Private Pay individuals who reimburse us for the services we provide. We currently experience a two percent claims rejection rate. With the acquisition of Amian, Amian Angels now has private pay clients as well as Veterans Administration Social Services clients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Esteemcare recognizes revenue related to product sales upon delivery to customers provided that we have received and verified any written documentation required to bill Medicare, other government agencies, third-party payers, and patients. For product shipments for which we have not yet received the required written documentation, revenue recognition is delayed until the period in which those documents are collected and verified. We record revenue at the amounts expected to be collected from government agencies, other third-party payers, and from patients directly. Government and insurance payers&#146; generally require patient compliance with product usage. Accordingly, most pay for the product purchases over a multi-month plan, generally 10 to 13 months. We record these revenues as received since the transfer of ownership is not guaranteed until the full purchase price is paid to us. We record, if necessary, contractual adjustments equal to the difference between the reimbursement amounts defined in the fee schedule and the revenue recorded per the billing system. These adjustments are recorded as a reduction of both gross revenues and accounts receivable. We analyze various factors in determining revenue recognition, including a review of specific transactions, current Medicare regulations and reimbursement rates, historical experience and the credit-worthiness of patients. Medicare reimburses at 80% of the government-determined prices for reimbursable supplies, and we bill the remaining balance to either third-party payers or directly to patients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CASH AND CASH EQUIVALENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company considers all highly liquid instruments, with an initial maturity of three (3) months or less to be cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ACCOUNTS RECEIVABLE</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company&#146;s receivables in its medical device segment are subject to credit risk, and the Company typically does not require collateral on its accounts receivable. Receivables are generally due within 30 days. The Company maintains an allowance for uncollectable receivables that reduces the receivables to amounts that are expected to be collected. .</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The lead time for account receivables in our Personal Care service divisions ranges from 14 to 90 days. The majority of the Company&#146;s receivables, approximately 90%, are collected within 14 days. We bill the State of Louisiana on a weekly basis and are reimbursed two weeks later via electronic funds transfer. We are able to resubmit any rejected claims an additional two times to Molina Healthcare, the EDI payment provider for payments within the next twelve months. Currently we maintain an allowance for uncollectible receivables at a rejection rate of 2% of outstanding receivables. We analyze our claim rejection rate on a quarterly basis and make quality improvements to reduce the number of rejected claims. Private pay customers are billed semi-monthly. Generally collections occur within 30 days. Veterans Administration (VA) customers are billed monthly. Generally collections occur within 45 to 60 days. Due to the recent governmental shutdown, the current lead time for payments is approximately 90 days. Upon final rejection of any resubmitted claims, the claims are resubmitted and after twelve months the receivables are written off to bad debt expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our medical products and technologies accounts receivable are generally due from Medicare, Medicaid, private insurance companies, and our private patients. Accounts receivable are reported net of allowances for contractual adjustments and uncollectible accounts. The collection process is time consuming, complex and typically involves the submission of claims to multiple layers of payers whose payment of claims may be contingent upon the payment of another payer. As a result, our collection efforts may be active for up to 18 to 24 months from the initial billing date. In accordance with regulatory requirements, we make reasonable and appropriate efforts to collect our accounts receivable, including deductible and co-payment amounts, in a manner consistent for all classes of payers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">INVENTORY</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Inventories are stated at cost and are held on a first-in, first-out basis. Our inventory in our medical device segment consists primarily of miscellaneous hardware parts. Our inventory in our medical products and technologies segment consists of masks, CPAP machines, BiPAP machines and other necessary breathing equipment and supplies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PROPERTY AND EQUIPMENT</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Property and equipment is recorded at cost. Depreciation is provided for on the straight-line method over the estimated useful lives of the related assets as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 72%; padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Furniture and fixtures</font></td> <td style="width: 28%; padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">5 to 10 years</font></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Computer equipment</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">5 years</font></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Equipment</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">5 to 10 years</font></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Software</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">3 to 5 years</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The cost of maintenance and repairs is charged to expense in the period incurred. Expenditures that increase the useful lives of assets are capitalized and depreciated over the remaining useful lives of the assets. When items are retired or disposed of, the cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">LONG-LIVED ASSETS<i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0">&#160;&#160;&#160;&#160;&#160;ASC 360 &#150; Property, Plant and Equipment addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment or whether the remaining balance of property and equipment, or other long-lived assets, should be evaluated for possible impairment. Instances that may lead to an impairment include: (i)&#160;a significant decrease in the market price of a long-lived asset group; (ii)&#160;a significant adverse change in the extent or manner in which a long-lived asset or asset group is being used or in its physical condition; (iii)&#160;a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset or asset group, including an adverse action or assessment by a regulatory agency; (iv)&#160;an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset or asset group; (v)&#160;a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset or asset group; or (vi)&#160;a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">An estimate of the related undiscounted cash flows, excluding interest, over the remaining life of the property and equipment and long-lived assets is used in assessing recoverability. Impairment loss is measured by the amount which the carrying amount of the asset(s) exceeds the fair value of the asset(s). The Company primarily employs two methodologies for determining the fair value of a long-lived asset: (i)&#160;the amount at which the asset could be bought or sold in a current transaction between willing parties or (ii)&#160;the present value of estimated expected future cash flows grouped at the lowest level for which there are identifiable independent cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">GOODWILL AND OTHER INTANGIBLE ASSETS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0">The Company adopted Accounting Standards Update 2011-08 &#147;Intangibles &#150; Goodwill and Other (Topic 350): Testing Goodwill for Impairment (&#147;ASU 2011-08&#148;) in the fourth quarter of fiscal 2014 due to its recent acquisition of Dotolo Research Corporation and Angels of Mercy, Inc. ASU 2011-08 permits an entity to first assess qualitative factors to determine whether it is more likely that not that the fair value of a reporting unit is less than its carrying amount. Goodwill represents the excess of the cost of a business combination over the fair value of the net assets acquired and these costs are subject to annual impairment tests.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0">&#160;We accounted for the acquisition of Dotolo, Amian and Esteemcare using the acquisition method of accounting under ASC 805 and ASC 810-10-65. The purchase price was allocated first to identifiable current then fixed assets as well as liabilities assumed. We then earmarked identifiable intangibles, with the remainder to goodwill. We identified patents as our identifiable asset for Dotolo Research Corporation. Amounts allocated to Goodwill for the acquisition of Dotolo are based on expanding our product into the medical market and the potential upside of the sale with a FDA medical device product with a reimbursement code. Dotolo is one of four companies worldwide with an FDA approved, Class II medical device product. Amounts allocated to goodwill for Amian and Esteemcare are based on increased clients and future revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0">The Company evaluates the recoverability of its indefinite lived intangible assets, which consist of Dotolo, Amian and Esteemcare, based on estimates of future royalty payments that are avoided through its ownership of the intangibles and patents, discounted to their present value. In determining the estimated fair value of the intangibles and patents, management considers current and projected future levels of revenue based on its plans for Dotolo, business trends, prospects and market and economic conditions. See Note 4 &#150; Acquisitions for further information on the acquisition of Dotolo.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin-right: 0; margin-left: 0">We follow the two step process in ASC 350-20-35 for impairment testing. In the first step we compare the fair value of the reporting unit as a whole to its carrying value, including goodwill. For both reporting units, we have determined that the reporting units&#146; fair value exceeds its carrying value. We also compare the carrying value of goodwill by itself for both reporting units.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following explains the results of our impairment testing. We have allocated $564,075 of goodwill to the Amian Angels, Inc. reporting unit. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 39%. We have allocated $1,217,704 of goodwill to the reporting unit Dotolo Research Corporation. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 18%. We have allocated $622,610 of goodwill the Esteemcare reporting unit. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 47%. In calculating the valuation, we used a discounted cash flow method based on the future 5 years cash flows of each reporting unit. We used a discount rate of 8% which is currently higher that the current long term interest rate. An increase in the overall national interest rate could have a negative impact on our valuation. An additional risk is the possibility of cash flow projections falling short of our 5 year estimate amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ADVERTISING COSTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Advertising costs included with selling, general and administrative expenses in the accompanying consolidated statements of operations were minimal for the three and nine months ended May 31, 2015 and 2014. Such costs are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">INCOME TAXES</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company adopted the provisions of FASB ASC 740 - Income Taxes provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Income taxes are determined using the asset and liability method. This method gives consideration to the future tax consequences associated with temporary differences between the carrying amounts of assets and liabilities for financial statement purposes and the amounts used for income tax purposes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">FAIR VALUE OF FINANCIAL INSTRUMENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable, accrued expenses, and notes payable approximate fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">STOCK-BASED COMPENSATION</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">The Company has a stock-based compensation plan, which is described more fully in Note 12. The Company accounts for stock-based compensation in accordance with ASC 718. Under the fair value recognition provisions of this statement, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation model. The fair value of all awards is amortized on a straight-line basis over the vesting periods. The expected term of awards granted represent the period of time they are expected to be outstanding. The Company determines the expected term based on historical experience with similar awards, giving consideration to the contractual terms and vesting schedules. The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of its common stock. The risk-free interest rate is based on the U.S. treasury security rate estimated for the expected life of the options at the date of grant. If actual results differ significantly from estimates, stock-based compensation could be impacted.</font></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">INVENTORY FINANCING AGREEMENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our inventory finance agreements consist of qualified for-sale equipment purchases. Qualifying inventory purchases are grouped into a 12 month finance agreements allowing the company to spread the payments for this inventory over a twelve month period. All inventory finance agreements are interest free and consist of only minor fees for setup.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CONVERTIBLE DEBT</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Interest on convertible debt is calculated using the simple interest method. The company recognizes a beneficial conversion feature to the extent the conversion price is less than the closing stock price on the issuance of the convertible notes. The Company also follows ASC 470-50 and ASC 470-20 regarding changes in the terms of the convertible notes and the induced conversion of its convertible debt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">RECLASSIFICATIONS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Certain prior year amounts have been reclassified to conform to the current year presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">STOCK INCENTIVE PLANS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Share based payment compensation costs for equity-based awards are measured on the grant date based on the fair value of the award on that date and is recognized over the required service period. The fair-value of stock option awards is estimated using the Black-Scholes model. Fair value of restricted stock awards is based upon the quoted market price of the common stock on the date of grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NET LOSS PER COMMON SHARE</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Basic earnings (loss)&#160;per share is calculated under the provisions of ASC 260 which provides for calculation of &#147;basic&#148; and &#147;diluted&#148; earnings per share. Basic earnings per share includes no dilution and is calculated by dividing income (loss)&#160;available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings (loss)&#160;per share is calculated based on the weighted average number of common shares outstanding during the period plus the dilutive effect of common stock purchase warrants and stock options using the treasury stock method and the dilutive effects of convertible notes payable and convertible preferred stock using the if-converted method. On Basic and diluted earnings per share for the three and nine months ended May 31, 2015 and 2014 are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">For the Nine Months Ended</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net gain (loss) attributable to common shareholders</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Continuing operations</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(525,438</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(238,952</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,494,096</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,152,393</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Discontinued operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">95,528</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(525,438</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(238,952</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,494,096</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,056,865</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">242,589,170</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">112,247,396</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">187,353,653</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">93,925,094</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss per common shares, basis and diluted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Continuing operations</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Discontinued operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.00</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.00</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the net losses during the three and nine months ended May 31, 2015 and 2014, basic and diluted loss per share was the same, as the effect of potentially dilutive securities would have been anti-dilutive. Shares attributable to convertible notes, stock options, preferred stock and warrants not included the diluted loss per share calculation. Below lists all dilutive securities as of May 31, 2015 and 2014:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <table border="0" cellpadding="0" cellspacing="0" style="width: 75%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">As of</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 4%">&#160;</td> <td style="width: 5%">&#160;</td> <td style="width: 5%">&#160;</td> <td style="width: 5%">&#160;</td> <td style="width: 5%">&#160;</td> <td style="width: 30%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 21%">May 31,</td> <td style="font-weight: bold; text-align: center; width: 2%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 21%">May 31,</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">2015</td> <td style="font-weight: bold; text-decoration: underline; text-align: center"><u></u></td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">2014</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; text-decoration: underline"><u></u></td> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; text-align: center">&#160;Underlying&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;Underlying&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="6" style="font-weight: bold; text-decoration: underline; text-align: center">Description</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">&#160;Common Shares&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">&#160;Common Shares&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="6">Convertible preferred stock</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;78,564,000</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;22,500,000</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="6">Convertible notes payable</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;210,272,886</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;81,383,460</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="6">Options</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,173,750</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,186,250</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="6">Warrants</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;21,000,000</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;26,583,333</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="6">Total potentially dilutive securities</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;316,010,636</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;136,653,043</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RECENT ACCOUNTING PRONOUNCEMENTS</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">New Accounting Standard</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2012, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update 2012-02 &#147;Intangibles &#150; Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment&#148; (&#147;ASU 2012-02&#148;). ASU 2012-02 permits entities to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. Under the amendments in ASU 2012-02, an entity is not required to calculate the fair value of an indefinite-lived intangible asset unless it determines that it is more likely than not that the fair value of the asset is less than its carrying amount. An entity also will have the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. ASU 2012-02 is effective for interim and annual indefinite-lived intangible asset impairment tests performed for fiscal years beginning on or after September 15, 2012, with early adoption permitted. The Company&#146;s adoption of ASU 2012-02 is not expected to have an impact on its consolidated financial statements.</p> <p style="margin: 0pt">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">For the Nine Months Ended</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net gain (loss) attributable to common shareholders</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">Continuing operations</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(525,438</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(238,952</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,494,096</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,152,393</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Discontinued operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">95,528</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(525,438</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(238,952</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,494,096</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,056,865</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">242,589,170</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">112,247,396</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">187,353,653</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">93,925,094</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss per common shares, basis and diluted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Continuing operations</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Discontinued operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.00</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.00</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.01</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <table border="0" cellpadding="0" cellspacing="0" style="width: 75%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">As of</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 4%">&#160;</td> <td style="width: 5%">&#160;</td> <td style="width: 5%">&#160;</td> <td style="width: 5%">&#160;</td> <td style="width: 5%">&#160;</td> <td style="width: 30%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 21%">May 31,</td> <td style="font-weight: bold; text-align: center; width: 2%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 21%">May 31,</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">2015</td> <td style="font-weight: bold; text-decoration: underline; text-align: center"><u></u></td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">2014</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; text-decoration: underline"><u></u></td> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; text-align: center">&#160;Underlying&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;Underlying&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="6" style="font-weight: bold; text-decoration: underline; text-align: center">Description</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">&#160;Common Shares&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">&#160;Common Shares&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="6">Convertible preferred stock</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;78,564,000</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;22,500,000</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="6">Convertible notes payable</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;210,272,886</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;81,383,460</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="6">Options</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,173,750</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,186,250</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="6">Warrants</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;21,000,000</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;26,583,333</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="6">Total potentially dilutive securities</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;316,010,636</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;136,653,043</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">August 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Furniture</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">14,118</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">12,688</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office Equipment</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">13,625</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,962</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Computers</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">24,409</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">22,321</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Software</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,497</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,497</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Equipment</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,623</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,763</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total property and equipment at cost</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">73,272</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">68,231</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(38,026</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(28,264</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,246</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">39,967</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><b>NOTE 4 &#150; ACQUISITIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><u>Amian Health Services</u></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 10, 2013, our subsidiary Angels of Mercy acquired the assets of Amian Health Services. Pursuant to the Agreement, the Owners sold all the assets for $100,000 represented by a down payment of $75,000 at closing and a one year Secured Promissory Note for $25,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The acquisition was accounted for using the acquisition method of accounting and the purchase price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values at the date of acquisition. Identifiable intangible assets include patents and purchased goodwill.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The purchase price was allocated to assets acquired and liabilities assumed as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash and cash equivalents</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">8,646</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Purchased goodwill</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">85,354</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total assets acquired</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">100,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 25, 2014, we acquired all the outstanding shares of Esteemcare Inc. and its wholly owned subsidiary, Affordable Medical Equipment Solutions Inc. in exchange for a $400,000 down payment, $100,000 note and payoff of $173,433 in operating leases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The acquisition was accounted for using the acquisition method of accounting and the purchase price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values at the date of acquisition. Identifiable intangible assets include patents and purchased goodwill.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The purchase price was allocated to assets acquired and liabilities assumed as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash and cash equivalents</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">12,449</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable (net)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">573,130</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Inventory</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">106,165</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">860</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,008</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deposits and other assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,551</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Purchased goodwill</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">622,610</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total assets acquired</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,328,773</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable and other accrued expenses</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">454,877</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Inventory financing agreements</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">125,463</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Notes payable</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">75,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total liabilities assumed</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">655,340</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash and cash equivalents</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">8,646</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Purchased goodwill</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">85,354</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total assets acquired</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">100,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Cash and cash equivalents</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">12,449</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts receivable (net)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">573,130</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Inventory</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">106,165</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">860</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,008</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deposits and other assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,551</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Purchased goodwill</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">622,610</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total assets acquired</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,328,773</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable and other accrued expenses</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">454,877</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Inventory financing agreements</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">125,463</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Notes payable</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">75,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total liabilities assumed</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">655,340</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><b>NOTE 5 &#150; DISCONTINUED OPERATIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During October 2013 the Company&#146;s management and Board of Directors determined to dispose of Oncologix Corporation its Brachytherapy medical device subsidiary. On November 1, 2013, the company entered into a settlement agreement with Firetag, Stoss &#38; Dowdell, PC., our former attorneys. Per the terms of the settlement agreement, we exchanged our 90% ownership and executed a $50,000 promissory note payable to Firetag in exchange for the forgiveness by Firetag of $145,522 in prior legal billings. The promissory note bears interest at 4% and requires 12 monthly payments of $4,257.49 beginning on December 1, 2013. Detailed below are the income and expenses related to these discontinued operations:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">For the Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">General and administrative</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">36</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income (expense):</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Loss from discontinued operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(36</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Gain on disposal of discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">95,564</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt">Loss from discontinued operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">95,528</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Less loss attributable to noncontrolling interest</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">95,528</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">For the Three Months Ended</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">For the Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-left: 10pt">General and administrative</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">36</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(36</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income (expense):</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Loss from discontinued operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(36</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Gain on disposal of discontinued operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">95,564</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt">Loss from discontinued operations</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">95,528</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt">Less loss attributable to noncontrolling interest</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss from discontinued operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">95,528</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 &#150; INVENTORY FINANCE AGREEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our inventory finance agreements consist of qualified for-sale inventory purchases. These finance agreements are held solely by Esteemcare. Qualifying inventory purchases are grouped into a 12 month finance agreements allowing the company to spread the payments for this inventory over a twelve month period. This allows the company to collect payments for the purchases of that inventory over that time period as most insurance plans spread the purchase payments over a multi-month period, generally 10 to 13 months. All inventory finance agreements are interest free and consist of only minor fees for setup. Below is a listing of our outstanding inventory finance agreements as of May 31, 2015 and 2014 as well as the monthly payment on each agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">As of May 31,</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Monthly Payment</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Wells Fargo (017)</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">8,331</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,165</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>VGM (322)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">23,787</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,947</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Wells Fargo (018)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">24,694</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,174</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>VGM (323)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">32,106</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,351</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>DLL (61942)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">90,781</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,348</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>DLL (67910)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,389</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,488</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>VGM (324)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">32,512</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,612</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>DLL (68936)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,263</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,126</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Wells Fargo (019)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">76,459</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,951</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>VGM (325)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">85,680</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,140</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>DLL (61649)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,126</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding leases</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">417,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">56,428</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 &#150; INVENTORY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have inventory, on hand in the amounts of $137,436 and $31,271 as of May 31, 2015 and 2014, respectively. Our inventory as of May 31, 2015 relates to our medical device manufacturing segment. Inventories at May 31, 2015 also included $106,165 related to our medical products and technologies division. Our inventory in our medical device segment consists primarily of miscellaneous parts. Our inventory in our medical products and technologies segment consists primarily of disposable products such as masks, oxygen tubing, and other breathing equipment supplies. We also hold minor amounts of CPAP machines and BiPAP machines. Our machine purchases are generally set up on a Just-in-time order system. We do not maintain any inventory for our personal service care segment or our medical products division. We are currently in the redesign and final bench testing phase of our Toxygen hardware system and disposable products. The new hardware design will position Dotolo Research with a unique technological advantage in the medical markets.. Currently, inventory on hand is made up of miscellaneous Toxygen hardware parts, custom tooling and molds.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 - PROPERTY AND EQUIPMENT</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">Property and equipment is composed of the following at May 31, 2015 and August 31, 2014 </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">August 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Furniture</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">14,118</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">12,688</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Office Equipment</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">13,625</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,962</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Computers</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">24,409</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">22,321</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Software</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,497</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,497</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Leasehold improvements</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Equipment</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,623</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16,763</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total property and equipment at cost</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">73,272</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">68,231</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(38,026</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(28,264</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,246</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">39,967</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr></table> <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 72%; padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Furniture and fixtures</font></td> <td style="width: 28%; padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">5 to 10 years</font></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Computer equipment</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">5 years</font></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Equipment</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">5 to 10 years</font></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">Software</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">3 to 5 years</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>NOTE 8 &#150; OFFICE LEASES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company leases office space in Alexandria and Lafayette Louisiana and in West Columbia and Charleston SC. Alexandria is on a three year lease; Lafayette a five year lease; West Columbia has one year remaining on its lease; and Charleston is on a three year lease. On March 28, 2014, Dotolo Research moved from its current manufacturing location in Phoenix AZ into E&#38;R Engineer manufacturing facilities located in Tempe, AZ. Rent expense for the three months ended May 31, 2015 and 2014 were $36,527 and $19,178, respectively.&#160;Rent expense for the nine months ended May 31, 2015 and 2014 were $112,055 and $64,680, respectively. Following are the minimum lease payments:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"></p> <table border="0" cellpadding="0" cellspacing="0" style="width: 30%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%">&#160;</td> <td style="width: 52%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2015</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33,495</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2016</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;126,424</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2017</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;114,808</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2018</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;42,448</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Totals</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;317,175</td></tr></table> <p style="margin: 0pt">&#160;</p> <table border="0" cellpadding="0" cellspacing="0" style="width: 30%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%">&#160;</td> <td style="width: 52%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2015</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;33,495</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2016</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;126,424</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2017</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;114,808</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2018</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;42,448</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Totals</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;317,175</td></tr></table> <p style="margin: 0pt"></p> 33495 126424 114808 42448 317175 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 9 &#150; GOODWILL, PATENTS AND OTHER INTANGIBLE ASSETS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We currently carry our patents and registrations net of amortization. As of May 31, 2015 and 2014, the Company has a capitalized cost of patents and registrations in the amount of $122,479 and accumulated amortization of 101,045. Our patents and registrations are amortized over a 20 year period. Amortization for each of the next 4 fiscal years, assuming no impairment, will be $6,124 per year.</p> <p style="margin: 0pt">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center">As of May 31,</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Monthly Payment</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Wells Fargo (017)</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">8,331</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,165</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>VGM (322)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">23,787</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,947</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Wells Fargo (018)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">24,694</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,174</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>VGM (323)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">32,106</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,351</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>DLL (61942)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">90,781</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,348</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>DLL (67910)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,389</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,488</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>VGM (324)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">32,512</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,612</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>DLL (68936)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,263</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,126</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Wells Fargo (019)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">76,459</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,951</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>VGM (325)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">85,680</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,140</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>DLL (61649)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,126</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding leases</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">417,001</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">56,428</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 11 &#151; NOTES PAYABLE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CONVERTIBLE NOTES PAYABLE:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Convertible notes payable consist of the following as of May 31, 2015 and 2014:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following is a summary of future minimum payments on convertible notes payable as of May 31, 2015:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: center; vertical-align: middle">Ref.</td><td>&#160;</td> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: middle">Numb.</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left; vertical-align: middle">&#160;</td><td style="width: 8%; text-align: left; vertical-align: middle">2210</td><td style="width: 1%; text-align: left; vertical-align: middle">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 50%; text-align: left">Conv. Note Payable (net of discount)</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">64,025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">235,025</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2218</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2232</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(567</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2238</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">5,300</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2239</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">7,260</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2247</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">4,918</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2250</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">68,429</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2261</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">8,100</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2265</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">12,370</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2267</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">24,897</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2271</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">16,911</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2274</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">11,123</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2276</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">17,161</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2278</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">56,910</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2281</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">13,095</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2290</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">31,918</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2292</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">18,885</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2294</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">15,579</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2297</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">17,680</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2310</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">15,650</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2312</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1,813</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2314</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">20,592</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2316</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">30,887</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2322</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: middle">&#160;</td><td style="padding-bottom: 1pt; text-align: left; vertical-align: middle">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>Subtotal</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">477,596</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">420,365</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td colspan="4" style="text-align: left; vertical-align: middle">Less:&#160;&#160;Long-Term portion</td><td style="text-align: right">&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">&#160;&#151;&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"></td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">(235,025</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle">&#160;</td><td colspan="3" style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle">Current portion</td> <td style="text-align: left"></td><td style="text-align: right"></td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right">477,596</td> <td style="text-align: left"></td><td style="text-align: right"></td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right">185,340</td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following is a summary of future minimum payments on convertible notes payable as of May 31, 2015:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: left; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle"><font style="font-size: 10pt; line-height: 93%"><b>Convertible</b></font></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; vertical-align: middle"><font style="font-size: 10pt; line-height: 93%"><b><u>Fiscal Year Ending August 31,</u></b></font></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle"><font style="font-size: 10pt; line-height: 93%"><b><u>Notes Payable</u></b></font></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 43%; text-align: left; vertical-align: middle">2015</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 43%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">2016</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">477,596</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2210 - </b>On April 1, 2009, we issued to Ms. Lindstrom, our former Chief Executive Officer, a convertible promissory note in lieu of payment of $235,025 in accrued salary owed to Ms. Lindstrom. This note accrues interest at a rate of 6% per annum and was originally due on March 31, 2012. On March 16, 2012, Ms. Lindstrom agreed to extend the due date of the note to September 30, 2013. There was no beneficial conversion feature recognized upon the issuance of this note. An outside party has entered into an assignment and settlement agreement with Ms. Lindstrom to purchase the note. The note assignment is currently in default. During fiscal 2014, the Assignee has converted $46,000 of principal into 8,788,171 shares of stock reducing the current balance of the note to $189,025. During fiscal 2015, the Holder assigned $125,000 of principal to another accredited investor. As of May 31, 2015, the Company has an outstanding principal balance of $64,025 and an accrued interest in the amount of $82,833.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2218 - </b>During May and June 2007, we issued nine Convertible Promissory Notes in an aggregate principal amount of $700,000. Eight of these notes we-+re converted into common stock in fiscal 2009. The remaining Convertible Promissory Note, in the principal amount of $125,000, was extended on January 28, 2010 initially to March 31, 2012, where the conversion rate was reduced to $.60, and then extended to September 30, 2013. In October 2013 and November 2014, the investor sold two $25,000 positions of principal in the note to another accredited investor. In May 2015, the investor sold the remaining $75,000 of principal in the note to another accredited investor. The note has been extended to December 31, 2015 and we are negotiating the final payment of accrued interest. As of May 31, 2015, the Company has accrued interest in the amount of $65,469.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2232 - </b>On October 2, 2013 we issued a convertible promissory note in the principal amount of $25,000. This promissory note bore interest at a rate of 8% per annum and is due on October 2, 2013. The note was convertible at a 45% discount of the average of the three lowest closing bid prices in the twenty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $25,000. On April 6, 2014 the holder elected to convert $17,074 in principal plus $690 in accrued interest into 5,383,007 shares of common stock at a conversion price of $.0033. In August 1, 2014 the remaining principal of $7,926 plus accrued interest of $530 was converted into 3,416,764 shares of common stock at a conversion rate of $.002475.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2238 - </b>On March 19, 2014 we issued a convertible promissory note in the principal amount of $26,500 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on March 19, 2015. The note was convertible at a 38% discount of the lowest closing bid prices in the thirty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $26,500. During fiscal 2015, the investor converted $26,500 of principal plus accrued interest of $1,384 into 16,801,705 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2239 - </b>On April 8, 2014 we issued a convertible promissory note in the principal amount of $50,000 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on April 8, 2015. The note is convertible at a 35% discount of the average 4 lowest closing bid prices in the twenty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $50,000. This note was paid in full on October 2, 2014.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2247 - </b>On April 25, 2014 we issued a convertible promissory note in the principal amount of $25,000 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on October 25, 2015. The note is convertible at a 35% discount of the average 4 lowest closing bid prices in the thirty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $25,000. During October and November 2014, the entire principal amount of $25,000 was converted into 8,284,469 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2250 -</b>On May 21, 2014 we issued a convertible promissory note in the principal amount of $115,000 to an unrelated accredited investor. This promissory note bore interest at a rate of 10% per annum. This principal includes a 10% OID in the amount of $10,000, which is being amortized over the term of the note. The note is due in 4 equal installments beginning on the 180<sup>th</sup> day after the execution of the note. The company may make the payments in common stock. The note is convertible at a $.009 per share. As additional consideration, the Company issued 9,583,333 5 year warrants with an exercise price of $.009. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $38,322 related to the issuance of the warrants. This note was paid in full on February 23, 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2253 - </b>On July 16, 2014 we issued a convertible promissory note in the principal amount of $26,500 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on July 26, 2015. The note is convertible at a 38% discount of the lowest closing bid prices in the thirty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $26,500. During the second quarter of fiscal 2015, the company converted $26,500 in principal plus $1,134 of accrued interest into 18,571,550 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2259 -</b>On November 17, 2014, the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $25,000 of the current convertible note holder note. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 30% discount into shares of the Company&#146;s common stock using a five-day average of the lowest closing stock prices immediately preceding the conversion date. The Company recorded a beneficial conversion feature of $10,545. During fiscal 2015, the investor converted the $25,000 in principal plus $85 in accrued interest into 9,641,872 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2261 -</b>On November 17, 2014 we issued a convertible promissory note in the principal amount of $25,000. This promissory note bears interest at a rate of 8% per annum and is due on October 2, 2013. The note is convertible at a 30% discount of the average of the five closing stock prices immediately preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $10,545. During fiscal 2015 the investor converted $11,989 of principal and $1,011 of interest into 6,211,180 shares of common stock. As of May 31, 2015 the company has accrued interest of $7.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2265 -</b>On January 22, 2015 we issued a convertible promissory note in the principal amount of $35,000. This promissory note bears interest at a rate of 8% per annum and is due on January 22, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $35,000. As of May 31, 2015 the company has accrued interest of $1,003.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2267 - </b>On January 30, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 12% per annum and is due on September 30, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $50,000. As of May 31, 2015 the company has accrued interest of $1,989.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2269 - </b>On February 5, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $50,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. The Company recorded a beneficial conversion feature of $50,000. During the second and third quarters of fiscal 2015, the investor converted the $50,198 in principal and interest into 16,669,092 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2274 - </b>On February 4, 2015 we issued a convertible promissory note in the principal amount of $35,000. This promissory note bears interest at a rate of 8% per annum and is due on February 4, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $35,000. As of May 31, 2015 the company has accrued interest of $1,128.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2271 - </b>On February 12, 2015 we issued a convertible promissory note in the principal amount of $75,000. This promissory note bears interest at a rate of 10% per annum and is due on February 12, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $75,000. As of May 31, 2015 the company has accrued interest of $2,250.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2281 - </b>On February 25, 2015 we issued a convertible promissory note in the principal amount of $30,000. This promissory note bears interest at a rate of 12% per annum and is due on October 25, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $30,000. As of May 31, 2015 the company has accrued interest of $937.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2276 - </b>On March 5, 2015 we issued a convertible promissory note in the principal amount of $36,750. This promissory note bears interest at a rate of 8% per annum and is due on March 5, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $711.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2283 - </b>On March 9, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $30,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. During the third quarter of fiscal 2015, the investor converted $30,096 of principal and interest into 9,180,298 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2278 - </b>On March 11, 2015 we issued a convertible promissory note in the principal amount of $88,000. This promissory note bears interest at a rate of 12% per annum and is due on September 11, 2015. The note is convertible at a 38% discount of the lowest closing price immediately during the 20 days preceding the date of conversion. The Company also paid an OID in the amount of $6,000. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $2,376.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2290 - </b>On March 25, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 10% per annum and is due on September 25, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $931.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2292 - </b>On March 30, 2015 we issued a convertible promissory note in the principal amount of $32,000. This promissory note bears interest at a rate of 8% per annum and is due on March 30, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $441.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2294 - </b>On April 7, 2015 we issued a convertible promissory note in the principal amount of $27,500. This promissory note bears interest at a rate of 12% per annum and is due on April 7, 2017. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. The Company also paid an OID in the amount of $6,000. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $330.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2297 - </b>On April 8, 2015 we issued a convertible promissory note in the principal amount of $58,000. The company received net proceeds of $50,000 with the balance of the note going for finders fees and processing fees. This promissory note bears interest at a rate of 8% per annum and is due on April 8, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $683.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2310 - </b>On May 7, 2015 we issued a convertible promissory note in the principal amount of $35,000. This promissory note bears interest at a rate of 12% per annum and is due on October 25, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $21,452. As of May 31, 2015 the company has accrued interest of $280.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2312 - </b>On May 8, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $45,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $29,715. During the third quarter of fiscal 2015, the investor converted $16,261 of principal into 9,400,000 shares of common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2314 - </b>On May 22, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 8% per annum and is due on December 31, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $30,645. As of May 31, 2015 the company has accrued interest of $100.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2316 - </b>On May 22, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $75,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares. We recorded a beneficial conversion feature of $45,968.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2322</b> - On January 2, 2015, The Company issued a $100,000 convertible promissory note in full payment of an outstanding invoice of an accredited investor. The Company issued to the accredited investor a convertible promissory note bearing interest at 4% and convertible at a 35% discount of the average of the last en closing stock prices immediately preceding the date of the conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">CONVERTIBLE RELATED PARTY NOTES PAYABLE:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of May 31, 2015, there are currently no related party convertible notes payable outstanding. The note related to our former CEO is now classified as non-related convertible debt for all comparable periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">RELATED PARTY NOTES PAYABLE:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">6.0% line of credit (2)</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">51,600</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding unsecured related party notes payable</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">51,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(1)&#160;&#160;Note payable to current CEO.</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the last two years, Wayne Erwin, our President and CEO, has advanced a total of $51,600 directly to Dotolo in an open advance account. Interest is being accrued at a rate of 6% per annum. As of May 31, 2015 the Company has repaid $51,600 of principal and $7,393 of accrued interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">OTHER NOTES PAYABLE:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: center; vertical-align: middle">Ref.</td><td>&#160;</td> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: middle">Numb.</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left; vertical-align: middle">&#160;</td><td style="width: 8%; text-align: left; vertical-align: middle">Dot 1</td><td style="width: 1%; text-align: left; vertical-align: middle">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 60%; text-align: left">Note Payable (net of discount)</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">60,600</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">Dot 2</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">Dot 3</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 1</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>Line of Credit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">43,149</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">44,469</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 2</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>Line of Credit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">37,467</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 3</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">130,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 4</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">142,109</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 5</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">68,409</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 6</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">42,080</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 7</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">228,215</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 8</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">67,400</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 9</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14,765</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">EST 1</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">73,552</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2226</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,833</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2227</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,689</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2228</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,844</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2229</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">21,076</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2230</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">68,510</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">70,659</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2231</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,692</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2236</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,533,584</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">275,155</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2237</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,444</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2255</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">22,909</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2257</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">68,920</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2258</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">22,973</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2263</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">56,215</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2264</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2300</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">416,466</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">498,179</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2432</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">25,499</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">78,915</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="padding-bottom: 1pt; text-align: left; vertical-align: middle">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>Subtotal</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,850,348</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,429,829</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td colspan="4" style="text-align: left; vertical-align: middle">Less:&#160;&#160;Long-Term portion</td><td style="text-align: right"></td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"></td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">&#160;(376,037</td> <td style="text-align: left">)</td><td style="text-align: right"></td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"></td> <td style="vertical-align: bottom; text-align: right; border-bottom: Black 1pt solid">&#160;(416,466</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle">&#160;</td><td colspan="3" style="text-align: left; vertical-align: middle">Current portion</td> <td style="text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right"></td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right">2,474,311</td> <td style="text-align: left"></td><td style="text-align: right"></td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double">1,013,363</td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Notes held by Dotolo</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>DOT 1 - </b>During April 2012, our subsidiary Dotolo, entered into a financing agreement to provide up to $150,000 in funding for the subsidiary. The financing agreement was due in January 2013. We entered into a settlement agreement whereby we paid $45,000 from amounts held in reserve by our senior lender and are required to make 10 monthly payments of $1,500. As of May 31, 2015, the current balance is $1,500.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>DOT 2 - </b>On February 27, 2013 our subsidiary Dotolo, entered into a note payable agreement to provide funding to its subsidiary in the principal amount of $30,000. The note bears interest at 18% payable monthly on the 15th and is due in full in January 2016. For the three months ended May 31, 2015, we made interest payments in the amount of $1,350. As of May 31, 2015, we have accrued interest of $1,965.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>DOT 3 - </b>On March 17, 2013 our subsidiary Dotolo, entered into a note payable agreement to provide funding to its subsidiary in the principal amount of $20,000. The note bears interest at 18% payable monthly on the 15th and is due in full in January 2016. For the year ended May 31, 2015, we made interest payments in the amount of $900. As of May 31, 2015, we have accrued interest of $1,090.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Notes held by Amian Angels</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>AA 1 &#150; </b>During fiscal 2014 we borrowed $45,000 from our $50,000 line of open line of credit with our bank. As of May 31, 2015 the outstanding balance of the line of credit loan was $43,149.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>AA 2 &#150; </b>During fiscal 2015 we borrowed $80,000 from our line of open line of credit with another lender. During the third quarter of fiscal 2015 we have repaid $42,533 of principal plus additional interest. As of May 31, 2015 the outstanding balance of the line of credit loan was $37,467.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>AA 3 &#150; </b>On April 18, 2014, the Company obtained a merchant loan for additional working capital in the amount of $120,000. This loan requires 189 daily payments in the amount of $800 for a total repayment amount of $151,200. We netted gross proceeds of $119,301 after paying loan fees. This note was paid in full in December 2014.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>AA 4 &#150; </b>On March 11, 2014, the Company obtained a merchant loan for additional working capital in the amount of $150,000. This loan requires 209 daily payments in the amount of $940 for a total repayment amount of $196,500. We netted gross proceeds of $146,750 after paying loan fees. This note was paid in full in December 2014.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>AA 5 &#150; </b>On May 22, 2015, the Company obtained a merchant loan for additional working capital in the amount of $50,000. This loan requires 132 daily payments in the amount of $530 for a total repayment amount of $70,000. The balance of this loan on May 31, 2015 was $68,409.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>AA 6 &#150; </b>On May 7, 2015, the Company obtained a merchant loan for additional working capital in the amount of $35,000. This loan requires 85 daily payments in the amount of $599 for a total repayment amount of $51,065. The balance of this loan on May 31, 2015 was $42,080.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>AA 7 &#150; </b>On December 15, 2014, the Company obtained a merchant loan for additional working capital in the amount of $300,000. This loan requires 252 daily payments in the amount of $1,607 for a total repayment amount of $405,000. We netted gross proceeds of $163,713 after paying loan fees and paying off our other 4 merchant loans. The balance of this loan on May 31, 2015 was $228,215.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>AA 8 &#150; </b>On April 30, 2015, the Company obtained a merchant loan for additional working capital in the amount of $60,000. This loan requires 87 daily payments in the amount of $999 for a total repayment amount of $87,450. The balance of this loan on May 31, 2015 was $67,400.</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">AA 9 &#150; <font style="font-weight: normal">In connection with the acquisition of Amian Health Services, the Company entered into a twelve month promissory note in the total principal amount of $25,000. The note bears interest at $6% and requires monthly payments of $2,152. This note was paid in full in December 2014.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Notes held by Esteemcare</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">EST 1 -<font style="font-weight: normal"> On September 25, 2014, as part of the terms and conditions of the acquisition of Esteemcare Inc. and Affordable Medical Inventory Solutions Inc., the company issued an 18 month note to Imad Siddiqui in the principal amount of $75,000. This note was executed on May 1, 2015 and requires monthly payments of $4,524. As a result of the delay in execution of the note, the Company accrued $2,688 of interested and added it to the balance of the note. </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Notes held by Oncologix Tech</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2216 - </b>On August 1, 2013, in connection with our acquisition of Angels of Mercy, Inc. we entered into a promissory note to pay $65,000 of broker&#146;s fees incurred in the acquisition. Monthly payments of $5,417 are due and payable beginning on August 15, 2013. This note bears no interest. This was paid in full in July 2014.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2227 &#38; 2228 - </b>On November 5, 2013 and November 8, 2013, the Company entered into two, one-year promissory notes with accredited investors to borrow a total principal amount of $20,000. Each promissory note is $10,000 in principal balance, bore interest at 18% and requires monthly interest payments of $150 each. The company also issued 3,000,000 in cashless warrants as finder&#146;s fees for these funds. The Company recorded a discount of $14,805 for the issuance of the warrants. These notes were paid in full in November 2014.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2229 - </b>On November 1, 2013, the Company entered into a Settlement Agreement with its former legal counsel. The current balance owed to prior counsel is $145,523. Pursuant to the settlement agreement, the Company agreed to pay $50,000 in the form of a one year promissory note and transfer its 90% ownership interest and all marketing rights of Oncologix Corporation, one of its subsidiaries as full settlement of the current balance owed. The promissory note bears interest of 4% and requires monthly payment of $4,257 beginning on December 1, 2013. This note was paid in full during November 2014.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2230 -<font style="font-weight: normal"> On December 3, 2013, The Company entered into a twelve month promissory note with an accredited investor to borrow a total principal amount of $75,000. The note bears interest of 18% per annum and calls for monthly payments of principal and interest of $1,375 beginning on January 15, 2014 with a balloon payment due December 15, 2014. The Company also issued as additional finders&#146; fees to the investor, 3,500,000 shares of common stock and 1,000,000 cashless warrants with an exercise price of $.025. As of May 31, 2015, the balance was $68,510. The Company recorded a discount of $5,992 for the issuance of the warrants.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2231 - </b>On December 20, 2013, the Company issued a 1-year promissory note to a non-related accredited investor in the principal amount of $12,000. This note bears interest at 10% per annum and matures in December 2014. This note was extended to June 2015. As additional consideration for the operating capital loan, the company issued 3,000,000 cashless two-year warrants with an exercise price of $0.02. The Company recorded a discount of $7,746 for the issuance of the warrants. As of May 31, 2015 the Company has accrued interest of $1,437.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2236 - </b>On January 3, 2014, the Company closed on a 4 million dollar line of credit facility, with an initial draw of $500,000. The Company must meet specific monthly reporting and collateral requirements to further draw on the revolving credit facility. The $500,000 initial draw is secured by a 14.5% promissory note, which is convertible ONLY upon default by the Company. In July 2014, we borrowed an additional $75,000 from the principal we repaid. This note is due in nine months with an automatic option to renew after nine months. On September 25, 2014, the Company took down a second draw from its $4 million dollar line of credit facility in the amount of $1,200,000. The Company must meet specific monthly reporting and collateral requirements to further draw on the revolving credit facility. The outstanding balance at the time of the draw was $1,533,584 which is secured by twelve month 14.5% promissory note, which is convertible ONLY upon default by the Company. This note is automatically renewable for an additional twelve months. The company is required to pay interest and fees only for the initial 3 months. The balance of this note on May 31, 2015 is $1,533,584.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2237 - </b>On February 7, 2014, the Company issued a 1-year promissory note in the principal amount of $15,000 to a non-related accredited investor. This note bears interest at 6% per annum and matures in February 2015. As additional consideration for the operating capital loan, the company issued 1,500,000 two-year warrants with an exercise price of $0.15 and 1,000,000 shares of common stock. The Company recorded an expense of $9,000 for the issuance of the common stock. The Company recorded a discount of $5,151 for the issuance of the warrants. On August 1, 2014 this investor used $10,000 to purchase 1,200,000 shares of common stock. This note was paid in February 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2255 - </b>On August 15, 2014 the Company issued a 1-year promissory note to a non-related accredited investor in the principal amount of $25,000. This note bears interest at 10% per annum and matures in August 2015. As additional consideration for the operating capital loan, the company issued 4,000,000 cashless two-year warrants with an exercise price of $0.065. The Company recorded a discount of $10,177 for the issuance of the warrants. As of May 31, 2015 the Company has accrued interest of $1,993.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2257 &#38; 2258 - </b>On September 25, 2014, the Company issued a $75,000 and $25,000 1-year promissory notes bearing interest at 6% in connection with the acquisition of Esteemcare Inc. and Affordable Medical Inventory Solutions Inc. As of May 31, 2015, the outstanding balances of these notes were $68,920 and $22,973, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2263 - </b>On November 16, 2014, the Company borrowed $60,000 in principal from an unrelated investor. This note bears interest at a rate of 12% and calls for 60 monthly payments of $1,334.67 beginning on January 19, 2015. The note matures on January 19, 2019. As of May 31, 2015, the outstanding balance of this note was 56,217.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2264 - </b>On December 16, 2014, the Company borrowed $48,000 in principal from an unrelated investor. This note bears calls for two interest payments, each in the amount of $8,500 in January and February 2015. The note matures on March 16, 2015. As of May 31, 2015, the outstanding balance of this note was 11,500.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2300 - </b>On August 1, 2013, in connection with our acquisition of Angels of Mercy, Inc. we entered into a promissory note to pay $550,000 for the purchase of Angels of Mercy, Inc. Monthly payments of $9,115 are due and payable beginning on November 1, 2013 with a final balloon payment of $205,705 due on October 1, 2017. This note bears interest at a rate of 6%. As of May 31, 2015, the outstanding balance of the note is $416,466.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2432 - </b>On July 26, 2013 the Company issued an 18 month promissory note in the principal amount of $100,000. These funds were used for the cash down payment for the Angels acquisition. The note bears interest at 18% and requires monthly interest payments of $1,200 beginning on September 26, 2013. In December 2013, we modified the loan agreement to make monthly payments of $6,200. As of May 31, 2015 the outstanding balance was $25,499.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of future minimum payments on r notes payable as of May 31, 2015:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#9;</p> <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 63%; padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%"><b>&#160;</b></font></td> <td style="width: 9%">&#160;</td> <td style="width: 28%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: center"><font style="font-size: 10pt; line-height: 93%"><b>Related Conv.</b></font></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-decoration: underline; border-bottom: Black 1pt solid"><font style="font-size: 10pt; line-height: 93%"><b style="text-decoration: none">Fiscal Year Ending August 31,</b></font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-decoration: underline; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt; line-height: 93%"><b><u style="text-decoration: none">Notes Payable</u></b></font></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">2015</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;2,394,130</font></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">2016</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;97,813</font></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">2017</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;326,226</font></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">2018</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;14,580</font></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">2019</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;17,599</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="margin: 0pt">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: center; vertical-align: middle">Ref.</td><td>&#160;</td> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: middle">Numb.</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left; vertical-align: middle">&#160;</td><td style="width: 8%; text-align: left; vertical-align: middle">2210</td><td style="width: 1%; text-align: left; vertical-align: middle">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 50%; text-align: left">Conv. Note Payable (net of discount)</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">64,025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">235,025</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2218</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2232</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">(567</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2238</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">5,300</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2239</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">7,260</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2247</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">4,918</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2250</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">68,429</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2261</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">8,100</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2265</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">12,370</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2267</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">24,897</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2271</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">16,911</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2274</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">11,123</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2276</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">17,161</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2278</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">56,910</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2281</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">13,095</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2290</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">31,918</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2292</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">18,885</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2294</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">15,579</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2297</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">17,680</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2310</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">15,650</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2312</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1,813</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2314</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">20,592</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2316</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">30,887</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2322</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Conv. Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: middle">&#160;</td><td style="padding-bottom: 1pt; text-align: left; vertical-align: middle">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>Subtotal</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">477,596</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">420,365</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td colspan="4" style="text-align: left; vertical-align: middle">Less:&#160;&#160;Long-Term portion</td><td style="text-align: right">&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">&#160;&#151;&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"></td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">(235,025</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle">&#160;</td><td colspan="3" style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle">Current portion</td> <td style="text-align: left"></td><td style="text-align: right"></td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right">477,596</td> <td style="text-align: left"></td><td style="text-align: right"></td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right">185,340</td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: left; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle"><font style="font-size: 10pt; line-height: 93%"><b>Convertible</b></font></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left; vertical-align: middle"><font style="font-size: 10pt; line-height: 93%"><b><u>Fiscal Year Ending August 31,</u></b></font></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle"><font style="font-size: 10pt; line-height: 93%"><b><u>Notes Payable</u></b></font></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 43%; text-align: left; vertical-align: middle">2015</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 43%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">2016</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">477,596</td><td style="text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">6.0% line of credit (2)</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">51,600</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding unsecured related party notes payable</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">51,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">(1)&#160;&#160;Note payable to current CEO.</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: center; vertical-align: middle">Ref.</td><td>&#160;</td> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">May 31,</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; vertical-align: middle">Numb.</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left; vertical-align: middle">&#160;</td><td style="width: 8%; text-align: left; vertical-align: middle">Dot 1</td><td style="width: 1%; text-align: left; vertical-align: middle">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 60%; text-align: left">Note Payable (net of discount)</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">60,600</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">Dot 2</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">Dot 3</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 1</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>Line of Credit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">43,149</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">44,469</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 2</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>Line of Credit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">37,467</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 3</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">130,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 4</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">142,109</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 5</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">68,409</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 6</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">42,080</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 7</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">228,215</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 8</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Merchant Loan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">67,400</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">AA 9</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14,765</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">EST 1</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">73,552</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2226</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,833</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2227</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,689</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2228</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,844</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2229</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">21,076</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2230</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">68,510</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">70,659</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2231</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">7,692</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2236</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,533,584</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">275,155</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2237</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,444</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2255</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">22,909</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2257</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">68,920</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2258</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">22,973</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2263</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">56,215</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2264</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2300</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">416,466</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">498,179</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">2432</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td style="text-align: left">Note Payable (net of discount)</td><td>&#160;</td> <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">25,499</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">78,915</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="padding-bottom: 1pt; text-align: left; vertical-align: middle">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>Subtotal</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,850,348</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,429,829</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">&#160;</td><td colspan="4" style="text-align: left; vertical-align: middle">Less:&#160;&#160;Long-Term portion</td><td style="text-align: right"></td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"></td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right">&#160;(376,037</td> <td style="text-align: left">)</td><td style="text-align: right"></td><td style="padding-bottom: 1pt; text-align: left; border-bottom: Black 1pt solid"></td> <td style="vertical-align: bottom; text-align: right; border-bottom: Black 1pt solid">&#160;(416,466</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td>&#160;</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left; vertical-align: middle">&#160;</td><td colspan="3" style="text-align: left; vertical-align: middle">Current portion</td> <td style="text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right"></td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right">2,474,311</td> <td style="text-align: left"></td><td style="text-align: right"></td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double">1,013,363</td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <table cellspacing="0" cellpadding="0" align="center" style="width: 65%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 63%; padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%"><b>&#160;</b></font></td> <td style="width: 9%">&#160;</td> <td style="width: 28%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: center"><font style="font-size: 10pt; line-height: 93%"><b>Related Conv.</b></font></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-decoration: underline; border-bottom: Black 1pt solid"><font style="font-size: 10pt; line-height: 93%"><b style="text-decoration: none">Fiscal Year Ending August 31,</b></font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-decoration: underline; text-align: center; border-bottom: Black 1pt solid"><font style="font-size: 10pt; line-height: 93%"><b><u style="text-decoration: none">Notes Payable</u></b></font></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">2015</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;2,394,130</font></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">2016</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;97,813</font></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">2017</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;326,226</font></td></tr> <tr style="vertical-align: top; background-color: White"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">2018</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;14,580</font></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">2019</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;17,599</font></td></tr> </table> <p style="margin: 0pt"></p> 1013363 2474311 <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: left">NOTE 12 &#151; STOCKHOLDERS EQUITY</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PREFERRED STOCK:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Series A Convertible Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is authorized to issue up to 10,000,000 shares of preferred stock, in one or more series, and to determine the price, rights, preferences and privileges of the shares of each such series without any further vote or action by the stockholders. The rights of the holders of common stock will be subject to, and may be adversely affected by, the rights of the holders of any shares of preferred stock that may be issued in the future.&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2003, our Board of Directors authorized up to 4,500,000 shares of Series A Convertible Preferred Stock.&#160;&#160;Each share of Series A Convertible Preferred stock has a par value of $0.001 and is convertible into one-half share of common stock in upon a cash payment by the holder to the Company of $0.40 per common share.&#160;&#160;The Series A Convertible Preferred Stock is entitled to receive, in preference to the common stock, of noncumulative dividends, if declared by the Board of Directors, and a claim on the Company's assets upon any liquidation of the Company senior to the common stock.&#160;&#160;These preferred shares are not entitled to voting rights. There are presently outstanding 129,062 shares of Series A Preferred Stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">On March 30, 2003, the Company completed the private placement of Units pursuant to the terms of a Unit Purchase Agreement (the &#147;Units&#148;) with accredited investors. Each Unit consists of the following underlying securities: (i) three shares of the Company&#146;s common stock; (ii) one share of Series A Convertible Preferred Stock, par value $.001 per share; and (iii) one three-year warrant to purchase one share of common stock at a per share price of $0.30. The warrants expired on March 31, 2006. Each share of Series A Convertible Preferred Stock is convertible into one half share of the Company&#146;s common stock in exchange for $0.40 per common share ($.20 for each Series A Convertible Preferred share converted). The securities underlying the Units are not to be separately tradable or transferable apart from the Units until such time as determined by the Company&#146;s Board of Directors. A total of 4,032,743 Units were issued. As of August 31, 2014 and August 31, 2013, there were 129,062 and 129,062 Units outstanding that had not been separated, respectively. These units are presented as their underlying securities on our balance sheet and consist of 64,531 shares of Series A Preferred Stock and 96,797 shares of common stock which is included in the issued and outstanding shares.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font>&#160;<font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">Below is a table detailing the outstanding Series A Convertible Preferred Stock shares outstanding during the last two fiscal years:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Preferred</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Number of&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Weighted Avg.</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Shares</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Common Shares</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Proceeds if</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Per Common Sh.</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">Convertible</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">Converted</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: left; vertical-align: middle">Outstanding, August 31, 2013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">129,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">64,531</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">25,812</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">0.40</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Expired/Retired</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Converted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.40</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: middle">Issued</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left; vertical-align: middle">Outstanding, August 31, 2014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,062</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">64,531</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,812</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Expired/Retired</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.40</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Converted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: middle">Issued</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left; vertical-align: middle">Outstanding, May 31, 2015</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,062</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">64,531</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,812</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal"></font></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><font style="font-weight: normal">Series D Convertible Preferred Stock</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">In March 2013, our Board of Directors authorized up to 60,000 shares of Series D Convertible Preferred Stock. Each share of Series D Convertible stock has a par value of $0.001 and is convertible into 1,000 shares of common stock beginning after March 1, 2014. Each share of Series D Convertible Preferred Stock has a stated liquidation value of $80.25. Each shares of Series D Convertible Preferred Stock shall have voting rights as stated below:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">March 1, 2013 to May 31, 2014, 400 votes per share;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">March 1, 2014 to May 31, 2015, 800 votes per share;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">March 1, 2015 to May 31, 2016, 1,200 votes per share;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">March 1, 2016 to May 31, 2017, 1,600 votes per share;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">March 1, 2017 and after, 2,000 votes per share;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">On March 22, 2013, the Company issued 58,564 shares of Series D Convertible Preferred Stock to acquire 100% of the outstanding common stock of Dotolo. On March 22, 2013 the issued shares had a fair market value of $585,640 based on the fair market value of the underlying common stock shares.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">On January 3, 2014, as payment for $150,000 of banking fees associated with our $4 million line of credit, we issued 20,000 shares of Series D Convertible Preferred Stock.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">Below is a table detailing the outstanding Series D Convertible Preferred Stock shares outstanding during the last two fiscal years:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr> <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Preferred</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Number of&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Weighted Avg.</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td></tr> <tr> <td style="text-align: center; vertical-align: bottom">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Shares</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Common Shares</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Proceeds if</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">Per Common Sh.</td><td style="font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td></tr> <tr> <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: middle">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">Convertible</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">Converted</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: bottom">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: left; vertical-align: middle">Outstanding, August 31, 2013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">58,564</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">58,564,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">80.25</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Expired/Retired</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Converted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: middle">Issued</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">80.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left; vertical-align: middle">Outstanding, August 31, 2014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,564,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Expired/Retired</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Converted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: middle">Issued</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left; vertical-align: middle">Outstanding, May 31, 2015</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,564,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">80.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><font style="font-weight: normal">&#160;</font></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">SUBSCRIBED COMMON STOCK:</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">Below is a table detailing the Common Stock Subscribed during the last two fiscal years:</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table border="0" cellpadding="0" cellspacing="0" style="width: 85%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td colspan="11" style="font-weight: bold; text-align: center">For the period Ended May 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 3%">&#160;</td> <td style="width: 4%">&#160;</td> <td style="width: 4%">&#160;</td> <td style="width: 4%">&#160;</td> <td style="width: 4%">&#160;</td> <td style="width: 4%">&#160;</td> <td style="width: 42%">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 15%">Shares</td> <td style="font-weight: bold; text-align: center; width: 4%">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 15%">Amount</td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="7">Shares issuable upon conversion of convertible notes payable</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="6">Total subscribed stock</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="11" style="font-weight: bold; text-align: center">For the period Ended August 31, 2014</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Shares</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Amount</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="7">Shares issuable upon conversion of convertible notes payable</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,058,201</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,000</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="6">Total subscribed stock</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,058,201</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,000</td> <td style="text-align: right">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">COMMON STOCK:</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">On March 7, 2014, the Company increased its authorized shares of common stock to 750,000,000. The increase was approved by a majority of the Company&#146;s shareholders on January 27, 2014. As of May 31, 2015, the Company has 276,746,130 shares outstanding. Please see Part II, Item II &#150; Sale of Unregistered Securities for information on recent sales of unregistered securities.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NON-CONTROLLING INTEREST</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 27, 2009, in connection with the Technology Agreement we entered into with Institut f&#252;r Umwelttechnologien GmbH, a German Company (&#147;IUT&#148;) whereunder the parties have agreed that the Company&#146;s marketing rights have been transferred to its subsidiary, Oncologix Corporation and have issued IUTM 10% of the equity ownership of that subsidiary. As of February 27, 2009, the value of the non-controlling interest was $212. It was determined at August 31, 2010 the value of the investment in IUTM was impaired. Accordingly, we recorded an impairment loss in the amount of $3,186 for the year ended August 31, 2010. As of May 31, 2015, as a result of the disposition of Oncologix Corporation, we do not have to recognize a non-controlling interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">WARRANTS:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table summarizes warrant activity in fiscal 2015 and 2014:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.2in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table border="0" cellpadding="0" cellspacing="0" style="width: 65%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 50%">&#160;</td> <td style="width: 2%">&#160;</td> <td style="width: 23%">&#160;</td> <td style="width: 2%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 23%">Weighted Avg.</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; text-decoration: underline; text-align: center">Number</td> <td style="font-weight: bold; text-decoration: underline; text-align: center"><u></u></td> <td style="font-weight: bold; text-decoration: underline; text-align: center">Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, August 31, 2013</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,000,000</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.012</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired/Retired</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td> <td>&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,583,333</td> <td>&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.011</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, August 31, 2014</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,583,333</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired/Retired</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(9,583,333)</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.009</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Issued</td> <td>&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding, May 31, 2015</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;21,000,000</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.012</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of warrants granted is estimated using the Black-Scholes option pricing model. This model utilizes the following factors to calculate the fair value of options granted: (i) annual dividend yield, (ii) weighted-average expected life, (iii) risk-free interest rate and (iv) expected volatility. The warrants were expensed and accounted for under ASC 718.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value for these warrants was estimated as of the date of grant using a Black-Scholes option-pricing model with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table border="0" cellpadding="0" cellspacing="0" style="width: 75%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="3" style="font-weight: bold; text-decoration: underline; text-align: center">For the Nine Months Ended May 31,</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 12%">&#160;</td> <td style="width: 12%">&#160;</td> <td style="width: 12%">&#160;</td> <td style="width: 10%">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 26%">2015</td> <td style="width: 4%">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 22%">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;124% - 702%&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2">Risk free rate</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">0.00%</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">0.25%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="2">Expected dividends</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;None&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;None&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="3">Expected term (in years)</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;2 to 5 years&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Details relative to the 21,000,000 immediately exercisable outstanding warrants at May 31, 2015 are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 9%">Weighted</td> <td style="width: 1%">&#160;</td> <td style="text-align: right; width: 13%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 18%">&#160;</td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; text-align: center">Average</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-weight: bold; text-align: center">Date of</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">Number</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">Exercise</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;Remaining&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">Expiration</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Grant</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">of Shares</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Price</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">&#160;Exercise Life&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Date</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, August 31, 2013</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,000,000</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>First quarter of fiscal 2014</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,500,000</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;0.012</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;3 years&#160;</td> <td>&#160;</td> <td>November 2017</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Second quarter of fiscal 2014</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,500,000</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;0.017</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;2 to 3 years&#160;</td> <td>&#160;</td> <td colspan="2">Dec 2015 to Dec 2016</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Third quarter of fiscal 2014</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9,583,333</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;0.012</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;5 years&#160;</td> <td>&#160;</td> <td>May 2019</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fourth quarter of fiscal 2014</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,000,000</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;0.007</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;2 years&#160;</td> <td>&#160;</td> <td>August 2016</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td> <td>&#160;</td> <td style="border-top: Black 0.5pt solid; text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding, August 31, 2014</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,583,333</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>First quarter of fiscal 2015</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Second quarter of fiscal 2015</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Third quarter of fiscal 2015</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(9,583,333)</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;0.009</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td> <td>&#160;</td> <td style="border-top: Black 0.5pt solid; text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, May 31, 2015</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;21,000,000</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 1, 2013, the company issued 1,000,000 four-year cashless warrants as additional consideration for the acquisition of Amian Angels. These warrants expire four years after the date of issuance and have an exercise price of $.015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 5, 2013, the company issued 6,000,000 three-year cashless warrants, to a related party, as finder&#146;s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.012.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 11, 2013, the company issued 1,500,000 three-year cashless warrants, to a related party, as finder&#146;s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On November 8, 2013, the company issued 3,000,000 three-year cashless warrants, to an unrelated party, as finder&#146;s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.01.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 3, 2014, the company issued 1,000,000 three-year cashless warrants, to an unrelated party, as finder&#146;s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 20, 2014, the company issued 3,000,000 two-year cashless warrants, to an unrelated party, as finder&#146;s fees related to a working capital investment. These warrants expire two years after the date of issuance and have an exercise price of $.016.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On February 7, 2014, the company issued 1,000,000 two-year cashless warrants, to an unrelated party, as finder&#146;s fees related to a working capital investment. These warrants expire two years after the date of issuance and have an exercise price of $.015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On May 21, 2014, the company issued 9,583,333 five-year cashless warrants, to an unrelated party, as finder&#146;s fees related to a working capital investment. These warrants expire five years after the date of issuance and have an exercise price of $.009.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 15, 2014, the company issued 4,000,000 two-year warrants, to an unrelated party, as finder&#146;s fees related to a working capital investment. These warrants expire two years after the date of issuance and have an exercise price of $.0065.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the third quarter of fiscal 2015, 9,583,333 warrants were exercised in a cashless transaction. 33,382,960 shares of Common stock were issued for the warrants&#146; exercise.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">The remaining contractual life of warrants outstanding as of May 31, 2015 was 1.17 years. Warrants for the purchase of 21,000,000 and 26,586,333 shares were immediately exercisable on May 31, 2015 and 2014, respectively with a weighted-average price of $0.012 and $0.011 per share, respectively.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">STOCK OPTIONS:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC 718 requires the estimation of forfeitures when recognizing compensation expense and that this estimate of forfeitures be adjusted over the requisite service period should actual forfeitures differ from such estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment, which is recognized in the period of change and which impacts the amount of unamortized compensation expense to be recognized in future periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">ASC 718 requires that modification of the terms or conditions of an equity award is to be treated as an exchange of the original award for a new award. This event is accounted for as if the entity repurchases the original instrument by issuing a new instrument of equal or greater value, incurring additional compensation cost for any incremental value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2000 Stock Incentive Plan</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is authorized to issue up to 7,500,000 shares of common stock under its 2000 Stock Incentive Plan. Shares may be issued as incentive stock options, non-statutory stock options, deferred shares or restricted shares. Options are granted at the fair market value of the common stock on the date of the grant and have terms of up to ten years. The 2000 Stock Incentive Plan also provides for an annual grant of options to members of our Board of Directors. For fiscal years ended August 31, 2008 through 2012, our Board of Directors elected to waive the grant of these annual options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 13, 2013, the Board of directors authorized the granting of 6,100,000 options to its three officers; 2,400,000 options to Wayne Erwin, our CEO; 2,100,000 options to Michael Kramarz, our CFO; and 1,600,000 options to Vickie Hart, President of Amian Angels. These options vest immediately and have an exercise price $.015, the closing stock price on December 13, 2013.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 20, 2014, the Company issued 20,000 options as part of its annual grant program to its two directors. These options vest in 1 year and have an exercise price of $.016, the closing stock price on December 20, 2013.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have 473,253 shares of common stock available for future issuance under our 2000 Stock Incentive Plan as of May 31, 2015. This plan has been approved by our shareholders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the three and nine months years ended May 31, 2015 and 2014, we granted 6,120,000 and nil options from the stock incentive plan described above, respectively. During the three and nine months ended May 31, 2015 and 2014, nil and nil options were exercised, respectively. During the three months ended May 31, 2015 and 2014, nil and nil options expired, respectively. During the nine months ended May 31, 2015 and 2014, nil and 150,835 options expired, respectively. During the three and nine months ended May 31, 2015 and 2014, $0 and $91,163 was expensed as stock based compensation, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Weighted Average</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Number of</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Option Price</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Exercise Price</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center; vertical-align: middle">&#160;</td><td style="padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Options Granted</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Per Share</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Per Share</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: left; vertical-align: middle">Outstanding, August 31, 2013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">217,085</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">$0.12 - $2.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1.120</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Granted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,120,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;$0.015 - $0.016&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.020</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Exercised</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: middle">Cancelled</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(163,335</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">$1.04 - $2.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1.380</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left; vertical-align: middle">Outstanding, August 31, 2014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,173,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$0.12 - $2.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.016</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Granted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left; vertical-align: middle">Exercised</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left; vertical-align: middle">Cancelled</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left; vertical-align: middle">Outstanding, May 31, 2015</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,173,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">$0.12 - $2.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.016</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between our closing stock price on the last trading day of the third quarter of fiscal 2015 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on May 31, 2015.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Expected volatility is based primarily on historical volatility. Historical volatility is computed using weekly average pricing observations for an applicable historic period. We believe this method produces an estimate that is representative of our expectations of the future volatility over the expected term of our options. We currently have no reason to believe future volatility over the expected life of these options is likely to differ materially from historical volatility. The weighted-average expected life is based upon share option exercises, pre and post vesting terminations and share option term expirations. The risk-free interest rate is based on the U.S. treasury security rate estimated for the expected life of the options at the date of grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The remaining contractual life of options outstanding as of May 31, 2015 was 8.49 years. Options for the purchase of 6,173,750 exercisable on May 31, 2015 with a weighted-average price of $0.016 and $0.016 per share, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table border="0" cellpadding="0" cellspacing="0" style="width: 80%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 18%">&#160;</td> <td style="width: 10%">&#160;</td> <td style="width: 10%">&#160;</td> <td style="width: 10%">&#160;</td> <td style="width: 8%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 20%">Options</td> <td style="width: 4%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 20%">Options</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Outstanding</td> <td>&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Exercisable</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="2">Number of options</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,173,750</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;6,173,750</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="4">Aggregate intrinsic value of options</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="5">Weighted average remaining contractual term (years)</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.74</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.74</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="3">Weighted average exercise price</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.016</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.016</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>2013 Omnibus Incentive Plan</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company is authorized to issue up to 10,000,000 shares of common stock under its 2013 Omnibus Incentive Plan to employees, officers, directors and consultants. The issuance adoption of this plan has been approved by the Company&#146;s Board of Directors on May 20, 2013 and was approved by our shareholders on January 27, 2014. Any options are granted at the fair market value of the common stock on the date of the grant and have terms of up to ten years. Under the 2013 Omnibus Incentive Plan the price of the granted common stock options are equal to the fair market value of such shares on the date of grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On September 11, 2013, we issued 1,000,000 S-8 shares to a consultant in payment for investor relations work for the Company. On January 3, 2014, we issued 1,000,000 S-8 shares to a consultant in payment for services to be provided for the Company. On November 15, 2014 we issued 1,000,000 S-8 shares to a consultant in payment for investor relations work for the Company. We have 7,000,000 shares of common stock available for future issuance under our 2013 Omnibus Incentive Plan as of May 31, 2015.<b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Number of Securities</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Number of Securities</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">To Be Issued Upon</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Remaining Available</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Exercise of Outstanding</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Exercise Price of</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">For Future</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Outstanding Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issuance Under Plans</td></tr> <tr> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Equity compensation plans</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 31%; text-align: left">approved by stockholders</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">0.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">7,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equity compensation plans</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">not approved by stockholders</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">TOTAL</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,000,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p> <p style="margin: 0pt">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center"><b>Options</b></td><td style="font-weight: bold">&#160;</td> <td colspan="4" style="font-weight: bold; text-align: center">Options</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: center"></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Outstanding</b></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="4" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercisable</td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="font-weight: bold; text-align: center"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Number of options</td><td style="width: 8%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">6,173,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">6,173,750</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Aggregate intrinsic value of options</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">$</td> <td style="text-align: right">-</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted average remaining contractual term (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8.74</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">8.74</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average exercise price</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.016</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: right">$</td> <td style="text-align: right">0.016</td></tr> </table> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Preferred</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Number of&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Weighted Avg.</td><td style="font-weight: bold; text-align: center">&#160;</td></tr> <tr> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Common Shares</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Proceeds if</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Per Common Sh.</td><td style="font-weight: bold; text-align: center">&#160;</td></tr> <tr> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Convertible</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Converted</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%; text-align: left">Outstanding, August 31, 2013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">129,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">64,531</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">25,812</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.40</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expired/Retired</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Converted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.40</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Issued</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left">Outstanding, August 31, 2014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,062</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">64,531</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,812</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expired/Retired</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.40</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Converted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Issued</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">Outstanding, May 31, 2015</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">129,062</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">64,531</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,812</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.40</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Preferred</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Number of&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Weighted Avg.</td><td style="font-weight: bold; text-align: center">&#160;</td></tr> <tr> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Common Shares</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Proceeds if</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Per Common Sh.</td><td style="font-weight: bold; text-align: center">&#160;</td></tr> <tr> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Convertible</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Converted</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 17%; text-align: left">Outstanding, August 31, 2013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">58,564</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">58,564,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">80.25</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expired/Retired</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Converted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left">Issued</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">80.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left">Outstanding, August 31, 2014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,564,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expired/Retired</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Converted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Issued</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">Outstanding, May 31, 2015</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,564</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,564,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">80.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td colspan="11" style="font-weight: bold; text-align: center">For the period Ended May 31, 2015</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 3%">&#160;</td> <td style="width: 4%">&#160;</td> <td style="width: 4%">&#160;</td> <td style="width: 4%">&#160;</td> <td style="width: 4%">&#160;</td> <td style="width: 4%">&#160;</td> <td style="width: 42%">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 15%">Shares</td> <td style="font-weight: bold; text-align: center; width: 4%">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 15%">Amount</td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="7">Shares issuable upon conversion of convertible notes payable</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,500,000</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,572</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="6">Total subscribed stock</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,500,000</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,572</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="11" style="font-weight: bold; text-align: center">For the period Ended August 31, 2014</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Shares</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Amount</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="7">Shares issuable upon conversion of convertible notes payable</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,058,201</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,000</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td colspan="6">Total subscribed stock</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,058,201</td> <td style="text-align: right">&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,000</td> <td style="text-align: right">&#160;</td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 75%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 54%">&#160;</td> <td style="width: 2%">&#160;</td> <td style="width: 19%">&#160;</td> <td style="width: 2%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 21%">Weighted Avg.</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; text-decoration: underline; text-align: center">Number</td> <td style="font-weight: bold; text-decoration: none; text-align: center"><u></u></td> <td style="font-weight: bold; text-decoration: underline; text-align: center">Exercise Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, August 31, 2013</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,000,000</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.012</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expired/Retired</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td> <td>&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,583,333</td> <td>&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.011</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, August 31, 2014</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,583,333</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired/Retired</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Issued</td> <td>&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding, May 31, 2015</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,583,333</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.011</td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 75%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="3" style="font-weight: bold; text-decoration: underline; text-align: center">For the Six Months Ended May 31,</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 12%">&#160;</td> <td style="width: 12%">&#160;</td> <td style="width: 12%">&#160;</td> <td style="width: 12%">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 26%">2015</td> <td style="width: 2%">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center; width: 22%">2014</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;124% - 384%&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2">Risk free rate</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">0.00%</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">0.25%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="2">Expected dividends</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;None&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;None&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="3">Expected term (in years)</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;2 to 3 years&#160;</td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 42%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 13%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 9%">Weighted</td> <td style="width: 1%">&#160;</td> <td style="text-align: right; width: 13%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 18%">&#160;</td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="font-weight: bold; text-align: center">Average</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-weight: bold; text-align: center">Date of</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">Number</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">Exercise</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;Remaining&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">Expiration</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Grant</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">of Shares</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Price</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">&#160;Exercise Life&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Date</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, August 31, 2013</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,000,000</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>First quarter of fiscal 2014</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,500,000</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;0.012</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;3 years&#160;</td> <td>&#160;</td> <td>November 2017</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Second quarter of fiscal 2014</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,500,000</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;0.017</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;2 to 3 years&#160;</td> <td>&#160;</td> <td colspan="2">Dec 2015 to Dec 2016</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Third quarter of fiscal 2014</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;9,583,333</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;0.012</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;5 years&#160;</td> <td>&#160;</td> <td>May 2019</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fourth quarter of fiscal 2014</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;4,000,000</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;0.007</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;2 years&#160;</td> <td>&#160;</td> <td>August 2016</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td> <td>&#160;</td> <td style="border-top: Black 0.5pt solid; text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding, August 31, 2014</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,583,333</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>First quarter of fiscal 2015</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Second quarter of fiscal 2015</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: center">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td> <td>&#160;</td> <td style="border-top: Black 0.5pt solid; text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding, May 31, 2015</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;30,583,333</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Weighted Average</td><td style="font-weight: bold; text-align: center">&#160;</td></tr> <tr> <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Option Price</td><td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold; text-align: center">&#160;</td></tr> <tr> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Granted</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Per Share</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Per Share</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: left">Outstanding, August 31, 2013</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">217,085</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">0.12 - 2.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">1.120</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,120,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#160;0.015 - 0.016&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.020</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Cancelled</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(163,335</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1.04 - 2.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1.380</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">Outstanding, August 31, 2014</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,173,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.12 - 2.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.016</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exercised</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left">Cancelled</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">Outstanding, May 31, 2015</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,173,750</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.12 - 2.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.016</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 32%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 21%">Number of Securities</td> <td style="font-weight: bold; text-align: center; width: 2%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 21%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 2%">&#160;</td> <td style="font-weight: bold; text-align: center; width: 21%">Number of Securities</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td style="font-weight: bold; text-align: center">To Be Issued Upon</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">Weighted Average</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">Remaining Available</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td style="font-weight: bold; text-align: center">Exercise of Outstanding</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">Exercise Price of</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; text-align: center">For Future</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Options</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Outstanding Options</td> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Issuance Under Plans</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Equity compensation plans</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>approved by stockholders</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="text-align: right">$0.00</td> <td>&#160;</td> <td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,000,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Equity compensation plans</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>not approved by stockholders</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">$0.00</td> <td>&#160;</td> <td style="border-bottom: Black 0.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>TOTAL</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&#160;&#160;&#160;</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">$0.00</td> <td>&#160;</td> <td style="border-bottom: Black 2pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;7,000,000</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>NOTE 13 - RELATED PARTY TRANSACTIONS AND CONTINGENCIES: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">FINANCING WITH RELATED PARTIES:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the three and six months ended May 31, 2015 and 2014, the Company entered into financing agreements with related parties of the Company. Please see Note 11 &#150; Notes Payable for further descriptions of these transactions.</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><font style="font-weight: normal">Below are the segment assets as of May 31, 2015.</font></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="27" style="font-weight: bold; text-align: center">As of May 31, 2015</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Personal Care</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Medical Device</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Med. Products</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Corporate</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Overhead</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Totals</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">ASSETS</td> <td colspan="10" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">76,633</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,008</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,724</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">120,485</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Accounts receivable (net)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">233,710</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">803,299</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,037,009</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Inventory</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,271</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">106,165</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">137,436</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Prepaid expenses and other current assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">2,946</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,965</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15,911</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaid commissions and finders' fees</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">85</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,889</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,974</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt">Total current assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">310,343</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,391</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">933,503</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">39,578</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,314,815</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment (net)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">16,211</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15,217</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,283</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">535</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">35,246</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deposits and other assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,307</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">32,303</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,866</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">33,202</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">77,678</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Goodwill</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">564,075</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,217,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">622,610</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,404,389</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Patents, registrations (net of amortization)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">19,903</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">19,903</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">892,936</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,316,518</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,569,262</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,852,031</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Below are the segment assets as of August 31, 2014.</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="27" style="font-weight: bold; text-align: center">As of August 31, 2014</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Personal Care</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Medical Device</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Med. Products</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Corporate</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Overhead</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Totals</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">ASSETS</td> <td colspan="10" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(110</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,278</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,504</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Accounts receivable (net)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">213,399</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">213,399</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Inventory</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,271</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,271</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Prepaid expenses and other current assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,307</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,307</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaid commissions</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,152</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,152</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt">Total current assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">222,735</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,161</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">19,737</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">274,633</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment (net)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">21,287</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">17,893</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">787</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">39,967</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deposits and other assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,082</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14,582</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Goodwill</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">564,075</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,217,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,781,779</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Patents, registrations (net of amortization)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,497</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,497</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">810,179</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,303,755</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,524</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,135,458</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Below are the statements of operations for the reporting periods presented.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="19" style="font-weight: bold; text-align: center">For the Three Months Ended May 31, 2015</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Personal Care</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Device</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Products</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Corporate</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Overhead</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Totals</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Revenues</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">812,626</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">423,030</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,235,656</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">698,215</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">187,381</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">885,596</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">114,411</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">235,649</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">350,060</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">81,451</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14,739</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">159,793</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">187,906</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">443,889</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Research and development Expense</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,262</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,423</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">253</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,022</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">83,713</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,162</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">160,046</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">187,990</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">448,911</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,698</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(17,162</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">75,603</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(187,990</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(98,851</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense):</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(81,952</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,500</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(3,076</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(351,380</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(437,908</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,307</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,321</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(70,645</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,486</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,076</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(351,380</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(426,587</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from continuing operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(39,947</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,648</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,527</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(539,370</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(525,438</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="19" style="font-weight: bold; text-align: center">For the Three Months Ended May 31, 2014</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Personal Care</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Device</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Products</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Corporate</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Overhead</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Totals</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Revenues</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">988,385</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">988,385</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">776,406</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,351</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">788,757</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">211,979</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(12,351</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">199,628</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">166,867</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,979</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">105,104</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">276,950</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,157</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,423</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,664</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">170,024</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,402</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">105,188</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">282,614</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">41,955</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(19,753</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(105,188</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(82,986</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income (expense):</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(80,786</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,250</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(84,438</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(167,474</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(791</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(791</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss on conversion of notes payable - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(62,151</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(62,151</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Loss on disposal of assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">74,667</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(217</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">74,450</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,119</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,258</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(146,589</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(155,966</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from continuing operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,836</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(23,011</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(251,777</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(238,952</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Below are the statements of operations for the reporting periods presented.</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="19" style="font-weight: bold; text-align: center">For the Nine Months Ended May 31, 2015</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Personal Care</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Device</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Products</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Corporate</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Overhead</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Totals</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Revenues</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,573,547</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,051,860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,625,407</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,129,572</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">499,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,628,797</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">443,975</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">552,635</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">996,610</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">317,165</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">58,489</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">424,693</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">579,422</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,379,769</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Research and development expense</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,289</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,269</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">546</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,356</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">323,454</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">75,758</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">425,239</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">579,674</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,404,125</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">120,521</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(75,758</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">127,396</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(579,674</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(407,515</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense):</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(244,613</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(5,500</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(3,848</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(836,052</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,090,013</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,051</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,051</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,541</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,854</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(204</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,483</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(236,072</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,405</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,848</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(836,256</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,086,581</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(115,551</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(86,163</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">123,548</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,415,930</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,494,096</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="19" style="font-weight: bold; text-align: center">For the Nine Months Ended May 31, 2014</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Personal Care</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Device</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Products</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Corporate</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Overhead</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Totals</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Revenues</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,696,776</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,696,776</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,030,450</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36,350</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,066,800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">666,326</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(36,350</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">629,976</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">506,387</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">28,222</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">465,301</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">999,910</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,636</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,268</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,156</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">516,023</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">35,490</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">465,553</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,017,066</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150,303</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(71,840</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(465,553</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(387,090</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income (expense):</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(171,837</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(8,560</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(454,436</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(634,833</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,348</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(15,708</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(18,056</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss on conversion of notes payable - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(155,728</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(155,728</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Loss on disposal of assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(28,748</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(28,748</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">72,775</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(713</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">72,062</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(127,810</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,621</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(625,872</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(765,303</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,493</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(83,461</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,091,425</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,152,393</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">NOTE 14 &#150; BUSINESS SEGMENTS</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">We identify our reportable segments based on our management structure, financial data and market. We have identified three business segments: Personal Care Services and Medical Device Products and Medical Products &#38; Technologies</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">Our Personal Care Service segment consists of the services of Angels of Mercy, Inc. This segment provides non-medical, Personal Care Attendant (PCA) services, Supervised Independent Living (SIL), Long-Term Senior Care, and other approved programs performed by a trained caregiver that will meet the health service needs of beneficiaries whose disabilities preclude the performance of certain independent living skills related to the activities of daily living (ADL).</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">Our Medical Device Manufacturing segment consists of the products of Dotolo Research Corporation. This segment designs, develops, manufactures and distributes the Toxygen hardware system with disposable speculums and medical grade tubing.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">Our Medical Products and Technologies segment will consist of Advanced Medical Products and Technologies, Esteemcare Inc. and Affordable Medical Inventory Solutions Inc. and future acquisitions.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">The accounting policies of the segments are the same as those described, or referred to, in Note 2 - Summary of Significant Accounting Policies. Assets and related depreciation expense in the column labeled &#147;Corporate Overhead&#148; pertain to capital assets maintained at the corporate level. Segment loss from operations in the &#147;Corporate Overhead&#148; column contains corporate related expenses not allocable to the operating segments. Intercompany transactions between operating segments were immaterial in all periods presented.&#9;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><font style="font-weight: normal">&#160;Below are the segment assets as of May 31, 2015.</font></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="27" style="font-weight: bold; text-align: center">As of May 31, 2015</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Personal Care</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Medical Device</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Med. Products</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Corporate</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Overhead</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Totals</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Unaudited)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">ASSETS</td> <td colspan="10" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">76,633</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,008</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,724</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">120,485</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Accounts receivable (net)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">233,710</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">803,299</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,037,009</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Inventory</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,271</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">106,165</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">137,436</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Prepaid expenses and other current assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">2,946</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,965</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15,911</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaid commissions and finders' fees</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">85</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,889</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,974</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt">Total current assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">310,343</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,391</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">933,503</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">39,578</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,314,815</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment (net)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">16,211</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">15,217</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,283</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">535</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">35,246</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deposits and other assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,307</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">32,303</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,866</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">33,202</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">77,678</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Goodwill</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">564,075</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,217,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">622,610</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,404,389</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Patents, registrations (net of amortization)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">19,903</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">19,903</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">892,936</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,316,518</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,569,262</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73,315</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,852,031</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Below are the segment assets as of August 31, 2014.</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="27" style="font-weight: bold; text-align: center">As of August 31, 2014</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Personal Care</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Medical Device</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Med. Products</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">Corporate</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Segment</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Overhead</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Totals</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">ASSETS</td> <td colspan="10" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">&#160;</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Assets:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,336</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(110</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,278</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,504</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Accounts receivable (net)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">213,399</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">213,399</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Inventory</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,271</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,271</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Prepaid expenses and other current assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,307</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,307</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaid commissions</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,152</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,152</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 20pt">Total current assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">222,735</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">31,161</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">19,737</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">274,633</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment (net)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">21,287</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">17,893</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">787</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">39,967</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deposits and other assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,082</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14,582</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Goodwill</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">564,075</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,217,704</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,781,779</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Patents, registrations (net of amortization)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,497</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,497</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 30pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">810,179</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,303,755</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,524</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,135,458</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Below are the statements of operations for the reporting periods presented.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="19" style="font-weight: bold; text-align: center">For the Three Months Ended May 31, 2015</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Personal Care</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Device</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Products</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Corporate</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Overhead</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Totals</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Revenues</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">812,626</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">423,030</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,235,656</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">698,215</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">187,381</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">885,596</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">114,411</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">235,649</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">350,060</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">81,451</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">14,739</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">159,793</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">187,906</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">443,889</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Research and development Expense</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,262</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,423</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">253</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,022</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">83,713</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,162</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">160,046</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">187,990</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">448,911</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,698</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(17,162</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">75,603</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(187,990</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(98,851</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense):</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(81,952</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,500</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(3,076</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(351,380</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(437,908</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,307</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,321</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(70,645</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,486</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,076</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(351,380</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(426,587</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from continuing operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(39,947</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,648</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,527</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(539,370</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(525,438</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="19" style="font-weight: bold; text-align: center">For the Three Months Ended May 31, 2014</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Personal Care</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Device</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Products</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Corporate</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Overhead</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Totals</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Revenues</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">988,385</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">988,385</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">776,406</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,351</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">788,757</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">211,979</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(12,351</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">199,628</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">166,867</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4,979</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">105,104</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">276,950</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,157</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,423</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,664</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">170,024</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,402</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">105,188</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">282,614</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">41,955</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(19,753</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(105,188</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(82,986</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income (expense):</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(80,786</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,250</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(84,438</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(167,474</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(791</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(791</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss on conversion of notes payable - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(62,151</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(62,151</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Loss on disposal of assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">74,667</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(217</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">74,450</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,119</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,258</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(146,589</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(155,966</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from continuing operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,836</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(23,011</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(251,777</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(238,952</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Below are the statements of operations for the reporting periods presented.</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="19" style="font-weight: bold; text-align: center">For the Nine Months Ended May 31, 2015</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Personal Care</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Device</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Products</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Corporate</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Overhead</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Totals</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Revenues</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,573,547</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,051,860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,625,407</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,129,572</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">499,225</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,628,797</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">443,975</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">552,635</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">996,610</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">317,165</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">58,489</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">424,693</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">579,422</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,379,769</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Research and development expense</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,289</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,269</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">546</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,356</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">323,454</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">75,758</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">425,239</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">579,674</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,404,125</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">120,521</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(75,758</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">127,396</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(579,674</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(407,515</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense):</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(244,613</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(5,500</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(3,848</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(836,052</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,090,013</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,051</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,051</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,541</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,854</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(204</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,483</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(236,072</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,405</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,848</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(836,256</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,086,581</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(115,551</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(86,163</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">123,548</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,415,930</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,494,096</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td colspan="19" style="font-weight: bold; text-align: center">For the Nine Months Ended May 31, 2014</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Personal Care</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Device</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Medical Products</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">Corporate</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td> <td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Segment</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Overhead</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center; vertical-align: middle">&#160;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center; vertical-align: middle">Totals</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center; vertical-align: middle">&#160;</td></tr> <tr> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td> <td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td><td style="text-align: center; vertical-align: middle">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Revenues</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,696,776</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#151;&#160;&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,696,776</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,030,450</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36,350</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,066,800</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Gross profit</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">666,326</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(36,350</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">629,976</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">506,387</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">28,222</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">465,301</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">999,910</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,636</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,268</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">252</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">17,156</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">516,023</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">35,490</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">465,553</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,017,066</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150,303</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(71,840</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(465,553</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(387,090</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income (expense):</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(171,837</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(8,560</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(454,436</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(634,833</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Interest and finance charges - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,348</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(15,708</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(18,056</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss on conversion of notes payable - related parties</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(155,728</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(155,728</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Loss on disposal of assets</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(28,748</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#151;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(28,748</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income (expenses)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">72,775</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(713</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">72,062</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(127,810</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,621</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(625,872</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(765,303</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,493</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(83,461</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#151;&#160;&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,091,425</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,152,393</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></p> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 15 - JOINT VENTURE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Institut f&#252;r Umwelttechnologien GmbH (IUT)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In February 2009, we entered into a Technology Agreement with Institut f&#252;r Umwelttechnologien GmbH, a German Company (&#147;IUT&#148;). On September 23, 2010, the Company signed a Memorandum of Understanding with Institut f&#252;r Umwelttechnologien GmbH and IUT Medical GMBH confirming certain understandings among the parties with respect to their future relationships and business activities as originally contemplated in their Technology Agreement of February 27, 2009, which was reaffirmed. On November 1, 2013, with the disposal of the Company&#146;s subsidiary Oncologix Corporation, the company also ended its relationship with IUT and IUTM.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>NOTE 16 - RETIREMENT PLAN</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Currently, the Company does not have a retirement plan in place.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 17 - RECENT ACCOUNTING PRONOUNCEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact on our financial condition or results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NEW ACCOUNTING STANDARD</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2012, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update 2012-02 &#147;Intangibles &#150; Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment&#148; (&#147;ASU 2012-02&#148;). ASU 2012-02 permits entities to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. Under the amendments in ASU 2012-02, an entity is not required to calculate the fair value of an indefinite-lived intangible asset unless it determines that it is more likely than not that the fair value of the asset is less than its carrying amount. An entity also will have the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. ASU 2012-02 is effective for interim and annual indefinite-lived intangible asset impairment tests performed for fiscal years beginning on or after September 15, 2012, with early adoption permitted. The Company&#146;s adoption of ASU 2012-02 is not expected to have an impact on its consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 18 &#150; STATEMENT OF CASH FLOWS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the nine months ended May 31, 2015, these supplemental non-cash investing and financing activities are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9; &#9; <u>Amount</u></p> <table cellspacing="1" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="width: 85%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On November 15, 2014, the Company issued 1,000,000 S-8 shares of common stock in payment for a investor relations consulting contract. &#160;&#160;</font></td> <td style="width: 15%; padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">4,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On November 15, 2014, the Company issued 5,000,000 shares of common stock in payment for&#160;&#160;investor relations consulting contract. &#160;&#160;</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">20,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On November 17, 2014, the Company issued a $25,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $10,545 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">10,545</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On November 17, 2014, the Company issued a $25,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $10,545 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">10,545</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 22, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $35,000 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">35,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 30, 2015, the Company issued 5,000,000 shares of common stock in payment for&#160;&#160;investor relations consulting contract. &#160;&#160;</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">38,500</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 30, 2015, the Company issued a $50,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $50,000 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">50,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 5 2015, the Company issued a $50,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $50,000 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">50,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 4, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $35,000 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">35,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 12, 2015, the Company issued a $75,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $75,000 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">75,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 25, 2015, the Company issued a $30,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $30,000 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">30,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; text-underline-style: double; line-height: 93%">&#160;</font></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;On March 5, 2015, the Company issued a $36,750 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $25,698 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">25,698</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; text-underline-style: double; line-height: 93%">&#160;</font></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;On March 11, 2015, the Company issued a $88,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $49,539 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">49,539</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;For the nine months ended May 31, 2015, these supplemental non-cash investing and financing activities are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9; &#9; <u>Amount</u></p> <table cellspacing="1" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="width: 85%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;On March 11, 2015, the Company issued a $30,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $20,100 related to that transaction.</font></td> <td style="width: 15%; padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">20,100</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On March 25, 2015, the Company issued a $50,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $29,404 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">29,404</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On March 30, 2015, the Company issued a $32,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $15,790 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">15,790</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On April 7, 2015, the Company issued a $27,500 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $10,372 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">10,372</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On April 8, 2015, the Company issued a $58,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $39,146 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">39,146</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On May 7, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $21,452 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">21,452</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On May 8, 2015, the Company issued a $45,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $29,715 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">29,715</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On May 22, 2015, the Company issued a $50,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $30,645 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">30,645</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On May 22, 2015, the Company issued a $75,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $45,968 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0"><u>45,968</u></p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">Total non-cash transactions from investing and financing activities.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">&#160;<font style="text-underline-style: double"><u>$&#160;&#160;&#160;&#160;&#160;&#160;676,419</u></font></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the nine months ended May 31, 2014, these supplemental non-cash investing and financing activities are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="1" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="width: 85%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On September 11, 2013, the Company issued 1,500,000 warrants to an affiliated party for additional compensation related to an operating capital investment.&#160;&#160;The value of these warrants was expensed as interest and finance charges.</font></td> <td style="width: 15%; padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">$ 15,656</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On September 11, 2013, the Company issued 1,000,000 S-8 shares of common stock in payment for a investor relations consulting contract. &#160;&#160;</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">11,500</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On October 2, 2013, the Company issued a $25,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $25,000 related to that transaction.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">25,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On October 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $15,620.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">15,620</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On November 5, 2013 and November 8, 2013, the Company issued a total of 3,000,000 warrants to a non-related party as additional compensation for an operating capital investment.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">14,805</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On December 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $12,069.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">12,069</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On December 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $9,720.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">9,720</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On December 3, 2013, the Company issued a total of 1,000,000 warrants as additional compensation.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">5,992</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On December 20, 2013, the Company issued a total of 3,000,000 warrants as additional compensation.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">7,746</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 3, 2014, the Company issued 2,000,000 shares of common stock in payment for a services contract.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">22,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 13, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $26,154.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">26,154</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 14, 2014, the Company issued 1,000,000 shares of common stock as partial compensation for a investor relations contract.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">19,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 21, 2014, the Company issued 3,500,000 shares of common stock as additional compensation for finder&#146;s fees.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">45,500</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 21, 2014, the Company issued 1,500,000 shares of common stock as additional compensation for finder&#146;s fees.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">30,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 31, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $16,667.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">16,667</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 7, 2014, the Company issued 1,000,000 shares of common stock as additional compensation for finder&#146;s fees. </font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">9,000</p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the nine months ended May 31, 2014, these supplemental non-cash investing and financing activities are summarized as follows (continued):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="1" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="width: 85%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 7, 2014, the Company issued 3,000,000 shares of common stock as additional compensation for finder&#146;s fees. </font></td> <td style="width: 15%; padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">5,151</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 24, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $2,308.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">2,308</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On March 19, 2014, the Company recorded a beneficial conversion feature on the issuance of a convertible note.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">26,500</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On March 31, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $30,000.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">30,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On April 6, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $1,468.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">1,468</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On April 6, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $30,683</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">30,683</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On April 8, 2014, the Company recorded a beneficial conversion feature on the issuance of a convertible note.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">50,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On April 25, 2014, the Company recorded a beneficial conversion feature on the issuance of a convertible note.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">25,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On May 21, the Company recorded a discount for the issuance of 9,583,333 warrants in connection with the issuance of a convertible note.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0">38,322</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total non-cash transactions from investing and financing activities.</font></td> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-size: 10pt; line-height: 93%">&#9;&#160;<font style="text-underline-style: double"><u>$&#160;&#160;&#160;&#160;&#160;&#160;495,861</u></font></font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 18 &#150; STATEMENT OF CASH FLOWS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the six months ended February 28, 2015, these supplemental non-cash investing and financing activities are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9; &#9;</p> <table cellspacing="1" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: center"> <u>Amount</u></td></tr> <tr style="vertical-align: top"> <td style="width: 89%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On November 15, 2014, the Company issued 1,000,000 S-8 shares of common stock in payment for a investor relations consulting contract. &#160;&#160;</font></td> <td style="width: 1%">&#160;</td> <td style="width: 10%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">4,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On November 15, 2014, the Company issued 5,000,000 shares of common stock in payment for&#160;&#160;investor relations consulting contract. &#160;&#160;</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">20,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On November 17, 2014, the Company issued a $25,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $10,545 related to that transaction.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">10,545</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On November 17, 2014, the Company issued a $25,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $10,545 related to that transaction.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">10,545</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 22, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $35,000 related to that transaction.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">35,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 30, 2015, the Company issued 5,000,000 shares of common stock in payment for&#160;&#160;investor relations consulting contract. &#160;&#160;</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">38,500</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 30, 2015, the Company issued a $50,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $50,000 related to that transaction.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">50,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 5 2015, the Company issued a $50,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $50,000 related to that transaction.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">50,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 4, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $35,000 related to that transaction.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">35,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 12, 2015, the Company issued a $75,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $75,000 related to that transaction.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">75,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 25, 2015, the Company issued a $30,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $30,000 related to that transaction.</font></td> <td style="border-bottom: Black 1pt solid">&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right; border-bottom: Black 1pt solid"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">30,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"><font style="font-size: 10pt; text-underline-style: double; line-height: 93%">&#160;</font></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total non-cash transactions from investing and financing activities.</font></td> <td style="border-bottom: Black 2.5pt double; text-align: right">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">&#9;&#160;358,590</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"><font style="font-size: 10pt; text-underline-style: double; line-height: 93%">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the six months ended February 28, 2014, these supplemental non-cash investing and financing activities are summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="1" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="width: 89%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On September 11, 2013, the Company issued 1,500,000 warrants to an affiliated party for additional compensation related to an operating capital investment.&#160;&#160;The value of these warrants was expensed as interest and finance charges.</font></td> <td style="width: 1%"><p style="margin-top: 0; margin-bottom: 0">&#160;</p> <p style="margin-top: 0; margin-bottom: 0">&#160;</p> <p style="margin-top: 0; margin-bottom: 0">$</p></td> <td style="width: 10%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right"> 15,656</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On September 11, 2013, the Company issued 1,000,000 S-8 shares of common stock in payment for a investor relations consulting contract. &#160;&#160;</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">11,500</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On October 2, 2013, the Company issued a $25,000 convertible promissory note to a non-related party.&#160;&#160;We recorded a beneficial conversion feature the in amount of $25,000 related to that transaction.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">25,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On October 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $15,620.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">15,620</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On November 5, 2013 and November 8, 2013, the Company issued a total of 3,000,000 warrants to a non-related party as additional compensation for an operating capital investment.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">14,805</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On December 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $12,069.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">12,069</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On December 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $9,720.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">9,720</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On December 3, 2013, the Company issued a total of 1,000,000 warrants as additional compensation.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">5,992</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On December 20, 2013, the Company issued a total of 3,000,000 warrants as additional compensation.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">7,746</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 3, 2014, the Company issued 2,000,000 shares of common stock in payment for a services contract.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">22,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 13, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $26,154.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">26,154</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 14, 2014, the Company issued 1,000,000 shares of common stock as partial compensation for a investor relations contract.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">19,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 21, 2014, the Company issued 3,500,000 shares of common stock as additional compensation for finder&#146;s fees.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">45,500</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 21, 2014, the Company issued 1,500,000 shares of common stock as additional compensation for finder&#146;s fees.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">30,000</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On January 31, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $16,667.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">16,667</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 7, 2014, the Company issued 1,000,000 shares of common stock as additional compensation for finder&#146;s fees. </font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">9,000</p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For the six months ended February 28, 2014, these supplemental non-cash investing and financing activities are summarized as follows (continued):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="1" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="width: 89%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 7, 2014, the Company issued 3,000,000 shares of common stock as additional compensation for finder&#146;s fees. </font></td> <td style="width: 1%">&#160;</td> <td style="width: 10%; padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">5,151</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right">&#160;</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif">On February 24, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $2,308.</font></td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">&#160;</p> <p style="font: 10pt/93% Times New Roman, Times, Serif; margin: 0; text-align: right">2,308</p></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: justify; text-indent: 0.25in">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"><font style="font-size: 10pt; line-height: 93%">&#160;</font></td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt"><font style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total non-cash transactions from investing and financing activities.</font></td> <td style="border-bottom: Black 2.5pt double; text-align: right">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">&#9;&#160;&#160;&#160;&#160;&#160;&#160;&#160;293,888</td></tr> <tr style="vertical-align: top"> <td style="padding-right: 4.5pt; padding-left: 4.5pt">&#160;</td> <td>&#160;</td> <td style="padding-right: 4.5pt; padding-left: 4.5pt; text-align: right"><font style="font-size: 10pt; text-underline-style: double; line-height: 93%">&#160;</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 19 - EMPLOYMENT AGREEMENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On March 22, 2013, Wayne Erwin, the Company&#146;s Chief Executive Officer, signed a three year employment agreement. The agreement provides for an annual salary of $120,000 along with a monthly auto allowance and health insurance allowance totaling $1,250. The annual salary was increased to $150,000 per year beginning March 2015. Annual increases are to be approved by the Company&#146;s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $97,500 and $101,250 was expensed as salary, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 1, 2013, Michael Kramarz, the Company&#146;s Chief Financial Officer, signed a three year employment agreement. The agreement provides for an annual salary of $80,000 along with a monthly auto allowance and health insurance allowance totaling $500. The annual salary was increased to $120,000 beginning on March 1, 2015.Annual increases are to be approved by the Company&#146;s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $76,333 and 62,669 was expensed as salary, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On August 1, 2013, Vickie Hart, the President of Amian Angels Inc., signed a three year employment agreement. The agreement provides for an annual salary of $52,000 along with a monthly health insurance allowance totaling $400. The annual salary was increased to $85,000 beginning on March 1, 2015. Annual increases are to be approved by the Company&#146;s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $49,900 and $46,214 was expensed as salary, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On July 16, 2014, Harold Halman, the President of our Medical Products Segment, signed a three year employment agreement. The agreement provides for an annual salary of $85,000, along with a monthly auto allowance and health insurance allowance totaling $1,300 plus bonus allowances. Annual increases are to be approved by the Company&#146;s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $63,750 and $0 was expensed as salary, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 20 &#150; COMMITMENTS AND CONTINGENCIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 6, 2014, the Company and its subsidiary Dotolo entered into a services agreement with E &#38; R Industries to provide the Company with retooling and redesign of Dotolo&#146;s disposable products. The contract calls for periodic cash payments totaling $60,000 along with the issuance of 5,000,000 common stock shares upon meeting certain milestones.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 6, 2014, the Company and its subsidiary Dotolo entered into a services agreement with Schmitt Engineering to provide the Company with engineering redesign services of its Toxygen hardware system. The contract calls for periodic cash payments totaling $30,000 along with the issuance of 3,000,000 common stock shares upon meeting certain milestones.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"><b>NOTE 21 - SUBSEQUENT EVENTS </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 3 2015, the Company entered into a 1 year consulting agreement. The Company agrees to pay consultant 4% of any monies raised by the efforts of the consultant. In addition, the Company issued 2,500,000 shares of its Common Stock as additional compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 15, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 8% per annum and is due on December 31, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 5, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $45,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company&#146;s then outstanding common stock shares.</p> 50000 45000 0.08 0.08 38322 45500 30000 9000 2308 1017066 282614 1404125 448911 -387090 -82986 -407515 -98851 72062 74450 4483 11321 -36 95564 95528 95528 -1152393 -251777 -115551 22493 -86163 -83461 -1415930 -1091425 -238952 123548 -1494096 -39947 35836 -18648 -23011 72527 -539370 -525438 -1056865 -238952 -1494096 -525438 -0.01 0.00 -0.01 0.00 0.00 93925094 112247396 187353653 242589170 -95528 -1152393 -1494097 28748 91163 18021 334437 155729 218415 302658 78100 -125813 -250480 -2686 -5829 -737 -43700 -52545 6691 626654 -60192 -6342 83424 80578 -546190 -390970 95528 -450662 -390970 -878 -2033 -75000 -560984 67232 563017 719933 596250 655128 1933000 10000 490798 918975 4600 51600 335608 224845 166099 664818 1056968 146924 102981 139823 66520 8646 0.08 36 -36 95564 477596 185340 -235025 125000 45000 75000 30000 100000 189025 2012-04-30 2013-02-27 2014-03-11 2015-05-22 2015-05-07 2014-12-15 2015-04-30 9000 10000 -155728 -62151 -155728 -62151 11307 14 11321 25000 15620 30000 1468 30683 -9583333 1058201 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 - GOING CONCERN</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses from operations over the past several years and anticipates additional losses in fiscal 2015 and prior to achieving breakeven. </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">During the year ended August 31, 2013 we acquired Dotolo Research Corporation and Angels of Mercy, Inc. In December 2013, through Amian Angels, we also acquired the assets of Amian Health Services and changed the company&#146;s name to Amian Angels Inc. In September 2014 we acquired Esteemcare Inc. and Affordable Medical Equipment Solutions Inc. While these acquisitions greatly increase the value of our Company, the combined operations of OCLG are not cash flow positive at this time. Amian and Esteemcare are currently cash flow positive but alone is unable to support all the corporate overhead or needs of our other subsidiary, Dotolo. We anticipate that we will require approximately $1,000,000 to operate through December 31, 2015. Approximately $500,000 will be required to fund corporate overhead including debt servicing with the balance to invest into raw material inventory, manufacturing and new product development at Dotolo Research - as well as beginning business with AMPT. Additional funding will allow us to meet our current sales demands and expenses of Dotolo, Amian Angels and Oncologix, while keeping our public filings current. </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">&#160;</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-weight: normal">Our Company is not profitable and we have to rely on debt and equity financings to fund operations. There is no assurance that the business activities of Dotolo will achieve breakeven status by the end of 2015. Significant delays in achieving break-even status could affect the ability to obtain future debt and equity funding. These factors raise substantial doubt about the Company&#146;s ability to continue as a going concern. After auditing our financial statements, our independent auditor issued a going concern opinion and our ability to continue is dependent on our ability to raise additional capital. Currently there is a substantial doubt in the Company&#146;s ability to continue as a going concern.</font></p> 0.012 0.011 0.014 0.012 1000000 1000000 0.18 0.18 0.15 0.06 0.18 0.10 0.145 0.06 0.12 0.06 0.18 <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"> The reclassification of a $100,000 convertible note from accounts payable and accrued expenses.</p> promissory note bears interest at 4% and requires 12 monthly payments In October 2013 and November 2014, the investor sold two $25,000 positions of principal in the note to another accredited investor and currently holds a note representing the remaining $75,000 in principal. EX-101.CAL 8 oclg-20150531_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 oclg-20150531_def.xml XBRL DEFINITION FILE EX-101.LAB 10 oclg-20150531_lab.xml XBRL LABEL FILE Furniture and Fixtures [Member] Property, Plant and Equipment, Type [Axis] Computer Equipment [Member] Equipment [Member] Software [Member] Option Outstanding [Member] Ptions Outstanding [Axis] Options Exercisable [Member] Options Exercisable [Axis] Series D Preferred Stock [Member] Noncash or Part Noncash Acquisitions by Unique Description [Axis] New Series D Convertible Preferred Stock [Member] Convertible Notes Payable [Member] Debt Instrument [Axis] Convertible Related Party Notes Payable [Member] Related Party Notes Payable [Member] Dot 2[Member] 6% note payable Due October 2017 [Member] Note payable [Member] Time payment lease due January 2014 [Member] 12% note payable due July 31, 2013 [Member] Related Party Notes Payable [Member] Preferred Units by Name [Axis] CEO [Member] Title of Individual [Axis] CFO [Member] Series A Preferred Stock [Member] Statement Class Of Stock [Axis] Esteemcare Inc. [Member] Business Acquisition [Axis] Angels of Mercy, Inc. [Member] Dotolo Research Corporation [Member] Debt Security [Axis] Angels of Mercy, Inc. #2 [Member] Minimum [Member] Range [Axis] Maximum [Member] Convertible Note 1 [Member] Convertible Note 2 [Member] Line of credit AA1 [Member] Dilutive shares [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Axis] Amian Health Services [Member] Corporate Overhead [Member] Segments [Axis] Personal Care Segment [Member] Medical Device Segment [Member] Conversion of promissory note #1 [Member] Transaction Type [Axis] Conversion of promissory note #2 [Member] Loss on conversion of promissory note #3 [Member] Loss on conversion of promissory note #4 [Member] Loss on conversion of promissory note #5 [Member] Warrants for additional compensation #1 [Member] Warrants for additional compensation #2 [Member] Warrants for additional compensation #3 [Member] Warrants for additional compensation #4 [Member] Common stock for finder fees #1 [Member] Common stock for finder fees #2 [Member] Common stock for finder fees #3 [Member] Common stock for finder fees #4 [Member] Common stock for a investor relations contract #1 [Member] Common stock for a investor relations contract #2 [Member] Omnibus [Member] Stock Incentative Plan [Member] Notes Payable [Member] Convertible Notes Payable 2247[Member] Convertible Note 2250 [Member] Convertible Note 2253 [Member] Loss on conversion of promissory note #6 [Member] Loss on conversion of promissory note #9 [Member] Loss on conversion of promissory note #8 [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Non-controlling Interest [Member] Common stock subscribed [Member] Indefinite-lived Intangible Assets [Axis] Convertible Note 3-Additional [Member] Medical Products Segment [Member] Loss on conversion of promissory note #10 [Member] Payments on a service contract #1 [Member] Payments on a service contract #2 [Member] Loss on conversion of promissory note #11 [Member] Loss on conversion of promissory note #12 [Member] Loss on conversion of promissory note #13 [Member] Service Agreement #1 [Member] Other Commitments [Axis] Service Agreement #2 [Member] Merchant Loan [Member] Subsequent Event Type [Axis] Convertible Debt [Member] Accredited Investor [Member] Consulting Contract [Member] Medical products and technologies [Member] Products and Services [Axis] Wells Fargo (13) [Member] Lender Name [Axis] Wells Fargo (15) [Member] LCA (4160) [Member] Wells Fargo (16) [Member] Wells Fargo (17) [Member] VGM (322) [Member] Wells Fargo (18) [Member] Convertible Note 2259 [Member] Convertible Note 2261 [Member] Dot 3 [Member] Esteemcare Reporting Unit [Member] VGM (323) [Member] VGM (324) [Member] DLL (61924) [Member] DLL (67910) [Member] DLL (61649) [Member] Convertible Note 2265 [Member] Convertible Note 2267[Member] Convertible Note 2269[Member] Convertible Note 2274[Member] Convertible Note 2271[Member] Convertible Note 2281[Member] Convertible Debt (1) [Member] Convertible Debt (2) [Member] Convertible Debt (3) [Member] Convertible Debt (4) [Member] Convertible Debt (5) [Member] Conversion of promissory note #3 [Member] Conversion of promissory note #4 [Member] Conversion of promissory note #5 [Member] Conversion of promissory note #6 [Member] Conversion of promissory note #7 [Member] Conversion of promissory note #8 [Member] Common stock for a investor relations contract #3 [Member] Additional Compensation 1 [Member] Additional Compensation 2 [Member] Finders Fee 1 [Member] Finders Fee 2 [Member] Finders Fee 3 [Member] Finders Fee 4 [Member] DLL (68936) [Member] Wells Fargo (019) [Member] VGM (325) [Member] DLL (68936)[Member] Convertible Notes Payable 2210[Member] Convertible Notes Payable 2218[Member] Convertible Notes Payable 2232[Member] Convertible Notes Payable 2238[Member] Convertible Notes Payable 2239[Member] Convertible Notes Payable 2247[Member] Convertible Notes Payable 2250[Member] Convertible Notes Payable 2261[Member] Convertible Notes Payable 2265[Member] Convertible Notes Payable 2267[Member] Convertible Notes Payable 2271[Member] Convertible Notes Payable 2274[Member] Convertible Notes Payable 2276[Member] Convertible Notes Payable 2278[Member] Convertible Notes Payable 2281[Member] Convertible Notes Payable 2290[Member] Convertible Notes Payable 2292[Member] Convertible Notes Payable 2294[Member] Convertible Notes Payable 2297[Member] Convertible Notes Payable 2310[Member] Convertible Notes Payable 2312[Member] Convertible Notes Payable 2314[Member] Convertible Notes Payable 2316[Member] Convertible Notes Payable Additional 2232[Member] Convertible Notes Payable Additional 2238[Member] Convertible Notes Payable 2283[Member] Dot 1 [Member] Dot 3[Member] Line of credit AA2 [Member] Merchant Loan AA3 [Member] Merchant Loan AA4 [Member] Merchant Loan AA5 [Member] Merchant Loan AA6 [Member] Merchant Loan AA7 [Member] Merchant Loan AA8 [Member] Note Payable AA9 [Member] Note Payable EST1 [Member] Note Payable 2226 [Member] Note Payable 2227 [Member] Note Payable 2228 [Member] Note Payable 2229 [Member] Note Payable 2230 [Member] Note Payable 2231 [Member] Note Payable 2236 [Member] Note Payable 2237 [Member] Note Payable 2255 [Member] Note Payable 2257 [Member] Note Payable 2258 [Member] Note Payable 2263 [Member] Note Payable 2264 [Member] Note Payable 2300 [Member] Note Payable 2432 [Member] Consultant[Member] Promissory Note[Member] Investor[Member] ServiceAgreement 1 [Member] ServiceAgreement 2 [Member] President [Member] Conversion of promissory note #9 [Member] Conversion of promissory note #10 [Member] Conversion of promissory note #11 [Member] Conversion of promissory note #12 [Member] Conversion of promissory note #13 [Member] Conversion of promissory note #14 [Member] Conversion of promissory note #15 [Member] Conversion of promissory note #16 [Member] Conversion of promissory note #17 [Member] Conversion of promissory note #18 [Member] Conversion of promissory note #19 [Member] Conversion of promissory note #20 [Member] Convertible Notes Payable 2322[Member] Underlying Series A preferred stock Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Amendment Statement [Table] Statement [Line Items] Class of Stock [Axis] ASSETS Current Assets: Cash and cash equivalents Accounts receivable (net of allowance of $71,000 and $9,000) Inventory Prepaid expenses and other current assets Prepaid commissions and finders' fees Total current assets Property and equipment (net of accumulated depreciation of $38,026 and $28,264) Deposits and other assets Goodwill Patents, registrations (net of amortization of $102,576 and $97,983) Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Convertible notes payable (net of discount of $405,429 and $99,491) Notes payable (net of discount of $2,091 and $18,596) Notes payable - related parties Inventory finance agreements Accounts payable and other accrued expenses Accrued interest payable Accrued interest payable - related parties Current portion of long term debt Total current liabilities Long-term liabilities: Notes payable (net of current portion) Convertible notes payable Total long-term liabilities Total liabilities Stockholders' Deficit: Preferred stock Common stock, par value $.001 per share; 750,000,000 shares authorized;; 750,000,000 shares authorized; 276,746,130 and 134,600,152 shares issued and outstanding at May 31, 2015 and August 31, 2014, respectively Additional paid-in capital Accumulated deficit prior to reentering development stage Common stock subscribed (0 and 1,058,201 shares issuable, respectively at February 28, 2015 and August 31, 2014) Noncontrolling interest Total stockholders' deficit Total liabilities and stockholders' deficit Allowance for doubtful accounts receivable Property and equipment, accumulated depreciation Patents and registrations,net of, amortization Notes payable, discount Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Common stock suscribed Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses: General and administrative Research and development expense Depreciation and amortization Total operating expenses Loss from operations Other income (expense): Acquisition costs Interest and finance charges Interest and finance charges - related parties Loss on conversion of notes payable - related parties Loss on disposal of assets Other income (expenses) Total other income (expense) Loss from continuing operations Discontinued operations Operating loss from discontinued operations Gain on disposal of discontinued operations Gain from discontinued operations Less loss attributable to noncontrolling interest Net gain from discontinued operations Net loss before income taxes Income taxes Net loss attributable to common shareholders Gain (loss) per common share, basic and diluted: Continuing operations Discontinued operations Common share, basic and diluted Weighted average number of shares outstanding - basic and diluted Statement of Cash Flows [Abstract] Operating activities: Net loss Net gain from discontinued operations Net loss from continuing operations Adjustments to reconcile net loss to net cash used in operating activities: Loss on disposal of property and equipment Stock based compensation Amortization of discount on notes payable and warrants Beneficial conversion feature notes payable Loss on conversion of notes payable - related parties Induced conversion expense notes payable Non-cash interest charges Issuance of stock and warrants for fees Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and other current assets Prepaid commissions and finders' fees Deposits and other assets Accounts payable and other accrued expenses Accrued interest payable - related parties Accrued interest payable Net operating cash flows - continuing operations Net operating cash flows - discontinued operations Net cash used in operating activities Investing activities: Purchase of property and equipment Cash acquired from Amian Health Services Acquisition of Amian Health Services Acquisition of Esteemcare and Affordable Net cash used in investing activities Financing activities: Proceeds from issuance of convertible notes Proceeds from issuance of notes payable Proceeds from the issuance of common stock Repayment of notes payable Repayment of notes payable - related parties Repayment of inventory financing agreements Repayment of convertible notes payable Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Accounting Policies [Abstract] Organization and Description of the Company Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Business Combinations [Abstract] Acquisitions Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations Inventory Disclosure [Abstract] Inventory Property, Plant and Equipment [Abstract] Property and Equipment Leases [Abstract] Leases Goodwill and Intangible Assets Disclosure [Abstract] Goodwill, Patents and Other Intangible Assets Debt Disclosure [Abstract] Inventory Financing Agreement Payables and Accruals [Abstract] Notes Payable Equity [Abstract] Stockholders' Equity Related Party Transactions [Abstract] Related Party Transactions Segment Reporting [Abstract] Business Segments Joint Ventures Compensation and Retirement Disclosure [Abstract] Retirement Plan Income Tax Disclosure [Abstract] Income Taxes Recent Accounting Prouncements Supplemental Cash Flow Elements [Abstract] Statement of Cash Flows Compensation Related Costs [Abstract] Employment Agreements Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events BASIS OF PRESENTATION PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES SEGMENT INFORMATION REVENUE RECOGNITION CASH AND CASH EQUIVALENTS ACCOUNTS RECEIVABLE INVENTORY PROPERTY AND EQUIPMENT LONG-LIVED ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS NONCONTROLLING INTEREST ADVERTISING COSTS INCOME TAXES FAIR VALUE OF FINANCIAL INSTRUMENTS STOCK-BASED COMPENSATION INVENTORY FINANCING AGREEMENTS CONVERTIBLE DEBT RECLASSIFICATIONS STOCK INCENTIVE PLANS NET LOSS PER COMMON SHARE RECENT ACCOUNTING PRONOUNCEMENTS NEW ACCOUNTING STANDARD Property and equipment, useful life Net Loss Per Common Share Dilutive Securities Dotolo Research Corporation Amian Health Services EsteemCare Discontinued Operations Property and Equipment Leases Tables Leases Financing Agreements Convertible Notes Payable Future minimum payments of Convertible Notes Payable Convertible Related Party Notes Payable Related Party Notes Payable Future minimum payments of Related Party Notes Payable Other Notes Payable Future Minimum payments related conv. notes payable Series A Convertible Preferred Stock Series D Convertible Preferred Stock Registered Securities Subscribed Stock issuable Common Stock Preferred Stock Converson Periods Sales of Unregistered Securities Warrant Activity Fair-Value of Warrants Exercisable outstanding warrants Stock Options Average Intrinsic Value of Options Business Segments Uncertain Tax Positions Income Tax Benefit Statutory Income Tax Rate Deferred Tax Assets (Liabilities) Supplemental Non-cash Investing and Financing Activities Description Of Company Details Debt relief Minimum Useful Life (Years) Maximum Useful Life (Years) Fair value exceeds the carrying value of goodwill Discount rate Summary Of Significant Accounting Policies - Net Loss Per Common Share -basic And Diluted Details Continuing operations Discontinued operations Weighted average shares outstanding Loss per common share, basic and diluted: Summary Of Significant Accounting Policies - Net Loss Per Common Share - Dilutive Securities Details Description Convertible preferred stock Convertible notes payable Options Warrants Total potentially dilutive securities Notes Payable Details Narrative 4 Amount needed to fund operations Amount needed to fund overhead Cash and cash equivalents Accounts receivable (net) Inventory Prepaid expenses and other current assets Property and equipment Deposits and other assets Intangible assets Patents, registrations Purchased Goodwill Total assets acquired Accounts payable and other accrued expenses Inventory financing agreements Customer deposits Notes payable Notes payable - related parties Accrued interst payable Accrued interest payable - related parties Total liabilities assumed Acquisitions Details Narrative Proceeds Stock received during Acquisition Purchase price Down payment received Promissory note for sale of stock Payoff operating leases Warrants issued Exercise price Broker fees Discountinued Operations Details Promissory note Legal Billings Payments, monthly Discountinued Operations Details 1 General and administrative Depreciation and amortization Total operating expenses Loss from operations Total other income (expense) Loss from discontinued operations Gain on disposal of discontinued operations Loss from discontinued operations Net loss from discontinued operations Property And Equipment Details Narrative Furniture Office Equipment Computers Software Leasehold improvements Equipment Total property and equipment at cost Less: accumulated depreciation and amortization Property and equipment (net of accumulated depreciation of $28,264 and $11,820) Leases Details 2015 2016 2017 2018 2019 Totals Future rent payments, monthly Rent Expense Patents and Registrations Accumulated Amortization Amortization Expense Line of Credit Facility [Table] Line of Credit Facility [Line Items] Finance Agreement Monthly payment Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Total unsecured convertible notes payable Long-term portion Less: Current portion Convertible Notes Payable Details 1 Future minimum payments Convertible promissory note Assigned principal to another investor Interest rate of note Convertible discount Per share conversion rate of note Beneficial conversion feature Interest accrued on promissory notes Note payable Extended convertible promissory notes Per share conversion rate of extended notes Interest accrued on promissory notes Loss on conversion of notes payable Shares issued Shares issued, amount Note reduction Credit Line Facility Credit line borrowed amount Credit line repaid Outstanding unsecured related party convertible notes payable Interest Rate Principal paid Interest paid Accrued interest Other Notes Payable Less: Long-term Portion Current Portion Date Financing Agreement Notes Payable Note payable - current Proceeds of Loan Interest rate of note Monthly installments Number of installments Total Payments Interest payments Accrued Interest Broker fees Loan fees Warrant issued for debt Debt Discount Converted debt, amount Shares issued for debt Maximum Useful Life (Years) Future minimum payments Number of Preferred Shares Shares Outstanding, beginning balance Shares Expired/Retired Shares Converted Shares Issued Shares Outstanding, ending balance Number of Common Shares Convertible Shares Outstanding, beginning balance Shares Expired/Retired Shares Converted Shares Issued Shares Outstanding, ending balance Proceeds if Shares Converted Amount converted, beginning balance Shares Expired/Retired Shares Issued Amount converted, ending balance Weighted Average Exercise Price Per Common Stock Shares Outstanding, beginning balance Shares Expired/Retired Shares Converted Shares Issued Sharess Outstanding, ending balance Stockholders Equity Details Narrative Series A convertible preferred stock authorized Series A convertible preferred stock par value Series A convertible preferred stock outstanding Stockholders Equity Additional Details Narrative Private Placement of Units Common stock unit Series A preferred stock unit Par value of Series A preferred stock Three year warrant to purchase one share of common stock Series A preferred stock convertible to oen-half share of common stock Total convertible units issued Units Outstanding Underlying Series A preferred stock Underlying common stock Shares Outstanding, beginning balance Series D Convertible Preferred Stock, authorized Series D Convertible Preferred Stock, par value Convertible common stock, shares Series D Convertible Preferred Stock, liquidation value Votes per share Series D Convertible Preferred Stock, issued Series D Convertible Preferred Stock, fair market value Stockholders Equity - Stock Subscribed Details Narrative Common stock subscribed Shares issued conversion of notes payable Stockholders Equity Details Narrative 2 Value of 10% IUTM noncontrolling interest Impairment loss on IUTM investment Cumulative net loss attributable to noncontrolling interest Outstanding Warrants Warrants Exercised Warrants issued Weighted Average Exercise Price Votality Risk free rate Expected dividends Exepected Term Stockholders Equity- Warrants Details Narrative 1 Shares authorized under stock option plans Shares issued under stock option plans Weighted Average Exercise Price Shares Cancelled Share compensation expense Exercise Price Range [Axis] Option Indexed to Issuer's Equity [Axis] Shares authorized Shares for future issuance Number of options Aggregate intrinsic value of options Weighted average remaining contractual term (years) Weighted average exercise price Number of Options Granted Shares Outstanding, beginning balance Shares Granted Shares Exercised Shares Cancelled Shares Outstanding, ending balance Accounts receivable Property and equipment (net of accumulated depreciation of $ $19,999 and $11,820) Patents, registrations (net of amortization of $94,921 and $91,859) Total operating expenses Loss from operations Loss on conversion of notes payable - related parties Other income (expenses) Total other income (expense) Loss from continuing operations 90 day related party promissory note Equity interest in IUTM IUTM assumption of company debt Debt reduction Tax Provision Current: Deferred: Federal State Income Tax Benefit. gross Less : Valuation Allowance Income Tax Benefit, net Statutory tax rate State income taxes Change in valuation allowance Effective tax rate Deferred tax assets (liabilities): Property and equipment Intangible assets General business credits Net operating loss carryforward Deferred Tax Asset, Gross Valuation allowance Deferred Tax Asset, Net Federal net operating loss carryforward Business credit loss carryforward Loss carry forward limitiation Valuation Allowance Valuation Allowance Current Year Issued warrants Additional Compensation Issued shares of common stock in payment for a investor relations consulting contract Conversion of 635,069 shares of common stock Conversion prommsiory note to nonrelated Loss on related party conversion of note payable Discount on convertible note Director and officer insurance premium note payable Issued warrants to a non-related party as additional compensation Loss on conversion of convertible debt Issued shares of common stock in payment for a services contract Beneficial conversion feature on issuance of convertible note Issued a total of 9,583,333 warrants for issuance of convertible debt Consideration for Acquisition Warrants issued Total noncash transactions from investing and financing activities Conversion expense reduction on notes Conversion loss related party notes Warrants Issued Shares Issued Other Commitments [Table] Other Commitments [Line Items] Company expense related party agreement Base Salary Officer's Salary Benefits Salary Increase Accrued Officer's Salary Common stock shares for services Service Agreement Share issued Subsequent Event [Table] Subsequent Event [Line Items] Loan obtained Interest rate Periodic Payments Total payments Proceeds of Loan Proceeds from sale of stock Down payment of stock sold Note receivable for stock sold Broker fees Accrued Interest Converted debt, amount Shares issued for debt Issuance of common stock, shares Price per share Acquisition Of Amian Health Services Additional Compensation 1 Member Additional Compensation 2 Member Amian Health Services Member Angel Of Mercy Inc, 2 Angel Of Mercy Inc Member Assigned Principal To Another Investor Business Acquisition Pro Forma Information Nonrecurring Adjustments1 Table TextBlock Business Acquisition Pro Forma Information Nonrecurring Adjustments 2 Table Text Block Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Interest Payable Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Interest Payable Related Parties Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Customer Deposits Capital Required For Overhead Amount needed to fund operations Warrants Underlying common stock Common Stock For Finder Fees 1 Member Common Stock For Finder Fees 2 Member Common Stock For Finder Fees 3 Member Common Stock For Finder Fees 1 Member Common Stock Investor Contract 1 Member Common Stock Investor Contract 2 Member Common Stock Investor Contract 3 Member Common Stock Subscribed Member Computers Consultant Member Conversion Of Promissory Note 10 Member Conversion Of Promissory Note 11 Member Conversion Of Promissory Note 12 Member Conversion Of Promissory Note 13 Member Conversion Of Promissory Note 14 Member Conversion Of Promissory Note 15 Member Conversion Of Promissory Note 16 Member Conversion Of Promissory Note 17 Member Conversion Of Promissory Note 18 Member Conversion Of Promissory Note 19 Member Conversion Of Promissory Note 1 Member Conversion Of Promissory Note 20 Member Conversion Of Promissory Note 2 Member Conversion Of Promissory Note 3 Member Conversion Of Promissory Note 4 Member Conversion Of Promissory Note 5 Member Conversion Of Promissory Note 6 Member Conversion Of Promissory Note 7Member Conversion Of Promissory Note 8 Member Conversion Of Promissory Note 9 Member Series A convertible preferred stock converted Convertible Debt 1 Member Convertible Debt 2 Member Convertible Debt 3 Member Convertible Debt 4 Member Convertible Debt 5 Member Long-term portion Convertible Debt Long Term Convertible Debt RelatedParty Member Convertible Note 1 Member Convertible Notes Payable 2347 Member Convertible Notes Payable 2250 Member Convertible Notes Payable 2253 Member Convertible Notes Payable 2259 Member Convertible Notes Payable 2261 Member Convertible Notes Payable 2265 Member Convertible Notes Payable 2267 Member Convertible Notes Payable 2269 Member Convertible Notes Payable 2271 Member Convertible Notes Payable 2274 Member Convertible Notes Payable 2281 Member Convertible Note 2 Member Convertible Note 3 Additional Member Convertible Notes Payable 2210 Member Convertible Notes Payable 2218 Member Convertible Notes Payable 2332 Additional Member Convertible Notes Payable 2232 Member Convertible Notes Payable 2238 Member Convertible Notes Payable 2239 Member Convertible Notes Payable 2247 Member Convertible Notes Payable 2250 Member Convertible Notes Payable 2261 Member Convertible Notes Payable 2265 Member Convertible Notes Payable 2267 Member Convertible Notes Payable 2271 Member Convertible Notes Payable 2274 Member Convertible Notes Payable 2276 Member Convertible Notes Payable 2278 Member Convertible Notes Payable 2281 Member Convertible Notes Payable 2283 Member Convertible Notes Payable 2290 Member Convertible Notes Payable 2292 Member Convertible Notes Payable 2294 Member Convertible Notes Payable 2297 Member Convertible Notes Payable 2310 Member Convertible Notes Payable 2312 Member Convertible Notes Payable 2314 Member Convertible Notes Payable 2316Member Convertible Notes Payable 2338 additional Member Total convertible units issued DLL 61649 Member DLL 61924 Member DLL 679104 Member DLL 68936 Member Conversion expense reduction on notes Debt Related Party Member Dilutive Shares Member Document And Entity Information Dot 1 Member Dot 2 Member Dot 3 Member Dotolo Research Corporation Member Extended convertible promissory notes due March 31, 2012 Interest accrued on promissory notes Private Placement of Units Common stock unit Series A preferred stock unit Esteemcare Inc Member Esteemcare Reporting Unit Member Fair Value Exceeds Carrying Value Of Goodwill Finders Fee 1 Member Finders Fee 2 Member Finders Fee 3 Member Finders Fee 4 Member Loss on conversion of notes payable related party Going Concern Details Narrative Increase Decrease From Beneficial Conversion Feature Notes Payable Increase Decrease Ininduced Conversion Expense Underlying Series A preferred stock Joint Ventures Details Narrative LCA 4160 Member Line Of Credit AA1 Member Line Of Credit AA2 Member Loss On Conversion Of Promissory Note 10 Member Loss On Conversion Of Promissory Note 11 Member Loss On Conversion Of Promissory Note 12 Member Loss On Conversion Of Promissory Note 13 Member Loss On Conversion Of Promissory Note 3 Member Loss On Conversion Of Promissory Note 4 Member Loss On Conversion Of Promissory Note 5 Member Loss On Conversion Of Promissory Note 6 Member Loss On Conversion Of Promissory Note 8 Member Loss On Conversion Of Promissory Note 9 Member Medical Device Manufacturing Member Medical Products Segment Member Line Of Credit AA3 Member Line Of Credit AA4 Member Line Of Credit AA5 Member Line Of Credit AA6 Member Line Of Credit AA7 Member Line Of Credit AA8 Member Merchant Loan Member Cumulative net loss attributable to noncontrolling interest Note Payable 2226 Member Note Payable 2227 Member Note Payable 2228 Member Note Payable 2229 Member Note Payable 2230 Member Note Payable 2231 Member Note Payable 2236 Member Note Payable 2237 Member Note Payable 2255 Member Note Payable 2257 Member Note Payable 2258 Member Note Payable 2263 Member Note Payable 2264 Member Note Payable 2300 Member Note Payable 2432 Member Line Of Credit AA9 Member Note Payable EST1 Member Notes Payable Details 2 Notes Payable Details Narrative 3 Notes Payable Other Payables Details Member Officers Salary Increase Ominbus Member Payments On A Service Contract 1 Member Payments On A Service Contract 2 Member Per Share Conversion Rate Of Extended Notes Personal Care Services Member Par value of Series A preferred stock Series A convertible preferred stock par value Series A convertible preferred stock authorized Series A convertible preferred stock outstanding Preferred Stock D TextBlock Shares Outstanding, beginning balance Preferred Stock Redemption Price Per Share 2 Promissory Note For Sale Of Stock Promissory Note Member Maximum Useful Life (Years) Minimum Useful Life (Years) 12% Note Payable May 23,2014 Member Schedule Of Future Minimum Lease Payments For Convertible Notes Payable Table Text Block Schedule of Future Minimum Lease Payments For Related Conv Notes Payable Table Tex tBlock Schedule Of Future Minimum Lease Payments For Related Party Notes Payable Table TextBlock Series D Convertible Preferred Stock Authorized Series D Convertible Preferred Stock Issued Series D Convertible Preferred Stock Par Value Series D Shares Outstanding Beginning Balance Service Agreement 1 Member Service Agreement 2 Member Service Agreements 2 Member Shares Converted Weighted average remaining contractual term (years) 6% Note Due October 2017 Statement Of Cash Flows Details Stock Incentative Plan Member Stockholders Equity Details Stockholders Equity Details Narrative 1 Stockholders Equity Details Narrative 2 Stockholders Equity Details Narrative 3 Stockholders Equity Details Narrative Shares converted by related party Summary Of Significant Accounting Policies - Net Loss Per Common Share -Basic And Diluted Details Summary Of Significant Accounting Policies - Net Loss Per Common Share - Dilutive Securities Details Time Payment Lease Due January 2014 Member Total Other Income Expense 12% Note Payable July 31,2013 Member VGM 322 Member VGM 323 Member VGM 324 Member VGM 325 Member Warrnts Fo rAdditional Compensation 1 Member Warrnts Fo rAdditional Compensation 2 Member Warrnts Fo rAdditional Compensation 3 Member Warrnts Fo rAdditional Compensation 4 Member WellsFargo 019 Member Wells Fargo13Member Wells Fargo15Member Wells Fargo16Member Wells Fargo17Member Wells Fargo18Member Convertible Notes Payable 2322 Member RelatedPartyNotesPayableDetailMember ConvertibleNotesPayable2247Member Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Gains (Losses) on Restructuring of Debt Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Other Expenses Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic and Diluted Share Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax Increase (Decrease) in Prepaid Expense Increase (Decrease) in Prepaid Expenses, Other Increase (Decrease) in Deposit Assets Increase (Decrease) in Accounts Payable and Other Operating Liabilities Increase (Decrease) in Due to Other Related Parties Increase (Decrease) in Other Accrued Liabilities Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Repayments of Related Party Debt Repayments of Lines of Credit Repayments of Convertible Debt Net Cash Provided by (Used in) Financing Activities, Continuing Operations Inventory Disclosure [Text Block] Disposal Groups, Including Discontinued Operations [Table Text Block] Property, Plant and Equipment [Table Text Block] Operating Leases of Lessee Disclosure [Table Text Block] Business Combination, Segment Allocation [Table Text Block] Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCustomerDeposits Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedInterstPayable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedInterstPayableRelatedParties Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Disposal Group, Including Discontinued Operation, General and Administrative Expense Disposal Group, Including Discontinued Operation, Depreciation and Amortization Discontinued Operation, Tax (Expense) Benefit from Provision for (Gain) Loss on Disposal Property, Plant and Equipment, Gross Operating Leases, Future Minimum Payments Due DueToAffiliateCurrent2 Other Notes Payable [Default Label] Long-term Debt, Gross Debt Instrument, Interest Rate, Effective Percentage Debt Issuance Cost NotesPayableDetailsNarrative3Abstract Payments for Loans Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Goods and Nonemployee Services Transaction, Shares Approved for Issuance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period PreferredStockRedemptionPricePerShare1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price IncrementalCommonSharesAttributableToConversionOfPreferredStock1 SeriesDSharesOutstandingBeginningBalance Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Operating Costs and Expenses Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest Increase (Decrease) in Notes Payable, Related Parties Other Nonoperating Expense TotalOtherIncomeExpense Deferred Tax Assets, Property, Plant and Equipment Deferred Tax Assets, Goodwill and Intangible Assets Deferred Tax Assets, Net Proceeds from Other Debt Stock Issued During Period, Shares, Other Proceeds from Bank Debt Payments for Fees Increase (Decrease) in Accrued Liabilities Debt Instrument, Convertible, If-converted Value in Excess of Principal NotesPayableDetails2Abstract StatementOfCashFlowsDetailsAbstract StockholdersEquityDetails4Abstract StockholdersEquityDetailsAbstract EX-101.PRE 11 oclg-20150531_pre.xml XBRL PRESENTATION FILE XML 12 R39.htm IDEA: XBRL DOCUMENT v3.2.0.727
Summary of Significant Accounting Policies - Property and Equipment (Details) (USD$)
 9 Months Ended
May. 31, 2015
yr
Computer Equipment [Member]  
Minimum Useful Life (Years) 5.0
Maximum Useful Life (Years) 5.0
Equipment [Member]  
Minimum Useful Life (Years) 5.0
Maximum Useful Life (Years) 10.0
Software [Member]  
Minimum Useful Life (Years) 5.0
Maximum Useful Life (Years) 5.0
Furniture and Fixtures [Member]  
Minimum Useful Life (Years) 5.0
Maximum Useful Life (Years) 10.0
XML 13 R54.htm IDEA: XBRL DOCUMENT v3.2.0.727
Convertible Notes Payable (Details) - USD ($)
May. 31, 2015
May. 31, 2014
Convertible Notes Payable [Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable $ 477,596 $ 420,365
Long-term portion   (235,025)
Less: Current portion 477,596 185,340
Convertible Notes Payable 2210[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable $ 64,025 235,025
Convertible Notes Payable 2218[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable   100,000
Convertible Notes Payable 2232[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable   (567)
Convertible Notes Payable 2238[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable   5,300
Convertible Notes Payable 2239[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable   7,260
Convertible Notes Payable 2247[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable   4,918
Convertible Notes Payable 2250[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable   $ 68,429
Convertible Notes Payable 2261[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable $ 8,100  
Convertible Notes Payable 2265[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 12,370  
Convertible Notes Payable 2267[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 24,897  
Convertible Notes Payable 2271[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 16,911  
Convertible Notes Payable 2274[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 11,123  
Convertible Notes Payable 2276[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 17,161  
Convertible Notes Payable 2278[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 56,910  
Convertible Notes Payable 2281[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 13,095  
Convertible Notes Payable 2290[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 31,918  
Convertible Notes Payable 2292[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 18,885  
Convertible Notes Payable 2294[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 15,579  
Convertible Notes Payable 2297[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 17,680  
Convertible Notes Payable 2310[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 15,650  
Convertible Notes Payable 2312[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 1,813  
Convertible Notes Payable 2314[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 20,592  
Convertible Notes Payable 2316[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable 30,887  
Convertible Notes Payable 2322[Member]    
Debt Instrument [Line Items]    
Total unsecured convertible notes payable $ 100,000  
XML 14 R48.htm IDEA: XBRL DOCUMENT v3.2.0.727
Inventory (Details Narrative) - USD ($)
May. 31, 2015
Aug. 31, 2014
May. 31, 2014
Inventory $ 137,436 $ 31,271 $ 31,271
Medical products and technologies [Member]      
Inventory $ 106,165    
EXCEL 15 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`%F3"D?G]9[`0P(``"DO```3````6T-O;G1E;G1?5'EP97-= M+GAM;,W:W6[3,!0'\%>I`&3N$W4)+9LK^O>'CO=$%0% M;;!*_YNFZ;'/.]_O;H;5P2H;JZ_[&T(?6L7'X^!DGM=&>^'OC&I=Q/9 M3^U)UJ7;;/K&MJZY'_.6.N72]EV.5XL[$])G,^84Y#"0.7#\I'6)D[!QO/U3]&GBO?VHVY']*K"C_=NSK885X3N]X_E?ITR%EB_FU= MY6A\4873C7_KK!_+T/RT_6U'.?_':SFYB?MQN`WFH3\IL+_8F,JQ'DT_G1O5 M@PN[[\[MWO(QL>6J6MLN?<@+0^K//"5Y\5V.1I)3_U?MYR>E<<&^J&!9>,&7 MHC/!ME]3R/,]_V[\NN!R?92YSM__-/0Y&,E\N"`2K^J#@?3!0?H0('U(D#X4 M2!\:I(\KD#[>@_1!5RB-H(A*44BE**92%%0IBJH4A56*XBI%@96BR,I09&4H MLC(461F*K`Q%5H8B*T.1E:'(RE!D92BRQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6: ME((C-Z."N[_8_`)02P,$%`````@`69,*1\`AU&6!`@``[2\``!H```!X;"]? M%>=-"%@;.Q80D8_JO/`L6G/C?K+^GTZ7+#\.8^OGN?I@N79E_3H=Z[+;OW2'5TC16 M3[=SJN>G/V>O7G>;:GK=N6KUM9L.J6RJ[\/TGH\IE5Q?O]S#O,!\^V-,_[/\ ML-^?MNEEV'Z[I+[\HZ+^M4!5+P?)AQ.>B1$N0:(&/#24)8<[1V@&O'\=H!L!U';`?(=ARS'4#; M<=1V@&W'<=L!N!U';@?H=AR['<#;M='#-D=O`7H+1V\! M>@M';P%Z"T=O`7H+1V\!>@M';P%Z"T=O`7H+1V\%>BM';P5Z*T=O!7HK::\$ M;99P]%:@MW+T5J"W5'+T#T#MP]`Y`[\#1.P"]`T?O M`/0.'+T-Z&TAM'+T-Z&TAMI+,FZ+`)1V\#>AM' M;P-Z&T=O`WH;1^\(](X*=77S[O_FUVG_@RI_SK9__P)4$L#!!0````(`%F3 M"D<2O$;:"`0``&D2```0````9&]C4')O<',O87!P+GAM;+U8VY+:.!#]%14O M.UNUQ,QD;CM%J&)@DLU6-E"!G3QKY`948TN.)),A7[\M&8P-DKD\+$^RW*=; MW7V.9-$5NO,P5C(#93AH\I8F0C_@Y(?6PICL(8HT6T!*]3LT$?AV)E5*#3ZJ M>21G,\Y@*%F>@C#15:=S&\&;`1%#W,Y*IZU>UT;I9UG"&35C"8:"JOMI+,9R#2C8A45 M3U^X>-7_9E,YI`:JJ/J+PON"*H@Q:,U[.>EL_EIAGHG%#A94S"&NVNZ_W-3B M&92VF5Y>O>O@KRS!9K[P#33F8CZF7.E>=VD>EL",5.LV+8T\NQM2+F1BTM@O3 M1,[("+GGUN,/4#<>4+T@'Q/YTV\\4G,J^"_GSF4]!,T4S]RSG/D#Y&E*U3BO(==,HG^18^$.U."S M6&(!I%IYWZXWQE719@R;V7)Y3;\`\L8?XY.4\4^>)'^0,1;[?8[JB+PD$^BW9ZT(F,>XPO[ETC#_M;Y`X MTEFMK.RW"%YIBDW:=G/@:/<'+!7@?0F^8N& M'[GU_;0,K[9)-%=W9V#N#\J(7$PM:_3OI^AI`SI!.Y]$FA%[Y#\4P,O%QEK6=UJR_IHA%T,PE"=GL.C]GZ=CKCMG8"[/P%P=/A;* MU,E7JBP;EX<9WB9UP@_]>^2N43V,'^/TD?L$XO"G8Z[]*M]R?W]A?K:%5-C$ MG(T*US;-4CUR'8TGX(V_X\U*;X<^F9;VSF%UOJ-ZN]+3,3<;:;OT<\&':Q,T2/.G/B!,XV[UQOEO!62$=BZE`_%SSQ\$K4L[7ZE^7>]=V7?U!+`P04````"`!9DPI' MJ@R)6#\!``!I`P``$0```&1O8U!R;W!S+V-O&ULS9--3\,P#(;_"NJ] M2[N-::JZ'@!Q8A(20R!N(?&VL.9#B:>N_Y[,*RT#+KMQJVN_CU_'22E<(:R' M1V\=>%00K@ZZ-J$0;I%L$5W!6!!;T#R,8H6)R;7UFF,,_88Y+G9\`VR<93.F M`;GDR-D1F+J>F%2E%(7PP-'Z#B]%CW=[7Q-,"@8U:#`86#[*65(]FYVQC2G9 MH*_*Z+CF`9=6JK4">=,.9;]3L3."U^$D!]FWI[]_>J`,2[K*0U!]5=,THV9" M=7'@G+TN'Y[H;%)E`G(C(*J"*K!UL$B^.K],;N]6]TDUSO+K-)NG>;;*Y\5X M5DRG;\?)SOP-AG4WQ+]U_&60MHL*:[APMZ21M%SZ))"$(+QRJ*RY"$>8;V*" MA?W[!PB\'-0)Z;+MH&VLEZ&B^S5$QY<35[:QOCVE?D1GKZKZ!%!+`P04```` M"`!9DPI'F5R<(Q`&``"<)P``$P```'AL+W1H96UE+W1H96UE,2YX;6SM6EMS MVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8- M[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P" MI`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L' MI4;1]E6\W*.76!4!EQC?-*HU+,76>)7`\:V@S&L%&KQMUAVC2/'K^!?F<-0H< MD1L=`F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T M$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG! MZ(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$5FJ?JH,@H% M\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3 MBUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU M^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7 M;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W M8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U M;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q M9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[V MW>/Z;I,[2$R<><41`71%`B.5'`86%S+D4.Z2D`83``>LX=SFWJXPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y M)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&M MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8V MH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0````(`%F3"D=_\MK^9P(``'(,```- M````>&PO9Z)1>2(:6GLO"J4F*452:(46_L^U./(<)A'/*:S9BJ M0"IJKB(XZ2#@XN]%AB/X=/GQ=RW4W0?@QHM/%Q?^T]7=$+^T"U<0.(YO602# MZ01ZKR<=^?YN8K,X()\>2/X2]X#ZYE#=+PL?TG\^F'Y?@G]2W)H47GO%<9@+ MWM_T&#H@#JMGL$14^P?&/1542*!T*6DM%N&(8>=QCRA))#%@CABA*P>/#6"K MK_5CA`MI<[L,PSPCO\\DBR2"?OM[?;JD9[>#V1ZA='M[&HC#$BF%)9_I"6CM M^:K4F^."8R?2^NWQ+B1:!>/)1H`==-Y$R`S++G,`UU`<4IPK'2!)L3"C$J61 M+I023!L9087@B!K*=41K:-H44_IHGO5?^19WDP/G8^[8A\"H6)OZ(%JS+P-[ MJ-XFF^/>I+T^BA9=`1Z.RI*NOE!2<82?603/1SO;1!SOHXQ"M6<%"2/*L M_4TAI!K`$H(EEHJDF\@?BJA9@N7,_D$>+NGZ9O^5V:<3#F2^;]4<(>$$AV-:\]E*FYZOM+>IJ5-4^^VY M*C.O.VHINHG60IE%R/8V]^-_&#:>X%``"A&```#P```'AL+W=O5.%%5WXK.3I+IM)AHT7`K56>6,/\FD>33SLJ:L7FE6J%FO8]5*:[X\7(E:+.>\;>^V"?7KN+(J3 M+$F*-\X5TEV-`= M`Y`$(,F;(.S=!0=0"J!T#+JR#N'[99B:L_.5T&MU@9`!(7N)<,S-DGUR#B(A M!T(^)ISK!>_DK^'!P_">"%-IN1J.U1Q`!8`*(I2^;;E^\'%Y9+,0#Q%I:9CQ%EWZQ*@]`,V"CPD1+S0K@)II_%@M(M\Y;.(!)0P)BS\ M(K@10:!H6TSH]EFI^DXVS5_LPEGCG?$//[=+H=UL"AZ.VL6$=YL^LT^R<_[[ MC!TNM!#;O4#[8D*_K\H*X^)YX+X@0$.T+:9TLZKZL51-[:KC'\,(VB`!*%E, M6';IWQ,NYQ?<9^%:\\[XRKF5>W0N)J0[ZHWLA#'L2BR&:8B-4;V8<.]?)[IE MWURS7@>93%"YA%#N4EBIA[%F%Z[\8%,4+R'$NQ25@&GI\N94[-U"F]ORV]"1H9$(8>=JN&O4P,#;V!`#T,"$\/%9M*VV[D?EXF,L+X8P,1Q0] M3`@/K_H;(W[V/I+3V^THT,7DK:4O*1&%6B:$EKM1^XA"-Y,7"B)[=^TGF/D3 M`>AG\OK:^,3"]QP*FQ+"TN6.BBI%@5-"X'7=(YNBL2EA[,ZJQ=XA*GAS$^8& M=8L,!M5-R5?WN("1(%0W)=0=U2"2@@ZG9#TE9S.5;'0X)1P.5Q!N3K8KWKF^ MG0C+91.@T.&4<'CG=$C?(PIM3@F;=Z*R*:ZYT.:,L'DW*D84VIP1-N]&)8A" MNS/"[F#=M!EM]I5K/W%O$85V9X3=0>G88V$E.<'W=!8L4`G-M]N&004H%#TC M1!_J44\5I`&+*+0](VS?BT;8_EQ4QKW#&9BAZQGA^N]JY'C:9.AZ M1KC^5",?FV(8.'USK5FCE[GZ'7^YJJ]ARCT.B>\=I/C MUG^I^IJ]5<%]=Q&%7N?DRF,'*L\1%7R!$5[O1A6(0J]SPNNP^1X+5[GXALO1 MZYSP>ITK8I2VA4*O<\+K[9C6X(U?B$*O<\)K$O5L*GZLHN8%5O'"0F6$ M*M#T`DTOJ%4V@=ICPUGF5N"("G8;7OC^&T>%%;Q`TPMJS4U&]=W7/5^X$(6N M%]1Z98P"$LZ_`ETOJ/4*&54RG4Z'`:XHHM+U\R^KU@7T"```F"0``&````'AL+W=O[%)I.YV+VFEE8S*B[0.OOVRX=:F*`W5?$< M?OR%4RA&0C]8C3'W/KNV9P>_YGS8!P&K:MPA]D(&W(LW5T([Q,4CO05LH!A= ME*EK`QB&:="AIO?+0K6]T;(@=]XV/7ZC'KMW':+_CK@EX\$'_MSPWMQJ+AN" ML@@6WZ7I<,\:TGL47P_^*]B?0"8E2O&[P2,S[CTY^#,A'_+AY^7@AW(,N,45 MEUT@<7G@$VY;V9,@_YTZ?3*ET;R?>_^NRA7#/R.&3Z3]TUQX+48;^MX%7]&] MY>]D_(&G&A+9845:IGZ]ZLXXZ6:+[W7H4U^;7EU'_28&D\UM@),!+H9=N&F( M)D.T&$"L*M4C4W5]0QR5!26C1_5D#$C..=A'XLM5'E.-5'\N41D3K8\R+(*' M[&920*4XF@JP*`+1]P*`+L!DAX8=N@`G4Q&Y`9$+$.D*(L,>N^VQRQYK>VS8 M$WM\6G$T%:D;D&P`$L.>V8!$`[2BUXH\3_.5,M(-2FI0=LXR3$7N!F0;@,Q< M!J&38$E6ELIN`[$S_=")L"0KBR7?0.2F/W8B+$GB1LC_AU6&?/GL(75";$VV M0G$&=Z98N71/N:U9HSC3.U/,<(+<3;$B'JY0G!&>*6:&(7!3+`UBMZ9EW)EQLCFHGNQ+"L1A$^"**KL6A97EH\97+VTQ^#;V-ZP=.AOE4 MLAR-RO]02P,$%`````@`69,*1^K]DHFE!```'A8``!@```!X;"]W;W)KK%[K<1* M;%2VO)(2=]]^J8/=H3$DB6%,*MC>3@M-^OQV?=V MLV[>^OIPJKZWB^[M>"S;_[95W5P>E["\/OAQ>-WWPX/59KVZQ>T.Q^K4'9K3 MHJU>'I=?X*%0HV14_'VH+AWYOQC,/S7-S^'FS]WC4@P>JKIZ[H20LW_SH7^KG,(I/^OI7\=FQOL/Y5=533U/X==OP]NQ7*QJU[*M[K_T5R^ M57,;]%#@A>6MV(P52ZVP#=Y:VF!O MV..K&L$Q>-$"@';.<55">M,F3^179\QHZG=AQKQ],V:ZGX M^1*IO#>)01I8FS0SO/SMAETEVUDS562ML:SI(I*!TBXQ5,#B\NJ'HDX)W@_0 M45!"H>.7=R0$Z\#:Q`('EIY73Q2?BETOVUDS5^6]8,%41#*IE$^-68[&0'&L M).^'@A:=E@+YA1X)`P-U&+B$)Q;*\PX#E,HJL2H@QU&@(%4\2($B4EFK/;\R M8AT:%*DVY6`*E*:*W<^V0$$I,:P.PQ*FB(1>&4AM?9"#*E"JWF-AWF*!$E.# M$8F$`7+,!`I-9?FV4QHJ"+MLJJ8<#H'R4/$\!(HZ$,XB>+[M5&A1>DSTLLQ! M45(H*K:FK:2TDX,E?BK*F(K.N,2V+G-8E!2+FL5B(2GM#*H$?F4.=9*B3@/? M91)RG!5/#C#2LL(N&P;VB1&HLO\IZ=HG*5'L)9>/(454ZDRI6$3-_:'$!_I# MY9"B(-,?\V:B*"@LGPZF-).3%?F2=RY?J[_*]O5PZA9/3=\WQ_$+WDO3]%4H M27P.';RORMWMIJY>^N&O'7I^^GPYW?3-^?HU]O9)>/,_4$L#!!0````(`%F3 M"D?II"IH&`,``!,.```8````>&PO=V]R:W-H965T&ULC9?? M;ILP%,9?!?$`Q7^P,542:66:MHM)52^V:YHX"2K@#)RF>_L93++CRCCTHH#Y MSCD_F\,7O+JH[JT_2JFCCZ9N^W5\U/KTF"3]]BB;LG]0)]F:.WO5-:4VE]TA MZ4^=+'=C4%,G!"&>-&75QIO5./;<;5;JK.NJE<]=U)^;INS^/LE:7=8QCJ\# M+]7AJ(>!9+-*;G&[JI%M7ZDVZN1^'7_!CP6A@V14_*KDI0?GT0#_JM3;C+YON%@E[T.>24)&R1.4$)^B@`J*;I+$U+]!$!]$:B$(A,C=$IF%L))V ME&08(>13%5"50Y�@,H%*!DGXHPBT)!$2H0X3Y5`55$$)[Z6=(`2PI9L'=9 M4E`%(\(R[ET7*,NS7%`_#`O`,`CSJ0V$A6&@"GI`"/M4Q;S*8>$!%@Y9J/NBP][QF@,Z7 M">\K.FDL;(I82KP.5SBZ/$_SN2F%G!1#*\WRF0PA`\1TP90<)EU!60N3\B\,'0O@;UO`.9.@P?<*ZQT MJ4+VA:%_">*G4+^1?#]7B1X:2^&E2Y5\'.0W.]%XGP0"L:]/[E%0.;R MA"R1T/N=2.@RGGF9Y4G`Y_NI/,B?97>HVCYZ5=KL!,;/]KU26IIDZ,$D/9H= MVNVBEGL]G&9#-;MGL1=:G:Y;L-L^&PO=V]R:W-H965T&ULC5E-<^(X$/TK%/<$ MJ?6=(E0-QEN[AZV:FL/.V2%.0@U@UG;"[+]?&=M$[6HI7`*8UY^2WFN4Y;FJ M?S5O9=G.?A_VQ^9Q_M:VIX?%HMF^E8>BN:].Y=%_\U+5AZ+U'^O717.JR^+Y M8G38+X`QO3@4N^-\M;P\^UZOEM5[N]\=R^_UK'D_'(KZOW6YK\Z/K^(/R:[.=-9>'=;\@OG>-?_JQLG*Y^.C\#!"X0-8(HBC( M)H3P*V+AXU^3`"J)(0($YD`%R$*$U60.7SK)(TY0FH)*4_2]$J&]H>TE92][ M>QG:6YRBZ3O10XY](T$HK32%RT*TMHS1U>E$=3JH MSC&R.AUV6WE")F%9"./.^<3)ZD*81VE.>LM#F`;G8BMG$AO;A+5%SJ]-],:& M]D!N;!ND*:6P]`;)0A@8[119]":$<>'779/N0I M">2A!CH;\9!2&1[*C'/T.5&H+YX@&,FQ&09R;:0A3]YF`O3M8US0K49(+:05 M(E)F2FYXJ#>^2WC`8:;02+'+X(*57@'[/,))3UQ#JQIWRP[4@9_H,`T%8I\@9:8.!7#K) M:"'))TBN0+A8H:1H#80.@`J-''@@-6'LE4`NZ`E\`(WZ$XN34@Z0*`[)YSF@ MWT5*!;,/CI12&%`H$BDQ.2@<*49,D")Y0"0?&TXAQ;>`^'8Z,XW)FAN33;$H M(!;E])@/]M9#86\]%/;+0S%6:6\_%"D.!\3A/.)"I(A2(**<3JA#KP2[L5<8 MF.@5!J9Z-4%ZK?>D&BF49,KQ2@0Q)8^Y2`W.`G$0)_-=BW"`)74P2T'CH0=E!/7QA[)^O5R$-[-M]7YLNU,4/+U>MG^#[CIW\GS-'S)./-_PA[R_ M2O]TOUJ>BM?R[Z)^W1V;V5/5MM7A<\^/AIR*P_JOI'7JCX7;?=8OZZ::UT6^Z'3^;0" MI>SJ7!POR\UZ:/M6;];56WLZ7LIO]:)Y.Y^+^I^\/%4?3TN]G!N^'U\/;=^P MVJQ7MW[[X[F\-,?JLJC+EZ?E5_VX)=-+!L6?Q_*C";XO^N"?J^I'__#[_FFI M^AC*4[EK>Q-%]_%>;LO3J;?4>?Y[,OKIL^\8?I^M_SJDVX7_7#3EMCK]==RW MARY:M5SLRY?B[=1^KSY^*Z<O?>&)@T,FIQI;HI59_WF`B074W<(NH/D8!LJ MG)4]H.0!QR0P#!"4;(`D`S0:(&9`\R"S,8U1I,FTB:],G8O$L&1+=^,`-N(PBT]A3*>JG_S%P M9$1'DVCTY+6VD<'5(C)F3XP'(&Z"?!*-GA")4%XQ3*>=@@A@M$B8.2)@$44\ M0>@)O8NM+"VB9G;%6*-$5&PGT>3*F`Q\Q%4*2II3RP"AR8O9;+NRVLM.QE9H"CP[)@R(/ MT9`"%(2`0I&W.81\>L@"9G`_*3Q!B">4US)HEC<8,F+B7- MR,D1A72RT.UD^57!==;'ZK$4PR!DF)&W((0(>[!(XJ+>WLF4]A`)*$4Z"$E' MD2D+0>>4R<1QW')9%S9%XDGQ$!@/$47R`JN^T'<(;$=8Y5UDFV**8\AJ,1+/2#DB]X5*BQ._Y4*;`4:6*8HH MFX^BK&BCF(D4?9#1A\3UEV,(%>,MR!S?,EVFO<=(+8$I]B!C#\E'*@S9HSM' MZKYNFV,*A=88':,4IBB%C%+W+_#950B?KHZ,KNE4>8<,/20?>)!5;5X[GT5" M8D+R*O.Q]%,P0P8S$L\\.?+Z3MM()PI M131B1(N4#,2(IFW'&1E]7`A`CB)G&TJQCQC[(H45L6.H,M9;&?S$*SUR.C90 M*4828Z21&4GLO*K`._F^B>O(^EAU1E-/C)PG;/H[O?2*KBA/9?UZW!SW2QVU=NE[:]$@];; M[?A7Z&]X[]IS_;@=[[@_S6S6U^*U_*.H7X^79O%&PO=V]R:W-H965T&UL?5/;CILP M$/T5RQ^P)H1LJX@@;;:JVH=*JWUHGQT8P%K;0VT3MG]?7PA+*M07/#.<<^:, M+^6$YLWV`(Z\*ZGMB?;.#4?&;-V#XO8!!]#^3XM&<>=3TS$[&.!-)"G)\BQ[ M9(H+3:LRUEY,5>+HI-#P8H@=E>+FSQDD3B>ZH[?"J^AZ%PJL*MG":X0";05J M8J`]T:?=\5P$1`3\%##954R"]POB6TB^-R>:!0L@H79!@?OE"L\@91#RC7_/ MFA\M`W$=W]2_QFF]^PNW\(SREVA<[\UFE#30\E&Z5YR^P3S"(0C6*&W\DGJT M#M6-0HGB[VD5.JY3^E,4,VV;D,^$?"%\SJ+QU"C:_,(=KTJ#$S%I:P<>3G!W MS/U&U,3&HDG3>Z/65Z_5[E"4[!J$9DP>,><[S()@7GUID6^UF.GYBIYOT_=; M]'URN+]S>-@6*+8$BB10_&_$A#G?8Q[_:<)6>ZK`=/'J6%+CJ.-%7567V_F4 MQS/Y@%?EP#OXP4TGM"47=/YDXS&TB`Z\B>SA0$GOW\^22&A="#_YV*0KE1*' MP^V!+*^T^@M02P,$%`````@`69,*1QHI+*&C`0``L0,``!@```!X;"]W;W)K MC^_?I"**G0ON"9X9PS9WPI1FT^;`?@T)<4RAYPYUR_)\16'4AF M;W0/RO]IM)',^=2TQ/8&6!U)4A":9;=$,JYP6<3:FRD+/3C!%;P99`08&4&\^MR"KK68Z'1!I^OT[1I]FQQNKQSNU@7R-8$\">3_&S%ACM>8 M^Q]-R&)/)9@V7AV+*CVH>%$7U?EV/M!X)M_PLNA9"Z_,M%Q9=-+.GVP\AD9K M!]Y$=K/#J//O9TX$-"Z$=SXVZ4JEQ.G^\D#F5UK^`U!+`P04````"`!9DPI' M-T*)F:(!``"Q`P``&````'AL+W=O[^?KHXKEL8>[%(^IQ# M4J3R$=.JLR?:.M=P$1`;\EC'9ADU#[!?$E.#^K$\U"":"@=$%!^.,*#Z!4$/*) M7R?-]Y2!N+1OZH^Q6U_]15AX0/5'5J[UQ6:45%"+0;EG''_`U,(^"):H;/R2 MY#, MWN@!E/_3:B.9\ZGIB!T,L":2I"`TR^Z(9%SAJHRU-U.5>G2"*W@SR(Y2,O/G M"$)/![S#E\([[WH7"J0JR<)KN`1EN5;(0'O`][O]L0B("/C%8;*K&`7O)ZT_ M0O+2''`6+("`V@4%YI MF\TP:J!EHW#O>GJ&>83;(%AK8>,7U:-U6EXH&$GVE5:NXCJE/WD^T[8)=";0 MA?`SB\93HVCSD3E6E49/R*2M'5@XP=V>^HVHD8U%DZ;W1JVOGJO='2W).0C- M&!HQQRO,@B!>?6E!MUK,=+JBTVUZOD7/D\/\RF&^+5!L"11)H/C?B`ESO,84 M_S0AJSV58+IX=2RJ]:CB15U5E]MY3^.9?,.K!/9S2U&O7\_2R*@=2'\X6.3KE1*G!XN#V1YI=5?4$L#!!0````(`%F3"D=5 M5^!MH@$``+$#```9````>&PO=V]R:W-H965TZ]> M>`*7@RRO93,_#^#T,,);_!4>.5-ZT*!%#F9>167H"S7 M"AFH3_AQ0_*I..`L60$#I@@+SRQ6>0(@@Y!O_ M&S4_6P;B,I[4?\1IO?L+L_"DQ5]>N=:;S3"JH&:]<*]Z^`GC"/L@6&IAXQ>5 MO75:3A2,)'M/*U=Q'=*?_41;)]"10&?"0Q:-IT;1YC-SK,B-'I!)6]NQ<(*; M(_4;42(;BR9-[XU:7[T6F\,^)]<@-&)HQ)QO,#.">/6Y!5UK,=+I@D[7Z=LU M^C8YW-XX/*P+[-8$=DE@]]V("7.^Q=Q_:4(6>RK!-/'J6%3J7L6+NJC.M_.1 MQC/YA!=YQQKXS4S#E447[?S)QF.HM7;@361W>XQ:_W[F1$#M0GCO8Y.N5$J< M[J8',K_2X@-02P,$%`````@`69,*1]8!*E:E`0``KP,``!D```!X;"]W;W)K M&UL?5/;;J0P#/V5*!_0,(%VNR,&J=.JZCZL5/5A M]SD#!J+F0I,P=/]^;4]@$/O4BA[P+USPYX06_<@ MF;W2`RC_I]5&,N==TQ$[&&!-!$E!:);=$,FXPE498\^F*O7H!%?P;)`=I63F MWQ&$G@YXAR^!%][U+@1(59(%UW`)RG*MD('V@.]V^V,1,F+"'PZ37=DH:#]I M_1J<7\T!9T$""*A=8&#^.,,]"!&(?.&WF?.C9`"N[0O[8^S6JS\Q"_=:_.6- MZ[W8#*,&6C8*]Z*G)YA;N`Z$M18V?E$]6J?E!8*19._IY"J>4_J3TQFV#:`S M@"Z`VRP*3X6BS`?F6%4:/2&3KG9@88*[/?4742,;@R9U[X5:'SU7>5&2<^"9 M4VA,.:Y3=DL&\>1+!;I588;3%9QNP_,M>)X$YNOJ-[?;!,4609$(BF\Z3"G' MXE.-GU]JD-6-2C!=7!R+:CVJN*:KZ+*;=W&$Y".]*@?6P6]F.JXL.FGGYQJ' MT&KMP(O(KJXQZOWK61P!K0OF#V^;M%#)<7JX/(_EC5;_`5!+`P04````"`!9 MDPI'ZFX0P*$!``"Q`P``&0```'AL+W=O<$S MPSEGSOA23MJ\VA[`H3Y#,WN@!E/_3:B.9\ZGIB!T,L":2 MI"`TR^Z(9%SAJHRU9U.5>G2"*W@VR(Y2,O/O"$)/!YSC2^&%=[T+!5*59.$U M7(*R7"MDH#W@AWQ_+`(B`GYSF.PJ1L'[2>O7D#PU!YP%"R"@=D&!^>4,CR!$ M$/*-_\Z:[RT#<1U?U'_$:;W[$[/PJ,4?WKC>F\TP:J!EHW`O>OH)\PBW0;#6 MPL8OJD?KM+Q0,)+L+:U8!4&\^M*";K68Z71% MI]OTW19]EQSNKAQ^TK_8$BB20/'5B`ESO,9\=$E6>RK!=/'J6%3K4<6+NJHN MM_.!QC-YAU?EP#KXQ4S'E44G[?S)QF-HM7;@360WMQCU_OTLB8#6A?#>QR9= MJ90X/5P>R/)*J_]02P,$%`````@`69,*1PF$O&UL?5/;;J,P$/T5RQ]0$X=LJX@@-:VJW8>5 MJCZTSPX,8-47:IO0_?OUA5!2H;[@F>&<,V=\*49MWFT'X-"G%,H><.=\P9?""V\[%PJD+,C,J[D$9;E6R$!SP/>;_3$/B`AXY3#:18R" M]Y/6[R'Y4Q]P%BR`@,H%!>:7,SR`$$'(-_Z8-+]:!N(ROJ@_Q6F]^Q.S\*#% M&Z]=Y\UF&-70L$&X%SW^AFF$71"LM+#QBZK!.BTO%(PD^TPK5W$=IS]W$VV= M0"<"G0EW632>&D6;C\RQLC!Z1"9M;<_""6[VU&]$A6PLFC2]-VI]]5QN;K<% M.0>A"4,CYGB%F1'$J\\MZ%J+B4X7=+I.WZ[1M\GA]LIAOBZ0KPGD22#_:<2$ M.5YC=M^:D,6>2C!MO#H657I0\:(NJO/MO*?Q3+[@9=&S%OXRTW)ET4D[?[+Q M&!JM'7@3V*VP?L0?L_#1K%G4]-RVQO@->1 MI"3+L^R1*2XT+8M8>S5E@8.30L.K(790BIL_9Y`XGNB&W@IOHNU<*+"R8#.O M%@JT%:B)@>9$GS?'\RX@(N"G@-$N8A*\7Q#?0_*]/M$L6``)E0L*W"]7>`$I M@Y!O_'O2_&P9B,OXIOXU3NO=7[B%%Y2_1.TZ;S:CI(:&#]*]X?@-IA'V0;!" M:>.75(-UJ&X42A3_2*O0<1W3G_UVHJT3\HF0SX2G+!I/C:+-+]SQLC`X$I.V MMN?A!#?'W&]$16PLFC2]-VI]]5IN#H\%NP:A"9-'S/D.,R.85Y];Y&LM)GJ^ MH.?K].T:?9L<;N\<'M8%=FL"NR2P^]^("7.^QSS]TX0M]E2!:>/5L:3"0<>+ MNJC.M_,YCV?R"2^+GK?P@YM6:$LNZ/S)QF-H$!UX$]G#GI+.OY\YD="X$!Y\ M;-*52HG#_O9`YE=:_@502P,$%`````@`69,*1['],ZND`0``L0,``!D```!X M;"]W;W)K&UL?5/;;MLP#/T501]0.4JZ9H%CH.DP MM`\#BCYTSXI-VT(ETY/DN/O[ZN*X[F#LQ2+IP.BBB2M&,^R;TP+V=$BC[%G4^0X."4[ M>#;$#EH+\_<$"L:J.-`LE@(+2!07ACPL\@%)!R"?^,VE^I@S$I7U5_QF[]=6? MA84'5+]EY5I?;$9)!;48E'O!\1&F%FZ#8(G*QB\I!^M07RF4:/&>3MG%7(#1A>,2<_C3#[A1=Z+!GX)T\C. MDC,Z/]DXAAK1@2\BN[FEI/7O9W84U"Z8=]XV::62X["_/I#YE18?4$L#!!0` M```(`%F3"D>#I;TWH@$``+$#```9````>&PO=V]R:W-H965T:,"*'\0V0_;OUP^& M,"NT%]S=5%57^U%.VGS8'L"A+RF4/>#>N6%/B*U[D,S>Z`&4_]-J(YGSJ>F( M'0RP)I*D(#3+[HAD7.&JC+4W4Y5Z=((K>#/(CE(R\^<(0D\'O,.7PCOO>A<* MI"K)PFNX!&6Y5LA`>\`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`YE=:?@-02P,$ M%`````@`69,*1[O?4->E`0``L0,``!D```!X;"]W;W)K&UL?5/+;MLP$/P5@A\0RK33.H8L($Y0M(<"00[MF996$A%2JY"4E?Y] M^9`5N1!Z$7=7,[.S?.0CFC?;`CCRH55GC[1UKC\P9LL6M+!WV$/G_]1HM'`^ M-0VSO0%119)6C&?9%Z:%[&B1Q]J+*7(.1;NBU\"J; MUH4"*W(V\RJIH;,2.V*@/M+'S>&T"X@(^"5AM(N8!.]GQ+>0_*B.-`L60$'I M@H+PRP6>0*D@Y!N_3YJ?+0-Q&5_5O\5IO?NSL/"$ZK>L7.O-9I144(M!N5<< MO\,TPGT0+%'9^"7E8!WJ*X42+3[2*KNXCNG/=C_1U@E\(O"9L,^B\=0HVGP6 M3A2YP9&8M+6]"">X.7"_$26QL6C2]-ZH]=5+L=GO? M6_"U%A.=+^A\G;Y=HV^3P^V-PX=U@=V:P"X)[/XW8L*<;C`/V3]-V&)/-9@F M7AU+2ARZ>%$7U?EV/O)X)I_P(N]%`S^%:61GR1F=/]EX##6B`V\BN[NGI/7O M9TX4U"Z$7WULTI5*BTQZYT;#I3:N@?%[1T.H/V?%HWBSJ>FHW8PP)M(4I*R//]`%1S95B:.30L.S(794BIO?)Y`X';,BNQ9>1->[4*!521=>(Q1H*U`3`^TQ>RP. MIWU`1,`/`9-=Q21X/R.^AN1;<\SR8`$DU"XH<+]O,(]P'P1KE#9^23U:A^I*R8CB M;VD5.JY3^L,>9MHV@'4LJ7'4\:*NJLOM?&3Q3-[A53GP M#KYSTPEMR1F=/]EX#"VB`V\BO[O/2._?SY)(:%T(/_K8I"N5$H?#]8$LK[3Z M`U!+`P04````"`!9DPI'2Y@Y#,WN@!E/_3 M:B.9\ZGIB!T,L":2I"`TRVZ)9%SAJHRU%U.5>G2"*W@QR(Y2,O/G!$)/1YSC M:^&5=[T+!5*59.$U7(*R7"MDH#WBN_QP*@(B`GYQF.PJ1L'[6>NWD#PW1YP% M"R"@=D&!^>4"]R!$$/*-WV?-SY:!N(ZOZH]Q6N_^S"S<:_&;-Z[W9C.,&FC9 M*-RKGIY@'F$?!&LM;/RB>K1.RRL%(\D^TLI57*?T9Y?/M&T"G0ET(7S/HO'4 M*-I\8(Y5I=$3,FEK!Q9.,#]0OQ$ULK%HTO3>J/752Y7_*$IR"4(SAD;,Z0MF M01"OOK2@6RUF.EW1Z39]MT7?)8>[=??]?EN@V!(HDD#QOQ$3YO05\V\3LMI3 M"::+5\>B6H\J7M15=;F==S2>R2>\*@?6P4]F.JXL.FOG3S8>0ZNU`V\BN]EC MU/OWLR0"6A?";SXVZ4JEQ.GA^D"65UK]!5!+`P04````"`!9DPI'E::X_*0! M``"Q`P``&0```'AL+W=O*VSOL0?L_#1K%G4]-RVQO@->1I"3+L^R>*2XT M+8M8>S%E@8.30L.+(790BIN_)Y`X'NF&7@NOHNU<*+"R8#.O%@JT%:B)@>9( MGS:'TRX@(N"7@-$N8A*\GQ'?0O*C/M(L6``)E0L*W"\7>`8I@Y!O_&?2_&@9 MB,OXJOXM3NO=G[F%9Y2_1>TZ;S:CI(:&#]*]XO@=IA'V0;!":>.75(-UJ*X4 M2A1_3ZO0<1W3GWTVT=8)^43(9\)C)+#4*-K\RATO"X,C,6EK>QY.<'/(_494 MQ,:B2=-[H]97+^7FRWW!+D%HPN01<[K!S`CFU><6^5J+B9XOZ/DZ?;M&WR:' MVQN'#^L"NS6!71+8_6_$A#G=8AX_-6&+/55@VGAU+*EPT/&B+JKS[7S*XYE\ MP,NBYRW\Y*85VI(S.G^R\1@:1`?>1':WIZ3S[V=.)#0NA`\^-NE*I<1A?WT@ M\RLM_P%02P,$%`````@`69,*1\>DO]*C`0``L0,``!D```!X;"]W;W)K&UL?5/;3N0P#/V5*!]`.IF!A5&G$@-"[,-*B(?=YTSK M7D02ER2=LG]/+IW21=6^-+9[SK$=._F(YLVV`(Y\**GM@;;.]7O&;-F"$O8* M>]#^3XU&">==TS#;&Q!5)"G)>);=,"4Z38L\QEY,D>/@9*?AQ1`[*"7,WR-( M'`]T0R^!UZYI70BP(FK7.N+ MS2BIH!:#=*\X/L/4PG40+%':^"7E8!VJ"X42)3[2V>EXCNG/;3;1U@E\(O!O M!)82Q3(?A1-%;G`D)EUM+\($-WON+Z(D-@9-ZMX7:GWT7&SN[G)V#D(3AD?, M\1_,C&!>?4[!UU),=+Z@\W7Z=HV^315NE]EOLG6!W9K`+@GL_M=BPAR7&+^V MWY*PQ9TJ,$U<'4M*''1A`0``L0,``!D```!X;"]W;W)K&UL?5/;;IPP M$/T5RQ\0LX:TT8I%RJ:*FH=(41[:9R\,8,478ILE_?OXPK*DHGW!,\,Y9\[X M4D[:O-D>P*$/*90]X-ZY84^(K7N0S-[H`93_TVHCF?.IZ8@=#+`FDJ0@-,N^ M$)_(R;,\2LF_ZL)6>VI!-/%JV-1K4<5+^JJNMS.>QK/ MY`JORH%U\,Q,QY5%)^W\R<9C:+5VX$UD-[<8]?[]+(F`UH7PNX]-NE(I<7JX M/)#EE5:?4$L#!!0````(`%F3"D&PO=V]R:W-H M965T*"TVK,M:>357BZ*30\&R('97BYN\9 M)$XGNJ.WPHOH>A<*K"K9PFN$`FT%:F*@/=''W?%#C!W3'W&U$3&XLF3>^-6E^]5GE6E.P:A&9, M'C'G-6:W()A77UKD6RUF>KYNL4W?;]'WR>'^@\/#MD"Q)5`D@>)_(R;,^2/F M_E,3MMI3!::+5\>2&D<=+^JJNMS.QSR>R3N\*@?>P4]N.J$MN:#S)QN/H45T MX$UD=P=*>O]^ED1"ZT+XQ<&PO=V]R:W-H965TA%W5S.S MLWSD(YHWVP(X\JY59X^T=:X_,&;+%K2P-]A#Y__4:+1P/C4-L[T!44625HQG MV3>FA>QHDMA?E[`H7CD6[HM?`BF]:%`BMR-O,JJ:&S M$CMBH#[2^\WAM`N("'B5,-I%3(+W,^);2)ZJ(\V"!5!0NJ`@_'*!!U`J"/G& M?R;-SY:!N(ROZC_CM-[]65AX0/5;5J[U9C-**JC%H-P+CH\PC;`/@B4J&[^D M'*Q#?:50HL5[6F47US']V?.)MD[@$X'/A+LL&D^-HLT?PHDB-S@2D[:V%^$$ M-P?N-Z(D-A9-FMX;M;YZ*7AVF[-+$)HP/&).2\QF1C"O/K?@:RTF.E^V6*=O MU^C;Y'#[Q>'=NL!N36"7!';_&S%A3E\QW_]IPA9[JL$T\>I84N+0Q8NZJ,ZW M\SX>(ON$%WDO&O@E3",[2\[H_,G&8Z@1'7@3VDM:_GSE14+L0WOK8I"N5 M$H?]]8',K[3X`%!+`P04````"`!9DPI'/?I4A:(!``"Q`P``&0```'AL+W=O M!-)2E*6YY^HXD)G51EKCZ8J<712:'@TQ(Y* M+("$V@4%[I<+W(.40<@W?IDUWUH&XCJ^JG^+TWKW9V[A'N5O MT;C>F\TSTD#+1^F>.7U*-UJ*Z4C"C^FE:AXSJE/^SK3-LF ML)G`%L*7/!I/C:+-!^YX51J[=P[_T7^_);!/`OO_C9@P MI_>8CR[I:D\5F"Y>'4MJ''6\J*OJS)!):%\+//C;I2J7$X7!](,LKK?X"4$L#!!0````(`%F3 M"D=MTM,BP@(``"L,```9````>&PO=V]R:W-H965T%]_IT MUG8AJ]4+;I(\N,F?B'/6UI8B$/\KOE=3>XC6_Q.B`_[\/.PB5-; M`V_X7ML4S%QN_)4WC-,K]1ONKTJ(=0N*H99_]M>[<]=Z_*?)'&!Y`'P%T M#%BEKO">R)7YC6E6E5+<(]E_VPNS1TB>J?D0^TBY1=GOWA2JS.JMHB0KDYM- M],!0A]E.,61$)";[2$$QBD!!_@UPP4P`WD40%!?#SP92(%K8`;RB("$[$^`MS-A#D"` MO3./#B#(IX-0$R#`X9E'!Q#DTT&H#Q!@\MRC`PCRZ2#4"@CP>>[1`03Y=!#J M!@18/??H`((\.J"A?D"!U7-M@!O+H@(;Z`056+W`=S$`^'83Z`056+SPZ@*"Y#I+),-=R M>7(SJXKVXMJY$7FR.L[%+]0-@U_PJKRP$__%Y*GN5+03VHR4;OX["J&YJ2)] M,E60^/C3\J.WMTMS+?I;M'[2X#*/Y^/^@^@]02P,$%`````@`69,*1V'1 M%_O"`0``>P0``!D```!X;"]W;W)K&UL?53=;J0@ M%'X5X@,4=4:W.W%,.FV:[L4F32^ZUXP>E13$`H[=MR\_CM4-VQN!P_=S#G(H M)B'?5`>@T0=GO3I&G=;#`6-5=<")NA$#]&:G$9(3;9:RQ6J00&I'X@RG<9QC M3F@?E86+/70*RIZ M)*$Y1G?)X91;A`.\4IC4:HYL[F"_:&U[DRR<81J:,C(](N8GF`N(;."E6#*?5$U M*BWXE1(A3C[\2'LW3GXG2V=:F)#.A'0AW,8N<6_DTGP@FI2%%!.2_F@'8O]@ MRC2[+?#%"LV8U&%.:TRR(+!17RS2D,5,3]<68?HN M1-_Y#'=K]RP+"^Q#`GLOL-^4^'-;HL><-I@\#IMDWYAD&X$D:++%_.S_,<&KV\%!MJX)%*K$V+N66T67/KMSUQ%_PJ$4*#22*^,:5VYB58%@P:;:<_S%SZYO`++89KJR_O3?D)4$L#!!0` M```(`%F3"D?0/Q+$L@$``!8$```9````>&PO=V]R:W-H965TIB9NW`!:SZ06T3.G\_?A`* M%>H&VY?SNM@F'Y1^-RV`19^"2W-,6FN[`\:F;$%0HB5[WE3,*K1J87@NI_)^!J.":;Y%IX8TUK?0$7 M.9YX%1,@#5,2::B/R?WF<-IY1`#\83"8V1SY[&>EWOWBI3HFJ8\`'$KK%:@; M+O``G'LA9_PQ:GY9>N)\?E5_"MVZ]&=JX$'QOZRRK0N;)JB"FO;J.R-5>)*29"@GW%D,HQ#?)-E(VV=0$8"F0AW:0@>C4+,1VIID6LU M(!T_;4?]#FX.Q'V($IE0U+%[%]2XZJ4@^UV.+UYHQ)"`.;7-Q,\VS@!N@GGTZ!2]3+&PO=V]R:W-H965T[^?KK8KC/XQ2)I MGL-#4BI&;=YM!^#0IQ3*GG'G7'\BQ%8=2&8?=`_*_VFTDG.`*7@VR@Y3,_+V`T.,9[_`<>.-MYT*`E`59<#67 MH"S7"AEHSOAI=[KD(2,F_.8PVI6-@O:KUN_!^5F?<18D@(#*!0;FCQL\@Q"! MR!?^F#B_2@;@VI[97V*W7OV567C6X@^O7>?%9AC5T+!!N#<]_H"IA4,@K+2P M\8NJP3HM9PA&DGVFDZMXCNG/889M`^@$H`O@6Q:%IT)1YG?F6%D8/2*31MNS ML,'=B?I!5,C&H$G=>Z'61V\E?&PO=V]R:W-H965T&,"*+]0V2_KW\84E;$5?L&>8P*$/*90]XMZY MX4"(K7N0S-[I`93_TVHCF?.AZ8@=#+`F@J0@-,L>B&1]"PE2E63!-5R"LEPK9*`]XJ?\<"I"12SXQ6&R MJST*WL]:OX?@I3GB+%@``;4+#,PO%W@&(0*1%_XSF\VPZB!EHW"O>GI!\PMW`?"6@L;OZ@>K=/R"L%(LH^TZ/69R\5 MW=.27`+17$-CS6E=DR\5Q+,O$G1+8H;3M<0V?+<%WR6'N[7Z_C_ZQ19!D0B* M&X+LML54&PO=V]R:W-H965TC-A^V`W#H4PIE3[ASKC\28JL.)+,/N@?E_S3:2.:\ M:UIB>P.LCB`I",VR/9&,*UP6,?9BRD(/3G`%+P;904IF_IU!Z/&$-_@6>.5M MYT*`E`69<367H"S7"AEH3OAI08A`Y`O_G3B_2P;@TKZQ_XS=>O479N%9BW=>N\Z+S3"JH6&#<*]Z M_`53"[M`6&EAXQ=5@W5:WB`82?:93J[B.4Y_]A-L'4`G`)T!^\R_4^NBUI(>\(-=`-.70F'->YFSF#.+9 MYQ)TK<0$I\L2Z_#M&GR;%&[O%.[6"?(U@CP1Y$OYA^U]BRGGG-\5V?]7A"SN M5()IX^I85.E!Q45=1.?M?*)Q)M_I9=&S%OXPTW)ET44[/]DXAD9K!UY$]K## MJ//O9W8$-"Z8!V^;M%+)<;J_/9#YE99?4$L#!!0````(`%F3"D<(Z3L+IP$` M`+$#```9````>&PO=V]R:W-H965T\HZY_HCI;;J0''[@#UH_Z=!H[CS1]-2VQO@=20I25F>?Z&*"YV5 M18R]FK+`P4FAX=40.RC%S=\S2!Q/V2:[!=Y$V[D0H&5!9UXM%&@K4!,#S2E[ MWAS/NX"(@%\"1KO8D^#]@O@>#C_J4Y8'"R"A5O4;O.F\TS4D/#!^G>.75(-UJ&Z4 MC"C^D5:AXSJF/]NGB;9.8!.!S81#'HVG1-'F5^YX61@8,.=[S--_2>CB3A68-HZ.)14..@[J(CI/YS.+ M/?F$ET7/6_C)32NT)1=TOK.Q#0VB`V\B?WC,2.??SWR0T+BPW?N]22.5#@[[ MVP.97VGY#U!+`P04````"`!9DPI'<W#=SL0GV)F_%UT`!)]4C*(4]!).1[#4%0=4"P> MV`B#>M(P3K%41]Z&8N2`:T.B)$RB:!]2W`]!69C:*R\+-DG2#_#*D9@HQ?S/ M&0B;3T$K*U\--3'SVU"=.M>Y[Z!78^@9T5V#DMQFZ+ M%G-V,?])F=TQR1R!U&OB8G9^D_T=D[TCD'E-7,S>;W*X8W)P!`Y>$Q>3^TWR M.R:Y(_#H-7$PC]$_)N'F?TZ!M^8Z"U2Q:3##8U-=)\938N[)%[PL1MS"3\S; M?A#HPJ2Z;>9J-(Q)4"&B!_71.C73U@.!1NKM0>VYO>;V(-EX&UKKY"S_`E!+ M`P04````"`!9DPI'SFAS0A@"``#C!@``&0```'AL+W=O8T[J)\LS9WF6>B8MF=0/O$JD+YU3^.P`3W3Y*HM'P M49\K;0TXS_#D5]8<&E6+!DDX[:/79'=(B(4XQ.\:.C6;(QO\48A/N_A9[J/8 MQ@`,"FTIJ!FN\`:,62:C_'<@O6E:Q_E\9/_NTC7A'ZF"-\'^U*6N3+1QA$HX MT0O3'Z+[`4,.2TM8"*;<%Q47I04?72+$Z5<_UHT;NWXG70]N802=$AV?_;EMH2)CMB?D2!E#/*/GL3J#+6:TZV28:OEFC`$(.@B(]Y'M[7ZH8C=G%.'2WX$>U#X)WM11)_$HPM6_ M`STH?Q*\KJ,.\2C"!^`.='\"\*P)<9!GUVL5*L2E<:U]9IWZ^:MKY_@&S[.6 MGN$7E>>Z4>@HM&F%KF^=A-!@HHA?S(VJS(LS+1BY#,WN@! ME/_3:B.9\Z[IB!T,L":"I"`TR^Z(9%SAJHRQ%U.5>G2"*W@QR(Y2,O/O"$)/ M!YSC2^"5=[T+`5*59,$U7(*R7"MDH#W@QWQ_+$)&3/C-8;(K&P7M)ZW?@O.S M.>`L2``!M0L,S!]G>`(A`I$O_'?F_"P9@&O[POXC=NO5GYB%)RW^\,;U7FR& M40,M&X5[U=,SS"W"D69WYEC56GTA$P:[<#"!O,]]8.HD8U!D[KW0JV/GJM=GI7D'(CF'!IS MCNN_F.FXLNBDG=]L7$.K MM0,O(KNYQ:CW[V=Q!+0NF-^\;=*52H[3P^6!+*^T^@!02P,$%`````@`69,* M1P_E0I6E`0``L0,``!D```!X;"]W;W)K&UL=5/; M;IPP$/T5RQ\0@V&;:L4B95-5[4.E*`_MLQ<&L.(+M< M.>,95[,V;W8`<.A="F5/>'!N/!)BFP$DLP]Z!.7_=-I(YOS1],2.!E@;25(0 MFF6?B&1#"P%25V3EM5R" MLEPK9*`[X:?\>"X#(@)^%QH^P2Z$.A*^)Q%XRE1M/F%.5971L_(I*L= M6>A@?J3^(AID8]"DZKU1ZZ/7NLAI1:Y!:,'0B#EO,?F*(%Y]34'W4BQTNJ'3 M?7JQ1R^2PV)+S_XC4.X)E$F@O"NQN"\Q8<[WF/*?)&1SIQ),'T?'HD9/*@[J M)KI.YQ.-/?F`U]7(>OC!3,^511?M?&=C&SJM'7@3V<,!H\&_G_4@H'-A^^CW M)HU4.C@]WA[(^DKKOU!+`P04````"`!9DPI'L5-@9JH!``"U`P``&0```'AL M+W=OCIA'-\2[SRKG$*SR!$$/*%_\Z:'R4#<3V_J7^/W7KW%V;A M68L_O'&]-YMAU$#+1N%>]?0#YA;V0;#6PL8_JD?KM+Q1,)+L/8U"X?\*H<6`>_ MF.FXLNBBG3_=>!2MU@Z\C>QACU'OW]`2"&A=F![\W*1KE0*GA]LC65YJ]1]0 M2P,$%`````@`69,*1VI3\TD5`@``.@<``!D```!X;"]W;W)K&ULC57;;N,@$/T5Y`^HC2^YR;'4=%5U'U:J^K#[3)Q);!6,%TC< M_?L%?*DM.<0O`8:95EJ;>\B2_E5T;*"=X'DE3$B_AV`\F;O M8:\W?)270AF#GZ7^$'$EF9/X@B62IX@T2;VYJ8OQ#O0IV('$EK%.WKM5"IK;T/H>Q#QX\?(T^4(1S%%UX.*8(@WF`:`X@;C5&$X`["F('0#P!"*>/3%J5 MK4]E?9)YBL1!D4PHHEF*Y#'%RD&QFE#$\P!K!\!Z01K6CS5N'!2;!6G8C"CP MG<]AZ^#83CCNB#0%>1?!7#[,1.?D3`6>+:V>!2](1N?D9IFMKIYE6EZK.Q"N M^L+1DG1$"X2ZBA#'2](1NSX.?]3;&(B+;>$2Y?Q:V8DQL@YCXCFTO?';/4MK MW:J&Q;>WM0O.XGU3`N ML_]02P,$%`````@`69,*1QVZ--A1`@``W`<``!D```!X;"]W;W)K&ULC57;CILP%/P5Q`74JA)H(\"T;>J6I(RRO:>HR:?^=#'M8J8`%K;G^>L65"]K<*;[7X$_35JUN>[.2 MH('F)L"!`$?"J.,F1`,A^B(L*Z"!@!X(@=F*-N*`!QBZ%O0V! M+L3!1D2A.XG(E00R^XPL/@JG$HE)PD!:DP0*492N7;B#C0-)"I)D[2# M)KZG4R&#V4TQ,R*K!9&5'6#.M7@A0/SP5ZK?U"YYG';Z0GYA=JI9[1RKD"ZV?TS.E@L@LPA=Y[TI9:L=! M3&ULC99-;Z,P$(;_"N+>@K\` M1PE20[+:/:Q4];`]NXF3H`+.8J?I_OO%F%`[ECK,HDIL#KYE\%$?>=&]VHJV9ZA[;?22/+6?;/JBN(AC'252S ML@GS>;_VW.9S<5)5V?#G-I"GNF;MOR6OQ'D1@O"R\%+N#THO1/D\&N.V9!+OY-B'?]\&N["&-=`Z_X1ND4K+M\\()7 ME<[4*?\=DGYIZD#[_I+]1V^W*_^-25Z(ZK7.\[MV**Y?-6G(/6;/>1Z:\*S$BW-YM`]HNMV9"N=[); M_<@12N?1ATXT,+!GEC:3$1^RLA$P$E%7P%@%]%4Q*$`K'/H$"IO($F\-WR99 MWTCBE(E\92+3+.0T*_,GP+X$V"3`=IO`E8W4],(P3<\\$$BP)61QA<-!E%$" M?=S*X0"F.*9>X;4+`@(117Z+9,(BL2W&5TK$*!%+B1(";W0RF9!)G$YB;R>3 M.SN9W-G)Y-Y.NF!,DBPA?HOIA,74^=JHKY/+U%*"&)*,@C3VD85-`@`A3M%U M]89<.626(H(2@KS[:),444ABBOT^LPF?F>T3Q]ZMS"PE+U%,$-3XLHF'^#$& M/FI]FW(,T0E#](Y_.?W6T`0Q&*+3AO28U(YN8XXCC=^TI%]^^[<>H.N2717O M,+JH.&,$I-[.#=!4ZZ:0H7<.H)Z7%^M+\&L`)[UE3Y\]>/]*WT^/[(]_\W:?=G(X$VH[I#03_2=$(IW=<>/ MW98_\1":_P=02P,$%`````@`69,*1Y70 M[*-+`@``^`8``!D```!X;"]W;W)K&ULC971CJ,@ M%(9?Q?@`(X(@::S)M,UF]V*3R5SL7C.65C,J+M`Z^_8+:"U.F&9[40'__YR/ M0WLH1B'?5,?4D!MZ;-R\I[1&?WR+_LWMUM"_,<7WHOW=''5M8$$<'?F)75K]*L;O M?-X"M@$KT2KW'547I45WL\11QSZF9].[YSB]H6"VA0UP-L#%L.0)&]!L0/]K MR&9#=C=DKC335EPA#DRSLI!BC.1T>`.SOY%TDYE25Y%RBW*JKRF%,JO7$F5I MD5QMH%D#G6:WUL"09N]K[E$20[!@P!#&G`*N4J!@"E\3A#CX"DK"%"A$@:9B MH!5%%@Z0A0)D4X!L%0"O(?&TC4G3.TU.,T@X M2+3#7B*:(HHR$B3:^T*8`IA#^E69R0,DLJH26:?*)R;BI2(I)6;_(=U^K":;(?()%RM=%>G!L]`$272'1(!+U,J6($(S`Y[_. MS.0K44I`"@CZ?'")US@Z+L^N`ZNH$I?>]7MO=6GRS]`UGKN\+`9VYC^9/#>] MBMZ$-NW+]9J3$)H;%/!DD&IS#2V3EI^T'>:6=>K,TT2+X7;/+)==^0]02P,$ M%`````@`69,*1XI1AMRW`0``'P0``!D```!X;"]W;W)K&UL?53;;IPP$/T5BP^(60.-NF*1LJFJ]J%2E(?VV0O#1;$]U#9+^O?U MA26L1,L#MHDG*OF@DJH,L1==E3A9,2AXT<1,4G+]YPP"YU-R2&Z!UZ'K MK0_0JJ0KKADD*#.@(AK:4_)T.)X+GQ$2?@XPF\V<>.\7Q#>_^-ZXOW,`SBE]#8WMG-DU(`RV?A'W% M^1LL)02'-0H3WJ2>C$5Y@R1$\OLSN"/[A(-\CR"-!?D?`[HM\C"YCCHI%IN'9%RK^ M(U3<"66[0L5&J-C3H9L3E*"[<%$-J7%2H2TVT;47GEBX`1_I53GR#GYPW0W* MD`M:=X_"H;>(%IR/],$9Z5VWK@L!K?731S?7\0+'A<7QUH[K/Z'Z"U!+`P04 M````"`!9DPI',2U978@"``"B"0``&0```'AL+W=OJ+,?CN?G=8_X/E58QO\LBYRM[[;I"K_*C4Z;$HY/;(>R8?Q(D/^LM> MC#U3>CH>"GD:.=M-3GU7H+*D1<_:(5\OI[7G<;T49]6U`W\>,WGN>S;^W?!. M7%%E_9P5&:A6"^+N]^N[?D@6S%D(]^O\B_PN(&%,9DL?K7\*IWWS"3_ M*L2;F?S8K?+2Y,`[OE4F!-/#A3_QKC.1-/G/'/2#:1S=]UOT;U.Y.OU7)OF3 MZ'ZW.W74V99YMN-[=N[4B[A^YW,-Q`3CN*:C79O3\S\0GA$>B.VF9P61UN]3E3J MUUE2GT(L!3L46I:1O2`)"O$H=9!"W%J(^UL\#$U@J(=I@ACJ M8*`LH^74"4[M<1;A`$TB0)/XM7.>C9LGPCA"620H"Y="RR!FX6!(74$5V0ZC M]2C(?/P@X2!HMKEM/`4:D00$E7LC^;(,D\!31:R@E'8!?4(6LY'E5&791$`I MC8,G\D684WD[1PA$0"F=`_Z$!,%3.D(48IN7$CN03\@07+E#A9JZKB*LE.+! ME3R.H%S)8X(U*D)*:1X\T5,(HVI/M0336%&I[@!>>Z#A_@!N@ZA)M(]!JD.` MWR*JX"$#;H^@A%3X?U3A'+\G=N`_V7AH!YF]"J5/\NG8W0NAN(Y6/NC\C_K" M=)]T?*_,:VT*LU<(.U'B=+L1W:]EZW]02P,$%`````@`69,*1P6-!;?4`0`` M%04``!D```!X;"]W;W)K&UL?53+CILP%/T5Q`>, M`?-H(X+4H:K:1:71+-JU`Y>`QL;4=L+T[^L'H7A$DD5L7\[KVN!RYN)-]@`J M>&=TE,>P5VHZ("2;'AB13WR"43_IN&!$Z:4X(SD)(*TE,8J2*,H1(\,85J6M MO8BJY!=%AQ%>1"`OC!'Q]QDHGX]A'-X*K\.Y5Z:`JA*MO'9@,,J!CX&`[AA^ MB0]U;A`6\&N`66[F@^?P=EA8R(]AP*NU_T%RDXNQ& M"0-&WMTXC':"'@#P3DDMF^OA)%JE+P.1#N+"9B MCCP^8+US32!M4;CMTIU)7;U6.$]+=#5""R:QF&O$84:+22/SVX/56UCLP[PXZ8,XJ1?GL^^3 MN3CI?9\-K-["BNQNFNQ!FFR;IMCO.MO8)/=M\@R!E^$G$>1AFA-4_4$L#!!0````(`%F3"D?-2;V0$`(``/$%```9````>&PO=V]R:W-H M965T(##(I8NXTUF=IL=B\VFVVT+<"R@!/OW'+:J59T0-++/GI.=L>M13C`[Y8.:C8'-OM) MB#>[^'G>1[&-0!FMM54@9KC3BC)FA8SQWU'SP](2Y_.'^G>W6Y/^1!2M!/O3 MGG5CPL81.-,+N3']*H8?=-Q"9@5KP93[!_5-:<$?E`AP\N['MG/CX)_@!RU, M0",!380\7B6D(R&=",FZ`QX)^(.`W='XK;B#.!)-RD**`4C_\GIBOY%DA\U1 MUT"YHO3G:XY"F>J]3'-4P+L5&C'(8:HY)ID0T*A/%BAD,=+1C!XT.*)%B#1L MD88L4K^+="&`PP(X)("]`%X(9,N4N4_I,9W#9+'YA6VR%9ML8;,)VF0SFP1G M&4)AG\V*SV;ADR]]/.:PQ&Q#6:K-+`M&61Y.DG])8C/D$_<+8;L2?;L6:XR^ MQ'S[E`K.;@"G\NI:B0*UN'7:?C&SZM2M#LC>H,_U?%?E@?IANZM<=X,?\F71 MDRO]1>2U[10X"6WNK;MD%R$T-:'C)_-B&]-_IP6C%VVGN9E+WY+\0HO^T6"G M+E_^!U!+`P04````"`!9DPI'R'3M0&4"``!N"```&0```'AL+W=OUJXO->`*YUR&0&*YX"VN*AE),/_M@UXY)=!\'J)_5^D*^7O$ M\)94?\H#+X1:WW4.^(C.%?\@W0_,?@Z=S5R>T01UE*2>=0 M7>X6R:\*K*"H3>XP9:2Z(.+LF+!>LD7BI]Y%!NI]`N6S,7T2:'/9F2Y@]/"$ M@%%%8%/1,P0&/+`1;$V/)+)J>!CD;2+(C9"'];"P"\GT@QM^%#C0Q-_ M)S'6$K5+H^LQ(1'.4$"3(K3CHQE\9.*A56+TA,1XAB(V*2(K16Q0?)OB2&8J ME9@L9E M6F-Z4F.,.3DY-UQ^:X9U')6O@;R,[^P;L-H"BWTG1ZNZO*_AL[1%)_P+T5/9 M,&=/N!@!ZKX^$L*QT.V_B+(68OB/FPH?N7R,9;WU.-0;3MIANH]_,;+_4$L# M!!0````(`%F3"D?O.,7,P@$``)0$```9````>&PO=V]R:W-H965T^"=WH;-<;T&XQUV8!@^D[VT-DWM52" M&1NJ(]:]`E9YDN`XC>,,"]9V49'[W),J&Z/C7$)7.1XXE6M@$ZWLD,*ZFWT(]GLJ4-XP$L+@Y[MD?-^D/+5!;^J;10[ M"\"A-$Z!V>4,.^#<"=G";Z/FOY*..-]?U!]]M];]@6G82?ZGK4QCS<81JJ!F M)VZ>Y?`3QA963K"47/LG*D_:2'&A1$BP]["VG5^'\(:2D;9,2$=".A$2>I-` M1@+Y7P(="?03`8=6_"#VS+`B5W)`*GR\GKDSDFRH'76)M$^J,%\["FVSYX+< MDQR?G="(23WF88Y)EQ"[*Y5X";*?0^ZS"8*MQ\EHNF24!J/IO`2]+K$./@.D M\Y"$K"G)EF"[.8PDZ3I90NV_1EU9)CD.`?M\SG?<<9TFV^E0& MS\Y#SX[PFZECVVETD,8>+7\.:BD-6+'X;A6AQEX14\"A-FZ[MGL5_IH0&-E? M[H#I(BH^`%!+`P04````"`!9DPI'7&>.)54"``#8!P``&0```'AL+W=O& M]D0\L9$.:N?,>$^DFO)+)$9.R6D.ZKL(Q#&.>M(.857.:R^\*ME5=NU`7W@@ MKGU/^+]GVK%I'R;A;>&UO312+T15&:UQI[:G@VC9$'!ZWH=?DUV=S))9\;NE MD[#&@88_,/:F)S]/^S#6#+2C1ZDMB'J]TYIVG792F?\NII\Y=:`]OKE_G\M5 M^`EM&[-EHT8-8\VQK@4]2.2[Q*(@6P4@`?!304P*'` M?@/H,T#&`#H&F0N9F3*,9I@U"4J2W*>J'17`>>Z'01LPR(&Y2Y,:&&2G@1BD M/E7MJ$"!@1\FW8!)'9C""Y-::0!"L5=5.RH`0>*'P1LPV(8I8F^;L)4&HL+; MR_JAR$')-E`R!^5!+?F&0>X8`&\MN=V_#`/H+<91X0Q#/TRQ`5,X,-#;Y<)* MDT&0`6^7;17.`7SP9?0)^9!&;UHXR(NSB$RF+S"/`?8"N3J0`XP>('G/N1N2 MICI^LW%8R:2C;=[=+W,J_]02P,$%`````@`69,*1WUL M8-76`0``W@0``!D```!X;"]W;W)K&UL?91=;YLP M%(;_BL4/J,%\.(T(TM*IVBXF5;W8KATP`=7&U'9"]^_G#\*@1$FZ4\0S5*2AJ7Q!E$ M<5Q`3OHAJDH7>Y%5*2Z:]0-]D4!=."?R[Y$R,1VB)+H%7OMSIVT`5B5<\IJ> MTT'U8@"2MH?H6[(_8JMP@M\]G=1J#FSM)R'>[.)GW]R?7;>F^A-1]$FP/WVC.U-L'(&&MN3"]*N8?M"YA=P: MUH(I]P3U16G!;RD1X.3#C_W@QFE^@^>T<`*:$]"2@'SA'N3*_$XTJ4HI)B#] MUH[$GF"R1V8C:J!<4/KN3:'*1*]5^EB4\&J-9@URFN-&D\>+!AK_!8)"D-1# MT`:"PP9IR"#W!JDS&)P!BI-\6R;V9:Y%:9H]YF%.=H>3;3F?ML.+CFM1@HH, M96%0?@>4;T$X"%J+DB3;Q;LPJ+@#*K:@71"T%IEVLB\X.,3)/`=OCG@7/""\ M/J`$)_CS"<'5MSN2,_U%Y+D?%#@);7X#]\VV0FAJS.('4WMG+IMEP6BK[13; MIOS_YQ=:C+?;9+G2JG]02P,$%`````@`69,*1[5-,T,$`@``=`4``!D```!X M;"]W;W)K&ULC53+;MLP$/P50A\0ZBW;D`7$LH/T M4"#(H3W3,FT)(465I*WT[\N'+-,&T_8BDJN9V5D^MAP9_Q`MQA)\4M*+==!* M.:P@%$V+*1)/;,"]^G-DG"*IEOP$Q<`Q.A@2)3`.PQQ2U/5!59K8&Z]*=I:D MZ_$;!^),*>*_-YBP<1U$P37PWIU:J0.P*N',.W04]Z)C/>#XN`Z>H]4NU0@# M^-'A43ASH+WO&?O0BV^'=1!J"YC@1FH%I(8+KC$A6D@E_C5IWE)JHCN_JK^8 M:I7[/1*X9N1G=Y"M,AL&X("/Z$SD.QM?\51"I@4;1H3Y@N8L)*-72@`H^K1C MUYMQM'^28J+Y"?%$B&?"G,=/2"9",D!;N]FY+9*H M*CD;`;>G/2!]J:)5ILZF`<($N3T0M7="12]5LER6\**%)DQL,!L7L\A\D*T+ MB68$5`9F%['/Q90A=NBQ+T'M(A:YU\,_179?B-S93'PV$[M9B5MED?H%4I]` M:@521R`-PWN3A=T+B^GMB>197/A0M8N*EE&Q\*&V=Z@H#K/,!]NYL#S-%^%# M9="Y4Q3SDWG-`C3LW$N].4YT;AC/L;Z3#_%-M*HC3WRK&HSM!S?YJAS0"7]' M_-3U`NR95"_!7-LC8Q(KV^&3>@&M:H'S@N"CU--"S;GM"G8AV7#M<7.CK?X` M4$L#!!0````(`%F3"D>K$ESDYP$``/P$```9````>&PO=V]R:W-H965TV$ MSM^/'X0XE=4-QI?SNL9V-7/Q+GL`A3X9'>4^ZI6:=G$LVQX8D0]\@E%_.7'! MB-)3T<5R$D".EL1HC).DB!D9QJBN;.U5U!4_*SJ,\"J0/#-&Q+\GH'S>1YOH M6G@;NEZ90EQ7\"'@EK#YA M0KH0TALALYVZ9+:O9Z)(70D^(^'^Q43,+]_L4KUR+9*V*-QRZ#_HCM;KW!ZVHB M'?PFHAM&B0Y2W-HKG3Z2:*3]>[9KWP MZO]02P,$%`````@`69,*1TZ>@(EX`P``1!(``!D```!X;"]W;W)K&ULC9C?;ILP%,9?!?$`!9]C_E5)I+73M%U,JGJQ7=/$25`! M9^`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`4FL!A#[@`64"D$&UF.IS10 MS`(O:`$5'/#!%IC<0H9YX5"BR`4^Z`*378.O+F.I%()-+T>\D*(7>M$+J>"@ M#[V06<^"Q$4$I.B%/O1"DUZ8.H7(?QEM>KEB%7O1"*C?H0R\TZ96E/''L M6*3HA3[TPM1Z%H!KNU$A1)M>CDV/%+W0BUY(Y09]Z(7%/\MUH)93].(^].(F MO=+"12].A9#;]')L`D[1BWO1BU.YX3[TXB:]\B3-';]A./ECBZ37_*N.F_3* M&'<)42'D5@C!58*"%_>"%Z=RPUWPLDM05.(DE1;'Q/>R.U5M M'[Q(I60SO1@X2JG$4"N^&YP[B_)P.ZC%48U?LW$CZ)<<^D#)R_+.YO;B:/<' M4$L#!!0````(`%F3"D<)AA^9N@0``(H;```9````>&PO=V]R:W-H965TUHJE5EFTKJ\7#>[[73M:[O;-N]] M=;FZKVW2O==UV?ZS=U5S?]Z(S7KAV^7MW(\7TMTV?;0[76IW[2[--6G=Z_/F M9_%TL/D8,D7\>7'WSGN?C,F_-,WW\7#'5Q5C3T- M(_^]=/K?F&-#__W:^Z^3W"']E[)SAZ;ZZW+JST.VV28YN=?RO>J_-???W*)! MCQT>FZJ;_B?']ZYOZK7))JG+'_/KY3J]WN=OP"S-X@WDTD`^&@@@&ZBE@?I? M@W3.;-+U2]F7NVW;W)-V7HQ;.:ZY>%+#S!V3;KK8SM,U*.N&JQ\[D&*;?HP= M+3%RBMG[,3(6S6W5X$*&>\`B`0@ MZ$"%(NT\#7/,=8ZQ5A1SMC?.35#J3R$"& M&,@$`^G80'OSB>XE'S],Y%I!%D_'$NG8(!UD(^7$1L@Y&Z$@,B@8&Z'PE!K( MXM-V\*.HY1G/&C2=\4LO'\0:(NKP94J$X,R)H.PI)#4KB]XE:-D`V?B'#!5U M\CI4:.4LU48PY"Y!LUPK#98K6=8"WRB! M=$%5-LDJ;9*J;9(L;JOI%PC`]H'U:YAB67JB'2?GZ$'Y:@ MY0S/4>=)RC8RL(U22!=10ZQZ"XY>194(E3%*UA(TZ\T%9EY%V48%ME&`=!$U MQ,IIDB67*A!*?;Z;]TO04HNDLIA>RC*.F+5JUEZJ0JA#$>O#U\2 M\@)C:,HX*C".0NA+4?BE6/REJ!*A2`);]?IP)4PAD*,5*.-`8!R%3!E0;`4L MM@*J1@"#K?80L)40$CEK@'(.!,Y1R`D/%%H!"ZV`*A+`0*L]^&@EK##8^E+. M@<`Y"CGA@6(K8+$54$4"&&RUAX"MAOV,G%=`.0<"YV`_OS0%5YH%5YJJ$IH! M5WOMPY5068']1J:^W3E1(H7FGRID#@',"2 MI?!*L_!*4U5"DWBUZO7Q2N1YCJTOY1P=.`>0(T]3>*59>&6H*F%(O%IOD?AX M);2VR&%C*.>8P#F`\)6A^,JP^,I05<)P^,H$?&5-CAPVAG*."9P#V-TKBJ\, MBZ\,>0>,PU*6R/,<6AS*.#8P#R(EG*;RR++RR5)&P)%XMOWZMCU?16Y.I]]3D5KZY/\KV M[7+MDI>F[YMZ>EKRVC2]&WK+O@RS=W;EZ?&A&UL?5/;3N,P$/T5RQ^`&(SF*D;>^T&I=Y_\ M:?N)U?%%_"MTZ]P=JH%;\+VMM[\PF M&+70T1.WKVK\#5,+&R_8*&["%S4G8Y6X4#`2]#.N3(9UC#O%KXFV3L@F0C83 MTN)'0CX1\F\$$IV%OAZII56IU8ATO(N!^BM/=[F;7(-,*.HX+M>9<=5S56R2 MDIR]T(3)`N9AB4G7,/42D\T8XCS,1K(U(WDTDBT$\G6!?$V@B`+Y0J!8NMS& M3B)&1LQVN[F[78/5U[#DFQ-R-=^!'N&9ZB.3!AV4=5<5YMHI9<'I)#<;C'KW M@N:$0V=]N'6QCC]53*P:+D]D?J?5/U!+`P04````"`!9DPI'#P:#3N$*```X M4```&0```'AL+W=ON.B[^VF]WA[N;M>'S_NEP>GMZZ[>KPI7_O=J=W7OK]=G4\ M_;E_71[>]]WJ^7S0=K.TQL3E=K7>W=S?GE_[?7]_VW\<-^M=]_M^WR_FXY_6VVQW6_6ZQ[U[N;GZAKX_6I,'F M;/+O=?=YJ'Y?#)_^6]__.?SQS^>[&S-\B&[3/1V'/:VX6S]W+ZF-S_*/__*T; M+R(,)WSJ-X?S_XNGC\.QWTZ'W"RVJ[\N/]>[\\_/RSO)CX>U#[#C`78^(!MX M@!L/OEDY^OZQ^JXNK_=]Y^+_64VWE?#I--7=QJYI\7A_.+^,ERG M*SN<7OU^[T.X77X?3C3:V+/-([,Q<;99GLX_.[$M)_[BQ#(GP@E?8+$+S-=+O-BLSO;6!>,#6T_`?@)S$]N^@F5'[+!&-/V$X&? MR/P4[N=B\\ALHN`D`2>)G8"XDW)QDJJ+,5^$FG'^A\5!]#.\63GRW%$8!67J"THY4R+!5U.[DR\FS!B:%S4: M[:8PD**-D(")*3C&]E79.K!SD0>P*?7)%==Z$D[1%/NX6I#7+!>$=$Q!L6!0 MK>1DC#RV2,K$=9J:6KXRRH(?I&9*"J51K><8?"R")R1IXIINKDX/S,BEW`ZI MK%PK"6F?F/BM,'BV*>LQI*S1A)1%:K6D""E;JQ5E18>V-(@EXHQLYCT3M21']OA8UN2P,G4>B]E81 M_IY5U3&;4\:1Q@]IVO,\+"Q"'M757E57>Z1"KZFK?9U@@UQ6>Y1@O6:+S(VD M^/=(T3XIXI\;)2'A>:1GGS7QGY4CAQ3MF5B=L#,-*+4&56H-2(5!4RX'9;D< MD`R#IESF1E*D!*3`H"F7N9$4*0%EU:#)JJ'.JMEF+V[U`NQW\8*YW8((03E+ M2,^!2U78Q(6F5*>H3*JH1"H,61.5;-=*X(*1#$/1A"5/K,(41I18(^]872TL M>>PEUHEUJ"QSX?\$QTCAD10K6JP5?MHM2+,6D<(C$V^6^JVH`QU5+>B(=!DU M3>C(MK%R!1.1*F-0A`XWDE:T"+O0FM85-Y)JOXAR;$R:2%%6S1'I.VK:T9'K MVTE#A]0=BV*1CG5'FG)(%(+4QT<23TSB6(_(14FJXC_9'6Y M(J%,FYPB_IF1V`!+2-%)TYA*M:+)!"\H("%%IX#B<@R75.?9++E!@DY6TJ*^$^UI$OTE),4>$C4B8NZ7:2DK`P\I.K$5)VEVV&H=,ZJTCFC MQ)HUI7-6ELX923IK2N>LZC1G).BL*9VY419:@AD).FL$G96"SDC0&0IZ\L0V MPE'8#&2DZ!P5.LNUHJ,E(JE&RDC3.2ETEFM-$Y4LQ0.\:7L9)T5I.A""ITQ(U%G!>FY6(7.N)%4T!6DY^(4.BM..7)( MT<4CG8WQ7[BBC<07($$7)F@I^Q;47RZJ_G)!$BR:_G*I)0BZ1`5)L&CZR\Q( M#DD(;FCZRT757S[-+"0W-!WFR>JG@T<&HAL&-IEG3H1UF<6UD@R$-PS?_@JM M7S)H_WM^]^?!20:)\?SN3\-SLE(,,40XC&87S*W$$"4#$0ZC8CB,:B=,!E(< M1K,7GJP40PA!#J.YHSM93;:P9E=>(PMN)+,ED1&4IO&FN-&EX$A:D4QK-F9TSI3IP+F(6]+@M#]HJ\*@O[6ITY@T"%^O2J+.QU61@R M6.156=CKLC"$L(A36-("YVNM6R=A?=2FM29?'-?RTC+9YK6FP`FZG3!$L2BH M=L*AEB?J;D`>BX)J)WQ%9$FJ@D@673%9PFPR**M(Y!U!(HLXDN7%>4"=:`JJ M5C2U<:OYDVB:T9/5N/A9,)E0FD'3C^96>'& M!+4YJVDRHTZ9$*&BJ%)F9/A&$B$<:L-6LS.5,KF5N*1#*(LXE25^_4[7HX)4 M%D55CRK6/2KP?4U(9E%4M:@BVP=+W^$@"&<1I[.\.`VP/HZZ^A@R5115'2I& M5050=D"FBI*J/DZZ^KC-7LVN--](F*S&P)'X!X*,%G%(2T(;J(U?39.9=/>* M(%M%'*Z2)I/15:BC"_$J2JI[14EWKP@B5I14]XJ2[EX19*R(0U;2@L,H*WO: M`(CS!1-P@NCDM.)PS$K"3`A25L0Q*R\5O9"S(AUH19"THBO42MB1,];*@R"% ML!6I:"O2X58$>2M2`5=75F*00N2*5,P5,>C*ED2B,ZAS%79%C+LB>;:@SE7D M%3'TJGCT$`'(7I$*OB).7T4;I;(4XE?$^2LO]6,A@$4Z`HL@@D4J!HN*%MJ` M%!:I,"S2<5@$02Q2D5BD0[$(LEBD@K&(TU@FBJ4!Q+%(Q6/1-9`EN8):YT26 MEQIX$,DB'9-%$,JB*RI+R!(,RT*W_2"712HPBW1D%D$TBU1L%NG@+`OA+*N" MLRR#LT[7+CTHQ4(XRW(XRTO/QFA35_,30U1WBFR;NIH_B5-$SF0URT5^^`7$ ML^P5GB4\.(1;%2`AG6:.Y571E)7T;TC;@K(N3'\FU<1!\9`;#K/[V>)J+ MU0.W\G^#GI;5L]BVW?[U_(RZP^*I_]@=AR>F5:_.#\)[.#^U[OKUTZ5\?1BN M9WC.VX]3W=^^KUZ[?ZWVK^O=8?&M/Q[[[=WP:+>7OC]VIX]HOIQ&\*U;/<]_ M;+J7X_#KL)?97YYK=_GCV+_?C<_IFQ\6>/]_4$L#!!0````(`%F3"D=$U,)& M\`$``/,%```9````>&PO=V]R:W-H965T76JY7J-AC+L@9&Y`/OH-4K%1>,*#T49RP[`>0TD!C%H>^GF)&F M]8I\F'L11<9*.^W7N#=)EZ;WM2AJ.M&5".!+"B1#$JX1H)$3W$N*1$-]+2$9"\@\! MV^S#SNV)(D4N>(^$/>V.F)\JV"3Z;$HDATEA#T3OG=2SUR)^BG)\-4(C)APP MSPXF"98P.Q<3+F'V<\PBXC!'/*83!.L@4YIP*4ULTX1.FMCUR&P:BVDM)LN2 MIW0)MIO#_.5*HI5*(J>29%D@7A&('8'%&@_QK,8D2/U/ZDQ6;!+')G-M+&;O M8-)/3-(5D_3_Q[)/[\N2K=ADCLWCHDTVL\FBV0]O7?#L]G3D##^(.#>M1$>N M]$4<;DW%N0(MY3_H?:GU"SP-*%3*=#/=%_91L@/%N]L3.[WSQ5]02P,$%``` M``@`69,*1TS9@CIW!0``MB```!D```!X;"]W;W)K&ULC9I-;^,V$(;_BN%[UR(Y_%#@&&A<%.VAP&(/[5F)E=A8R7(E)=[^^TJ6 MY')V.=.YQ%]#:F;$E^\C*=MKTW[MCF79K[[5U;E[7!_[_O*PV70OQ[(NND_- MI3P/O[PV;5WTP\?V;=-=VK(XW`;5U49GF=O4Q>F\WFUOWWUN=]OFO:].Y_)S MN^K>Z[IH_WDJJ^;ZN%;KY8LOI[=C/WZQV6TW]W&'4UV>NU-S7K7EZ^/Z9_6P MS[,QY!;QYZF\=M'[U9C\<]-\'3_\?GA<9V,.956^].,4Q?#R4>[+JAIG&H[\ M]SSI?\<N;>AFR7M7%M^GU=+Z]7J=?()N'I0?H>8"^#U#`#C#S`//= M@,V4V:VN7XJ^V&W;YKIJIY-Q*<9SKA[,T+F757?[LIW:-536#=]^["#/MYN/ M<:(Y1M]BGN(8G8K8QQ'!W4,V0P+W+'0J"YBRT-%XFV7I"4QJ`C--8.(RM$Y/ M`$P&$-<8/*[23WV88LYSC,T,A%3-,.B'/).110L0$ M@5DT0;)H%%;D@I@Z:;3``5:_AM&,4JE<14R1%L<"D%M7+N8XQ M@HUM#IIW+)T%"GPY[1A`]5+))C6QU&M%]7)V8IRD7H2'.FA%N+'AM&,0]RF" M^PP'?D9$?H8S"B-A/X.XSI,[%G#2`<1UBN`ZX+@.1%P'G%&`@.OVH-&.Y1UQ M?H&3#B!@HY8(<,`&(F`#SB=``FP0DY@WUE)'XJ0#B,0406+`D1B(2`PXFP`! MB>TA1BR5!4.(#SCE`$(L15"+Y1#+BA#+R_Q%9CV=L6B*\4U3&.KZR(KRSG$5;"5S;FJX&N M/"$]R^G&(KS2Q`9O.;RR(KQRG$@3A.^XCBHTU'_#Y]=2M>$XY M'D&=)J`N<%`71%`7.-<)`JA["C'464=>A`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`275+GF:V6F?4,03\89M:W"!8\LYXAZ,4PLQ>C M2P+*(8%I\0Q"[PS+BG?&,3$,O3@I149T5$2CICJR5C6: M6M7(.(R65E4;!5`9109A](95.;;%+8G^R/)J#(;HCVU>326@8(ETLRD:@C^V M2$>/1L1XCLD0_%'Q[%$L,)AC-@1_;&'.Y!DQG*/"64!"C*Q.CJ8Z.3$"TV"( M?6T40+.46$Y-8HC]I*IDW!(G1G.B5?*\+]EFU>"&@CPQGI,WQ'Y2/%?`6&(T MIV"(_=327,#RE!C**1I"/RF494`M8J([QPIF07';Y?02^BF;0I\!F(HE]'4E M#=JVQ/)IJI;0;_/I:8<2[94SFG,+*NI%<@&>8&=!9#)AE520GGP7T M;ID1G9V!LZSJY(3V'3(#.GL#:+D%VD40>9D!G2UM;U9M[X!7P\R@S@IJ./VL M[\VFOC?30QQ+WZN-`FC1,T,Z6_K>W);(B9#&H,Z6S>3<0IUR@"=3C.EBZ7I+ MRW1%6:8PH(NEZRTMT`4P5AC,Q=+T%K6)E0/JRPJCN2B:!>RC%-;S%E//6QB` MQ7(<6Z):4V!(%I95B^(4;-IIHX3\,)B+I=\M;8D\91@T=?105E?(($L55B$7 M4X5<&7_5LI-<6_XR?H"5$5@U@?T3]=H2F$IUR!.#L-*,.GM2-7)T`*#*&*R6 M\YRJ,FHJ8.6O+*56E5(%M"B5G>=4TWE.90A6RWE.;;O41&*%05@IA+.G%L*I M1@/K=6405@TAN@2#L)H@E(&+&BP8SE8_/;Z5@8%X>O6G2]QL==VI1*ZH3&+0 M[6H%XVI9/+<'T!U52PP*R#B`D:D3UE#@D?U`!1.#AA+).P9&Y>E52_10I<-@ M`7.VF@^6R1Q3M<-@87.V^FGT,#A/KS8S#.H^&1B>IU<-,\Q%1V+B4P856#$Z MT)%(7Y]T]48!O7IK`0TN@L5+N)!):,5Z]=422O9MA:N9E)PIHN0N?:'25;UE M*EN%JY"T#`D^T+9R)86/<"624#'AO"PI+5(J\,!`N!I)R9&@D$M982577[5T M=54LB4342:S/:+7E\B:IEDRB!$ZG/5;XR*C&2;3("642I7**M4(I(<5=*9AB M[&\VS5;-\HV'QJ6+BG@'MN:EKV2:(512)J*AI!E4RY3`AL9LU9SD(V>4>"UH M0EQHJXQ2#M4]B:/2P^NX]/FL1^LW53Z)RQ8NE/:)5UA4_B1:_P2Y:)'/&9VI M2%\G=?6ED(,;5%T== MO>F=:S@]3,PH2OI$0I4"RL5/UW'KC[&S4*6(YFH*5?5QVJGP1BA3"90H#12, M5&6%4PE504DQ'?TJ'52"G\D1*H62&RT4^*2W$D-U/O^S;/[4QOOJV_C/U>[; MZ]M^\65[.&PW#\<_L?%UNSV,T\6&7Z8P>!E7S]J*=7@D[-6K:-: MZ^X90E75E!/U)#K:FC0DZ:-RL+%WF19B(MF M34O?)%`7SHG\MZ%,].LHB6Z!]^9<:QN`90%'W;'AM%6-:(&DIW7TDCSOL24< M\+NAO9K,@BZ%:P/\U1UR;9.`)'>B(7IM]%_X,.1\BL8268? M?FQ:-_;^398.LK``#0(T"I+\2T$Z"-*[`'\IP(,`?U>0#8+LNX)\$.0/`NB+ MY4J](YJ4A10]D/YZ=,3>PN0Y-Q^S`LH%I?^"IMC*1*]EEF4%O%JC@4&.VAPUPR`![`SS+`,^S7/BJ>:9U3++(5JL0M9U1.%O&(6HWI5*4(Y2'L-7D%-Y=OU"@4I<6FV_PB0ZMJ079"_Q0WQC6I7O M+'>;LNC(F?XB\MRT"AR$-K^(N\\G(30U"<9/YE^J33,=%XR>M)TNS%SZ_N(7 M6G2W;CFV[/(_4$L#!!0````(`%F3"D?#]C%)JP(``((*```9````>&PO=V]R M:W-H965TK% M[K6;.`DJX*SM)-VW7Q^`XFIPDXL`YI^9;R;V9*H;XV_B1*D,WKNV%YOP).7Y M(8K$[D0[(E;L3'OUYL!X1Z1ZY,=(G#DE>V/4M1&.XSSJ2-.'=676GGE=L8ML MFYX^\T!B.HJFNSV34=[T;`^X/2P"1_1PQ:5 M6F(4OQMZ$[/[0,._,O:F'W[N-V&L&6A+=U*[(.IRI5O:MMJ3BOQWG-]6;?I.O!##;`@P&>#*8XL$$R&"0?!KG)U)*9O+X12>J*LUO` M[8]Q)OHW1P^)JMPN$&:1VW*IS(1:O=99CJKHJAT-&FPT3W,-J-@Z7K)\TD2* M8,+`$,80`L\<8##$7)'$<(0$BI#81!,G40P[2"$'J760.@X2%S*SD%;3VS22 MK$S4!XZ4>2)ELTAY!MOGGE1SAS2%'10>@,)QD$&I/A6S5!%>QSD&*^*1.3BE M!Z=T<'(0I[P/QR-S<-:>\JX=G`)VH#O(8D+ZY9<%'D26-4^S!($9>60N$-@% M1B!T1XD'T9=`RS(7".P'0XT1ON>X(O#`CSFY)[Z$A_0LLP%`OO,6.1YH\F*A::*P%8SYI3[=O)ZR"F?P<:K%!)M%T4N MC*]M(:=O%9^VISXHAJ;PT0RJ[:+*Q?&U+>3TK0+#M2GOJL]5IW'K$9F3XD-?5F1SI+\*/32^"5R;5X&&FA`-CDBJ*>*6V MRTD-A--#2P]2WQ9Z4]H1R3Y(=AXGOFGLK/\#4$L#!!0````(`%F3"D=+3$2> ML0$```P$```9````>&PO=V]R:W-H965T;-<.'()5&S/;">W;UW\(@PHU%[%].-_W^XR! M8E#ZU;0`%KU)T9ECTEK;'S`V50N2F8WJH7-7&J4ELVZI+]CT&E@=1%)@2L@. M2\:[I"Q"[5F7A;I:P3MXULAZ%%WYIK2_@LL"3KN82.L-5 MAS0TQ^0Q/9QRWQ$:_G`8S&R.?/:S4J]^\:L^)L1'``&5]0[,#3=X`B&\D0/_ M&SW_([UP/K^[_PB[=>G/S,"3$G]Y;5L7EB2HAH9=A7U1PT\8MQ`25DJ8\(^J MJ[%*WB4)DNPMCKP+XQ"O/)!1MBZ@HX!.@C0(<`2%F-^9966AU8!TO+4]\R>8 M'JB[$14RH:CC[EU0XZJW,M]O"WSS1F,/#3VG>4]&=E,/=OX3A*Y!MA%"%Y!L MW6"[9I!%@^W"(%^FS&/*V-/%E#GQOW50]@4H6X!V2]!#!&4S$-D0DJYC\B\P M^0*S7]U//L.D]!O9T4\S6G MA8#&^NG>T^+3&A=6]?=W;_H`E!]02P,$%`````@`69,*1[WEV;\*`@``;`8` M`!D```!X;"]W;W)K&ULC57;CJ,@&'X5XP,45#PU MUF3:9K-[LFFLM]08H"S#SSDU+.M&PSN/DLO-? M@NTQUX@1\*LA@[#FGLY^8NQ=+WZ<=S[4$0@EE=0*6`UW"NA29,.&+V-B9T(0XV(H(N MR'%IE,\8H$+.24-7TL@D#6V!#+H%(I<`,@+10B!8IHQ-2H/I3"%N"[1B@186 MH=,"61:!VR)>L8@7%M'2(C,6L64!-Q`^L4E6;)*%#7)5LD\L&P2C,$5/6I:N M'&NZ,(K=`ME*TLP2<.8\9';'PQPF[H.Q80F*HR==RU>RY(MB$F>:_&MI;%B> MI'GZ*0VPWO,>7\E/S*]-)[P3D^K*&-_O"V.2*"VX49JUNOKG!247J:>I-C.W MH5E(UC_N]OD#4_X#4$L#!!0````(`%F3"D?0Z4;IH@(``#X*```9````>&PO M=V]R:W-H965T0A8#/GS(R-#Z=X8O).:X28\]&U/3VX-6/# MWO-H5:,.TAT>4,^?7#'I(.-#B]ZR#Y=T0M?AYII@WN'H.O!?0'[$\@% M1")^-^A)M7M'B#]C_"X&/R\'UQ<:4(LJ)E)`?GF@$VI;D8DS_QV3?G**0/U^ MROY=VN7RSY"B$V[_-!=6<[6^ZUS0%=Y;]H:?/]#H(18)*]Q2^>]4=\IP-X6X M3@<_U+7IY?6IGD3Y&&8/",:`8`Z8>>P!X1@0?@8DTJE2)GU]@PR6!<%/AZC- M&*#8<[`/^WRR8C4QE$;V!.F*@-1($-NL'E/-:IKI-/J"Z*@X6Q23 MK8C)-JQ[IJ^[SW]VFGR%)C=H$JOG?)/G990A1M28Q2T4#S4Y"R\!L)[LT1`` M&W9Q!&EB]<7371G(^"O2E&4]Z9.L8,-^CB!M0Y?)K(=^(@LW[.H(VK(&JTA3 MEK643+L;;2E&8*U&@-A(D2^D6"L3P*@3Z9*1M4(!5BM%/JZ:7@0R?Q?$"TQK M50`892#+3"9Q7"15MI%JK1(`HQ2D@2+3(;W99@2Y&F?ZPZ1FVQCJ%/A M>R^[)FUV;I5>`OFY_X27Q0!OZ!:-W/S MH$57)FY3\6JK]D8-&!ZF;FUN&(+]JY60(``.(' M```9````>&PO=V]R:W-H965T:9Z1"Z^K%K]2AUV:!M&_&UR3?NWZ[C7P5IU++@->GGD3[U@UN&45:1V* M3VOWR5^]I!(Q`'Y7N&?:V)&Y'PCYD).?Q[4+9`JXQ@67"D@\/O$6U[44$L9_ M1LV;I23JXZOZ?EBMR/Z`&-Z2^KTZ\E(D"USGB$_H4O,WTO_`XQ*@%"Q(S89_ MI[@P3IHKQ74:]*6>53L\>_4&1B/-3@A&0C`1_'G"L8D-F\2Z:;%F M`Q,8?5/;9,8F,6Q2NT`Z(Y#JAT,KFY;G)M7R#(`=M-5!_C=*.P,4V$'/J;'[ M5LQ>QX3_G39/NW<:3,]#3V%.02XME]^5%IW:UE,@[ZV[^,9?[57WNBYZIESH%P<2L.5]B)$(Y%&UL?5/+;N,@%/T5Y`\HF#AI)W(L35I5G<5(51R]FJK4%R>X@E>#[$5*9KZ.(/1PR/+L MUGCCY\Z%!JY*//$:+D%9KA4RT!ZRG_G^6`1$!/SA,-C9'(7L)ZW?0_&K.60D M1``!M0L*S`]7>`0A@I`W_A@U_UD&XGQ^4W^.N_7I3\S"HQ9_>>,Z'Y9DJ(&6 M781[T\,+C%O8!L%:"QN_J+Y8I^6-DB')/M/(51R'M/)`1MHZ@8X$.A%^Q-S) M)Z9\8HY5I=$#,NED>Q8N,-]3?PXULK%ITN9]3NN[UVI'\A)?@]"(H1%SG&,* MLILPV.M/)G3-9)-,Z,*$K@MLU@2*)+!9"&R6*>]3RH11$;,EA*R[%/]Q*18N MQ=)EFUR*F4M.M@]T=F;)",\NH&=G^,W,F2N+3MKYJXP'WVKMP*N1.Z_:^0&ULC53;CML@$/T5RQ^PX/LV M1D28RB&.,<,=+U857:W*NH M2GY1M.OA503RPA@1?W=`^;@-H_"6>.O.K3()5)5HYITZ!KWL>!\(:+;AUVCS MDAF$!?SJ8)2+>6!J/W+^;H(?IVV(30E`H59&@>CA"GN@U`AIXS^3YG]+0US. M;^K?;+>Z^B.1L.?T=W=2K2X6A\$)&G*AZHV/WV%JP598E MH,65&\@9?A)Q[GH9'+G2M]=>M89S!5H*/VFM5C];NS:-(C^6^.:W%<^\!\-']7IS&5#4.1!'W>H&MRRBK0>Q<>5_P:66P`EHHC? M%;XSX]Z3YG>$?,J'GX>5'TH/N,9[+E,@<;GA$M>US"24_W9)GYHRT+Q_9/^N MRA7V=XCADM1_J@,_"[>A[QWP$5UK_D'N/W!7@W*X)S53_][^RCAI'B&^UZ`O M?:U:=;WK-VG2A;D#HBX@Z@-Z'7=`W`7$SX!IA:0+2)X!Z60`[`+@0"'0M:N> MVR".BIR2NT?U<%^0G%5@"<78[#VF&JD>$-%W3+3>BA1$>7"3B3HF4LS:9("+ MV)@$A&G/!,)!;R-RV>@D(B.!TT1I$EGJ=&$B<>A"MB8"YPNWT=AE--']%5O] M%=LB4!>CF587`T+UC&SCAB%:B!,$MN>MY_)C^I<4C[AY)G3ZXY5 M`UM2H=;"\#2WW[S9/N:$`'Y5\$JT:XOG?D#HDP_VQ[GM\A1@#0O*'0`[?<$E MK&MNQ`+_49[WD%RH7]_<-^)N6?8'0.`2U;^K(RU9LJYM'>$)7&KZ@:X[J&XA MXH8%JHGXM8H+H:BY26RK`=_R7+7B?)7_Q+Z2F06^$OB]H(]C%@1*$-P%X5-! MJ`3AJX)(":)7!;$2Q*\*$B5(7A5,E6#ZJB!5@G0D<&3_1/=7@((\P^AJ8;EB M.\`?#&^6LO556$1,8KFH6/\)F_W*8S_-G"]NI!A?,`N=\7K"8>Y]"-\40LE] M3>Z;`BQU8AJ;D)6.Q(%K8M8Z8T8V0QO/Q&R'C#'CW9`)3,Q>9Z(D-1#R(\SW.KW\E>YY)1W$$/HB<]B/0>>*/%/96EC;1` M[L3U?!.U&E'N-!T>)M'Z/]8RR@[K&3^H:#U(> MA4ED76-]07A>'(S".-J[LH'X+'9:8A7HTE+^&&NS_6;^)O:\T?S"FRWEGGRW MR;,.G.%/@,]52ZP#HNQ-+EZ[)X0H9.FY$U:&DGV&](,:GBB_3/@"E#NS'%#4 MW;XS^H^=_!]02P,$%`````@`69,*1_&R%%[2`@``\@H``!D```!X;"]W;W)K M&ULC9;1$!)`$"Z"`S5=NZ%SO3Z<7V M.M6H3(&X)-;NVV]"(B5,2+T1"=]__L/)24A^I>T'.Q'"O:^Z:MC2/W%^7@0! MVYU(C=F,GDDCGAQH6V,N;MMCP,XMP?M.5%=!"$`2U+AL_"+OQE[:(J<77I4- M>6D]=JEKW/Y;D8I>ES[T;P.OY?'$Y4!0Y$&OVYD_XX96=/JK=SSD\@6^-Z>'/"EXJ_TNB7Z';H,=[1BW:^WNS!.ZYO$ M]VK\I:YETUVOZDD"M6X0V"RT/#8NYS6(]9"*8V)B-$2<& M-N;19*"->3*9T,8\FTQD8[8F$]L+$]D*$ZO:1T8`9)JDJC"*:3IF#F$2V6UB MATULV"3V`,@1`!D!4C-/I"89#?),8!JE"-B-$H=18AB-FE%N1-(I&3C!&4SM M-JG#)C5L1@VIF)7!3+U+YC#)C``3RV;N"#"_H^KS>ZLNBS?I)!_^7'=-_51X M:-UM;D[05?I,&\&!$9@!.-&RT+KIW)R,U8G"B1"NY0F-]8DBZPS`X0*-TRBT M;R?,_IA;_`=02P,$%`````@`69,*1WX(F88[`@``%0<` M`!D```!X;"]W;W)K&ULC57+CILP%/T5Q+[#*S8D M(DB3C$;MHM)H%NW:(4Y`8V-J.V'Z]_6#$",Y=+((]O6YYYQKPW4Y,/XA&HQE M\$E))[9A(V6_B2)1-Y@B\<1ZW*F5$^,4237EYTCT'*.C2:(D2N,81A2U75B5 M)O;&JY)=)&D[_,8#<:$4\;\[3-BP#9/P%GAOSXW4@:@JHRGOV%+G M;?B<;/:)@1C$KQ8/PAD'VOR!L0\]^7'TR(9E+*?T;2 MNZ9.=,`$VEUIFIZP5)5)6< M#0&WA]$C?>;))E,[5P?"!+G=+E694-%K!<&JC*Z::,2D!K-S,8D/L7<1`,`) M$RD'DXW49V.42!V"U"OA(K+8KY#Y%#);:#8K%/@)5CZ"E258S0C@W"2P)BVF MLV5DH,C4SZ\$%I3`3"GW*>V`H_1MO:0$%Y3@3"GU$^0+NYI_95>+!0>%^^9` MX*VU<&J%29[E(/;NOHM+DSPN'OA9+_A9?^&4US,_JB_&#]Y'W48>*NE%1ZKP M2HV@\9P3J$[Y05&)]RN_:"_K_/BT!K*G*Z$,7\;+JS"&IVZ"`Y.J%YK&=6),8N4D?E*.&G5'31."3U(/ M MN6%/J6UZ4-P^X`#:?^G0*.Y\:2[4#@9X&TE*TC+/MU1QH;.ZBKTG4U=X=5)H M>#+$7I7BYM\1)(Z'K,CNC6=QZ5UHT+JB,Z\5"K05J(F![I!]+?8G%A`1\%O` M:!=S$K*?$5]"\;,]9'F(`!(:%Q2X'VYP`BF#D#?^.VF^60;BDA8Y?I7O&\0=,2]@$P0:EC6_27*U#=:=D1/'7-`H=QS%] MV;&)MDXH)T(Y$XK'3PEL(K`/!)J2Q75]XX[7E<&1F'06`P]'7NR9W[F&V-@T M:;O\RJSOWNKMYDM%;T%HPI01(E MLJ07X+L+X,$"RO5;<_C6/M=UM_BQV^[;F^5SU[U7A\_^WRXO6Y>N^UF7W\^+-K7 MW:XZ_'M7;YNWFZ5=3A]\V3P]=\,'J]OKU7N[A\VNWK>;9K\XU(\WRU_MU2=/ M@^2H^&M3O[79WXO!_->F^3:\^>/A9FD&#_6VON^&+JK^Y7N]KK?;H:?^R?^, MG?Y\YM`P_WOJ_;=CN+W]KU5;KYOMWYN'[KEW:Y:+A_JQ>MUV7YJWW^LQAJ/# M^V;;'O]=W+^V7;.;FBP7N^K'Z76S/[Z^G;Z)9FPF-X"Q`;PWL$YM@&,#G-O` MC0W`I&,AM6+D]2NW=J3WF[<\B#:=::=:(=R.Q@< M>M%-+D,+P8J9+JN89:]8]KEE$BW[W#(E:T7'N2JA";*5H%@)N14Q+7>!S9D@ MIGC-1)9`=A(5)S%W$D0GD8VC==&*R5OG.@C.(\IVDF(G,9K)TSSE01,X>5HQ M54J^,$K#5E1T,WSY,SOB8KH;-:<'A>!#%.TPF744"V-E1=9/?G+`.B/[L?DP M..,PRA1@0ANB#25B6Q'9DR=@0X:R*MT3+B%O!G-?Y9!L!"8G*V!9^O M8986CD`L;&A68Z#-(?B_+6W-$J`59@^YA4LVSD,.A3SRG0`$(HQ:8P`F(%U8(SP4-A\ MF0PLQ`(C0&,$X&6P`UOZ^3;/[#"5*6$=-#J`4[`^#5A>M)%W)LAUJZ;CCK3J M#J@`==Z%1AOP"H:GH'*,Q`3IO!::@F(Z:VSQ;*$!!P(+JI07$1#3^23.@#!H M@("D0'A*2UZ[]&<4.2>YZ!>;<9&?EC36H"D@F'>AP0:MC$QVY.*P*93X:T7& M_6BH09@!8%3/D#@#P*BM9W27`8R.!8NID!,NL[Z4$VTU(\W`+[+C&H&5><=E M(:8"&U!C`_K+^,5\S6//7[D283(+9$KK0",#!@7`DY_`'M17R^=W`I,C3<@] M:;4(Q@*"F2EV-BO6U4RFU-6HD0N3`O3)#R,76D]6/@Z="0T&*JQ5IP',&9:D MTKV*"+`1Z<[.0+K3D.-`0?IT-<.K%F.BN-R9K%<5)K/3^.6P`'7F)R];HD$H MU MN*!L$--3,"&07HXPY,^8V,!_"E$HJT^H=L`=.\"XT?!`I8)[,,#.03G(_2.!UH'D%( M(P@ABZFP69!(AI&JY&90E=0+9E*H.F6%K7@((-:?:R8+$`HW.*2!@7R!JKP+ M;=53D&G)>]#6*46%@E-.6$D`R$UQGA0P#O. M')^C`Q%,:10T=GB4R9E^U'__GP6W_P%02P,$%`````@`69,*1ZLA70T6"@``4S@``!D` M``!X;"]W;W)K&ULC5O+;B,Y$OP5P?<>D]H<_ MC\]==YK]M=WLCE^OGD^GU^OY_'C_W&W7QU_VK]VN_N5Q?]BN3_77P]/\^'KH MU@_GA[:;.1D3Y]OUR^[J]N;\V6^'VYO]]]/F9=?]=I@=OV^WZ\/_[KK-_NWK ME;T:/_C]Y>GYU'\PO[V9OS_W\++M=L>7_6YVZ!Z_7OUJKU?E##DC_O/2O1V; M_\_ZSG_;[__L?_G7P]AVW3WI[Z)=?WQHUMTFTW?4GWS?X=&?[ZS?[#] M_]CZ/\[AUNY_6Q^[Q7[SQ\O#Z;GVUES-'KK']??-Z??]VS^[(8;0-WB_WQS/ M_\[NOQ]/^^WXR-5LN_[K\O-E=_[Y=OE+C,-C_`,T/$#O#[R_AW_`#0^XGP]X M]0$_/.`_^X8P/!`F;YA?8C^/W')]6M_>'/9OL\-ENE_7_:JRUZ'.S?WL>/[P M<)F0.G;'^NF/VQCSS?Q'W]"`H3/FKL7DP$&6+<2^(^:U`^^](*X7PQNH>9RX M%RQ:1(YL'_ZVD970"'33<=WTE\%R[?.3L4J72"Z0W64@R(48(H=;M+B2LYN. MZP6V;&$N4O`F<;A5BZ-88DI">%X)S[?A%7Q/N(3GF_?D'$*)'&S1PE+.*20. MMO30:\JIL+@5X$Q=IL;PT04ENM!$5PP;76A'.U1&96&+%F9+J1UGHVMA%14M MV]JJA44J19JYR,7F+K'%-C9A_R5E;%+[/+$+.S7=]-YE?H$L6ABE6`(;]+*% M65?G/;+-K1*,82E6F/BL!)?;X!S;G=QVQQAI>17E+:5]BV>'L#1O"8:('4`` MQ>C9_K8@Z]V48X;!`U2R05A8O9R*8?5__!E78+?-@!G71B[6LJ$!CC)%RT<' M..N-M\2^>(5`8U/E!B%&5@/'&%OUXAGM;L!<7O6E,G808@13-!NBWY><'I,LZ8F$+@'V)9*6>`\Z&D!HIQ*ZSZC5V/4+765Y<#:#A7=4K M>.E5FM#9!*]R_"@E6,440V9=UP*`R7M!["QJ9Q;6+S16;0X)\6E:9S/$Q^ZI MAS: M6B+0^N(-+P.K"=(&FY]HP%%( M+GC>B2-02S2(5:.Q[Y")\:G&@!F,<DE\:8"<#%&1](LLE(Y>`IJ MI5)*.T@3+8*DC$\\*,`:]H+Q`IBM.6)D.7L).%=M<12&J,4%$UT63!-ITD:0 MF4E,H2D606[&)Q8$61=%/K,`E+/3G'P*V+#_'>2&PO9PFH8YR+SXG,)A1F4_B/A8 M44.<2=/,:RRI`8Z\C]-%-=;4`%B9HJX_(49-ZURK=58J+3BU[NB@"=[;.]02 M9Z3.:MF/P^R''>F5@X1%L>).XWZ'"0N[L>\<9!@UO_=LG70!N.2C0/X`R\'S MNP,;H]2(*(:G,;_#I(9WX@Z2FEB%G=W6"",7C6!=$&@I9:E@YC3-<9@EL4-^ MYR!+R$[8E-%>==9@*_;CZ4.R\I*I.TQ[7:D^,T@1K[.Y:=L_" M#O!:$N!;_A3JJ1Y*7.2$00&8BTYRK%YC8P]LS%<^/)+BQPZ-)7LL6RD]TJI6 M'JI6@L/T&G5Z<.&\P_3`G#XY82K`7'^PX,,Z!E3(7C!0`*-,)&3[7CVP`0/. ME[9]2]9*;=MK7.W!I_,FU+>L29YXI_8IU-(C`PN'`U.4M`HW'/>0.O`'UR+MR=(BKF:4P=8!3 M`D2U`BA-442]B505.B`/<)!,,;+-"V\!K- MF@>TY@(%!TU?`EISWL4&/,3P?&:R0!A9_M`<42Y/4]AQ'ASN+\$E!4U?`F8# MO(<-D`TXXO?[$F&U,;ZZNYK@*AT)LA_4PWY,+GA>#WA\D:-G[W0L$$?.\%6Z M)>)RM)%/+"6D(7*L,!JCTY.?Y08@DX7PJ1X/.#)A`!!$*X.-)R=7_KQ_.)'.!"H&J+ M^1Y%K>X2H>XBK)VH\6L$I\^[X@CT&JK?95?S$G">?)02LJA1<02G+[6@,7$$ MI\][U`BN>^I@QH#`P7OI.HY&G!&,.<\^$8QY-,;SYQ:`\]2?.`D]T@@Q@H/G MK6`$/UT-!^_P`&:IIDO2$*E7EL!X"\XM:NP5P=WRSBUBD<(DOO@P@67)M$2- MNB*>O0KL%S6NB7C^*=WDTAQ?0L)JDL4-"]\4?DBU5()* MFHE([2[,`K$D]>H@[$)AT2P!SO<7(X0(L[:K,TB^((]9V]09))^7QPS7!7B[KV*&L^0OKJT`5^<]!&G6--K* M8&IXVP-[P4RI%TN6)?Y M>@@"L_]POVA]LT M:RR?+@J6WNH^XS/C)0)S_XT15N56"*RPG(3Q+)JH%'2*O*LJX!2#*R[Q^PZ! M%&Q*O`%#H/4U.YU6)<8X$6F*]1^*`//F&U/;[O!T_J[:<7:__[X[]135?/K^ M?;A?J?_&U>3S.WN]L,SG2WN]NGS;[6?SMS>OZZ?NW^O#T\ON./NV/YWVV_.7 MLA[W^U-7NVY^J7/ZW*T?WG_9=(^G_K^]ZSM6T?QV_PO?^/<+;_P-0 M2P,$%`````@`69,*1R`9SUO;`0``VP0``!D```!X;"]W;W)K&ULC53);MLP$/T50A\0:G5<0Q80VRG:0X$@A_9,2Z,%(465I*ST M[\M%EA6#72XB9S3OS>,,A_G$Q9ML`11Z9[27^Z!5:MAA+,L6&)$/?(!>_ZFY M8$1I4S18#@)(94&,XC@,-YB1K@^*W/I>1)'S4=&NAQ>!Y,@8$;\.0/FT#Z+@ MZGCMFE89!RYRO."JCD$O.]XC`?4^>(IVSZF)L`'?.YCD:H^,]C/G;\;X6NV# MT$@`"J4R#$0O%S@"I89()_XY<]Y2&N!Z?V7_;$^KU9^)A".G/[I*M5IL&*`* M:C)2]E$A: MIW`-T;63VGLI-IM/.;X8HCDFMC&'=N.%SAN+#]2E9WK/B-U!+`P04````"`!9 MDPI'O6[DD,($```!&P``&0```'AL+W=OJ*IK_ M-JZL[Z\+L7C<^'X^GKKAQG*]6C[;[<^5N[3G^I(T[O"Z^"Q>M@8&D]'B[[.[ MM][O9`C^K:Y_#!=_[E\7Z1"#*]VN&[HH^J]WMW5E.?34>_YW[O3#Y]#0__WH M_[JLAT_D]VM[>KJ MT6215,7/Z?M\&;_OTS]Y.C<+-Y!S`_EL\/03;J#F!NJC@1XSG2(;\_JCZ(KU MJJGO23--QK48YER\J'[D=DD[WFRFX>HS:_N[[VN3R=7R?>AHMI&CS<:W$4^+ M9=_[TX4,N9B;2Z]YT,'6M\A-V(,*>=!3$@HEH;"/;/(QV5RF*"!-T[`;S;C1 MOAL!V`U,;K3G1N5*RK`;8-P`RD:'LMF`Y\9D1@L;C,8WTQ9R0TR?8<(Q*!P( M=Y`Q'62H`Q,*=)/Y@?J3XV?C&PD!U!3F3"PYBB4+=V"9#FQ$,M9?:BF5C6\E M++D@!RDBHQG^],+)B2Z"`O#H`BM`>!W-1G.P8"05;%`''IY\S$T>')7-;#1[ M2D&',<-F,C66"(B3#8%T(R?8$)PD"!TS>D@44GJJ.540$#-Z$#=ZOIG-R-GD M9$$@7<@)G1.<,(@L9O`0]=I0:YRC7N0Q8Y?[LP04MLA,]F5`$P%Q*B*0C.0J MW(7DT)=IQ.#-1H^51WOB%$**B-&3OD(`*7K(3!AC"`F6G)!(+"3$!$@.?:EB MJOF(?%A#Z-CRR"J%O+5'>%,>T0DQ;8GNA M.*85Q,3JPYIEFGJ`XF!5"%8R70Y6A6`E'H\4VN@#O0@X"A6BT!(U37$4*AL3 M+$TA?F;D\-((+TL4*\WAI45$L%I$52'-T:4179:H0IJC2ZN86%54>='LPSBF MBUCTFJ-+QU1,C4HA&)MCL_GUPB]F]/AS%&I,(5%>-$>ACBF9&E%H01$ZJCD* M-::0FD..0AU3"S5^G!;4R`)'(6`*B7R!HQ!BML'@4RBM3@G>@<,0?`PS,E\. M0XC9WX*/H8#,4IXX#D&C8(DJ!^P+KQ@.`3_:JHQZL\8!!@8%2W7!`08Q@($/ MF+*"JLG``08Y"I8H<\`!!C&``0),:""&Q7"`F10%2RQ[PP%F8@`S&+!,$$7* M<(`9#!C5!0>8B0',^(#UC]^:\L0!9C!@Q$HR'&"&!6Q^I6S0RV*PO[UI67HG M"Y5KCN.)2YOLZMNE&U[E>W>?ISJ?Y7`R\&ULC57+CILP%/T5BP\87@&2B"!-4E7MHM)H%NW:`2>@L3&U M39C^??T`8BJ')HM@7]_SN+9\G0^4??`:(0$^"6[YP:N%Z/:^S\L:$"%WA1X;ZZU4`&_R/T95S4$M;RA+6#HP_TIC%2*SOC9H(%;8Z#,GRG] M4)/OU<$+E`>$42D4!92?&SHAC!635/X]DMXU%=`>3^Q?=;G2_AER=*+X5U.) M6KH-/%"A"^RQ>*?#-S36D"C"DF*N_T'9&6TWC-Z6Y%:&<)I5GB)E`W^BOR?U^.8],2VALX+ M-VF%"[O9`PKGA9HHHF?L1I;=Q&G7MUH%0>RJ6R@')>U;H>ZF%9W;]*ONTO_$ MCZI]ZQ9TIRGR#E[1#\BN3>>X`#9'GC_9LX,R:3C[;IQ"H] M2WEYS#*Q/[.6B@=^89WZ6,-OJQ2D4\=K?3I+W9&ME]D][E"WK!,U[Y*>'5?I M%_"XA4A#!L3/FMV$]9[HXG>WY+^G%]7*A>AN"1J,G<)V+H[,<95(,M5._[N@1P MF;WK1`8#!\R3C<%5X<-LW#S(AWEV,=X\7VV,MYJMC5B0.R138N^*H4]Q,2J& M5CPA@03(EP"-"9`C`_L3%)$*"B*ENG MVL,MI19LX\!P'IQ=O3,&Z]$?/YU?`QJI*C6_WH*V#@SD`(86`O#N)5-%(+84 MS!`9T#1&0:*8A8'MX1*&4L1,#&:Y&,1L#&;X^!DX1HY,=WEDB"$ M?+"M`R.0D("70,SS(&KZ2;KM>AP4'G,]<&P/@5]X&7:=2^7='R8J>X-`*)3" MNT-,:ZJ:LZ9@S-0PCZTI(QC:;L4PJ!?&S`K!C#4%;;,65178/EP8@=;9[A84 M/9?AC(/$@`Q34+C7^1,/BJTI<_P:4/C\S:QKUH6>V`_:G^I.)#LNU8UMN%X= M.9=,)&UL MC93;;J,P$(9?Q>(!:D(X2!%!VG2U:B\J5;W8O79@"%9]8&TGM&^_/A`6=A-4 M+F)[F/F_WX/C]3\BW2%\_E5_8??K75_)!H>)?M%&]-9LW&$&FC)F9DW.3S! MN(7,"=:2:?^+ZK,VDE]+(L3)1QBI\.,0WA3Y6':[(!D+DJG`TIWQ`/(VOQ-# MJE+)`:G0VIZX+[C9);81-=(^J,+NK5%MHY>J2)(27YS0F)/XG,,\)XWS*0=; M_0F2W(*D`9(L(-O;`ML5@>U"(%VZ+(++D"-\3A[;YS8F7<&D"TRVQ&0!D\XP M61S?!V4KH&P!NM/1?$4@_T)#\IG3[7V?Q0JF^$)#BG\Q_X'P[$CVY`0O1)VH MT.@HC3W=_BBV4AJP:O>WL'3(M&+3&30N'"W^KL#"ROUX2TTU5_0%02P,$ M%`````@`69,*1UT'G:WY`0``(P8``!D```!X;"]W;W)K&ULC57+CILP%/T5Q`>,P;R2B"`U4XW:1:71+-JU`R:@L3%C.V'Z]_6# M4*P"#8OX=>XY]URX3CXP_BX:C*7W24DGCGXC97\`0)0-ID@\L1YWZJ1FG"*I MEOP"1,\QJDP0)0`&00HH:CN_R,W>*R]R=I6D[?`K]\254L1_GS!AP]$/_?O& M6WMII-X`10ZFN*JEN!,MZSR.ZZ/_)3R<0J@A!O&SQ8.8S3V=_)FQ=[WX7AW] M0.>`"2ZEID!JN.%G3(AF4LH?(^E?31TXG]_97XQ=E?X9"?S,R*^VDHW*-O"] M"M?H2N0;&[[AT4.B"4M&A/GURJN0C-Y#?(^B3SNVG1D'>Y+NQ[#E`#@&P"E` MJ>O$K9!)\RN2J,@Y&SQN:]LC_0K#`U2%*#UA-KEUKQ(5:O=69##+P4T3C1AH M,*L9AL99$X&H6LULU:SF=5DW>AN0V;GR$!7 MQF).0+6F&UL[+W9,)%4NH;; MCAN1D9)(8`]KK[WFX0]YOO&VR^1OV_@LVRXW__'5H-O[RONT2)?Y?WSUM-FL MWOS^]_GL*5Y$>2M;Q4OXYB%;+Z(-_+E^_'V^6L?1/'^*X\TB_7W0;O=_OXB2 MY5=__$.>_/$/FS^>9[/M(EYNO&@Y]R;+3;)Y\2Z6/$*2+;U3+W^*UG'^A]]O M_OB'W^,[_-[(>Y\M-T\YO#./Y^5OWT)W'NC3W8PD.\7L=S+]]DLQ_+K\BJ;^/')-^L(]C+5;2(RT]= M+V=9FCTFG[R[>/8$>YRU&@8Z`W"LHQ0>F<>?O/^,7\K/&9C=O:PJ\W3:IW]N M?.$&MI0AG.?>>;2IO`M@0ZBI__;?ZD`SAB'F-,S;-'HL?[M9;ROCG6T!:OA\ MDL]@0W^)HW7CW*>G[>%IMU/^^"+76!%Y/\1I>OKC,GM>PME$>;:$$[G(\VV\ M_C_*KUUENP;Z/DL!E:/U"ZPLK7G;//N['(YUE:TWA`^;:+/-/=E4Y:6_5)%4 M)J1)O#/8]&.VKISF=!&E^+V=Z"Q;K*)EY4&-'MEB`1=CBJCH>U.Z'=[U=I-O MX`K!ZXV'+Z<@./`6/JXL^,_=?6_3&=:^:]"C]`72BC?Y*IK%__$5W*0\7G^, MO_JC=_<4>^MXED9YGCPD,[[MV0.ZMHI<(OT+*`1\"_LV]^!.0H#S.*W?K+%OF69K,X1#FWK=1&BUG M,0`/R%(.-.;#]-P[/CJI;&G[:,A(KPFYQWD.@[RI?!WE3[2T&?X2_VV;?(Q2 M>+X*-[T?@$8,#^&6CI?QAH"1IMDS+17^.!IT$"PTZ-$(?ZTL^`(`MMS4(-G- M.EY%B84/#9)MG@#O9K*/B/;1].(,L"Z!HP(PTKL/"1+*_'?>0US%^[ML`ZBR M;V#@%FN\CC`:@F=%:&9V/@.\VZ9T7/,8\&:6&!0YZ@[]=M!G0`1#/^CW*I`X MA]N4)QMWH_7K>)=E\^AT2E-HOLD33;`>JHX5;H0]@[H904P`9']PJ6N,^&K$4L8BP.WI MS[_9][T7#/K^H-?W.UTFIYUNS^_#XYTPT(\G*%C,&=TL<_6BC2=2$HF/]#VP MB2V@C6842#+R53S;)!_CM$*)Q_-Y@L<"X$+">IHL@4.L$@!?#5XZ))``!J)H MDJV]3093Q(BNN*1Y#/-D3#YAG8]5,/MTO$.+Z)\$X^Q1L0==*3'2*'X?B@`WGS;'N_>=BF M5NBQ0L)A#-5OY*0-#(]>+_`\G^F*7^!Y!][1*UX"<(D,U(G_W8*6^(HV#/ITM8L_,Z?WW\3UB\&Q3`>HMT,OEMH:;9SGQ MSW7#]^_660XGN\X>JL1'=@?46$LC%=[V+E[&J-:3NC)?)$NY81\K9WD+2E*T MGK'ZX%)W&;M&UK7R,0V_XZ(RAZX3'YF?W2VRT*UH&WNM5L]Z#EQW^(D\4MB$,[.(;%VPC%U`8U2>#>>!Z'7Z?Q_*\@ZO(220J'MV8) M*E)Z+,1%^)VL/MN5;8\ M)8`:%;V).:#F(N8RENSO.GN*EL@^BD=%%)T&V*6#UYCOZO#,CDL; M>1"T/@CI=KS_"@JV%R/KS#3Y/JR]V8*@`IAW.+:R811%`I0FZ>J-%TFT]+Z+ MHW3SA&Z7C\FLSIQCI0B8[$O>F>2;.%[,@#2QWOH`"#%O.K$"O)(:6)1?>DO" MR#YXK;-9',^%YB0.OI:MW746TX97=UZ>XFL@8Y1FM6I050Z%(4GPW#='\Y/[ MI:G"NTG)-$C0;#0.%EZMP*^1FNC#!7S]F("BX=T7IFL\8'P1>/\Z1GP_GL?\ MVXE')IP#K?V-;@'@MZ!T+Y=$"AZ0QR=951UM?CM&0U73>]?KQVBI*3^^?QZC MPKO2%P.QHL'K)/0-EW63I4#W`;#-NM75]=W$ZZA3[_KVW?CJXK_&=Q?75][X MZMP[GTS/;B]NZ._KM][==Q/O[/K]S?CJ+U[1->J3;Q205$5`WHA//"1P2(MX MCK83#P4DHH.\7N\Y`0)@Z5D>/S)[AE/1KX`.!=3!]YZ(6M#]SX5B$#3T=RA#OI?A)IJ2JN/OWD].^/RV:[I=E6>\XW-\!N0'YF=P M8LA?<<7K'X&?M;RWP`31,3)+$\8<"WZ9/O?>GH^]:(5_.H#G;>6^(C'-CGP@ M5'E-=GY7VG47(6#6FC9M\WZ;)TN4_0$A$G)"JQA1L$$!&:== M9MMU`K?#&9]-)BWR.0J:?_X'0"!;KS(Z4G%M`=*A_'8?TX6X1T$C1^\L6FA+ M8%`X5=W.R^@)J[H"L>L)&!9AG]!P02&5_!L9S1B MHRK\'J#U^IFT6Q!/T`Z]]I;1@E2&K[Z%U2%!0IE]NQ0':@Y_KE>MK[SQQB,` M;9(%SF9)W7.V3N?/B&/DJ0#Y88.L0&WB-%X]9,3R!2$#BF$O+2`1WI^V`#@,*"F#R"#+(H.+AX,T7,SB M,`J&,6+)G^`"Z+MUYQ`"(4['7\$#7YT(FJ]QYLT3((^9&C:9.3A])I@&$/5I MC<^`)C!O]KR$7:-)/IDGT1HV=@TK`MI"-O;`)U#X33A01S=]5DL>X,0VO*9E M_%P""=,7D,X6G_\);^'@^$HT_XC(:4G) M!CCN1J\ISQX0P=%<"?/`V-[0"=S!?20/F4C9-?76%H#,:(@!0`)Y.YC6([*XX]D#7R) M([@?T7/TX@/2S/6UX\O[9'`5[M(V1=JV0>K$M%R\4\O,>P1\`04G)HG.TNXH M!7Q--G2F\QA=>,F2#B/:**LUB.2#'IKM"GV&O/HD-W.#>%2+RD!,<%%HTG,E M"'(Q`55A&L"^+5CU2X94;9.K11Q)$,&F2(^!J4:/L8D&^S:+UB33G,.5G(%0 MF!M"00;EVB5%/(GW;0'T@C]*CL"]<&^W:WP*5&,0$**.7T.4]&7'Y&B.R.`1&(5?!05T+"6NLN.%L`UOS MC!W8W>#QYY_X:[HI$1TWAY[!)0)>J*41OWQC'9%EK4AH"D)!/Z:OEDGC+G!Q M3R_S=7:*8`9^X"5K8%A"P^ZSYQ@Y.PC@LB[&R=;.M8.$&RT=-949WI`C%/(X M38%]PID_:P5-X(\2@!'-Z'+/M@`K(+QD]#!G,&JW_W?S%1#C#/8XA]]S1;!"Z]]L-FU@V"5KN0>K^F*RS M)>$L/-D,,%@CL[L-$3O<8;8DSK]=J^/>B<@+Y/'4@A?<.SP%/&%D8H[(&34* MG4@Z9?Y36HTFQBUOFJ#.1W35JL4^LKVGZ"/I3/`+G$/RN*2(+-B2=H6P[LBX M@=`&]F&E6Q@VW3("TP,.PX7U:C_NO$R8CXSW7T#/M& M/S=\;75#%#O,23TD**#I4__\#Y"KYL0*?F`PVR<%JY'@`>ZBU0(%#N2/&OL- M]L%5BA$05D:YYQOO8:P0QV554)U`RQ(*+C'?SD!&RA^VB'KDK6>Q`!_3!$FD MR$A+/V#D_V6V/)4E^E9K.4/(C#<;8*$1:B,W9^,3(POZWG2[PM^1 M/&/H*G%:P*%+8*NPF./IQ240+`ILN<-HDFF\Q%B&,[(U.U$]&OM9N-;CX]H> MU]$B1PU7Q.5[C.4$/92X&DKACZ1E$>^D8UK$,7.FTEA+LH<`..ZU+9-<_2"4 MY43T;?0!.M8`N?E89&8QG2@0.$CI2)S-IKS9_,<$B9FV?,BANR+&@S>/$L`+ M>>%X?'YY0BBK!3U\00MZ;.N20S)GAQ_"Z2$1%:Q`QRAAB1%?.FV-*/RV*N%` M`7?$XMED7/,N+\_8;E;[+;Z6QI_P*=2TUS%2S@?$>N,ZWF0*>*=9>DM&$O4X MEV,Z)84*_SLUB@8=LGH456+KG*T"J M%2*=J(D;)'FYB_&NRJ2_UZ!!;5(X&=RV4U9)DKGW0\0&!0;)FD:[=<:YC9]X ML<1^?F^OIFJ^FC6`U.!'KO(]2I`HN1&41/LW<5+"J\Y%/T=87](C9%*#D<_0 M-J<#?94(6.4[ M/`U@-GE+C9&0%QSQLOUEG-I+0+SQ/HZ71M'+V(/HF)Q>EO`5FHE(?2.%4L(4 MD',(M1IK94;KE3>NM,>;7&,ZF6;KE6"8>K#0ZVGTB`](**&UT,LFI0%U@ M`6@Y(2>,('$UP4`-*UO-3O%4O\BB:[6!DNB`ET6<5O2@$BBLH M&O]#LL;3,_03``>/S?#V3&D/T6H):$='DJ,U>YO+YO2&F,-G,Y#L4Q7E92&Z;;Q0)O`%)01W:O,=S76NL# M[_/_\*8?WK\?W_X%+?/3BW=7%V\OSL97=][X[.SZP]7=Q=4[=7-]>7%V,9EZ MWXZG%U-\\.9V,IU3[\F-!1O*N$G"VT147CCL??1ZI$G[,B]!3V!0D=@5N3G,0KO"%>Q1L%9/X`\X%$.RY(9*[E^,DI7PWD)FR(+=T#Q M)5!;5(H>.?HK?4%J$*]XHP2R#TNB#&14%^&+#,7>\5'"7H`FP5QK)@5V MH7!MS1*]TA+12,L(80;E,`-S0@FI=FPZ^QAS!!\_B2<7>:B`D:$#8'A[<75V M<7,Y(00^N[Z:`E:?,P:C'6"[C+9,J&=.,*^J!;@V4FZ>UC$SC25*I0N.8"0S M8S54G&0"C9[Z5FA`U]ESU6Z^1V=QN+G(523\BB;A[Y!1_K=HL?JF*J4X0HKO M\BC#LG>Q9<^P9<5CP?93$V[^^2<['LI`LDNK@.`\5N)S-HUX"&MB%G(5?XSF MD?'UP->:F2K>D[-"\LC^\`1^_(`&QM;&C.UJBH'%1$30LF MAUT@33V$"GD'4Z$==$4U7MI7T)5R@(TV_,W2#(4,\>SC1FPN6?D=)<9RO*V: MC];>6_&/3\^\8-@^[;0IN6&))V"L8\:A'>4DHF=+S1,CXV2,[@%K MQ5:5,[ZX$$BVNFU-^1/7R6D'#_E#V3"3!-LUE!\M,.3SS=/!?X M:E-+DX7VB3Q52'N-=TN#ZIMFVS?INTQ*@&(UJ+O'1&"T>X\M=8VQ`?`T$AO* M7R>ZXI7I2LN[G7P_N?HP@9]GUR!=T:%+&#J"'\,(@:C\G:1OY?H::FZV(]=- M46V*UG-T^\YM%NT=2&$SHLS3,Z2<_7;8HM?6>`SIB^'>Q;D5B]+BF'C(T,9) M%HUU0A98(H\@Y;XAL&VCG`S@:'^06"*BR6LT7TFT.HA:?D#"3:,]3??ZG\>63N\KQZXEN*<8. M6I\-22M94(Z_.WL[/O%+1AAE;26,P\9:8BCG3HL-/<5QJ-L5.N-P>4!KX.\S M=-2\MRJ!=Y-&2X[R7?,QX,:5-L5PB\_=G(WM324S[SWZ4N+3 MIRA]`!JS!3EO3#9S4*H>DH<-\MWC3GCB`02VPMWT@`LTF][;^`@E&(CR)'RP M)>+)'@6:O&")1:,]SL]B9FFMN/Q%]"E9;!?X:<XJ? MT*L*D9P=_!K701G'Q$DAM0GK MH!S#@U8Z+4$1,JCB^389X/"<;T1_OXE>''"Q/<'@M+>U@K(]-`-OMG@;DHX\ M%T1:C$>)O,USA@"8X5)F:90L\*K\-2:1RD,&!R\C/2PYM(SEKBCM@L;P3`1( MFQT`*L;N&^&:4%?,S8[5'I.CO%HPS!A2FFOZHAP/0-'#2O?#4$9R:&F_I8G5 M84>&N.3YCXRHS[L27>*/,NEF`$KM?[9HM7Q)( M:H$%X`1K0<3?)*EVQ6`1BV1IO*KDNI'16$<4!H'.=@=DA'(X_GINIA/Q48N" MB(8S.;5[9QQF";5P8Y`V0$_1>\9<-Z=PAA0(W#MG*)*`@&D1H^>7/__#$=@% M='H8$OU`!#9B@3Z3;0ZK*K)[M<@XJ]U<1?WP2J*WP MN*=,FKM>H\\F"--CXI#1BBBB3WR0UB$SZ=(\I781/2\X38TM=BR6Z8I*&V\YN0K[=;`;7*SX; M3[^C,&CZ9?+G#Q??CR]!#9RZ,:ED=$K(8@\73CTECT_D(8:+3\1ALV;JYHN* MC^;'A-Q]"TR^02F8MH\ZT7'W1)NB8%%IG.O(UG+D>$L;>:>HG4Q@7=]>3LJ1 MLA:W"(%0$"YI6*)Z>>Q_O?\K*?Z9'*2W3O(?_7+(E[=Y64E@SCR+F0QH*H8O*'16ES^VZ MI'9HZ=5$0WMK3F`B1M/IX70C=]>+Z*^9Q8^FH_45Z1V?R%0!,!RUO_:+G%2# M%*;@P7]P[DI5I/1(!P"R^B/:$T!A%)+EWMPY"7KX3*[HR+V/H&IBQ/&&/548 MP)D;YF'">G3N))I>[A?)AD0A%A#1?,L"(YZMK;>!$[&/!MY[S_8]ZW-C+\7D M_,+3224K[5W'PY$/

A?1B36'PFKT]Q>FU#LLXWIPE0#/X-#?5$ M>?FVV:!6X?0-K3L+.:T"L60R2TC(&$5^9Z%642?>-WVS/KDQ)SOS\ M1X#]\F[M_*AK19Y[D-H*B)HJ&0J9O;ZYO)[=U?2#Q&R?B& M_"/UY8R46*Q926*@M[Q"`93$L:!0#`K?$&0;6*[@-"4O;;QYRN:L]>*WVD$S MQXQ?++B$AIE)XQA9.MX_D:]W:[A+FPE8/TA^82_YQXQ%5"8*;Z> MK,M;)-$6!A)ZKR;.)^XKT^QA0V?9Q8]UH#X3)@X6(=DBIOHGBM4L#%!H!I\"#H`M<#, M56;X5(7Y:%\>A4;1;4057[8^2]8`-L[Y$[^T]LCPZ2,KD'H)I/IKOE6X),H< MYL..Q'^/;(*QZ,IUNG3CJQ18QJ3$;MT$HN1/Z&95]['CMR3!"\Z2"+\%)#(E MO5NS/Q;7,E*@+<@%`]YXQ\D)AIXY;GZ=ZBVW2*+VQ2!%CMCR*M%2LUU]`V-5 M!HOF&.NL`[WUQ01-0D`FC,F8-J/*Z>-3SBR(OI14QM4*LK7V59E(9J#DK`31 M@@Y841H_*R+U/AU;%"33+'"UY%-"FXI4SV\Y'B]52%,`D4AS",U:=&6G&G&M@#"I>-Z M'80WR6@8^K"FF$Q]%1S>?)R?T'W!=!FR>.F8L(WE M_UF4&:E30MB<\'0ZZ)/7AM?08HZE%UN2`YWZ/(2Y+*CB(/`9!OJF&$WO>,PV M)B.0TS<>$E*'W+0B.V;+>W=]??[#Q>4ER6Q"2NYG-TQQY=T MP_;)&^].RN+HY\BX[J`A1:%\T.-C-(IVGV28>*O-41S:1A7F*412L@434?,H M/[O@XBW%/*IR#G!]RINS%!2:%EP@'',K)'"==#2Y8&(1XZA2S0LI&T(<"D:Z M24@O*5&V#1FT32)W&;6M^$>!`_`^&^F1)%)YCN*U;-F36,>"C;E(#F2&9>J'P&;(JKIX8(P[$D7(;!_F M,[BU\ZS8Q$KA/5RY30S13I:'25!2VLX@LK+V_:RRC:2H;5?HZ]+8AU$16MK! MA.?ZDAWZB:*#=I9A)(FL,<'Z#42B']C:I9.:;.43[3USJ]SX^\KX-$#NT86< M067E5AIS@::5Z[F-/5D:SJ']NJT"^;;ZG)AT'8ZO11I$G`_]\2X$W,.@\1\MW1O74M=?%W`PLKY,M@*D:32UOJ6G,-:>] M'C)BIY2=%#+DPA6%X%ZQ==7>7J)+;+>BAU`B@_->:?,V,F:DHL#73X/V:3>D M61P%><.LOJ5S?9ALTA#/8L,78;MZ#(;;*>)V%-Z`&0V&RQMV1Z^Y:J&EA1AZ M1&$01=[)UF2R992JG)2"MNGAS_]0SO*T<%M=`KO4TCPK[*SX#.[.$`"0KV&4 M.'W@VC@UZV169`-K@8*FZ()6O$P.(9?R"G5P_T%V:0G04=CO^>U!6%B(N*]J M7I7J#K^EV`?>9D2%#"!QS``K- M>8[9RA-Y=7JHEI`,8>(H*B)?VH;LZ">HQV"XOBU,)(D=V/Q MD\DQD5 ML,5+8^!$$SB>?XP_T9&O;"4T[-/"SII-R7_XV%@4WB:@))JH._F3 M;GI:*5/2EM?A,G,X*&8XZE#W5^>KM;SIEB0'K0'(RBA*S7H2+J[.KM]/O+OQ M_SDI1C5I_1,G)\\,AZS`4M^.I]\2SQGTVMZI)[6S[[!VMJU%8D+('[?)W,1/ M;.I3?(IQ;&+[,%85FU:$\N%VJ2MX;*)/'K6+XE@:FXWA5(PIYQ*U]'*IU#?! MQ>$^COY"8KF;L/0BMQ036\A`0U?VD1PC6A01BUGF7F!<)7X?_VT;DT&[8JR+ M%T@NUR].7&->"&PL*96D-3:D89&(40-@T*30VF8S`G30TU8R&)SRZ.9AX-WC MBUOO^_'E!TIQ>WMQ-;XZNQA?`M9,[VX_O#>A<'6R'$?LN>E,)A2N#'>T<,(A MKV,,'<`4>[X^Z+4W-'$=@R07F<((K@"EXS*MS"NN?&60Q>2HS4#[Y7)LSOP2 MBAO/",DEDJ`$=$=_=1J%E+M9^5+"!^WEW??:?I]^.IY-S*JHZ MN9J:G%:C1SR1T$7YTJ?56N$2[6MH^SS678+(K,%%C*B6)F M&51=+A/>_[JI4)C13/9.?#6"0N_XYE-I>$":Y#G(/!&G8BDJN- M9D2.CN/SV'K!QC#ENIJE"@)^]%*(B50<$^E$M!4!9FZ5-G.YDYM#JX\C9B:; M+)(4^#6OTD<*JUFG(;$ZULN-$L()%F],'9.I%B0G=@NZP5$T`*UW`37@!$61&(<,4D.V2 M76&N9CNNQT*C:"G?EO8`#!'I6B'_7S)ABUX92QDZ$`< M82$@L:K#E4[(_61^,28QH>7^FYU[8LZ.' MMHD3%/@F=GXR?D5`'EFJJEM`I)4_QCH)A`9-G/HDN[%<.G&*@A/TO)*FX8;Z MV5SD--VY>5RJ,BCRH*5`!R14$P.NG+1)8'(>;[:K%M9*("$7?0SGDV_O/-.' MQW33H:`K10&%J!R(#E,@9'`E5ZF#IR((25P+`\/)HHIL@;;:9A-R><5W+O=8 M'E(F7<3:U>D)$`!MI2%QX?-7;EU\.YA34;[$]=`X((%`Q,EZ@_9IV#8F:/PS M:*/'.EIS26C;9H(,,$1GFN8R\E52;9IA2(%]AXN.WD[.+L?3*95O00%@2F6W M(JY6EDDRH9;];%4"VX>7C9I2TD3#5VMS]+9;_D0D#Q3]X?I=?#_Q;B[',"DU M)1;BHZ/O"J(`ZQ*4]4D56^3V"S_A/&-Q6\K9O)9AZQJZ(LI7DSOO\GHZ]6XFMR@Q.!,T9":*Z>Y M$(E3Y4ML)+2B*$:U"_IMD1R-UD:AM]J,P2C[^2=J`/3YGV1>_?R3-`&"O_4: M[.2MTNK<9;$FC?DBW$?(E/TMK/?^A=(CQ"./&HG>H5/^H+;UDO:4/S>W-W+? M*G8Y,AEVC$;JG#=I-[('S`7D_J(5<+T*Y8A@JW0K1;T)7!\IM!9=>%FQ_X?U MDIF..:;$DF']%LFM*$$/B!Y+T>+5N7(IY-'0OU@8D?EV56PWZ,R:/)S*@W@G MA']<+P5?06UE]>LX=\&V[]VA=X)_!-VA/PH#_J/C]T8]OSWJZS\[ M8>!W1UWO1#6TD,.R8?QO%/IA,%2O&[\=]OUA/X3Q*VW$:I`ZZ`5^.!SYG4'; MZW0"/^@-8'5]KS.$GR'FTW>]4=!$F:0=5NM=N\ MUL)O'?>W_:#!=]6!H^G:]=H9+R%9SGU^-=K6-''CP"![)73!_SQ:<`%TDJ@, M?3#^VO1%F2LMN@-[58U9ED0)+#!YJA]LL210U_"N1`C\(I7Q*P0`+[:A2FAW M,0&[AMA4]^8P(&`H,<7)440[*L9UNXFJQGP-RC>*+/WE.VSOK"(;1DJ*@OU5 MN9UVI+^>`*7PESK;0?T&0Y\*-(33M!U^_!_>T-VUX?+B1< MC'ZHKH6"]^$6=?U!B-]UAGT_"-OJ!PW:;AON6=?O=KM>9Z!;:"MN4.G@0BWT M\,(/8.BPW_5@]D[0]@,`SO^J>/1;5SQJ+'3D%#AJSO>RGC(+-+Q`-IY,E>/) MBAU?YAPIW%"3BYP43K?U>29M+KC>.K=X@NG$]6/+P9-1``3<^+DNM,WI[0+\ M@J8W9Z5J0^&XW\3QYY_0+4&1:KRH/7%SP6D[:(Z;4WOBYBY,Y,;I)45NV'&\ M,5OFBQ%U("[;F#J>UVO1W;E2CI[9(L$,FF:-)$.O1J^%J/TOZ`P?%2R:[(4F$O MD;7D41;HRRK*XJG4@@7PQ\1%R>)+3@FXB&BY=BHZ,Q3Q"&G1AAWCZ;MT`IGM+Q]4MMA_K M`*[U3U8Z"&>X#1`:@$E56L.Z]:9]?,C6I91B3T[1V\QE>T[/WCUM`;O>J??N MFIWD5V>36W9/-;NU:[F%E32Y,&8L=2I][GUC:PPF:+4OXGP3Y=6S]W0`QD-6TZ;^&:6*MDDA^+!#$0)]$TH MS);\$8/+,!'=B/T<=4!2OC1Z$.FT6ZBEOJL,;'-(](73+8([10CK5L4`HF>) MAGI5QPA2ZYV&%C-[`QI[6RA8D5,V7HKHFVF_O,@L/__#4T)B()7?<6+JU"-F MJI*3T\E_-(07XS\$6W0BHJ3HN"CRX%V?7;XS%8J=V!**+O@HI:8DD;S5'#!J MA;Z:,;`)491BKSY,"EEJI4JW[](5'&U[0T3=)W0O9&O;^P1W1$DT3O\YWXD5 M=!#:TY7()/Z<:[04:QL<=;2V@&O1O3*U&%CJI]8)6VIO$%KK,D7-:RB$6WN?8HV5)"5+F4Q%J>-N34Q$9J<=IU1)8F$"*X1@ M-CHW/C.Y3!NGIVYN#M%>%B+`;/Y<9ERODT]*!!]EX%9LFR-09W`1X8P]0S:) M4VR-!5>2O@C?"K7QJ:"H]/A(+LGMXJ$YE1VOK4.[=P* MV>L(\]7<]GCS;(MODC*[*8@(RIEL)Q\;DTA"=L/NM MGBW6=VC"3G!N0Y,BNWX5XVUY-ULLTZII!\3HS3_$*J&Z`, M?-01:FQ".MBC$GES:MUAJXT<#4)Z$-.`Q;-*PA`F8;#@,D4#48PB9(9U4-`W M34%$-$]`;[,PYD:M4X*.SB"B);TB(\CDFNQ*^M$]N6HRGFJ2>E31)Y>LZP/5 MRH$1SE)!TJI/`C()GM(5P.3XH(@H.Y@K&P5_5[LS5=C9@;LJ>#0:>XM[1][0 M[_?ZJKXDA]TVV""NUX:[MEBI?@ MH58DW-$JR']54P+.&.?,>"[T>]23A;MWP;=W!FVQDFOR@I66\):@Q;77[7J% MOE%8HE@'%?POY/^?%OE!N^_U1K7UIXZ7\>;$"^%P.]VVNC#!-YUVW^_T0T4] M6Q)'4+,E/QP,G`T;4<^--^J@-[#?55<%YP0S#%E3W;D<>?T0 M*$>O[94Y=<'==FU$R0,?HSV=ZZHJ[S!FZ\O8?(AL_OQB>G:-K9$^3,X55C"2 M@!O6V[UKD/BT2EWV*AS0Y]C)8\IT@0-2+VN;'C65F#J+$. MH(8-R:(K=)ULK=D:P_!)&`1I1S]*!+R'3N[`,Z%47")%"J`)$2]/>T_&(1/M M%FU4[VNI_2--572H8.KD4N)T/3\(!ZW>J&B`M$(CGQM6OI+DB'OR;NHT-0G! M+^B(NH(%TWZNFU'GO#XHMF$*&/@OAS9<&TZH%_E&O6M.B#E"A[K[7[>O"I6_ MZ!T.I-5IK0/P7`4-U`V_)D'CKM][T2Q,T<@?"S#G+S1$]1^ M6UB)G:3A!,HSOJ-:53!L'&UN.K'* MIF4<=;H#D-/ZA$I'@+?!H+,K*``KUE-&+[6L*E?B?+B7\LU'.%&KE%UE0EM54*=_(LA51(2[>!)H0XB,_%"*42I MI,I_E8/%32=`<@ZNN$SDG[94)?*4Q=HJE2"VR^1O E<(::X6(;NTUDJZL5BU'D M+;E6@U;8//FBBFJ(.4;M;/I MJ?KR@E\BM0Z\TWVU-E51\4@D_$9J:[&$I/,7*H1H6?9.]8Q08#]WPJ5LY4Q0 M1'I^IS-D7:L_'"J.I7$V##)J/PCQZU$_,/4T-"96MF5\X,`YBAZW7Z_@!4%@EX:BC0)<5>0>T+!H'7'_I!MT-\ M\XU;EM*;[Q1.CKM#OQU@/.0Q*&%!OP><'F2:T`]Z?11N1K#5084CTFXJ&@]_ MNH\S#A5PQNNW;R_.)M[E9#PMY>FR.0).^H%4!D0BBI1(XT^P>&H`!GNXC!ZB M%Q#5W=Z+$LST`PH#9UFZ7=S+PV=P2U+X%,/T-=9$(Y)72NMHFI@4H_=$6N`XQ`95)CI.55%RPHL. M7^3;9(H@M6SIW3QE\1)DY?%_L3HU(27I%H1F$.OC>%UZU?:-]W1-`ACD+EZL M8KA%_X4-#Y:F7'1(, MTFV'_/%1OP>WNEV>Y:VE):*V4*KZ=L$'8A2B-TPTX$K@A0[QKSY0@K[?"WKX MQ\#KP%D-VT/\8^CUT%PSY!N,DF87;G9G$%;#(=A(`@36L3FQ<%^)P6IZF=ZI M1FP=+JR.*%9,*KK!4L9WE,=F2KNI:FFW'XK>X37R+63^SB[6H#3J,OFYTG71 M'>)36[;""K5N(`6G#3O%?DV)L<89O8)@K4BN!@K=&XR8"CHDLD`1X<%.N^.W M>Z$T,&N<@-SD.IU5)\4%;(=C'MY$DR\R)$O*- M3_H(A.N@9]JR55B[55>#5K,PRY]'F>I3%'U%KC?'TJI?K25$KO9TFE5+6IE%28(>+,OM+H4HJ^/+0K MY1.*427MPESLV4;Y7L?'8>Q?CEY.T_>+:DBY&S"V;F,=JFG41!WG8[?!>[%7PY&G?8)[J$[')&%RN^!<"Q#]FC($&X(?=/O!/+6<-3M MG^!`0;]+0P+1ZI>7.CKQ!L!!PQ$O=00+DG'#$W3<`;_&;X!U]MIZJ?W>Z,0. M>.V[^6N-+G* M?&_4;?S0JIA;KT!`1NNPS3VQBE<0`'G`S;;8$2\`)V>6,2T"X\;;@%DG` M`2@F\!N^/#ST94(!\8K"B]W@52\>AZ#^G.![KYL0;A=/-WK5:P.X+OA:;_"J MUWK^J`."9Q`>#%)Z#73&7C""]_J=0]\;`OEHT_OX6GCH:R"'=P?VO8-W!X1L M"#JTO#)F@0(\Z'?->[^#WD*ITS7O]@]\#$M6W\QV,*R&NT\!E>/C^NGY[ M%.KW1@=L^UV0%-@&=(E5R^^P3`V5U6-'U+%04"!I8GLTWQZ9A'B$^"^`J_=?D#_AIN,_T(^0<_W.?O@)[0#WYDB#]:'I$+^IO' M&?!L(U[)B)<@)Z#AM"0S5-5H MGR,:5=&2OLR,2X8;AC;S^$I!)'(EEQPZ[%/WSB;7'$#[[#D5/"+\9'FJ';[E M,B&VT145-F5KO*[S5-BM*NYV1^YKO]7^VJ-"4ICFSTT_CP/+DSM^'Y@R7!U7 M:MPN=$[ZL^FMJGOY#'I"M.4WO';!4O]9LZ M'JMEJ^0DN>(>+3JYU#R'M(5+/?IN/#MX)];W69U/(/ M>J6[[Y6`7^$?:CR&I5T*-IXQ-O:ZH,J,O%[/[_5'^$10?@)=OWU4[O#;+D7= M/J'KY3*+B()W8$$]'KU7\VT/]3L:.2Q]B\)>>R0#]TM?PFMMTK7PRT'IRP`] M`P!Q_G98'G>`ZY$O1_M`1&OT!\"E)M.[_4>'>=QAP-)#T#]D<."LW2X^/3C@ MZ3Y(&2C_@G9XR,/#'NHMP2&;##I^>]!'!:"][VDXF!`XP0!P,\3%=/="!:W: M`'*0D48!OK`7,(#_78#DL.<%@]#OA*A!=0\!$,C#/=IT&.Y%_L`?,7[!TWO' MADV/@K8\O1?Z./:@*\K#WFL(0K6@:X`.K7VP8>)`DEA[[V'U0+/H]4'6&H$F M-(#CZG7W4A(,0!R-L'["J!-:L2WPAV$;[2QP/*"&^4-0Q9I$M^/NH.^WXY&BZP]M9R*=VA3)I4J6!\;4Y!T2U0 M"A(L6E%+87"ZWAG"7CE\RO0;*J0!U$?.>4?]4NA<;=Q<@'5KQ'Y+`V'<,[%* M2M9)4_2GN?F.O58)[$XP.=/)4U4?H.Y%'-NBK4*V;*0MXF]2MHOP/3"'T;@3 M5#&'L1BN:4HG8+M6/@#:.9S+Q2*:>]-D/L<6\J8%9-T!#,P!N(#3D958,!1E M`M?&M?L<>GX8]`K-9S4H*/6*HR^IJH9M+XC3%I%,9!=U1%$!^)S&"`GKCN;4 MLM%DN3B-!?6(Y?.U$;1W,?IZ`Y;ZD6MQ`"OQ)/J$50Y@(X0"-H51!\W>?>%] MT/U'<'LH>=!KF)S(Z<#WV7J-L9PB?)KS4K7G57]AT)4V=(1*B6U'$S!*_W5G M5A0@W9&..GYW$*I"*.J?HN46E5%)@._I>)Q[])ID-D4(&SG9L%5YN*:.HL;B M0N[T`S7$H98-,=>QX.!6AI4/)Z&S1FTR2+'6*NS$YJ5B;#_53#"%A/1)`"ZN M9XE)*<`]MT!7K^N0X!<0#6_)$8L1Q4W9)K6VACZI$?X(%%+3\;-4<5(O#'7: M+NNX74;/KNC,K!2'%EE#1M8^J[Y]UF3;I-[V2/M^C25!N9:$]4'&9U;@ M,].W;Y!A8@#'N.!0N#$EG::VU.72/43>EJF$N6*,AD<=+J?=17J8.J'`04#.GRKX-CU4G$`7)=RDMO= MHC2&`F<:2RYW`0:QVU07PQ.W=I2?+8^G6X>BL$-%ARE_'(^%ZY)+NV; MD:[NO'EE2/K.I3NB"V=*$G(X(C=ASI82NG=*84NZZS862!(`J<+4Y2KRD5/I MT,HM[5971!$CY<2?5HF44I;S)?[=[K^2K)C;6$1X&A-)EE; M`T5;)X#C=))U_2W492*T!)T_Q=(?QXFRZ`.C!/F7;ZG:0;3HQ5'?'XP&33J` M:6EBLF026^Y=],AJ7KE$-2F2ESD#BAL1:?QQ7SF(BS66:B[Z*MR(Q#?.Y;LR MI9]-O=SQQ\>6JBLFB@']TM?N@9(MS;>M@@/&7>Z9*:H\TV4SN?TW@4?3?'Q'0OI_0L+ MH>]KEP)S[E](P4VS>Q6")^I\)YY<:"YLJH+490A71,M^@URY<[)Z!E!:X)=* MDYU=FKDU)G!)/=ZRG&9+U?*EW7#3_8TB;EIBY3"[WF&[A4J]';P14!6N!X_K M\HDL@6GM(LKUG)2"^X9WHO0%`3@X&-+S/?38?&2]V@H%[CN]TCNA[PWWO1.6 MWNG[`,I@WUO]TEL#?*N_[RW.'*!3@[_IC"O/&TDR"-P,\[.BR3*DLL:O1%DN MF,<5R#IM3`9_J-!C5XBC:R-%S6R&1Z"/Q_(!609ROXC+6DC'!8L_(09&PCVN M=J`H/XH*D2=GY.+A;@UQDWC]KRWI4*;8N`!:O#?]\.WT[/;B6^Y=1^U)V(ZV M!^?T,1(^3;?WNE_=?CS210PD#']226;2>,0=O_5?9*S%=9"V7VS'TQS.G>C9LRP0ZGSJE6A6M[5]=4I5I^YO;Z\Q(*Z M%U=WDUMT5P*'>QO?KYW=MD=D**OS^M[II.D7QQ*#!5=<7Q8]?;',-\EF"TSI M__U_UMZ'Q7.<;IPT_:7W;G'_'7`O[UV,)>P-&(\__W3QX8X,.JB*.CV$`&!) M+.5\*7/#Z=A=*)6#?-41MVS]7ZV52XW0A%+_;8TOX^=3Y3JX7`Z":1BL[CV( M$4:*D/J-I8[UT<9S*^@P\M3`>>-6C&4'Y/+4*9EANZ^1WRC`/IH7_$>QAVGQ M\K>K`[,]C+.TE[P+'$6756]1T7KJ.I:^$/O7_B@EE:2E`#:5ZBBDZY&@T\7& M$,9+U5A_N%U_D:(:KR\E_I-?#^]K;1DC6J=4.K"E1:5E%S9]+@+3B6C[87Q[ M.[ZZFY9S+IAML+<+&\KI#B*ZI.A+75EF;O91E"M$WGB-,&":9V`/F$Y08;6G M0/CU>/R7YO1=TX$#W^SLYNY.OX[3/7,:V7?0*>ZDIL^H MMC0JW0GTH+9HNDCZFFOVFBZFB71,\[;8^?+O<5XR[CHM"ZJU^96MV%QLI\K6 M7RD2K[T`WDL2IW.?[;RZV]:I[D-4:('IB]6VJ=LFVW4_GJB:/J`E>RP9Y&P3 M;4Z)E5;N5.V/R*3IC5N"M]Q*X#QVP,B%=V3LVH56<'(.4>TIG!9.P;((I]X# MYL:N2A6B*BVN:D*#O[PQ4FN>X$7=Z(%+K1/=?&DL)7R4?C(7(0.EE@91"V M^$H,0#D&VT*Y4O&BU!),DPPU9OQ1YP+^,O6X-94*Z,)R@O([.B-4R+360A4P M]#N7V(45!SR0ZJBWU/'C;\"A-JPI63K7<_R01W*INP(T4QH.-7T%XDH&Z-DP M2E@:9<#P[QKXSXQM0G[O8\OS=>.`AD"99>FS1,"C]Q\P#YW,S?MJNRMJXXIX M``$4K>%`@KH+A"&+[D`X=X$H1,F_><-A@20?"5$^B!*#G"<+=XW]JA039I]_ M`+"QFZD:!%.,N2EVH-`80+L;J(I=7L$,O&Y%,D$OAB!K"D* M!TMWV]V&.W;;MP7HK5>MLEV?#$C%C`,263C8"(5.LK`X"1>1]YRMR?8B91"4 M%;_*NQ=GFU->Y%_N'@L9<\(#4 M5)-`S:[3`LF:0-GR3)_.4N-4QWE7 ME&4W`@DE=UP!_>I$/Y5C2+A[_/4-5FUI`%CG6:\5P!-M^B*EJ();W MY];U9"`2+YMI,6^*I'$]?-UV26O)7FDL"B3]ZY82"XJ]X4'H-0TSE5CH\R?N M#,-GZHXS3QX>X&T*#Z)P(#TAG-T913R1NISYR>EJU<*0(*56<28+'3?)P MS0%B*&TVI[X[^@R=D,!U*5<&R0!;8*-G#'E(:;]5:'O"(= M8'L*3N1\AU'26$@+=T<]Q6*QW/C28HX*Q[@*EP-MJJUF^RW.UF24AZ=HA!;: MF=LF3@2=!8@36"'T\'CRP;ZD"38_H3V];C:J1VH:.Q?#I+F+GCQ7;.BLT'I+ M?96H!%2IV_.\%/B:83E'@&A"=A[C,%_9ZF_:TNAVR:QQPA=VIL1CK]D0_LZF M,<.'3*@JPVH3+S7E1?@VPH-S6-`[!:IS+@>HC8V/8ME1VB()`R](AC5]V.KB M`=^6>U'66.#;0T,E`NI"V1`M%*=D,4-4>(X2:0&JU\761+U:6611UNYT79W+ M3#"O"T?ZXCP(2_R^-OK[^1-*!^]97OD]F/2>Q]!^*$[U0#:+!PZ!=1]%$N&]TA MQI#<*F*J]$=BW!=^60/D76I.*8(F*.[(R4CD3B$._@%RPB\+`_SGS!Y?W0:1 MOG?8]>-L3S5H)H?M4/;2M1VE>UA#-^PZ\2C%*&?3MYLZLS*[,=(C$RH\Y1T7 MLR)3"3O`4GODYN6V]>):5O=<3=/U()<$4%T;#^NA*JF'ZE[0!B'JV=*L/K5& M%S$-QC&7SH85ZT!IO1=:[3S6[OGH/OM8EJ94XRH/J-KJTS+*RRD*SV7IK3R? M^M)I)#Y]Q_B'[D+IX3%N:M@-7S'%%X#LB`_P:-3Q._TN-2*R7IU)]E*V]$ZS"T";BRO:WW;Z"`&OU86FI=HOJX!P% M+3*<@[X1M-6["K*2-$^&;_RESP;KH.UX&-W8(;RA*>:L'`-L0`D)O1/OJ--J M]PHS=8?MW>9XK*+8]0=AN[),6H19IMM/8M^*).Q75W-J-KCOF9P;=SV"D/<8 M49H[""S+/)F)#U*GO7/:`-Y8VTZ/14N=X!N?;J)/]GV18([9I MNERIX`Y=/:=A!`R=8!819=>[[MGOZC[6]>^WUHD-\/\1^;VC\Y*4JP+U,$1W8V MV_;#&Y.EZ&Q$&8TV+KA.90PC\14J2]/A4=FJ*,^X4;PLN3*^5QU?VSG84:T/ M#GO62Y_[3*O*N@TO?$CN%G"W:`1@A: M^:[88(_D"5E,G;5)Z3',Q=EO;!IBTRE1>32'J;,U6=*XPX:D#C,62;L=_K7) M6&3XG?PLQ.Y.[!H<[JFW;==J?E/C*MGV*J$C1Q*@:3BT7G^]<8_C$2088=@: M].B_ZMME%<%S^"G\).9\O5@F]]O\B[7\VJSQ1C6_;D*6GV&H>+%*LY<8+X]6 MUGQ7]9/4+>`45+J`^KE8"^]<+A&AG0ST6^0DL(E"G/">5P50XX7`<4B^R]8^&N,C)T^R5M`@S MM?J2J7/==YEMB6*FF==.;5LCFL(FU6VK7V#;6B,>[+NW1B=6^W3B9KRJT8H= MNND$*==]J.XR[]O8D^#!#\ALRRJ,$^(T-LLU^@LJ-E7B+7H-A=;"QM[2QBS5 M=U[0GUWH3?-EPIWE2FI\%*RJ5%9?N;3&+4;AZ`,V?*IY&`Q//6`H;#EX?3>^ MK!N]4KQ$EU&YH?J7=]8M5>D\TOSDOE8CG:XZ+14SO;L=7TW'9]*J_`H3,+"C MZ;O)U=G%9/I&VDE@@/D/%W??Z9<5ODS?UZK/>?+I($N`&VY?B#BO[25+DH3K MLTPJZ?N%B'PJ#->AFFF%RK5B2.)")7-;V3(WTJKK%:QV[S+-XJ?<5JUR0/(Y MW`"J#0>[^*)R,U35[=L/TXNKR72JII-WW,WCAU@EW$F9.=V:9N$P9UF0E3ZI MW9OM-8L>"FPT!)*5@!@C8:--).54D$U8.B33).R(`HC>R\Z5GN@-&AJXX=P9 M\E#3WAZ'TS7,SKEAX(W;X$]_9S[D6D9W;M^_Z^U:U0Y?[0B8Z?ZQ,CU:;[EJ M'M(XH"TO/I=9([N??MT8Z]$Q(?WA_.*.U'@#''N.5/WXYFQ\8J;PO>EVA;\C MH"\`R5>(Z5B6,_F()WX\O;@\\9UB@E.N_7%&8FUD6RMK,B+&6=SX$]?ITTW_EI3KA@F#\3(&<2V)N%#/4\8] M7VW#9>Q.1EVWQ6-(N2A2C0JD/.PTJ!)G=RGO+O\Q2=-"?`!'"%)(O5S+>80* MM[QP/#Z_/*&6/JJ$%N_K&EY63M:T=C2IG+8CEY,_4#I@[B)(SB50(+(5_&:; M;<7<`G../86PQ:GX^IIZ%Q+U<9H7HEZR3;=2[T]W%X0C1&!2I\GB=@OH?U?7 MWY*.U*F`,-8UB/<.X>\I)Z@JY02]8CE!>E[D""?.D]59M@H;NF!^!&3W>\GC2VQ=PV7"2[._/,_$?.IJ2;E$W!X M"Y?U4;K?IE4,9F:`%+&JI=F`T_/6:7,KRVB85U:'&B3,D=NQE=Z;Z5%,,@?U MN)>2UVP5T+V,]4%(O6G3KD\';]8#3BQCKM+@J)(V7O*C;WX3[$V(2`N_M2 M,6IJ5(PYT53>U*"*Y2ZZ++HQI&0ZPZ&X7 M&_8A+M0WV&0H=;"8<`>7&&`]0!_+^X?=4%ID8NMOS"AS=RRS!WZWC04$X4?7 M&_G#?A^#NX)VX`T&?G\P5*9]'R4D#T(LEM`9^(-VS^O#,?;Y:-`?W`<=P! MV'/=>,[B&/C8SH':DH3MWJX[A167^1KQ/_F@]BI)PW?ZX]57"%NE$X;1_[5W MQ_:4QWK$_'_]30F0;"!2=ZB-#6\;4&;0'7C!H(>D9OD<#?3ST1^5:`.'H M4-N:#MY>?Q"&#C)@TQIH`N$P!10@*/I8MN=OCJ3 MGIQK_6I_I#L'>)WA`*@8(?UP&&*;%O5NC>(*R-4/R8:ZI_:X5QH-U^->`$`&Q/Y8OPT" M!L!^"$`X4=Q.-ED";0`Z)=.?O%&F+8@P6=*Z9J!U8'SH,T4G(S]W2R041!.EA14Z<`;>`)2L]Z`V`)`&<8?TN^#@/H8 M8Z`*;G-$3(1;][R)8#KO/^YGASWB?1\,A@""TL0KZ/_FB>I$'V*:Q30(; MP$^.8@!/#\)!\1Z#L`02V0A@Q(^>&`%D!#1D^-J;W.GW070:8(>[`4NG[=#O MM'M4%V,4MO=<2N1Y`[F42'GP3O;[O>8[V0'4:0-UQZ8F@9EO./2"(8IDO?KK MV,.[$L*>@=#`U:<]'^LW`=$PHA_1\$NO(C;FY![M/C:LXO&'/<8PC&T98-^' M+[J#QX.1/23^@_=8*>52KBC3>*&/^]@``4KWP62]L[R$&H*UT1DP"L$ZY'$X/KSY]W`E!_:!^&ONI`'"F(8N(R`,[ M'<\VB@Q"E$>$0`3=H5#/)M%`'2@:>#6B06/"^Z\N&0#QPQ8]O8$5!MH`AV'? M2`==N/5`"D%$K1`5P(T`=3&Z9SV@#T$0LLH#A`*+:18I"[+MT8">"$$5Z7?I MU]&HCZK2:^D*]6,'U3,<`H,8@4B#'7-!LQN,@%8$*/?!;X/^#B$AMD)"Q]3" M,G_LH4N@5,*LV.USY(7`]`/`%9!6NB!$-9*F+J!<+^PAJQ^$V&$>-%"0;G#) M?;C\'5(4.T%83Z(Z)+9VX(KSZ]A%"-MS]8%7R0C($=N@X73"+Z9400_@V$$* M>!Q:J6'88RK8[0-VB$C1'K6Q/\V7T2S",DNUY,]&TC$$#.W00L*>W/^@C;\! M^1AV]Y"/`%<]X%5CZZVPLJ<@[,N>ADA4.@5*4A0B.M@0,V2R<3SL4\0F]T?% M6S2D1T`,!H+4%4$"_AR!"C3J.Z+$SOO_JTH2<`VQ[NV@7Y4ES%=U%[^-7_#AUW0/H[E87WL?2`>(QC^E3<_;,,P(/1A4[.` M24\?N_5V@)2,L!OKGJL+=P4X`%[=(2T:;R[0DETW-^P`"H$$@MKBJ*VG#$%2 MP!Y-`]QVPZ7%!E$HU@^`IO8TX]U_S/(&D<8QL12]( MQM`?-[$^Q%82N1414R6\%-23>B^D)O/TMAMV*T MD`HX9*===.^C(PY]*$`"X3X#$F\I^)3"-DQ4Q^'KH6L`TQN*^N[]M]]AA;N' M!,,X'[7SDH-A]`0Y$A.)5M`(+5$%%&8H;I7$Q-28B)VG9,4F-.T"=YV=:':5 M#,'T!1>QP7BY:&-R,6'`6OAGM27D.$?SF5I\1@^X(33&%@*3="J6*=+DW#=5 M"J*S9>N::JXY"?2`+L!_7PF-X*ICM#<,Q2E_?>:&TN`@ MSO/G28X1[0CU?5$L?8IBN;NXG6!$A'=S.;[RSG343,USH^.SL^@-%UW@WM]=7 M\/O91,=T\`)C#-'C+-P5$V@WY]0V9YN^2*HB+OFM'EDDY"W8< M[7]&E?'"%%'\_$]P1Z`D&;282 MV>^4M[-MFYZ?8N9UE`M`+9YT)/T38#*UL'AR@U=-N&?$,1RRHY1VE-@=$7^F M[@A2.I*K-]Y'><+[U&L@$EU8Q1)N29XC:<&6)1P^0@OX&S9_T=NQQ2;5AHHU MVLC7"#Z=,YK"570`YE,&!*=CAD+:>G@_D:#M#C`W0.B@H]4MLMPER* M=T4"POT&)?^TO$A5761Q"C<,ZJ&2TM;M7TK)/OJ-0( M>D7?8BG!RF/;U2K5A0#,8]XD%1K_10&&U!862/,=\]'KM][9>/J=]_;R^H>I MI]7=2BJDJI1,SK'`JK,^JM**:^3(9T)_H[707X[LM':JL\[=8HJZSG5=1'9M M+X':N/!RZ'0I-CNJB\Z64&XWMZ.EJ*+.X8L)]\5P[P\2KUV&M#JJB]OM='^K[_?`N7-=CI[KO#@M]K/X(#]#*K[ MD0;FS>?S6Z%;]P!TZQITX\83^_;2I[3/7W\O`&2,$MFY%W[&[J53VXG";F8X M_(T.IC?RP^YH]V;X&54C.*IJ%M"O(S@>!M7?#-U!F.OL0W=^QFYFW]W]S5A% M,$(?Z)[-T#-V,_NX>#?XK42]T!^,]IP,/X.;&:_622K%6!OW$E#5M=]&;.T. M@KUB*SQC]S+<@V2_%1WJCOQ.K[^'0=`S2NK$[CF5WTP4"3!*;[63D#SI[U")^1N]DGTKTF]&P+HU/9"J,+8-!2WY?`+F%Z%;:49B(/H4MAJ)X8K3.QJ$X$L M-2OXQ2&'@2$C6`#]_`T6`$P.3XY^[)^^>D:=ZADU'T9+`?4>!85Y=%F<+T"& M71,-L`EBP?JVPT(;O-(&&-FT? M@WRUT__\U*2/(>\`?OI9L)_M'`R+[L\, MBQ#S&8J6S-I+^?-3!;_;'@)1P!^.76FT9_+=8HE4WC)UFRKKPL40)0I=`]"O MA/Y\[]S[QY:!_J]S^?Q>'P!./W[MN5'!&W:5_"B91'[APPY+T`YJ?:?>Y/W-Y?5?*+QB_.YV(N%^UIAK M%"0JLPXOX72E#0R7^ M7EE6Y>S5Z\Z^AW5@A"KTL+1-[_##I[#ICI&`X-"S=`YGGRZB9V>=I\+3G-A MZ\,.ND;Z@"5(A;4E"AX4\AXOL1;:JQY^17Y%T,:XT+/K]^\O[EA>J=0%980$ M0-1)Y!1=C^&P3N:)U.PK%/ET##]1,25I(N4@;S$2?XOU^3A@7M"O()U*_LXF MRU(1!!7,0(7_;+%`/'&G=I^N)LCHK2TM&%2>,FISK'0RXSI%8JW*'8SL5]B? M*]_VU+16@^UA9V+3^P]RIU MU*DW_?#M=/+G#Z@#3+[7\C\=;K?J.E2E$Y3^2XZ_I42<]3G1QWQ+HA>W&G7O M:TZ*>$&JA1=I'5'14J&),5:)-(4VE7T1*PD:ZTR#I;=JZDLHJ9G.8KK'Q&.1 M7"*I0Z?(]T%*.ZC(0-Q6F&I<#EG4+9Y*+]Y3`H'UJVTP)TQ*GP^_)G4#>=J" MKQ@0C6VQ?97;02J6M>2%I=*071C+Z,HZ0T3J8F>Z%PMR7F!CN`[=R^4^F7.Q M][S07&QNV0\0YWGTPH5;X[G^5%=OMR8`D((VV+MCDRQB:M&'CW&):KT"6KTL MW7Y`>">]N.)/F":"D_1:H]'7I6++2%0W3]2-QA;FKKF']ISU,>_`]]P6'B=] M'_N#E(@7"J`S8/94O]&:SB/,=$M33E[2)=;*M@4!04FN44B48EL-OFYXO%BZ M^86.M1!X[)G,.#*Q2AS7;*;,%FIDQQ562Q?+U-.MV>7.>X'HC:?@(CB@HO1G M:,91]44XZOV,.*J^$$>]GPE'JZ1^3TE:3Y>D]8[U;R>52N'CZ<44\VIN;B=3 MH/QC++-^T$-(>W$;V2I9BAG3EO'VE6`'[Y$.!:1)E)GSI[A<'5>G8Q4+XW'& MO,^\]P%-_%R5VBUE_SO=B14>IB+1F)1JN\_FOI)JQ:R!IR]<0&"]`(*\CJ7/ M*7"$>`&#VU1!N66898UI=+:G4;84@R$EHFUTHV&G^C#3>\SF?.0:$^D+5B?& MX`?3]_;#DFX,)59QX4NX:G!ZWO%7V(?'>S<>WWQU@M4MX3K2"FNS9DT#6Z=\ M.G;MC'ZT/7NX@G0$EW:A&TIB&$%$Z7"T&*XH%,^%0>6V'H+OI8FIP^WK\AQ\ M"+K^`5P0;BNCLVRIB.-V@T='C5>5VVS8+O1WMLLQO^,L40H$`T*80==TKP'JP7%>2W6[WB4 M:/-6%^@M)-6IVJ/29/O5_?L,8NO[I(_()LICWC[7CC=2]S-<#\3U9U2AC0A. MI[BC-#DF"(LR\L\3OV"=D=KTF$&,G^+WJKGX=TVE?//Z^YL[&GUW.7`SYL04 M$C7EP!6/!=M/3;_OSS_9\3`%6W9)@](V<)[+#*N&`PJZFT8,AC51GR+O*OX8 MS2-3XYH8``^L>$_."JG:/V#Z$Y;10FZ.DGG:NV\#V MHXO3A/I]$>%0%LEP665D_3"=()9.IG<7[\=WD^F^[PF#5T1?(IU0:C!7.9B; MD"B#FT;B?0BY\PXF=SL(F&JD#J\@8/2J0\,\J::OK0S,ZMD"L6EX1Y7:F>'O MM5=<-R=TFETX"S*UC5SBZ4HDY<)NFK`J3=EFU*W0I:9GM]^[Z6QM4\0OW1@V'[M-/V*"4:STQ'4RE;39_;#H*6JD%N"W3JYL(VA(3Z_AQFU)N-*N"ZFRORXGM2O7>!D3(>3Q+2,1Z MRIX]L?7-<($`9Y![=6<01'O*9)<3T5TG"AG9A4:$NE6T*;^B0?6-:;TPYQ); MBT(_B6.F54`25[HN%U%%8[LX)@IVXC9Q4"NWS\+&);3'1,WP8R9<7IEP5>N( MH,K_88(E0*[?75W4H4G-(YY4^>*NC[,,Z-S?265WB[O448_:LAAGV9S()"$% MU[N@:A5G2,S[;;28TS#P5OIB1)'BW.H9I6@4`.F.4E0(R=*@K&&Y$*+8BWCS MA@"]C?*$RIF@/7JFJS*05U@H4?P)VWM\`Z>&!0'6?,;9C,Y\_@U-DF.K5HS^ M4-S_3+2B^^T+(ANP_>13+!5-I(0#GL`WHNT0_V)"\\);P2:6\,0+T;LUUM0I M%8WA-J$O!@`B5SC:&D!DW)CJ.?QS0#*>Y#8CN)O3Y'RUAJ[3J M9'&_7>>LG*HXPEJ(VJK]^2"F!PNG-& MN#R@3NA/1Z7ZO=5ON$,9%418\S'@QI7M9O,"(`(1D3>ON][@+R%]&G9,%5L#K^,`AI=3E6-^R';0_7 M>XJ?T*OY"5XK%P"^=8V#_(.KQ-D0MJ:V"J-<@OT1J6^0=!BBMC0&UU<1WB9- MG!,N.4+"!"[,"'7<>KYXOM\C=H%L548?/.<;N"8XQDWTXH"+9&>+T][6RN[V MT`R\2]UHD:^#E(V6WXAZU\.?5*-IED;)`J_*7R7.!%DBO*P-QDY#&^,7+0K@ MH/X\$P%:R;+)A)HFFA=KNY+>L2KMN(SI\FK+E<,-*CS+I92)/Z/K5KMGQ)(*E%'(`3K`41?Y,P=Y)*-W`W>5;I122C ML<(K#`(MS0[(G+P",YV(J%K<=*O`W#OC,$NHA1N#M`%ZBM[3(#0E>5K>.VM.W%D:8*_)YXBI+4U(`5TW"\UTD@8 M<#6[&!CCJMI6:W\DD.#L3F>R9&*;53_%]DKS/O5D^UW.-^^T5(W>9!LD^JYM%7&ER!F8/G3+*[5/:B[1HDZR?*." M%Y<(G0E9HK#!;/J%"!N\"F0R+7$[4:IQB5^$T"&*U9*6TCC-"#$W]#(*@&NL MKXZ1E>('7T"B^\C"`,RO<9`QE1B:JF:WJ=(-ZT=Z8'!(PNYR3U[XW),+O:$S M-;UCJC7,MR7N4U8XE>I7+)4\"[QV]"^P$F[)%3MV?$S"1"9W_.'T/WXZ^_GH M'.V&HQM:AD'2T5)E4GBHTF()N8^4"K54$R@BBQW M3_I3]ID&:=1CS:N:87YHLA<2M\A8C<]09EQ*U!1S))R-[QT6/ M2+X3SKE9B=-UYJX_3?ZRU!`5NMJ$R_1^)<4+G&&7ODYLFBV/%*;@P7\Q7J7+ MO,8D;0`"_ROJ.BBM(2%'$T?<$4N);58177G\&83:*<[WM%P`7KL'QEK;)!F+ M8K5$48T/%4DWGV;KF#VF_\+K%*SI9&':P'$B/&RZJW>LW&3!BC@P(H>G)VLJ5^H MBM2]@SY4<@L)^DK]?WM\31IJ@ M!N=&%75@`54B=E,9%UG*.`]SX\&^A(NT>".%XD3)>IJQ9A6K(O5+%I,%/`EB M[2T_QX>+%CLH<&P;"NA$]2V)XP:],:D"Y(8>*)3B3X_DE31XO_S M4KI="OW\5'$J@G\F,P*[+?74HH+K7#XI44GR/%/&.DH[R&PFO1>X>[QZN3ID M(WC-$:[?`WTF;WS'[+D<\'9Y(,]&4&>J@(O9EA>+*?MW`4I1,;%8"7A..G)] M(0Y3=7:![F27[_\4_*`*_JK@OC6942-ERDE\@$$H_!,: M&PA#\ZN#L%CFHQ!:$C4GZ"R"5O&C^LD_>5 MC/XT6?T53OCXZN@*?KXE,2&)W\S,WR-=$5'[)MP`("`^?C"*+));A!`"/";O MRZO3]Q_^1'PXLN!7:/(9URKV5W6,A.*=93V^J?H)6Q8@G-44I&>LS:TK.4MEE*A[;*;3>/O\!`^-:D-3 MF-57JF00$\4"N9^2\I*2_!GQOSZX2GPZ-?YB=KE>WJ\)``K\LV@ML!X7+2'& M94IY+R*6%C%+,)$T3H-!+&VOY+-2_[`QX9`K"M[->-5L!Q/.XM2^?QK25(D< M)Z33@C-!^0KXP@ERL2==%0B$Z)N//]S(7OWR: MP"%\HC37=Y%5Y)I'^+14I@C+@8$3+[_$#Q-23W-8Y&PEO1U(2<'^/PXXGU]> M_'AP?O;SZ4G,)5PW-D"+9E34Y#,NX9D5^+P'??G``L,%($K3YDK#VBWN5]AI M58"AS@NMCHIS&*!7L,@F+<_8E*RD=S%10FGT7*G\Y=//BOS>SI[@F)&?16)- M^DEIB&)H0;HD0AI)XR&)J/6H(G7Y]\0H/_HKMI(J="I4!#X50K`KE5!G?*6W MKIR)5A_1@AW=F#4$B`N$NR<#U+`CN-U/Q)NF5"7W!X\>7%1$45<6`%C1B1?/I`W23 MJ?EIQ(CMD<(D?3LG2.`S98<"PY%"IZ=W#\9>NZ5B6ZB53&YES06=!3ZZ>2&V M2G$WI'1^P2U]WA>.LHQ!)-]'D:O&1HE-)"?*E499PIE:U331"@3M(:ML*A%S MMZA(T@+$ICW""G&!4G0Y$#A;)Y;!0:5K(B,PP%Q6'RE>#\B;?80++Y$*6!,UHMYW<*.WR9K:8F3>G=]LT4-\_O:W$G M7?8?$:\!4X9W[;()]V@S6*@O/98A>EY(/^+IG>50"F`EX%@Z)"<^LBE1IC`^ M^-`F^0WUL1X^D>5/@JP3NC&SZ?_0J-*A".$G0%SH`2"MX@+@I;5HVB_; M8-'RO=6^<#IFP0J=6".W%@0TZQ$DQ0ESI-V*%$',I$E>ME]M0XX_A#T8.2,* M%HN=F#MA<&%LA$9BK!E#<$0P0R*(A$M#C0\MWTZ?9%N+,:2XEE]1M=T^4;RM]$;GF6 M]6#Y&X.M)#^,S55:U$T\3064KP1'0AH8&?QY)5&-V4M* MC_C#V*;L1HWC99#'R5?H!WXM(1W,QWK5`0"DG" MKTLR\Y2\ M&J3_!RHBK&$9J^)A\\E&/H_O0Y&(VMP^S*=@:_"N6(],WE*H(?OZ*+3MK)1D M`SV%P1#O+90D@@>7!J[')>X`Q:SG1S0!2NA#)Q/)1;T].>KK<.3PHH5M[[Y= MHF..6.,,L^T0ZK]GE9[0G\9?ED]SV.3=5!D5<1[IN);$QZC;BL_.`E,'3N[! M/#D%RI$!RM:AZ;P!RI5G<:J5CI\F4R9RNR,(9(L][D\U*X`G$I.%R=]IT0EVV\`.FL MPZI/S;-%JNRA1=))D]KG1C2-=[%:<"K#`UU;H^6;%P6I_F(Q#,0/F+[=QK4B MNSJ?B++=\F`5!E[#H'FI;4RX!+72P_8=BQE`!7A]'U=!I?8&A9 MB83X2+](GN4>Z2<)H-J[6NC7I0 M5%P-Q:Z!!4=^*./`&&W2$%^$H>+)5_ML;3J[1T3MR%L$8U84E5?DCKJ9XJ;& MA>C)15XE-NUDE3GI2`S7"45X>XU__;^1L3S)-+M+8+LAUD,S=V:WP=TI!`!\ M.XPRG=_3N?G6R:1(^RD#!IVCG3WB9>JBA<_^E7599(VE;408:/S M1//8ZR$#"#)(DY=(A2'UKL\4*H;W7G2OO2O,DCQKDB8M?6OL@<5`J)*QV/C; M%YNUOL5&K^H\Q]KQ]E+1]&WZ3`;.\-N7%97-:WI=LI*@1'!,`3 MV"??2@Y)(29V2B/T)779AMR#\A%Z;]O70"?3F\0,2&=",EN9P1"S!]8>BC>G MK+]4V1:>I([^94?8(TT*I4!`9`T$".94R8_9Z"+$15$/=#%]T%4`53U0?4XT M@>'>@$XVTI&8M8^*?.JST^J8%:`(EC%7'^%@Y)NL1%(:J7*0G+GC-73R\^G[ M#V?76&7T^/+:55@[#>*C.PJ$7G$H\&JM%>-D\Z>X`[*J/H3KF*L@(YD^T`S& MM7:G'%#6_H@OV^50Z&N4)DA'F2'OB55Y.;?'>O(504X0;B-P1LK!WI*,8KEK M6BX>H4'9#-F(6'XS?NU%8`",6B*E$J&#!S+^2#9G(@MZ&L@!5XG?*9/(K4_! M./V$J/CIQ7!!75D^J#V!E2320%2>R*/J'#!(::@AU,$;TFOL602;"!,1'ZIH M[`#2VZ.S]_'/1^<_40#DV[.+HXOCLZ/S^.SB^L/[G][YO!9'="&P\W&:[)YI M1KLI_\7^S:%>%\#D:8K>&UB"G=\J.DXHC/TT!3X3M?V"/338.^F$JSERX4T1 M*7!308^W()M3065S?N%W/;V=K>1PSK49TC4Z+K^P$P&F?7B>ZD!&]D;!Q`>J MD>DA9QR/&Z3XX?+X?QR\.;H^Q01.[ZY.+Z[]D8J!=I9P])$X24H0<,!':"7L M98]P1;#@R=\^S6[(#>J)O;7)U$!<=I;WDM?(0\#K#+=$.EDK5E2V.`& MS$@!&V.M\<6JQY!P%@C?KDC'8ZB,9<3J`UD#29]G,P!N9>`OF&E,Y),Q<)+. M!Z8U13*=J8Q2-<]()QUPY^%4%DL1PTMKLY#7F_D$CO3Z%J6`E2PSK"@XW-#= M="XX9EMUAIJ7+Z2\1"^R3\BYH"V<7$5L;P-VXPOL1+#CV@\5V106"U;: M-M..C\>(KQ;^]&)YLT;LS6KX(MH'9A5V[D^N+LWO:\Z,P.S3;`Y,"*\R0=0N MR;O"[=)+S_3OP@E6(A2'3T&&`JP"5VHO$/`,C&WJ'.RDV5;,=,20:`&AL:?A ML7@YR+$=W"/C8;.!:$,UAZ7T&>LG>@DO,E//"SGMF]A:4'6U'=.\(T&T%_=- M>P!*C.C02G@A(K)M$Q9Y/*BS2Z(@2E)F#V9=O8R0])02A`BX1)VH=Y2-8'B( MGE>3+.*B4@^M(D-+1$IP4C["(1Z0FDZ;P%0XSF'\']3NA0UKN1+(N<5P4&FVZ>.LI_/!S>/ M2XT4T-U+WM4%L?IHFCDY?>,X8?6_'O8B<45'FDD7F350*2.%Q;KP4P0,*MR6=,5O$^FVL3;,T71T$)A&- M(A74I,T5U$)D8F)T(#PNW$S?>C"=DJJ'@$CG(E/\(RTMF_1`Y*Q$S3[^FF.= MG(?)$Z=.^L@>_H*A9DP7FDNQEK,%^F[?F?M7R$CWP6/WQ,\?GQ]=7Y^]/3LF MCL1A)YT&\;&0!N!@EB)$5K+).OT'7!'JH/FUD6LG\7[R/J103;W-#$5^%@N8 MUV-X[6<_G\97YT?N(KV-XNN/6E\MO4,MAH>E.HI_ID1,`L<)JLD1]\*2+>Y_ M6[9$N"!P#X='B0QCO;!2R9@/DT/!P0^\O(C!/)AN!7ZV1'`A;]52(TX]M`8` M9TF:J)\:T8@EQ\'^]_,26_7]D`12T^13-+=)CY.]\?1#?'YY?1U?G;ZG5*C` M"U__\>A]/VK)3Q*"O>,WP"7=HK$*%>JK:`\]$BBVFSG0/M913*W-O5(2D3H5 MS+:5E%>IL_B-_?IWY,MN?_U_I&;_]>]WL_DSC`R_RS7HR0][JS.7Q0H2#(Z* M:0AI^K77>_-"L4#"XP.E1[E#(P_)4ET'#BU2C4E/C"]3Y"@1QD4F.AWK8?9: M61$H*G"583(ZX4WJC6PX9NNE[+2".YT-6G"ME*R8X(R.ZS/YD:,I=]DK@:*L MI;H2DTS#IK@E_6(T]T4-A,Z!0B/1[%>]5>96411OOXR]Y MT29=E?,O65)V99)VM?PUJ_*DZ(IX/\)LS;+@CCG>K_\I_NNJI,K;:+OQTZI. MVKJ"\7_I0[D'J/,R3ZJV2[(FC;,L3_*R@=75<=;"OQ6FJ2CBKD@ZK![2E=$Y M.E<]4BR#\4P2([Y+`$GXJ-+#-.6U6C]EYD^;CP;[1B-'PT`K2?/1*4.X_!GO M>6NPY1W?FCMFQS/])+Y,1$S.!%,PBE\T?E!V^_E+I)ZTD1CUBU;/$R\#6&-V M(!L>,ENQ\@!M#Q$D-I9)'`2`#UMA)=1P*0=RA6S8D">D?HQ/2/3VJ+.Z8HH,/Q?H-`3&(_9HV M(8,?0$ZN$AU;/>@0(XE-\RQ-\B9/VK:.VRPIVB(IZS2Z%"B\AF?$^>#AI[;& M@B#1+_)LG]Y`3\?;R'K;AI$V?FT$SI>N_:&B_K><"OEO:"8LI"FGBTFLI@A MOJYES'K7^6R*IBK*5@[3"<,5NQ'5V<_F)NY?K#T<7)T?L3I]GT MB\^?#XV'5)0!`#'GP`V5$RWR^O]QS8&]7_^.]A)RS^.];'`6S`_2/.PL&&UP M%CQ3[BH'Y^2NHL>)C]AD8+L1`F^H'0EQ;EBI\N;#WR/IS4>N?"(U_Z[.?+'K MS+<8=.9#-;#:D=\!AV)=:#]3D2R#:5#?N]9>A0X"6R]E4CHA6"""76LCJ.%_ M9RJ>`9DO[E1>1^/`$L/O<68E&W*BWNW&`]L5+N?/"](/S-:VRA/CG+8^ M7VWJVNPE>;2(Q*Y(CZ#?GM;T47SOR^-DM9)'J0!#1S&(:B(O0UN5BUK$.KA' MN@ZAR=].K<&W)]G7P`7&?('&19&<2F18!J#*Y,D<4B4*C=B+C-Q%VE.LY'J$ MN8^-ZKZ9/%6SBK_"_1Y;]$E^\KNO1![$0RA]>*.71\8?Z+F]Z-FW8.TG00 M#2$S=@H4*3-E;L!1;/8Q^DFQ9X&=5PENOTWJLH[\B!).`X_U2JB4[K3#6UL! MW)?B$/J1!Z\`Z_%Y.24RR1?OV$5HVZ\;7F%9=M[T&7L@>>_'%=QH5J31F;(7 M92G<;EU%E*E_9F1VUI'[RHF8M]0"C`2.!DL%M9C!$OV#S"%$5[CTJLI\9R<< M%<.'EQ1YFS1-H3=GJMC$+#VG#JQ+6I5)VS3&AHT*IMI$EB&2K(OHPE+>-5RR ME=?DB8R`\>L*+KUT+]7"0I<:"P7@V'_5(PC:]>SKM].S2Q7:*4_NA^C'L%_> M*\2BYO^*.K(R)U`?]F/@/RC<^^M_BM-<.E/J1C`<$0LR0?LP^!X@COWH4GB+ MDP/5GAAF_PKM1(]R=TFFL$S_DBQ_@LK0GYC5Z3$=;G-9()VGZ-@0(J? M/G^Q6"[(%6+)/IW*3&IN[D(HVH;G=*Z2YW;`V7KOFIO;"IHE)(H*FS95U!PF MO/4RR;*6T5G=MA'G/C>FS8"YR"O\W-6YXCM76*B\3#LD?D6>&3^8N27B MN\$7L@>,69HC)[8'>"ZO2P`W>%@5<%4UOK`.MMHXUW+.Q1A#Q%%\YJ_]CW3V M,#*>2X4W`<082'F9E_A+`RP=8$[`YO!+&Y=(6%H^"(2:`@XH:RK'TT-A62/O MM2HL%5JFI^TX$FZYJAN8[9THA7G%]E[@9K$\CS_3@'OJ=M\%N5=&73'Z#=1U"KNQ);()M4RK[%?ESD"=!4[EL` ML3LY/X_WZJPK8=PNA7$S_)8!08,#Y8]-EZ7[N(>B[0@!)B6`O1BRI"&K+.\-%C^.0,4'!C._[V&^["2LLXXK=NJVZ-0!%V*ULMNI6)ET&*`(K;V_3 M#9!DF7?0K\[&]FOA5:74'[M58[L!C2@:W6_T[N!]MT`T1+]F]#*!8G19IOJ5 MH_OA8RM4OWIT/WBYM9YO-*Q4N$YU+NWX_0&+WU6R7S?ZVN%5=D33N=_HMY"U M()[J^<:?)_`Q3:?ZC;YW)/RM/)=B/*:`^;"B@.PW?G])FQ6JV^CMY2!(P2'* M?J/!I4CA."58`ZD;O4PANU+'Z^<;JA\;ETT#RZB!.TB3`@@H,SWGF#OC`_K_ M4A`6L_][`H,"2A-94]775VHD=O66?\ M)W1'.V6"IWE5>^Q(<$\I,TYZ"XY%4&1\NZ(DU=NO+ZQ'J@_3US%YA:,#"N=> MWLLU'9ZLJ%G#W;=EJQA]C+]AE`Y&>JEP?0,I/EL"ICWEC%8%NG=)^L%>^J9"4GU\1/W^^7)"SRB#!94\>NGY6B+O M22-7O:](<=-.#%SW/D*WE/A`_-CT/N8HC\")\]>V/VZ#ZQ$?NTU'1&L$D:J* M3J\_;+XZ$*FJ*F<4#K+1B,$!O14%MFY&M*X!U2,3`ISKF,9MB.#9ON\E2TWGCZ.'93"`YNXS,$SD:`:XYB M]*:S8>1`Y##=>%DEL'=E#02O`W:T@>LJBXV8!#6+78?*^2ZK-.W,D[9*40:$ MZP%>.&F!'P[1S[T"9+@4KFP_WI-+\-%1$-*;,BF(_P0(!%ZMJ%TG%4%+W_5I MJ:0(M\026!0A1-6(>Q!T,QJBFY%%-]&*59(>FJAGUR`3Q%J'(H?K`ZF3M`Z` M*ZJ6&G7(F%5=YYA#K4JZIUQ)-R1H7D\I1>^1Q3)<*2,*C36*4.D^%\IO55G, MCCX_'$8^VPUF[A3)&>YM6^:A1:/-U1TKC]#3KX!W,>O<%3I=FQU,C1K2Q0(P M1)>D=8[B:T5*#H#!-D-V,3T$,?_TZR-JU?_P7J1'56I#XN[TE,;?J=\9>]+8 MS0<64G[#0NB[=RDPY^:%6)YNPZMPWH<`DY-_>C"IR%XH_E'L/[0(F M^FXL9HA^-$8>A!FV8IK&3*6?_K8EC067X`)H\1X._P&3BA-H!(W"&@!TF]CW MQ^C#,GXSC<62J7:``3)LBW^ODCH>28__2-T[C&9"B0T/E$=@^10S"5"67K.# M_-N9#')BWRO,-;U1@+"P"#H-+-QH(/H MP^6'HW-W8-=5YD9&1].;Y;BML<+(6RO>05C=3#B1CY>S:,G?Y!P<,F/'8H6C M!$IIK1>B?9,+F\-*[X%M_)Z6WI7V7M7W7"SZB8!(0-I?TT#JK-5IZ+P=X4Z` MA8)GGP$HG.\6MA3O91L4IX`#O3ZRW$$@!P!.*O0CHU4,]L&&>!5"9; M'XR?`W\,HR%C3%J!P\9A0-C/TJ50.F9L!=M]X[%'R_"S#FT^`$):OH9_BK9\ M';W'##043$JAR?@47\>((%_C`;#?&\4I8:8P8`(74_J?_D@1XGNS!3M][<.X M.6H6"N&SYWA)\`D2!)I>2%^VV;B$ITB@TNA$!*CU04NC6+I-CA3\D6`5T;4D MU&26E'W.,00;!QP)DL`WHSMO(&&H^=`)=M7)7*#5$E>+#'-TC:G6[D*C5+U1 M&ON03Z:W(L/34OY<8Z*5I^"`G0)*N2R9A@EA!SEUP$=#B5!+]2)I@!17Q`.( M@Z(UC'QM0T=8(86@-S9T1-78-^B5/"2UW`KX)!V/-/WG8?H`)?";(,@_BOP- MR!)R4*OZ:1C@,%U92CKT]!#N"][9(9U^!K^ED1RV3K+%QS]%1P\/ M&"U.=97D"I1SN>PHCNG`]>742<'["37B/8&,V\.FI/^YO:<2/#GZ]Y4))5G= MW_@;F3)25M[>SF>$8ILBF:Q0%1Y4:6M[04V'D9N]+K+KZ<#/4=YK=5 M]<)E?KYI))8;]_^]A%/XB!D;V!4BVOMI,7F^F\$![<E&TUX/:7%P`XF9+!BB3O.K;PIP72 MH\[PCT,O@RQ!D^`5!7D;1M!__O&NE>V9NKR%"75I`/19?%'>H[TP+=9JH& M-6P%.K,@+/A]>/B4,M0<9KC$'#512=Z"C`P(C;UP!MP:\Z1(474%_Q1`(=NZ M1K>:/,WCIDGJIHU4.F*9WE(GD909&E%KG)1IB3X@T95,ZOI$PJ5R'I1ESPS/ M(5;4=DF7%N*\^!?;DQ)NO8,+*,C&EJ`#;L4>5B#C=DE>HS($D$O!+D%)6^4` M&9D(+>P]O\AZ?CU$+E]@7_[X31_A#H^J`U*%A[&79>SZG0G:UR1H12=#<)66 M0V\*U:O\C/@_\0?O4Q*.C?3+UD\(70()PNC_WK>C?2#_O93EK/`]`1WFM_'M` M#DX+I0&#JRG0T:&.CD5:?E4)N^ZDF9`#0-C-K6TK-(L#^T;1'T_+^]F:/`O+ MC+[3<"4[O57`?E+XP5;.R``:99616;'H`'<#)`-8XA*ZM([+DDB'3AW/!<8^ MPR4R3)^*['"&ZRSRBL/NS#EA3$#7.7#751&W*&BE>1[V;6Z1_A;LK0//H(:M MEAPITW4IK+(EJNCU>@89!,X6$!7WW4>O]!J0_9[L#0P&G'U;90,^T2H+DR"R M7(J3JKO!^X$SY*"@/;:&P0\%&C#IAPK=$NEO98&'VL(T@\,=6+X%,].SFP_7 MN\@5V>(0RV7JX6?DQSOHS[V'AM.RXK67;1U<.T6IH$>=/N3;4)P18K.R$5%1 M&`O"T5,-8*\)=*\1CQ*Q#SX)NNZ#+_)#$`G!>R.'@RYFJ]MX[Q%EJST M/\<2WTH%>P9$`T^?]KPG>P*@0=^N'0I/V/`4T4.8W<`QX$J,WY8BA`^$[`:- MO#N]P;VFTY?$O_`>'>6OK?`=>-![-5!&NGKUDQK2C)+H\S/#B`#9$`"$/63# MY7KA;V65;D`&(*UD':,`]"L0EU/BTZ<_9Q6('V0\WXP%@#*US"(B# MSEY>(3_2]$,J0ZQ!-)(UB#VL@1.P^KMQ!H#\T!^G;#0SD,(YM+7B#B@J`QY3 MXR(5@(T<93%Z9R7@ASRO6.2I,:RKZV$6)-M=0RTJ$$7J@G[LNIIBQ+;$*Q2K M`*)GU0*!Z("E0==]D.R:#G!%CGP?_-34`TS"5#,)F3)FJE\VX"40*F%6]*_N MX@J(?@ZP`MQ*`4Q4$#45`')E52*I;RJ,O@`)%+@;7'(-CS\C03'+*S^*RHAM MS>")+0W#TY`E+$%"2]_W\H)P'/ M$-X?<`_`9R#E;O)6$G'Z M<8C3P"BZ1BY(C"'_%.8[<@#B"J^@T'P'@FJ^`7$@?FU)D03/'DB:0%A[2`]; M1B@-05X11A@YL*Y=0<@"X_!-?@-1*'H)5DXB"(]92M8>0*=BU'N]I;RS09\X MK+E.'6![%\O%`>G*4(6U4@6CC?@\MM/['%PN/YR"/(M)DZX_''V@3%58>N#X MZ/J/\=OSRU^N5/#UC4A.X(&)K*-'3:LH%X>7B%G)Q,VMQ M1CBW6IPHZX>94F06>)7?4'A`7"ZT'56D?RDYOY1,VROR1ND\!]<'K4J#T##][=,=C;0A=3-E-C9*Q+[" M'`(@\,LQ*:_@Q"JL>AAQFW_&_?SWR8*?2FX\%<]VBM]K.V+BP>UP&W,[P".$ MM_-;03T(;M46RX!3K=+?Z53%Q(.G6JE'K!!J]4^UF_*?`N35=K(-3[CYO?;3 MC-A/X^XGKS;1Q MMI[,Q6YPCYS:WLR+:.;H_J*K]XA*:V&I!$X]RM@TMCD.+<#F7M^LE M.>P-K.7W9$'R$0\^5P]>[J;P[<98Q=PK\DT&]R8W_H)-# MR;6#!="_O\,".A#3X>;HG\W3NW>4N7<4O@S@&)*NRZUY\G1G8!B:J$F:LK;8 MQ@'1(M^2>9W(ZA\K4S[+^PQSYIWSNU]A7B=95<("Z%]K`>4HH3FPZ M%Q7`L!*M=OVSR+.!I12*I(67,O2^V2,-L[VB2QI([%5?:!B% M=_KOCTUJM,G!\=._%N,W)%F/@81M]D^7/UZ5]!OR5?&>RJBV_\/H\RB^\WE@ M/'=FL^'>A_G],4-2I"T@!OSG>['->8?>.JV32]%(_D`)/WA+>R=4[-;5:;Z; M`$4PSIMK[!=.+SV?3^&Q(R'\2A-'IR)_$>+-== MK+FAZN7)3:`E$B_K$?_\CBC@_W)&$D'?/W&N9PI9V?L3^7R[DWX=VW3SO"H7 M7ZB!G6'ZK9P M:\L>[0#X].904=\!K#N4!;"7V#H03!,()G7^/BHI=;_3CTL18W\[?5JH4XDO M<`[L.HRC`R=GYT-TQHR=\V)C5;P`/,%R^?WSPLS?.K*],.H/)M@^B.U\VR'B MZDVX'<0-?D]RIY7*!_UC`.MYTT(/H*Y!'!STZ0^G,_4EC?;?;B!C2C"']'#6 M]/%0*F$]+P\.)!/R\."Q M$N_RWO_DX` MAC1*6;>9.6/R?,P>F^PS[#874:HWI.BY?TR,417%6JEHQX$.9 M`FCKXXRS@0/=F/':5^AC8\KJ\!O=ZK%(WZA'Z1M%972GMQ\7P$<]S,:B-)>' M'S6[&N/(&F/CTU-RFR0R*"FCG;R9`<9_P#-'%QB5AEE-N8\]769:T>1K*I1VDB^)[`!^P.]V&,4>!SGLC:L5E6IAZ M)K&(E(IUW3*W(MEV$&L,^-Z,OO(05W7.1P/797X+[68LO#F MZ':Z$44HMQT$[-L9UQ0@C>3?F*0\A(9VJ M/-3"'JK=.%01;B$SF&,J\N$VG,A\PTP;1^'$YJ,V1@G.-\Q7;=P9)3P/M0GF MEQVE3D#%T=D"7LLSZT<&@(=QIL[0&LS`XQ+:QLO7R!X_>)&=.W M/QU,E;Y+KR+?J==NW4J]JIUT[[:G9:85/NU*O>J==. ML-'NM*]NIUON=H+Y;JGB$IX8C6O*Q=XTZ/OL"6MC,JV8*#Z`\?9*'+Z."PE`Y\Z>UB@ M(\;3#-B\1TQ2@RY%T@N?C<0NTRADWB>1V\LW=.U365_I^MK:-#8TB@Z3$(7' M,).AO2>OEBA$R(VT?*[.Q/J8"%.<=W1@'IYO-Y%XF:#8.9G4:Q7XNN9J[`-& M0F>K9>4;ZLV0<])65S*5B_+.'@;V(VU?'6(WLMRW_,)K-1D[69`2%=ZSS?%MQ:1LQ0?MS%RT M1=`&YSO9,\/ST/&3TRX"RMMFA>J>]9>E<@BD9"ZD\(/7II&P<`90#HD+77UQ M2FFN])"4?8?E#I!Z49^T(B<[PE(BW%E6D-9IR:0',KI&R5F=2LCVX1S$=J6- M$;+9E=H0IM,9NH>!(AY!0!U3=6.TA*<(S7N/5?I($!^I['56XI;C&*MX!(5TK-O]^R'-TRC`'[+>O1+9O1+=M@2ZO8P=%1F#18#4^O/X1/WFI)A3[&M@QO MJ-]RY(:HO,?(ED68$/=;CMY[,7KOQ>B]5V%0ZK<R!)94AK/%L` M29G/_=9GE3ETJ!7K&*\"\B'[;C1BL8X15%&AD'PI*=%9@!*IR@:P2L0TSORN M/M_A<;U\\KL)G'*6B84[QF]*39R+KXZ\C5^;T$>VFU>AD>WK=7K+_.;"^1/- MW'?3&V=3I"4^"0ADEMP7'"(K#ROW7`B=HZ-H@+LA6]C->DB:=-Y(2%40>!19 M/N@N9&I"G.HNYD?'*]3\V'A7+A8NUJN66QS=K,B7W#EIL]R`K"5C,$JOXC\( MOZX@8,]42<7>TU4$-`8]- M33++91W]^"4V9H;R\$NGCRO/R[)P7VG[B#-L./J3KT' M?"1].S84*O[S#1^@B3(R),+8,;:+N.@C754>1AQ(N8R%]#B?K-=S!\UI6 MN!TYN1\BI"OZUA3*U!J&_-G5X*K\1;"%_R5NX)X+?QW<;9-ZS4*5?S0/>`Q" MQZ`HQ=0G]5N-^;VF?N]OLZ?ST7C,[L?A#7C6'\!AFK(!IX(%Y03O]ZC+O_5[ MOHJQ/)!W/#LN<9<7V+<1&%,KB#)2/]E/T/ MFO0'(@Z]W-38HD(#XXG@[V*;\0I_$R-<)TT'Q`Z,2R(:9)S[W^)7#OX2$94& M&@LJX/JE;H)H:HNZ-7\3E;PVCM6K8O.W`9R,<.AR>[*BCUF7+!BM:($;/A," MMV#S_I/Y?I#-^,6_SWXY*E5R*K"^X:]!XB1E;UFF:>SFLB*^_+0`$FV[^,J_ MR<,,;D_,2T'4["XS$R4N^RW=FD4'\1N6^N/KC]/I>I1Q<7=O]/@5EG#IND%_ M]"UJ87`RCC+I\HR'[&#(JG.'M)+)RI2P89N1E6QV;'.5C'93!Y6L5B>E#37U M7IA;>,J*LHY?#=S>&6?X_##Y2D&4^M>8O5?6/@,J%SF<`5L/^T0L=0\8"M/1 MP1!=GA=%DZ=%W59ETU1YYR"4$R$%.?&>[NP)LJWNNPED_ASCK7:L90OTZOD$ M/QDIAX`7%H9KOQX">>5=X_X'1:.-Z4#B_Q:VK8DJF]\WK=.W+C=LD#JVQ+M^ M/-?`/OVI=4W=D,]@,.B&A<-)[.@K!KOEVG?>]"8_I6#'L"UQ0\=-GD?!CF'+ M[8:.8:/KAHYA&^RV0!D^9D/9>FRR?AM?G4JD%!AA[$1AT'G+I>+BM],A=U.S MU;BQPH=AMMH9P#8YTX410-CJO:GG)F_<<,_=T=7.3S?;^6BSG1]OMO/KS79^ MOMG0^QWN&8:A,4S`WM4$G0P^3M?(D(7E`27E#^5Z'*!+JK_?U#EN^#``CNL? M!L/33X_S)3,`GNC!<4'$DZ>P0L;4&3CF`/8V03P]6_/$0Y%A;S#:_AHDD"=' MR<:!OT__N@I\%QRCRV:=7H;![VWX&\^"'/$3!J_Z*(_<$7)\QQ3!_3!=W)K) M17;3O7.N"2,`=`#VG,9^-5+`T]Z=*0R&J/8'^8ZBL='TZ!?"=` M]]A9!\''2$:`?A%A/A)S6=[`VA?NF5A1%>Y'9B[&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"%`,4````"`!9DPI'$KQ&V@@$``!I$@``$``````````` M````@`$;!@``9&]C4')O<',O87!P+GAM;%!+`0(4`Q0````(`%F3"D>J#(E8 M/P$``&D#```1``````````````"``5$*``!D;V-097)PC$`8``)PG```3``````````````"``;\+``!X M;"]T:&5M92]T:&5M93$N>&UL4$L!`A0#%`````@`69,*1W_RVOYG`@``<@P` M``T``````````````(`!`!(``'AL+W-T>6QEX%``"A&```#P``````````````@`&2%```>&PO=V]R:V)O;VLN M>&UL4$L!`A0#%`````@`69,*1U.'M8%]`@``)@D``!@``````````````(`! MK1H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M69,*1P'O/N0V!0``L!@``!@``````````````(`!B24``'AL+W=O,[$LZ,!``"Q`P``&```````````````@`%(,```>&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`69,*1QHI+*&C`0``L0,` M`!@``````````````(`!(3(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`69,*1U57X&VB`0``L0,``!D``````````````(`! MJC<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`69,*1PF$O&PO=V]R:W-H965TQ_3.KI`$``+$#```9``````````````"``>M```!X M;"]W;W)K&UL4$L!`A0#%`````@`69,*1X.EO3>B M`0``L0,``!D``````````````(`!QD(``'AL+W=O&PO=V]R:W-H965T[WU#7I0$``+$#```9``````````````"``7E&``!X;"]W;W)K&UL4$L!`A0#%`````@`69,*1\2$">BC`0``L0,``!D````` M`````````(`!54@``'AL+W=O&PO=V]R M:W-H965T5IKC\I`$``+$# M```9``````````````"``0E,``!X;"]W;W)K&UL M4$L!`A0#%`````@`69,*1\>DO]*C`0``L0,``!D``````````````(`!Y$T` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M69,*1]RRT<.D`0``L0,``!D``````````````(`!<%,``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`69,*1V'1%_O"`0`` M>P0``!D``````````````(`!'5H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`69,*1RX!/5>F`0``L0,``!D````````` M`````(`!W%\``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`69,*1W'*]D;<`0``104``!D``````````````(`!=&4``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`69,* M1P_E0I6E`0``L0,``!D``````````````(`!M&L``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`69,*1QVZ--A1`@``W`<` M`!D``````````````(`!O7$``'AL+W=O&PO=V]R:W-H965T5T.RC M2P(``/@&```9``````````````"``4MW``!X;"]W;W)K&UL4$L!`A0#%`````@`69,*1XI1AMRW`0``'P0``!D````````````` M`(`!S7D``'AL+W=OP``>&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`69,*1\U)O9`0`@``\04``!D``````````````(`!A8```'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@`69,*1UQG MCB55`@``V`<``!D``````````````(`!88<``'AL+W=O!```&0`````````` M````@`'MB0``>&PO=V]R:W-H965TU33-#!`(``'0%```9``````````````"``?J+``!X;"]W;W)K&UL4$L!`A0#%`````@`69,*1ZL27.3G`0``_`0``!D` M`````````````(`!-8X``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`69,*1[!E4=&<`0``LP,``!D``````````````(`! M\Y@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`69,*1TS9@CIW!0``MB```!D``````````````(`!!:@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`69,*1\/V,4FK M`@``@@H``!D``````````````(`!`[H``'AL+W=O&PO=V]R:W-H965T]Y=F_"@(``&P&```9``````````````"``&UL4$L!`A0#%`````@`69,*1]#I1NFB`@``/@H``!D````` M`````````(`!#L$``'AL+W=O&PO=V]R M:W-H965TK"#&G0$``*(# M```9``````````````"``7?&``!X;"]W;W)K&UL M4$L!`A0#%`````@`69,*1QOE)3[8`0``*`4``!D``````````````(`!2\@` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M69,*1_&R%%[2`@``\@H``!D``````````````(`!^\\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`69,*1]LQX9?B!0`` M92```!D``````````````(`!1]<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`69,*1[UNY)#"!````1L``!D````````` M`````(`!O^D``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`69,*1T7'U].^`0``M00``!D``````````````(`!'_0``'AL M+W=O=K?D! M```C!@``&0``````````````@`$4]@``>&PO=V]R:W-H965T v3.2.0.727
Stockholders Equity - 2000 Stock Incentatvie Plan (Details)
 9 Months Ended
May. 31, 2015
USD ($)
Number
$ / shares
shares
May. 31, 2014
USD ($)
Dec. 20, 2014
$ / shares
shares
Aug. 31, 2014
shares
Dec. 13, 2013
$ / shares
shares
Aug. 31, 2013
shares
Feb. 28, 2000
shares
Stock based compensation | $   $ 91,163          
Option Outstanding [Member]              
Number of options 6,173,750            
Weighted average remaining contractual term (years) | Number 1.17            
Weighted average exercise price | $ / shares $ .016            
Options Exercisable [Member]              
Number of options 6,173,750            
Weighted average remaining contractual term (years) | Number 1.17            
Weighted average exercise price | $ / shares $ 0.016            
Stock Incentative Plan [Member]              
Shares authorized 473,253   20,000   6,100,000   7,500,000
Number of options 6,173,750     6,173,750   217,085  
Weighted average exercise price | $ / shares     $ .016   $ 0.015    

XML 17 R55.htm IDEA: XBRL DOCUMENT v3.2.0.727
Convertible Notes Payable (Details 1) - USD ($)
Aug. 31, 2016
Aug. 31, 2015
Convertible Notes Payable Details 1    
Future minimum payments $ 477,596 $ 0
XML 18 R78.htm IDEA: XBRL DOCUMENT v3.2.0.727
Employment Agreements (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended
Mar. 22, 2013
Mar. 30, 2015
May. 31, 2013
May. 31, 2015
May. 31, 2014
Medical Products Segment [Member]          
Other Commitments [Line Items]          
Base Salary       $ 85,000  
Officer's Salary       63,750  
Benefits       1,300  
CEO [Member]          
Other Commitments [Line Items]          
Base Salary $ 120,000 $ 150,000      
Officer's Salary       97,500 $ 101,250
Benefits $ 1,250        
CFO [Member]          
Other Commitments [Line Items]          
Base Salary     $ 80,000    
Officer's Salary       76,333 62,669
Benefits     $ 500    
Salary Increase       120,000  
Angels of Mercy, Inc. [Member]          
Other Commitments [Line Items]          
Base Salary       52,000  
Officer's Salary       49,900 $ 46,214
Benefits       400  
Salary Increase       $ 85,000  
XML 19 R46.htm IDEA: XBRL DOCUMENT v3.2.0.727
Discountinued Operations (Details) - USD ($)
 9 Months Ended
May. 31, 2015
Nov. 01, 2013
Discountinued Operations Details    
Promissory note   $ 50,000
Legal Billings   $ 145,522
Payments, monthly [1] $ 4,257  
[1] promissory note bears interest at 4% and requires 12 monthly payments
XML 20 R33.htm IDEA: XBRL DOCUMENT v3.2.0.727
Inventory Financing Agreement (Tables)
 9 Months Ended
May. 31, 2015
Debt Disclosure [Abstract]  
Financing Agreements

 

   As of May 31,   
   2015  2014  Monthly Payment
Wells Fargo (017)  $8,331   $—     $4,165 
VGM (322)   23,787    —      5,947 
Wells Fargo (018)   24,694    —      6,174 
VGM (323)   32,106    —      5,351 
DLL (61942)   90,781    —      11,348 
DLL (67910)   31,389    —      3,488 
VGM (324)   32,512    —      3,612 
DLL (68936)   11,263    —      1,126 
Wells Fargo (019)   76,459    —      6,951 
VGM (325)   85,680    —      7,140 
DLL (61649)   —           1,126 
                
                
Outstanding leases  $417,001   $—     $56,428 
XML 21 R79.htm IDEA: XBRL DOCUMENT v3.2.0.727
Commitments and Contingencies (Details Narrative) - Aug. 31, 2014 - USD ($)
Total
Service Agreement #1 [Member]  
Service Agreement $ 60,000
Share issued 5,000,000
Service Agreement #2 [Member]  
Service Agreement $ 30,000
Share issued 3,000,000
XML 22 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 23 R73.htm IDEA: XBRL DOCUMENT v3.2.0.727
Business Segments - Balance Sheet(Details) - USD ($)
May. 31, 2015
Aug. 31, 2014
May. 31, 2014
Aug. 31, 2013
Current Assets:        
Cash and cash equivalents $ 120,485 $ 17,504 $ 186,380 $ 39,456
Accounts receivable 1,037,009 213,399    
Inventory 137,436 31,271 $ 31,271  
Prepaid expenses and other current assets 15,911 9,307    
Prepaid commissions and finders' fees 3,974 3,152    
Total current assets 1,314,815 274,633    
Property and equipment (net of accumulated depreciation of $ $19,999 and $11,820) 35,246 39,967    
Deposits and other assets 77,678 14,582    
Goodwill 2,404,389 1,781,779    
Patents, registrations (net of amortization of $94,921 and $91,859) 19,903 24,497    
Total assets 3,852,031 2,135,458    
Personal Care Segment [Member]        
Current Assets:        
Cash and cash equivalents 76,633 9,336    
Accounts receivable $ 233,710 $ 213,399    
Inventory        
Prepaid expenses and other current assets        
Prepaid commissions and finders' fees        
Total current assets $ 310,343 $ 222,735    
Property and equipment (net of accumulated depreciation of $ $19,999 and $11,820) 16,211 21,287    
Deposits and other assets 2,307 2,082    
Goodwill $ 564,075 $ 564,075    
Patents, registrations (net of amortization of $94,921 and $91,859)        
Total assets $ 892,936 $ 810,179    
Medical Device Segment [Member]        
Current Assets:        
Cash and cash equivalents $ 120 $ (110)    
Accounts receivable        
Inventory $ 31,271 $ 31,271    
Prepaid expenses and other current assets        
Prepaid commissions and finders' fees        
Total current assets $ 31,391 $ 31,161    
Property and equipment (net of accumulated depreciation of $ $19,999 and $11,820) 15,217 17,893    
Deposits and other assets 32,303 12,500    
Goodwill 1,217,704 1,217,704    
Patents, registrations (net of amortization of $94,921 and $91,859) 19,903 24,497    
Total assets 1,316,518 1,303,755    
Medical Products Segment [Member]        
Current Assets:        
Cash and cash equivalents 21,008 $ 1,000    
Accounts receivable 803,299      
Inventory 106,165      
Prepaid expenses and other current assets 2,946      
Prepaid commissions and finders' fees 85      
Total current assets 933,503 $ 1,000    
Property and equipment (net of accumulated depreciation of $ $19,999 and $11,820) 3,283      
Deposits and other assets 9,866      
Goodwill $ 622,610      
Patents, registrations (net of amortization of $94,921 and $91,859)        
Total assets $ 1,569,262 $ 1,000    
Corporate Overhead [Member]        
Current Assets:        
Cash and cash equivalents $ 22,724 $ 7,278    
Accounts receivable        
Inventory        
Prepaid expenses and other current assets $ 12,965 $ 9,307    
Prepaid commissions and finders' fees 3,889 3,152    
Total current assets 39,578 19,737    
Property and equipment (net of accumulated depreciation of $ $19,999 and $11,820) 535 $ 787    
Deposits and other assets $ 33,202      
Goodwill        
Patents, registrations (net of amortization of $94,921 and $91,859)        
Total assets $ 73,315 $ 20,524    
XML 24 R57.htm IDEA: XBRL DOCUMENT v3.2.0.727
Notes Payable - Related Party (Details) - USD ($)
Aug. 31, 2016
Aug. 31, 2015
May. 31, 2015
May. 31, 2014
Principal paid $ 477,596 $ 0    
Convertible Related Party Notes Payable [Member]        
Outstanding unsecured related party convertible notes payable       $ 51,600
Interest Rate     6.00%  
Principal paid     $ 51,600  
Accrued interest     $ 7,393  
XML 25 R76.htm IDEA: XBRL DOCUMENT v3.2.0.727
Statement of Cash Flows (Details 1) - USD ($)
 9 Months Ended
May. 31, 2015
May. 31, 2014
Conversion prommsiory note to nonrelated   $ 25,000
Warrants issued   38,322
Total noncash transactions from investing and financing activities $ 676,419 495,861
Common stock for a investor relations contract #1 [Member]    
Issued shares of common stock in payment for a investor relations consulting contract 4,000 11,500
Common stock for a investor relations contract #2 [Member]    
Issued shares of common stock in payment for a investor relations consulting contract 20,000 19,000
Conversion of promissory note #1 [Member]    
Loss on conversion of convertible debt   15,620
Beneficial conversion feature on issuance of convertible note 10,545 12,069
Conversion of promissory note #2 [Member]    
Loss on conversion of convertible debt   30,000
Beneficial conversion feature on issuance of convertible note 10,545 9,720
Conversion of promissory note #3 [Member]    
Loss on conversion of convertible debt   1,468
Beneficial conversion feature on issuance of convertible note 35,000 26,154
Conversion of promissory note #4 [Member]    
Loss on conversion of convertible debt   30,683
Beneficial conversion feature on issuance of convertible note 50,000 16,667
Conversion of promissory note #5 [Member]    
Beneficial conversion feature on issuance of convertible note 50,000 9,000
Conversion of promissory note #6 [Member]    
Beneficial conversion feature on issuance of convertible note 35,000 2,308
Conversion of promissory note #7 [Member]    
Beneficial conversion feature on issuance of convertible note 75,000 26,500
Conversion of promissory note #8 [Member]    
Beneficial conversion feature on issuance of convertible note 30,000 50,000
Common stock for a investor relations contract #3 [Member]    
Issued shares of common stock in payment for a investor relations consulting contract 38,500  
Additional Compensation 1 [Member]    
Issued warrants Additional Compensation   5,992
Additional Compensation 2 [Member]    
Issued warrants Additional Compensation   7,746
Finders Fee 1 [Member]    
Warrants issued   45,500
Finders Fee 2 [Member]    
Warrants issued   30,000
Finders Fee 3 [Member]    
Warrants issued   9,000
Finders Fee 4 [Member]    
Warrants issued   2,308
Conversion of promissory note #9 [Member]    
Beneficial conversion feature on issuance of convertible note 25,698 $ 25,000
Conversion of promissory note #10 [Member]    
Beneficial conversion feature on issuance of convertible note 49,539  
Conversion of promissory note #11 [Member]    
Beneficial conversion feature on issuance of convertible note 20,100  
Conversion of promissory note #12 [Member]    
Beneficial conversion feature on issuance of convertible note 29,404  
Conversion of promissory note #13 [Member]    
Beneficial conversion feature on issuance of convertible note 15,790  
Conversion of promissory note #14 [Member]    
Beneficial conversion feature on issuance of convertible note 10,372  
Conversion of promissory note #15 [Member]    
Beneficial conversion feature on issuance of convertible note 39,146  
Conversion of promissory note #16 [Member]    
Beneficial conversion feature on issuance of convertible note 21,452  
Conversion of promissory note #17 [Member]    
Beneficial conversion feature on issuance of convertible note 29,715  
Conversion of promissory note #18 [Member]    
Beneficial conversion feature on issuance of convertible note 30,645  
Conversion of promissory note #19 [Member]    
Beneficial conversion feature on issuance of convertible note $ 45,968  
XML 26 R77.htm IDEA: XBRL DOCUMENT v3.2.0.727
Statement of Cash Flows (Details 1) (Parenthetical) - shares
 9 Months Ended
May. 31, 2015
May. 31, 2014
Warrants for additional compensation #1 [Member]    
Warrants Issued   1,500,000
Warrants for additional compensation #2 [Member]    
Warrants Issued   1,000,000
Warrants for additional compensation #3 [Member]    
Warrants Issued   3,000,000
Common stock for a investor relations contract #1 [Member]    
Warrants Issued 1,000,000  
Common stock for a investor relations contract #2 [Member]    
Warrants Issued 5,000,000  
XML 27 R71.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity - 2000 Stock Incentatvie Plan (Details 1) - shares
 9 Months Ended 12 Months Ended
May. 31, 2015
Aug. 31, 2014
Number of Options Granted    
Shares Granted   23,583,333
Shares Exercised (9,583,333)  
Stock Incentative Plan [Member]    
Number of Options Granted    
Shares Outstanding, beginning balance 6,173,750 217,085
Shares Granted   6,120,000
Shares Cancelled   (163,335)
Shares Outstanding, ending balance 6,173,750 6,173,750
XML 28 R25.htm IDEA: XBRL DOCUMENT v3.2.0.727
Commitments and Contingencies
 9 Months Ended
May. 31, 2015
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

NOTE 20 – COMMITMENTS AND CONTINGENCIES

 

On June 6, 2014, the Company and its subsidiary Dotolo entered into a services agreement with E & R Industries to provide the Company with retooling and redesign of Dotolo’s disposable products. The contract calls for periodic cash payments totaling $60,000 along with the issuance of 5,000,000 common stock shares upon meeting certain milestones.

 

On June 6, 2014, the Company and its subsidiary Dotolo entered into a services agreement with Schmitt Engineering to provide the Company with engineering redesign services of its Toxygen hardware system. The contract calls for periodic cash payments totaling $30,000 along with the issuance of 3,000,000 common stock shares upon meeting certain milestones.
XML 29 R50.htm IDEA: XBRL DOCUMENT v3.2.0.727
Leases (Details)
May. 31, 2015
USD ($)
Leases Details  
2015 $ 33,495
2016 126,424
2017 114,808
2018 42,448
Totals $ 317,175
XML 30 R42.htm IDEA: XBRL DOCUMENT v3.2.0.727
Summary of Significant Accounting Policies - Net Loss Per Common Share - Dilutive Securities (Details) - USD ($)
 6 Months Ended 9 Months Ended
Feb. 28, 2014
May. 31, 2015
May. 31, 2014
Description      
Convertible preferred stock   78,564,000 22,500,000
Convertible notes payable 81,383,460 210,272,886  
Options $ 6,186,250 $ 6,173,750  
Warrants 26,583,333 21,000,000  
Total potentially dilutive securities 136,653,043 316,010,636  
XML 31 R75.htm IDEA: XBRL DOCUMENT v3.2.0.727
Income Taxes - Income Tax Benefit (Details) - USD ($)
None in scaling factor is -9223372036854775296
 3 Months Ended 9 Months Ended
May. 31, 2015
May. 31, 2014
May. 31, 2015
May. 31, 2014
Deferred:        
Income Tax Benefit, net        
XML 32 R37.htm IDEA: XBRL DOCUMENT v3.2.0.727
Statement of Cash Flows (Tables)
 9 Months Ended
May. 31, 2015
Supplemental Cash Flow Elements [Abstract]  
Supplemental Non-cash Investing and Financing Activities

NOTE 18 – STATEMENT OF CASH FLOWS

 

For the six months ended February 28, 2015, these supplemental non-cash investing and financing activities are summarized as follows:

    Amount
On November 15, 2014, the Company issued 1,000,000 S-8 shares of common stock in payment for a investor relations consulting contract.     

 

4,000

     
On November 15, 2014, the Company issued 5,000,000 shares of common stock in payment for  investor relations consulting contract.     

 

20,000

     
On November 17, 2014, the Company issued a $25,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $10,545 related to that transaction.  

 

 

10,545

     
On November 17, 2014, the Company issued a $25,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $10,545 related to that transaction.  

 

 

10,545

     
On January 22, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $35,000 related to that transaction.  

 

 

35,000

     
On January 30, 2015, the Company issued 5,000,000 shares of common stock in payment for  investor relations consulting contract.     

 

38,500

     
On January 30, 2015, the Company issued a $50,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $50,000 related to that transaction.  

 

 

50,000

     
On February 5 2015, the Company issued a $50,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $50,000 related to that transaction.  

 

 

50,000

     
On February 4, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $35,000 related to that transaction.  

 

 

35,000

     
On February 12, 2015, the Company issued a $75,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $75,000 related to that transaction.  

 

 

75,000

     
On February 25, 2015, the Company issued a $30,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $30,000 related to that transaction.  

 

 

30,000

     
       Total non-cash transactions from investing and financing activities. $  358,590
     

 

 

For the six months ended February 28, 2014, these supplemental non-cash investing and financing activities are summarized as follows:

 

On September 11, 2013, the Company issued 1,500,000 warrants to an affiliated party for additional compensation related to an operating capital investment.  The value of these warrants was expensed as interest and finance charges.

 

 

$

 

 

15,656

     
On September 11, 2013, the Company issued 1,000,000 S-8 shares of common stock in payment for a investor relations consulting contract.     

 

11,500

     
On October 2, 2013, the Company issued a $25,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $25,000 related to that transaction.  

 

 

25,000

     
On October 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $15,620.  

 

15,620

     
On November 5, 2013 and November 8, 2013, the Company issued a total of 3,000,000 warrants to a non-related party as additional compensation for an operating capital investment.  

 

 

14,805

     
On December 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $12,069.  

 

12,069

     
On December 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $9,720.  

 

9,720

     
On December 3, 2013, the Company issued a total of 1,000,000 warrants as additional compensation.  

 

5,992

     
On December 20, 2013, the Company issued a total of 3,000,000 warrants as additional compensation.  

 

7,746

     
On January 3, 2014, the Company issued 2,000,000 shares of common stock in payment for a services contract.  

 

22,000

     
On January 13, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $26,154.  

 

26,154

     
On January 14, 2014, the Company issued 1,000,000 shares of common stock as partial compensation for a investor relations contract.  

 

19,000

     
On January 21, 2014, the Company issued 3,500,000 shares of common stock as additional compensation for finder’s fees.  

 

45,500

     
On January 21, 2014, the Company issued 1,500,000 shares of common stock as additional compensation for finder’s fees.  

 

30,000

     
On January 31, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $16,667.  

 

16,667

     
On February 7, 2014, the Company issued 1,000,000 shares of common stock as additional compensation for finder’s fees.  

 

9,000

  

For the six months ended February 28, 2014, these supplemental non-cash investing and financing activities are summarized as follows (continued):

 

On February 7, 2014, the Company issued 3,000,000 shares of common stock as additional compensation for finder’s fees.  

 

5,151

     
On February 24, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $2,308.  

 

2,308

     
       Total non-cash transactions from investing and financing activities. $        293,888
     

 

 
XML 33 R52.htm IDEA: XBRL DOCUMENT v3.2.0.727
Goodwill, Patents and Other Intangible Assets (Details Narrative) - USD ($)
 9 Months Ended
May. 31, 2015
Aug. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]    
Patents and Registrations $ 122,479  
Accumulated Amortization 102,576 $ 97,983
Amortization Expense $ 6,124  
XML 34 R67.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity (Details Narrative 2) - USD ($)
Aug. 31, 2014
Aug. 31, 2013
Aug. 31, 2010
Feb. 27, 2009
Stockholders Equity Details Narrative 2        
Value of 10% IUTM noncontrolling interest       $ 212
Impairment loss on IUTM investment     $ 3,186  
Cumulative net loss attributable to noncontrolling interest $ 3,734 $ 3,701    
XML 35 R61.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity (Details) - $ / shares
 9 Months Ended 12 Months Ended
May. 31, 2015
Aug. 31, 2014
Proceeds if Shares Converted    
Shares Issued   23,583,333
Series A Preferred Stock [Member]    
Number of Preferred Shares    
Shares Outstanding, beginning balance 129,062 129,062
Shares Outstanding, ending balance 129,062 129,062
Number of Common Shares Convertible    
Shares Outstanding, beginning balance 64,531 64,531
Shares Outstanding, ending balance 64,531 64,531
Proceeds if Shares Converted    
Amount converted, beginning balance 25,812 25,812
Amount converted, ending balance 25,812 25,812
Weighted Average Exercise Price Per Common Stock    
Shares Outstanding, beginning balance $ 0.40 $ 0.40
Shares Converted 0.40 0.40
Sharess Outstanding, ending balance $ 0.40 $ 0.40
XML 36 R47.htm IDEA: XBRL DOCUMENT v3.2.0.727
Discountinued Operations (Details 1) - USD ($)
 3 Months Ended 9 Months Ended
May. 31, 2015
May. 31, 2014
May. 31, 2015
May. 31, 2014
Operating expenses:        
General and administrative       $ 36
Depreciation and amortization        
Total operating expenses       $ 36
Loss from operations       $ (36)
Other income (expense):        
Total other income (expense)        
Loss from discontinued operations       $ (36)
Gain on disposal of discontinued operations       95,564
Loss from discontinued operations       $ 95,528
Less loss attributable to noncontrolling interest        
Net loss from discontinued operations       $ 95,528
XML 37 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727
Acquisitions
 9 Months Ended
May. 31, 2015
Business Combinations [Abstract]  
Acquisitions

NOTE 4 – ACQUISITIONS

 

Amian Health Services

 

On December 10, 2013, our subsidiary Angels of Mercy acquired the assets of Amian Health Services. Pursuant to the Agreement, the Owners sold all the assets for $100,000 represented by a down payment of $75,000 at closing and a one year Secured Promissory Note for $25,000.

 

The acquisition was accounted for using the acquisition method of accounting and the purchase price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values at the date of acquisition. Identifiable intangible assets include patents and purchased goodwill.

 

The purchase price was allocated to assets acquired and liabilities assumed as follows:

 

      
Cash and cash equivalents  $8,646 
Property and equipment   6,000 
Purchased goodwill   85,354 
      
Total assets acquired  $100,000 

 

On September 25, 2014, we acquired all the outstanding shares of Esteemcare Inc. and its wholly owned subsidiary, Affordable Medical Equipment Solutions Inc. in exchange for a $400,000 down payment, $100,000 note and payoff of $173,433 in operating leases.

 

The acquisition was accounted for using the acquisition method of accounting and the purchase price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values at the date of acquisition. Identifiable intangible assets include patents and purchased goodwill.

 

The purchase price was allocated to assets acquired and liabilities assumed as follows:

 

Cash and cash equivalents  $12,449 
Accounts receivable (net)   573,130 
Inventory   106,165 
Prepaid expenses and other current assets   860 
Property and equipment   3,008 
Deposits and other assets   10,551 
Purchased goodwill   622,610 
      
Total assets acquired  $1,328,773 
      
Accounts payable and other accrued expenses  $454,877 
Inventory financing agreements   125,463 
Notes payable   75,000 
      
Total liabilities assumed  $655,340 

 
XML 38 R62.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity (Details Narrative) - 1 months ended Jan. 31, 2003 - $ / shares
Total
Stockholders Equity Details Narrative  
Series A convertible preferred stock authorized 4,500,000
Series A convertible preferred stock par value $ 0.001
Series A convertible preferred stock outstanding 129,062
XML 39 R43.htm IDEA: XBRL DOCUMENT v3.2.0.727
Going Concern (Details Narrative)
 9 Months Ended
May. 31, 2015
USD ($)
Notes Payable Details Narrative 4  
Amount needed to fund operations $ 1,000,000
Amount needed to fund overhead $ 500,000
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727
Acquisitions (Tables)
 9 Months Ended
May. 31, 2015
Business Combinations [Abstract]  
Amian Health Services
      
Cash and cash equivalents  $8,646 
Property and equipment   6,000 
Purchased goodwill   85,354 
      
Total assets acquired  $100,000 
EsteemCare
Cash and cash equivalents  $12,449 
Accounts receivable (net)   573,130 
Inventory   106,165 
Prepaid expenses and other current assets   860 
Property and equipment   3,008 
Deposits and other assets   10,551 
Purchased goodwill   622,610 
      
Total assets acquired  $1,328,773 
      
Accounts payable and other accrued expenses  $454,877 
Inventory financing agreements   125,463 
Notes payable   75,000 
      
Total liabilities assumed  $655,340 
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
May. 31, 2015
Accounting Policies [Abstract]  
Property and equipment, useful life
Furniture and fixtures 5 to 10 years
Computer equipment 5 years
Equipment 5 to 10 years
Software 3 to 5 years
Net Loss Per Common Share

 

   For the Three Months Ended  For the Nine Months Ended
   May 31,  May 31,  May 31,  May 31,
   2015  2014  2015  2014
             
             
Net gain (loss) attributable to common shareholders                    
Continuing operations  $(525,438)  $(238,952)  $(1,494,096)  $(1,152,393)
Discontinued operations   —      —      —      95,528 
                     
                     
   $(525,438)  $(238,952)  $(1,494,096)  $(1,056,865)
                     
Weighted average shares outstanding   242,589,170    112,247,396    187,353,653    93,925,094 
                     
Loss per common shares, basis and diluted                    
Continuing operations  $(0.00)  $(0.00)  $(0.01)  $(0.01)
Discontinued operations   —      —      —      0.00 
                     
                     
   $(0.00)  $(0.00)  $(0.01)  $(0.01)
Dilutive Securities

 

            As of
            May 31,   May 31,
            2015 2014
           Underlying     Underlying 
Description  Common Shares     Common Shares 
Convertible preferred stock            78,564,000              22,500,000
Convertible notes payable          210,272,886              81,383,460
Options              6,173,750                6,186,250
Warrants            21,000,000              26,583,333
                 
Total potentially dilutive securities          316,010,636            136,653,043
XML 42 R56.htm IDEA: XBRL DOCUMENT v3.2.0.727
Convertible Notes Payable (Details Narrative 1) - May. 31, 2015 - USD ($)
Total
Convertible Note 1 [Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 235,025
Assigned principal to another investor $ 125,000
Interest rate of note 6.00%
Per share conversion rate of note $ 0.20
Interest accrued on promissory notes $ 82,833
Note payable $ 64,025
Shares issued 8,788,171
Shares issued, amount $ 46,000
Note reduction 189,025
Convertible Notes Payable 2218[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 700,000
Convertible discount 60.00%
Interest accrued on promissory notes $ 65,469
Extended convertible promissory notes [1] 125,000
Convertible Notes Payable 2232[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 25,000
Interest rate of note 8.00%
Convertible discount 45.00%
Beneficial conversion feature $ 25,000
Extended convertible promissory notes $ 17,074
Per share conversion rate of extended notes $ 0.0033
Interest accrued on promissory notes $ 690
Shares issued 5,383,007
Convertible Notes Payable Additional 2232[Member]  
Debt Instrument [Line Items]  
Extended convertible promissory notes $ 7,926
Per share conversion rate of extended notes $ 0.002475
Interest accrued on promissory notes $ 530
Shares issued 3,416,764
Convertible Notes Payable 2238[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 26,500
Interest rate of note 12.00%
Convertible discount 38.00%
Beneficial conversion feature $ 26,500
Interest accrued on promissory notes $ 1,384
Shares issued 16,801,705
Convertible Notes Payable Additional 2238[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 50,000
Interest rate of note 12.00%
Convertible discount 35.00%
Beneficial conversion feature $ 50,000
Convertible Notes Payable 2247[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 25,000
Interest rate of note 12.00%
Convertible discount 35.00%
Shares issued 8,284,469
Shares issued, amount $ 25,000
Convertible Note 2250 [Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 115,000
Interest rate of note 10.00%
Per share conversion rate of note $ 0.009
Beneficial conversion feature $ 38,322
Convertible Note 2253 [Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 26,500
Interest rate of note 12.00%
Convertible discount 38.00%
Beneficial conversion feature $ 26,500
Interest accrued on promissory notes $ 1,134
Shares issued 18,571,550
Convertible Note 2259 [Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 25,000
Interest rate of note 8.00%
Beneficial conversion feature $ 10,545
Interest accrued on promissory notes 85
Note payable $ 10,545
Shares issued 9,641,872
Shares issued, amount $ 25,000
Convertible Note 2261 [Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 25,000
Interest rate of note 8.00%
Convertible discount 30.00%
Beneficial conversion feature $ 10,545
Interest accrued on promissory notes $ 567
Shares issued 6,211,180
Shares issued, amount $ 11,989
Convertible Note 2265 [Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 35,000
Interest rate of note 8.00%
Convertible discount 38.00%
Beneficial conversion feature $ 35,000
Interest accrued on promissory notes 1,003
Convertible Note 2267[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 50,000
Interest rate of note 8.00%
Convertible discount 38.00%
Beneficial conversion feature $ 50,000
Interest accrued on promissory notes 1,989
Convertible Note 2269[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 50,000
Interest rate of note 8.00%
Convertible discount 38.00%
Beneficial conversion feature $ 50,000
Shares issued 16,669,092
Shares issued, amount $ 50,198
Convertible Note 2274[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 35,000
Interest rate of note 8.00%
Convertible discount 38.00%
Beneficial conversion feature $ 35,000
Interest accrued on promissory notes 1,128
Convertible Note 2271[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 75,000
Interest rate of note 10.00%
Convertible discount 38.00%
Beneficial conversion feature $ 75,000
Interest accrued on promissory notes 250
Convertible Note 2281[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 30,000
Interest rate of note 12.00%
Convertible discount 38.00%
Beneficial conversion feature $ 30,000
Interest accrued on promissory notes 937
Convertible Notes Payable 2276[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 36,750
Interest rate of note 8.00%
Convertible discount 38.00%
Interest accrued on promissory notes $ 711
Convertible Notes Payable 2283[Member]  
Debt Instrument [Line Items]  
Assigned principal to another investor $ 30,000
Interest rate of note 8.00%
Convertible discount 38.00%
Shares issued 9,180,298
Shares issued, amount $ 30,096
Convertible Notes Payable 2278[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 88,000
Interest rate of note 12.00%
Convertible discount 38.00%
Interest accrued on promissory notes $ 2,376
Convertible Notes Payable 2290[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 50,000
Interest rate of note 10.00%
Interest accrued on promissory notes $ 931
Convertible Notes Payable 2292[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 32,000
Interest rate of note 8.00%
Interest accrued on promissory notes $ 441
Convertible Notes Payable 2294[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 27,500
Interest rate of note 12.00%
Convertible discount 38.00%
Beneficial conversion feature $ 6,000
Interest accrued on promissory notes 330
Convertible Notes Payable 2297[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 58,000
Interest rate of note 8.00%
Interest accrued on promissory notes $ 683
Convertible Notes Payable 2310[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 35,000
Interest rate of note 8.00%
Convertible discount 38.00%
Beneficial conversion feature $ 21,452
Interest accrued on promissory notes 280
Convertible Notes Payable 2312[Member]  
Debt Instrument [Line Items]  
Assigned principal to another investor $ 45,000
Interest rate of note 8.00%
Convertible discount 38.00%
Beneficial conversion feature $ 29,715
Interest accrued on promissory notes $ 100
Shares issued 9,400,000
Shares issued, amount $ 16,261
Convertible Notes Payable 2314[Member]  
Debt Instrument [Line Items]  
Convertible promissory note $ 50,000
Interest rate of note 8.00%
Convertible discount 38.00%
Beneficial conversion feature $ 30,645
Interest accrued on promissory notes 100
Convertible Notes Payable 2316[Member]  
Debt Instrument [Line Items]  
Assigned principal to another investor $ 75,000
Interest rate of note 8.00%
Convertible discount 38.00%
Beneficial conversion feature $ 45,968
Convertible Notes Payable 2322[Member]  
Debt Instrument [Line Items]  
Assigned principal to another investor $ 100,000
Interest rate of note 4.00%
Convertible discount 35.00%
[1] In October 2013 and November 2014, the investor sold two $25,000 positions of principal in the note to another accredited investor and currently holds a note representing the remaining $75,000 in principal.
XML 43 R44.htm IDEA: XBRL DOCUMENT v3.2.0.727
Acquisitions - Acquisitions (Details)
May. 31, 2015
USD ($)
Amian Health Services [Member]  
Cash and cash equivalents $ 8,646
Property and equipment 6,000
Purchased Goodwill 85,354
Total assets acquired 100,000
Esteemcare Inc. [Member]  
Cash and cash equivalents 12,449
Accounts receivable (net) 573,130
Inventory 106,165
Prepaid expenses and other current assets 860
Property and equipment 3,008
Deposits and other assets 10,551
Purchased Goodwill 622,610
Total assets acquired 1,328,773
Accounts payable and other accrued expenses 454,877
Inventory financing agreements 125,463
Notes payable 75,000
Total liabilities assumed $ 655,340
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727
Discontinued Operations (Tables)
 9 Months Ended
May. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations
   For the Three Months Ended  For the Six Months Ended
   May 31,  May 31,  May 31,  May 31,
   2015  2014  2015  2014
Operating expenses:                    
General and administrative  $—     $—     $—     $36 
Depreciation and amortization   —      —      —      —   
                     
Total operating expenses   —      —      —      36 
                     
Loss from operations   —      —      —      (36)
                     
Other income (expense):                    
                     
Total other income (expense)   —      —      —      —   
                     
Loss from discontinued operations   —      —      —      (36)
Gain on disposal of discontinued operations   —      —      —      95,564 
                     
Loss from discontinued operations   —      —      —      95,528 
                     
Less loss attributable to noncontrolling interest   —      —      —      —   
                     
Net loss from discontinued operations  $—     $—     $—     $95,528 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727
Property and Equipment (Tables)
 9 Months Ended
May. 31, 2015
Property, Plant and Equipment [Abstract]  
Property and Equipment

 

   May 31,  August 31,
   2015  2014
Furniture  $14,118   $12,688 
Office Equipment   13,625    12,962 
Computers   24,409    22,321 
Software   3,497    3,497 
Leasehold improvements   —      —   
Equipment   17,623    16,763 
           
Total property and equipment at cost   73,272    68,231 
           
Less: accumulated depreciation and amortization   (38,026)   (28,264)
           
   $35,246   $39,967 
XML 46 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727
Going Concern
 9 Months Ended
May. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

NOTE 3 - GOING CONCERN

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses from operations over the past several years and anticipates additional losses in fiscal 2015 and prior to achieving breakeven.

 

During the year ended August 31, 2013 we acquired Dotolo Research Corporation and Angels of Mercy, Inc. In December 2013, through Amian Angels, we also acquired the assets of Amian Health Services and changed the company’s name to Amian Angels Inc. In September 2014 we acquired Esteemcare Inc. and Affordable Medical Equipment Solutions Inc. While these acquisitions greatly increase the value of our Company, the combined operations of OCLG are not cash flow positive at this time. Amian and Esteemcare are currently cash flow positive but alone is unable to support all the corporate overhead or needs of our other subsidiary, Dotolo. We anticipate that we will require approximately $1,000,000 to operate through December 31, 2015. Approximately $500,000 will be required to fund corporate overhead including debt servicing with the balance to invest into raw material inventory, manufacturing and new product development at Dotolo Research - as well as beginning business with AMPT. Additional funding will allow us to meet our current sales demands and expenses of Dotolo, Amian Angels and Oncologix, while keeping our public filings current.

 

Our Company is not profitable and we have to rely on debt and equity financings to fund operations. There is no assurance that the business activities of Dotolo will achieve breakeven status by the end of 2015. Significant delays in achieving break-even status could affect the ability to obtain future debt and equity funding. These factors raise substantial doubt about the Company’s ability to continue as a going concern. After auditing our financial statements, our independent auditor issued a going concern opinion and our ability to continue is dependent on our ability to raise additional capital. Currently there is a substantial doubt in the Company’s ability to continue as a going concern.
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727
Leases (Tables)
 9 Months Ended
May. 31, 2015
Leases Tables  
Leases

 

   
2015  $             33,495
2016               126,424
2017               114,808
2018                 42,448
   
   
Totals  $           317,175
XML 48 R40.htm IDEA: XBRL DOCUMENT v3.2.0.727
Summary of Significant Accounting Policies - Goodwill (Details) - USD ($)
 9 Months Ended
May. 31, 2014
May. 31, 2015
Aug. 31, 2014
Goodwill   $ 2,404,389 $ 1,781,779
Discount rate 8.00%    
Angels of Mercy, Inc. [Member]      
Goodwill   $ 564,075  
Fair value exceeds the carrying value of goodwill   39.00%  
Dotolo Research Corporation [Member]      
Goodwill   $ 1,217,704  
Fair value exceeds the carrying value of goodwill   18.00%  
Esteemcare Reporting Unit [Member]      
Goodwill   $ 622,610  
Fair value exceeds the carrying value of goodwill   47.00%  
XML 49 R53.htm IDEA: XBRL DOCUMENT v3.2.0.727
Inventory Financing Agreement - Financing Agreements (Details) - May. 31, 2015 - USD ($)
Total
Line of Credit Facility [Line Items]  
Finance Agreement $ 417,001
Monthly payment 56,428
Wells Fargo (17) [Member]  
Line of Credit Facility [Line Items]  
Finance Agreement 8,331
Monthly payment 4,165
VGM (322) [Member]  
Line of Credit Facility [Line Items]  
Finance Agreement 23,787
Monthly payment 5,947
Wells Fargo (18) [Member]  
Line of Credit Facility [Line Items]  
Finance Agreement 24,694
Monthly payment 6,174
VGM (323) [Member]  
Line of Credit Facility [Line Items]  
Finance Agreement 32,106
Monthly payment 5,351
DLL (61924) [Member]  
Line of Credit Facility [Line Items]  
Finance Agreement 90,781
Monthly payment 11,348
DLL (67910) [Member]  
Line of Credit Facility [Line Items]  
Finance Agreement 31,389
Monthly payment 3,488
VGM (324) [Member]  
Line of Credit Facility [Line Items]  
Finance Agreement 32,512
Monthly payment 3,612
DLL (68936) [Member]  
Line of Credit Facility [Line Items]  
Finance Agreement 76,459
Monthly payment 1,126
Wells Fargo (019) [Member]  
Line of Credit Facility [Line Items]  
Finance Agreement 11,263
Monthly payment 6,951
VGM (325) [Member]  
Line of Credit Facility [Line Items]  
Finance Agreement 85,680
Monthly payment $ 7,140
DLL (61649) [Member]  
Line of Credit Facility [Line Items]  
Finance Agreement  
Monthly payment $ 1,126
XML 50 R72.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity - 2013 Omnibus (Details) - Omnibus [Member] - shares
May. 31, 2015
Aug. 31, 2013
Shares authorized   10,000,000
Shares for future issuance 7,000,000  
XML 51 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727
Consolidated Balance Sheets - USD ($)
May. 31, 2015
Aug. 31, 2014
Current Assets:    
Cash and cash equivalents $ 120,485 $ 17,504
Accounts receivable (net of allowance of $71,000 and $9,000) 1,037,009 213,399
Inventory 137,436 31,271
Prepaid expenses and other current assets 15,911 9,307
Prepaid commissions and finders' fees 3,974 3,152
Total current assets 1,314,815 274,633
Property and equipment (net of accumulated depreciation of $38,026 and $28,264) 35,246 39,967
Deposits and other assets 77,678 14,582
Goodwill 2,404,389 1,781,779
Patents, registrations (net of amortization of $102,576 and $97,983) 19,903 24,497
Total assets 3,852,031 2,135,458
Current liabilities:    
Convertible notes payable (net of discount of $405,429 and $99,491) 477,596 436,308
Notes payable (net of discount of $2,091 and $18,596) $ 2,377,667 946,104
Notes payable - related parties   $ 51,600
Inventory finance agreements $ 417,000  
Accounts payable and other accrued expenses 1,087,319 $ 732,934
Accrued interest payable $ 208,736 148,681
Accrued interest payable - related parties   6,342
Current portion of long term debt $ 96,644 82,532
Total current liabilities 4,664,962 2,404,501
Long-term liabilities:    
Notes payable (net of current portion) $ 376,037 $ 395,675
Convertible notes payable    
Total long-term liabilities $ 376,037 $ 395,675
Total liabilities 5,040,999 2,800,176
Stockholders' Deficit:    
Common stock, par value $.001 per share; 750,000,000 shares authorized;; 750,000,000 shares authorized; 276,746,130 and 134,600,152 shares issued and outstanding at May 31, 2015 and August 31, 2014, respectively 276,746 134,600
Additional paid-in capital 48,398,569 47,565,869
Accumulated deficit prior to reentering development stage (49,864,491) (48,370,395)
Common stock subscribed (0 and 1,058,201 shares issuable, respectively at February 28, 2015 and August 31, 2014)   5,000
Total stockholders' deficit (1,188,968) (664,718)
Total liabilities and stockholders' deficit 3,852,031 2,135,458
Series A Preferred Stock [Member]    
Stockholders' Deficit:    
Preferred stock 129 129
Series D Preferred Stock [Member]    
Stockholders' Deficit:    
Preferred stock $ 79 $ 79
ZIP 52 0001471242-15-000066-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001471242-15-000066-xbrl.zip M4$L#!!0````(`/&("D>0>D-H!(\F&(?_./GJ3M#YR6\H0,2-0_*/ MD]]=/TD_":^QC\C)13AY\5&,Z!>SDLY/C`^V>]+K,;SV=Q1X(?G^[6;YVN'('QU?X7DK^C#*&1[W4.8D!%:OBL<^4__K5UJBFI.W'==_5-5 M?KH?WL94B4LWI@^DW]`'E#[]1U4>5>MP&(W2Z M^)6/@[^*?J&+,O2S].L?;K1ZO'R!]F' MS;/9E[E'<>&CUNQ1O'C40VO/16CTX2E\/:-?T.=5HZ>H/5U=/$[0>*O(UAG] M=O$@CD)#4^U=^LV>6/P@BTJ_MRIS^2@*8AR_+S]=?HZ]])LQIBYL*AG*V6P!X<7-_YQ^7JGV\6S]QZOB MS@K+FY?V0NT=>@523-M8_'FEP+*(^3?K[\^]:?'AW![;C71-PLFL,3FT&N-P M5I\F+>_/.;5_7B M7GP\PO%,UA,/TR=G/=YA3PU*M;OZF>"7]'U?WA\I98,W')U^ M7CR\W0P?SPI+S$I[5BQN-39H_9,X[:@^KVIN6<+RNXV?T2YU\:-Y%:^*]W(_ M.3I2:6R0Q(@L#2XA3UML`#"5A4EFB`">FCS10SB.?[D$W02TXG#TU_U+3"M##)!FNMP$'GI#WF-X$T4)'=NG.,7OLW_S M+&T8H&EN,F'T&@#UAM%;`!"I[A^>J3/XXD;(2ST$_=9-=9M^&@V2^#DD^&_D M?:=LD$RUIRXG^O)^]8;("$=H2$>7Z!OU)VM.1P9&9KV1HJ?#Y5EO-/N[J%/*&2_T/JHS5KH^[E>..>Z?&2GM1[6>9G?62`L%CNK5*:UZ3]/^?*`O M0='ED*`Q(@1Y4S$DRT!JL6_(IS&.ESK8=W$Y2%=_ MSO=J+C@()H#`/PA-=@MS$"[#6!.\QEFLAZ,#,\ M6')!IZZPI-5A2>[`9[L#$]]X*DK/-E5>.HWP--LK6_& MTV+%=KD<\XS1^.H-C9(8OZ+[\1B/$!$#ID<>(TM]?^&Y$M9^J5I054JB]J+-#J^6!/G#`-P?&\1/LMO@#(7/(F#G@ M+4NL/7\`'/#$09/^8+X@=!7%=*`WFFZS&8E1_5^2"`4JD2-.93N<(`GR40,>`HV`^?T M:WN:N5*PVRX>[IO8>&3U`SP8\>AR[,B?G?.S>AVS;5-37BS'[\#"/&<+\YV, MB``CWC#BSV6S>B/(\^`HSZ.[W@@PX@@C_KS1WIWBZ?8Y50QH6+:'9]05?#VP MJ`."ZF^O^CGO;XJWF]_B@+KA"X(\'`\&HH-2J&V[B2)'3QC2>VIZKEYWIQ;F M"AS92)!ER>5Z75/7%Q2'48,)=H-_(=>/GZE-7FD0*LAA"[MSJ[:J+7A$13V- MMMJR0?]6E8ZYS;7!RE2=7GTO-U(UMN/$F1*`$JES\W8/(:3 MO(2$%BD8/HLXX&'VNFC]#,ZZ0AT>N?XE2(]ZY03)V1W%"J:1W`J@XAZI3G@I";HY"[N[X(L"&%VSX\S9K6^G^ATL(]=O7 M(1EXWC2!CX[B,O>I"^^?&`T`4V$U@R6\KV(T`(!5,UBZ[&#I`%;%N&HR"8-I M?N,-#3/H9X3&&S&AE2!\+[A?=XBLZL-)^+YOO^Z`4TF9G?:2*D"1S62GE_/O)_@X$G; M-6^/@$7M'-FCIQMQ=2"`1P(6M7/DP(>6H2E``)<$S&NGD0P4((!/`AJ/]X`` MK@AH(@M-!Q_`,0%''?/M..,":."&!LY/M]B:S)H[,S$:NN_I-?%BP%-T`.`J MMW&'XH)'$^L09`UP'S\C,O];D`FE71CL45UP$-;3G`$$#D%H*/=Y_="CCBVT M<'Y*$-/YW)IFV.*VM*(SFE<:B]_`&$_I!@@@/:"L934#-^)2ZFD$4H3CZ\G[G_E](I@L7O.5%-[QXN4;#91B'?O@- M1<@EH^?%*0/4MC)SL<@EHWAQ&I`8+:K$"6>%^D.+JW8..,#$&TS\;>K?>0HG`,0!0%RXK>:2.E"C3I[=-S&#IFL%H\8_;\B6.%4TY/,SMFVWSHD2IP_*EUS5C` MV$&#;78?FE$:QJR=CYK4N!@-SB=&Q`CFYLKYG_TK5'\CW MHVN7/(6J(+LD;G&`[L<7!'DXOG9'V*?"9T\+WE`8%J089HZ!$XF=Q.^_W>F: M($/\/=6>514<`X-C`#8D:@`W)G($A3X4;X`S*.0-@0QYG<'E[:ZF.)%6>5Q8<`LO,`/`A MIU.P'561I]8SVH);8'0+0(B4CD&U#$%R"%AZ@Z6RX!98HP7@0RZGL+EX;HI1 M_R72!4QP$@>DEP`OX#0L0;8_E8``]LD=XC2`%W`:EB"19@D(8#ARB-,`7L!I MV(),6K%#8,/4Y@%.`W@!IZ'9HF=!;]48G$8EIP&\@-/H2P=!'YS&`4X#>!'4 M:=@9I]'OY-V5N09F5VE@_0:.Q^UG[.QTW\[]*G9V&K`S;3-ZIA/4>[JRW$-Z M\8S1^.H-C9(8OZ+[\1B/$!'#KSWBV*<:W00>?L5>XOKY_:,[-&^U/YS75NG^ M4,_<]-7TY4Q"7L2ZA1]^KEOE_!JF8N^3Q6:(2!0&KG_A$C0_GE20FS=8KN'9 MKGTG_4\3MW7J6_P/@,0A2$85D%KV2/.KL2Y1:L0[-TC&[BA."`Z>Y,%IGPW` M.Y7T3@`5YU!UV%/!)88<7&(HBH<"F'B#J5.>:3FG%)*7D-`BI0!H.9^4UQI\ M4,DYI-EJ0VKZ^S%MB!,<12%Y3Q<>!%EG>21N$-&HAW[X^/Z"-A9:=J@.,TNU MP23((?U58.+A0@=N8=J;*5!D44$.XJD"$QS:5+=G`IC`,]7FF03)@JT"$Z1/ MU^V9`";P3+5Y)D&V#U>!"?:=U^V9`";P3+5Y)DM>F"P.8!++,P%,X)EJ\TR" MG)Y0!28X=J-NSP0P@6>JS3,):3,)@>O?;#;4M M_8Q0(\>$FE^"]91]NH-O*NV;MII4@BR4?;J#=ZH/)PGR4/;I#CB5W6;I>3BU MM.M3X[[0JG#3_Q+>,>U4&R"J!2+AW=%.M0&BDA!=X\"C`YEK)'YR[H:J`$ME M6(3W,ANJ`BR581%^_+ZA*L!2&1;A4]0V5`58&/>E=?E,*6XW.W4Z&KKO+OU;TU1%C)IG/6][ M4W/!02C,$P,0^`+!X,DC")(P6`&$EO(%>?4(``)XA-0T4L]W^ M%#-/(/2EC1'Z$"-DS>%(.Z'DM#^AQ!4(TN8C..WG(W`%@K2C!@=ES2#NA MY,"$4L8Q<@2!KC+#4'$"8F4/6&&&I.8`P,X>L,XM+S04'P>HI M_>X=49,QTER!XQB)]6("V!'$P8X@SD^+.(`EV$L"+-7'TNH@6GFI6KVWMJ(AL`7]5'M,`4'TPU-@:6%BW[.=Z&V@K?PG14N^A)RH;8R5[CHYVT5:BMSA8N^ZZ-0 M6[DJ/$V.6>RK&XA^G5>1LH)7MP'5S4MUMQ"A9RQP]?`H>B)(H;:"M^_M%:YI MFN@1>J&V@E?X=H<.%2Z92ZKM M3ZVVWL*APB5KX5)-K>KM3ZVVWL*APN5JX:;H*5LX5+A0+;SL,6^B!W!L85%RGS0C$#2=C`3%EF(*T7F&%AYB(,HL1/$Y#%P.4A^1&AGPE]P=4K M_>?Q_05EF%G7%G`IB=.-K*D3-UE[ M?J4$;MHV_>U7"@YQXY!L`EC"!NLR%KTU4^@E"F@L$.PK=K]=ULLM>O'B^YP5 M&`SZ;^1NNH=%\4E,SO]=N:Z&B(QHZ]D#Q`O]LW(1EVB$)ZZ_M8A97F^R\@0L M97@(GU]-6_U%.)F$P4,?Q*EK]W#P=#)O;-_0.-M9VSU%/SU)7S?] M8L[JB3<3-/IT>O/U^O2S;BBJ1EVG]?&,K;2%;`N/."3HQ<7>U=L+]95H$'CW M\3,B@RA"<721$$+M7B0@]4A]ZEPR`J9.(2,=C<8<7;$_GI4HJ%[9EHFA-*(. M`]>_H)9X0.05CU`T[\W6I'^+\'F`_4^GM']`IR=G-A&2EY"Z:E0L!1?\KV>XEI%9U1S+ MY*#1SJN?#H*]9!1'#[.8B@,@F23*F52;>N?6,-A=W::CJ@<)5TM/H=F&I>LK M.6HIL;R_SB1C'2B8[M0FV"&] M@>K8NEVWA:H(HCNFW3\N0^6=I*HHRG'Q*2^3H^NF4EMK8W+'NFKT55:G0S6B M@_?X?>B[04R=]=7/!+^DNGU%E3VQ[CA6+FC97D1-XASJIE6MWY#`]?APU=+R M76YC%C[(CZIVW]%;L?-A8IN:VC#/57RRW33#580T=;--;FL:"]3!8OF^1-?Z MS;:>W=*86GY,PB[.K$>J'.BKNFF8&]%'Z4(.],%]55%MI[H4]?0$?4=S=*LV M6QSF)W5%M\V-R*.R20X41K5,M09*JG@Y3:&-XW`[5.H%='TS^#N4AWIB\4-! MJ""%:3F:I1TLR&Y'V#967CF3&;;Z!X;-DL;M/F2 MN<\BL\X3&\O,+6VYEV&GO14^A5^>D=<9AYV1G<7P7'7J*]EMBP5XBS93#F5G ML7N_SR4S#DOTRE4GE)&=I:WJ&I^RLW2DFLUE6W68@BTN>==5%MZY"F`RLK,P MPV5;'7@>3K?=N#YC+W60%H/1*$R">%EXX-%/2(*\6^S^P#Z5!!V:.&/KFJ-G M9RO9BZQ96J;E;:5OZZI3B[@W5`*"HG@_&BQV5(V^U<],`Q:_O;H,+-;14NM8 M966X3-!C^`WY;HR\H4MJ8,K2CB)GXA5;[[*T>':#QCNZ M=)E-,/M$V[,8;5CY&##_WBKE,H4#MF4;%GNYJ]AVZ&+O)KAP7W#L^I77*FW3 M,OM6-E@K+N``.9AZRK[N],T*%,TZOIKYOI5U MNVJ%\&W+EE8:)"G9H=$>>6H0OUIXQXWXU<*_+>+;M+,UVC=^5Z37NXU.L?@5 MC6\>9/Q,?#MTR3UYB%//-@UUAXA,?\[E$'2K5ILV:DNHFBY$`[S<:,JJGMD&A6 MS`'2,-MG-I)4]5WV892&S9?78R`V7U&FAZS'5`5R+:[C*@ZPOD=HG/BW>(SN MW#<\229J3D:&.ZJN$SINBQ.2KI!:HN'#3O M*;4::5D-ZR22+BTTK#4-5\O,(X+21UU_WM7-`J8X)OA'$JY@TFQ< M7U;Q@P9(EF'JN57Z@T3GPA*'#'1S(2__QE@[\[>^<7/GL-AO"=ZPV#B>.!,0 MS_,%D*]S/2>[G:=ZIZ= MV/N-LN4J[K&A!G!UU_[ZFP)L"PQ8@'BQ=V(C=MPNC)Y,I5*9J50F)A;"J?X[ MB:P/.F3GK"PKHCFVSE96(QZ7>DZ\.>T"Q(XMWV^C7SU7@:.M$0N7!$LJQE2' M5-JSK/(HI3#&C[YW0K;DM@/SPCBJ/PL"L!OB!?[^[?#(O?,6%[@%TV(Y?^$/ MBFYK4L=2*I3,028OD%;&R-0SZ?'*@8^",W\PY?C&>2PML.'PW29R7QFW1O_- M.93+2_Z#0Z5'$`HXA)&I6:0'!L7[8?S3Q]-O?SS]]M^8^_0,6^@,=E+GB3VP MC>/R1`W86Z.`%\YPUCP+4ZK@1)7*WE4Y/MI&KWB1I*&H.@>NGB]#LX;?(7DJ ML0OSIR-%@0P-EBA*S773 MLCMC;H0B0T*2"\0/CAQ0UXF"G*^2;[^PQ3:($XB2@Z4[/[AVPF=4L0&Y?`&H5]:8>D:L71= M+)!_,0R0"Y[N?8F+HS^W*Y303RZ6_KAOXVGKX6+EWY*BW[A,!2B?EHL5P*BOSTX)1!T0G;5+;,&) M5NJJAXE36GW?MD7MVJ6<*=*Y33@UP-`=*MSVLC(4C"Y$<1]8O/.#&W_[&*VV MZUVIL4,DLFUWVVR7A#I#*LV))M7I(+YJ!L=J>=':6"5AY4 M&<6'S64(>R-*HM1-&5&6=L7[(O1/5?N,TA%.5?NTZX&GJO8UD]ZGJBK+02U1 M=::J,N.Z.X7RU@F44A&)TN/8EQ6>7K6Z_L\669^*F;Y2)RF3KA1=!:0HWIYV4P$4: MCW1V@_],4"6DF9.`7MG;`"[%5"S?US5W4[=VYCTQ`/F)!8NW#]Y" M`J=!CE1S3(2P=2;D2/:N/0]JI#IJVOI9*(*:O38I,>A9+*&: M[2!-A,Z,*JD&G;K84>8/PR-^A#T@D]5/`DRO!>JJ^7HT$TK("JD(19WDXM:C8E8WM-`E6K&,K"Z@6%>6- M.I7,0]IPW[?,6[S-5\H\GY_*LVO+A^L)9K'+\Q.R2LVGD4'>K<>?<'E=L)%!)GLN MZZ7&WL@@[RRI;/VH,2,V]W)1;E&/#+*U9W*IH2&/^"A#:QXDJ7-QIM9]6BZ\ M*A:5ODE%9?8XE:P>,G7T=%!I?E!ZE#?-&.7\C(N>&MTY:\I96<]U+7]&6`VH M/?QFRV0T\)NMBM'`;[8(>H1?GJZK5NZQK5%<#;PX7;<>:+72WA-HI3)N)@G2 MPS"Z;\S73O@\\Y;\/[>_;]U79PTF4SB+KIT@>'.]IZI\^I.=S73;($+=&:FQ ME`&4ZBIL$O%RQ2``=R;O?;.>O[:N#\;BQ@TV=!):-7O,:@ M4]&R7?-@9-3LYYF5(RQVU!V&_4UP8VSB(970R8:/R**Z-;A(M.ZYD+'[QK`Z MZ].`@8BA9?R4ZC#$2%@CA+ONH7'%P(B%ARZB;9I>(UT7C[XK!U&%J.7.V"]F M-;LYUG53W`9[Y7/=;>]4&^*V/!P@7`_>+MS/3=\9LN??7\9-M7S.L*F$.,L?GEK"/65Y"EQ MDH?06$^K@Z#2:^IXPE0Z1CW)EB)E69]'O0\LXWWTNZ!5[A!MA;2)CT,1)9TO MIE-95888DNIJ0>^$->529]SA7WYSU^OF,48+F::P.>Y>V&"@EK8YH88FIKPU M0:+&2U"!1.4FA##,D1@*5L":X0$IWE!D:.]QJ,9-0SM8!C=^Y*_]!Q8R)U@\ M[XAW?:_OJ>Y@&ZLO\@UZ$//*Y9J2*:F.3AB:H5LME7&.Z-LP8FRS``7XP&#: M>2?U7P&!0JK%VF&YWAIK)PS=E$T]J]M0D7E6?3NIN/+\$$W MJ::?8$-^_/?;T/58R%N%/[I>K)+W[=N MP);\K?"UNW:Y],+?MANV3"/:0C2[EHJ0VZ$0-@Q!276+?W3OH MN89):5@++8/-\84'T=K]VXJ9)?-B7HQ1:-7*F9XZ3>J%BK*QK)G0TY>"/BU/-!"Q?ON!,V?7!6[*5"V2RC^XK M_V?D>$_N_K<="%K>MNZ1FG$SLN'N2G1BC(*;\6ZN*E\YP=? MP(:9K^+,4!4,2RL1G1RK^N80+.J`.2&;+1;@X"UWA:WKWRV4J@ECT]+;6B5` M>D(O=?M7LRN:D@R&OGYI!$RMBI+M8R!$M@"?H9=>3!L+(5*5WI!MEQ9WE"0D MO747PN*/77()S*=SMW3;0&*!F_P@34`0`025"0>9%M+50J`"!%,F]H*Y5:,6 M@RE@L&2.LPQB*9X)2X!@RV7MB_DOIR!;O_!7A#_#*Z+P@Y?Y/\L6;O+;._?(K M,&E4*,-:](R8C?4YJ/V[LS")..@[%R861-@280#`\,IX-+PN/\F_,S\-SD^L MJ>+G*,3SSG&3MEIQ`''WJA>VX*4K_#6`6(,)P'NB21@QF07[R?7:5AH>GJ,K[.CE'IU)%.H1VBME-H#VXX?_*`:3:CDHPJ62GE8RD*=GQ*347*`=D;);`#?NJ[MDWK(3*6NS,D\!&TQE M?&7!IAVG?KK'_Y33N7RLSK%E!/*G>]("6[[8OK/A^9'_XK,9+DZ5_#^D$A\$B-NV;@+S\M"$` M:ZTFX(&],F_+"J/>!6OPQ&F934U3X.;NY74&K3@M:GK?FY@Z,OD!3JN*WS-BJ[1F$ M;6)B5]7$%KUH6-]`)ZH]A#9PFR]0M90A/L[$?S="A8=QD[&H_R2*9T&'E#/P< M^&$(/%RYA2G2=>UCBFU;#!T)KZ\YF\>F1%1O&AJ';F:H9C;FBWB:FE.I8 MU8SU90XWYU*[*M4Y:U@MK_J1[@[MX/HK^M2-"K"O^I',^OL<(1B$H>,UK;06 M36T>G3A@H]D"+(WI5V_V(F08"'6U"[4-DB`[4]*L"[[UK&^[,G:G.6NW2UXU MJ"BN$VHHFK-P&/.IG9ZAKX<(FK%%)W<,\%CCKF;><+3>\5F$4Q-F;//7" MD[KQ(J$);3NC":N'5("PA6U\=,"5J9[6!W+%MK6.S$QERNYI4&^#$XWJ8G_& M0>>AE<8FEI$I$3?D9+0B!%L8XZ%GI,F:)J9M](N\A4>1]9(IT<4>BX/HT6JA M,*E-^M;TZF/WV*#B7?4Q+%(U]HT2_IZHP63:(`1],J^+1`J##+W.VGIXE%JT MUQU3H;>5*PI@ZKW*4U?.FI%U:T%$9/CE][AIZJ4=?/#JS>U<.8#K5V6L=UB3DPS]L%$`VL#\SYL\#? MR_*K M6O'PQ*1JMJ9UJ=G5^U)3"]E=KF#U/M34TDRKPZ7\T19UN19VE*V),.H3= MA:_@`BB*5Y\],S;4U@XJ+N7*\UN#JWX-!IM4CN'JQ<80U M0OI"5SM1G!)LU@07=V.:KU9@``3A%V?M!&^[Q@*U'<1GEZWVK>+2=TI=\M4. MC:&*H2A$V[@9N$5JH;S9LJ_^#)Y;N[#)IOUVI3N(I"BOBRL"8HRL8L3N$E[K M^]%4TZ;:$9\%"HKA]4B!+M5_R]2X+SP6Q+/E,FZ;YJQECLEM?M&T%73<*[.I M72D\M5A-]/$@+UF8N;Q:JU*J<7[KX#;M];YESO6N2\ZAQ&3:.R*]KYZ1@%>%&^##DK#RLF MY!HD[PTN*B'Z^`LD$5`_SH>FR^N@X86$6SF4RK46!]>>_:3K%* M2B\>C)D`4*I9*QG)=$N)IFG0TM:RG6+E+O0SZ'G>4G,V.]Y(B]+TLG7:!@,K M8ZM3TQA("`1%.IO94HE@C>55=&)2)T3M0CK`*AA*#9KZ?:6I9>.>D15Z%T7( M".H?&96:3%TG8K9M<; ML#AE5J>!J$%IS]#D;&E,#+'EM02R75?L^2YV[SWQ&HIU^PY([@5&=H\J&[PC MD/7M*@,3O:"9>T]XL^:*S')&).M-#0I8:I7;E(P&\'$TI""NKPTIP5F\,ALV M&!*B(S@H7IE-W-`&51'U/03+S%39[QEO-F0OXR:0006X_FZ+-6)J#23X9-/9 M4*[K+-OW@)?NJ2MQ6OX%WLC"V7W`5@SVY67<<+>(&^4=BPUA%OLE=GRLSN7` M6!?+:I!Y-V(?W5<>:H]@2'X&.0M#%H6SQ6*[V:X=_J:RBTC9WGW5X673M@33 MI_[`W4"7RM/1P&&D*K%71J5AHD`-O3CKACE&AZP-=)2U`09H:5RO#$;MHZ4Z MO5*+3\`Q-HXW]_*NP7HN_'<2W2`DD6.+NX(DZQQ(HL=.6@5)=8[[AB/IV&H_ M^UFJM9;.@Z1CT_3<23*/_=NS)ZF6>C@+DJQ+(ZDR"[2<-'H&RKPR8[&<-.,, MK(G*%,'+$,A#SF9=(L]J_LSCJ-MES!^0=JFB"=O`I=GR!]+L2[-#]J3IZ#A` M>#&DU=GASHRT"Q;(BU7^.JXED)UOV4DLMEF.(B4@^P_MLZ#P.F)30:5,#628^3S(+`I(E M9%*,$++.=#8+PE]E4DLIM37[+*>STG\OH9?HEJYIYKF36W%AL>P.E8&HF2VJ M>X:$'WN,I7)M:2ASD'^.]!:XD65:&705MNM8@.,CM\A)*2/7J'L_["2YAT=G MGK?EU7/2\\WTO%,B@5(@C+_Q@<4'O?=.$+U)I4[1\H3Z8DP*Z3AY0#\0-"H! MS3#-3%?N)OCN`W_!V#*NF\*SL1IDI,ID3.8S4O.CJH95/P?5TOI%V"#K%-F9 M9F8]0Y3*,S6H28;CHDQF*;4,S1X,H4PNJ8$U:S@>RF2/(JJ;8J'%SB'6OT&3 MOT%^$F)6>?[J.4F>$EO>N.&"W^:Z#]C&W6[R980D+F(4U'@H6CI6WFR3A-,C M)5+7JHB=]ZM&2(C,-0K3-$IWU]$0(B-;!!$T=D(*BB04I1PBLS11KQ8E)_-+ MR])+9XL%6_.:7]E?\N3HFF5U#\ZL^"(9P\E;M@LB@+W<1MQB?_J7SOK=9JL//.6NT(>-;G"?P:_NO,#67&2K;G2 M@H;QLD/:TT;Y2BP7R0[I.,M1*:+QLJ,R`A._GM],^."],O@NN(87!,ZBX%KE M^0M&,T[(QY0[Y$3\R\>\DD[?MXV>_8!O\[]Z2Q;$1"1OO%\[AXL?\<6.!Z[4 MTV_X^.G(57=!4)'EHA>%8\IOLF@HOS\/1,O8^5IX1>8/OJK@Z_$=F#_XJH*O M>(I->;Z:?_!57EZU/^2U$_TJR=>KS`GQ'VPM9RNI*:YBQ'E,?+U)+^N6>,*_ MN='S!V_IOKK+K;/.0P2O@I\K.E[NLG#69-I9G/.-ZSUNCUO,5)O9F=,W-5A[ MY`&O#P[;A;7C06IO\VP_AW=_YY,JRQ#SN";JV?$#9`+A*=)5\(.B"^"'P?F! M-17\.*KT>'[\ M<)E,00D+Y%XPC@O>W'!PF9(0-J6&46OP^X"]..XR[9G2DG8=B7V6"E_==OR= MA,FWSSO5:4P:0>.6@\H0Y'A0M[-=5YP8#$>^!DZ==F]=RFJ;-G2Z9=D]K2&5 M_?I:RD[]-H<6Z7CVJF?)%MO72HV?/2R_84D[)=B^8PW?51FFX_/?S%4S[Q@U#/W@KOL%4E(%`\A?A MZ^(=%^F,:)5J#I`M"GJVM,K48[P0&2ZXR'6Y MM,IDA.F5Y?C/AU:I-+[*5AGG0VN#^JGG2FM!]:J+E>&"LE8%N7B706M!O:NZ MG8P&I;4B9ZRE?8RU_)WWLZ99QCZV33S2:6[D$LB8CB-668VF67K_.99QHR^M'F6H=D>+,DN=$TRSB*(S:R&TVS5+_#,PYF%=$LTQ3ETAP,&9I'O%,I*N%3M^?D^=$L MU3L3YLJ"QD5T&R;%7V)SX]F MJ0BO1L__1*:R/FM1R1^;7I+A+=<+<\,*S MW:T*B993W89V21%0)-?LU;0O:J:E8J":GJ]U>]Y$2^42V*B\X,\Y$BT5'CMC M$[20:*E@T1G;H(5$RT6+SM<(+21:QB(;L17:*$0F9X4J\Z3GUQ]__ML]"^(+ M+H>G>*^!^>KV>\2\)5O&SD&W`;&JN[6\=;P\SB$IJRA??8)&;)BD"94[&2@! M)7=YH/"G,FLO5Y^VY$TML!KJL&)-%SNXJ\BAH8[15NHD)JBQ3KI M&&Z+9GY2UTNZX)S,GIV_Y#P6:J!@4FL,JTPN M\P,12L:!5DYNT1@V![ED"ZP1L3S^@&BE4K(URQJ#45/4F599/&(>/;.@IM-P MXQ>4HCZ9`WLTD@HHXN/Q[]//X0V+''==4G8GU]X%VY;HQJ@!6M!1HR50;!%- M-ZR.@8YH@CV@$HJ@([EG3^>/CV;214L,DS:-:L$4+=? MODJ5[]")F"W6-:LPQE+A0,W2]5Y1R4@[I99RQ5`)2DK6+;%`:P^@I!*6D&;2 M_F1=LH\EM0CJ42U(HC(U2OIP(P^H),N^]*E"91MX4ENYLFK=F18172=6KXM0 M"AJ<,5??LD+HTC6VS5T.H#%7G[*`RGBRA';@;5>PH0]4].^3.^+N/0$FAZIH= MNB9U;Q%1@RHW.ROX(0G+MI#9IX5G2-:@,.P^-QXY5*9EUUKA8D>*S[ZWJ*Q5 MK_AD99H7N&(PS2&K/PR:ZB;5=+,NY+8=4WZ.>\+6[/TB$%+6(@GL;ET7(P5J M@8Z"#;O9_]*JMU;NV*0;/BV9^[=;+W*CMP?VY(81?^BSLY&](?:GG^;>PE_[ M3^[WR5>V>)X`M5?_^Z]E;ST>]9KQCL?K#]Z2??\O]B8]+.>-:=O4-L31]K,OSG_)VXZ'_8>_WL*B#-[NW#4+9*^7Y8?+O:5` MNA,^/+`7/XA<[^D+Z(&M_&C_9&%&N@O?=CQJC.8:V/WD!_(KZ@LH'_C=9/_Z M"=R.\=?"=/['_KV35P]*;RX;B$U1N,?RX:;O^FXV2? M?0^V1&%_V3Z&B\!-=&N)\7*R61;))?)4C9%'Q%O!.<'B>09+B[VRM?_"R4C[ MS]2\+ZFNCY5*5'5[2AUG21UX6XFK$R+2EYUJ_#0`0Y4T>U*!:SP3"(#T\:V- M"E2J^ZUU@&T8,2O"-=12+,!2=TRPIX/8NM^W`4T:HT91X#YN(^Y+?O6OA5(% MW"O\PL`I="-7^MZ\A-^&-&QBRQ)J`TYYKQ-M"G*;60;NF&>)%0,:&S MC0]6(SSEKK?<*SP\^>70:SP$(0-Y@Q$6\3/\+[\"\@8S6A"Q1Z9NBJGO[2!U M3V#U1!81:%&LGL"X]L/UV@G!POO-X9YW-`\>>*_WSUNN4.:KPWNON36]?/^6 M/A>F#X9(Y9),,\&5X.J203M]\7Z^V2+3EP[@1M MHSC6,E_=.H$'6VRXJ_^1B)6R&=41U9!&=4')*@'8&]6-IACIE!)=,_2.J1;N M2=P':?]MP=F*0P7+7U]\[Z#**X+2$J(;UP`JN:DABZ`C(J1%TK0(-501$2_A M.\<-_N&LMPRFD[$EK-4@>(/9B[^;KW[V_>4W=[V6"*[/O">VGJ]XLN$;[-%' M1AV(`P^]%A3SX;4RZX#IB(`;/_+7_LZLW%FGP+`:I/";ER,@Y3:,&-LL0`+V M\2.^==8@Q#";$;*3RQLW?/%#9_USX&]?0!Q`5<"/X%L.WO5`*.O%`6JN:BI,^;I->$4=K@Y9OS1+F)6GW)<:`&_82P`<3$XU`.6& M2]&_XG\VG)#AP/7+N?A@$1[QBX]M^N74"3!J.%,@WH[K??3!-O1V6+FQ7_#@ M9P9NP%?GNXI%;A."KP%8,0II8@>*7O M;P5$*DAK(-0$R$?>@_[97R\_;%X"_S6.KM1FR2GAK#=(PQ7PR5D\N["UOBF3 M?D1-*OA"Y0.T@R(UO2;%C:#L)E\=4[!-A?57^OY60*18HE.QC*(TD&OGQ8V< MM?NO)']C&X&OZJ^B;V`QMV*,;F3J,9T8104J&2XU0Y6$>-(G&G.$%R=$NWC1 M[F7R0\B0AXWXPF'Q$$+,<6\DSE]E M'\$#6-X[41/-F%N?V!`S)DM>?V32B5G(1R9(.F.V_T.EL2 M0^KJ_G'K(QE@PQ`D66*PH`CUF&DB#0MKCYDFJ7J%"-F6?48TRV+LW8"EX6_.4^Q<31?K=P%O$3,72UQ MP?4I3NA*/N/#\?VSRU:WW]DB/A=(WRA[,5+,I)7`II`>LILG/9VGF`[8(!V/ MU_V7I\,:CHP*<3L5A2]0#7B,=-3)6LE."QF,G%R"B3[5M?:KA;07,YXFX4:Q MOPV_N(ZC4D\,Q)U56?5[Z&F:U>PI8(G3+MFY,I=+68)`$=A=CG\>:X.:6C7` M)E<*XC.VFSC=*TF0%<_>[OQ@EZU]!GO$EQX1$RQUUUL/9#Y7R,U9V/C\V M*JNM@'"[!A_P6(65G5?GCZO;42>6>;IS%NZ:9[`[+_`I>IN].NZ:&R7P^Z^! MLV3W6UXP)JQ<<;7#?\H`R#C`!C(SS&LV^G%27,2`V;LDPP>V!F<:/.H@*DSL MKWN`,4661C(I?:7#M41F"#O5<<>85FF9]9%TGP;??MX&Q]158OX4:03U(7(5 M3&U'`,[4YNQTS71UJT`!*R61Y.:>F%I?O,OKFVIDIMV+4/9T.T/Y4AD"5=UP M>&^:I9?;(@HVV*$Q]7A_11VWVNT-/:F1GF[?*.?J$*@ZO!'4'DG=$7GB3\@S M?U@X]^++"MM4.I-K)RJ\`MYS0LQK.C6F"HQU]VM>50CU#K%MNE23814)C9@M MYB9'Q.4'T74E!ENFD1.8TO%:@^O0E53!J/J[[G"L5.@B]<+:H:990COU*5HJ M-U,ERT^YH:D2U>"2W)-95!N7@ITESO9.K1\E.\G4Y'?!\O43=R/4'KYV&`!L M'_NH(%V;X>MZL!8E%E(UOL0,Y\JC\?N6^080^>&3M+NQ MD!^@/KI>?'[ZP!;^D\?Q?UC"^G=7KK-/W)LMDC?.O.5'^)H?)+@LA+]M-VR9 ME@1*GH2W,/X7G\Q62U/`*:12)G0,Z MP=V;7-T'[,5QEZD:X"D`7"L4["MJF&?1/J2LBJC>.!N/V8G\$=$[[A9_#]P2 M_[!8\(2S&G56ZS)O:A##,LU.V5=.4)?7[1>^XL8 M"B\J"'[8X4&8B-O5BBVBN5=U;1?A0^8H?$::A*5\S!,E`'NG/K;%L;%SW.`S MJ4Z_&8)Z0=Q2P0K@%=Y34J!$R.)+DJ0/(EF2Y7222F3JAEXM]_6`Y"D[52P< M!!&!4)YVBPX8JTJ!P]X7;-GR/O!70(7+8T=WC(77Y?6U90`@@Q`L7!:L'J4J M;:Q5,A@J3@9K.-Y.5W)_-[QS@B"3)MG"Q" MK9*$W:-`:U).PWN*2PJ$#X>RGY]VQ*RT9L\E$8GRR*16[*&W- MGFFYN^TRQ16HH8D%>XH&[@:<9$$+I!&C)C[Q;T+.J;N/:63O>HG;/D/2]63"R]S@/)7MK851&V(D+QLT) M(^T(V\EGVT9J=WZP8NZ^ZM?W%S@78GJ;U#B2[>R:S^,TO4PAN\.?2(%H4^^V)Z MN\W7T#K'KNB";ZZTGZ89@QC$0RNS%E>`LQRT3+M[TZ7NK0W#L&Q4%%D\A2K) M;N)WA@Z)0EM^&777/2#<]WJXY[6%P5',]+SC41SX4>"OU_#([C*TDFM`NF5J M(J>[@3H<0U2YC=.\WWB!C%+LL2*L$8PNEV/J?65$M,R=O$OC6&>EKG)N^J7Q MK;,*6R:RC,M6_DIB$]-\<.+2&*6L[E@^+G)IC*I]S]G"=JZ7\Z7Q0WDL"&%3 MMR^89[T5@1M0"$YH"VDS7[L:D&U9I/=`67S; M&A[U=U%LA5VY3:QECIU*AFH#J!AU4"L^9!H&T89>.&K.B94NB-XA MU8UA&(;5\=I3'T28FAHUNE?3BCUYTZ`T7RFQ/U:W]`H-*U_CLC]^MVR^@@9G M>GV70I17WQNM-0LG6+>W*\OQC8""1"MKA98X^+?PRR?)F:%Q>LN#+-R6ID3"K@G M64B]K]VPI>:F"'6W*W9CB>N8="1\/=FR7]GBV?/7_M/;;J;BA.F:JYN]\K@NX"'Q@-@I4QY`B-3++$$4N_(I0K[::.$+E6'C_=L[Q)ZA?IL*2\( MC1*ZC,`@NXG`\%,C)WR>![R(1/H/H5CK/YSUELU7QW5\"]M/U'6J#)M85#CV M:`RF4ZKJ[H[4I`:R.Z!J5X_VANTK9LR\Y7LG=,/YZCY@(2\&P[_]"A2\7X,< MR9+STY_7T8\ODS!Z6[/_\Z<5_.AO$Z2]1).O[H:%D\_LV^3!WSC>N^2+=Q-> M.&'UXV3C!$^N][>)EOSO"A/7^W'"1YPZ:_<)_O+_0+;=U5OZI>OQ:M%_FTR3 M1__TYZ?H1S[T(__P>?[U=H+^_!](_W$ZF3_\//O\X?_.OGZ8?Y[,/M],;FZ_ M7#]\N(__/;^;?/WE=G(]_W0_^_Q/_H*_/NY>]=>7^!-_2_)_+2E+,#J;EQ__ M`U&MDR%D.*9=[?@UA_T=EK7[?<*7^+L)[/=7$S>,D3B3I?L*-I*[YM\6;..GKFMO[I)-?N'5KE,39G(+"^R%TQ4#^>&73[=_B1^^ MV09QP:&CYR8_W/!G0H`%6K.']8$%QU,'_L"B\FMSYP<3E:GWM1/'MD$3%+X3P@$@()<3Q;. M2XXMB>!ZQ9S(BRX@_.P'(+ZS#2RBA7,U_'H.]&+AQ M`GM>4M,]G/`HQ-7^HOF-+\ZU#].X='D9H73. M([9F+\^^QYT4X>6I*EDSV+M60(RW2)14*A$`CC_.Z]Z`"/%G8>-SXR8$\&_X M#=\[`WCN.?"W3\^Q_+D\&<9CT;O)MV=W\C:R=^WP%1XE.99MU]E&Q\T%W])B6:[.DA,YH4Q%'BID_9/ MF/P==,E.37T5=&NJ\W_8\Q\>W'_^2ZH]`HXK>H9UN`<&;/`%5;&+)`'/W\44 M?(/5!EC\;U[*EW#["*QUG>!-Q#P'S*#(X=L)QN]BMKTKDZ.BS>H=_T/`5C## M48+0@V609=_59"ZP-%$1Z<.)C#EA/+/`6K;V$_T-T^7D>0[2/WD$"_KYC;O& MSLO;Y(?``8IB04N_^LL[T$KK=:,,7>(;MOK.2-?T#O+3HLV%< M;>,*7#&SPVT(#OXRG2@8(;\.8*UNUWRSB?@VD6RRP)]D`YH\@7PYL&P9'_RPJ8*-#2^-XOE?PO/!!@1D M&;\[QK!(TN;@JQ7H/R_6$>'V!>0\I<(-]^,_OA4O!E!:'!C,:H(WW>\F?#6` M]N)ZYK`:%DEC.B#AS>=J-4J$=<,<+S6*GMGAZ8*M$Y2_D]0&BQ]_[SO!DD.] M`16P`!?(^,T&II,5XTLD2%O3D;AOP)S=^`'8>L//%"?8S MG0SIK-]E&,"9'H!1QEX3,#ZWSOZ7K;WC&PDHT"5[C*XFPGXXHIUQ3%A@Z7UR M`MB'$O7)%YZ@]A-E!Z829[U_*+P'\/Q$#]SX$0C!Y`'6?/P:411^."BFY+&, M-G+BI?3`GF`?!H4%AM_.#'^7UYR"K1XD.Q/W&C!)EW>R-QXL4S[_'/#SVS+P MIUQ(83^?N`$8(ND.\^A_8]R<92!H"=9DS5]5TO/(GAQOYZSL+-?8D+'L6.Y# M7B9V`I;J\ANW'/E7J?1RTW?OG\2*-`FT@-`^.B';2["M:?^Y_Q-LES[0N83/ M,(F+V(1*["5N0L08^'?"?A@C$NSB25IZD^^D.V.<&]9@\F_5;A+OO5LG-R_W\K5SNL>PD MXZ"UP;Y>QEOT;\DD''Z1K@*^^8"L\W9(.P.3VSB[%;.75EB"C#/F8)<^)OH5 M?'08&B3-_W:T/&)V)Q8IAQMN%V`7AZLM%U7&Q30Q]/ACXA:0NK&)6Q8WAHHU MO;_AK8UV&_!DS1P@[0^W*J^P9]LG>.A@*7U+_=:=K5ZJK&=@$Z]C\?X$/LM; MUG;G:GHV_R3HZ*O=#_81!<_WIND\OCO$0O@)&+A=$=B`SB[&<7\]^\O>40*: MMR_\,[<?"FNK/#_N M+[=7(HE[OGL_Q_<4.!L`R@+!QP15XX!MZ\1F&??EG^(83FS\Q3*]^?_L_6MS MVTB2,`I_?R*>_U#18<>ZXX4T!'AO[VR$+,L]FK4EK:7N/O-^.0&111';(,#& M1;+FUY_,K"I<2(`W@21(5LRNFR*!JLRLO%565B;GPJV:&0\EE,CTR#T.>@*< M%)1OV).$Y(\DT5$T(:@9!/_*V:E:KC\2,L\#"F4X&:1=@73XIX/6(A!UDY6K MF_651VQH.R!(\H4/%Y^__DQRKG8W^(+:W5Q,'#!.&47:\)\S MI3/25T#LDK!J`'H-Q%D)+$549C-?9IB;TX""DZB%"D3H%P0$!Q3*DD MM`@H1N@3A%G-EHT;J=_/):TP[BA=0="J9R(*XPS9'[8(20O2!#3:]\PXW_E8 M`$P>V]]2%4P@E:OA`J(J=D!'['?!*%N/=IOWR?6)!DVHLA>`FP9Y!.^[!H222*7\I%S+XEP^>P) ME7WF../5@Y_P"(+M7XW43*6)6*-P8EKH;F8L]X6*4*F0XUWV;"<;?R2-E[=U MW^X>,J8.5V7&$YT]=A&\4'1>DYZWH'<-8C5PIB#S&7>+V'I`+))N=LCS=D+T MQVV<7\:O:%.Q'".9Z7*:?F]B_G'`[.!G+U1N_A?P0<'%-!"=X/!>*`!`5M'O01HBROC@P2WC*T/ M!M29+S4FJ6S_TP;3G>]F3V-O@"03PWS(ZD[H?&2Q8!"N*#A'(<<;H MAR[G()^/`&E,TBPBE4XH=M>,P!:.^F`.X+\(B@MCP)`'U[=I98?KH4KXX)_.$K_C:Q M7RGZ`TL/UH`.X_P?KT_<.R_1'/.=EU?/=)EK0Y*&FRX&`VS+3/?FP74"=5]) M?LPCN(AOT67M;S_TNKDI*"Y,^> MPMH8-26[#1!@B!5_`!LUP9T?QY@G6E=YP`JZ;`0[1PP.)^!;8FP9E!(>7;JORAKRJ4"8R/>;1Y:1$G?DKIZ23S(G\+^=WY^S M7R\N[M)S>-#2=-:!4V4.(U/:!9Q*R;O4Y[M=CHG(8NW+- MP?7!947@7J5=AOD"80I3@,%L):"R&3`Q74(P3#)P(,X#U.HY%#$7)\3/=""C MGL15M1G&M.F\Z83]\KOOUS>7UW=?KTC57=[>W(/:_[Q;75<[O8;';;%GQ\)E M1;T!EGV(2DHX<$7BIC(QHG'`A1OM851K`K".@8LQEX)]`Y=%I$B8(DV*]LE* M:2E=J42L*+DED=?R'0%)XN9GN-F@<\%IPDS4V5BRMY?ZJO=Q?H>_8(-O9+W[ M9!.T:*/#DDV.C(3A^$`^3`("V0(4C M?L.?[:&=9"C"SVIKD@E`(?X9Z"G#%#3@&$]#@+.\W/LX/.BE[($F64:5HYBP M"#G'&#_#8`7J[31ZQ?$PV)-6-3%^@HD1Q*,7;9KWM_LK5&I7]P_7WRX>=NC) MUE*A95,C,-M+*3&17)4J,CP.`!8#7D4_;16OAJWLT2SP20B,4F._AD]"KV;< M$I6S,7!]W*#C@R*-ZXF"&H7OI!F!G*'>5WO/0LV?;E(1)"'A*5!),D+6)\KL MDN5K1%OJP:C\)8)!.2PBF2WK)$5T=NW(S!>\@A+_/8EF5[]1DE]`X<"H&/_A3)M7-E18TKB16\L2?Y5I/M8GHY&IV;"&0`_I.30[`.Y""H7.DV"*;VO`F^@ MRX!?"^^`%7D&1R7$Y?-^O_K]ZN:W*_;]ZO+VUYOKT]YK?!?V`84NX`,?G+Y_ M4[PY"9]&R6$L>_"GSB#G:=]?9KW>3J-]3L,$ M*(3N:[*'S\,CSMXIH"PS1T<^)H_1Z7C@4)H;N;43#LBAT,1V2+F'>(XMDF<8 M^=1)JV*PA4Z(DBCS!H2\4NPZX,./-`DF7_(@HV6DD*'$RH._Q_@5%0GLOYP? M,KU;)6ZC1'VD;^1&0,7B"34;Y?H1G9>00OSG[%)I#D/FD8-E!;`40>0&+ZO_ M<*0AX([Y2V24Z>J4RE?%/_()5;D3[95/#3.9@?4*5-1(BL26C1;6F3S&`6:E MP8()I](&(YCDF:6B@%XJY26(54G%(KE?1(GKF7L`\O!*YAO0DDJC!G(PD\3P MX1^77RY^-F;R(-2YAQPB-0))XD+B3BY,GJ"G,,UXR.(IIN@CF&#$X>]+3#[^ MEL9AV9UKD\=/\"(7(T%$-EV2"_<*6H`N'=-U$9DSA\_>75ZD9H\R[!XQ*YB? MC6UW!$8[#L[Q>I8+\A2!#(XBW'Y^,-L_,Z!&+-U_->`$,],>T_M;0L?Y\A(5 M7A\X+>FT;/:!"%8WZ;1:3<8 MPGR&W]"KX<^HJ68)03:?HH)X50:AQ1F1SIXX8>/)^1][$>DZ,E=17"I2:F-J MHV)2/HPC#K;$Y4Q,H%&!!2/1*?GU+LN-P76_DP>$=_9KAFSBT#+A?Q:G,:ET M`1/:BZ3#Q%?"C4G@<'5WSF;1BX^$&"`X`]=V)BA:_\LITL#0FX0!T`3-)&92I5>)DB6F.I0 MV2NY?4PR4?/7*4AI)):7LM+5!87D$%"7$Q`;25-Z#09?9,G81('OBHTWUQ M23E!9RP"@(+9DSSWY&[`*X\D)23\8LLMLS`*84]]($E5M4T">@$\J`DBQU7I MP;!C1X6E+DY0.K$<39Q(2.=#W;S)D(]D$.<(ALF4,NB@`@@HEP.Y@H^9L82[ M44@_0=H2*HKX-;Z;)$L,Z2:8"Q;@U\QPM.<"QXB<33%`YH)"&OJ1I%3#T0;4 M=5(75:U3'`*$>5>38)G@-3C4!DI7J1>FH#CQ@D,H;M'88#S#J;NBA$ M*12P5P8"F4T9;L\25MQ=3*,P8#*_@+8\7&!E9"Y>=D@S4 M?<'LZM/YD8*3";<4+P"B:0!PXBP+;[^F_.GFV1T(*;<#]([F$IYTLDF>D3&R-GT:O@9PRY M?6C^K,X^@<-?Q?.A#RI0IF@1/^:21Z6?%V]#J5=VV'/A<& M7?DMZ%'A-4V8P!?S*4N5<1N%M?J>PD>SI^X'WA)%D0"(FPTVM%_#7"F;I/Q- M2#$P#)R17D:E'GM)<,KE61*D10?(OO)0*O?,`WYB]\7I&,!4YB^>LWJ%CO8. M"RX/7D85]3XHGB#6?6;9*9*'$8-\)$]%-)*21XP"FS*7UVPA_?M95IC8_^NG M&G(9_PO?F&)6/^A\#YBLWWAOY#<4BN=@.C'1'QDW8#[4P"A.!![DGWB8@\FN MPC/+.B9#VOCC,X+_23;8LV,SK)@3B31I+!02)OYR^B52(-/D[32&\^GR-_@H)_E1=CL)%DU^& MBA1T?1)6'$;F[C-/]@-);!==I4PUJC)I=&:D41T(VS-1$"2P]5[<+D^3^3,O MYIQ;@>`=812G%`<4R!-Q$;E(/".Z;X!G3GG MB'Z>1(PH[)+L]''19'`+/%ZYMZ*-8*+9%#F0PRDV+TX"9G1=6;#JP^\7/Q?/ MM\I4:DU;;42THR;[+&,;$V87.WK!:7EA)+52;"2QX2PT47+''/.Z75\3P4F M_-&(5+D]I/(G*H'@^+WS\FMFP!A%Y0$%3V2/3PJVG`5VFQ1VT=T.%:I,PR#) M;3!YS5-$>Z5@J6T312Y+9DZ25CPNZDDIY1/*>AB%,0&:+*^9%&K"MJ220^4G M5$4K5$_A(.4.$6.]^P#/PI.)'X-U45/RJ6>DY=$>`<4SB//)MQ0Y)$"/>D+MB>"5C3@.;L0407,?!&5PS(( M6]_1(=T\I!M3#?ZV6%*XTWB7.&,1V148Z*+6'JJ[-'JS*N(`? M)`$NM?'A0B4GYXR&BWHTCK1DERPV5#T65SY3G.>;N4+@_(R<(<3!#?L($)G*$Q+E:6D-'.N0E M^T(I%:$\B'/$10]0:0,..SV/^[%0"DF1'(R&+9NC/*]G;EJZ!!/^"32\O+NX M@\\#"@D:[).3_3LY#!":+[UPDEZJ*[AYZ1Q9HM^B>PFW=U??'_Y%P3F,R]UA M,N`QQ8I*I>A22=8Z(`?.DDV7S)`1Y=-!7&%EUR MO*I\YM*E!!Z-_:$X6,%?518IN!DA'\4NEJ<15D3XIN(04:3*"L8-90)0^$O= MV%$$4E#8PZF-B1E8-)W^GN+&4_Y-0__]IP&5$?A)@?KB#*/Q+ZS3?O^1K0[V M(R4KG%$D:1KR7YCZ]%,*'0(6J&F>L5X&J!6%8.1/811[\.=3`&9^2+79@E]8 M\/3XP6JT#*O9,ZQV^^=T.+R*2D,.9R#O6@"YQ/,L$'?36^?M:91^B_="Y9?E M]]I#Y]]<(/^1(<>5%]W[S/;WU)0[`EXIE1;R1\P,_A_,7;Z/A5> M4@=>G.MCW2^*]0W&MJKL)(-I*ELB2>81*.NLK MV?(J$94]HV3.)'5:I"5+-XUG/*_TL+[(\Q(CGH.H<$]<39=AI(BRET0%,U6\ M6<8>D\W58!!/8C?9>`VS7J(89>(GBLLH'C@! MR()H#2%OR:I[!D*L,9CX0G<3J'AP4N8NMSTZ#P#A)1"ARE1,;2IL$[P%*<@/F5O MI.27HOT+^^#\G'*"G;N%/.12^0E]*>.[5-97Y+[1#;19L#$9+`8'X(-3/K(] MQ,*1J@BJTL?`\)*8,N"9I%G:A?R!3V:F1(U%W0-0M9*RE`D%237(@>^)DTB" M;AWP7/XDZD13!7T:.CFK3"Z;#5QB'$%Z<8$S5Y M5"!OQB5!`JJ1FXE@4VKH*^+XG$712TV$"O935[D,YJ+B-/\QD"EM:69JM@5, MDG.0-*-(\\%%Z%O$JD4=+GF$M@QI`#<'K3K%.Y-6.BW(B*.KVC#"5(%E>J0$ M.I&F))/W7M7=BP6O^C@V8^L$/9A&8(=M.C(TX>RH.-&`>3[P,. MOK3R+RI!/@[G5KJ4;;'Z-^#N%"$O26TG#2\,AOT50!W]B0>7\(V'R2W&33H]])I%!K^G&(W#`?2QK5P4^X\!+0 M9@);0K%[>$4<69L*2Z>UAH#[I>Q1%088PRARWY1%D"G,15:![IC/*G744G&8 M=E"RDUNN&.C#CB=)0LE%I*J M/0F(E?I(&3Q5?#&%PE*V$4(F@K0X$'R'%>Q<+!J:N:@0)7T61(7?D4/!RVQE M\73,$PG\_WI[^_F/ZZ]?*?!_^_"/J^_L^N;AXN;7ZT]?KS+^]X%3HE(?_V'F M6JH]]*D<1^']X-^F5-'":ICF6:.7N0]Y[<$S3P[EH&3\_E]]?RC:18#^HA;0 M[(.X5MQL-W[^A3UP45--/9?DJV<45NX"\F]J[NQ%9'5CP<>V02H52M0I"=%7 MHTI)LAN'(T_0J0]5[NK93-DC291\)Z/BC@D9L'!G,:%,4`_+#,OJG70H*=6S MS,BR1>Z!]`*I*+#,W4_BFJCJU,M0VY M]!YGTG+!<8]S===EFDY8;>+WEG;,?ZBRT,HQ*/!P4[935Q[3(@]TZ2,.E?7+ MOJ6.X$;97;*X8HH%0'H-42!,[<5[)A8$.>NTA1V>N72$G;-4X8RAY%24DZQ1 M28PAQI+D97FYENG]RUS9'-$F&!,8U=X&Y,$.:,LWG+58B>HP4K=7>$=T:]9G M3Y)!*2%2OL<:RAK@E%'S* M4C!A;P(AP^(Y`JH8Z3"]X.LE+I*Z$U9;X9\UI6E@2:9I9GQRM?O!:4:86\:9 M\&53<4A"-\+ADUDBRW2&2'Q.63*IBD5=&@4A_5?;%;>X9"ZPN@)@/_OR^J[H M4(H0IO<9)4]F!%9=KA4);NDN*)-DFQ8^58UZK[TYWS[UB^.IHDQ^=K:Z5X3[01T&&B89XD=FT,I0P MSS&)`R1WYWB=`--"L>9EX@0F7A"]FHV3I=8&+XO3I=2\2R5R.2D6/-/H7!$YK\;^CE,\\\@MHF*A4T\C,+=D6@K6P!S#<(H^X?@ M(5=]",RUBS>KDO"KJI@G&_X5L>,?NW6D9C6X[MQ[R@D%!0=3\LE#" M,FXG9"GCI,+K#&=G@RV+V:#9?U\(I6E89M?H-EI%+K[P_7]]HPQI/0JT9>.(BXJ M*X.`$9UO.`E64B!%)'3DFY\EE6@=Y9QFFC1D*Y[/M&-(6R6#RL2"?S`HME#( M5L=;NP3Z.;N/:7>D(D@2.BHPDN3C'/VBR^LCE[??KMC#Q?^SG8+5M>/H[+F2 M"EPK3J)4=G&_&GCOR\7])]IQ=%L-=H:N&#:J>K!_\$P_VZ0.WE/L#).+O5%Q M\>9\+1EYG)86)\-^UC]!2/%W_E?,*15D[H2: M3]`K#%XSM8;"7+&AF6AS$DY6`<29@MNT#RX@]C0.\%0Y+7&HRA?$LERCS"H3 MQ)4/UV'/L_T4LR\7U]_9[Q=??Z.*]5^N;RYN+J\OOK+KF_N'[[]].ZF*-$6! MI+0*4K:(=5*19E:6,$T#A#?@>#47&\P).X>W81,7/N`N?[:3AI#9B(VJ>Y4& MWN056>G'2R605)YCSF8)#ES_B`%)B\J3LC2)GX/]8->Q4W0K%=7LS3 M:O'BNC',P).'Q+E$>FT]0ZIZ"I\L`B'Q.,Q:B,?+IRG+\5*:JNE&`DDX_3^DH8>,$YQ/@*Z.3T/7NC M0/:YQ*]>O)5:'`24)9\E500Y63#$N6.`\D&$T8/WM6!FP*^T&YY/D.*P2$X,X< M8V9P6SR>``EC46D60WB`PX_V/=?]3O9PR6=5TAV,A(;B^*]4;24Y;R(XIW;&:[9* M?FM_T;K&BI+R"\J+OOF57?SZ_>IJ:TYTK9R%A75STOH&PHL&%?\$@I)6GLV< M3U.*$V5H`/N?40Y#FLJ:%.<]9_]#S[V*!%DU?%J\EPKNR&1(2J*PP92*D%`9 M$+8ZVQ':2);P\UD(JM4>9FO'J`KG=#=)S2W+!6=K+*6=E5QW(1$07&FTI>H8 MJ5!6AC34/114,NY&N-SOPD8XGIY(B.KR]H;BL9B0^?GJTU:J,M0*ZP6%3B2; MD%KV*#2K=F=4KPM/L"4'^;:O;.&LW=W8A5G9.NOQZ<7]/';MQ]W<:0:%+&7,%_O1E:XYL(#)M M>PD2@UENPFQ1_2V*Z2CQ4">G-$*VD_-1Z>TT7,"N;R[!Z;G^_8K=?;TX$6:Y M'Z?9B*I\VMR>7)PT42\<:APNW6RYF1.-K.35&JD.U]TURPM:XHVY+;38@J:W MB&0RM:HJF]U$XP1GA5OES-XV>^FJ>-&U?M(5)Y<_7`OM[>W[.[J^\8,OQV M>\/N_W'Q71:U8R*K,"@?\'Y=YBH8-LB@4-NL.Y=$[_)A.NK@ MV6G(R&)R,DDE/E4&DG!:TFLQ&'P:9%J0J=S7](FAX\88,TJ?44"S!,!SED>' M94`7:0)8_9S14.H^3!ZGQU>J:2TO/.)I7"%),AU#_43Z<1[0-I3#*V\DBB`M MJE;,0'K*%BG.OA7FRBU(U% ML$L0\YD*?^*ME\Q8PJM6=S5DA0'AR.9CGJG63@-2](`\Y4WJV\[/%\J&QC/. MLCPG4EO7Y%=P>T:<*A^("=*9G=&9?!"5O-R/W'J2HQ0$P]EU2.FNEFWM]`^1 MMKZ'DG('H:#*($@+W64+V\T6OI-0EM:H^\AD%3:ST5BCZMVJI>T>_2CR)T55 MG@K(G-8T2BLMY8YZ,&99M#[%M9H`1:"$]_>?NC^5CE:ZF?LBF?F!F/F;X.$K MY.':@GJ#TK8`TM4K=M5BU9H;D$*J%PW74<*U3P9.J[N)L4%)JNINVZ1&4EU4 MS4J[.IR;488F08#&]&@P:1T-)L>[)B'BWK=-!V#1:_9;1 MZ'=."66S;1G-?K,RE/?MD)0JH<]X,Y[T$!\N4D.UL`IML_QH^6A,GT;RX)'L MMXVV56X3:^C`K+>Q?\.KQ=,OCHV5Z-@58%MGW+5\T`*D-X=24U!34%/P,"FX M*\>NUO;NZ`RX1NCD$-J+FV6ECT.]YHAK!(\* M,5X[R'!\=%L6@])TVS24I2E71KE&NV/T.N6)%F^AG':BM(G6"!T!0GMVHOZ8 MO7,P?\6@ICI[TUWP*LK;:EE&N]U=UF\0T3UEL)+;6SIET!C=`1(+039ZT0I*_8 M5!-O,^9N@AJR+)RH!RQNX![Y$FB$-$('*/5;R41:+1VRDM4HCY"5A+\:YXWR MO=.*P4$-^=J0FZ<*^5Y,L\X1/!ASH)$\>"375\RU,>DZ65`G:FD*:@IJ"NXA M=%KJUM7:VAV=^=8(G1Q"^W:S3CQ9<*'#K/.V--&J)%IY_$83;<=$FU6[?Z," M&KFOCKI:Y7[G+9IMYI_=3G[LRUT*R^Q)'F+3EYF*N6L7A!6'KH/L MH2L-G2DV^V*+ZKNA/<&.B;+O5%*!=^IC)PS'=EW1T2DIFBO[/&'GQI>TXSEU M#[#AA3/UX#F[%VEZ\P5R9DKM&BQ7R]>8*[&K2NA75K9/B0)M0;2G=;EM7TDV+I%T@4[YQ MU[)GM'5IU2.LZ*C+>,XO^HIQD#>7;%QKL&)XMEU5RAVJU>O3JNWZX"\JO+8*JOZ=EG>_:64.&K0ZDO@K;`R<@C+ M*JV%U^T9[4[+:"P((U<'1UV)8%E&N]'8#A'VEX5_6=;):`[)=1>EVH,\TVH: MK;9EM'I5)4SM&Z..T6HVC?Z"V_3U/)G$KVZG=4S^[!AFMVETV\?#(6:O`^M0 MIQ3!C8L(_B&CL>LX"`>>3]1L&.U>TV@V5[_8JC.R\EJ_B_9VHB0:F7!.9Y+\"B#7?`$VAU=4>#-Q`2?V[0:AK4@ M+K^5B@*S&1Z'G&^P@S0"G9A2)2'OKW[]=G7SP*YOOMQ^_W;Q<'U[XTSL\&&?.1X6#9)7/63Z24A?YIPZJD_17_Z(V?2W[;TR^]&/ M(]F,.^13.\#&]#"8[0W`2C''&_G!1+3DQHO^:6?KL1WA-_S9=F/J)1WPI]BU M`S!LHKTU@7`III%D:W4^ANQR[/`1N_H!1H^LW^UHY`QX0,D8XKB\?;8?\%4$S"A_@"!#7CHQ\&`BS($\*2-:3;4N1FH0>![`RX:93^,.9,@ M,;"Y`=`#X!U3A@RFX3QBQV=XF2G2P>+P(7H+,/\S@`)KY<4C>Q!1$H^!,X2^ M!S\/,"7M;S_LKOOMS?P^?(*I>O^)$3J#RY2GE*NQFRBB\$`W,)$K.ZQ M,)D=#$/VVW1H8Q0.F,>/G\8B70EY$C^D0A1&\)V0Q!=./=A#O)=+"5P^)3P] M')B2H+`!C0CP03D$GAU$N^.6@\BOP_'2M6%J7?8/6)V(=.VQ M?\:@Y*R&:1G$F(EZ)6@*"!BR3S[\AWU0:KO[\ MTBS7'IDZV)>=?07C,63IF.P"]#Z(&&A\=@WBX@0H"3^94M(8`#-#SA9 M&WX9"L4&=C=#/`.@%T1[IR3?((BRYXQS?_YMS@\ M>[+MZ2_WH*$=\&!A`5)->0?C#$"7/("^_@0^[)__]7__#T87_E.]]0G%]W9T M!XXMC$R^]X4W7&TL!!0-P7<^^OM/7P)_@IEM9XW^6<.,?,S7.VNTSYKF3_^U M/1_ST\7]]3V[_0+^X]4]>(Y;VY`=M$T6B@($23`EC&T_$2<9RR`W:2@; MC[:+VQ@6CCD7>PG0J"ZQHY+2C)L)(SH>O,T-T%_AF(U<_R4TZ"W*;9#-:_^# MH5)&'2T2[LG;M8<(/HTC8$'>=X3Y]3V0/1C_7ES<)=^`D0?!@GTN3E7HHDM# M%6;6!/7"Q/X3]@5`!O3)P\17`7T73\0!JS`NMKAF@0#"/'Y`FP@R'6+G34Z* M`8;)?G1</"9>S$7"X3*R`,#`;H9MIE$Y3!VY9K#9AV7%8%3=S=@/B`R MB'H&X/\(4U#9#)CGZ#,1PR0#!Y1.D*R>XY)!`E*2)0"HU9-DKM@H=H7R+E1Z M;U%?LZKP,E&[,`H]_5HG57?W_?KF\OKNZQ7IN\O;F_O;K]>?=ZOP:J?<3BDC1LXCRQ0AH/*30G9KG"O3V@I!A-1"3`N;_ZL1/"'W:6@*C6`%X*)@+K/=M#C$4F/Y]+X`7?)OAG MH,>1[T$-PK+8`7"6EWL?AP?E%*;:1IC')-RI6`1!C0+;"\')(^6=7G7CK@/. MLS2MB05,U%"ATENDJ&:5VF\AOQU=)>IY_VKLM_LKU%]7]P_7WRX>KK82ZCL< MW34-1!A<>F:C7+0DH[-P0P;9<5_#!Z%7,VZ( MO%`:#EP_C`,R^Z*&X!/.7OR.T*A1&OB4>^E")4\BEX`DA#D%2OI`8W$6\%W-+\1[7]Z( M/O+21UY[//)B'X2M_[GT[.L#>0`_9\_`5*@J.0=CV3,P>`,]`OQ:&']69/B+ M`RRKB.:L/'\7FN8['_C@)=1S9_']ZO>KF]^NV/>KR]M?;ZY/>T>4%SZ0_(.2<;%,4/N<.`RZ]MV&NUS&B9`671?D^UZ M'AX"YF6,I1+``24C"!ZT_X(S#P*'SO'(>9UP0`YE)X:-,ITU.H#P0`6_*?-6 MFGS^`RL:?`1!Q%AK(,36'Y`88QHFEGC@X*8'&64C90T%5]:>>(Q?49_`+LOY MH8X=9<3*@4B3I)@F@D&>Q1!Y#8N MJP9QI"'@CC%MLL>X]PIM](L<$5J]4VKDDES[[!'ZW(X(O\SMA:0""%,"U.N, MM$92)#9FM+#.Y#$.0A&,%_ZD#;;0GH**QG5*10$=5.1+N2J9PS1\%/AV2.5% MD@.8H32$[!_<=L46+3EO!#FX&.)95!BIO?0_+K]<_"Q8Z3,:XB@Y:8(YY1"I M+?B''TZ=R'933S)]B8#TR8#F..C11C1C\`/``0`PP9;#WY?P+?N6AES9G6N3 MLT_P(A054XP.:@!5@L"2*M'3U[=WF16C\Z"GH$8?;XV=AV1V"[ MXP#>C)@+\A2!#(XBW&1^,-L_,Z!&+#U_->`$5A'?5_05.DX(,L;DX$MQ#,,H M1Y``R$8=Z-@)81"ANAEX$86)_<.9Q!/\UC1Z5IL@!".,39T:#&$^PV_HU?!G MU%2SA"#33P%`,/T>0HLS(IV3DT$ANG+/;.$C4QM1&Q:1< M&4< MT@5,:'_._N`9EPGW)(&#FEKL>ECT0F=M>.^1#5S;F:!H_2^G>`)#IQ(&0!,D M0E-_(3;)&12N6#Y[`O'V'R88"UC1SG,9R5`OK[7 M)*/]*KU,*"PQU:&R5W+G*$Y1\.!4F!EIGDAI))873ZUA+A\VZ&$BG&)+\"*3 MAF`"3G8.&?`9P7;HCU?V$N`1)8SF#^))<@RB3L25B)/8"L$)N,%\.JU_`HT< M>,3RH*V\`04HH[$3#,]0%J00R;.=*0Q,"\Z^^$&*SEB$^02SBWV/@AG#_J\\ MDI20\(O=MCRN+X0]]8&"U(L6IMX%>%`31([P@N2!-2@L,;/8CZO1Q.&#=#XD M*;+D(QG$.8)A,J6,-ZC80?;P]C$SEG`W"NDG2%M"11&EQG<5.9/3]7/V:V8X MVGJ!8T3.IA@@=4,R41])2C4<[4-=)W51U3K%(4"8=S4)EHD/)@&U@=)5ZH4I M*$[0&&A`4,?:8#S28`$Z:L#'M# MJ>\H/(^*!R,KH,(PJ`"71?_\W9LPV2A"9+Y!G)S(M@0@-;@)RD7!#67O$CTD8QPBN"A.G3-4%7K#ID)O8[!# M?D#^>FHJ$Y(.@`1.=/8"^_2QB#=@(;I$7V6FD\-C<3G6:[Q7(<54D,\R[B9Q ME"`%2H=ZF^(U83P%.>-2-[Z(U9/K.[$%P=2Q.G`2=TJT`B:EY/)K%-1%$8FE MP86Y(TX['%]X0_P/'L@\@^V!L>L7D;B\N/\'N[CYS.C#U?_\=OW[Q=>320S. M1=$P'P+3)W"G3[",G:O&NUZM@:PS` M?6C^K`XZ@=%$\IFP9)BYP5.>*#YX6H5]YB-@2L'4D-%D!OH]QKZN@,D^?;W: M__K7E!>S0>;4:B2F`<,K,\%<&>4E&Q7&C_]+YT2^5,\L<,(_C41G*X:/7J+//.`G/H$X-`.8RGS) M8<'E<;D-A(+11*Q!K/O,LE.4#Z,)^2B?BG;@QCPDUX*"GJ'PV]8/.](#)^HWW1GZSH7@.IA,3_9%Q$>;#$(QB M2.!=_HGG/4G?TYS3,J2@`#XC^)]D@ST[-N,X9^![X'"-8F\8)KZTS#G`R$=$A[E1<&5@1Q!$/,@M#B7MB=1K<5K@3"C& M*9`F8J-R$'C'E&Y,1]$YHI\GT20*R211`%PT&?@";UCNNVB3F&@V10[D<(K; MBU."&5U7%LCZ\/O%S\7SK3*56M-6&Q'MJ,D^R[B'W#LAK8$K4N\:S^S'<32$ M_9V(S*H=05[<$\Y!2L\(FISI-PR@X+FJFUDO.N1X39A<[?D%I>6$DM5)L)+' MA+!1;GB..>?T.A7`ED$+?S0B56[CD<=CI/(*3C@@AO'7E6XF%FU'"^PV*>PT M:*7BOD82QDQ#).+\/=F0^2(2+`5+;:DR5Y+F9DYR6;":.C*24CXBLE42+Z#) M\II)H29L2RHYC*Y3A-)_"@6WH[L?3^BV)T5N^`_A("5.D>,]^\"/LN0Z\FL8 M2E:7K(RI.QB:@9>9*_>4([6[?*&`F%+/R4LB]`,*A_R0)`^'HI(4!$I?L#T1 MT*(!S]F%B#A@0HPA=&:*(,?S](C2AW%@.[WK$4\I/M3#?ZV6%*XT%B;.'\0> M1D9!*.,'LXGG#EUES,`/DN"7V@UQH9*3LT41("`%`KR`K*`@I&KR!+&(LBB!AWX9XI&TL\SZ(`8\QD\ZF1.:>W)+1PP_$!Y*M&?+$[)%K]L M]S2[S[KVGF%X(,,75.MC/L2K;O*E&NRTKF]^APW\[?=_G:XZ5"OD2,-!Z6I# MY:X,,/*JG+PQ=X?"TZ`;@#"8(3]A.A'Y'.)XRU&KKGS?DBV89,!0GH#R"%*.'\41!BFD2%%=QMT+A6202L^)S%V!R5_2*I[/1A3=, M$I;K%[2X^WY[=_7]X5\4(C1E(.?[Y% M1UKI:G'!K,B?5E27MXL%7%5!HD`4%FZ)>D3YQN:MM$(3C(.XYJI`A\Z_N4#^ M(T...1O+*L7]IJA/^R4.P'?!K&9DTI'S`S^+:ELX0%K6:(7"M59O1T#3OLUL MB&NRI;`65&-:>^E6KA.Y370QI!/C]B[5(>NMSV[69/NKL4G'R6WB?%7K]3@I M&;GW1Q&Z@C5/:>]!;G@>$$-,R1YXFGC#2386:!W M-`#O_TD<2,C@E%[IP7F1YR5&/`=1X9ZX$2[#-A%E$M$Q>CCU,4SNCV2L+]EA M#0;QA&J""!"&62]1C#+QDR3BW&U/49WBE3W9E!4I&L5A413510Y/PN@V?.&. M9-5=QNSNY#-EDX:WH[38S.WHJ^\]46&:"Z+%/V#/"$/^!BA_>J6O]G1AZ.OM MS:]G7Z]_O_K,+N[OK\2IO8._D*KXFY.(9S6"L:(T*#"59FHD7PBE-+?;6?$3 MIO`C],U.(UMI2"VU2/@5C)?>@@5U")*#\9_T,E#F1I\43'D'3>5B92J=)/R- MAZ$C8$/4K4F-%"4C*C.'.5BLX40'`I?)<2%<.+"NL$3W$2X:LJ+9+\4MQ_81^D0.6A_G3\&E*X!Y2(.`TDZ-8!S^5/ M\+ZJ645#)^>%R9VP@4N,(T@O[E9F[I:F-9OF299'))>$YB70V/),*,B41!*L M\4HA["2*3*F;KXCC'9Z<(>4EJL6`(C%%8J,M83EYUU4(D8_KN,-$[+PYF M&*>NQ@P_/'*DAI!/CWXGD4*MZ<]9I8Y:"O63RCJRD\NH&/R# M>>2ELO-,6;[$29N`.L:[9>KBD)1-E2O.9^NOY7S-#^'/)-I\&"9%W0B*^<)N M\.B,[4V"[GPR=?W7D+(I1*A1A,_5%61D)O9U$3S"S4*EZB MP1JBQ.7$S716I:0FDZ2;Y#B_R&,X/!9PA-CG+9182"K#(R!6ZB-E\%3QQ10> M2]E&")D(W.)`\!V\!F;CF;N9BP0H;^)T%F\Q`OLZ%-!$YL7="!TX)&,6^M]O M]*/GS]Q4+3KQZA;@[=?;V\]_7'_]2J<%MP__N/K.KF\>+FY^O?[T M]2KCH-=;HK5Z"E"TI/YHK59HO-%I07A3GSA5- ME5<._#@`JRKSE42-$:J'2`6-AJ)IO"./N5%GY.^.S50GDD1)*Q11$1YQI0S[ MG?-@\"I+$67`8JJR:5JG\PVE3=5ASXPECQ:6-\ULINB6XO+*F\DJ!5RJ-=G9 M_D>2M"%5O@JNV!E7ECPJZ2@JXS=?!1132U1D9""O0,E\V)!+]W(F=U95QIRO ME5KIS;LM;:G_D/9IH#R'`A=I=KF5Z@ MS)6\PA,0OHQU2F6HHD M+'&=#!#TTUVQS">0NV.5$I[TKV'Q%"]!*+'!*Y-JK_+E\\5LRH.:0CZ1OYDU M\/&NK803M(#O)8[*2*0OR;PQ]N('+B`[Y,FU"IQ+W5LWV"7F[[#KZY+I2RCX ME*5@PMX$0H;%D/72WPH=:FKML(_:TK3R)/,IF_VJZXAB43=E6>OOWLR_NWHO`^0IA> M2)0\F1%8=3M69*&EVZ1,)FQ:I%08!$ILFW7^4\=YWG*43I>IX95>'5*J*E/( M^7]SGC@YVMG*6!GNP^VJBPG#J=HP4DL7P<##$#,P?;SD%ZE4Z$2088$]?P+. M31(]DHF7]YRS&Y!PULHZ1Q>I0A$SCM!_H6!66BE))FX4*I_:"H+4^B(W1!2@ MA#T@L.A498**NN:7Z`:>68VS9EO4Q@Z(RYU&V MHIG?;02,86MWWI`)49P-E,(1EI6O8+UQ$\6U6%*93SG*BY,7M M>3(%\E0]&YS!(`[6[)E?$J+2S$3)79O>>VFDG3!;#`YT)&V(I&)(;GSXB`7H MC21N*,N:7*0>D-K4DLL@-\9BET55:C*OR4"7[&SC\2<[Z4@@ZNRC,"7THDDR M5YWP9J(J$2/.B1+W)*5A&O.6F>NVB)"%8R"2DE=!S322*G>7A6IG3PIH_[&? M;,+NDGC:;`#N8D@9-;@CO,3M'Z'IM<7=[>'T6L;=,CA72Q M9'!#94TD-]6HQ!Q=?Y$W?T3"1>:JVC-/"[8ZR@_,]"[(-<_(=RF0!UGH65)K M+!P4.PMD*\FM713\G-W'M!%1P1H)'17C2/)EBIA]">_.QYHQJ^3!_E$_'K^^ MN;S]=L4>+OZ?[=1SKATG9\]V5&Q8<1"EF(M[QL!SV,N*G/INJ\'.F%A$!JO( MDV3T,*T5]Q0[P^2":U1:24'9FE-9176B&&\@*[01O8/-&=R*(]+;4]MU<`H MXX0@I/@[_ROFE(XQ=TK,)^CZ!:^9>CQAKB#/3$`WB=BJ&-U,/6K1*6B>V-,X MP)/=M`R@NL8?RY*&,MM+$%<^7'(9I5A^9^7\"[B%OZ/K=SM*"O5>IU4^=GRN M)#+:+ZZ_L]\OOOY&I=N_7-]7WQEUS?W#]]_.YV.C0\E49FT)E"VLG.R M9+-2@TD1(*8!Q\NHOB/KN]/]S\0C#[C+GS&91H92,N$/504JC6+)2Z'2+9?B MGI19']B>:/N8A4$6`^,#4E7R;NJ,R&2"Z5A%ZU7<@81O@IBG9=/%!5N8@2E$[0ZI"T5B)Y>*8C0&"8V!O,4@96+,*.CQ4SBBKHKBC,]4?HE'3WG]_'SS09? ML,$FE1#,F7T[3-*\DT/*9WGXK-H>9&F5;T@U/Q>13W8D#`5\.1^!6LN?W0\P MXABJSH7))AQ6:\A=,>/,Z2V>I;W063L6@)A@$$)EC],=V?P-/E&1HP0CF12; MUM[!B`/.(<970">'OMGL=R0G*FGXZC57P4=%]K$4;UI:)$^\7-_(60"2!2RN M:R=V1L[$<>U`0FJ@%Z7V.XD;E3EBR%4HP$E"62I44$.5(0Q+EC@/))@7&#][ M1`-L"GLCN>3YIAP$A.#.'&-F<%L\G@`)@S!G(]R-Y2,[F*::'9;:KD4!2<@K M[!\'5/*,@*#G,P9;.M4)6MDD-,6V,PU&"`]P@M$2YAJDR;8?^6P_NB^0T%"< M.I6JK2072T2EU"XQ=Y5EM@7!^C:OM$P`[3F_^,&EY)/P-K@3A9,KL):/F%1V M-$&KI':!\GUO?F47OWZ_VEZS\L,(Z.2+`PC?%\S-$PAM6CTU$;'^&FZ9U)@]IS]#SWW*I)(U?!I`5HJ#",3!BF/P`:S+D(U94#8ZH!%:$99 M:LYG(:AY>YBM<:*J=-.='C6W+'F;K064-@9RW85$0'"E`R'5V$B%F#*DH6:7 M8!YP#\'E?A0VJO&T!N6#"@HJ+%4>\Q>8'J//26RB3L&KR]L;BM!B-N3GJT]; MJ:-P&.)\K1B4C)-'T4FUFZ.*5GB0H[II9QT[<$VF;L9.R\"/+'@DA"U3$=UF M27U_5TY$-XA&W!;1'S][GT7Z,O(A&6*3I9W3'#YZ"IB+?!MR2N0=&_$3MI!7 M-XG2`47]'MJZSNP*\)195G$@+[_5;9RU&[D,,OS*:N#%$9LJ:,OK+DE46OA< M9?,E\218AGA`KD%"A\0E2M]!\IUV3R-<="GCKL")OFQAD0U&IDT@@V1U1)*8;%BL!$$=D=((V>;&916C M\DL]RPM7=`6!\WL4DUN5R(0NX]7][=T^XHL4%&'7-Y?@3EW_?L7NOEZ<"(N0 M0R_W,ZJ`V%SD09PM4:<8ZJ`M-Q-RRRK:/,F++5+=K1L;D->CQ!MS@0*QT4[O M\,A,9557-1LJP`G."@,"F1U\]LI3<6Q`A@*^)."JZ#V:%]#KXFR/MI[)J)GN M.SC@7[&/3\U>N)3^7[IWE8_G]WM%L/M_7'S79;!SL&"?\0$F:]-R$@`?\%99Y@(4MFV@0-ZL MFY3$!O-!0&HOV6G(N&5R%DC%)55BCW`&TKL>&-H:9!ICJ83.](FAX\88D4J? M44"S!,!SED>'94`7!_)8=YO14.J21QZGQU>JIBRO^>&Y5B%),NTL_43J MFT1&9D">JR:5 M5>?G"V6'W1DG5)[7J,UH\BLX&2-.]_W%!.G,SNA,/HC*5?KYMY[D*`7!<'8= M4KIOWGV=B]:GN&H1H`B4\/[^4_>GTM%*Z_Q\D+U%`MK$+;+*XB?52F M3R-Y\$CVVT;;*K>)-71@UMO8O^'5XND7Q\9*=.P*L*TS[EH^:`'2FT.I*:@I MJ"EXF!3OO:%> M<\0U@D>%&*\=9#@^NBV+06FZ;1K*TI0KHURCW3%ZG?)$B[=03CM1VD1KA(X` MH3T[47_,WCF8OV)04YV]Z2YX%>5MM2RCW>L;9K=1B?:NO:NZ36*:IF58K:[1 MK,B).&UB]H"0[:;1:9>?M&EBKDC,?M/HPWZJT2]/ZZV$EMI9TZZ`1N@($-J) MLU8(TE=L)8FW&7,W00U9=$Y4X!4W<(]\"31"&J$#E/JM9"*ME@Y9R6J41\A* MPE^-\T;YWFG%X*"&?&W(S5.%?"^F6><('HPYT$@>/)+K*^;:F'2=+*@3M30% M-04U!?<0.BUUZVIM[8[.?&N$3@ZA?;M9)YXLN-!AUGE;FFA5$JT\?J.)MF.B MS:K=OU$!C=Q71UVMD52751WC:*ZPN`D]717J*\K2R]T MV^^3FGI%M7:W4UZWR*=_67]'?IS/O:W"VP5*U!:V7*7+,\-0K8V+D+1/Y,UF M8_U75RR.*6>P3#%#05':2H;?(_S;YN:Z*X?*E4WY`A5N8AJTB2D(`F=4T&PE MV?588L@'OC@:_T7TJ\!&JN4%+6',..&,]-,ND7UKL=F#8-"-EFW])=HUV`4< ME8Q*G91=;/VX[9GV`__6/8/$D>DL=636D_K/U%:;MB^[E?:4D)W8P:=NSVAW6D8C'US>$-Z#P-BRC':C M,8MQ13Q4GJJW@'$H(I(\+YL0U8^8EMDPK*YE]'J=4^&5GFDT>TVCU=D&KVRB M;T1O\_`PJ%?TJ6.8W:;1;9^,NBDA0J\#:[Y7#?2'C*PN)^-Z5GQO>MU$G;XK M2W8@-.D8;=!?S>;LK=S]7_T\SN=VJ+LJ'6'7RN?!CVPW>^!4=#2SH11:2X^X MMR=P3;-C-,!/ZC1WXB/5#G^SV<$:`$:CM4SCZ,-_??B_^6REU,PTJ%[<;'JV M-S7,>3$88#MZ>.DN\#WX..#8@3P4;]:O6?7W*^P0SRXN+V]_NWFXOOF5W7V_ MO8'/EU??X(?3:!G_!Q?9"!P;HU/S8CSH3Y>20+K'FD'4&?VW*;8VQ\P',%Q/ MX[39.?6#=SS;&X`]`NCA.UI\]L*I/7*(5^8HM\*G7(1'[CK\&3,T7MF+`U,2 M%#;#3NX!#N%,IO8@VSM=IQ!$A8*ZKN3-2F[Z\N78]IYX6!,9+24"CI<"S11S MUF!U:L0IUQ[[9PQ^(2R399!T?E'22=`4$#!DGWSX#_L@\6AU/WZYN/^D_NI] M_%G)<>'+0C70A&<-*]-F_MJ#9YXP5!>J;]N`S:^^/T3))W!0,]P"E`'[\.!/ MG0%KMAL__\(>>$BS7`-^H%W`.S[["D[ND*5CLHLPY)'H='\-.L,)D/53H+/H M7-S_IN#+8'7.LM\C-%,>3)P(T\4BD>04^:#<@C!B-N::A>RO&)8!=!PZW"-0 M4WY`SPQYA&]ZG+V,.6'C1-@:?N*##G2=/[F+'>IMCS0@?(B$V@28&:I?CIE4 MMD<@."G&+F'LI!@C$#2N0_BB8@U!=8JB(4@'!0>2+@^)QP<`OQV\(KB`)CP] M(2``(T16H.2D=*1\.EB%$.V5)@,L`_Y73"!B M&IO,+>.%:+,%*`L>(;1CS\45`'02:H>"ENO3FI!1Q*1AZ0U<^H$=!'CN!L@B MJP./B'61V-ENZ&?L%@XD0;K1(J'E6V&5/7H0ELKQ MATE:WS3P!YQCHF+`!Y&;74V$><&",K&8F45#W$42(W$S0.;@.9(S(7-M>UZ, MUG@&4,FCL\#FIPD53``ICCMR0F`!]LIM$)='#FJ-.!2(AN08P:2@]*;@.#S" M)[-M2.7UXD1C!N\`FO904EE(*+@KYP3)`R!\Z%.Z')]T.A(FXP/UHUMW^ MA,FH%][PLTC3?,#=WAL-8H5Q;4&_0MBV`=)]-FC<@Q?&WK]=P MK0?7"789UZWE#Q>3XUV3$Q3$56\T:W@UO#L1D+=@N'8I`CU9!9/MNZ:EC,]& M[,EV//8![Q;^7'";,:UU.P;>YT%-*^BM^N()E@#1"-4=H9U4SE0W!F=;B%=0 MWW;VREW-.J,OZ]AV=*W@E[5:.SJ$E_=(.T*4S;9E-/OE34C617G?#HDNY7LP MID\C>?!(]MM&VRJWB35T8'0%7UT]55-04U!34#<_J\&F72.D$3K&.)&NX+M6 M\$B75MTL!J7IMFDH2U.NC'*-=L?H=G:@_*),$ M[X'`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`:YNC1VC/)8QF_8>O/`Q_8?9@$$]BU\8:T4,^#?C` MH6,F4DGVQ`?`_FW/YH@>N7_R`62P8:U>S;C<05G]NN,14,T"S=59O=3NZE2K M4T/[PU`U1X>0[D6T\_O+S;9AM4ZDI/LVR-NO\;AY$S>I5?.MZ0XX`-QTM(](@?;FX?KEB+J3`>#')Q M^3^_7=]?/US?WMP3)1_S-,UGOFP=X/.V`GEI%LX.87'E=;6+B6-[[!_<=J,Q MCOGL#&1:7*RI-@O+K<<^\P&?//(`IC$8,'_38'X<$"QA_!@Z0\<.7MF%]\1= MO*/.OO%@\`I./(@@WML!(6-V&/*(?BPD_CF[BX,P!BEGD4\O7#P%G`X(#/KS M]L7C08B^'FP`7#2%#]@AP@$Y\\?`"",4Q`(1W MW38]B"$-UP^QE#%M+)COP@\"L`3<Z<23!<#S*D02. MPSQ<42A?82%@>/+]X8OCNIJ'YGAH?KD)D-R2K[C<\%\06'CQ)?QE&\CE;?(, M(;=F?W]:-'#%*:V=6J6TZMUC%;F'W499>MJE'8Y)E@;X`2/_H`L+C^AGTQGW MD*5G-4NS]'I&9\$6\0"3].X*3V1J)A^=@KN_AR(:J\>G[Y0=9\J&GU`PM=,*60G-EM\5F_MFFIWIX MCO?:89-[/HU$W,1J4]RD91`@+SRS=9&QC$SKVZ0;[HA=A1'GDP'\R:Z]P3G9 M?P?$XV7LX^5._\7#LBA)",9@%R/890]I$_"-#U'(T]1^=N_C;3ZLDXAMV.Q=2T91LD$3(PVN8%4-L:.U7_W1B,(I6'N@U6SB:++M#&#A M8K9GJ'>X.DJBHR2G'"4Y7$(??I!%APQ6#!F8EM%JE=\D.L"8P86P$2$+^(## MJB#+?O!XM*7F>QOO>]K@.YC-0PLC?FRMK5G=N/OS@8Q/V)N7WL@^% MXS_SJ1\Z49;3:\GA9L-HMP\M3UW'>M>*]78LR^B8J\>C=+!7!WMUL'?58*_1 MM'I&M[OZ=<-*PKU:P`Y6P/)[.EG,..LG#`8!MOU6SO)VUF/=%NNM=LOH=>M4 MQ&`SQRS9ZK&1X]G>@"*O*D&Q=MZ9U39:"VXR'Q;CE[MGF)`9%M7U/G+/3"2O M:L=,VXVM.69%IT(GXYQUVFVCV3JJD_AJSCTJAZ#TQ">]`535?1YU3^CV\NNO M18/>!?X7/YC8U]X(_X-?W?A>@-<`:.PA@DS6WLKWFUSKHM#AG!QIS:W3NAWGMR?K!+ M/YCZ@@VIA,RGP!Z,7]'?M:>O;"*+Q0PYEN,E0-*R,N+:@:+#RL'J42.:VVT;8L?&T:./"\RY^`WF`97&`%P(NJ>LQ,_$^@!IYU^R$R+38!CQ^ZK*M=#='D'1J[=/6_U81A@4@\YSL_6 M`[?1+;C8JUD[OHO#(L-(3(.L,Z$2RK)4X-`I%8J6L!CP&;#C*I3]7]` MUYUF,9&%";05'W:;C4:=\C^SI,PU;%_=@4G:OW?7:_].,WR14O@P!@W`OJ%( MA.P*F*+@F!<`NH,6,U52HKD!);[9KZQI&AJNHX1KGPQ<'NS8*C5@ MT[DP$D$0H%]_-)B49YP>&B;'NR;[#IW0L[=);4CE4/YR["$KC9!&Z`"CI$M/ M=N0.I%64S%H:#_T5=L8!'E5CKYWAQ/&<,$*%\%Q^XB#G:>XAP]62/WQYP)>6M%K\ZFIJJEZ$E1=L.W7[ER=;*M&2".DW;D% M[MQ7S%464:(8U0_<1=&VN-D$;H4*5WY\=GA;;]A'9=>B^KJ:JI MJJFJLZ4.VO9JA#1")^ONE9ZDE92-J.?*K*N`#Y+]-)('C^2BXK:_]94U50]1JKVVT:[4_OV;ZMVA*FMB3TZGT$C M='(([=G+$PZ=I?>$]>3!(XE^@56GAD[:!=`(:81.VP58$.A)_0*LH^RB M`\QJ)^;N0SS_?03PA\JIZ<5$@^HWD)KJFJJ:JH>:FJ`]@$U0AHA M[0,N[Z)TPR/A!*X5(2I3=P??4:DBM;]1HR5-5DU63=8:D'5)2&_+7=7$5S/_ MN+MNIK.]V1X+Z/*8!^4__U95_[?9?G+W@S$?QBZ_':TU\C7=DKB/[(B:7WVR M7=L;\/LQY]&%-[P`?L#';#>%($Q`6*L%G>YAM$1;Z!Y&;_(Q][QHQ]^31\.E M>QCI?CFZAU'M,=$]C.H1)=((:82.,3"I>QAM$)DYVAXUFAZ:'KJ'D>YA5.># M=TU5355-U5.FJJ[*H3=-&J%#1>BP_#W=PTB;3TU53=63IJKN870@ME4CI!'2 M[ISN8:3-HZ:JIJJFZCQ5=0^CFMM3C9!&Z,1<.)%3IGL8:80T0@KUDAJ)"M&4O

GI4U3V,#M-7UPAIA`YP>ZA[&!WU3D(C>2Q(ZAY&M=?'&B&- MT&FY``L"/;J'D=Y":ZIJJFJJUI2JV@?4'H9&Z`@0JHD/J'L8Z:XPFJR:K)JL MA]'#*&W@LX>&.[,]?S[S1WSITIXZD>U^Y7;(PSKFX?;[O]B7ZYN+F\LK=O'K]ZNK;_#E/1'Z,5F"BELWY4&; M6?FMS5K8,$I^Z7A#C@,VSMN.1^#=QGCEXQF^]8-7-G(\9`UF/P6<>"4DD&`M M0R>,,//GKQ@&'CG@#8S\X`PXD&=>G\;!8(P<<QCSD!>,Q.^!LS-TA[K:X M^\H>7]E5&,&O`_CEG/T/C?\JPDQR7((A&9M&0*=H"D`X\`"SF6FQ"?;U*9S0 M=?T7'`\[`($@3&WO%8-:X33@]I"^G=JOXMD1-0IRP@Q./OAFS"80HA?N/G,Y M$TB7XP\144?.$<[.@!VD^"":'9ZG=$**1F,[FIV/OHM@?>4TS`YAVC`B,!P/ M1(VPG((@ASE$Y,#IE`)\-HG=R#G+0FZP)U$?'M8`!`;`-9L"-5B]"]==SA6X M#BH4"-XBYU1I.<,KO@=C3QP/L!YQ+M`/>11/S]DG#@1C2#GFPM.X//@",*,? M1V$$`^4XH!0$HJ!LAL-0K1`,J&N09+!>+OX724.H`3R2,IC1QNW!.!WQ?&?" M6&0(=MHUKFBVBINE==NZ5UK:KNDBRZ>;;W,S;6PJW6A62=&:=^HYWIY#!XK) M-ZF7[X1>WE/L4XVZJ-$*O?<'*D3V!?2LSSXTS&[Y_5@UU#YZ0[1*>T/TC&;3 M7/K^VUMBU`SM#3?&1TN/EF%VRE7A7KN$++S%^/NOW]B'IF7-B]U^8\56T^CV MNL<5^#[N-*VVT6]5M6#[OOY79)EZM1.1EM'IESLMA\4])R$B'-S$G(@&D:S5:=DM@7ZG[!^=V^V:@;YS>!CKW^D3#%27!^TVCUZL3XJVI_ MZ?^T:B20\<1*,;QJF5=5. MK8XAH7[=1*3;,5IM[1T=$)(=HU^KO?$J(:%VW=B^US8ZO<:1<,1)L'W7,%M5 M+=@>0D*=5NU4_TFPS=$A5#EMF/7R7M[PZ@%=85P3:7T)5%/PT"BHK\P> MH_71"-7"ILZ"5'+#E(:XS63SNW19:&6Q/_A;8RVS:S0:Y;ME?>M.7V;<`UG; M':.UO\N,F4LG>[SLLKW9'@OH\KA34$JO^LU`1;"D=TM7O=@Y>R'T6MW12A]. MGMW9)=`5UH1NAG8*+X;N89$.@5_^X&QL/V?N=QIX:6X,UEQ>0Z1[=?8$G(>( M[C>],YM=H]7LT!V\=TW3L+HF6W!%SV#`6%,^B)QG[KZ>L_Q=U((7`^[:$1=7 M_R*?K@M.^!#=&C;DS\Z``ZI>/+('41R@QQ'R)[K9QQ23.GA]-)J!Q@U]['KF MQD,.8)N-#N;&R[F&;&:>:>`/XX&Z?@B(1'PP]L!S>L*QA\ZS$SJ^-XL+5M"? M!U:"IZY,AC"X`VOEN*^(^03DB;NN[7$_AI_L(`IGAE7+4`0?FX-M\6RRNC_> M`4R&"&.\'QD"4<,_@9O\'Z]/'!8]?@3:&C0!M8PC,!X#;D=C)#K_*W:F-%,8 M3Z>N@[>!@96(S&/?'5#A:R1<@+B#B\-XB"`EUQB!A2<@`]Y"()("./] M5I<]<@\H#AQ.%V*G=)-77HM]D-0?V\'PA8`@7.CE@K4[)R`>8!H/M$+RDISQ MQ7$!7#^D>__LLQ\!C[#O/.0VD!9^C6#96>PY?\4\PT.(HSU\MH%@3UQAH9`' M3OJ3P[SG[%(A:DC^3&XV"^6!MWXG]I#30LVR^1R:Q/<&4"\$;P2$T:<*A#C, M!'@I/"\R98M,TJSYN@NPJDWT>@<0H/V[4MR[3W-68+FZ[(S=?;^]N_K^\"]V M^ M:KYXS[CI?5N:H>R2^;[A2F7HC3&K*M>DSA>CC_JR^I[N=;<[XAKNESCP'-@D M\%("[_/:;J?TVB[LF4RS/'9SX->5%^!M&9T%6=GUO*^\,(1_.QKA?B)Q-VMV M,F$VC8Y5KGX.ZY@%N*??J5-&\ZI'BY?@I<:@9>O6D<5J&:W&L>1M6I;1M`XF MI_'>'T6X,:X9$9M&JW\LY0^JQ*46:>`4S*?0FS.9!OZS+*!6+ZJ?4D+@=I'< M:V)=N4-SO#E-9A>0P<:"6R^K.RCEM4*/D&H6 M:*Y*VJ//4FT'YT5'IFJ.#J&]['"7)?Z^Z>7:9PTWVX;56ET)ZJ3K&?+UC7ZG M/*A8:=(U?9QO'K-.IM-LEE3:>.9R;'M/_-J["$,>?>>1$U`T\?81H"3/X`%G MWBQE*LT+R>:!S.:)$#W^_I-,+9@Y`NRLDPN2'%[/)Y>LFB82^=.*CJ:[UOO4 M.PO$J7NKJ%-;*Y4%MR#O)W3^S07R'YGK>/QL+(_P^\V9LV^9>/@#/XMH<"XC M:)7#7JNW(Z#;U*"DP5ZY'93#NI9I*%FZE>W"-M%5!W]I&&#-]=G-FFQ_-=81 MI%W@?%7K]3@I&;VN:WED;+J[TW(YPI\_Y/M.;Q?_. MK;;CK9+H>B8>3=;C$3]04G1/4"Z]TG/[YG5Q?[63YFXU2HS&9/]+ MV7Q,7+5E/B49B9L1X%%1TOZ%RW^`X0\WCR M#^SK=>F[\>11/@P<&+CPK>^Q^\OS[%!.*"Y=1&/L`X:,+V#XF$X@$K'!X7C. M/Y"?9HS7?CSY!#"X[7C4',QC3A2J5V9@*9O\G-UZ[!O=:;!Z(G5;W$F8O?$P M\9^QH1TVO,59Y%6-F;!Z MG` M4BKN>/;"P:E[U^P8;:LK[F"9?GC19N493=,R&FWQ M];M."XM;S5[M^I+FUP=<7!R!A9W$$[%22;^Z7[8A1V_4-^4I[&+[4+A+*Y$I?UEFRE5"J+5Q1FA[X:L5A7/>G"0SFVZ]_-6B`->[ MPKR.G7YJ8O[2;.KF_LXV@:Z=M]-U_Y],"^_-[SN/O8S$W:,@,=CG7F,VS7NO MK-L[!KH6?6I91FNNP'\MN/G-$=X&Q6,WJT*U/V;;]'AF1TB]>5DIQR7<<$FM M58O%[-X$-\TN^-AE]K9D4[]T+SZ[>9?-W+VG+>WB$U^Y^)A%>\#:`]8>L/:` MM0>L/>!#I*OV@+4'O/=EU1YP03AWSO%,W,W46U[=^5WB-G^),=?AFX@\RX;S MX>>8RY)%.=?Y`N;)N,M8#DG\\-O]YY_8D`^<":PF>K;_U6R"NU$*[I))-P3Y MVGMX\?^%!XR;0@WF'*SYVF"G$V\..1YHO`UVLP5F`BE(_O9 MTI&_WMY^_N/ZZU>#W5T\7-T\W%-)KMN'?UQ])Q5W??-PO5^SB_O[J M8PM*1:;V[@1U@]3,`CI2%27S/!YA M.:[L-8-S=K&H?&24.?+&@V,;YJ+RI'+I;.R7`E+@H&J6%K@&7;[ MXLY#YD)$%C`$)JUV`@DQ79%9HG![#",)WBHZOEXM=MV`A0^0]3W>^3L7<

3VMXZT,=J"8?,-D&3!VT@':\_Y3A:P;916Q9CI#=LNO MINVS(%BKM"!8SV@NN+![X'70RM%6+NB:]4..EAXM+-5=/=J[ZDQIU:TKG]4T MNKUCJ>.TH;`<%I)MH]\ZJF)5,Y:I5SL1:1F=?KG3!CKUC*?A[$IS?-%H+"J;75_M+_Z=5.PFPC+9Y M+/7N3D0".I4MV(Y4?Z_?[-2-\<&$6@O*LQX63YP$XYN&N:!<73U5_SHAH7[= M1*3;,5IM[1T=$)(=HU^KO?$J(:%VW=B^U\:;_D?"$2?!]EW#;%6U8'L("75: MM5/])\$V1X=0W3RDC;MMK$"!XRLMO!G2NN6&IN"A45"W$CA&ZZ,1JH5-G05I M/KLTK3I]&T=A9'M#J@-'MUY6%ON#+UW=,KM&HU&^6]:EOU>ZE[GN%D&3=3%9 MVUB,H/R$J]**ZDH/O?4BZ\JW96:OV5P,!GA%*;RS7Q&""V\(WP0Q'WYU[$?Y M\CXOT248/^('NB]GFBSE?(9?W;.[BW]=?/IZ1:1YS!/I:"[#%7OS^]7W M![H.F"/$5JI=UA!_WR.[C3>S/#^"T::"CY$_0T?GJS"^`IGL> MEA((*KZ$:#8:.[V%^(:;4K.33)SAT!5N.!BA\XTW+BMZ.55&JXE[EUF[3+>2AFWCR.,]$NPLST7"?>3@(G.G"-G@'=7?QJ.^3[NGJ9=&E MLX6LO8)VDT/WUAW:LLSR4[_MP[OYG<%VZ?U5="G/V0VX*TSNB=@'63]B"/L@ MW"PMO=+:WL==QME7,SD)+:-A;>$R8]WQMIKM[2"^IRCBVV1F7<%>/<=W4\@J MB2UO)*^5S%S.FH=_HK\N;K"1,!J-0\L`J8FH-5=/)M:B=O*B]J&]H-UGX0QO M[7-\B.:KJ+225G=#MD;=6BU>JXD7WOVO63FKHQ6O0S)DJ]>#T)*V MFJ1U#7.-@)*6M*,V9#K1H^ID"/03=OVI#UC%Y/&S)MR$B\=&BQ:O%J&^UN MS:&K+E&$$R+UZJ&K+-&IK46K],P9,TU MVBEI25M-THR>J0^CM1TCZ=(;LJJ3%AM&>XTHDA:O4[%C.M>CZAA^P^CU='JP M-F0H7I9V$ZMV$RNMVZ3EJSI+MFY7FK>*XJ[G6ZF)S18F6?!J\4+H#EFZO]/! M4?#XO8$=CK/D1_9;LUXK=7M&NU^58T] M]XZ-U3"::Q0*T*:FEK)26_[2IN9H34W28Z'UTT9C?^5A^$O1+OVK#P[O`P\F M;.H'"QM@+%VBRO:>*[2%V'2R=3N5*#98$?E\*&37TK(#LK]YT[<>@3\4M!*8 M5\BG5V=96T9M&0_;,J[8S?/M!C-M2E3%E)=Q$'`O*C*6ZRQ[18I]+\U;U]/@ M!3NX0R74&@;O+10S>VVCV6HLGWG=!L`%4KZH_>TQ]GW<[[Q%L\W\)['__27:)G%%,"[J0=MJ[;4*:(=>"YH#K M.$ MR97*R"$"^9BH"QQHH3E_,QEVLD-QE`F#)MRLS.66JI;CUU,`\@;[(7# M;C6,^9!%/OL6GK.O,&88!?[$8'X<@)$*)CQ@EV.'C]C5#SZ((^>9L]O1R!GP MP(!];F8'RZ;P'@SGP[87-[+,\<#0\A@WL7+3BQ_?J7,4A`0>L0>#`"$(;9[[BL;QAPWWM_L8#`F1P^A`%5BG;-;];79H=VV9>2!8/93P`5P0'T. M8T>P[\`I=F@X9J(!$!,$'D^>^0>!S(ZME@30!&W*:(0<`'_I,';LN0Q5/X'H?'Y;*]@9Q.TN2<77BP7E'H#&$5["!Z96.8 MA!PE>!DHY0,MF!V&P$6T#DB9D$>1R\6?B!E^(E!>G&@\@SH,,(V!-G;($RP) M'[DFZ<@`TD`$IH':L+Q#/K)C-SIGG^,`?>R1<+N!("V#AKJ@=SDGD"4[\2$! M\J[5P>!,X4W"IF=T>SW#[)HL'-O`!?A(&/G@2`+",48C:&P)"=@P M-R5:ND;OS%X?6;$`N#8!1U#\`YPS9"D!YQ#>LMKS8!&)?7@G(`[E0["12/IG M8%$_@!6:"^8(]"_]R=3VQ(+98A4C6VQ'DL$)C`P.[T0W=UI%.Y6@1"(QRU9C>K-3W81[!,\(#= MI2I0;!Y0P<'_/8&`/:&62!DFLSI=<0/CG%VA;R"Y-!1\&L)T9_^_@&>41*1D M>N!/)J`7!./#3`G[-OI".`,^L1T/45D`I*'XI1`VR>P&JBV"0>@^``%F_J?M MQ:BTK1ZQ=`-&@0EMH6$] MELR85:L$2ZI:KSUV.XA\U+?X!;U\XS\+#9PJ&R6/N->$\5Y@+BG,4S]T\!@M MG-4V.8TQ+^+2C"DQO_9(QE/YGIDQMRCON@6*9.F,&:6B%#`!@1KDD<_0ZS,? M2"LDM8XPBJ`<8"D\_N3#( MJ`V$QJ5'7X"RX._9KX@22,%0<;GRUE(E!&P=H4L6P0K"PKW28V-A]K,N@P0Y M_8*TL/!`I&X<<#%1Z[S??Z]>5L(A^*S5^1@*Q98U]CE=+H8\9W\()S`8TO*F M'B,K\!8S"TFP*(^?"6^VE46*NWP0"06A<'IG=HU&MX7D2WEDZL8A"&J_P9Q" M-P/>;QO-7A-F[68\,8$+02'PH?7-P$Q+11"?-QI-H;YE\-7,0)MJRA0DLI=& MW^H(X.:`PM_;S4:6Q1(E#>`VC1:X]]U.:PY<5@RJVE@@I%:KV];ZJE1?]6;U M%3D`8L?9E\M:B;KJ&&VPFF)3$WL!=VUDYA(+F5-IR2EKF5K#"4RK7*?)':)` MI[U,I35[\RI-:"_AS@D-Q@JTU]@)MJV]4J&0HK!'[:6LB5S;T@U9ZDZEKK#B MAYP75:X<3%!8+:&[0!/T&J;1;;2S2GQ&(VB!+Q7X?GF(J5>AO+=I=[0?>1=]RA;6C3+1+/5+1=-+&?C.H4; MBYV)9UD8.KM#E&994;XDR@)\Z02+&2;GGJN8KM5K84A`;!P*W7,M\?6%)=4^ M[08[F]D(O#(K/6RI1O68YK9U3R.C>Y(ATCC=P(V''),]\<';Z\\%,2ZS(8.G M8P>V#0X&Z%!^X`E`^-]R8PH"%`CU@G??,KHAK]!0Z\$,+<;_BFE^$'/7%;FD MCQR6C';*\IS(%!6,PYAX(AK3Q3)6;DXUX,7_5'.21#3#^0!!:JP MB?VG".`F2:R.EY?/Q2H8-]%]HBF)-X43,3D&9Q?^`1YA`?WA;R.!11V12([I M&^U>TV@VFZS-7C%[Z\4.`AN!H8,K&P.@/!@X(<_'&?H;;)12/JF;P]3L&4W+ M8HKI`;CYXT&>D&:98_6%/P8BDM^4MK0&"J6FRJTYZUK],W9?<2]9K7K;9Y2# M,+(ZJ[E5.L;QMA@'SA_"&+`"H-B#2*`T%_E0>G@^\%$0LC4-L]DJ.L%)"6+V MC';7--I@K+6OM:8*Z,_X-\H'%K'.KI'QA97QRB=CX(+#ZD<.`!J!A@Y'*(DJ M"R,Q9`7"CK="7CAH;3QD2Q(+ M>TZZ8U)9-@CA,S\C;RE_#C6S410O*>TVF0!RH,%`A29J+?%E,FH!M9Q8'$6F MMO77[4TS86.@6-I6>Y*%MY"2(H%DG1%H]O4\=`A&KW&VR2TI%1!L/4:;8:)[AY4"L[ MGXBUFGB"3FCH1-!R$9T[.,G*J,PWK$9&Z\KHHMW[7.IYQ6):NJ\O%E,@ MU^F>9VXNIF#2M9B6BNEA*KN=C=R)=W0F2*%Y8&,93 MA)W)YZ=M.0QN]GOY;3FI]IS[;G:,3J=O-/IZ'UY8XN6Q`(#TMG9=-%BWM5"# MM0Y@,Y`<&@E@.WO=#&S)RSCVS8!I]>J@+@Y';,V%8FM6N8GOOD5N<\D+98(K MP:U8?^H+=83%7&8#7F=5O[^'7S&W6P MK7+[^L9=?+]9AVAX#4#(6M!.^36A2L6R8W3;6_!ZQ0V@MG9YWRZ2JXN5`B5S MS&2:=>#KFIJ_N1RU5,;ZQQ0;:^K86.6QL2H/TS=5%.(*0$Y99")NN3#;PBA; M]I@<>:7?F3\FGTUR,7L-P^KW]"V$38S[HCO`9H76O=?;^N&9@G?C_-=$0D4: M>D8X"9"-G.NL@K+=T!>9W*"-B^\?=*3_6B;2BB([$NLR^[]!FHEE-+L=+8AE M@MB?*_^6"F*EN]^WG6(O"%*E@KB=_>^I1:D6.]O")RO?QVIGNUS4YNKTI*)6 M:<)(T]K..8ZLT]706]K];FE;K0.0LIE_*@5-=HVHV:%/[<^D^G-'R>EE_VZ% M^L?JBGM+E?OJM1^PH.9&KTJ/.]GZ MIJN#[.H\8T52'N%@R!YAQC\G("APA\,6E<-]\ND6D1]@%<@A9B^-.%YN]X9B MO)#\9/QN307`$N=#A+J6%-G9DO^1\?"%X=W/*=?6*P9N(,7):5>G5XO$\$.Q MN\WY$NM(]VYR#[P&V5OZ>+G.Q\N6:;3:UAN20'JU2`$Y'($MV*F_@MU)!?8H M#L5::]_8UH=B!WHHMG:!X+[1-=MO/DPC2-Z9'0-O-OMSW1GZ1DM4M*]Q@OKA M**VYW3U5T[(J=C/>%,=?$%R<*T"OW8P]9+%U\%KYQEGB#>UFK"6Q!1EN,Q)[ M%'Y&5_L9VL\H]C/`!>UW:G&SI):QPJ9EI?H!E,6MH'E274%U5BF0")OT,0G> M$E-/M?VRS5SR:PV"Y,OJB+:8OK3%S#:%LD5"*0[CURBHG63:V#`,>-I1CO"'>:__+VYO>K[P_7G[Y> ML>]77R\>KCZSNXOO#_]B-[(V%4,?4%=(L=AL[(0>V+WWAG\I4YK37D MCQ'Y3^!)";\ZH(EA<^3XP^T(\0';PZW"(OYW;L%LJX!U)AXEP')"2^ZLB'ZWW]J_$1_AU-[H/[.-XD?^*YK3T,. M=D)^^LB29MV-]Z*-^BJ4_BF%QUW>]3I].FW]7$#IHJ;-VAG3$>BQL=']HF+3>N.A%O>>#I\8;7;/Q^]7IVC^3?-]GGHK-(I7;UHSKZ9- MXR4<;;/<>UTT+.'0]\7W#J\73+Q;C MS3EEG7'G.'M-I#>'\F@IN*YNJ("JNU+M2\BW[O)MNCP;,_"Z$QX90CM1JK,@ MS7M)UGE;ROIM)NH6>W3T`KO\?#PA%T-868C2.=ZL3V@H-O1CF']M"[KFB)4K M$YJJ.B5]\&1=XJ]40CZMC;4VKJLVIF<_F#\7*94;#,>J8"WV)I='RG@Z?.R+ M<70(S7+7WRC^EWZU]&!G/U'*W0!1RWA\)BF0CE6C%Y\:[(4B<>4/^]7C["IX M<6!"/"FY"SBVZP,!Q;0*$%)#Y!`-G_%V"1Y51WYDNR*]C,P>&SH!'^"I#4CW M9S\"'4+M9CSF3[FGWL2393SR/6?726D.<5M"=D^424JY*R:=7*_&DE2GRTRJ M$^:A.,,$LKFR(.^Z1K/?I./QF:2H.ASC;!V"[+EL7<]I;A_^:V?D5#5J^SD+K"5<49S=;.&!;RT$T\ M>9QGHMW%_80UY>$@<*;8RG;U!:_YB8X^FZKX;*KH7&(A:Z]S3K/FT."/,7/9 MJ%L$N+WQP5*G47:\0SO*.[FC_("7H\&?4RF%2X_^-H?H#4==LZ^F6S03RR]L MLD`[6XBMH-UI'/`)7]6RLK9$6]4,M>VXQ9J"NM]8B:@Z>B2!GTJ1V;49W;MX M-;5X5R2$L9JQERMIF&V^DI4A;47FF87^*Q[)$*S89:&-CMS$G0@GMPWCM>OO8A]]>WY MP.(),..^D31AP]2JE4=W2'9J-NZJI4Q+6:&4M2S#;-3)&ZR]`2L_G-&BM2+7 M=7J@VH]E/W4PKN$AV:^.%K(W[_,MH]$[EO#>P0A9[U49;1/ MRIY=W3_4Z+3X>,2NVS3:[=5/%.LM7MK"52(@EF4=2.SCH$3M-"QL8G9X^0%M#T@XD-J(EK7Z2UFNMGMB@S5M6Z'381`O= M9H<=IM'HKKXET?:MN7K,6HO:RJJ_9[3-8SD,Z#:,3KM.+N,!&;*F#D1N(7!@ M'=%-L*[1Z5<55#T)>Z7CC5N0**/=;!KM7E7;E7WC8W7;AMG6IV>;29B.+>K- MUV9JQ#1:M0IYU-V8K:&BM*BMK/PMHZ_3];6!*Y"V$O+H6\>R*3L8J:N] M@=.G9]LQ<-VJ$B?VC5.[!V;?L\PNW4ZMJZY*6LUZU,MKDY" MM5+M^$W8=+6B]&VCU:]/,'._Q.CVC'YE+OA)F M>2O>X9L71E/@U`WX#L=;E6'PJ_OXD?J]UNV$T6ZO'I^OM[II&R^H; MO342Y[5UK+OHU);9CBYQI9;QF-V9FZ2M5NNGC<;^RL/PEZ+HUEYZ5K,L;G=55-BMK3;%N^SFUNLO8[D.SVS$:^A:C,G* MM%IST_FA()`UKUQG2:8-GC9XVN#5V^#-:B?KO%UID**@O>1:8U_*SO0%QFZ= M12U;D4(M2#1@0S]^='FIG:EHQ`3$\L9]*XRXGHVTC%:W931-LVIJ[H-4Q7`O M'5KN\!IFTVCFH*<"6'E7>!C8P0]X M2A.R,7>'[/&5??8CT/$$B;.M55R%0HWS+!\]%A#JL6;@?;Y]8"8[8REPG^,` MA)M=3`/')V4\! MYQ,T5_##-/"?G2%G\13_>F>VJ3\=O,1&8*#Q\9$?L&C,,U.<[^X+,PA3R*7/%6YOTQ/`*<\\+9U':&[%VK32"- M`G_"[`F>]4GV@AD"'O+@F1,(\`Z1@GL.@.QR(&W`;&_([(##@W_%#DX-$T_L M/SDL(9O`6H[=5YCF%6<.\3CQ'66@G+,+^DMV0D<$V@9182`M_:/M`O:`9:A> MJ1'K'`!G6SG.OO78%_X8(+,(QNX2S9LK\K:'!\-3>3!$K!Q8Z,R0P M$:XKR!0P\]1V)8L1&,@/HA^J8'F:YY';08@S`P0A,&[$S-[[9';%4[X8UFQ' M8^)!)Q&*4>RZ,\+1.6=?I)1%8X!>C!(2#,C&PQE&!-&8V$.>`I%PL,1&X"#Y MN=DNX6<89FP_P].#01`+:HKAQ'O]3KN8J:MU"19:E)IP[`$(5'-6H+[9P6!, M4)GUD29KM]+T"J.S1(((BLVDJ%]F$Y;(4*-?"\-0*Y?P8N+8'KOPGK@;ULHQ MW"&55A9M;(#+5"8I##+K#1)L(R>$;35R9`L9$K:5@?_"9UPG%/YWTKUS94-. M?\J]Y(\!=>=D+PX(&3[\:'M_%C$]R88?1V%DDQH0SI?TA^!9_'EF3->'%4?' M\)UH47MB,K'.:EMKK'8[O]J]1GZUEZZR#2H8O&WI*Y\SN<$0?H@3#-E?H%-! MFO&]S*P$A5)\`9=>NH6E)/#)5/E/W3AD&)+`H)CM)LIQ%:YB"SF*0$BY2O1P MU5Q5RE7-8JZZ]0@NVE&"X:65:(F-SJ4_F=H>F-['R`;2PRZ*3507#B(\[@LS M:_OB!W_BL@WLJ1/16L]YHJGQ!_M-8\A=F?!TS5Z?#6TGNR&;'Z2'#(XS,THN M(?9[%3O(S$QMT[!P)MAR>K#'!.B?`C\,T8$9<#Z4.SVS;S0;)K-'R.(PC!(P M@1[GH025'!7D,^+TC-/QF0_XY!%>1K)I[BOEOM9"[B-'E9GFEKFOO9C[K,8* MW-=OK<)]_8Z((2SFOE;'Z+8;FONVSGWM)=P'FP8K&^*IGO>6L)[9M):S7KNY M`NMU,]NKG/U4\_I>WN@"7Q$([T2KRSIPT8'LN;'YXU+&ZFZ7KYKM,KYB/>&E M+6>K?G\Y6X$Y;73:Z[$5>82-7BVVOX?#4MV%+)5H?&2I;1K+9F.)L6ROH+%, MH]/H+F>N5D-R\6)SV6D:7;,IS"7!($PF2\PE!8;DE_YH1#L@L;UIY=P6/;Q7]V(/M9WM-LPO04>/`5;GJT7>' MM?+>M@T0]M";Y2&<.0O%V0O'!(Y?P$D.)K9+[UT+#AOXGL<'R"HBUD'K.H#5 M#XE_<'U$(/(?W';A=P#VV1D@V%E>G`F-1R_!5^.B2><2E M!])0,U%PXA6KO30"_J[SGI198LP+#RHMPVQ;B_8(!$/Q/@%I5S.5L1^-MCQ: M?15&G$\&=L#W$*NNIV12GSUVMJI`$IBW'DPZC20C)NX+L6P0J2`?K,5$&'(0 M7Z'H0_7;C/"FZ\*NO<$YO70Q`E4]I).C;WR(J6;PVS-`[\MSY7O?C<6@^(X\ MT9>B#J*,!SB@$E'`2*Q#\ZXD]9/<.F!X`H>R,2VS`LAYY(I7\!Q_$X-B( M8S!A"Y0I6"[H+:-MM2AD:F.^0^PFY!IRUZ8S-S&!I$PD-4M>D\D#*K';LXQ. MKX?/*K5#B`_1NJ*RH\.^:-:8B5'/V7XT2`T/LFX]S%]]LBXB$.I`WDW5E#C7[[K*&FLT(Z,0"'\-40$O\RET\T:Y'Q MR!H$Y%U''(/!^X^!_R?L'P3)6IV/PA&D[0-(,^;V#!,G,(7AG'TK$LRVT3*[ ME%V$A]%R^T':YY$#]3S:B2B\U9ZMF54.9/L)!,_/G([0`T4AOW_&[JL.]RWD M.TMMH9N]CPR[>,VP(4%WXS\+2R37A!8O^;*GN+/4$XQ>?`.6EI]1@L$,VX7R M<&T@CJKHG6=85Q_)I#FYJ2AV%.7FY%/B:F':6I.JE[TN%;>`L MG,VF5139&NDESJ9`R)`YXS"[<%:5G;3=T%?&LHD0*"@&=CAV>8B<&P0V#@(< M/,+%R@J/4;[P%BCP?AV)EF1!'= M+.!`6)D_>80F@NX@D,2E#L6E'TS]P$;C0XJ&?+5LJI7#A7@A,Z<(JCRKHDQ5 MI)Z@ZZPRF=F!PONMQ1M0Z99:[6[>TJF=9I8S%IYB#47"P<&+XK9W7-BM:_T- M5[+Q;RHA?=@PM"&S18IL6FK2V)PY$X)1M#LJCGW`,Y3]1WG;7CP1.T&0%F$P MBG9'&=/IS67?-;OB%"3'I"I34,70)7(H)ZX/ORL>1Y]N+N!^GB-AUA3:N4P7 M8?;"U.ZE?J;42HI^!JQ.6QK1<&RCM&&6BS\!;&&A_<&?A)F96-IY,ZM6!W:! MP<`):6LJ3.*[\X;5SF3;S&1`9K=X(B1)[ M!=0+`6F:F^:L:;7,N.B'-@M"01:>K`]0 M&+Z`TP5CO,-%(5(7)32@4RERU(15!*D8Q0&=?(K9A+`&_-EWGXGM\T`*$!1` M.4B5?/T7BZ=(*#ZR M,70)0V2H>LZN,U$-(Y?/BOY&(L\B;MG-Y#/G%="+RD3-*HOTFH"'ZR-NU:3. M3!P!*!N99B&H)AC'+9+IA';C8*<75#O%,X'J4UBU3@J.1E)S[F4 M93+\E?-#UV`UX?0N9;<</G>S!)HMVEE#5S8\X>'A.@LX?'3I:&A[A;VI&*[RZ\8M@M$M]ESM%" MOT?HIE7\)\&&,NY;Z!QU%OA&"HWE;@];P>61A^4Y_,UD1[*FMR//L]+-2O&. MIGB#(<,H,/*4>Z$8LB_T?8E+M'S,^4V+V397V+3(';0*W'30,L]O-;06WL9NR.KNP4G+:*DB0> MBSVEH_,>7EGHRV:@(DGIF-;[-,B=J*9.:6V29K-UWIDY=4D"VGU#ZNDDOJX4 M^?Q3_5*&+-W4Y38EZ+=08RQ]Z[*QO'I0 M[Q==L\0=0+:N`C+IS,:CB,OD7;Z.D7H,RY2>.*$IXS&S-L5U:LEC35BEVJ19 MM>7!N?2N1`ZTVA25CE^86M4W3-Q++DNM2@Z.):;J+`]K4[GJ1$_`D3FYMAIM MH]MHT]`PR.T@\M,QNJNJ[L[[M6QZ]F@^2>&1!6LU>Y>P=ZLY5R=*!(L[ACSB M@C4O<@TS2;QKQ7`R\565FR0<+]KLJVT#;E4HRIMC+?6K9/-<_N"";/^RQ*R" MNC1)$#@G!;,^85$%O)R2*_%#M=$*G8^.N%)? MO#$J=1K$!2KJ9;05+M\7\]*\#Y0>!$KFA786F*`=QI,)FDBLF!&C6603QW,F M\23+*F0J`^G7)Y66Y@C[RQ:Q2:5NIG!DOY2&5!B4#;B+M7*Q\-_??VK\1'_+ MLJ/T-Y'I[S_)[&D%Z(LSC,:_L$[[_4>V.M"R/BJ=64Q#_@M3G](T%P*LM.1P MY$_31^?+I2JHF@"5*IT:B%2`EJ@PK+[%JJ[RR_(T@M#Y-Q>(?:13G;.QS"OH M-]^O&,[*Y1DL+/4J8>^_+Y*`5=ZT>NM@O3`W_@V4^"[=V$O?>SY?@1CN.A6G MERS_NL@/,;!$T:Y?P`$'SD345JZ)OR&1&/ZZ$ M%I;1.U`H:_/9NEQ5$3'GN6S;!%8?XN64INL?"?ZR$R&1)DZ(62W[OK79P"ZT M&I6$VC-3E8,_LB>.^_K+8E,SJT,+/EE&L]\RS&9CJVN[%)NRH+*M<(HY)[GNGOMA%G\R6T>YM5^_74.[[FA4*6*%K MM/OEE"E@A=E^&O6/=Y1.\9]_B\.S)]N>_G(QH&/U4+K`%][P0AR&?W7L1\P/ M='CX&;8EKA_&`7\`A_J3ZP_^_*__^W^0'_Y3#7,_&/-A[/+;T6?^&#W@4,FS M&+!&3_P['_W]IR^!/\&CDK-&_ZQA1CZZG&>-]EG3_.F_J<0RQ]2E4"@6MBW)W&O!J4O&V:D$_(R#Z M^0Q?5];0JQ3*U0,9F^),,\@(VX'`M6Y[K8IY9-VVAQD>NHDGC_-,5-:I:)-V MU"O$!3[SV++.Q;-`MPMO:.)S<;A1`18-1:)=A[$R%S-@'C].!F\K/*V]CJD;?&*XB M8M%8Y:WLU)NSKZ;-XCHMHV&5R^&RJ5=?CYKA;6'%T6T@?EAMDS<9#P1[]9;S MV^ZY6C;OYO):R6J95Q:QM-;;PV%+2^%C0M:*OBUC6L3IT$ MK>YFK+6ZJ=?2=?+2U3+Z:VS;M1G+"%I[=:VD!>WD!0W[3UFK.S[:CG5,+5[5 MLF#/,"O;LARSAC@Q.]8I/^[0@K99:-LRFETM:=J.D7CI_5C%K&FUC%Y_S8"V M%J_C-V1=[3%6;<@Z1M]+U5O$S#M)I:O+0AFY&TCI:T MBB6M:YAK!)2TI!VU(=.)'E4G0Z"?J`,>VI#-2%I/[\BJ-F1-H]%?/6"K)>V8 M#5E?GT!7S)I-L\)\""U>1V/(^CK?OFI#UC-Z/6W(M"$C\=*AQ:K%JVVTNU6E M&VGQ.AY#ID^CJP\M=GHZ]J$-&=X>7R,(IL5K54/662/36HO7:1BRIJEW9%5+ M6E+\4PO:R=LQO2&K.FFQ8;37B")I\3H5.Z9S/:J.X3>,7D^G!VM#AN)E:3>Q M:C>QTKI-6KZJLV3+:IE6+8J[GJ^@U.=.)EGP:O%"K#=&Y=.ONR[;6.\Y47OS MPFH*;I>"Q^\-['"\51EN%[9Q3;37XKN]&/OZ('12>]6:BL]]_!CYD>W6C-=: M7>RDL?KFOMZ2T[(:1G.-0@':U-125FK+7]K4'*VI27HLM'[::.RO/`Q_*=JE M?_7!X7W@P81-_6!A`XRE2U39WG.53IX;3K9NIQ+%!BLBGP^%[%I:=D#V-V_Z MUB/PAX)6`O,*^?3J+&O+J"WC85O&69UDS;5K-W=98<3U-'C!#NY0";6&P7L+QVVBV&LMG+N3G M]:1\4=O)N2:)^/Q,A\=%K1E5&\?;RZ^_9A[\$D=QP+\YGC.))U^Y'?([^W4" M,A5^\0,\P$-BP3C415V>XM6YYR.MW]]_DBWZ9KAB00O(3GNW'2#E&TLZLZUC MF588ZJU.S#:A7?L\8W>D6Z'W)HZW?L->?.N1[%@J:`3D8R+A)0UK*R3#3MSS M9?N0"A>S@JFVN=3X(<8/7YP0)F#_XG;`KCQ4:.PB?HK#*&DH&B=+M`8_%.XN MMRLKNSB=K`^#;%\;)"Q"1E?ESM2-)6K4]W/5E5?],IMK-_AJ-E)V-I],BH]SJMJ,U/Y!J6\@?UW[MH1'][9 M0?3Z$-A>:`\PC!#6>8.S\HYFUTWMM^_XZP[R.UF0FONDX^HIN*YNJ$DB\BJJ?1?;C/J12EFF:B5*L(T;+CL8V/]ZH_8MVJ,BDY]MY421\\69?X*Y60 M3VMCK8WKJHU%HIWY75[?NR+<70(;2_Y8[6P9GE8 M]&)`=[-5-/7"&\(W01VS:$_^Q$K[P:R?8#;&X>:.XVR@.^:Y5HJ@^@-P>_95[/E_]K;B'W7'>U. MXX!C_GN]>8,2?2#5E?915VGCW5.SAO65ZH',P=Z!W52\5B_'JL5K58ZTCDF\ M*D7F^$W6Q<4"'W37(H5??94I))>40E(SYFHU#;-5LQXBFR/3,EJ=JI`Y*4,$ M0E,?-Z_V0M/L`I_5K/KL6P/Y]2^367NSW#<>#,:V%[&OOCT?6#P!9MPW MDB9LF%JU\N@.R4X=2-<"+67[EK*699B-.GF#M3=@J]?^TZ)5PG6='JCV8]E/ M'8QK>$CVZT!Z@=19R$"S-^K6CO'XA:SVYNM`VI[66;(L"Q3H@B0-+5HG;[]Z M6LK>["1V*]S_[QN9@Q&RVMNOU;<-^B2X5MRY;R3-EM&M5>'^@[%G5_LJG'Y25DXD+H#B8MH MJ:N;U'6,3D\?H*TA:0<2&]&25C])Z[563VS0YBTK=#ILHH5NL\,.TVATMU7N M]1CM6W/UF+46M955?\]HF\=R&-!M&)UVG5S&`S)D31V(W$+@P#JBFV!=H].O M*JAZ$O9*QQNW(%%&N]DTVKVJMBO[QL?JM@VSK4_/-I,P'5O4FZ_-U(AIM&H5 M\JB[,5M#16E16UGY6T9?I^MK`U.95-V,%)7>P.G3\^V8^"Z M525.[!N9@Q&U`S)PG0.I6G!04M?NZ%LTVL#-B=J!E"XX*%$S%],W8=/5 MBM*WC5:_/L',_1*CVS/ZE;G@)V4R5QAOI0Z06YADP:O%A-QSP]2M>(=O7AA- M@5,WX#L<;U6&P:_NX\?(CVRW9NZA9?3:#:/96CT^76]WUS1:5M_HK9$XKZUC MW46GMLQV=(DKM8S'[,[<)&VU6C]M-/97'H:_%$6WOOI@M1]X,&%3/UC8\ZQD M7=[HK*ZR65EKBG7;SZG57<9V'YK=CM'(9]ZMP?CE/:MJ0==B3%:FU9J;S@\% M@:QYY3I+,FWPM,'3!J_>!F_%QNAOMX/-S>S@I>Q576#LUEG4LA79N-]\52,F M()8W[EMAQ/5LI&6TNBVC:9I54W,?I"J&>^G0_U77J M7K_3MNK:?7OY]=?,0%_B*`[X-\=S)O'D*[=##D-.0-["+WX@^X%?^MXSG@^H MV?;=PCO;LGNVI3=QRM]_DAV7U6RJ>6E[C:[=B8,TWP?\IQ6U!57S M?=K!-Q`]=UM"":MOD?'EEPES(!YJ).K7&SK_Y@*QC\QU/'XVE@U\^\WWR5N/ M!<1^3/@-QUG-SY2P]S?N7VKUUL&ZM)_V&RDA.9PABY^O0(RUC/*2Y5\7^2$? M^(&--O`7!@:>!XC:RMNF44^Q9"#S?$W+PQ0D!YP3'?W$[8%<>XL`NXJ.^_K+8E,SJT,+/EE&L]\R3%E88EMKN_)F8>(X;Y[?[S3PQ<:F=BNR&&"?[+;)C-9J>9AE;*P'D+ MV.W*P;9:W5;3--<'^SZ")1C[+FQDPJN_8B=ZQ9<^P];-]4-8V3=&_,^T2O..;FX?KN!WEB;[L_N'V\O__L?MU\]7W^_9U?_\=OWPK[)X MT0QP:\&5!^A_8?V27CC?D.&#CO.UX!,O#F`-E)E/;>V5.R.PX&OL! MV+@AP1+Y\&48+'_^6#"-`2Z$WL5_S:'@*CA=Q]9?9H M!+\#:1Y?#1JU<`[\$P$NI:E8B[$=J1EH489(:1QF1!;NO/0ZT5X9K$ZP7'OL MG[87V\$KLQJ-IL'\.&"??#L8JF7^[`2P8'Z0E03)_"V\@S;#^ZLIEX)UN2+& MQ7'*AB&([O)\P,8V``8>'S"U[<;T[KO&>:-A$ON!_`XR<#@>0.VCBVJ[HW2R M'"<#!\53^,MF`SL!`?AA%@Y@C4 M#VC",+)%0-NT^D:C8Q4Q[]ZLX4$HC<)]U(O<]7E^`!XN/7/2;'8!H-QN& M5#%9A@`6F+H<[8&T?<^P^6!3UQYP$CM8E-_`@P[9-`["&!O;2=Y!DRG,!#W` M[F)L?`?<\6CG1<[ M""11IY*`0N]GI\^I1["X=CJT\%:D[FLVA-<@!P7%]6/J((#PLN0!DWB@(XF[ MCK9/M&&1/F=Y?;Z0U*F:YS^P5>(3KF=0HKO9AW?G5H-`P8?(N5JR&N(]"24? M_BQHDG)'EF<04,'>2J4!/NA%<5A,$`106%%@#VU%#E2=0-H0IJ+SB]@( M-G:9H6+0BJYP`2.0=@8&,O$P$T5?0)YYW7\.2-+-!/RV932:E@$[5H)$3/6" M"E9X7O`LL7EZ2LAPLTFLE_].:`!XD=Y62AB?4Y_%X%E539[>V!X2C1XYEP(C MR30$=YF'4P`:+)S[2A0'31`GE)7Z']`'8L#D3E`LN>Q`TL%G.UX`S<>IDZL=&EQ MA"PMQ##G\W&C@[`),W8L02#W]5L&.AA*?.)@1`@^W&4RD1$SI.B1T@W995_) M6U0LEGEO"+PMAW-MX.#HQ6__FLBD&9,93.D9C.H\OER M\\E.'YG,V#$;C372IU;-D1)I%:LF=:N%6]<1GUJBM)=X`\X'X;,&>G5J1U*=^`' M)Q)T$(9\D;U>=CV_^A78_8Q+K^AOC;6V-_-FJ[D3$=L^$+=I/'.]1=^7BM%\ ML!4@LL>#F@].G@\61`XU%QP_%US]X,'`"?$4S!G41R'LNDR..M!YOWG)2W6+ MNU,PQL)R'AG#;,P>\R^;K0J`-[ZP7L'D9FMFC&S[74ID.&$*B"2)PR1`>>F6 MY7A;;:-G'NC"OP5OS)ZJ'NN]U`C<)*J\C7)BR]Y;=_EK7AY+(Z01VC%"^RYH MN!5-<3L>IVAY&$>SMD92(UFM MDEJX5:NW`[7.4>(Z3+#NN`NUVC5=VRB=JW:]:NI`U#=+GJ:JIJJFZBZINF:! MZQH3<7"\YNR];+ZW'4G^NIG0YJ0*Q)RR1'3 M4='Q3=T$-CJITN1;3+Z%NZA*B'>4T>FZ;J+K`Y6#TBROKP2R.I MD=1QY3JZ/OJT2R.ID=1'\I5&$/7AESY0T%355-54U8=?>SO\>G,*QP&<@WVS M7]4A6'OE]3CHH+D^!#L`0NI#,'T(=DJ'8+,=L&;^<6M9Z!7A7K,^[?K=E]:$ M/4_P?13,79.*HOXQ@?=Y40WD3:A=!R;)+\CA(7"=;?8@RKPGO638XCXRG9(F M,@O7N;B'0`%_;-HGQIP!*E>T_9$#+3TLK&V/(A[(_@8R2>J M$"!&(OAD&044D,SFHV6P%K`E=O`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`!GHC5([:LC\$TDAI)'6$^+*=(GXAI)#626E]5 M&I#4QV#Z&$)355-54_6@C\SV1\Q:)',B`)'&X_^W3_>7WZT]7G]GE[;=OMS?L_N'V\K]_ MV2]P=6K/M(VBS:H8$A5DOH\?PT'@//)A[0HQ[W=Y%@JY(*O0GDFQY16*+\OK MM+WV^X]L02'F36LOK^_;OY2&I>`!0,#[^T^F^5,ATY659:#1OO@!,=(4P/2' M[`H6;[C(R:YBGU*.2Y[ZS8TO8+?TF\O>W.!V>P%7%?HE#?)+%I1!4Y?5VP*& M^7J);ZICMSEMMH7@Q038/UIY;`K6232""[$] M!G5]2UL*>*)YC_UJS]296L-I+J5T88+&$7\Z6_+@4O*ND]VRK05ZMW\Z'N!J M5"3QI0=;J_+!J3U7G>0L M%(.HF:3JB(/Z9!J--E"L8>H]_AL^M6USY3G7TFO2^OD2H^@IWP M;C1Q>1**N\7CYDH&?BQ`]'&-6;>;"J+S/RIM5?_-#@9CUE6-ZF7:!RC>5^9X M@X#;(>A:)PJ9'4=C/W#^C:I7]N9&YYOUS:_L M^N;AZOO5_^\(?@XQ8-/H&\""!`OM3CP^($U^<:$R2\<`' M8P]\L:=7=O$4<#Y![GSAC';K*.\>R#(]?>W!U%$<,=GEV6I;'P/VV^2%NU&D M1G&XQWZ=//[#`*G^E0-;>(GL?5"BW/UX_=N#^J/W\6>"[64,TX%CR&6`"Z0. M)6AL/W-F(V!#^-Z.RE0#D.M/'F$J&AEH^>(C!W"BP/9"T3H<]1(J,/0=G:$# M1#+8K3<@P'\0&)=^,/4#(:V@$,0P#MU@8P#U-UB[]TQJ*/Y7##J+^2\>Z*.Q M,Q7?`XSI\$HC%:P)CO!LNS%7PWF^!UZQ%P6^BVEW(A^/5B&,2&>^LTSK'-00 M_3'D\,O$\0`NF#$?`FS,#^YXSS`,+:[C"4QP%`<(B?42`,[!`)P\F-<%FL#Z M@YY"IV](8,`JBB=I`- MP&@@.*%0RW8`ZC-B-IB-9]1V(/OII!U,O;&"XJX`I;016;..WY;CW#CYU MBRI='SY:V_O4.&^8UJY/CQ84:--KM>FGC?.R-)&W2_A5CP:V:0&4*=*RIF7M MD#_M4]86FK3YPE9;.'?>:PZ0U33:O:;1;%;H,M8/R]U^0N_+W*-96+4SQ*YS M*)((2.1/%4[T6NX'N=UN%-7"J/A3L[$CYJ];:DF=/M56^5=I^;<5NZEI/I?> M#NY)6#213TU+'<$>\$-?F>&?#Q>)W7X"%[/1WZ-R/_Z-49T^[4SKZV4X&KNP M4AW3D]\!6F;U1TLGO@-SI\/+E#R*GBK)];"=($P-E MD+TZW!T:\!/\]B)3+\YL4)+V$V?\QY0/$`O7&7%Z")X*G/#/LU'`>9(&R`($ M`A.9/CC/(ADU>?/9!P@!D^A5Y+`KBL%D@9C`PZ1X?-D>##`5$O["%$B1R7IQ M?\FZ9D\G&BYB1)DQ*E/N4PK;64:TPR0K%%<+/A-?2`:U"]GS+,>>:[2V`[\&2U;OV3U6H?GTLN-#:7UH!8+_U(U8>X@8?8-QAR'.;K:&[! MT5PU9]#LVK/?[V?6G-L>BG[^#'\S(#T;WMRY1:02<.9,)'SK@*[BOC(MC90HD9&HGY`,X=I0[66!VP#&,(Z(OVXFW M''AHQ03GI^ZQE=FMYANVUYN_N?E%P`TF7>\B8#]_#W";@!4,)!\:`[>(7E%RR%?DW$.SJ'3!3-F/U58,$,S MZ`%=,]-ZZY#88E6]]<4)0%/]%=L!D`,3X]+R;!7>YZV#WFH9[5T7^MF@;OE< MAO,NSI`*A:&YZ/QH`T!*)??=V&H[83"_,,-K<3>/@+S-7? M9+1=F(@O?AQ$XY.0B-;N2R1N)A&-NIB(K4B$C"K,&H*:;BRVL8%+[W%N=G^X M#CO)>@Q1ATW_+K1T7&J"[7W=C M0:SW@"5N+Y4`-XQC+8AZ:DDX_*U9W9\[I*WC+A3B-FB[]UBF9IJ=Z8Y:UDO< MLKFMLOJA9M4)D`&JKN]Z.^^7%P1AV,!W8X M=GD8II7_L%'Q<$A=B<&CAJUMZ(#1[(2MZMTAD+8WX&E;:AB3J]L$6.J.'GMW#EI) M%QPL88'V$A;H)"P0C0/.2WC`P)0>6UR6AY>P5_DK=;`>X=R!1)WZDH\X#Y,' MZ:T7/_@3:P\.[*D3V2Y!D7;GGF4/)EF#P*F"-RS-&[.\<<^GDO%'R]^%=JCH[ECECN^\,<@MH-7UEU=?1PG:1B901C).J/1J8/B^!P'JE=&E#U^)5#R1[!&1F)G.TK(?FU`0*!J M(L01/!/:`PPHG;,FO-FSC'ZGP4(J]8%TN/0G$]\#;/W!GV(LN>@C/TAVLTG0 M*5G+9,;]43!341&G**Q,X?G!Q':+%#0^5I.@YXH(/$CA#%1E(`PBP@(/(FQM M@KU*LKU9LO4591>,7%5%;)-AGIM=(4?G[`_UGHI%3N-@,+9#&C13SA%&)"BL M#K!BAUA1,I-@GK)JC]Y,44<03J%SX%4L>`OZ'EZA7AOV?$N65&SI^E,"!?UI MLBGH`((B/]SYKE:Z%NX`S7O_<'OYW^SV[N'Z]N9^=[U)YNA@U=$ODFUU@$?^ MBIU`-AF2O6*P9I72N'XPXDX4$U./N0?/#_PGS_FWD+D)-N\1<7O9R(>X.1K; M$6KPM/L,FQGK$1X<(HR@7?UG:;8(EM"!IT,>/&/9(H0"&-KQA\#3?NQBBR`2 M\>Q80V\)G@%3D#;"R;Z,%5453FB(QX$?/Z'< M#>))+`JY$A0"6C3&!E;)@5F<,/LB3$":0@`+V`YH9B*'?![\B$$D"&U/L,\1 M/A9[\#F(:(Q">H)K\*B477:V48P(R`G#&ACOFG,W<.3$!U9Q!CD&)U^#!Q.P M"@$:$7$J138"?25X/7IE-E@2ZNI%BP&>!%<-E#*_H3Y"1POC((8>9(]"@=5-'+" MR3*_`5R`!SP/@S\1Z+)ME`%/#>(@4&6'\+]]X9&S>(JBV$U.DE(??I#UX44'.0>4;M%B,%R(5VTC2+.*>A^4/+DCZ$DW"GL/NJ#!?9M+@XD7?,I_@K>-G@#8"OM*=I`:63`R\9!":ZQ[\(D MVIHLB."BSD>Y\1Q/2.Y$=-/,&OZ22-A+ZA.!4;&2>!N,E1ARL>/'J01/I`X; M+2&X+8/`>42OZA%6<#8L[W&-!N0[IU8S'=]TS`[&,!/R]AXDS'+I\04K\ M:8ZH":H)NK415^P651&-MS5;Q9.H;EBLH#/1KO"9ORZF>5?S[O))1'.DF3Y. MAXC($:Z-"$.SN38QAXC+$2Y/TNMF;PNTEM(OO(%K+FI[\U82[WY&N:E)IH3) M=L0[VYMYL]7KB#BMM_#[TB.:%[8"Q!WX*70BK+E`L8W8E@!NO:$'\YLG-ULS8Z0E.2RS M:S1Z[1.FP+O&N6FQ,_;..L]75#D<.KQ[`_HF8+\%M+=:.:HHTK+.2JRE.)8Y M<.L"\99P[:9(ILN=''P>"3[IBW15H8V"C!\Z&[#!3C`ME]5B!`&9!?*Y>Z%< MQ][O1#Y5,.-8)%2^V#;+#X$UDG66V)W@MA/[NDX8;!V>6'?S@E=?R/<#J]/OYA,CVSCQOM);N&XZ#]\I5X&:T M,\^;O:W2;->>3G&14"H[6U0F],W2]$S^VO MNDVCVUZ=NS4IWQ28.2IRKJEG5Z&BV`QOE7HZUJ,W64>YR3IFW'0L2$NP1E*+ MLHX%'>!^?&M!C0WY]3BH6G64HZ$#0X?#?SIBM%K$J*S)SO%NRG6XZ"!(J<-% M!QHN*F^ZM)^;QJ=99`$+-]E/3P%_PK)/CA<%CAP)4X MV/-A;CM$,?,3L.?F8//CJU+(5`@M5ZX-T'&=/[&45>2K$JJ(;."`&+R*VBHE MJX7Z9ZXL<7Y*&%VL?CS%FCV82B_QRU5/`NX#BI+X3['()!9=HK(B0!;'DR3% M7[,C"*)171);4@PA"ISPS[,1EB)Q,,T>RS<%I!\5*%))_79^?RZ5%)`TQO)] M',A-E3;Q^5R=V%)JIO6FHEP%/JI:4Z^J)'N'A5:GJ%(WP:*(FJC6Y<6Z>^>M MOJIBJ"YO%=7J3ESV1?6WA;58J=AV1U2M$1\7%MJNF-Z)$_18L+:/V_*0%KI> MPK<0SFM2WV6%>B\R3;V'-5T6U'[9M-S+^I&`EV7A5)58W]O\-D#CP%[=`-45 M[SZI2T$2-BF]*P.VP8V,R@"K*/)4RF^K(E;WYQ80OG"O6]KR6RS-;%RKG@!> MI09F7]%*>!;TK??WGRSZ.2FZH2QK?3EEV7V1.GTJ#`.>./H5<7GYP6;"VBWZ M^6(^^)'6R:Z,VU==GG?[7Y4Z?3JK@.'UFFQQ3?9BD]KT="=,'#=FE+NBG@B_^T/6KE;WN?LPGM-CULV M[);$YCLE$1`K=TOZC58DHIY)"U9DG#DS2-KCB!+V&5A29,1Q&+5GP_G*T*&^ MAHI7/'WBM+R!S#V?1K+)CBP=)?HY%HX?/9H;?]` M'C;]U@T_'"`7/?CL$V?7PH3]-O6]VD&X>9.&'0'X/8FW7B2&]^3X**FI#O)4 MP^QZ<<-QG)SNSX'OR4V7&4YSI5>/)C+Z1JATO=J44CBZJ\8HU5*T<_"0E73X-=V;?3THH:H;HCM+^J?MJ9TPC5%*%];W;* M`QR>'[&UG3Q=P*J<$+H:TRD4L#I"1MRJX3XM=:\1JCM"NS;(Y06?'FX?+KZN M+-?'4W>K(D6G"W&]P?8>-/&VR9S+XT*ZI-F2V<3_SJVVXZV2C7&%-U25IQY\_"IS M&$V_)=?Q'^@?!0W=,X0_OO/1WW_Z$O@3S(P]:_3/&F;D8]KH6:-]UC1_^J_< M6B04+I:U[><3]MIU2B=<6=T4G-*7)=\I_LLF$J3,5Z0.JDAZ:6V0]+)VJL/: MZGF-G,6WN5AO2+NI.GMCPU2-E&]F$KG6Y)VJTE'69*B5<"RO+;(90O7AOXJZ ME+<[XJQK8K`V(`&V[KFNI?B(OC5N@5%JMN> MU[)+Q=MPRUY;WO#%O=6K6$2N-Q:OJ$%(IZ!JP;Y9Y.TC[+H40R$KE)=?V)^J M6%P?_,`TPB8E!!;NX(JVM'O=F<[ND^\"/N)!P(>TT]YL`UNK6VU;5G-OO,FU MYK6P-SO.58*8L,K6T#U>VB5[AAT@?KQ4/+3!:D6\S*W!I_-MTF^E2RM:)U<" M(GD*:]V'TH2CP2Y%>0A-OXV=`7_`^3!DSAKW137U%/7`%T@XL#[*>%L)4TMS MF-Y,Y[?/L!E%*N6?ZB9;Y;YY(QHD5G+GJ=:K-.Z[81UJNT MTU7*5[+8^5+MZ5AR[A)<8IES;5HOXJ>1L^BDZB#7JL[I.!K)HT.REDEC^W,Z MEL<`-"MJ)#625:>7+=BZU-M!V>@T1=0=+L58W[&OZ1U[355-54W5O14FV1\Q M=^*0;GJ3>L$)0'F*OKY+ON)=\F4'"9J0*Q)RR7G$4=%Q"Y4AEAQK:/(M*ZRQ M8(NQE6H0>PF-UG5'6)\(MD9((W2`AR8;UE35)R4:28UD)4B>4%!3'XW4C/"Y.F>M^J3$AU]UE355-54U2_GUUYEG/B^=Y47N6HW3/:G?+K/<="@/+R5H(`"YL\UIH( M;REQM>'Q[H'3H[ST50^[3U:/MJY]576*GD9((W2P"-4B"UO?Z-!(:B2K0?)T M<[$+0=(7/#22&DFM5'15K&H"C)7FBRY-^;8:"V,AFGHK4$]3<',*;JC'CH.J M5=_?6!S0JLDU#5W0:C-FVO.M@N[BDP--Q[7HN);).&A:;N&*044V0Y.U/F2M M19"TKGO#^L2R-4(:H0,\/M%5L`XS**:1/!8D=7A3'Y_4CRLUDL>"Y-'J%UT? M2\>L-54U5355:W"^LC]BUN(D7M?'VO_!@::C/H`YZ9."(R;K>L?WE=?.6E@4 M2U7.4@6V[@=C/HQ=?CNB!S^]7KIV&":/;U!#2Y`M*9^U0CFM7,VL!;6U-BVG MM;Z)?2G=K<$#@('W]Y],,X%_]7N77_R`16/.I@"F/V17WI`/%YG7*MR%[I4[1)ZMAM+M6 MM>3:-N>ONE"G]EQUK'UH(^Q.UW;HYP<_LET6QH_A('`>.<(,'F]U*UB\?UAU M4W8RRG8=BFA=JW6MUK4'P'';V"F^-J4K;43K()YZ MVZD^F4:CW3-`L^AMYQL^M:OW);5RU][1L7I'>B=:(_U[8#O1_:G?HDX]2PX2 M%YP[HN_QR0[Y\-*?3+D7VA&X'#3([10_AA>#R'EVHM<'G'4O1Y/==OU/)O,0 MMS<_K'I#=%M95WE9F'7ZU:U'C+?ML./G6+ZJH#.Q<6 M3>13TU)Z#Z@%[!@^'4*\Y?BW@W7ZM#-1U,MP2,*ZT!JN5'%"[WOUOK?J3ZO$ M?)8DO&R8P3*;$_/%=H+?;3?FU]X4I.$B#'D4_D]L>Y$3P9#/\/W(#R8TNLZ% M.>",SC3_K[GT8;\HH.YM6J[[1; M'0'#8D.XE5RJM\%M)7!OXZ+.JF[_[[X+HN."YJVA$M#;R7UO-W:776Y:K??L MC#5[K??[<;%3DV/1S]^=\$\V"CAG8%P6W.'9+=>#+]9XO[_UPKI-[_>DKF87 MZ.K'E`\P3W4(GN.0>\,%5^+VI9IN?(_72\[*(=J=@#7SZP=F<<(^.!Y[Y780 M_JP-1[T_G=6!C2T6^:PI.&9E=B[:I&Z^I7S3A0U/E)V[F$X#/G#H]^^(9GCQ M8@?#_=_G.(A2%&Z#2=>[T-'/W^?8)F`%<<&]$$B]V=O. MI-L."-0^++-V98$+H(K]5('[_';3LKOG=A4W6GT9/L,6AOFC*E=V._SRUEM6 MNX)3I2;4'])TU.]\8CL>V/MM3U0MH:>.B.X>F"1N7!3EU\!>I3AG_:N[^"-V M/*5JYFY$'BHBZ;S);<^OSFBM*$7]D?R\86Q!LY(4Q0\>6L.NBM%8H" M5XW6!O64YDHE["):7R@,"R/UFW/]C?_,,5Z`'-:MJ]Z\YP/?&YZ$6+0/1BP6 M<,L.Q6+Y*=:&Q)LY*O_,!Y0IC-/)SYT]VHF'L1.W.GC_E3;?CN`(SCHJ"L5H.GPHZ[5#PU0'>_CD>] M7"WM+Q_1MF3OL1S-/]O5';6L?:/C+H?*GV^N5K/)];UU[PM>!('M/?$)>!.? M7M-'[NQ7_(HFDN!0QGAX[=U1,UCZ"Q-@K[TH<+S0&=#]QC??)5SQ`N&".X.Y MNX6;7B!U?#-^P2U MDMRC6E=Q:V[F@E\=`#L`V@D;6MCQ;.^P'0#Y%K:,VY]"*?3FS>(MX3H*1SI` MR<`P9,5T?OL,FU&D4OZI;C+IXC+R:O-%#)8OS+9E0J]5_HXDV"#:J.A5TJNT MZS#1WC7_.H.MQJ6[YLAU,'CC5"LT='D;/^K5T*NA5V-37'96TU&.*B.#3>M] M":2K7HDN&M4L&W0%\JK:8F^H)_7FRBU#Y,"[]Z`>./U_7386(_EBVUR:/J:1 MK*6$[02W^L84+FT/C\C7C5E6&)^H?(^TK0U1,?]\,#N8_E+NW:Y.OY_K1[9R M:=J,6N9YH[7,(SX.AJN>5FFV:_>@.)6-,B*+DME6V63/]J@IIP_-4QU7 M644]XS;CJQ4HL*DN*Q\ZMRWH-HUN>W56.VA2KBFEJU!PE4V_IN$R&L[7?JF8 M>CJ.H/<&&K<#V/?HD,,!<^5)('FTHJ=##K4,.6S(/\=!U:KWU0T=BC@<_CO( M&$793<#CW1'J`$6]-](,=5F/ MBMRA-W@"R[;AD M.XZ">Y*[?"`9&3^[_BN2OX1X$(TNO_@!^Q)'\=PUG+KSSL8]V:0[5*.EV1R5 M5#C8$:&%=@,CB.PW#P9@=Z[MU=(N'NYSNZ#@U5^Q$[V"ZYUN5MAT=BGK3J@Z M$=2>3@/_&3R4QU<8&3968Q`S'JP@\DMO]>A/-?VTY^*5[V9CYULNTZ4_%7XJ M;$]YK%9P968Y<'5>`_MX*J3V_(AM;CW7\V.U7CND3SNSKYLR4<466//R\7Y: M@Y>U[W#8!NWA]N'BZX;2OL]:POK3<1BNY3RT"[NE.?GMGU;=6B[)35@C'6`V MJ>`[=^T(,Q:"Z/4A@/V//:!(]F=;ZWSB,G-&K_-+QAAS'/A./_J2(]X@?;FX?KIC9)`J>L>]77R\> MKCZSNXOO#_]B#]\O;NXO+A^N;V_NV<7-9W9Y>_-P??/KU`_,VO[(_KAW\H5Z"'P&*?6>6#3F\/\!Y\SV0,4Z M/PB4"ZF5'.V9W+[9`3!"%`!+J#,]-DDH9MP!"_"MF= M_4JY02,_8"/L4\P#-N3A('!D:4XQ<`BH9;3(>4KT5'&MH7)FM=6G.'0\'H8` M_B.@3!7Y^1/E6KGP/'WQAA+W.Y6YO?'CFN+TB;O^"T%G!YR8)Q0D9W88EJE=+X5;!D2MFBPLWC85)M?K.Y/A8RU\,C[8HZ3 MWKBU6V]WG/-YYZ!>_5`^(4)S`QK<\2#T/=MEEXN*L^X+NF]\B%1FG_GS6H6^ M=P<>F+3`'\:#:#9I8?_07?K!U`_`]M4.LLIB*54*W!LK?KZ)(-*KT,">-K"W MP.5CV$L?!K0/?F2[;\W5.@()+DE^2^[=$00??O/L>.C`1J2\+)1&2".D$2I' M:*MNPP;;A_O[JX?[58AA-JITDFKLOVG0C@ZT30"H5%BW4D3F,@X"C"E=4$SI ME\VQ7C3)"@N^SMGUFR;4"&F$-$)OF7`G%7C4->'9)@0(7NJ:X5\BPBJ4F1V. MZ=AF@!_X7['S;+MX)E.*^>:77]_<8J"\PT"W8W2:NVBL42^TM])6H>8X6Z;1 M:/1.#VW+Z%KE56V/%6WL3-':1L.8?;N2I1KY8C"`.:*0!7S`01OC*=L'CT?S M&_']&DFKV32Z9LUZAKS5Y!]ED<%>HVE8_7Z]D#B)E=H82;!Q3*T9C4^"D9JF877->B&SKOXR&QW#[)3[`(>U(B?!=B9HKU:S MO"S:D?AJ=P&?VLZ0\1]X-9.'M)/V*>-P(*.$(O.L9LMS$CQX2$BNJQ(MH]^J M2KKVO4XF(',TVMUL&WVS*GN[E\84)?WGEVC`@3^9.&%(^=6H!$>81AJ$_\%& M?*Y6W;S'J`MR'T5U:4W5@Z+J@K":IMQ"RC6-7J]\:ZZ)MX1X_>[J[=EJ7!J^ MUHY(73U=C9!&Z&01VK-#+WQW2_GNE(1=[T!%TVP8S5;YP?YA\5/3-)K]F@5C M-T:FWVP:[<;1+$W?:'?+LPH."QE@,[-E]!;TF-$.U?Z-@49((Z01VK]FVJQU M[UW@3V&*5XIV8M[DE`H-U#%3Q^P85F4QZ;TCTP9DND>"3-.P>L?B0;6;QW*& MTP06J^QT;=]GU_3L9S[U0R?*GD_7IUC.6^&?:O5 ML(X$F6[7Z%2V;]VJ-X5?_>K[PQ?'=6M&Q':G932ZQV*^3'20C&ZC_(SEL/#I M6);1T8GFAX2D9;3`76DN.",]+">JO++!G1WA;3F#!?S)":/`%B4&<1N(!<+L MB0_P_9N^+:^D<'QGO#IA8QM4-?M&?X%+J:FG>5)3]2BHNGU)W[JO7UOGY.B\ M+8V01NC0$:J?AV]ALZ/9W)EF/G>F)(A:IJ9IR&HL$PU5V-1BA3LE:XZ8R1CN M6T9_P;6N$AI69=:@HLIV&T"$ZZ> M^:_)-WMDVVM;1J-9?IY>"07+V^J(KV;^<6O2%."4&R50]PDVTWF"0+&SW2&/-09T+7'% M1A.GUU^C:U@++A0=*]9FUV@ON#&CVTSL[2J)V32:NGF!1E(C>>C"IYM0G"@; MU;$)A5ZQDT>R4K:LK:.G>U34F`4UDL>"9/^(2M=4B]3:>+MEGBZ^/+Z+];?Q=((:80.'2'=S6+-%;`LR^@> M3YEAP4X"2;-EM"N3,=T3XRA8XLAZ8IR$')\$DJ;1[<'_=^N49*U;9>BGZ^PO;971:!K=MNY4L#D%%Z4T:>HMII[5,-I6>;A0DV\)^0RSV39:[2UW MNCF.-AEKS5]$D*U,`8,\XH>9OA:1'7%,$*%F!)@Y(N-X(S^@!P(^Q4">]\3@ M-\))-NP84D]DCG!]-NV94D]LCGB!UF\<4T]\CG")-FB=4T]$CG!M]CO) M6A[)TN.2K:&[O9DW.\7:R;)O'XAEW7X*R;XOEM<\H'E`\X#F`;VQP(K>:=+B+?N2M?\@%\CI!'2"+T-H5TGR:2=<.BI[_R9>S$_ ML)8V/=,R.M;I-;79,#'W6,G1LII&HWEZG6\T&W@S=^::;:/3WH(^T!G5VG)K MA#1"-4%HU\YBV26<2S^DJY#!,N_Q^&[Q=/I`MKEDFC7.I4[[$M2&KHNFZD*J MFKVNT>R5E[C4Y--,N7.J]GIMH]TO=\H/_,)C!6F?JZ54K+-22X9:RS79)EB: M1II&FD::1CNE47WNHXJ+ITE?IU\#/PS9-/!'SGS>PWZWL*;9,EKFL11/W]#1 M.RPD*1C:THVH#PC)9KMA-#I5%:C47G&=K9"FD::1II&F45UHM&^OF)Z]%=>S MO:>D^_,O-3/11^=S:(0T0H>.4"T:NZ7;>.Z!%G.IL+\]G#B>+![[/'_5<;_K MT#.-5OM8]O1FR^@VCV6W:[;[1O=H>JW@L62_47X"=%C8M%I-H]<[OO+7,UKL M.P^Y'0S&I,:&_)F[ONBS="4\LYJMRDG$AS22&DF-9*U\OUS60HDJ_(69U@&E9#B^3!#+L#I;;3U_W,1K6>4.H2;>8N*U->DV3=]:O::HIER. MGFT.N_>#!>DT9((W2P"!V`4RZJ_/MS!TXG9*!Z3:-K:L=HT\L6 M77[U;@B;?3`R_9_07I+-JY[RFCH5&2".D M$3IZY_PK7H08!?XDT[#CA,Q3LV%T^JMWHM'&/4>]#Y5YYJ?4UKG;-CH-O1G< MF.D^]'M&;T$*VN94T^ZW]H4T0AJA^B&T%_>;GKV-QCQ@CC?P)YQ] MD`'OG_4-"XV01D@CM'6EM94TY6NLY,[#B/+J1HYG>P/.!F,[>"HXRMOOHGSH MF4:_7;XO77$WL&#0-!K=-:\CU`^'MFDT>X>^$JTF7@TI#W7M M;*]7W?6O11J)G;&`NW;$A_`V@%8['25?U'GI&DF-Y"DA61\';Y7SH<*=;'A* MD5,3K'^CNP[".ER?O2RL*:=KY&JJ'C=544=:M4_RTGU!-$(:(8W0R3GQ\@9& MX:'4"5FI#]V&T6E5T4GDI*AF&JU>%=<'3HIHBP/?FF@;1=HUV8I#^U;':/>J M"%'L--Y_6AZ#1D@CI!$Z-J_;.F_/7:08^%[D>#%>==[@3D4ZXILM$@W%AG[\ MZ/*UF\"N.6+6BO>-?FMU:T1COMF,'S[9S!YL3E:_BJ+)1D-V+:-M5<-L&T1N M#YY\']H@KWR`90TJ]F_H$GIFI:+$XO`C_L MP9GPD-WP%_;=G]B>(;XPV#T/G-%'-K&#)P>@:/R43#N=F:*J@1\+%OIQZ[,6 M#4R$9`/NNG)]_OY3XR?Z.YS:`_5WGCG`;W#M:K31Z;:FS<:[S^R58'\ M*;>HRWR7#79,6:IMV'H!4`1*>'__R>S_5#I&X?LRAOR(?MFO[*F:3"K,7B2B9D_LED"3ISAT.6KZO25T-M@ MDF+XMS5;Q9/<\2#T/=MEEW8P7X#XP)`YPO7YQH?X"_O,GYV!7J#ZH:06Z"[P MA_$@*M__'0@^1[A$EWXP]6%[KL7G4%#:U21K>21+H^M;0W=[,V]V[+&39=\^ M$/?\"=LOK+RU([+OB^4U#V@>T#R@>4#SP%:`N(7?QMP>:B8X82:@]+FUJJ)M M%?4]Q\NVR$\U!?801M0$U02M]XB:H)J@%8^XZWP@>>S7;+^GI[[S9^[%"QH9 MR.>M]VNOHCI@?+_VD;9\LS_S9GITW>_UC&:O/`M^V=0KK&\M\=[PYI\FAR;' MZ9%C:TI"9Y3K]%Z-D$:H)@CMVH,LNWUTZ8<1\T4X)-WVUNM1+5/[[R"[.75,H/66:DE M0ZWEF6P3+$TC32--(TVCG=*H/M=Q9^K=_!K@9=QIX(^<^?2=_>Y@+=,T^MW^ MD>S'/RS9?13.5K?2V!MZJX>U4B>!I-GO&QUKS1KGVAD^2..C::1II&FD:507 M&NW;&:9G;T6]&>^)J4KMNN>81D@CI!':GZ>[_NZ=>Z#%7.KJ8P\GCN>$$6JU MY_F+NGO>;G0Z1J]3'I`_+*YJ'5%?>[/?!KP@4.5`H7:F_@`Y;_IBU**'-\)9],PMWN^>TUN3+;[][EM'9;K=;[;-K!THCI!&J M"4*'Y;.G_7DV:,IS^.:I91K]=A6M+T_2N'\P^T:W745T_90:$VH_?3N\6)FC M?DK,^`'\\_Y6^MAJMUS[2!HAC5!-$-JW6T[/WA;VFM?)R!HAC9!&:.OZJ[ID MY&NL3LK#B-+R1HYG>P/.!F,[>"HX[MOO2GSH-8SN`@]WQ2W`GI&PP."LF05: M-QPVW/<>EMQ_Z+46-D`]B)7Z8':Z1JN[9@[U-C:`_Q][U];;MJZLWP]P_@,1 M(#@NP&;I?FEV-]"F746!E;9(LK&?%8FVM98L>4MRLK-^_2%I*8DODB5%LBEI M'EHXMD3.-QR2'\GA3"=Q$,H&+_0>Q21P4N+1MZF4P@UGX^A%I@W1$\1OIE&` M?+LMBD7=^(E/%"(W"FGU";M;$4U1&*5T\%LZ3SP5-`R"`!)`MC>$&`J6^QX/ MJ!40PG+"?%3T_&09)BO<<;R9B. MTTT-&R6A#\"'H]P909';T-V8#*[AT`.&"%H]Q>"HE1QB"'(5H,KRH@]L9'#T M"@`!H-X"Z@%[SZ[O[G51&M$L-3&P+!='_`(:NE=I*ITKP?<:6.;IM3J1-0/K M%O3@NFK3=6P;HMX$`%8.@``0`!HD*UH^(+4S:MT4VT<$*\_@*C6Q+[TTNT<.*93Z60]C7#(=R$$)L%47"0$MWODDB#(NM/' M,^F,_YTL'3?_>[,O4^X7.,N$?$#YITOTZ'OIG-FL='Z)JMKOV48?/,0_&ZQZ M7VNX88HB"I%J(OQX)MMGA<5MMH3+S##F5?R>F>L//R3HFKXV3]!7VC0>NG:> MD"ICI$CR=@B676)>D6"O*[Y$V_I;^)X7D*HS<"5T#2K9+W]7M;5+^L0WL25-@^E`@*!86* M72(H%!3:UXYK]V*^?GB>6T'A.Q->^O- MUTER=5/%NE;LH7&H\@HM+"3RAAX_0U6'C"5=QI91?$MSJ,C!$#;4H6)#T;$F M=3`B0&(`<,@&0`!($$#')HQ%5\>NHB1E4'?/%"PK-J6@D/H5;I(* MI%7-MK&B0'8X,$J!M*I08FYAT^XTR-@I*7H+#LO5O('JM-6!HFK1DR[%`AV! MCD!'H*.CZDC8H,[?8G:=>AE'4W_79>>TRUA-4[%M%G/+7B[*AQWE5]P5A)& MM5]@-$7#AJT.!(UNVEA3BH_+^X5&QBK%8QIMV=JIF5?A0'9#$N+$[IR/9!YY M($&T9-<)\V)>=8HZ17[O8*%/!S($L`"`") M!Z@'_/PE7UR#)'$#F*`4">M*]31G,+]OJ&_2&CD?4Z9<63&Q:L-F>5.C:X^4 MC\GJ)IID8GTG45(;:@,&#G0(``$@\0"=A('S9W^F M`$``"`!U/FAUXG[\G455)DG*_>NF?NB$+D'NW(EG>P[T3MLH$T73L"'7]-?? M70^<&(6.];I.G,)A4+&E%6\1]`.#I1I8*G'2Z@<*&4NVA*6W]@JQ+G>5#4KH M/8I)X*3$HV]3T80;IK(7A^V*/N%!P?O==T;14*,`V88UBL/0JISQ[%V*)F/: M^[2PKL$A3].-8TK@6G%?&Y/%-1Q*P13+39$.F&"(]1P`L685\WU!W*\@&P<` M`D``:%";IS6N1^P]*QK1)#51V/Y:*^D[1J4V6<*:U(5'QZ"U5KXA#4HKW`%7 M6KEH.RJUR5BR#*Q;;>P^''4??ERL`0`!(``T-.:M7.AM7'-X*>;-$Q$O"GG1 MZCX@M7.NUBSQ]2PDZU@O.?38B_C-TW?_]4:G;MFHOGL&:N-%R@I+!5Z=89>I MK<$V=^_U1TFC1CNLK19[_H#E%6K.UK!4XW)-''9LXC++7&.+L2FY9Q<')&%X.:#7!($F55^/)/.^-_)TG'S MOS<[!25*@;-,R`>4?[I$>29U23J_1&M`A[&<;9CR(;+68(GX6L,-,SQ0B%03 MX<.A:^<)J3)&BB1O MGR?NLMB*%'1=\27:UM_"][R`5)W,*J%K4,E^^;NJK>5*?I$XB4(G0%=.O!OC MN&=@!M@^U\1COZ`OY,%WH8'$@Y0WT*\X\E9N6KST[0F>`3;1510OH]A)H?OT M!=*Q*JG%2`Z>)G0&M[N:FQWT'*79NQ?BELQ8AH?*ZUFN]E.9/-@`V`#8`-@` MV$`G0ORDO\V)XX$1C-@(N,M@K1AMG4(_\7Y9A_8DJ+!]*!$4"@H5NT10*"BT MY1*/[?^4G?JI^CE_ZH8\D'!5DEDA>UXYK]V*^?GB>>V3_.Q->^O-5YF/L&$; MV#2+#^P/55ZAA85$WO"&**@#U#$^=70X3(`7/;@T`R``)`B@8[/(HCM75U&2 MHFB*XD.T829%IR8JWD(U6FK`T758B==B@4Z`AV!CD!'1]61.->0MV+]?(O9)>1E'$W] M73>>TZYB#3J)JTKQYEJ_UN23`^N/O;5!P&$`V5'G4FQLE^Q<`QD>SN0#.@(= M@8Y`1Z+HZ-1DF#_[`L_ M]).4C6H/NQ=V3]L.ND17OY8Y$*M2Z)RCU,R[)2R842QW-4/'JE0SP8ZP:&R; M+M[EFGM)PM*Q>L')OY!E3%R?1TMBOK;D@2"BP)``$@00&=FICS9W^F=*)Q-)2L8U/J>4M-9`M+)>ZEI]_PJCW$\:.= M*$1N%-+J$W:3(IJB,$KI"+=TGG@":!CI`"2`;',HI&.ATONQL`T4PE*_?%ST M_&09)\\NV^[U)1K1+#61%1-;)2&2@(CN5YN,#:4X3!9H#8CFT6S14'1LF6U0S3$9 MX\3DH>ZZ6((#,0>6!(``D'B`!"'FRH7>QN79EV+>/`WQHI`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`";OSU_N6X1U;I$=\2= MAY2[SW+G9*:0&B./`$VU95[]`_!S%7/I]K9N;FIL+$K\A#9>-*5&PK[/6I_^ M_2FO=<#57&:LD^,WO_3K$N"0>,_O`?6$#2R>WW/]YA]$=$)^([$B^H M_*$?Q;Q@S*UP?9[B+)DDS",^CF:QLT@0+75*E4&_NG_B(C@HC1UJ_AYRZYU%"F#.J M<^\'/O/!1RSW0;#R""\EJYU?4*(ONW2I2^M>=_Y7*(,URN0O*D+R[-6?1KP, MQTWIS[QL6H3G^,%3_L+DTY<_WEWTU#`'T[.V!L=K)UQ-'38\\S8MZ&#+?+2D M?W^)4CI(HAN2$"=VY^@JBNE5",[`V0:QM8PY^/=$^&PL?T#*[X^.X]\`&HCTS]G81&'VE MYD$6;(1_I7+Z@4)Y8H;<4`:6>+IOR/SW7NR8D M6=T7Z!._P,'M)9_[O-#NYELZKK+'WF@Y%='&'"+.A/Z9H6.&E62UY8P,;:"Y0MZ5"P M9^,X%ZVB+!D"M@"D=28O=7%9Q1J$+4@7Z'D/;BS^9SKW/Z[[W(FD'3QPE@GY@/)/EW0Z]M(Y,R/I M_!)5-:F7TZXJAV9[S\:H!%30\..98I[M-;'=!,$NZ^PQ+^W3CB6]\6"O@3M! MH=35MYZ?E:`VT,'F.E8TZ3:7'R**=_',-(63[GF:%DZRUD[2V^QP>SU=CZ20 MC'^!L.,6]IE.]T):[NR]/>R-L`=?HG)?R?5I[+]"9^7Y=)U1?`0-@``0`"H& MU"EM:+!\N+W]FAT4'U"&++5)D@3F;R#:X$1K(D"KG;63<-=7JSAF>TKK[5D( M9\Q,FEWT@_UGY#T[`SC\*D6?5 M*.>U'5SSG=X]\AUP9,W>M+?>?!7;PCGE]R(08'%WVH_-DE2LV+98($;14HU!TCE.->D\UU:C'86`%J8E MR!SA!-/Q*`Q)E;%B%E_([,7X)4L&EHUB#M"O%AF%V7*A9OM$CHB1N$>A0WV"63=(5'!MM96[SIU.\D4S&!&=UG'MMS6?"M( M<)"RJ'WY".A&BX6?)-RI.DL_Y9$X^3\T)7L2L&PSQN$$L6HXZ$!$-=#JT;5: MLJT&FBO5G(HMJWAI#LH[H#S;+-[(AC#<@IYA`B``!(!Z3>C7W%W9C+@M]$:% M*DM8U6HF[!76GE09J[9@F[&-P=BJBO62:+W]0J/:6#=KIL@2%@PU,UG#ULZ= M1-'W7X56*LQN``@`"0;H)(0JV_AD,2/2)[[;R?PFESS0@(B>.K*!E=;VI$\. M1J=@S(&`4;%B#85!Z>I0SG!4:F*MG:Z=^NR:/_N%+*/$3U^?3PNYW%.P*@VF M;RNER4SZ!<;&EC&4\V:Z;E6DXN0\_0)CFMAH;=W:*9MB7WV+(H^%WQ-,B;JA M8:DD;W*_3$)F!`F;4O$92[_P&(J"#7`T[Q-(!6N4KJ@E9Z3](E'%D0U^.2F[ M+8<1BYFWKG7%]8/8)M)5Y@HOBO,X^\6DUH\7D:0.T"R%D%TR514)` MSHD=^WDCCVZP>B\4O/JP#FDG(.W$/ND@[42M#B=RP.V^)$\`,+T&TYNT%Y70 M0%J,-\8\!WE!7N'EA903@G`W$&UPHC41H-7."BDGX'03``&@4P."E!.OWNPB M,KV-U9*3\*'&XY_()9[XA^HM]H`6$BM+-#&^_!HF5DHN%`T5M6QBO>3&#*29 M.-E5$EG%*B0O`)``LN^=#Y)0C-2,1$Q"`2TV>I"MFJ6P1`]R5`AL@@!R*"#M M`86N:1-+/W-8%((?WE73AKT3+O""5D&K@]"JBF6]^GTJ4-YQE0?!E^N_*#[% M`D``J.^`()M%S190%`6;PPF3*V/9&,JN;OE9?\^PV-3*AK(7H9@:-M2VXN@" MF8*9#0`!(/$`02:+*I.!C!5K*#.;;&++'DJ`^%&<\9B#L3W5QK8ATA'/B%)< M2-90D@_("M8'LVH:Q0@V"I"RAO76^ACDQ!B$20PL)\8H^O$H0,K8M.@_4R0G M:TB5`3X-/=>JHF'-+E[@@/;`)D&K@]!J]ST=4F4,AFT!(`#4=T#B,7Q(E;'; M[)8L8;ED50=Q]@^FRI!4;.J0J:"Y!LM.AW(?>>B=ZN3K88]#9R>)PNI.'.T$8-5MAL$ M8?T],^B[>4P(NJ;OS1/TE0Z`'KIVGO+\)-OT;7?Q4G'ED4=1WU;@PO>\@%2= M9RN&:J]=R7[YNZJMY4H:)E01$\P`VZ=I2ADQT0RX@>KGU1$3SP";J$%F(3&! M#+!M3EM)+49R\#2I,[C=U=SLD.\HS=Z]$(>2(>U5^ZE,'FP`;`!L`&P`;*`3 M(0[FD@,C&+X1[$W!=SH3J,1.#RBO;DL+[O\`@``0`'H;H&/[$+TD"N)/W9`' M$JY(SS+^6+*"#65\.7\:^BT/51V:HF))'5]B(#"#<.M*H:IC0^]@/`"')><#)NJ;<>9IL:YU+COB#6D+J#54JW* MEHE5JS@"**@/C/+H6K4L'>MV,2GO^7W0%MP^J[E4U&FI`T75HB9=B@4Z`AV! MCD!'1]61.-=UU_=RG]->?8NC)$'+.)KZNWX/IUW"RK*&-7DHL>4;$KU^@>2; MH1KDZ>X12%67L&2T%;\36+'(LQ#H"'0$.@(=B:*C4[-B_NS/]?7LDH%O"\!XZW\,,LMN[#[E7'T[:#)6--'\J: M7M:PJ0YEM2OK-C8'DXJ&'4O:4O$)4+_0:)J*+6MXT<&W1K$;DA`G=N=\&//( M`PFB=1JJKVMF)EBKC&)_"$`"2``I%/?;\%HH&$J_D&5,7)_''5NSPE>9%0K5 M,#Q/$`4K1G$6('"C.:`\32DFA*"\M?8VCB/;[Q>X_X$($,`#,!F]94VV%^A./S:#2=)(TCN?%8F..2M+7DE. M;N;7WR)EM]^.Y$B69!4&Z(EMB>0Y+)*'9)%5_,76J"8$A(!:"Z@%HCP+@A"M M;3AU:(#JZ]1641CM>]C"IBI.9_9FSU*H8E1Z*N"HZ1-+ZD[^8!)(W\H:?I\Z M.]Q949PW5%@@(`2$@(Y>G/\A#D(,XFBT$+"C0\.3KE#+R1^H!P?W)?9ZI2GS M+D6]MDUJ*3@9W-OF2A/D73*ZGM.G_1TN:/NSAO(;M1`"0D#-`U2+_);/WJ9# M%A,>>M&(D=YTP?L7/&&!@!`0`JJ\TZK$3?E*W.3.DE3ZU0UXZ(8>(][0C9\V M;.756RF]ODH=<_N\-.=LH&80*C5W!+%N!P:=*G;!XPC-PV"J5.^WO28,71P- MV;[4=;"Y7GG'OW;U2.2,Q"QP4^;#VU"TQO51TQ?1+QU!(L@N@6R.P,NS/[1Q M)IMT:>54A=%?L8L`QN7ZQD8NL'C>KHH_4&N_DA7%!$!`"0D"=$_'3 M$Q@;-Z4Z-$KU;(5:1AF11#K%FDJ-?AG'!SI%VNZ%;R1MKY5VI&WSTKYF4;-? MQA+%0=?[NZ48$!`"0D#'IKJU*,O]JY1]X8CS+5EQ.GRW\D`<^ M8@FY82_D+AJY(Q7QP049N_,2A%,K)SVS'*UF4E?#CAHI^K#S730E+ M(HG'@F!:/Q].E!/Y.1F[WNSSLG&`;@C<<<)^([._+L@LO+FBG%Z0O(4\6:K4 MM[3+'C.F1=;V#+T`$(&)\,.)ZIQL36[9C#TFW+!D%E^CF*1#1AZ&,6/D&MX; M)N1+Z#.?7+NO1%%U59=3DF4Y7Y!5`D?<]P.6MT_/!6^/3#:7OZK< M2L[D.XN3*'0#^8>5E#S(,TJZ'L<^1,OW3[_ M:PF>(ZRBRR@>1S`]Q^;3%DB'RJ20(GES=;TRN-7EO-^VQT&JO?I"W+,G$7XA M]]1.TEZ7R:,-H`V@#:`-H`U44HA;^&W(7!^-H,-&(-WG"MV*5BGTFM?+*K2G MAA:V#2DBH4AHLU-$0I'0DE,\M#_0=-M/-T_E4W?LF863'8$,IL]KIX5K<;;! M>%IX2WOZIK/RYGSKVNGWJ=[?[@7_5M8YZK>1N/<\^8=T(!W=HZ.R3@(]RM&] M%P$AH(8`.K2"W';ZZ#)*4A(-2/R6I#R^XTNV;5%C1\QZO'IA]]4+&M5+N=>[ MD^SM*?N0563U\!TE:'+;K/0FJCK5>0G>R_D\@XK4U!M)%5(F518+.4*.D"/D MZ*`<->V_,/C;FUK2KL?=4 MJ^VJJ4Z`5!V'6EK!.\Y1#+=R\$&.D"/D"#EJ"D=UBV'Y[&UVWTSX1&8WM6/, M,02$@!!0?4JW^.R=A="+!3*JC^N/>,B35/1JS^L'=6N>;E@6[5O;%^3;957& M$:U+=&.VJYA45;;'UV@7&LVVJ&,6C++66#56['[NSVP<,X_+FP*S;F\402G_ MEE]L9>3X=CAUJE:[OWG,Y&G4T'0D#ST6FL-J'X,_[Z#/G4KBV*(L1XV$@!!00P#5+$,W?MJPW5=O3?3Z"K5W M*-R<4X":06@PX!3T`FT:ACWGO>UJ][V^L3,`:BMJJJ=:-C7L@C[454P`*[D' M85?G13*.$N'& M.B!NDK`-(8JQP2!(!(D@#PRR9A69QYEHX_9&TJ7M=-N@UHZK#]"'8[2IL-8B;[7J#+K9[6G&A8U^]B"B])FFM2QFGH2`%4Y M`D)`".@H5;EV;JX=Q_6B,.7A1-RCL\?)W'F*[QZ19%+$CR:/`2L<4;M@B@MW M7IJTK^MN$\=,_^-6$5X6QW[?DV%Z]_\JY5_X(GQ+%L1%21;."(/?,02R%TT M(GYYXW`U#"*MQ5"VCWQ6!!,F].'$^5$?D[&KC?[O-R60?L% M[CAAOY'97Q?DA?OI4-BL4?@7.CVR&1S^:O*K>1,OK,XB4(W()?031V<.JR?MS*Y9K[X MA7QFS]S#"FH>I%D%?8\C?^)M\"QN&9XCK*++*`91!>(+ZZ8ED`Z522%%\N9> M265PJ\MYOTVL@U1[]86X9T]B.I9[(BYIK\ODT0;0!M`&T`;0!BHIQ"W\-F2N MCT;082.0SI*%;DJN%'K-ZV45VE-#"]N&%)%0)+39*2*A2&C)*1[ZAHGIKI]N MGLJG[M@S"R<[8IY-G]=."]?B;'_QM+`#PO1-9^7-Q2"YIJU3T]CNH?%6YCEJ MN)'(]_3X.58Z5*J8*NU;VT]I'BMR-(0E.G1J:28UE`IZ!`P,@`[9"`@!-030 MH07CMJ-CEU&2BEO'XK<4Y/&=/=.HJCD@03'T*YXD;1"KAN-03I[93Z25C=4KT$AR6\WD#%:FK-Y(J)$^J+!9RA!PA1\C103EJ[*7.WV)Q MG'H<1P.^[K)3[S36,'3JV-NU92LGY<=]RZ]I@O;2L-FH2IN MY2B$'"%'R!%RU!2.ZE;%\MG;[-J`\(G,;N/'8,,("`$AH/J4;O%I/`NA%PMD MN$[7'_&0)ZGHU9[73^G66P^Z:E/5.I89HMFGQHYK5-L%QM`,:CGZD:`Q;8<: MVO;M\G:A4:D.>&RK+%NK6WEM[.K%$ MI"I44!A] MHOB+S=='"`@!M1U0"V3Y-";+VR-(W!$, M4)I"32U_F#,_^"AR<0$`)"0)5W6I6X'U^) M6Y59DDK_N@$/W=!CQ!NZ\=.&#;UZ*Z6G&0:UU(+^^NOS@9I1F-0LZL39.`PZ M[1O;EPC:@:&O6U39X:35#A0J51R%*N]M%+O;3BB29?6/OO4-'"39]^%8Q!P MI;BO=U>%K@>,3& MO:(.#5(]3:ROE1*^HU.TJ0HUE"H\.HZ:M=T+TDC:UA5PK92#MIVB3:5*WZ)F MOXS5AX.NPW=+-2`@!(2`CDUY:^=F&<<R"221$_FCP&K'#,U8(I+HY" MJDG-'9L>&Q&_>_AN/V\P=*M6_M4SI$TFJ6HB%'A^A;V+MCV6N5O/'XA&`QJL MHV_W_$'+V\J<8U"EP.&:(LRMCG"_IBX49O[5RC_PQ'B6K;@-/KL&7B[^D`<^ M8@FY82_D+AJY(Q7QP049N_,2A*,IRR?Z:)"D?O$Z_Y*'/1*H*#T]^ M%G&\4IR#%V+9"P(IE;YX40YD9^3L>O-/B\W"A!*@3M.V&]D M]M<%F4525Y33"Y(!>AO+R9(IOR76]I@B+C*\9X0'@`A,A!].5.=D:W++->$Q MX0\FL_@:Q20=,G+#0T:NX;5A0KY`U?CDVGTENDJ)IJBK^XGK*C:G!,TROB"K M_(VX[PF6PN?U6YE9S)=Q8G4>@&Y-*-U^\X;AF8(ZR?:^:+7\AG M]LP]K*#F09I5T/NGWJVQ(\1UA%EU$\CF(WQ>;3%DB'RJ20(GES-Z$R MN-7EO-]&ST&JO?I"W+,G$>$A]WQ6TEZ7R:,-H`V@#:`-H`U44HA;^&W(7!^- MH,-&(%T&"]W15BGTFM?+*K2GAA:V#2DBH4AHLU-$0I'0DE,\M/_3=-=/-T_E M4W?LF863'9$5IL]KIX5K<;:_>%IX)W_ZIK/RYD+D(VHY%K7M[1OV;V6>HX8; MB7S/$Z)(!]+1/3HJ[";0BQY=FA$0`FH(H$.KR&UGKBZC)"71@,1OR'4,LGKLK$)7:5FTO^..TI;?,%."$W,^#Z$B M=?5&4H74297%0HZ0(^0(.3HH1\TYAKQRU\^W6!Q"'L?1@*^[\=0[B[5@$->U M[8MK[9J3]]Z8?VS,#2\<1I`5-2[-HFNX9E4ETI&&"GL6@2)U.ZE3;:J6<@E\(]>W&Z$.CT<)(B`$U'9`[5+LTW!":^NM'1JA M3-6BBE9IQ+MCID\WJ>&@ZS;J]0:Q*E:43!.;]+Z:G2H@VQ4+97L[)`<"0D`( MJ$NR_5W1B8Y@@#(5JBLXON\;8]!6:=\H0[-W*3(C2O5*;+$\K=XE8^SI?5#H MI(][0C9\V[/G56Q,]54Q3]8)^R4T[E=OK4]/"D\7- M;_@]PS2HL<-MLQ55U;-T`QK-]NGTP::`E=R(L*O[(FAE(VKD/K M1C/2J+XCDG%$+VB3A) M$0U(&*70PXW=5QD`&GLZ!(D@R^P*H2_46M\7EH&BL=)OUB_Z/!E'B7!:'1`W M2=B&V,1U*Z`^M5$"M:#=(\AC`5E*FZM9!^;Q^]FX#Y%T:>/;UJAMFT4`H[?% MDNEJ@VP^R>IRLVN)V]4J/*A]J>M!HM7%T\@D!(:"V`VJ!>I\>MMWH2]2A M4:JG:C;M[[@B"87H9MI4:FG;K\E"UE!H'LP6+: M&M5+Z@K?DN._IL)Q;_[5RC_PQ'B6K0CAD<7ND"M'Y(&/6$)NV`NYBT9N2+,O M*+EG,1]>@SD:K"PY.?11RO%.?@A5BV'%F< M?_PZ27'?\VSU[&L'C=VPLKI`.GS[SQ`NB9!*S!TCL4Q!Y__GG__Z/L+%_ MS%Z9>8=?A3]"L;X6PZO"2_+WB(?IOR$Q>#FYC;^[<1JR.!GRJW"V M%$6\8X,/)U]!&6B*:IPISIFBIA'\;9XIYIFNGOQS`T?OI^=GC3R*/VYN'[X0 MU21GY/?;JYL'\N\O-P\_[KY(BAX+U%WYU79N[JBXBLNRS-%5"%^FDY0,LJ)H MIG81DQ^C%Q:D*?.&(:C&)\Y"\FWT^"]9J-[5CX=?:N"P+KZVUMU52+ZRQWCB MQJ]$4Q2'DA=&F&PXOBP.-)6(N.1A1N,K^?@4,R;:(GGAZ9`4(I]"4M]8#.4G ME]%H[(:OI#>EP[`OH%)F'_H7OYR3VQ#0C5,V>F2Q+(RF4RBEJE"2#MG/%!)` MRGQ(^9J-H(6'_F0DO`%_`-@X2>&SN,FR>%GEH1(H$B3KBVD)^7;]*;,>Z!X& M/!Z)9#V8L[@\))/%S!)QT3W\*`HY]\WT;.DG:B2<>!=`A"(%CPN92$6JF)6>]9% M0I+)8\)]+O*[#3U)[/_!@&201VYPL<:;)$R+3JH"*F%7)] MOFF`V+NW7QTV!!86)C+_CZ'_!?B-7AG[Q$(VX.GWP`V3GT/.P4:*[+]S#=IM MG@9^ECVZ:2BQ9*6=D;LO#U=W7ZYA."'?__AX4VUG^)[B'Z*W7.\8+R=Q#%\% MK\M]C1]!LF&4DJ'[S*#+B5G*8]G"9'&@*8:B(<+_/;;13(M8UZIE?G(3GMP. M/GI>-`GE_;R-$RHV$99U*:SJX^7E[8^;AZN;;^3[W>T-_'TIS>V^MG%W5M05 MD^IL4;8:_Y\LLV_V[`83.;C`D$/F=B>+="]&.S?V$_)C[+OB/%(ZC*/)TW24 M@&_D']FQ3`[C!0R/J6PJ,!I"5TUXDDQ$TM"K^Y%L5(\LX$RT*VAI+QRRG+:R M$;P8BR0XM$(8/\4AJ$DF">;)0UOPN0PU$\5BI)T$D!$,>_-5O?/NZKR;+W\N M-LC[AX\WGS_>?:Z_8$TB"<3P[Y-`"&%5R[K]KS/KDJ59Z'CGQO\I@O\MJMBO M'^\_+>^&,`,&>+98#F6Q3YHF'(XHB&DWF` M]QZB,?>(;BJ__`;R+Y&Y7`$^:!T\96=_\&E"$#:"E7T*2$[H,1 M[&>A%^%\O/\Q*]^2.%_\7@Y](.N%=(.$,KD*(A<$I3B<#9F!DOWO!*HAE1'O MR`!:<13+9WR6BC=#!F*49;XP*7!&0,HS$O#_,*B0=`C#JN@@X(\TZU6@S$3T M3DP>_`FG11#JN1A5@XY65@J2<@\*+\0 MLE!<@`E/CV0A`)$`FT'B3`E"C/27F5F M@#)F_YW((D)^,/'P)L'/SG0%-MD!.;,1"7L2!J(&`,Y/MI.,R^)<2S`S,F6R M\@U1]9X;QZ^"/YC^@*F#C63U,D4G-?Z\6Q<)16/980/.Q]>Q*]-B2X:2V8Z< MP8A*$@-#CEH.Y8-053R2XTMFH''D,7CQL M,&!>9LV1<.`20]0H"W,6AA,Q6*T4=#:?7BGLI&[8-/H?;A@N-.K,-?J:SEZ;(KK) M\&L0O=Q/QN-`@G*#^8)D#=/#35*\OSAPP(#_D$WV;K^2RX_W_R)?_[C]L^-2 M?*MY?(VR3CL4P]((*$+,NU^TKT;%W$E#(A8219L`1H)^&9!R8"/<#S M=#">7U`B/RTLZL3BY1$4E/^=#4J#*`#3FH:X/K!8=2[(_[-WKDLEWK[2(O M(!9WI)MB4VD;1`Q@N2&6H;H3H,ICN$>*O"]:ZAKA&7%?C MVJG!M:^\T3FVTWI.,QX(0F3Z`%^(XB=>V$GA.Z[,B2R6=7HZ+D/J[VSS<,2R M7MC+[_@N0K8:FM6+FE"?[S(R?5AHS-TYQBAOB*9:II57C^+;DBSHC_UIPGS4 M:'J,5-`+26*DD'20=)!TD'20=)!T#D8Z__*G(HM(+RR!E7".T2/.275!SNF] M)#%2R#G(.66<8V@UG(.+)CV&M:M:"&N$]1:P!E?"TOKC2J2ZH"O1>TD6+M0B MYZQQ3GX*PD+*0DX2#K/1)*# MI(.D4TTZNK7!T^E1=&5@=/5,)!E]BZZZII(R0";!7U1T8(ID7GHB#*9TP+_V M+J]TQ#^[IT(4=':9MF5&?<"NW(V!2G=E6O\->.R3'X_NE4T<9JN.U1,.`[ZU M/1JIE>$AB_9I96W,+'G*;5/:QNZIA*Y:QNO]SCO7D\8 MDEZM<^#BZJ$Y+&>?32NK?;)(:G$M-&PNF_)#%22#A(.,LQU=,F_Z9/QP!THIH6^C?/0)(8 M*:0;I)M5NMG@W9A]HAM/=0C6AGH&DL1((=T@W:S2S::Z4'W:H3(TU<9:=,]! MDA@IY!ODF[9\TZ<#CN!K>3;FZ3\'26&:L2>&C(M;S=A[;G!#"I)-0;?14HYJ M`<>),@&2:9"UVC'@R]I7/'[1X(!%\?FZTQK+N'FS2[*E[=BJ2;P5U"UU4L-3 M'R\X(SOO[[L56:E]RA9 M:?'0;WX,-#[CEU/ZX+U-)D$8++Q"<8/26%PUR_V^Q87.1<<.'DUOGF650_W' M8,:O!&3&RTRZU+ED5_(5+UH$$.3:L$O:V>5[TT28=)#>=UZ``5C-/5AE^SD% MD[J[E_2&W?AC6[@AB/[C=OS4\WO>7A=O$(+UC!'+JU@>CF810[)>`^2>W<:B M8\FM9R))QY);2#F5E&.444Z!%\(H2=@-W0528#?(UY(0,(6XNKYXOL+6-62$ M#2<;H(\0IXC3TJO:Q/E-@X?M^8=NK<,PXZO,@#\C#P*6%BG6'06V0%"U1L$C M@TV+$PCP/D@BINIJN.F-5+)$)6=T)%AC3W.^KFJVAY10"U3>1PA4!.H!@>JI M#OKF]9)X%R%,$:;-8;KNA9-U+[S:W48\UDFR5,_#,RN(QW(\ZMK683$"W?F>`=1%B%#%Z*(RR\N^N@1BMGTBS+D*0(DB70.IB,'K@%5WT#4 M+40GEM9#=/8-G?QR&5*)RG&0C+A_.DGW]8L(]%3+-53#,!9'D@/N`T\I+ZJI M?`MF]XC;75U>5S5TK!^`N"TD>2_WIAWDR^.+[C^].P3@OPNC;32%/[`RFI3!*P#-,;J$I M[\-H].ZCBUKU+;?ICXU[N)@2H%[2,LJA)NOOP%CCT15.6`/J?NW!,'6>V*0I61 MRAX(:?^&\RHH1W\%6Q[(.0?AG+K#*SV[7XEHJF5:,NY70IIZ><*%=2!'(D)=0I-$CBC2D7=.)%/GRA!NO('\)*?(0 MQ;FT&HK$U;U7S'>&^_)/UR+E](URP"L3F?3]\,I27=`KZRM+'53X:SCS@11Y MB`I`%C(D,N0+$(X,B0S9#4.:N+2'%/D2A./2'E)D-Q1)-FQ_.#WB2`80,MHJ'A$N^ZL=>T![MK=SP..PFZ\ M^VQ/[I*.GGZ?[[ZAC[,TB5^4*3B1QK[(O?(?`V;%PGB929>&++>@UU<_G//R50($N3;?P(SI M=R9*F'3`3O;#RPHP`*NY!ZML/^>N'!XO`D*8^0!,@9MZ^F,V@S8L4;7^3R]E MO"GWQ.O[#(_-/P_A[&RU;=D]"K9P7>MYKVLUGEEZ6CH$%^^[.6%%,)<7>48B MSPQ'LXBQC%Y#,CT[@ZKC#F._2>JPM4QPAQ$9L@N&-,H84OX-1Q!(Z(WO(4," MZ\;+XH.`'((<(HE#\EH?(DG!X.MJ^8=NK>\UX]MDP`V+N[Z75A'7?:Y-EWYO M7#U$\GFMWA,Q55?#"A[(?+*8[XR.!,GMR7W25)XEX MJH,AV($YA(\!4@A2R%XH9#W8(NO!5G54A5QQV+/)JN>]\*O%D"L.P16ZMO7* M#))%3\G"41T3$W60+*07PZHIXJRW*[\'U)+0^&LPHLDB&0=9XZ"[RCKN*B-M M=$`;I)0WI"]IZ+9*+!-)Y+`DP@E6<46N M,/HDAZ<3XJ%/@G32Q6T+I(9.C/PL6S6=U"6?3)CJ685QT_XQ42:T^:$RI)). MA)L6'BM`*MDWE1"DDI=');TK.X-4\C*HQ"BE$OD99+9JVPZ2R&%#&SX(2")( M(I)()*\#4W?79I.5DBW\$06YY+"99&W\D7V4O5T2RM(H=E?F3G^A&+H&.(CJ%LHM%+]]#D;\2KAN9B M='G8?7@V!L@A2H'E MAD'>+G+S7KTKD767-YY+_>F'>3+XXON/[VY&]W0\#^EP<@KPOX#0^*80:Y\% MR0CLDVZA9>]#B'Q^^?O?F$W\E+WFM!#Z?!:E(DZC9)9\H%,:^V'^ M'$_M@1\^T\G/1Q=`+\PC&FC>0".SB-VN,="L@4&.?NEP%+(NNAK>GBO$4P;* M^:?KC\/__W1^=:N?II2K M#^, M8-[Z%LSN01)??`J?%'_.:IRP-2%>@YC-0D,7WR8_YJ?R&&SWQNB MZI:6ZL.E*JG$;[R\\2BF?I(N:X&`-R2]_?21QJ)Y=Q0Z?\I>E?8F&/^Q ME3TO%K#@^3N0\LA:"[UT]U35O^\C/QZS)I\%$%?,HACBB5@I8I/K`Q\\!+,9 MI,2)\>>,Y;%^=?_*&:+PCU@H\B\Y0(;Y) M'BGS%&CX='QXX^T9D++27WD%UD_!Z-ZGPH+_-_;AS7]M0-.%<,C`:/:$)K<# M,($YM8!2"N<%@J*,DE)C/7X6,')LU3!$I29;5VW;0Q!M!:*3^1?XT@)#_PY& M?P9B.OK5CV<"/]?0AP%[F(WKR4,`YGTR_4+#1+F$7T7@^FB6@R!<&+FFH MY"HL(X?/9!PKJFR_T&!N7CA/E+MH"O_-OY0<8FK40\]VU`=*X5> M:^=N$5TV#0M+PDEH`AO*Y&0*C["=VB\4W!R:+$+2_@:5NI95MK?@F=/AIT^7 MMSRF5$ZNSN#GJ]O+JP_G5Z>7YX>(,MLL%!R43,!@[9(]DQ3-8R4`JDCF=T`F M`8/T632+P@CF%':US)A=,1,5#SHOV($C_3P=(L/]4?D,3L`8-(I9R@`\E=+' MTD8-?RBFLR@*T[50K@=(HHRE."2Y`D6TCH/D,4K\=.>&DYN@JNR$DP*\%PJ: M@L@PB(`(%;X.FY[63@K,8J\YWKQT>9+,&;MDOH:5[UDO[52G&]CS1_CD@5)1 MF9/&,S^`GX.0G<":9BNY?9XZ7Y@5WHSN&5)_?'.MB?$-5C:?"Y,*X9T\4&Y^>W]S_G^_L=7*\W_S664O MS/T\H&JLW]&"3"ERQ<2K/B2V:HXQ^+20%+S4. MDE[AK7RC:4<+%F^28O$(G#L*'J&C"\D68E&764R0K#UX!Q96O.D._@4CF?'K M\=RW?"68Q20/BYD$'`9V>UZQF%P>L3.C%/HD2^KRUQKP/O`U1IEB/"<$ON)_ MR2[C2R,H"$68+HPVF='?!6/6,)@WN!+!PP.$8J`BQ#_C1>@`[NS8?V(-!+7& MV:?CM"F+=)5CY60&.BHS&#,8*@&$>P@!H2&I%KP%J?J+#S@HA:$+L'X?42'( M//:\M]G#)>$0?`RNUWR6`*SX`R733A_`\#R\[0P>&\@SH2,P#IY?R],%)LR2 ME_T:MA(V@@`7V(D_EQ[Q!\;Z1L.0,Y<"+XG9`T5KYN8@3&8EIA<4"OX*O&^2 M)A&7B6!,/8]']Q!:*V],L1J6VL\&@?DM0S%E7,]6)D#0`_SB]'S(MEGE<8/3"++1($P)@102V^,U>K/<85B?CF6FR)<:4S?!?VM:LF,IE97/#D^^2"4M+(JJTJ MJ]Z3EGH#+8UJOMB3ED8#+;U#*VDV4%(WBIAII.0PN]/F7*R%)S+@033B:+:] M4&5-RE9J@&BCC1JZJ]O$[$"+M165VLXP-9/HEFPUK$)G-%'#-%V/D&VTN)R" M@T(_LDQ^";8Q,%Q'\[02119RME2EK7T,7-USRZQ4AB:M;&1@:HY%RFQD9U7: MVLG`)'S-AN^$;6DFWY/@W30(?SZ"69X>*3]L(Z9!QV\2 MPZDRWC&-GO#X61?!NU9EFUN,.GM-3Q`!W1EXM*U[,34Y6HI MQ^2Y$A_B:/YX%JR:8YT#.M&@ MRBTL&B?4C^E-FLG7I&DP6%9Q`>I03:M9E=^R:;IN]L0(J\8L/;5P1EF3 M/OG3^<0?S?@&6Y.1H;,2V M:Y'F$;.XU](CHM]`Z(;K67HO%-]`#MF)IO1`4X-A(;IAF>[AV[:9&!JUK5OG MIO76$3$]4_/LPW=OB5^XJR]@>)[9#R]GS6W;K66&Y1K]'K+=IDKBVGU`?,W` M[=8^W=!(#UR!S>/7GJT=W=+[C;G^D'59_V_EN%@0GCH]\,1:9PM8NF4:4I"> M_RK=='U/IW02;)NNUVSIKI$T:6N83:7)699L)$W"6LX5G2W6BTZ^^D$H%CO% ML1Y^JD?D4B?O_80=QI.QH*-9MFL7_/R62G30AIT]_EXT84?7\_!MV)G`=FS" MN1^S$B4)^(4W+).??^ED.CX+PCD[2+&-]5_S-R5K*=(#[5@K."$;1$O0=*.- M5VD*BFI[5K3>DGO3I1OMM9,NW38K!<`QG,#$`F)6)'"I4JU[N8$=:7S`CFD. MIJYRC+93NB&P>J1TRHYD44,V9@Z3J+5)V,#J2$%>LI"]NJTW'+]I*[ MDD7LXJQ=&DMF/XK'"^'\^?=9[$ MNUN&=DX_>W>1L7?CLS+?/&7_)$GHUF=/5LZ-.<7%ZQII.RHF`<:9M\^*T!7J MY!;\)7*7)NQTXUE:3^`ZI@_!_$'*6497*YX. MV2A3BI)MX6H8IFDX.VBY:K@W>3D,271-+,O1O6I0+0G<63L9>7,K)\Y%9[WX<^]-9`JY-MBTZ MC$]#/WB00M&&IMM6@:-;*2!=^[:=[KBDN+:QF_(K0W0Y/1EQI">?Z8@&7\45 MBS+\+7#ZR;*[M5&P+&5;NR\0)INN)EO9:U9%)QA+/!4ZT.WB">1-(F6HV+HO M+;=(W+)53#BG=+?+MZ7PUKWD&$[S3A)R-VM[1B$4#&:2_=L!^`I:+3C6Y?3VMO7?BQKF`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`KOZ2Z2,.M;%+PD_SRSPNJ#^;QU3V?$\,S]6--'+> M09UY*HU@8LH+CJY M[^<)FS03'H0OHO.=ERB6MR%LTUY?%&BK2922]F;<)+WI3!LR=SSSO'Q&QC)HSE@>_SG"M^_NR@89"-@) M!.=I7UPNL67M;U>[TDI:K8#DH[XTI+XH'RO=-K*?\B&RK!TPC&0M"?1+H52* M6G?HJKBA[WAX!1ZXY\,YOF2;)>OQ9E)5%L'+%&=LRH_J/ED=V; M(OD%T$H]\IH?>ZNO&2O?P>2`O[LR;R/QP?)3<]2J7-^UJ_3PWQQK@*M<4V5US8V(OB*-C+H3<[=E5[B^Z:"SZ095L+PU%W[VJ M!.7"JG[%XC9U>?;+,W'IE^KM#V(>^ M3Q=\WX$+5?<&PCN5%O`^P]MNV[IHFUD+=U`Z*JBN`0J&\&[;3)MT$E!_";PD M-$SQSD+'Z1GXZ%RNF;&J`?CZ!CXJ:%ZIUP!\@W5\5K/:][+4OF`7SY_C.`F^ MJ[+\7FRT6!O-1Q.\^_5W474-H$"%_=1R6.E=5NCIRI?];=#?)L#5VZ7;"VA_#*4YG!TATI:.@^T,I'P>P*'!'RPI]Z!K]W?&>;\= M3P=)7EW_=,7!0-;-SG@*J"_2D88K_O^#@A\R/>1K81X^)ZYM]ZR=)XU.VW$V MKI,Y5HI;>^?9A48T0M,ZT0-EJSTVS#?*/'L,:58'X>B>]5B;?1G^\?"%W0X? M;N^_/N#KCEL4[$3TVP>[E_\X!JS\H0P]@15:YWT9:JA\%MU\L`=6$[``-21B M$FS/*4CBFH4J!FVCP6MF./S4&_]`$KC]VI M5`6*?14)E!]/6>%N0S7/]>M!CXK^?P@X'_2H,F5=D"'8M5 M-ID2>3I%EW_9(FI!HE8D$1W7.32@6EU8G[ECRT-W2!I7VR=Y^=SD\D:Z&-PD M+.0S@8IH4B-TA`$0?A-1NH1X4>+Z/DF%F(TQI2[Q0YSZOHH]"D',9T)L=9CR MFPHR;5%4_K]3"<4`6))7J@\0)D1Z`K:0!@NT31UMB@S\X`&8-?"KLKBPXE;! MFBM#`&6:K<]PWY0AP%"!H\.3*?,#-6>4#D1"E\)3^%HF+`4=.\^%`&P0`H,] MRAJLXS8`TI9ZW"R%]E&A8%!9%A+_(-4DBT`/\%60H\PG7=2E3`4'O#$+,8RN MX(KVKU84+,P'D6Q>H+A/16`]:/=`F<8 M_R$>+1Q1Z-E*_7*M[NMF=\I5]/,*B(PK"DH>UNAGJ&.;;,DBJ@Q\#1?[3%1) M_',N04-1%BX/\*0/5B)I^QK^2Q71C_F<(?$81P%\"2]0"C-S@8+4+81N(M)3 M;2#T0P1*:QK(9=TFVS@C!J@]'_C1L M_##`1L]`733.F1`I-5JN&RSA`9B=)P"HI\U/Y-E\L'DUHE;9UK#0,!S#BXE\ M`CLGF_@N1(14L>XH2S@';':$0P$)`AD$Z`^:2+PM'!1BT,:=5YD:,2"UT[^3JQMI8I=5G: MB5KJ+E\=;%WJ6:ZRY&"`M16N!7E5H,+N@JQ0(%5?VS[[!H*2/G3:(5I3P!?D MO"Q]%%U)VZB%4(Q5%H`/Y/MBG.IAB5*:+*C#<5.._D^&`>J;$M#&1;Q"#X^F MK<"EBCG,E5BRFC4P#Z<-4"_,&TQWSQC(M%.Y(KS3!W1\Z%L8S]#*SCY]LP2>PCBCJA[%HYS;_A2(YY!*H5 MG+/;Y1B4%MK!-P5%.$#JVR6U%=$6*3UCGL8DL?*TKEH*6`<3&DY(]+\M5D7R MD'-GSF,OGT\;Z<+7XK"+F?9C#`[0MNBLWL:<>/?]$K819A@M7\*^M2@IV'K%;,*0:'E\!UK8^'T MV74ZJ[RT70W0&[&Q&85T7#;6\Q#K4T=X`N>>?!&8E^5'<:!=*W!CQ&M6.0UD MGI"M!>4-^-C<5WB'?.#)\N)@N>/4:IH=V:I/RI)A,([SJ09'UJ#Y'&WMR=ZA MWI59VMP^W<'2L]&KC6)I\]#'#I8NWH$M;1U\WKLQ#6IUXL_&Q3>(I9Y5IW]X M%ZUTT7M3E\$3\MJ!\AY^2<2RC.K>GO&[?M)VJ:&-9+1!^NBS@JA0D!&5H MI8SVVF(Q#GB2T+(2054^X^RCK=>4\P6DY28R+J4)O?_&\YS0+,I3&M!.FTZ; MNUQ6/3<7)IZ33B&]0(;?KWVE4B0"WL5W]D2/TD4$T@">:*/G+'\:*Y31-$VC MZTYG/I^?/[EQ<*[B2:=K6;T.ONY@P;.\^H)`H,:E>N%OGJJXJ'8:8QM]^!U@ MM"VK;17/`^Z*`!I//_\??+6*NEK'[L1E$CP>%]7`KWN`YR4ZN-K6+FHL/D?) MKX'("2G]&`NWK>X94[$GXE_/[$V4=01@/R,`NPD"L)\7@+U+`$6=)8A@W2H# M>ZZC7NO@#!$M83S-`G@>3D"!P_9_OIU]CI9!.=J87-JFEGD'@SLC%S^1+>7; M.`FSNVP&7<$T6+`B2]$OG1(G)V.PNX7!/T(V'*>JV#4E7A[4C]4FI=X1E,49 MS40%'DOGBGWL]FD?2^_:Y3N$47&8DN4KIL08;LWKHY74Y>`41'BK*FEC=;D6 MBY<]X_HI?1F+""0APK0(38C%C$O::OIXJ>G+<$7U?+NDUYYB9P5O?NF@#.4U M_H0__P902P,$%`````@`\8@*1S`0!],-&```5$@!`!4`'`!O8VQG+3(P,34P M-3,Q7V-A;"YX;6Q55`D``Y82R566$LE5=7@+``$$)0X```0Y`0``[3UK<]LX MDM^O:O\#S[M7EZTZQ9:=Q$EV\Y8E=L3-[]VD*(B$)-12I`4G9WE^_ M`/@023PIDP3LO50JD2ATLU]`=P,-X*>_/JQ#;PMQ@N+HT\'T]=&!!R,_#E"T M_'3PXW9R=CN[O#SPDA1$`0CC"'XZB.*#O_[W'_[-(W]^^O?)Q+M`,`P^>N>Q M/[F,%O%?O&]@#3]Z7V$$,4AC_!?O%Q!F]$E\@4*(O5F\WH0PA>2'_,4?O3>O M3X$WF1B@_05&08Q_?+^LT*[2=//Q\/#^_OYU%&_!?8Q_2U[[L1FZVSC#/JQP MQ7ZX_(_C\^.CZ=LU>#R9_CH]^AV\?E@0)LY!2AK07TB#H_?DG^G1W?3=QQ/R M]\3P92E(LZ1ZV='#4?$G!_\I1-%O'^D_ M'A\=30__]^>K6W\%UV""(JHA'QZ44!2+"&[ZX<.'0_9KV91K^3#'8?F.D\.2 MG`HS^14IVMG$Q?/R3!02E\ M)D$F`6L:$:O_H;?[./YK`IH\;TF,21`W^P#O+VX1X829-1!1&U[(N,<)7Y,Q9W!P+S'JJ%Z(NTRVI*>%V.M^7,->R+@ M!L>$M_21.AFB@`T="'2TJ&!Z(NL*$B>L55&S56]])P[N41C>D&&1#(J$R6OB M2?!E1,*.)9J'\"Q)#+QD1S1]V],%BH@[)#W[;(DA--&J`6A/1'Z+4TA<]".8 M4S1JJD1M>_.6L?_;*@X#DB10.TZUG5`.T1-)WV%(S"4@X4OZ>(=!E`#?:*S2 MP?45G64)BF"2W,(E"QBT,9FD?4_D_(UXKI3D:VF&]6.%L'%O:DL19CWEA@2A M>F6)6OPQ2@4#\"ZT%']<`3T6A;$/0C"?IQS88O&9?QA4GR0W$-)2.H]L5P'`R!PGRZ5PX"C.2_??+]SZO=$$HC#*TA;?0SS") MVF`RAERT;QU@8K]XPS>`:=BWU4ZEF<`.$&5/ZE\,=6$*/P"Y7:5J`MMGHI!Q MT;ZIHS*"'H74Z=-HG0X5KW?5O19PP-2K*ZU=YJ M4_>Q_DEHAT^$)_PC4TMY&M;>9D,)%3BEHJSGPH8LF$&/0JIV+#8$'X78RE"? M2#6/9X"9E$E]5<[0,$SA^ZK+H8/"'O:K@QM"FNR=7<=!O@[?5?4/>;>`]7X3.S1%?2XAF/CF#1A MCR\C6A8"TBV"M&IF;_]DBM$:2_LHR!3ED$Q-3Z[7$9IGQM.M79`,M&HWJ6\: M",SH[H)C,+);#\R7=_9`-42Q7M>AU0BX__73R0\Z64[>%I&O-W&W.>RN>`8@ MO_K\&49P@=(]*->@&(!HMHF-3N]4#[^3+'@/THT0#<#`.5Q`C&%`ON6S;%<( MS%'892UJ3W3],]-]1EP+.F!5@;D+U<..0&:G_6V=$0U8C=K5*KK@&+Y:M2OU M>Z`:J)K5>"5;":8BCMB/GX5LM>V*?&]`P(<41@&L`@-*XE/WOI+'%,E1_F?J M3;P2JOX11(&7H_`:.(:C7;S'M4'L,:&PZI3D,S&,)`Y10*=LO0+>*Q`4=):4 MAK'?H"ZD^Y=CW-1K01S;I+P`R9SM5,Z2R1*`S2'5]R$,TZ1\PBQ@9K!F.V?8]V),TI)/!Y4S`-AO6`R_>[QH<9C0*A**9H*(993P M"QRO5?(N9!OOPTI=+X2*`^\>HN4J9=1;U.,-AAN`@B\/&Q@EL%R`-#1'(V`S M'1Y;U6$'*3BGP:+XB3H]MB1!=^80*Z0K:E`UE*C!S+1V8E5K1IP[IZ_ZNCA* M5C"@10")7%&R]F8:>F-50VI>G5--.C3@.3_$-?9@R\(B5\(% MV6CU++Q)67]&YZ73>A&:TIFHH=R(`*0]0<^P&%YGK)KR"'<<.`2=>@8=4XS92FE7!.[%FYX:(GDVXPX)^G:Q+8V1!*U MM3EKL2LW/(=S!=U<0]NAA5SH[>D(,8O.65&9O!45=,3SDB<>=T5:\T;E$>@B1!"P0#K?(Z(;$=(!EK,LA?Q2!*3,=+)9"9 M^MXYHCXUZ\ZIZRJ.EG<0KVETI8]_18W-U'-J7ST*5MU3"XK@]6*&88#2"^!3 M_AYG8$,^I8]G6X!":EL7,;[#((`W&?97]4,I19G+?OC,E/O>`>4^26`.ZK_B M^UL<^1T2TWIS-W+3LM^)3M54YJIB0(=R5UXU\O15)07GS$_DR;IY;Z<25*V> M5/PZIYP:8T8C@E-=1CI\/VTNP*)QZ3D2F)]K-B4_9)@W+5%;N\O<>:TRHTM3 MJ25L;+M[*$YXYM:Y9:PZ9U'%044&.N%;VN[=Q@J1,>F<-G9;=V\`"BXC$AJC M%"B6EZ0`MJU\8`=T984^Z`WC8/QE4.@$,[V#.8^`Z)"`,[I[6<4Q9AM M%LB7/>2:XEO:GIXTUHV,2>>T40N=24[6)3350]J.]4QYDV<3SR8QZL*?[I(3 M&9L_';:YO"+?Q]FA(]X`U]BN M#=IB&5M.1+0L"H`5CE;0U&:5%[M--*0E$<&:UI2G^8Z^@C@Y&UI`V\.<5"7M M\C`S"3CGHL[A!D,?E1<#GJUCG!;W!"HJ#E1`M@=N4XT9<.ZUE&C#;F;"IQHRX=TYG%7?Y[GYZ_+7!L%YO[,P8R'/0+D^6:I+7 MRL1R83*FYY#C>*&:CF@TVM M]V:1X"55DV)>G;.EDMR"SOK)KWK]"(&L]_4.2E)P[9RFO@(4)73D@LEU1/QY MBC,_S3`9U*X7ZM)_/:3U,,9`9Z;\.^@O">64\.OH'"6;XA2NZX5NKYL&S/9< MOJG.M)R[IS#&6I&6:IV5L+'MR7H3Y2BX=&[PJUUV,HL3YSG1#LKS@S_ESOM!5@R ML[2="7;IN-TQVDXP>NN\^PK3/?.0B&1W^50EDORTT(QFQ]SBKG$<8XS7[O$^ ME68ODR2CR^FZ"1$5C*.Q2T<5\T<":83D7,8G)KE66]95O0U01P.3(;0L$)ES MROX.-\58?;TPVR(FAW`T='F::G4"G&IG54(Y&)/VI5B8H]]1; M'VO,>JP"#\;/8[UFW0^-3I91`MB=>!^^NYB=3.3087]'DI]PF;Z;9 M%HCMTQX&UZM01!JMCCP7?XV7("IJ[EBI0;7#@D5\&Q#M5K(;,_/OZ/T&*/'# M.,DP)%_JF-B%!S5<=+(^74&OPCA@/3+5/7Z\7MRB9806R*<3K7YQ&?OR)@Z1 M7\_T&SR=MGDJD%'R:^B\'3YOAW`XEK[&Y$W$!'V()?=.O&\3SD"\"F8XVFI3 M9!*A?FC3U@09\/H.\M*\W\)`4YD^/6H360?V1%,4_=-;'0DN)G':)K'6?CBB MR@4+X5I%@[[C-GTE:'[[";^JTS^Q^87W8O).VN25C8?LMT9WV(OI?<-WZ1S; M?WD%/B97AM';H?3:91T#VBE_5[V8E;=2R_4J%%X-QW"D"P/H!JV<6V,@'I=C M#+$J+MVVU*"0=U(UP/_TVIO3^B>TGES>81`EP%>,K)QK*L`]!N\U$0QX'U+K MFD@QL9RO*L&\'=QP-#8NB102>,SY*0;C[8"&5'N*,.NA=/%:3![GHW9`7@XU MY+!4W=PG)HYS4#F$5X`,*3EZJ6TM",7D@P_E=GC,.:L<12/P;"`987^?KE;G MF/-8N\*=9JW.@-2*+NH34\LYI1VH5X<=CE;%M7QBDCG?5,/`@H$6CB&3K.8% M?6)Z!>E4">:5<+83065">,PY+_.$T'M5?AIV^ZT1EW)'PR/F\+CSFB`?E ML)XN*O@XX5QC'7`42L4)IXIFSE]*TLY1R!>E>BKB#1.^46C/DSD5M9+\;Q3J M%!F3BF3.H2KSIE$XJ2=0*M(Y[]I(HT8AE<^G5`1SOE6458U"=SM345'->5@N M7QG)OJO06T4MYTWK`?A(-L$'LRJ*>=\H#FG'<2^"N?GVSJP.)`H#(1.:&"O!])(.:3\Z(=(ABYURJ%XKWZ<7O^)Q=D4\X`*I7.>>5. MPBA?X91-?(,IW?QU`W%1@T1/`YO,08)\NF2%PHP=YZ80"N?\.PF%O-^C!'B$ M`B\GP6,T>)//E(A\M2LGXQD(CE&*MO`6^AEFRYM*V?%I?4^R\TI"O!TEXXBO MOJ!6O.\;P/EI,6(AJ=91B9T5`S]ZNG1R6)-D:!D7`#$+= M;ME!7VJQ=*-/OHJ+W6N7NH\C3]%[;==9CV"DK0J3<33I7%U9KVSG1ZCG+7>7 MHX]EQM*WVRXG?^;&K-'JBS9IKGID6!L6%)_8*I1_WD;+5_V\9"MM=-$;##<` M!<61!F5YS)@!6@=R;.\9>-Y6WEGO+[H7['%LPDBOM[V%XGE;^3ZG.[PU(X4?CA;9WPSQODQ7H[E_$5FN]]&X% MHG(%9VP+EI)A9M?#7?OZ4NQ:H^<7;NT!7*"(Z/D*;7FAC&7K&B+,+/W#_UOZ M4W3\HNW\&QPI!60O>B%"*Z+5^@_Y4K3^+(&1R7A):U4U4QT^$]'K=H1#\H;E M:Y8E:;R&^!RR\XUE1^Z-3<1+6I$2F*P-D?9OL.Z-R;MKJFN_E=?6JX\"&9F, ME[1Z-XP]*VH6IF(>N/V+6AZ\Z3@[H8V,Z"VW@W&W`WID"U+L2]3PP.U.U&PXK#-D M]5Q><2D3N]A4[FQT$8#;TF"5?O=]GQJ-Q&WB'>T$\S` M!J4@I$%F2>QMO$CO`8::OJ"'M#U5N%>7,!6(RTD8-9?7Z M6C];9VS.ZQQN,/01TS7Y'$)F.U%PMHYQ6AS#OL<^D_[>X&R`+)_>Z5N\AA.1 MSD2A9ZK[Q$T1V+P@W8S&8JKTR;Q6>&R/31V5V[YP?2^I.>>;#=FXC.[NX_^# M0)A\=I-('97M07@4$^!E]XRM@+P5]F8'-62V9RS&L@1.?L_7%B[B#/=E"C5< MMN="1K($3GK/V!#0MKQPJ).V#LNWS("XM M>,O5=^B9&+BV0,U&U0LD_'#E'@;\5#@'YJS.SJ1YMZ_"S+CBCR87[9N81C$U M-EB9=I1W7/E'/M99Z"(-#3`JC,;P=USQ1UL'.4HBNQRMO&Y1;VNCL3-@C>L&4C]&\.@Y>8W'\_4X" M[HJGW@ZY,Y97O?Y8S)_@_@HC[1V/K;V_TU='AIG1*1<7B-56(K6O+BE_XEYW MRM]HP3.HY&_\_G=,FK#'EQ&]JA"D6P3I:J'*$Y_REU4(%4EQ%YVPAIW=*&G+ M3^OXE2C6*/0P8]B&BJ0R="VO(^4R0=O6TU]^BM4"U?AV$$2SLW?JT[XU9JC$;#MY5L3'7:0@G,:+(_9 M(52S'']WG+ZR]M+H"8:4O/J MG&J:PT#'X:_C@#?A/T^YZT/70 M'EHB^6['18]:&X`/N666H33,_S=V(T[?KT_.5'O/XL3EGP4491) M91L/8K/+P(B0%=*],L&:!NAI/B5=$*?H23I`VX&85D7M/F<&O?K>I]:6 M)V54(`>R':MUU9R!!)S3VG>80$(.G34\AUL8QBS>U/8Z#9CMZ*ZKYHRDX)3S M^UN,HO070B0]X\%L_9-;E&KS9S*N+U"JY(I;>6]QM?OJ%>BS$@.SGFRBEYZME[DHS!W MQ+,521OA952R11KD*0]="\MU$(;Q/5V"-;#7)^"V'2\2,MW+7 M2`WYGYUP22KVE7-D6D`'7%1%F^8L&5E[VP[)4#D2QR3FWCE_]"2'\RP\2D]J M[.0Z+)YF6QM=C1*N]UR=8F,D';V\E+@AFM5>+VAYT`41M?H8V/>"JL,"A1%#VOJPW8+U&Z;K8T3J+Z?'!2TA"2=/N(]CP6&%D>U@;.$?O3]D\ M@;]G=)IHJ]N:^I[?#U%!>SEX.T`LQC;ZSQPDD#SY)U!+`P04````"`#QB`I' M'BO$CSY"```GQP0`%0`<`&]C;&`L``00E#@``!#D!``#M?5MSW+B2YOM&['^H].ZS_^^N[KW<'B[O3R\MTD MBBW?L;S`1[^^\X-W__E__N?_F.#_^^?_.CB87+C(^$X1?;R^WW3[%\?,O[]]_^_;M9S]XL;X%X9_1SW8@UMU=D(0VVO85V-[C MO\W.9A^F1QOK;3Y=33_\9?W\NL9"G%DQ;D#^!3?X\`G_S_3#_?3C+W/\_W/! MC\56G$3;CWUX_9#_7T;^3\_U__R%_,^#%:$)1L:/?GF-W%_?E43\-O\Y"!_? MSSY\F+[_?U^N[NPGM+$.7)\@9*-W!17IA48W/3DY>9_^:]&TT?+U(?2*;\S? M%^QL>\;_ZL1;@G+CH_?9/Y:;NHRN2TQ'[B]1*LE58%MQ.A:Y'$W`%N2W@Z+9 M`?G3P71V,)_^_!HY[PJ<4F6'@8=NT7I"_HO'U/:KMOLGP>7XY.3CR>%[\J_O M,9C)!OGQPG?._=B-WPBRX2;E%DN0=O<4HO6O[\@@.B`#Y<-1]LU_$:&-WY[Q MY(I<,C?>3=YW9?.SY1&=WCTA%$<\OJB-^V#DQ@JQ^$\H=FW+:\45E5(2BV0^ M(H)+M%POG\EJA?'@*HU-U0-KIU;T=.$%WUIQUB"2Q-@R?+1\]^]4:#R" M'/$9RZ:2Q-JE_X)G7A!RAW^CH20&;L(`RQ:_$2.#`7@F"P&/%Q:-)+:N$#;" M7(BJK:3-G<#YYGK>#5X6\:*(A5QB2Q)>^GC;\>@^>&@110)6LF4WLL?3A>MC M!S'")OK->B#=L+FBM95F+0/[SZ?`<[`_0<9QS)V$ M,(4DEFZ1AX>+@[S\ M%[9<,7;MXB3DKQ74QM)@B]TPG2DW>!/*!XO66MH"8`<;=&^]\C5":2I-'S:J M[')"_(.-A,:,"*WL[7*7W7)_F^5S3!^\I9Y?L0!SV6+12&(+;[(W;KS)C=EI MNC5Z1+[('EB`5-J>_2%"?R7X2^B#$G0MNCIR#&))]2JM<@QA2M;?^;<#'>A#OH84,NQB%,T=OF M7'!IX=#UM!,68XY-)7\'*#K:`((>MUFB8/(H92W!E&CB&8HMU^.OP'S202WP M`6VUS1GZ&CER3+/@1X85O(BX"`*W7Z_#BG:-XJL@BFY02+;2@7_W9(7HX,&* M7)O$PETOP=Z_7+F[?%('I:27:^VO+;I0ZH[)C@\J8W[8$188VRJ84^;VJ_U>W7;OR-\T/R3Z$C9KU=I MT5#,11@3599]84$1Q*@'896[%@N2#\+L=J#NR76SGQXB*0?E4SG!@2%*+^M> M#ED4.HQ?'ET?VDR_V78=%.^A-Y:=MD.W11>]!=M$?28>8=\,"@\$\1YZ8WGA M.*F;8'G[,\_OJV_-UQ,!QF M^^,PZQ^'/\BW_/9[[@Y=#2]$AZG`[ZL_,6:X2?KG2Y]<"['B%Q>16S.=[9-H MC\I$Z@*0:)=]"C6=+S>^^Y`(AUO;=-+3J=U!.6G`$>.[31^]L5W[@_CQ3H>N M^KBLUW9I%2*6?WYZ\)4$R_'7?/SK3=`NAMVVGQ[8W_[\&?EH[<8=..=TT0/3 M:;X;">]L_WB+O>`.K`MUU(,`9VB-PA`Y^+_054^W685/LIED+.:L MT"[XHS4N?Q=(I"WR>X5\K?*/7&/D.VOH%I,-] M4]_QGTDG'[+_FTX.)@55^4?+=R99%Y-*'[VQ3L]PK_`ZPPQN33+^&9N%*/!< MAQS83'+Z2=Y!SF;!J!?8%>X\4KT@"*DC(D5R;44/*9Q)=/!H6<_OR6K_'GEQ M5/PE7?\//DSS<@7_DO]YM>40JP1=XA^WTGC6`_+2;Z_RQK2V[S5@_;Z<^L=@ M.V]79WDW+!9AP7P^'037G&P._D+NV>.!=.ZE7\/S./.8"\[68;#AZC/77<"4 MH*Q@S,B[21`Z*/SUW?3#CALP\& M`[*:4KB7A4FQ'=AWL>L,6BH=A-M<+6YW*,3.WN(FS$,Q*=M?\JTRN,[!1"O: M.-P/R>KV'4"),56"5KR#\TOM@I>Q?=8%)RK1ZM`(G&#>(9P.U>*4Q3$7#U$< M6G8,0U-MMSI6@X;P1H["+@2`VO4L8_0T"4G84!2&6G-5:,!*IH%!8UK3S9H5 M/9'P(OX/.0Y]L;PTX!B?6F'XYOJ/:?D_QG9!A%PM9@PL@HZR@'9([?3*LH9( MM#B]RT=*6F`IR%54Q)IF+#)#H./+`&[QE$)6OE/N1D_((1?H&4XLO;TA(#&8 M!S<,2M'!^YMGRW7.7Y^QNX**9(:*U#!4`L2&X"8J"03BD48@MH3-9*!$H/FH MSWY0S(TO/(M;VXG*/'W#*PJ`P!B"L"A-88@.%$*09'C"&N_:&&(XBOLLDZ!%"J=FD;*7*,@"D-`8;(/ M@J1#?(UGR`T!0&`=FJKU]TL7,K$!HR1K<2-LHCUH'P)M)0@(I]I80$D&X1`I M3*,*LBY(@%BV"J.JC164$K_/T`,#LEI##7`2#Y!26`?A4.OUIU%`/`"O`LLO MDIJYCB:#R"28>&*`D*F-!I3SSTLE"(CDY%S27;O($8-0K!/C(&TA%@BQVF@# M,>/+]6F('#>^L&RBA;=3ZQG_A`W#B^5Z1+Z+(+P/+0?=)*']5'YH@6;^NO1G M$O![2`B.`;41C.*H)A_->)W"?PD3Y#35PS^S$NC$)+3;B@5"K#9"@MU6%*(H M%K6[]/8F`<>0`#PK5AM0.4O0?5`S)3R<8!J3L.)(`>*E-K9R%?B/]RC&@"I-.`[RZ!E;X"N>&.Z6QNN/0]@A![$/0*$YYRQ^W$,"EWM(D4*B\@X@HOM2Q+?EZ8[G. MI7]J/;NQQ;C]!!"8A`]+!!`FM4&(6U)LQT?.N17ZKO\8+6P[V21ID.L,*]EV M&9:)3VL2>(+2@#BJ#5J4EH;TB9\HKZ/[7'E8F;D<4NA,PD]`$A`[M6&*+ZX? MA&G%F>PT`$:KWM(D?*B\@XBH#4O`+Z>+[,]-0@7@'L1%FU@#U?/H?F71),R$ M9`$1+`4B_OF^)N85_G60*E7T$I"5DE5S\9)5DY\J_?UC+&$UEK`:2UB)5+L9 M2UAI5#%I+&&E&2!C":NQA-58PHJ/TUC"2O<25N0\[=+'CD56XY:Y7:"UU7N? M`$NG6ZV=*J?7U@;QK!),H6:SP-`U"Y2FJ-KM%>1AH_.^86_\=-XV`,^H\@P2 MDVSU48U)XLX?\`81(`.$V4>UIJG,;9J]GO\<\5#C$*X^&8&;B!00(5J2B[2FK\I)PVW:RF\M=6R64UVXL#X:MV,:T<@#Z' MR';3APSPSQY*5>T[BTV`EYR_T[^#E7$8R$OZ@@�JJD>@:_2'F^&%VY+\BI M%R`IB5\6$QX9[?O2?PQTES:RR*)GX*0C$51!.MT MIB%'YQ]"3'E9T0;GEU&4M$4KHS$3J3+OH%.J'4K+)(ZPU79<_[$=5"5",_%J M"`"!IC;'I70!L+U-$R#6'SQA(<"`@BX`BILR!I%1@+4S8FH381IL\RP80&`@ M0"*V2W'-TP;/0I:+164@3L(V2W'M4^C6^@-R/B?8L73;SBPJO8$`,N0`H2Q% M1`:]VKJ5,EJNE\\HM"I)%]5KK8>U:ZT[VDFPGI2IWP_![O9Q=CJW1TQN"?$D MI^Z-VV7X:/EY0&SA.V=HF]2!N0\VSY;_1N?](WF4UXW(S['P`+U8W@>?:I2SMJDC'=9'R MS@CWI>XFN_XFNPY[D^BW`'_H-/!M%`)/)7^J\YV23+8TO;&VL/]*W,AES,>3 M.FM5DMXX2P.%!"*\K''6C.F'.H]EXF'6C.TC/'0.IW4.2^U[XZDX):$=-E79 MF]79*TBSQ[IWQ+WQ>H7*)2FKW,WKW!6->YRQ6>G^&[R:9\]?4>O&T]D];$[F MK+=_G^3]I5I->YSLNIP4??8_1B]23E'Y2[:`WGC\G$=X61]%==F<+X+5AH0JRR8ZN-Q;_"QOJ^'?\$?QI.G^S MAG5*:28[HAXQC]TPG9ODH)S.7<,R[8@F&56/ZY$=;-"]]0IIKF&6,HI)3M*C MWFQ4V72&^`<;P6-PUC!161>5C6:ED_Z=%Y[O,FO8J9TC,Y3O(4.,><,@E@F'8)3N6[)8;EA)P,,<@GN:6\?B7="Y&X+US'%C,0OX M>D,PQW"/6!PWS"C321I"D+*WQ.*\85,K/M,0G#:=)Q:_#8M*;K59S#9L:'G#/60PW+2)]#SN(5:%$WL](T2R/SOQA M,VQ9C;?G?4Q^RGM1OSDYH-F>G+NOD4,7LV$[6^Q:8&-5Z&3RT]>[LW\=2YJ, M)4V^VY(F8+;#Y[=[_&UVMK(0L=[IRRWDURWG`V2=,,Y+GQ4B5I/EW`8203"; M&M$N`[IO-'7.B^X5<;USIC?/28S"+=O\;&DJP4K-#:,V\ZUQY0B20\_%5ABA MND2*+G]UAX8F`(B)\@M\Z2BZ"];Q-RM$M3-TT1A"=.L:&N\U@!R9`%M65?4`MM[3+'X<)0CL3R]^@W> MD7R-T#KQKMPU^H*5N$DV4PHNI(L6/:R.=+TDVT40"**NNXT]$+)>]T4H[\%\ MA,J"".PRAKW&+!8C*ZY[,6-_C4.95D&QXA.ET*`&0:0Q_C7&O_I`Z=+/]4LO M#O'Y[8OUWT&8EBADQ\):=Z1W7*RC7G1SVSAB[(00*3G7J3,U,;2N\+4:!"SM M:1=?4ST2=(Z_*1LM_<3F@-WRPG]$WG+]!2^4;Y>^#7J4I#&UK:I0P#[3,!"1 M27H<`$#@+(@#+[A%$<)?>3H-PN<@N]O$Q()#I?SG48S0QK9" M=(N>25$E__$K%I")#I-&54EI2=CP98.045QRNO#A8`M6M%#W]HZ@*'K MH'&_N9)5OV5ZLNUFJ.2(@_(O3!@;5YXKJ1+US(DQ&#P&@[_W8'!Q?;XT\ME! M7Y!`[^`N1T[=@K@T=LF/(>(&Z@1(U01H>1#P`:-J0+NP:Y_8Z1Q2E8SOL('2 MC6OY_Q=97OQTA\(7UV9R*EM^+CJ)D M@QR2.)9?4'FQO'+2/+P$]O-=5=%9X;WD`.+KO>.1(GCVVDW6;438B>+=2% M`RUOR&%8^^@/->QHLK-N17PGXRS?[Y;_(7^)O59L?Q"O`V;CAQJ+8MH`1^?W M$Y-N*F)X3[C^\1]\)/)]XFG7\#5PWMZO/*=)%`<;%)ZAYR!RJ9:6<#$L$_J. M,46Z`,?:]Q-UO@Y\NZ&,J\!_O$?AY@P]#!1]YK*A[]A4I@UP='X_X6BJ(@8T MQO#WQ_$H8)*[QJF5F&2\V0V3U/-'813#?DC_MHC*B;X#3J5"P*'7-8ZMS]`K M/9SF4D]'%.F]RM3I M(Z$1=-1XN&3WY!%M^&B0TME8*L9LU#$;5R0.=17Z8P*L,$(FRES5@?5.A@<75+M-4)D`Z9Y;*`%'G-S%RIGD% MWRO-%!;IY\P2*B#ZE^`OOU?I1D_((7>WF-5O:>VU]^(8;$/`J/+%&*_C<7;4 MC3?R.,_>#>.=96^OLIRQHT8=\^*]U@%#)_W"9/>)2?:-@25G/*Y[T/P3>\PUZCJQ7]P] MH/U5CVI)9.U;KD]#Y+CQA663D-.;@*O*(5-HDVB<<1Q8!HDVOJP03C6[Q56% M&1XN30RVEPM3*/-T^5CPL=/9\:6.3[(^ASSWBD^IQ@WF(L`'C*8`[3SB_I#3 MV3^6C.Z@E9?^0)X775CA8S`]9M;_:394Y0(+SXZ`R[UT7QC0\N^_?9G/9DS] MEINH\F*[:+;!-Z33S@7*^2/WD^C(S1NN/IJC7X![2,L?^QBY<_[(S9NL/IFC MV0;?D$X_R7Z4XNKJX_1D=LA^@Z+2"-L$[3<9A/[R//4J/JHLRR<6T5C-%#UE3(6B1:@W8US/,&%^K]!_S`Z_ M;I$?YY7>\I>QR5\LCQ';%>W!*/C:"07&F10=.I\&_@L*8W*T=QW$J$@29YZ@ M-9X5*74R27N9Y-UH<4Q&4NTN_2@.$\&[G""!PLE7Y8ES*$9MK,UQ&`>/VO1B M"&[&$5A5`/;A%ZVMLF,OEN99&.E\U%7E5.0A8)A"S=$60]-CH? M7NV-G\XW.X'=!.^F)Y-,T1,CW.D3M!-!]GH(^*T`']B%^\!T9;ETJDX?17$0 M%P)<_@:#@GU^QJ53=5PI!XJR$!`4LJ.](#=S]B$QET[5R:84*"I"0%#(C@W# MW'2<%06=JJ-0.5"4A8"@D!TZAKEAASVY=,I.3^5@49$"=C6'0N.0?5&(2Z?L ML%4*&E4I0#0&,]Y''?=1!9VR`UHI:%2E`-$8S'Y_G'9#HZ!3=J8K!8VJ%"`: M@YGPC^QS2"Z=LJ-?.6A4I`#1&,R*?^QH-S[N;FR:C$9%"CCD-10:QQU7JH). MV>FR%#2J4H!H#&;%C]DWJKATJYG)5KPJ!8C&8%;\F'T-BTNWFIELQ:M2@&@, M9L6/.SKB!=UJ9K(5KTH!HC&8%?_4T6X4=*NYR5:\*@5\ZC$4&B<=O;^";C4W MV8I7I0#1&,R*GW2,WA9TJ[G)5KPJ!8C&8%;\I..>JJ!;S4VVXE4I0#0&L^(G M';V_@FXU-]F*5Z4`T1C*BL\[GKYNZ5:'!EOQFA3@H=]05GP^[68WMG2K0X.M M>$T*$(VAK/A\VLUN;.E6AP9;\9H4(!I#6?'YM)LOOJ5;'1ILQ6M2@&@,9<5Y M2>Q"#,%X_J M\&=)N;7N^N:R#AXQ]:KL_`6%J9BRB]8&*KO*.A@)U#)QAUXY_JA1O)^?N=-O MZ7BV%-O:@H`XC5K^`N)L^R2"Z7+9O3$LQZ2D,2EI..3&I"2-P!B3DL:DI#$I MJ86WW.J`M#A/U&$SVLHK+C$^_+Y?*M=TUWXU-<\,U[D'M=ZS`6Z;-U?.-#// MNM:Y![7>NS5MEQ]7RBB;F6A-J]S#KG+O6F^YA]EECIEH3:O<@UKOW9I^;+FN M?]R6(C71FE:Y![7>NS5ME]=6S@0ST9I6N0>UWKLU;9?;6K:F$G,VY^995T@*$(V>K6PI3ZZ5[]JD6\W-L[J0 M%"`:/5M?B1FT<_.L,20%B,9`0689.9OF66E("A"-GJVUQ)Q-DS.A:E)`:`R6 M";5_SN:A>7LI2`H0C<'V5'OG;!Z:O*>J2@&B,=2>2D+.IL&7*VI2@&@,EY>V M=\ZFP76E5*4`TALLNWS=G4X_DG'US-IEY.D>#99?O MG;-Y9/#]R)H4(!J*GQ0#V,]3OBC(L9,?<[K5D191E*MN&9P5(2#@)%_E7D21 M^^@CYR9T?=M]MKS[8.$'\1,*+S&/4:F;VBSB$^H.1ALI(#1TRENY]&,48IYO MK1C=Q?A_G!L4VN3MLT?AK#!6'[KCV5$@\/Q$.;39,D'R2_(%`SD[P8A`;%2Y MY`8!*B@+&%U3CN6.V]+BOY,*KS_V+LF6-TL971B$:0MYP!V^GKA^1CY6N.U: MWDZ<"V3%22B\$(OU9CK:7-'`[:M:X!-T'RS)+N$6>:E-L;`\*,HW<`O?N0Y\ MF[>5;=.+*4"W%@D"^*-2@(LR'V+E9&BM#0$,9AT"YEBN_Y&.F,5Z[7HN'B^< MTB;TQKJKFLB-8$'%H(`L%R M,L`$F+69`#,3%,_B''2N)<P*7*)?;I&X)K#)C)! M]2(2@!"H#W`P7;]T,D>7490@A^,^B?>C.ZA["`7BK'FT8[$)$OJ^0%09>0_? M"[85<4!4U<8]4F-ZBYS$CDL5A9K85=L9@A"-:1`'M7$*(LIR?1HBQXTO+!N; MX/CMB_7J;I+-YR`,@V^N_WAJ/>-_B=\87DZ+7@S!L+U((,)J`Q(T0?(]UIX( M0[T8C#!;)!!AQ1$)BB`+WT\L;WMTA=WW#3/@)-Z'P>BR!`*Q+04U!JTA6@Z[ M')1"9F]YL\9KV=-I4U8=W7IA-=TK&>9J_U-`&ECZ4TQU*:^F(SEM*4%9,L'882?LI[ M`-%+C'0ZLPILPC+HN[]9ISNN+471 M<\[6#$-+YUF$VC`<&4*`.QBE"!8#[_SU&6\64J,!`T9IK#T^$,_@;N1'NP:E M.X"MA8&0/504D4IYI[P$0XU$??Q0CT2EY,#++^-K+^-K+^-K+V9%I\;77L80 ME9G8C"$J62&J\FX@M>_YSU%NUYEQ*C%B`X)5XH+(7O6@BZ-!S*Z_MVM@PGLO M-6[!]4F^%MG9XKL&)CS54N,6]"[D:Y%=_V[7P(0756K<0EJ47>SCJG2=8;%@ M3VYJVY4!-3U@QB$URZ[B4>6`/?NI;;'U-4W/%P+4MJNI M`1:0P3FH:=GFL,H#N\(2M>UJ:H`]9'`.:EJV1:SRP*Z!2&V+M^RF:;K".1P- MZ573["K%U+:KF7$6L<(YJ&G9%I'XZ\6K;@OV4QBTIJN9`?809AQ4LVQS6&+A M_.Z>[;-0VZYF!IA#!N>@IF6;PQ(/L]F,;0ZI;58[XMWF^:1:QR#FJZ5XMXQ`[D4=L:\;P`@W-0T[U: MQ*,68_IH.S),LXA5SD%-]VH1CUKLIXNV1CP+P.`K(,(M8XQS4=)\6\7#. MOH)`;;LZ,LPBUC@'-=W9(LJY?]I(?Z"`DK=M-%T=:?%,X17G,CW`-X2(6CR* M^K1$1)%D(GI[0Y!A,0\&O_6:+MSW6R`*0R!BLP_&8W0H+Y2RGE]6OK;"T(K= MEUTR1R6M:\HK,)2E>16)79-M=V.*UYCB-:9XC2E>JK<-8XK7F.(UIGCUDTND MPS9-.)5HT'0LX40B`^)1-6[!M41A(I$!L:8:MV!T6KM$(@.B2S#CD)K[S=?J MDDAT;)J:RXQ#:C[6+HM(B]!"ER0B5E#A1+\4(OG[L:%2B%B;K6GG1U#Z2R&B M;0"UUG2%R60F2:1:QR#FJZ5XO8*85H;II%K'(.:KI7B]@IA6ANFD6L<@YJ MNE>+V"V%R#2+6.4@IGNUB)U2B`Y-LXA5SD%-]VD1.Z80&681:YQ#FC[JTR)V3"$R MS"+6.`H]#U'\^L&$TI\%!U4B'2)-7KJM4%;HH$$%XZW4;] MZB<1GN7AJA>$;YK\=G%4J(_&CB0"&C94" MUBJ7C)J'900\(.=@Z$(I*C=A8"/D1!=8:G(@STAM:30U!!&`;W#CK-&R5GZ. M\QS;79MDXNWW0"FE&T-P["`3N)'4"&/,LQLXKMWRF=(:F9$84F6`,/NH$687 M(?HK0;[]MEQWA`_NP4@D>>)`H!ZK-7X9B]%R?>'ZEF^3#7`0Q2P;"%`8`AJ; M?0BD3QK-O-KH*JQ`QU6S(#<$OA:R0%B>:(3EI6^'R(K0PK;#!#EML03(C<22 M*0OH@&L07XFB!*\CB+-L-IJ:!%*3;Q`0U15U+#]U=J((+^P7B.$?-)H:`@C` M-PB(VI`'D>TT\%]02!+/LY]B,KL+\H'#@2U499ZS-7:!&'L_HT<4HJ'!.YN0K1QD\TU:A&*9G1B$-BM)`+A51^T MV0W:9>@^XMVU1_Z:A66%YS.%U"`H!>0``50;D5E^\Z,G*T17R'=(,)TL,8]I M.9`[\N=\C8%1%*,W!,HVPH!XEJ(UBNNB.;6Z:-O)6"V,-A,JC-:LBS:9_J,D MJFQQ[N+`_O,I\+!2H_._$C=^RQF@"S&O"U&FGV0=;&N[J:SH=A=;,1(LYD9K MJW"MV++#*>%6;Z=-]398][6%@"ZI&37;MKR?>E84+=?I1&"7;F.0**O@!D`` MX`3)JMO9?9E/7H4P6ELU==OX:@ZXG(-'\VI#.?L!HG.QMOU!ZZ=:FZ15#H4N MBA;835JC,$1.RC9X7[!0"4RDJ`(<8Z8$;5C7<[5+=\V?+6P73X/-,Q[75J;, M[;;Z\]NN21[,7WRS0B11"2?V3@V\OW5-4-$]^M]"$%\-W]F*!Z5SPW5U4PZ/Y#T[-FY$RALA@70]0D-/[>7>_E2=[[9W.R,5 M"VZ#B7%(*](Y-/S57IO>B?A;$#C1PB?N(]H\>\$;0GYV MWC\_A\$+']*_RV]&*AR4:YR,`YK%0IG MW5+0)-&VF*7+=3:!O_J80[P3PQ*Z+PC/>KK";CP\\7$S+R$>2;K_*G#A>GZ# M?'X<\(-K&QSM:F^^ESV&TO'*-J;(N!'+)54UR@8'->B@%W`\F!J?K>R\R>SK MT;[#'_M!QUQ?F@1'J:'QVJ$VH%IM,PT?FVVVCEV#J,"Y*6\IGP'GH%RZ'VTH MB"L%A-;0(&5S@<6:/7]]=D,KRXK+Q_4?R'U\PEI88&58C^C\%86V&Z&;T+51 MC^=%,MG[T0:U=KH'YT[7"">P+%:/%FZ1@S:I*"E'-_GQ+W1'1(S8.`^U+S"# M3IH#1X*A(449VM5T]1Q'NGZK*OMNGN)4`IYB(HYF"DG[GC12^1AG2;=9(A\$ M<%IH?M6:IXFJFZEH3H@S,4Z(?B9$2P3`V2#Y!K?0W@\*1X@1CR.JXY:;';B8 ME0+Z@U98`$L2;$LB;)FNU"8X;%.;8%=?8=CJ"J7S/B&ACD2$VG6J7+[\\T`- MC(^M()J.!23&`A)C`8FQ@(1I]0K&`A*:`3(6D%!;0.*L2P$)*I$9!21`UO5< M[?I)8^HO;CT6D!`M(*%V7(T%)-05D%![/;.SIL8"$AJ,NP&T"&Y7Q@(28P&) M?@I(F'KUG];'.@[:CVN5=1S4!LW'BF::#](^*YHIKJHPUA#Y@<:Q!C5$ MU-:,&&N(2,\IW;.&B*DA^K&&R/>1QRRV/S0T9#_6$#%O;+9Q6R3'T<<:(OK4 M$#$T0C[6$/EN![5VN@?G3M?P^EA#1#F8>00& MB9JR%5R=LR"BB*Q=Z$1WXMA4]+<,;*XSS7Q8VWLQ%J7[Q4,4*^"M!9RBR0S?=Y;+-6^<.];9^ M>^I)MRH$'''(\L1;AUMTH<9X[@M9JP'0U)AVMG9(S'6VQ8K&A1FDMN-C05*?35)*H3;W36TSU;$VM_"-/K")<8Z M:)OTB!"D?%]AP^PZV>6L]!\0,[]6@%A[U$1E@.!3FSE0Y?[W(";U.,C!BTB$ MM$%C&%@-UL']P[#VB5R'[+QUR(CU1:*E#!`D7=^=E'7XL^7R+`GQ(,K.+%.# M6O956,="8CWH"V0702`T2QD`BD];#[)+[LD#<2X?L$Q"CQU\$CE\S?\ZV76N MRZ,'VZ_/Z.*==#Q;G@TKS<$?Y,M^'`F!=OQ!#+2B4RI8&IP_-R;H>'0^'IW+ M."\B-WG8APFE)GH?#S1DZ3T&D7X1C->2)I46:D+P3;4$`'_28^8RU*9S%%M4 MM3J'G;]@16Z2#2_07&DV>&@9&JH!AT?IL6)).K=>A71>;C;X'5!!G3=X!)TY M+=[,R3=ZRS"-"`B5^^=1KJ;RERC)04TG`Y:7!YF%0UH MW9?^V':52?8628\T1$7E(_0?)3W(J^=YDL2:U6I25@49^/['7"M%Z'EP=F&Y MV0'L`B_0FV(=?D8VEN7WP,,*\=SX[18K%!Y/XGWH/R3:RJ+G>1I-BELW^O,B M1.@2>Y#8\,;M,:7U8":BL"2RS][ZGZ5G[HOK(-_I/D?+/9B))RR)G@=W+!GN M4;CIAB.A-!N_G00&'-%!QSSTS,CCJ<`Y#_.8A^1(#GJ.-<--,NE^*_IXKC6>:WVWYUKC\^4:9X6.SY=KEI4R M/E_.D4[ZV1UT:;"\'\";$F*PP5.B])(=2+"BC2DMWB(7X!N<)SI&I_,'%K99 M$&EARU+D/:U@^?FM$K02N'?1R\,,+60J$U!>6MV+Q]39(5['"+2 M!B,/(>TV`*:/1JVW(":/6)UO+F7L\R[1E%OU,$SVJ*,F9RD)V-*"'J#:G53& MYR66^!4Y]T%Z?Z&(C&7_R]X^! M?H?W0`V]!JIO))11<*'I!_/?A^_2G;('`654I6!+I7'4TM3PM[+!LN<8Z#M( MSAIN:J_6&%H&91QH@%(T#5:J+:WTG8R6;H*;%#/L].!O_XL/Y6/?RYCJ23-& M!$2G\^7&=Q^2B)D(?R@:`IW.)WE_8^;[&/$<(YYCQ-/8`-L8\=0,D#'B*2WB MN=RX/K;1S"!GI8W>^>U-5L$),%XG%[QEK>@]R^&OD[,JEX_7R3M?KOZNQH^P MQ`(;H4%]OL])A/4017>9_8H./EL>8?;N":'88;E\1W67K^AJ4O1%_I;U-DF[ M&QV^T>'[<1R^^LP2=/KH9(8X?BR9>W_^!^2"^;8-ETJQD\=4:=!"#NDNWY`P M&.':28)J4$?O!H51X.,-#-[_WN%]BVLCMM<'$PQ]M:7-J`]$!1AHK?J"'->V MO#-$/O_%\I,U2:@@1Q5,Y?/(!J^HTA$#(3E`*/K!XB8,G,2."^Y%<*"2#!X) MV0\#6`9-0R2G0?@G4#!<&YZ!!4(O&(HI0')TFV%/V8_[U M.FIS_4,75$R/6' MK848$(S':F>7;0<)8=EWKH,81;?(1E@,[(E=(]8L8Y'I#YL`^Q!F_ M8/&"\.T"ZS)Z0LYO0>`PG'YZ>_T!8O$-(7.B%)F;$#U;KD.>WO`CA`?6,GY" M8659AV$2(-8?,V$A6,$V;1!LB9FA*(GAHM$&4'#CIS\.;>:%VKOIV'][1F'\ M1G)U8CRMR4;GF8C(W"&PJ/1'A\\]");:;?D9>@XB-\Y&%^NPM=1,?S@H[(+Z M5[N?)ON4;VYZA`6HOFBAO]:KG((*5[LC3C<9EWYL^8\NWK]G0X2Y,D$4^@/" MYAP$2.W&F+<4F;(&B2P^,WTN6=2C@=G%B*_1MLOJ78N/0GC!+%>/%BO'@Q7KPP[^+% M+7I!?H(8.]NBQ6JFN_->Y112N-I:#*=!%"_7.:>LL5]JIK_F*>Q"ZE<75'^0!$60 MOF.2-&F0C]GW,-L+9T.N:L1A6MEI)Q=&)IF1(`I(!$*H]IS^##V'R':S-%(\!C=!&+M_VM)LH,P=C)^1P'&D`6%3>]WBTK>##;K"^ZP+K`SR;HGK)UB(7)K` MCW`++R$U*&_(2,3*C^/0?4AB$G._#ZX#G\0DL8XQ:X^7?HQ"%#$V//U\S\@! MTZ[;3*3SDCT1422?BPB:\W(AEJZPWC@[['H[=6A)J[Y^H2% MY=`T(%FPG/-ZBSSLU3DW5AB_\?&B$)D+&B@,B)Q:?P;+&B(K0F&RMEAM>C$1V[;2@6"K]7Q^PUHB&X&E?^9&Z4U1K._EFG?SC$EF M'IP"XH#X*79^B,AX/Q84&P*N380HS$.-+0D(6->C"N"@]#Z(+:\D`PP`:0ZT M-DCY7"E`Q:L]I+A%48*;+=<5+P/3C"G6L,O% M]IQTN29%%"Z\X%O$?`OU$^4MU+R+2;">D$XF:2_CBZ=C5L*/D)5P'UI^A'=% M6+WW^%OL7`1J8[TS$!CRZ5;MO\0JK[8\I:F:;`26>D$@-"_ROP\..JV)0YA["X.-@&!QVQ""G6QT;B4&9>PB# MX\$P..J(04ZW^F0D!F7N(0P^#8;!QXX8Y'2K$R,Q*',/87`R&`;''3$XWJ:8 M&@E"A7TX!#48#)\ZPO"ID$/1Z>&>,%38!V&0G:K,<%IXVR,>X6JJMV$0XQ]$ M0K9M6#A.JI;TS:WMPUQL7XU)H^P874C_`JS#`8M!5,]VT9@TJYG.\2(!UD'5 MRPX67;@^>4G[`G&B$HUVJYG.L2"`75"MLH,_N^^S1W&CW6JF:Z1RP`=@%U2H[1+/[/CL8HOQ#R(Q7/AEVOE,9&O?S8S`5/D'D1@N M"#/M>C(RW1VRF8E$A7\(B?EP<9AIU_.1@G`UU]D!%>4?1$)^*`9DJ.LI24&X MFNOLCXKR#R(A_P8#R%#7LY*"<#77V6T5Y1]$8L!+#%U/3`K"U5QG3U>4?Q") MX:XR3+N>FQ2$J[G.SK$H_R`2PUUHF'8].BD(5W.=_6E1_D$DAG.PIUT][()P M-3?3Q:[R#R(QG(\]Z^IC%X2KN9D^=I5_$(G./K:D9(\G*T2?K0@YY;.(18AE M?\S*W+[MFMQ8;^1/BV]6Z"QL&WDDV;)*26JZ4*`N;O[W\+75H:(=G7B:26]2 M0Z-*<3X$LI_\P`L>WXIJ[&FE'WA8``3Z(\MD'`SF*"X7^!#O%JWL)SR^+OTH M#I-TY&W(&[E3&"W1'O2'KYTDX!*NN#3`KC0/9YHUFNJ/$,`R!(7:>B:[2BRW MZ#D)[2>\GB_79)#M1A2,C@BU_H")2P%AJ+8:>[ERZ')]X?J6;Y=*U9$,Y/0) M<1A'T1[TQ[*=)!">JBMU1@G>9]F(W#?#FW,L"N']`K'K?X%$^J/&91X"2FV) MF]T..'WS'7-\'?AH\^P%;VC[JD_))3NUGMW8\MR_R=Y8S.?HU+'^@$L1$!H4 M:BN?$FL2$7."L$$Y?R5ULA(W>LH*1Q"CPC:G3%+]@144`8).[?,.G9U>\N9V M_+;;+41I5:C[)\M?/J=5?WY'4;I)OT&A&SAI.:\+RPU_MSS6^REJ^-%_D*G4 M"QB^4%M'H+I;S=U"\O)R5J;)=LG%W<)KO$`6J;?%=I?;]J;_L.DN%0BZZD?( M=H'<-"LA\_TOHRA!#B,:PJ;3'T@1_D'(U(:RBA?8\,+U@)V3+#3J1ZZ3UP!, M]SQ9J2X&@&UZT1_.]M*`X*J-:]V$@8V0DU;Y3RT+>[M';:X_7`RV05S4!KG( M^PE6]+0,24PN_V5AX[U`5I,QM>[+=:D:W@*O)!OF#.S(30-:@" M'-]6K?D%0O`A`&D/-=<8#S[;H*[5^E'-:NWI.K&PL]A;7K6=%_+*G>)5P;\#T\H)F_W;GFOU+X\[%#[.Q%N98"W.LA5F[ MUC/6PNP3BK$6IJ$XC+4P=:[^9^1ER!+SLM>MP4O_F9E45>9>>@@6P""["-*U M`*`@M=:E8=O(`%J2@5%A)[L)4FM=*;:-#*#!&!@5=N*;(+76I6/;R`"A(COK MZ@\K#/TXN@C"+N6A!*FU+B;;1@8(%=D96#R>V!9>D%KK\K)M9(!0D9V-Q>.) M;>T%J;4N.-M&!@@5V9E9/)[8UEZ06NL2M&UD@%"17PEE6_T0\Y45*B(W-(7? M2:!1:5Z$EL\[I'WYU4_HO`@_CT"CTKW\K`#S<,QW(`"$2Y[2J'0O/"O`/.R8 M#P0`K]`)DVHUU=D5%V(>!&#`1UKV?BMGJK/O+3`L2FL^,M+Q'G#ME)Z,9O[$L]S99ZW^B!)-.M6L@7Z[^#D%RT MB+*,PYQG\H(ZYU8)GU+-91]0\T%+]D'`U%[\Z0\QG:\%24*UGRM"$B^"$R6D MT6OBN9&TS&@1QZ'[D,1DL;D/3BW/R],O%[Y#(M\6LUC%'ITJ>]ZFW97Q?833 M/-I]8=55`9P'BM*`CA/2S*D^=./(4I% M+9(`KLFPB]V7W7:AN'RAQL_I27?B#E^@X,X,V34K&5^<=Y#9&6$AQE^DF8B^A'#(C%E(AT>45IP>V&B`7 MX`PC9%PJ-0NCF$J#%G)(7QF'A$'G-4XV5(/6`OB"'%*"YR8,G,2."TZ8VW06 MR>!I'FV&?M!"!DC_BF^=E-^<*%VVN4,>_M3C;\A'H>4M?&?A;+#*HS@[:CE_ M)0E%**WD5Z**MBY-WB-LI?K]KK+LB+;G#4.H`1IYBG%+HK^L!X1.8S. M(PI1.5F-L@K!UT1D/5'AJU+GXJWY7U$(3YNE`L'9PC71J) M.2"Q)1C(>RB&2CJ[WXJ*CL`6B-Y8?XWS>(=TK;:L[\*VPP0YQ;I[FH0A\[4J M>GO]T1%@'P)([<-4G=]IR.Y%9?>EBL<8&+L(F9\Q9CCT(#4TBDJ5FP>]?5;2 M!MY/D=0FO)M&ODWNO@I=0OM8OX16ZG%B^&SNMC]^RO.C=E7/> MU1^`0-'%+4<7,E4/Q<&;J<9-^%@ M(E4U(%N\$\;F7=.0.BM7*/O[11`6CZ2R-M=M^M$>S`[B""QZPSZIDCQ$Z*\$ M"WO^4LJDHONNQXT'5+;4DXQ\ZZ\J]5*K,HGXJB"%RDE798KGMU);Z^.]"K6*']9.%E/+!\S@6L>D-%3BM__`<\KO54H:RSP"D73&JM*,]Q'U676 M(57+KBY98X']\@^]L:H'&?91=9EU2-7RWV'P([P'MCC7\>O-5+VTT%:]3:8A MQ*O+4/WT?6SU/&+TI,+:1!G1TE>)))%RN3T/DN/&%9;N> M&[]E7+MV?L\3!E.`V!0DA44!`W4:33#PRE:&-1/UO^GT1&,4-:M#8%/9AW,/*B%)G?L`J685:4_LXB-7_R M9V>(W*[C6B$C+U:`V!3A'M>C4%^OUEA(.E M^MX=WO^=!4/@%94$!%%M@$?Z/7U#8..*`(?%]9UT_5W8-P35+E*!0*L-UC!% MN4;?TG_J"O"6_KL`MB8-"*C:X$!Y$&(#;R,L0OHW!H80B3&PL04`D2J%`*"D MF?SOY'\>\(8:_^7_`U!+`P04````"`#QB`I'TW8K]Z2A``#"P@D`%0`<`&]C M;&`L``00E#@``!#D! M``#MO7MSY+J1)_K_C;C?`='83X(P?OJW/WR]?[.X/[NZ^@/*)7\=W3CK?%?T&<_')/_/S;\6.[E1=9\[.WWM]7_ ME>S_(PKC?_R%_L>CEV%$+!-G?_F>A?_VAXZ*WX[_G*1//Q^]?7OX\__Y:B[8BXCL\.3GYF?U:DW*4WQ_3J/[&\<^U.$W+Y-=00=^1 M)`O_DC'QKA/?RQG`M)]!4@KZO][49&_HG]X<'KTY/OSS]RSX0]WYK`?3),)W M>(68FG_)7S<$M%E(,?>'ZF_/*5Z)A8G2]&?*_W.,GXC!`_JA$_JAPP_T0_]2 M_?G:>\31'Q"E)%"4ZG72:ZMB^MFVL+;_GL]S194?"TGNYPSB)VSHL\NGO%_1K1/UZ3?_5$ MQ-]SLE;BH!:2-J&8@=D7V,)0M=VTGOB]=B,ZFR>I4'?6Y,K+'EF[1?;FR?,V M/]-%\V<'E;3][]4?_[[99'&85ZD>!$'E^%W^J_L"UX_XN9K M3-5_^X,)P\]#/2CK(JV5\5)?TR,5Q<]^0M:S3?XF*ON^9%^ER=I,CJKO$A/J MOT>/S1?*WB9"2%3ID9$6F"OVS39X#1_O26BYT2SB]^*<+/&<7[Z^D"^O?@>9I+^ M,.*TB;@1JG2A9\`&!H/FL@[!6',>(,;+(-EP'R#*C?Y&^8'@DNZ(BARGC8S* M24]*;1-_&I&[F).0@L&96KXAMFKJ%E#`)CDS$#D%CP%HH(+%#"10L5&#]SY9 MY=^\%%_%9+/^%#Y&>)%EV&S:T?"ZF(2,U!%-24I&,)@;(^T0B34/,"#>YXG_ MC^6&1H64H!/0V0285,PNF#@B,,"1238$24F"ED7.`KUA_`0,+J6`5V0[^YW& M1*ZRK"#;=3K+YJ_E?RI\=U-FF\`:IU`7;6:<8"`X2ES.CZ>\61^7@-QV@_G+ MW=2EF[5`3EC&RWIYZ&0[HPHWCC!U^L+]FBR)_ M3M+PGSCX2H9$VIF@Z4XU.WVMU,*W:>CC.Z*X*BHQRY>LKJ_S=55OA=[]9\`, MF?ET,QIY@*;C>YR&.#N_)4WB-,4!4U?M7:HXK(X#O>@]/,O)X>!2*R.W56$< MZ!PU/(@Q`9O>;X@YO>QYF=YZ:5[]CX5/7)DL9./C]/5K'/Y6X'.<^6G(QHQB M"I_OJ\@L#R[_MS% M-OWN'8Y8PAE9R5^%LXXIDPUHC%.`PL2,PSED1HFIFGDJ)N:9OX3RH]RT)ES63&ZN0@,%/0L,B!C+.83.A_^&8L*!-M5$ M0%A1Q4NOC'R<>V;H>M;+_!FGU;^SXU1I(&;&!@-FHV3E M0T8=G,T,JX=PC8ELU)&^QEY&1\2_>W'AI:^$]IT<5&9\UB`U1HT&4"9,,.`T M0M(AF"@K!1/;*D64&05DZJK8Z=3U;G:,?CT^)/3'"IP9 M\]K#VDAU6KP9,@+!W#AIA[@[/!HLF`QUA!<='QY0V!W/#;NNO]^=C\LI6`XY M,SYKDN7TUK=,=;M=V=3FE"JY_C<,\.WVE=X:5-U)D MY':OH:B%[M\]$=,ZG]$,!>1OF=2G(8R>GM-1#E`G+E: MA3Y.U2)%B MCI+0VD214MPN?H2$8)"CDHYWZ@DM2E:HI88W)UV&L1?[H1<9STDR#NMSDEIT M;DX2DX-!EEY&;DZZA#8GE8 MT/H]F(9*SB(ORY8K)J,J/5M.;_<2DT;L_F4F"3$<>&DDY,!5TR/&@):K&EQS MI@9<9#G&:Y_=UO/EX00AF;7H@4+()E@@H'$.!8U@W&W>601/V'BE7W!J?^J MG$DDA-;F$J6@S6PBI'(.!JUH0QPPVHSNL1CYP6[G%7GZ1Q(E=SC#I'N>SY)T MDZ2>]`:B&8O-1!$3X;O9(RIZ&)`Q$U*09T*X4,V&.GS`EB::&'6/_2)57[#F MR6SGMHJ$'&:V=FF[H[KGRQCB\ M>]ZZV]GL=U!Q_B_>=_T\T*>Q.@^(Q.O-`UT",#@02<7-`R7-W!N2P=6N0Z,[ M+SU*%Q==!***;K=TR)S;7B^;[@8=.K0,!H7?**-T!0:9WR@F`PD&M=_(@6%W M'J,$#-=AC)>KLQ0'8;Y8*"8&":$U*"@%;9`@I((!!)5H0QQ06KI[\!DU(N2S MAZS"B*6ZE.5H%'$J(9V]X)1"S#8B)2""@0&%9%P@H2)%&:,%ME-8Q'D8U,J4 MT8X09Q??_:@(<'!)#%:6PF2QLN7JPDOC,'[*;G%:5D%Z%3>@V'O,^D6;WJR% MKNOZQC-^SOF8LJ4'I4,J.8`-OW7 M!R&ZDBT#*KM%6H0B]LNR]$B&F7S:W@Q%;]!C8X!!G8,I>2"WR4;*OEL0:B,L65L)W!+3!-F69*^&H7%E4R6 M@Z(&"@SBHPH.&#`R%5,<-&ST-*0]D%$R`9B&U,D5Y#F-6>\<]XY1I#X#,^&`@;9RPW"$1X48$;+X:=[,7 MZ-!IH2@_9,P*!G>R(D2&?/N!.W4I(D/P\.=^\GXN[]/N'N M_2YP]WYNW/WJI6F<9Y=)N@@"=K'(B[HONBBVD<:LUG`W4ID&=X9\,'`W3M@A M[BBW1Z.?JR1%7M,`P6';PBYWF1-AI]@V&+."@9UL"V'(MQ^P4V\GS&`W^ZY" MIX1B5V',"@9VLEV%(=]^P$Z]JS"#W>R;"IT2BDV%,2L8V,DV%89\^P$[]:;" M#':S[RF(P.LD9E4GB"*7(7V,[Q+C3'DTH&&Q&)$S$KX3CU/2PX"5F9!\+(YR MH8R5#Z&06C%&M"*<%GPUF=#*T*Z&Q3F,Y&%=)3UL&.E"NBH8S>Y[R816^%Q: M%NY+R816^%!:%N1IJ8N8_2;D@X,S`BY*P@,?92%]*@[/9O:OE.HP?"T6*Z8#`&GJ$@C5`Z?T* M`Q,BD;@WZ==Q2&CF-FH%3/K8A4065E';>Z9+*W+[/)>4%`80M/+Q M)3_I;-#A0)0%6,*>]!4HY>T7+9?==^&-5.B__ZYD<0ZX<7**'N>R]ASDL`;` MT3O%$X(*8F=U%SB!I:47&DKG^#`2S_P]:\IJ&R;OWXZ`24OL#B9#@>4PJ2F! MPF0@GKY.!^&P/HN\5\8!I<0.X2&/_4DHH<)#%^_CX>$\#?/#]'2X#]:A,U(9 MXW2X#Y!@-4[8B>EP'USC[F0Z[D[`X>YD(NY.]@EW)[O`W8EKW'V:CKM/X'#W M:2+N/NT3[C[M`G>?@`4/FOOV%[\58?Y*,V*2V+0*@IC'214$E?C"*@@B!NF%P%9]YFS#WQ`\I&_)8+9]F(GZO`)J*`0RP3*3D*D6U:9*4Z[*\:Q MJY.8F!T0)Q%I^NDJSC'IL%QS#*-BL7L&HQ>^?P`CIP<#,`,A^:.7^$V'!]5, M%O-*[HO'S$_#1QP8)93PY"XR261"BU)(AK3.\6(HH#)I)&MX@$U+5W%`ILLX MS/%U^(+)ZIT3'6CT=Y%EF+Y/_\7[KR1ECUHJ=GVC6[$Y>4U4L3N?C6S".62W MDWN(Y+:5-Q%M!K7MH+(A&_5FFC.,X]9Y-#Y$$O"X.DN2BB\[4N(8G,-KC)3: M`Z;C-YW-@)T:?+=I$A1^7M>/E*-(36^[]IY2[&'=/2$Q#.082"BKMU?SV*JX MIXO['BK2',QYP<3JA^H8!^L/0>5$C)1V8KC^HX8"#,5$RN\FS%1^'EH:QDM7E#02ZXXH*"`1,`2,FN)V@Y MH$-*?3E!!RGGQ?L.54\S&?/"62.E#S@9,L*`VTAIIZZ1LT]H6CT4\YHY+QST MR68Y4\8]09]ZSC-%G_NY;XO*I8?VTU['JF../E!)L2.EG8J^W>7-[BB?I_0- M%D\I9@DDZL-,*;75'!ZUR+WL'3&I<\29R<>_6U+Z<0TYO&+P[,82/>4(<]W; M.&)2FT!2"=M%D8@.#(04PG%W5BDIZM#.&Z+GP*WPNN2T]NZM:L1M;ZU*")U# MPD0Z@SEE=@?I"T[]9R_.KQ/59681E<7HNDS$3DQ]2`(#`%*Y^/AY28@H);!U MA)ZGX]\*FM'Z0OZ#OE^A2C"645MU2]0B]]P2,:ES_)C)QTTA#35BY+M\;617 MR<3-^>(Y?E0G6$EH[285*\3M)Q8+",&@2"6=Z@28$@.;CNK2,$KD#(GLYK.( M!.RGJW0IP(!$*)8@DY.]',_23*H:.[``4V*+$TH+&)'Z%X77 M>'&`KLZ8=W7I^6$4YJ^*F4-.;M=K40O==UK$M,YA9"@@=\Z$68W<&V\] M\X.>'80K7AX34;F8/V3OB?$DS@VOEDL]?[S?W?PA.[P^6[P[_*#*8.T3V#N& M%@G6GC5W?X5A8I%(W&@^6Z"?*-7L=NT`3E$Y243E8CC+ZB'Q)#!L+95+/9P_ MV#2[HD:CB,J%V655&7D2<&97UV'LF_WC[&;_Y?.7XR/%<6O_=VNF%HG5&+G[ M(PSS"B0:&I:0H)\(DRP2*:LQIR4$@8D=.*9%,F9#G&:]]+\1W>)"D] MK/H:AXK[R1H&:Y8V$KPQOI(:!AY,1.2*[#4\J&%"E,O*#D`Q^/N_V]T!R":` M[H\P3"Z02+(#V&%D7V51Q1MW_=_M6E3V>EWW1T`65;]+5UGTW>P6/;^^_G!X MHK+ID,+>,BT4K5VJ>S_#L*Q0)F[)OKY&/S$R*];]>'+X5F/>'HE5^PJ$ZQFX M\SL<"_-"B4U,Z>P,X`_O%%OR(87=`QP%A__.K# MF,#M!P"!VZ'`"G2`6D9TXIF@X\0V.CXJ'R^7$KM#QU!@.3H^@O(A=>(9H./C M.^OH&!/5_P@@JC\46($.V%']CZ.C^A\/;:/CTQAT?`*`CJ'`6NV0@82#^2.K)1SF/U(:"&BV!^E1 MNH*#P>ZC0P82#N;[CA(.\Y]8#`0TBW;V*%W!P2#.V2$#"0?S"&<)A_FO@LAK MX6G7#26399`8*##`BX(#$G3T8HI1)"U..'LNDUQN[=*C9`*`*/6"I."`CBB3 M94J*J'?N$*5=O91,`!"E7M,4'-`19;+221%EZ5A/\7[].&7M7Z,S5L``4:`N MV9F*.1)1']PA2GM@K&0"@"CU`;*"`SJB3`Z4I8CZZ`Y1BKMA!DP`$"6[.:;E M@(XH];TR#:(^67Q,M*ZP=E95Q%)N]O1<+IX6U:@@>F%4P@(%589R*M\;724I M\E!8%]!+<>31%_:RSKLPL^\`VV?]B&@;'&=,!,4IE8;!&KJ,!&^`I:2&@2D3 M$14OM'>9T.P7V<3"*DZS-`R.82,[VU)20X:-^J1+!IO9"XU?AK184G:)L6*& M$1!9@X=4P`82'`4,&,C$&IJ^HD.$Z5US M6QS="A=50.3`W#('E*.`9FZU>]DU]^RN8RN4XK!`0.3`W++#`(X"FKG5P?ZN MN6>/[-/;0)].CA5!UR&%U;M5O&B]NU7MSS!,+)1)?+>*DEDL9_3V4'$Q0DCF MH*`1)Z2@HE%#`\/B?-(/W/:S?[/;KU7C_S[Z.A04;/5@,G5;0"Y`K); M`3P'C/%H*J;NED"&*DY$69W!27N2I&0"`"?U29*"`SJ<3$Z2)'#ZY`I.QV8W M#V1,[N$T5$`/IV-0$1Q3,EX^NQT[&YV M,K^;+V("`"?#N_H\!W0XC;N[WX.3Y4O\K=#OS`N!B)CDV M;Z;2CD'5.\N%0UJAWT_9X+T'M,$;*J!'U?O]V."]G[[!>^]L@S>B4K2(R3V< M3"M'\QS`X32RDG073A\L%Y_H"&U>&TW$!`!.AK72>`[H0[@3`]CGK@*8QY/R?$]!I3CRRF@A=/Q?N3X#L4<`:=C9SF^QX<3 M?*<.$P`XC?6=&@[H<)KL.Q%69W":X#MUF`#`::SOU'!`A]-DWXFP.H/3A*AX MAPD`G,9&Q1L.Z'":'!4GK.YN(+1E2";=1>#9G4-,H93)_80A+VS8R04V!V"G M$HV[ZPNM$),N,HC976-1I90.BR)>T%A4"#P5B^Z.=\P>`9$QN<8=KX#!\0ZH M8BNF8HXZWCF>NSI'HGI:JONKO:H;D"T[]9R_.KQ,O7BP4RZR$T!H.E((V.!!2P<"!2K0A#FI: M1(D)#&:O6]873A$CDQ`Z@H$L%B:D@@@#=?>$4L4`)H2,8R.)[0BJ(,%#'[(8PF/WU#1J^ MJ4.+"T4M$C&=-1"HQ&PP("*"`0&%9$,$4-(V4+LXL0B`B_L'161-0N@"`KR@ M(@RT5.!`P(FF1`&EM@B#HZ,CA7,H(70!`UY0$0Q:*G`PX$13PH!2VX6!PCF4 M$#J"@GH'E`90@#NSN% M8].=PK'CG<)04`D,X.X4CD?M%([M[A3>*\X6)81N8#`45`R#]Z#.%E6B:6#P M?O:SQ;YPIK/!>\>SP5!0"0S@S@;O1\T&[RW/!J9Q@_>.XP9#024P@!LW>#\J M;O#>;MS@@R+]3$+H!@9#0<4P^``J_4PEF@8&'V9//^L+IT@_DQ`Z@H$L_4Q( M!1$&ZO2S(0QF3S_K"G?\UC!\U"%T`@-.4"$,&BIX,!B*IH8!H;8)@W>J1YDD MA$Y@P`DJA,$[6`\NJ413PX!0SPV#LR3.BBCWXER.`)[&YETOH7C=JUT]`A@F MET@EN+A5DDK!9C]Q,06$-RQTB0N%O24F=(4+F=DC4Z":MWZF2/D91WE6_X5AY\W;PS<5>NH)[I9T3AA@B9LF MI;*!&8V(W65D0.(<*6JY^$6[HK+@E),U+PN3>+GJ.Q7:YRF53)9+-!@H,"C1 MH.!PCI518HI+-%`^>O-XTWI_,=WP_15)(KGTL0,T%`5?JYP)4+.!Q9?)@@!Q7L_O+"LFUI4K57!!PI2Y6 MJF(!CRN3%V@\AQ=J'*IC@ M:D^B[8=;A=L/'<;;CR;%VX\@Q=N'*AC@ZFA/XNU'6\7;CRS%VP4O<1Q-><'I M"-`+3D,%]&^D'`&,B>K%'/-&RM'<[U*<)WY!TQT6<7`1YV'^>A6ODG3MT=<( M%H]9GGI^+E+6C,]BP7=S-3K%R_5,,*`U0M(ANK[&`4ZCUS!^0OJG&'GT(J M?9S?>&L\T%Q.9@-6.B$IBF0TSD&C$6R(D9(4M;2($KN#Q1F!>NI%5P2ZW_\7 M?I4JQ]'9!89$S#XR!D2`H"&63(*-BA@Q:D3(7:"CG@8?2+,"M?H_V\*"2*@: M`MW?0%A>(!#_+$9)@BB-2RO?DN4J(>M=<.[E*G,/Z&S;72CF$``](E!($$DF MA41)C`@UHN0NT+$@@@14F,O(>Q+H-?C=%AJ$8M4HZ/T(POHBB896;V@0)7)A MZ[.".*E$QC#SO>@_L)?*)P,YJ2T$Z(2MP2"C`X$+C7#KCNI$;OO5DJ(08#(1$+N7E:&*D_3 M0Y3SS3\H*ZIY4X4V2YF'\=)][>2$'BHS<\AY6*?1@*RND!80>I8!2$/TQ M0PT'*EE0U9)#-#$TGY%U]"E)Y1&0`95=[`A%[$.F1P((*2*Y))$/1HIJ6G>` MN"T>H]"_C!)O&)"7T-@%@T"\/A0Z!("`P$LE@4%)B!BEPS4F6:^3^)Y&[>^? M/=(=RR+/H9$8=;IQQ&"0))..FE-30:8(:9 M#J4;Q'"BBO'2D`%$RU`V'598K,894IK8XCG._#3'Q+#JVNF%Y4[E*&$-#N5D:*_46(@@WB193C/)'F%,B*; M@UQP MM^3Y"PS8G'G9\R(.Z']=_%:$+UY$1,P6^9F7IC3)]1O'W[ MEH'R7T_H/_\$`XNTN&U,VGZ]#.,P>\;!YR0)9/LD&;%-]*D%'I8?YBG!X$TI MGJ@&,2.&@9K;%&^\,+CXOL%QALF(6>;/..UY"A*MC3@M%R`U5650E%3'!@9I MYK(*BI=23H1+UHS-7PGE1G[EZGFL&8BP'`-$`-`S!AML>)D!RD_6]!9LF,0E MIE8AO7.6_1&M,`8")I/9S.&\I9VAW,U%>9)[D2I`93+U/-!&@,XRR0:G^>LM MD9==KR3[BPT-M\F]=S6+W3E'+WQ_ZI'3`YJ!M$(*WM)@+&SVP35]Z[S[?K$N M(B_'`0KPAKCW(;LYRWSYXT\';X\^E+[\T:>#HP_O@#CSYWB39&%>#B])7PUH M;&)/*%X7;#T",.@22<4=E9HBH?X-#`@& M`@WM7_\,P]S,O[^*^.LG);<)!)W07'C):,'#1",BM1F2AB?/L M`*75??J<><;-:K2FJ>;_;%>@P[='!^\_5DO0R<>#DT_'0)8@Y=KC8M&1KS8. MEAE#SUCI$D-:5ZY#[S&,PCS$-&S*#H^?DXCNY*@+EK]J#NG,V6TB9JQ274R9 M\H*9J$8*/(3D]=7B].KZZN'JXAXM;L[1_#0X3)930\31M$[S!KP'1V\/3DLH7?XZ>#] MR0=(T*N4O,,L[G7KI6R&IJF!X2K$@0$435NP#LUQJG%0-6.'!=U1,JNA_(;L M2\M8Z*9L!@9HK\,8+U=G*0["_-+SJ6?P>N9MR+^(W_KBA1$5_C))'U(OP+>D M@Y^]#,OVIE,;L^L);J-PWTNNZI%;QW""JE!@,JK8BFP`+K62;QTP-.US3JH,:8D-*J3R@7M>?P\61@ MX"27318(9*67RK.PB#`C@JHU"@@[$/B8NF6NO2\S)\NQ+Z4]-#/VF_HY99UH M,A#8=,;!#3&>V2F%ALG57"170#8M\1P@9RBIF-S9&&%ZPV8F>.<6HN#FB#BH M^^"R:509#(04PIG%D?W^V@-*-^5@E25).#*[SK)8R+YWW*D3\G:?A/'/QWW>_HZ..'@X_O/AP<'I>%(0Z/WQU\(.2'[X]J\I"^81&4 MYWMM>5_DY>B+]XJ.#P\0!1/[?5$\%5E>_^T=O4N0;;"?AR\X`E(V8!$$(=V[ M>M&M%P97\9FW"8D[(#LGE5%;/9]6B]P[BQ:3@D&_6C[NR*:A1O3&]ILP1G[) M``-+=SCWPA@'%UX:DR&1+=H;FY4/(.D&$T:;"#-7I`LV/1<8W!F+*C@U[%S" M991HDX9)BO*$S&Z8'B;2V3#`9(I+R@N\9(I\`A*GX,J[WQ>/35U=V993Q^1H MK5!^\??_I@$"ANW33H%E_(:9+]R5^ M3`OZ_-#1)_GZ#22^^R6,B;M"7X\N3^XE/74F!0R4\)MVX]V]ZW")69@$5IA-*I\XVI;U(B352@H#.+KKA_HX MHX0-TH5130A7R`,+<(;2:H.];*$##,=%7;/Q,DG/D^(Q7Q51G6S;UH/4I%J/ M:\/J9G:*>KTM[I@&P*RP4Z3F]B)--<\5V7\$52LTW7I8`!0(DKN;K+9^$?EW MA.D_:-9YIZJ$M(*2K$MWUKSERP8[[93!382=M`UGU.Q6(;,"7`?2RELPAA6M MU9KC:[*5"X;573K]U>T72>].:H1G<@=#F0)R^`TY@,).(J86;MSQ/%S87;&< M@!&]43.XAEM?CIC$),X2,1K%")IF-?4ZXD%2)J\ET MK/A@0/(J]I,U;EXXU]S2DU+;K26F%+E?3$Q("@96:OGXPHJ4&C7DZ&\U`Y"W MY>_P"XX+Z?7?]F>[]P'Z0O6S_LO?P`!B(-`0`?7/,,Q]EF3YS1V M%R>!>/TUJ$,`!@(BJ?@5)6,U3%)0>/B<)EEVFR8KZ5VA'H75M[%XT7K/8[4_ M@\$!+Q/W2!:E0!M&`@,!RPVFR1CQ$P4H36VM'C'--'Z%`9_5I[-,U>B]H:5C M`H,L4TF'>&OXFFJX0,H"?,8QD2RB&73!FK[^S5*"7G"EEVR`Z;BL3E!F*O0F M+34+&+B9RGPP,'>',TPZ])FH==[>EU0C3L-CURLV$+_O*BL8 MP&#-1$K>J2YY&-2Z=U^K60X&WKHYPX-484E?*#DLOU.K$WWP:JV,'`S.]#(* M7K1M7SUFDQJX+-5F?:_]`9W_T-(Y\89G`8,9B6!\\9F&#/F4#@8^ZBH1;,/PJ-F_R8A=O*0C%ECT MDDZ?$@QNE.+Q1U_50R?4G/-SPM:PVNY4CR?K&>S&ODT5*(7 M^M3PV,'A28G#&#]1:*B\=D-YA2X\6R]I`?FL>J$GWH>W1*G&5/QE?!YFFZ1< M^)>K\L*OHI<4/+9!J15_B$@I`T0XZH2583%@'#0HL4(>8X`!.+8+J0X-U%Z< MD-+Z]E$L*K=G[).!65_ELAGM#C,@U?B8<+IH9Y_&.E"44)_4; M)G`A4U:!@DF'@T:CQ9J6F2#K=O!?19;3(\N'Y);6\[W%Y#^#X2KO13>84#]X MWS6AUKD^9O7,<=8.ZQU7SO(E,.-J5O6X0]+.Q_9C#/:G'2')*5XE*2X)21>, MZ>QQ-UD>>FAJSF`SQW*UZT&US5>< M#Z[MNT@[R*9_`O9@VUHO+D61-#@,B4`?=$S0SVE2;&Z27-E-[>(M[^1IK5D> M1-NH/!@L4YJ"-"BVD%\(?OCKC'Y;N,CS-'PL8-6+X>,E*QP5T10VXP2!XML@BU;&I_9`SU>49.66"`M=&A.I4YQ3&67]65 M4MMW6*0B\SX(1PH&8&KY)*4>`*&'X+N=N1@DZB@PMZ`!2P$Q7+R-5CV*UO`X*RI/J4E'3'H`U7UX-F^YORP M97==MHN33H2$=X3_BF6#_B=+EBBG:JD9JMXU,;LSG_;:=P%\C36@+C#&PE_A#K M=6/(*UM#,6N.'A3S-6K1&ZBCH:DXN5R=>=GS991\TUW75K/8?:):+WS_L6HY M/1B4&@@YQ&);-I2@CS(AQ@6NB"A9_ZETMVGR$@8X.'W]FM$G`YOS@X6?AR_E MT\EJ"$YIR'*X::*B@XC3R%;`@'BRZ/+L-Z]A4>[\?ZP@(CC7<*H"LG@BC(E) MN%MAX*4W,R^3E&I+XU-\VO.8+9)IB\YWQ^-4U^Z`S9J#!O7M5=GCXV]]JDQ] M>MJ[C5__SY*]<[1Z\9W,\DE*G&$O?;TBWDK63ZZI&3/21Y.S=^84"58RU_R= M/RX);#YYP+@T`#I!>B@'_8Y;>YDH>TCN,!T"881[O@1Q(7:R-9CG4U9+1LW8 M6;VR4S-\!\QHG5$YKOQ5^REZ()[6'T-Q/3QI%BCYMT]WY@7Y"J*7"\9N;%P4 M^+CW(KQAN4]!!QNBGM(11>7]N#(P2!9+Z-)/8]-2@&7O[(()/ZM"%D= M9!AXJ\\8<$!VD7315)4^EA%;C3LJ!>Y%'(648+"E%(^/,M)'KAXI-DH"L57N8H]!N>H'",EB%*$AE/K51S& M0>%3_Z063EP!;C2WLXE3KY)TGI2S.@?@-'GYNQ&,O`O%JF@8Q"F0NB]7,:WX M2?=20^79/DT^%YHRVWW-98Q"_8==3#B=HW22N%S4-8G?L%!.?9476+7J+"MH MA6,R^=,-VR(.?JW15ZXEI:X&]>&U;.1*>KU#C/&-``& ML5.DYF;7J@V6H\8V\]W-$EHE*7$XP<"86TO:R"P+?NG?LS;EMWRT-TZMP3F< M&3,8[9*PKZ,W`S5K<@E2NCABC/!Q^@ M4ID%S[=2PNX<"GONK+V.ZD2![`69DHUG?=TZQ:-='J,V8;B@(]0W\TT-&H0/ M^_'*2)W:[I%J-2Y\/Z79RK#>JA6,_0(_)$SOSO-@8X:#O`''$[A&,;:`N#]LM!6!0 M/5ID$82U5V-`H_8J?B%^V@X*6"@;`H!B`T4-T*QH!3JJ]:+S*6T5![Q[7K?> M:W5!;N'_5H0IOJTN"=T2#?)%'%S4]X0DG32F`9OH':]8%[7FW�.EID[HB& M2/-,]JK0KXK5BEXF*5'1QSA@M[%/BRR,,7V#G>C:WKA>K%9DJ^WE4B=B>G,N MX#Q5:1&XQ[8%#NH3%>`2C*CCX96#)BCOT2_6H1>COV(ORI]1G5HW4[X[&Z[- M(^WTP^5WZ\\..L&0QUINNZGX34:[CL$YS,9(R0?N&C8ZC\Z"HYE6_G;$W!>/ M61B$7AJRH60\A8YKRJDW,$)9I5]@T(YS/.]`>`W,+[(5!(6%/T@!\ MO%K@R&^]$X"Z1=MN:V8'PB.G4PAWU+CK\;F?UP1JZ*>W#A-(!*HD54,Q?\:#":]\ MZ8(V``.-=WA3;?&6*X.Y3DYN]RU2M=#]ET?%M"[V)ZJMB4;.(= M3N[EJ\)C4[.XPI=,>!G&AO20<2:1U1QK4!-CNTI>TP`_F;I3'$B?ME70N\*= M4&P9Z'K$D!$G$E0)-QI?B0E*7NFUKWIS^I1B]FX)0+2=M5L:PZF.XW"%.(GH M,LP-R"&C3BRJ$G?\MD^G=JX49A!ORW3J0U;M+IQR2?&N7%B^AD<(O3,`F&=RTDW3BN"=NITF.5&V9& MF_*#V9-/$%J$X;`B13\%%?&?Z$D.@S8]BF3_P.T''#T;)=9V009VFKZ2`?>+ M%Q4C;#M@M/Q$U(89Z3XGFP35O#5.='%2CL""!^@1/X5QS.Y\K%`IS(]IUF,' M9KV(E9[8.,%'&!73"\8FYK183KR\!$VTNDVBT#=X=T3!8+6`N%;P7N5P*368 MQ4(KHN3^.ITC:@YP+V'6Z8KG.//3<$.]-3*RZ)-Y9)=S2[J0#`SFPSW@[_EI M)#],F-*033A.5[0+T_&M@('O9-&YES#3)R^N2^#3>;33(IT]Z1$%?<7!BU]A M8/P^?(K#5>C3#'1N#.MP;\LZIV!';=L$^4Z[HSL&=M(P MF"&R2VU4,_T!ZK7.)OYN^W28-5]`[2?`>3PTRS@G$P$1\SPI'O/%8U+DGQ,R M'YQ14*9:3V=,`U97A=&*]58&8VXPT!\M\A#?C!95Q##067MIQ(%Z)*.)14\U M<[N:Q86/K1)>Y$V+Z,&@S$!([@V=B@5U>[ZYS0I-KH)>W0K5I]>F:9B[PV6<4V`@?,TN;DJKMUJ-VTS9:2D?@BU;`G< MDM!7]"KVHR(@@U?<,?2O49(5*=8M!=LW:WD$[*03!D-BJS8AC9%=*&(X:&", MBJLZ8ZS51_OFBX+#;N%+K>C]4I=2(8 M9LKI4$4/KXJJ5E8IX&!`2UJ#1S.+&?!9OA]DIL;@?I":"N"1`(-9P6Q_##QZWY?'G;+?35\,,`[#5-Y]/MZ(=$ M-D$G%K`+JSX%&.`(Q>+>A&9$X*:Q4JSEZII6^L+FDG%H(.!M,])$GP+HZBL)D>DI!=(RF>$C+>C(]NPBEFVP5;-MA54-@-YKVNDO6XJ'=L(.%0K)]EQ+>P7KO7'\F4C9$?CY2R'A"*< M'1_Q.(>!:'H)T'@ZEA%;#7(K!>Z%KH648!"G%(]_8>\QASPQ4OG8Q89-2._C M,3>D%5=[Y&[.;AMJ8Y0:@L^$%Q0<1P@L#U6WE=,6]>5T&!BMJHBP"IWT@2@O MTNV.E1R6"[#J1!_46961@\&;7D8NV%)QE$52*QYP,R'_>B3_;)FYKSBY-0<7 MIJ:J++A--;8I,*C>3G[NBBZKMG`+J=H"#7+FKYIY<1/0Q\E)$"EWS:6X$O]7$]+%J]?+239G!('"LQ-R]I0[_ M'U'9`@Q\=JM[/:1>G-$*'?H$=3V;W0)%9DKTJQ2I>P@\>K^6PIARX,O-[C)[IWO\.;)&4/`JCG2CFY MU15;(W1O@9;0@L&81D!N^2W)44,/;@H<*C3"033A=`DT4Z=0SP86?N936W.- MK&H"R(S6/MCS-0YC/TF)8G0*_OZGMFF6 M\U$M6"WW-UZU7NDP1,DKQJZ`5O>\`2,G!H$PO(W]\33D088$\'PKTTE^U4K$XQIGFJI6<'C+2])D2-=2@ M>(M5*;VVOIA$60&=U0H7,C%[I2J&1&"@(I.,7]]\/*CVEI)_^9">>;@O-IN( M">1%M"KM991\NXB,"KJ9L=HM/V6N3+_PE)X/#/I&",N7(VQ9$:M!3)E1S0UN ME:S5Z\H](A?1G-UVE?LQ2@W+99OP@@'K2('Y<^BJAA\M[=<`%LC4V=T!=6L* MC8C'B-E<[5U52LCVJR(>..@S$U098ZD/]Q@CO!E2HN%GL@U/O6A,3$7-#@&3 M,J5,L#GD!8]1B/4&4#5O`!)>1TLMF&#K-E@,N]<*Y+"-D?(&D^ZH1L"!6COR5%)#VY2 M'"ID4KQ<0N\25-K2Y$)BL+#2/TTQP!4,,`D>@R'S\5;/IVS7I(.X^%;*"T+H MD]H#`^P=*,%EM2WNK^[1\A+=WEW<7]P\+!ZNEC7AVLNQ M[.7D(9%-)(D%[&*G3P$&+4*QAOCX>G]!@7%Q_W#U9?%P<0\#%,,LX1+K9G.0 M(:_+O&ZE.JK,;B$C&,"-D9;S`2\^?R'+'[JZN5S>?0$T/]UAXI(6^`[["5GF MS9="`SZ[MZD,U>C?H=(P@8&>J:1<7L3%+Q9,(*!X1AIN8C=XOZO:'%SCM@_+O[WUZM?%M=D2@2R)-,,(J(0 MK95B.@'*&>S.?#K!^U.>C!H,R+0BYTUZ-4+$ZJ_"N$%U;Y%]"#P9:!D%SJZ0U90A^6=_\!`U/2`MQF MLY8Y.XA2Z@8SFBDO&`R.%)B/>"QO+^X>_H.MI709O:4;"QC@/,>Y%T;9?'YS??7+Q3E:W-]?0/$GAP5QZ8*38Z:I[GZTCL_R/6@S M-0;WG=5,8"!I*BE7M'BY//_UZOJ:3<++A[]>W*&KFX?%S>IYD*O;J<:A8PH#.3D]MUG_]"W-"K>XJV ML^4]E/FNN5QHAC$YN9-KG@:HDM&"@9-&0'Y_?;;\%O\'RNG<)7%.?_&B M`B]755UN+[J*Z?/6ZS;<*5'>D-7PS8"`]77;N^/EA>?:_WIPN[LDNF4RWMQ=.B]OV#:%AF7.+TZ! M[(?OL!]Y6<:R:EGU6OE1Z)#.\M&R6,S!B7*?"`Q29)+Q23)GUXO[^ZO+JS.V M*`*99NHZ7ZQ"_/);55>1KO47]\M;Y7IHQFKUA8D1RO3>G3#@`P.X$<(*'32R MWS@CR]S5+Q?H]GH!!H=>&H?Q4W:+4^:0F@56M%Q6T6>F0@]X:A8XF#.2DXL6 M7SR@Z^7]/;J]N*,;@B_+&W3_U\4=D,29&_RM<]4D3>*VEM.85.GQS=@$Y50E MNR@=VP88V$X47+!TTZSJ*@.,;A9N[Y8WY-]GD#8,K:9GST1Z_3TZ%8.#1\H4 M@@O>(1-0@X&=5D1^HORUBZ[[A\7-^>+N'`:N[OUG'!017JY*;:YB=HK=%GM= M/D;A$_-]'V@^I?9JR?3VK$8&MU6[%Q^19O5;QH1-$+[+ZBS@X#Z,BQ\%(\(]LS0WT)ZDL!OZHI@#"?HK\ MW#R/#@DJ"% MGA44Y>UMOF_,1\'N/N1F@.RZH\1C9U=?`3BL=JP:]SI[U31JVX8QUDZKAW@6 M/EG[LO*R79I<)NG:NXI7]+_HGVZ2.*6"I_2-J>"_BJPL1F2TU.ST"U:K9NR^ M:WI%-';7/)CQM'N=N(&4Y$F4H#N<8:+C,UF]RM=Y2+/;#JC$CY[8,'G[OAHD MR[/KS]OI=*0<(C.T;V.`S-8M='CLO''G@V,NC;@BOV(OR9[+.I"^A MO_TJ,\>@.)QY4'#M[\>@D'3+;@;%X0\W*,0:<75LLQSC]1G`O1HI*6AA33S45QD^E;,O5-7'+,#9/_!S3@,VI:+QBW2G)G!O:U#1:TOE M1:?X"=R+)!W_%C_F(P]@12R.MDE2X27[&8X>(-:D0O*/+,3L9C`A13=)3A;H M6^^5,L[DEK4B7A;T8?@O81RNBS6;=\F7&;S+.R6U6$RJ2BA]"&VW[5MS`^?H MEL9]W&7CSK$^ET;0SM8C+.89'BZJ:M>LG]6X]NK4&C<=*5";I0^K%&=DM,G7'^0ZFS;C!ZC@E MQ<@U:P,@CD<)SK_P/!N2M_-&NEK-XHZ8?@":/S*N8\8Z)&:M.Q\%LZDTPB79 MHT6@RL^O-:=G&KZ?%CBX#KW'>E,\;D&8TJ2CC,7)RDMR$T>WYWRX[%")X0!9 MYL\X!;AP4'=MSG5#US[09<.L6R:N&NK&G8^"N322K!E?AFM&6BT8Q*(O?T8Q M&S(;2`O&+6D+IRD.V$UK_5FPA-KN`;!2Y/ZIKY#4.2S-Y.-NMN.4/C6\Z$5& MFB80:V.FB;@OZ+ER4I736IL@=>(VDYV,T#E"3*23X.-\3GSLVDUMKRS0*@\! MF7COL!>$T>L7+_T'SL`HS6MXW`'?U MI:,G'7:GKV>T@,X(*(NY'&%6I8($G"(6B"A4R"EZ?=A/P\=Z+D5AEA5P7+G. M[65VZ[*LG5/D6>[%-`_R+HDBXN9^\]*QUWA'M^?H#OLTM25WV,?#5OYM1F!Y2US> M)("RYM/+NAE9)?X+^_E#\H4,./JIUSL\CBQ+>MEA:>JRQ46'ML0 M'&!O(3WG87@19@<-7^-T+WQ;85GEV"F=L[$J5X4#YU4M3+\Y1S01C8#2%\Z_B#?&XRH>0_G=!!`UI;8<7W+EX M:#0@MFG0R<,(DQ47OI8PNC4PP-]:!>Z`@33XAK5(EX<*_ONX'L1E,'.QV:38 M#]GO=^'3,^DCNB69;[F8]EVPJ\DVW3AYL9GR43!#TI:FW"7Q[SCUPXR2HJ3= MAZ-O>S6&%U38I_*J[&M+4AV?LEZI^NXST^HJ+K=F['^=>SF9\/(TC+/09Y/8 M3L;WS#)!&OM6NG_,O#"K0'LS9]CH!6Z/R$(@5;-`)H\M.^<73':Z]+':B^\; MLHG&P4-"_]2)6K+?FGG4;/9P+)3[%YYL&T#_6)0MB>!,(!"Z@:OE]()3[PFC M9O)!S<8"U+125_`A7?<8QJ63AI]8%T7LLZ;;Z"D-N2@&.%Y14K:,U*IWBIAR`MG M/A\G\!"77TEOIKD7QHAPHMND+$L&!9W=D^--$M-QTU&4KD!QAD]QC%?AV'OH M$UITED,P375I%L&XYN`@?6L=N`<)&2]#?L4&#?<7JQ7VR^ALI>8=V:/=88J@ M,`JG//\PI4E'9?`G*R^IA3^Z/8#8GZP$OVOW\H(>"Z/.,*!M01L#YU6J!9&O M/+4@&XSI5\9&MN;JVOL$E65WX4;_LXTA79UQKCMR<*2I+7)PQ30&$_!3Y^&$RUID1S&BRIF&%,K+;-R%1,U"CHDSK&? MTJN6EZ0MXDG1N(QD4!KPV7[JVTB-X:/?2B;G`!PK*8_`QYQ>;`WQ:K;;AI+2 MMU_9PVG7X:J^PWLH&ERCV"W>21RM5.>:HC&O MG9[+.39'BRI\OH)0HG0'84E909_Z_.P^?(K#5>C3B;I]O9R^5$ZVQ3J9^Y.ZRM^S/7EYR/#"OJ\2$A]CVZ1^]\$;6?1/4W MT1LD?3,7O7FD'T?DZZCZO,E6?\;YLSR^H,*6[Y:R]VZ(.NU[-Z+Y4\_U]R-H MV2@C9!84CJV(46+T#M"<48SNJTCJ1Y&:=QU:U84ACJU:A&?H'>FC?`[*.0P& M;L%-L7[$:977W$DG',QU!KZ084OPS+ZE'MR5Q*HYY%7IE1F[&-R]\^'(])I7 MW44VUK#\_=BJ,7.-\GE%$[Q[BQB(JC5AA8ZM1U[)>&+&N07&49<36_;I*X+;$CZ8M)+=E$ MWQ:J=F$YH1DP>)TNN^H=DTU32RF#4]*+[*;2*GVFL[ADBSQ/P\>BK`69M&J6 M#[FTXUB^@=^N59N`WU$7#((NVS0);;^V&W548P-@?>[%FCI$]&WKX>(UJ%=P MA\E:%K)<9?;+USC,90-CVT9MCHO==$!W6&S7(ICE82=J<$\[[.;^IV2[RZJL M+E=5]9IERDIJ-'&71OXS+XIP4?TEE.VLX*1D(?B<$#'/*$S2 MN(K6W-#A2K^NBE^:\5F;T,>HT4S:)DS.`3A6TB&X>H]#U0$YU'"C=W-Y&-XF M)+"^P[\5(;W&E)SB7W$457\._XD#L1-APF;/3S!7HG4%]#PP0&4N*%>VA,UF M*,:8S'TH3]"JB$T/5G<'JM2N`"0068:;#BE(N/#R&:*D M8H+A#`KJG-`KQ4\QA?]50!?D5Z"OO8/JE\OV[F.2W8HT#>GVM2G5^\2)Z M2U_B2\S]4<<%4=T\H>%JS0^=:^CE:NN^8:GLV'?N3%=:@D7W.I^OW'&W>]&>DVQ1LO M#*JJ5(2>O5%=_F9[=E3+LJ_C=G1W6UEV58+\R.-^;"<(7M2B+`B7/!GSNQ/V MKKM?-HT\QO_CS1O22\(6S*;X]K[."]KNG&L>D'[XA_2_==KR`[RD9P,;U\0_ MWFCN381LWK,]^U8?W=?Q*^]`*PLX^^+O9J7N:LMG&V]H/>#N4ORC+L%7<4XT M#RU%O'I?V]=A*NBR^3;.S:=^R*64UX_?-=<4OX,AV)F9'IZ]6%)PQI$,^S]< M-=T[_R"6"/"##VVUUIRW[-$LJ.P`E:_N[BBA`.*H#_`JC,,<7X?LEE6@&<"V]L%B1<5)R:73C;RJO1]O?%9!@>X/U8%YE3)K+S"A MDF%?Q[!Q]\X\M,I+_C9W]=(5P6XFUP4M&J>PO">4HQW\D*C)'M_7G7/ MBBQ/UCBM8_>B#';;$EB[9>"F:YN;"W8_#V48NU.=2]>NR%!0T?UXB_(-&0%< M]UPG\=,#3M>TNH2%.=9`AGU=J(V[=ZXE6RL`E%'O4GGQU4Y015)F[Q9;OKCJ MXS_4*+?BD@T1OZM!.5E_PEG;$$P.P1!QHPN(IIZ=A<'%1S M)\8/XJ(K.]F2GRZ4`)]W[7C^?3FV>XG#ZD%X MJYSX\#MJ.>A!.&69:85F8F9A62W*7X)DR+KR"T9PEHNF_.QH0K=^57#XAR# MX^047%B.ESJQ\#8-?;R(V-?)W^GK MLK%?;S95R^(J59=';T#1?^QDZ[1^1M[.0#8,;.'%K)TE_1AC8( M8S2Q$E&5ST3G#?ULKN2P^DZ%7O3>>Q1R[Y7 MVM=AEB7I*XU;7R;IO1?AY8JM&R*W2$UO\QUVK=C=A]>EQ,YA8BJA8(FO6-@[ M"VB5I"@C7/2M:T!/D0BV>M6F+B6#('YJWP)]PC%]H*HL.-EN!\VWD&/;=1PQ MF-8-FAC!N$:=@W_7FO`7T5Z3U:HN:DL\WPA[8/)=ZY3%B!,,?$>).X3B:9K\ M`Z=HA6?+G&+ORA?#E^E-GG\VY;2V*QZG2K,_-F-SCJ?QLG*!E2XS:KEA/7', M$@C5%U?[)':];EZXOI/<_NX<,0JA-.$4&$BH4D>(;"NR.693Z"6F-TI8=HIL MNM4P65WCC!3HK6U*#C"(,A)SB+%K_.1%Z#2,(OJJ&`R(T9L)[=[M%J=A$H1^ MY402'Y%L\C:>K!=,F:V^LSY*H=Z;ZT:<8"`X2EQ!8&Q=EFA:)W'^'&U=T'R2 M<'^^1@#84=ZV&A0R#37IAMDLR+/J=)L;F*Z0.09$YF MT@]5_XQC\J]H$0>+8!W&53VS%US5!Y>-SAU^P.KTN?..Z4VQ.VL=6HW;G6LV M'%D5%ZOBX?7X]FY$G>--BOVPC&*17E@G:1[^TU/D)^RJ<:`CR:!#)HXB1^L4KY(4EPE[ M#]YW>=_.\2W+(V:^[AJ,I=U_"-(HFTT[+OI#>!"UX@[?6+:_\M"+[\HTZZF- M05UO>(6G+C5M2Y#P/UU\R0+#*@R&C!#]5"TRRGE7NV"G9N*_"O+S`D[R$]+3@,DGY;AG3YY.:=^Z@;-$IVL$V MH>V]&%W3]>(B2(00D>UO4)'13/$)`PO(NESO8\IIA';`KK:";8M_/[9[;QJG M.PN1J+3YD>99'OW+E9#P!I,E:N2><$+CSN?8R1VBG6%'MPS)S=V=.ER]+YRC M:.X1)+^]Q9ZE[+Y@.:;@P#A^F[>[1JO5O>UES.P^#+_3?V5D3IOSK5;L[A0J)7:..5,)AQAKZ(&`J!*Y M.VJ4()+36P613NP>B&3$<$"DD7`(HN5J%?JXG:)F6ACI18F"^M.B^;;SH[4E MC1.H6:^:7YS;5"@.5Z>\_AW&+'#F;<+A96<&@RLM")R=R1W MY<'LK(H;VP#>$B%S4S3IF"S7<#-08%#"3<$!J^*ED:SB`]5-O;6G:6NXV=I[ M.?*33(F^&:VU\/UB7;#JM=W4.O+O"`NR\J3JB^RZJ[9M'9^:OTNP<\WXM2[+ M_D*?]ZL_0U\3FI;XZ&*H2VKAJN@MGY%/'^A=6:71N_X0_RG&.3VDD]J3_/:O M1Y\.CCZ\8YS_>GAX\.GHK3+98HL]-7.D3.Y%2PBM[;65@C;[;B&5Z]A&;#HKTQ3LSFGC6G`.RZW$ M'D*6HF:O@'H5/WQ+:(E0F2,]H1V`<.75G(#8MI%]`RTGN0"W'_8-M^2K>#?( M[;0$$[N`]V2OP;MV M.M)?D2DV?@H[#SZFC;C6X%W.W8+'02/QC9'?@MPI6JZ$BU70UUEA]\: M)JMU28T4Z"4E*#G`3"5&8G)@ZS#!6I>NPQ@O5VIJ;4'*@F@7]C3'])UQHT;]=Y7@M3>I5\[B& M&">^#F8-`VBH#:4TAAO[@7$"Q)Q!![A#E`Y`(/$BV]JSIXHP6CRE&,-)V)5O M'*O`Q:CPEH(=QB9?K)39?K_/"P9[(P4>XO)+&5RJPTTP4-DO*JYRM824[@J] M2]TK`1D8!,EEXVY#^<\X*,K7/:^3^.E-CM,UHORH;2"#Y6'UM=/Y5E)J=YA2 M^E,24J#8TOE0`R0!])W.DO@%DVTJP;?!`SE2:JO7.M4B]VYSBDG!H$DMG_CB M2D%60K\@KAGR6V[VNDY&%SW*/]OM[^9[%-ATPGP@\^5`-S6IQ9OA2F$[]\2% M=,XA8B`<7W"J7L$V-/*T?5C3#`=55O+P;5PUJ2L<#(65X:"F`XF#@7#BZTH5 MD3TL=&J]9(8QA_7GYJN8[#*( M='=>CN]SFDUQBTEWQKGW9!;75#?@;F4U44R^OJJXG6-ULLA#V-8L*"7D-'`* MYV%?MC=BTS,MXEU-U#1KJ%:7JJGH%P->V]@T5F<(2RTC*$2:2JM:C(/JD4PX M6&Q5Z,C9JDI6#!\/PR83^-W-EP9JR:=+!3,H;(Z1F,LJ)2MY]NR1O8G?,`"= M.(5JEH\C^*$7M0I?8H_NML;VF+(I$!`V4-8(S8IVX`-;+_P0XRU'%^2KD@<( MO@O\D+"GENXPR_Z]]8BVSKZ?LG<%XN&&'D@$J3[W,3BA%9-:37A3"-M+?!/0@8&70CCNH0I",O/!*P/[ M8K4*HY!`777>)J.T%NA1B]H$=\1DSLVOEXVK5_H]QW$P.(S?]2PB>Z8$I_?4 MMVP7:KI36JYJF1AX11H:,MI[F&2,(NV+)"9<,"`U1M116PAPJR\@84`76QC0"*N(K5'!4 MZ+?7@G/0;B4VE\W-:%#(B/8$L>4KOY.QVK"#0NE`J5'XK'CW!YE]@968/*!E MPL&<4#"G\PX'A=^M'C!0?TAD$V=B`;MHZE.`P8Q0+&'<(*V)8$#B6G!/](OW MG295G29IFGP+XZ@UEV1CJ/RD\0G9I?)ER@3#@CN_` M`#>:1FK^X:LZH1S.DE)#J*KE0?63J"ZDM+DX*$3M`DM`!F::E\LF'=HZJ/PH M&4SPAOH4Z065+=G!7UB9$\:@9UH99"T)Z*S65Y*)V2ND-"2"AB.9@)SWQNX7 M]2[OPD!+G71%9ROM[D)&["+532RP*-FM3PEFN5"*)RXOT!:;N-U-@8&99AS- M:XA21J[NEV::Z0M+7N,APP$6RRR-D(^TU+;A#FI%JRBA2,"@Q699'Q0N:0K:^5Z(#WU[N'&!?$3_3Q\P5O4)A&V`:,\B4(]LX,K M00.PESXSX?>L7$FK'M$D3(+0'U.;CN-QATV)^'(L#AC`S($SXLB M0,7G^MIM0)S#EZQ?L0IG?C@@;-^ M7'2Y:K;%9TDF?>I,3F[5W=,(W?/Z)+1@P*414%R!_!94>4WE?%VO_E/F^I87 MS*HZ5,=X=:T9P0!OC+2*E`6X0+R*_90^8%,=S(\"HI37Y=9#J8YJRR%D!`I$ MM;2RI(LK4$D73*,L*^CS7*KE5$!G'5\B,3DL=8E`;E$%`G)%LM+D'\0-6V$X M-86\F(5TLHPL^I=87E"(H[.;8B$1LY]=,2`",[O()..OX'LQ('!H+[W^ZJ6I M1_W&=+EAKV1O>>=>WAZHB\TZM4?==)8U!@:\VVHP!'E%7EV&1JLD10'Y!!S( M=X]VO?+U9AR<5V5E;U.\#HOU#38]J%>VX/*@WD`UU4&]@AT4=,?)+'RZ[1Q< M2>%V/"[3\(GLV2/ZUS%5)(1\[F99A1KRV53`!`IZ)I)*2EF3B9%.BK!*12R_ MQ:P$V35FE[X6=!Y_PL.Z+)(.,66VFG$Y2J%>_J41)Q@TCA)76;QD9^NUI)"8 MX#&J&^HPT%.^8]4[8H:,ULJ*C5*DJ2YFQ`5E]SM:8N[`K"Q!@;YF>%5$Z#I< M8?33?V`OS?X$8\:K8]R72:I,/>'(7!Q%#(44'4'4-%`@I)%OKU[X8O/DJ9?A MX"Q9TPMW'MT-=>;:T]>6I%)X\D*^J.DP^;ZF$W@SMMA M7?C/\R4PR_NLZLF/DLGN:853>NF_=!$$H6R[=# M-^SRR&Y8O?BC!_ M;3?]=$59X9`N&[+5>^Z/[L64.JH#=S*U&GUQ_Z?8,6I*1N[%]TU(AOW/=SBG M_SW3SFNRAJ5BG8XOK/H\PT>L[>AFZZ!F][?S+S@?/K.J)1DN#?V>KVGL M"BW[JR?ZRZ,[1)IU$J.^4Q6"N4K,5BFJ-GVBDDI:"KK( M\S1\+')Z'/&0=$Y@5_U95&*,K5NU6Z%N)UW0KV:W59-@!M5N]/@]1M*TLTH5 MMFBW8];G-8$$/\;:*>U:.^LE]WEHIX3V5;<3D=OUD/^<)$%65HS$ZTV4O&)\ MC].7T,?9`^FKS&./C513XF:3)B\X(#U09[!K>W_K]MT,UQUUBW@P;MDXW*&V M&\5^\%B==H+YS%*DG2V9P\__&.NEN%/M+);];\,=OE;TAA@;!+@[`E=T>E<* M[6ODL5OUJ%ZPEJM2^J]Q@%/20:1WPA=,%D#QF+HEZI#AX$<%58]U2QU^4<<9 M+7W;50VLV;M35E=KM@^#"6[8U%9:_RM<(9@^7'>ZZAR8-%+*[L<8\-D<2\9J M=,>!E@D,ADTEY2[;L_LP];M"]#'5'RT`UX](T)#]7+L&U9?V8H.@[ZI=)@$+ M/@/-GYM/Q?T,A$WKA7GWZON\(Y]_W_UC[ZYGV4-OD?.I6X6/1.E\!DS6\,5W MG/IAAF_3T,=SY?_L5K9]6@]V:HZ97+;I@CF?$"#V!E?5I6)%%2^JF1'C1N0# M3481GS(IXZQ*+RSRYR2E=7@- M(G$&33B:\8R5DTQ]6GX8<)PF-(=)1HT6]\1K^,6+BC'QXA%-`4&K5EE#U$K;V0?TZH2?A.*-EZ(7VIK#*;;C M8_MM`(&M7+U1LVRW@7T`JE3J20A-VG:<>:"'V[F@AR!]4$ZI$4[HX;YYH4.! M3=S0%M?6/-+J1E.5)U_++)P5I:36(*81MH&3A`X&=-3"\3<*PA?Z*/-MY/DL MSD.+CWR-P^W+.AL!HBQXLER5?[W'?I$2A-8E\2^3],S+G@W08MJ.(RB-4U." M,[-&(()PE.3\FQPL;Z5<.PN"3*O`9! MZ@`.G;X9@:OV76\2LLUBVZL)6Y$>,Y`]B$`AP\U'AQ,&^,:*RRW>]5Z7+MHR MZ,$X-*V?J5O$P1T]&A(5BAP<2:E9;!Y+F@C?/4=4T3M'W@@AN:?'"2(P>L4$ M=M^J=P3S!&V(5,]>1D`88Y31K3*%H]]9MF%`L%-$KS_P;I*8_!/C-;UQOTSO MFG^S&;]Z5Y$-1$E7[J1E^]=;=](5_`78K9H%,SQVIXNQC]`-&I%QE1#Z9R]: MS3.FE'>2!&JS&-A]\9CY:5B>^`O]B7'\EF\JC5-K<&G)C-DY?J=*S,WU2>Y% M/4A2%[9^B`[&C/Z5+%9962P%!Q=>2I/.=84_-#PV9V$C\;OSJY+!.?+&2#E$ M&XLX=7,U9IK>MBRY(YSRMF_3VC2X*_6;J7';!J&DP>U2&1[;`4ZC5YIX--<> M3;J8,RWH%UJQ3[TLE*W="G*+2[56Z,[*+*5U/AT:"JA`BP5WKP3D.7?`>5K? MX3HM4^6$9U3&O/;."$>JTQX0&C*"FJ]&"NWD[IX:=U(_M4UI4BANQ&T;>R-4 M&J+/@!7&K#9:7LD6^+S[L$'W04O:R,'\"6DZ/>KXZY0^:'G!('"HCC'^:L;] M0-]`VFG8VUD:V:YBES(_0AJ^DC/8C33J!.\'$&74SJ%G+")_?MW"K.O1'91Q M/2#/9_>'T'7X6Q$&9:U*]@.6%Z8WXK1;!]58%?G39$(V,"`TEW7:[!>U+4*: M!?MJ_Y+D],EL=G9EU$]]!G>0%`DN1V*7&B@`!2(.<4=(".PV."UG/4<.79G" M,<6IJ#G!.'-]58Q=N9+-.8[&RSIM(H-T6M'1Z;Q(R8`IK\HR7W7ADPDW8^D? MTH?2C=FMWM@>J53ONK4AKW.T3A1X&F177IBBM9?^`^>S7F3A4\S+$\+R(!BIL.(Z@6%+SI&\$_%-KAJ\*>&,VD;'73FPLR4M0Z"]\W#- MME3``>]A$4-YE9G666,XT*MGMS!K>2C7F5S;W-UQ$[IQHP!6VI$=8+#^&K;H M?"[;J1J2PY'2?ZS28&@K-`TK+O.*C)XL9U6$)&/8F-OF MC#M2I>[4:LCJ'*G3Y.6"._4=A,.W_PU=?7WX0J;(F'1P3KX;TKQ\O?%H*T)&Z2_D\T6*;[TTC\FJ(TP3F]:. M-2=C&S4;;V-*(\Z1NZWDW'ZP6!=1Z63$N$*KUTF&I)<40$_T9Y&795OG`U MH2$PX0BEHL8A"&$K8*`[673N\8X*P,VC':[>;-Z[A\GL!E[)RF;U83)9F+;! M"ZC#S2UU[\SH#M[1,/XZJ&+8N^W278Y3PT_#FV)=B,F@`2=1/F/%A($^+3<8L(\669#+Y5$2N,"D M8[O*!!J1!X",J:%`45+9#XA$JM!YRN)_1&R08%B%TE M3`%(>?8">!U!><#A"G&4R%E6PO%V60G'(+,2.*5&9"4<[UM6PE!@@ZR$-TT0 M5I"?<`ACXIN\Q:MK0@[?6MCU5E+^G;T(.NBZ:2?A!=E'G(^MN363I*>U-Z11 M0>M&U!7FV:J!-H0%B-NA#I8+.VU2V%W2$IR#$:6JYBKK\G`6>TN:RAZ'ILF7 M400L:<(<$O!NCVGD%-J!5C9I2!'^3O_MZGZ?6'ZCY>;TE5]P%M_%M6IF^,R^ M8&$W2@HBF)TE&#$&]#?*\I^.D%1JO4?* MS>5EEINRBI_F!Y2]9MVB6/]&$GM\47C3$/%FVZE=C M)'VYN^9M>DN[[I3NJ-A5VV!\GQTKI(WR[>&XZ=Q%O\,93E^8XI<%=?AV.8#, MO@-V)(WIILE#RN0C^SFV1F@F&62K)$4K1L^BC;NH?0LC"M#)32P/&>;/@:R_ MLT^[?&DWS9076WX$S&B;2[/A:"M_I'>%RP`^Z-@]K_ZC1/U.5/(JSM,PSD)? M^.B>C0^ZC[OOLN/T4?5=?`W60)Q3Q>&(7#P]I?B)O@$Y*Z3VS0I^S(X']".%9>> M>'G5B5=:-X#\M@64DR;03_2)Q^Q/@);F+3R3SH3HX&:9\=?WR5<>V:6[]*`- M/^U\]+O15SOH<1UCWP`ZYE9D"_%3I_IUOXEM0OFF MLAHUB%VE!G8F##X68?Q23H M<3SQN"K*`NX@>PL=));=]^HLG3PK2XEK/VJ=%I6*>Y6E!MXCL;N*E![)11S8 M]4F$?;X@%PS*3E?SVK^A?#T\.3DY.&.^_'AX>?#IZJXR- MSIF1F#_C]"HF\\$3+6._R#*<9Q*SRFCA#3BMI)PYB:7(4#L@8^TIS*IJU5EK MSG62YN$_6Q.>O#LX.3HL#7A"#/C^!$AP>TE0Z>4LBI_E5?X[39V6U4E7T-N, M86G%[N?"2HCM>H6T:)$Z]54MYA"##[1!E-1<==([D(2&MN+O);$L5D.?M<-Z)=)G^1*T M.7U6+8=CD7X&47O6XQ%,8A%1,L5D*W".R_^^BIE+>5L^'E,5D:>%N.6/%(UK MPO*8&:W<8"08\P/$]UC9A:@E'HKB=2'TAK@XI5^Z*=N"`6OFL9$AVBQ_U6*I MCGVJ796MG6)+?Q5RDRKFG7Q2# M1$UJ+4]*(VR3RR2A@P(,`QDEGJP(&J[VN7)2DN__W@ M?1>O*^;<\/;"$V27>T-^XW;MT#&2#/;NRR+9F+=C#1FM302C%&FF!2,NYX>B MHT4=8NOD+0J\UYY3\HHVI//"+$O25^:]P'!1FCJ*G??++LAPH$[4P[.7GWF1 MST)^-SAG$2=&?(M3%G>GT<48!_=>U.4G+MY50/X1KD+BW.&4/I7F/6FKN-J0 MP$G]37M=*RSE.?_GG0]8=SISU_/+"]SU"T_D'^S=,AB#_1P_YEP:-/WGE-A5NZ\:4E1+SX%06D M)8BH&N[X+Y.T//SOG+\H.T7=@#ODF2@FQZ**&R@Z#40>XI4V0+R>H/`I7&'` MD^P"%L%_%=5L?H_S/&(9"/3PXFM<9(47W:;)2T@C2[+@XL@V;()TDGI=G(YJ M``Q4ITC-[>B][Z@A@@'6LR)-RZ%7[E^KD,0ICO$JE,V?.B:K[S`:*=![A5') M`09P1F+R;X,RIK_``%==*T*B@^CT27.19*L67509V4)U43V1"YUZ.B6MR33XU M$8EF3;C`XQCE1*@TX0>'S1%"\V^#@'F!2[,(3%LZ0"WM$Y9O<%@;!Z^2&M'= M347X9_24)AF0I(A&F3M,K1M&91+QV3.]&G`5USK3#1[+<*4AVO+V0!0EWQ2% M\';1L/U@OJ*%'#8.C@_P1TR7 M)ZP34S]I':`8`XEP7ZQ6V*?'OBTBR0K>1^4BKQQ/NKH71)#7'K&DFW;2LLU) M:X==T47U#IH%,VWM3A>1X\B(44[&"9QW7$TT%OO+TG3>[9J$-B)TRH\="K+V M]FH,:)00[IKJS+N<$NX/^%F28?.G^.DJQ^NLRB78H@?5S4(;!":=,'8@J-K< MJ\%@H`AWN,#\8)IA\M(XLIZ)(^MZ;(A"RZ.Z3MR`>[RK%-,C6\0-',,*D;G$ MJ+H!8+X+K4^0Q/3D>+GB=I1T=0J]1S(B:0:9YC!L4DM6SV:GJ]H[L!W?#!@8 M3Y===MC%X.PQ?O13U++_"=@I6*.EM#*`)@AITH"+N*^Y8J(0L)X;VM6'T9*; M57D`BM;/21)\"Z.(Z#4L?6#:/\HFG"+60#DE9A7\X%&KEYT/$=9DU7P+%++, ME3?MAHK8*0Q[`BL!QRC!+.9*\8;H^8QC&F]#CT46QC3^[Q/.$`J(FK(:]%;: MF9>FKZLDI?6PS(^_QC7AI`[*".6$I5$,^,&`6J>GJ9P2T?N*?JL#'R`_093E+`]%-_<,?Z M$\_MP1S,GY3(B]EK-\HBC],/X'^!&K#D5.H$!%07F#1<3O$G5D&)O3X+K,P" M,V%-YK\;*/D%O",K=1[.DS7.\M`W=HD-6G*[^3!65;TST38#=]TVEEV2ZHSB MO704R3_.V!ZLIW*U3SNMMFFF?6C8F%.HCU)8B7:CEN`"?HSX0\R?]O?O>X-V M^2#??IH`.X5O.77#1;!69F&U(0935%&B*%P3I\73W93>SZV*W7344;932"O? MIX#)$(:6+`ZN--@.=3*``ZJN^*+_P%X*8^F9_/;"PO=Q1.>U/B>M]"SIZWD^ MM1>//!ITUDY>_5!\!\P4.Z-RW"$@>ZP(?:.%V.@S$HN`.(&$A>R"NBW`&(D/ MV'^.DRAY>KW'Z4OHXXQ539?THI3::CD1M/QIKSP%O[1DG,)M;T*TQ^.WQ^\_7`B002,":930/M5 M-;4(Z&Q.*E(Q^^5H!T1@)A*99`K\T%J?:_*OJM8GRA/RWW%5#Q0&=CY[84QW MI9B5CXE)^LNR+.D!<,9$<*S)W: M5;^W[S_D+/\/3OUD,O**E`8"R.Z#5G=F99+BX!(K'BI1<-BM/Z`5O1\KDI*# M@9M>1AYA*?:I'T^3H9/5BFP3:'G_JAFRCN-U6*P!SHWMAIIFTI:O,,9XO8F2 M5XSK#<\#T2+S6#'.,V\3YEX4_I-NM0T".A-;=1.[V:H+Q&&:24V"&0B[T4,7 M?"%>K4?]VC=]M\++D->&97QP81GJ1V74(\+$E;KX3G?L19@]4_>I=*<4_I>& MS[;/:Z3&T.%5,H&!L*FD9N]%=;T'.*6S)P=.RS+SK=M?IKX_/'MQ]8#R+SAC ML8^R8C-[NZ8ICK_K*.Z6PNQ%N'\G';Z3`X&M)`$SNIVJOV7L-ZO63PAAWK8C MSMH9KJR@Y(=>U(:D+K%'7[*1A7S'M@,S_#M9"R[+J.'IKB.KDHNN+F1S4;`= MPF!M@;,S;95=KNXID,OP=XGU0TDGZICL7ENH4/C+S/X9Q=>(;9V%0E9!@^Y(R2T.& MTW%-V$3M%.6Z&![##P;1$X06')ZT]`S("Y\L]5D(9]]XFR8^Q@%[JIEY'8J] MHH36)A*5XG8A)R2$MKRKA!QBZ==Z/@S9I`D#/?2I;B][7J;T'+'Z'QV(,_]T MN>H6(*'O/LFGP"W:LXG"K=7N(G5R8V!FRFTU$+]*&Y<-H;R-Z%5OFY9Y*C0G MA0:X5_4!#*)$+^$NGLJ6/'0Z>.D,XT'.2=4O&EIKSYGJQ&U>,)41.D>8B72* MC(7J*>/V]2ZZRV&OK,.8/OF7Y-DJL/#+`\3J17EY3K`1L^7RWR,4&F1M&W`Z M!^0D<14(93=]^B<-T/!)!QT-,]#H$0M?98L\3\/'(JUISL#"_E0Y2G_8*D$_+HA>E0.=%2OR*,NA:*JNJ@V3" M:/5I2/0#XH'``)K=4J2"IQ>^6. M1(1@9C:5=$/0,%K4(49_8^3_"1-`UV&,6=UE0]4[]"Z!Q(FM`E-##!900PD- M0$59$.,!@JQNQG@GR^8>1^133]5%=[+F+X)U&(>TSBRMC%P]E<)"7!VN[-

6;]6V,H96F(LU^])TS]\F69%)IU\Q1DWI41JU6_=H0R/<_6@`\,ID<(RYWS>P2.C/\5 M!OI&H,T]NDS1!!H](]!2D?XQ@P49ZA"135^25E-Q/5NK'"XQO74W5B4VY\:* MB.'`2".A.,-H^_K#DN.7&M4E4.L0K.C(0$9I[>A%+6IS\"(F2D MWC*Z6`87Z\Q=F;.WVV_L1?*YJGMVDE,N^@"8`3*'5H(=:IOP7>6!TQRT.M4; MQOCJ!+W(-J=\?.L)QWXH]?64');?GM*)/GAC2D8.!I=Z&;F5OT036@"+>*@. MAZ\3R.@'D[7T$[[NJGIUXD7+]/PJ;H%DK2PPR&H(S1U?2F5D0VV8FY MP(#06%2N:&;RK:V)5*,/94D$9,]\0Z\%+N*`SL[9'?9Q^$)#D#CI5'R0:F[&ZO<4N5T9]AYWG@X:W M$3++\K;JL!X,)$I+YEVMFN=36$62J_CBNX^)L[JZ3Z"I\1DVZ"ZU, M4]ZHBJ)!>]"0O@-=Q(4V6Q63S"5;7_>65<"L M+GR7:1_,QX)30%"IU@W^QGZ:E*C480:3H,0I9(S)AA.,SS]*7%$)S+:R99NP M>5!E;`(!9R>YBDR*/B8JLK_)ND1.;STY624VEV@L(H8#-(V$?%B-)F9NR$:! M8X/L[-FLU;QPT<^O0. MHW2H",F`F4(E(V<'2DP7%T9.+V8>H",`!C#K_SWH_I&][W((9%GX%#.7L8QF M/"2+.*$;Y:OJP6?>'%H68+8QE9=B^"_BJR\NW7(KB<\X._Y*=D5_H.S[RX;AX6$ M&33C#E^J3W2+^1/\)(A]!74^@[K?0=T/(?8EU'QJ[Q!V-"?"CGY8A(DUFP%A MQ`MN(8:<8ZSSB,8=]I.GF+[*>!402<-52.4D$S'.RSY-<4!/T+ER\=4)>O>' M\@2*'4!EN:"ZM"L98"+6?@=(@=T1!;6RH*XPJ)0&U>*053E`G>^B2B)4B=3_ M;7`VB6[U[]S^0&.@4[\N%`39G$OTNQ\?PNX`-UI0)2:JY/SQ1L\962^3-7UX M9Y.0==;V4!E^_OO7,SCB*/)O!4#TPLT[OPZ3F_*6@(;KFZIQNF<@[RH@@' MIZ_U0Q0582:PYY8-`C/V;K21O>?AQ.+EDR0T=Z)]7^?4RT*1,>6TP.RD%71H M@J]Q@-/HE48#NNDDCBU"LYE#*AG-:9:=)VOHP5I&(:RD)!MC8\M:R8@HI].# M99DZLO,R#?U^V$I]@J:TE;JMC@+9Z-])6[_;)5N_V M?@ZL#_YH`<34\W.#)4O"`M9B:GF51JM94$96_,-F(-X\T&9!4; MZF2PD$E8]L9L(Y8SWFQ`%C1ZK=]/PT<C+,BRKTXEV*[3P"M;X72">ZO561.@5L'-NB%NV0= M9EF2OM(+\8=OY9VO80%G#C-Y%2]%+U>H946L7L#A6YAFDWO+.I:],9O.6U:: MS:VW+-5)[BWK6/;&;#IO66DVM]ZR5">YMZQCV1NSZ;QEI=G<>LM2G>01(!W+ MWIA-%P=2FNT=3+.]'V^V]WMFMO?;F.T]3+-]&&^V#WMFM@_;F.T#3+-]'&^V MCWMFMH_;F.TC3+-]&F^V3WMFMD_;F.T33+.=C#?;R9Z9[60;LYW`--MXJ^V9 MT;:Q&4B3'8T/;!WM66#K:)O`UA',P-;X`,F>Q4>V"8_`C(Z,#X[L66QDF]`( MS,C(^,#(GL5%M@F+P(R*C`^*[%E,9)N0",R(R/B`R)[%0[8)A\",AHP/ANQ9 M+&2;4,A'B!8;'P?9LS#(-E$0F$&0\3&0/0N!;!,!@1(`*3.U6#7,L[H$\Y'2 M9$(.N"93B2MX@)U=;45^6](:;5*\PBF]/%F^(N'7K;@S'1.,%N%6!ZR&9!"- M))%14AZ<&812`XA&-9*K8QE#,M!&,(E:=(S@/E#12*Z.3@S)0!O!)`[1,8+[ MT$,CN3K>,"0#;023R$+'".Z#"8WDZ@C"D`RT$4QB!1TCN`\/-))753%$]Z6% M=*#-,!"2?Q4]?GJ3XW2--DE*FP30_U0F^N2KKO]K.M#]/Q!2.PXH/:(,``S1 MJ<[T:C8Q\1R@C2,55VNF+B>,F4M_!CXD`VL:T]/NTAY`#K@;R8^.WJE#E`)* MT*;@Q-19(VL*IQT=OW.?F]51Y+TZXT!`"=PR[TWR"X26(:R@+&.P">Q30K>, M^5:0LPR0;6&EB#H6+*"$;AF3V*_$,NY#OQU%/ABN]RTE<,M\&+?J=RWS`90' M\,%@(]^GA&X9\^T\9QD@6_M*$6/?[,-^^&8?)OMFA!6498S7F0_[L$;AGSV#UG&2!Q_%*13\9CYM-^ MC)E/T\?,)TACQM`L^V"3<2$R(`>^+%N[?;/0S!P<`VC#R*35FN@8=1YS!&.M MK!K)1T>:2C0*#M#VDHH[9I(#4(5&I)`Z]U+!L2\6,\F]E%C,?>JE0*'CH[&3 MHXIW3ZPH%7S,4`Y]L:,DP?C,2#WI*/0Z.GS>+^FS^/IT^>6.P' M.55O%3(]*>0Y]L1B/\C)848U\L]F.8Y]L=CT[.=/@+*? M6X5.1L<\3O8KYG$R/>9Q`C+F<3+ZM.5DOTY;3J:?MIR`/&TY&>W=G^R7=W\R MW;L_`>G=GXR.>9SL5\SC9'K,XP1BS.-X=`K/\7ZE\`S%'9-``#*%YUCS()&" M8U\L-GD=.P;P&)%(H;'KV#'D-VWTXHZR&,1U[%CS,(J"8U\L-CE*U;`",EB; MYC4^14?$NQ=&5`@^*DON$_*`9'Y]_>'PPSM9ZE7_9UCV$,HV['%"A!B5P_'" M!#TYDKD6_9\!]O%0-G$?$RK'??SQY/"MJI,[O\/K95XX83UE(H"SOC[!L<9 M1F2A+7S:/"+_'U.OR)59#.JJ[4,QM5$5U+I5TY#KLFGG853DX0LN2TO+3"`@ M`F8`N81<]U>DJ*1UV?>55HLXN(CS,'^]BE=)NF9*+A[)`/?\G+>%`1,PVYA+ MS-FJ8D6$%Y7,J,/MQFC24>KZ,'UOH&P M`I,0+E2SH0Z?2T,5^"%9K%9A%!(O2UK%6DP&S"PJ&8?6N/B>XS@@;F4W)+9I MWVQAOCX*"HR^,&L='QZ@H[>'1V!LQ+_9(B;;`QO)7F>YBG-,I,B1Y_MI06Q% M1LK01"[LCYF_F:S0 M5QI)=F^(FX).HLM5^==[[!=IF(6GZ2N1B?UNN/B=)\"V,(LY4AGRPC#9.Z*'Y*#=B MI*CB1W4#U9^7*U2WX<26(=EMI-DEEKZWP5$`LX]$/,X2)1TBA$XC9:V\LH`9 M1P&UP]7ALVZ'NPRCM?+*HFD`HH':X.OV@V^$N M,Q`^>V%\G639,K[W(K(FM7[W#19L_]7DL$QA)"O_#ER6T9B,WYZ;)ZLJV&4W1#/P*,'F]*C0Q,F8`8TEWAH1L:* M*EY4,:.&VX71R,8HQ5Z&SW'YWY?DIU,+M%>$#K&5+J&X2T391VRCJI,14S?9S@R&`XRHFZT/AXZ`5]J),W]%B0VV&N/A*/:N(;9-E<4$78/AWLB3EOQ!MR823&:_:1ERPS#I&Y*'M&"^J MF6$LW-=GBW>''V3717N_PC*$2#3.WSU;($KD<`MR'<;$.S\C@S/,%PM9*$E( M!:R_%2)R_4YH:?RNI$:$'(P%9+$E(15D"ZAC3)P%7`::RGUJ?ZVKDP*H0G8ZJ>DTE,YSAHQ[9E#-;&AF4*=SI$Y# MZ;1IR+AG!M5,KF8&!3WERD+^IHQ[9E#U`8&A05V>'>@TG&K/O33G+JP)V9BR MXR%#OOTRIOHHRCM;I)ZLI8\BW7\94UY(Q,Z;+NL@Z_61E20SY]LN8ZD(F9L9T6>;D M"PY"WXO.\4OHXR]>7*P\/R_2,'Z26%''`,M\AM(.[5:QH9(/]1C=&XO@AY96 MR.[Q$U5>;2@A,4@CJ225&:CF01634^.D_K,7Y]>)%R\6LEV@D`J:.>0B:J/; M+C=S?<%E6S!RV]077+9)$E)! MMH!F`S2T@,N]3E]P6<%N(15D"Z@+AW70I6@\L)OM1 M/O-O2B/`[#9=`^Y&=[$N(I8/AF*7V\@+@EGY6B6BS@!@O*!C M(R_H&+X7=#S*"SH&XP6]EP5AA52`#?!>'80=&."]RQAL7VZC$?`>_@AX/VH$ MO(_A[P/>C]H'O`>S#_@@.PL54@$VP`?U6>C``!]<'H7VY98=A0JI M(!M`?10Z-(#+D]"NW,=O339B#15<`PQ%5!N`4`,QP+MCV:T9(15<`PQ%5!N` M4,,PP&)A$`IJB,!V_U!"[1$58:>GJWW51$L74JV>#:SNMS&KC,?;Z?[4E6-PMF,O5*O1QFMU[D9>^ MUE6?.+.)R6"922GCT"PU,2JI44WNQ`;K,'XL9".F]RNP'A>(QG5T2>,0XF2T M42VR9;RXQRF]VG!&^MSAE->;::U]W7HZ7J_KE)+82\G8SX0)FNQ$B<_8C MRS]C[MZ.H^QT"]V\,<5:<&3#+(F]Z(P^$U^"2[8NR4G!64LMI\!$C($^"(#K M(>9T`>M59EP$04AU]:*R`.--?K*Q30OI*D=][GZ__8M&F!@8\XU?E68O\ M.4G#?^)@K-$Y_GTRMDSX24;VFF:@6GE9Y%GNQ4$8/TTS<[>!_;.S0/I)AD[: M=MQ;^OP!?\]/(_(OC45;0LB6XZ3D'W:LC<'HT3EJ.-P;XPX'>+VAFMZFQ'DS M74AE;)`-I9&9&UAL!*+.$#Q`C_@IC&-ZD>?1B^B3@6`-R+]A:\:VAP:4O7$[ M''*N4S2ZGV87#PSRHFAV4PK*6^I?L$;PD2CS6RG?^]N M!]+50[:U%Q!!-H=Z.S\P@\M]?+(AOLSK+9$O7\0!?8QU0]7\FN%5$5V'*_S% M^QZNB[5HH3+F!6>ID8)S5XW+GU')@"@'^ND_L)=F?X)JQ3">;L6*=_^LV!>< MLV+Y,Q0KWI7/C-'+T*_\V;QD7C1A@F6W$1(/#79X]-]0+[/HB_>*CHX/CMX> MNDPQO?>?<5#0M?>RH-?9*UQ=T\/;^G"$OF?=[AN[>C^P_Y#NU';9."P@S*`9 MM[6H/D']F_(CJ![T[#.H.;NBGE#G2_T7PM!#^9_D:\C9=M*PNZKA1779/O[##0SU;:;SVJDL6]) M9S1W2&,!U?/.K#N(U#9!;DW?XV9Z+M*4R,S$.WUM2:I-R^*;E[(H;OY:K:(XN(IOR4R<"%*/=OX% M8.:?23W)X7M#[PPLCWI='X>Z+MDAX*6?)V2Z/7I[**LTI&8!%CKN^K M.ID!6(PG]DN%7S`]B9:-?"DI-/MHY.3-PL)4+0>B+/-6>V#??$ZB`*=9Z>Y4 M('BG'NUZ+HN#W52%/H24+`"A9"*O$%(5(RHY34;Y'(":A"=(S[LG=I0*/LVB3O*,]& M+-9K+WU=KN[#ISAR<4Z?&KK%Z5FR7B=Q'3$- M_44IOHC>(?!:Q%YSI1:+R MR]5]HC?LXXA\'56?=QH0F-Z)3'HR&.^Q7Z1A'F)][&?&C_TPV#35="YXHEH` MU$K@$J$/X;I.1F0)@^<%_G$KPR88*%F!$2#RU/6>LTRBJIDD:Q M*W;D^*K!0Y)[$:O85[ZD=_&='M7P23L2.F!64@K)&8925]4*2WI4,3@QQ#<< MO>#.Z4B56/OO1?1Z?$A0(JNU;\H(S%3CI-9>W*%\Z/B0WMQQ69W_E\]?CH]D M>2+='V%90R#9L,<)"2(TKOM6-@JZ/P+L6S6:R[YUCEO9FY368M@Q/-]U$EL5JR`?+(N.$YK)@ M2FYTF:`./^HVX#3O5:>=;%4UY-LO4ZK78A-3NERI==K)%G%#OOTRI7KI-S&E M2\=`IYW,9S#DVR]3JCT-$U.Z]$-^Q5&477KI4_+V4/9JCX`&F(FD`O)9GS4E M(J0@^EVZA^=)H/:Z9E_."%&/TG&7RQQOG@1LEZN=\&Z7OP?1Y;*GF7D2L%VN M?I2YV^4?0'2Y+$&<)P';Y>H$\&Z7?P31Y;+'9WD2L%VN?G:VV^6?W'6YI%S/ MD3S.JN6`91!3<8?VD5<7.G(;J)VO[MCQWZ/'R)KE>OIU+39*UJ'93)@AC;.C M=[+%1DKO'; M$>6&4!OU?4L(L_L%\BDMT-*[-X*FZV%VN$DW.^I:/A-9U,,\%:".5@BGRH'_ M8YT$O\CS-'PL0K8Q%58P4Y,5!93M'1EIN,,W2 MCY^J7#?AK,01`3*#7#;N6=::LL[KQ:BLA:,WT*D-WGUG"(H&YCJ&GMH+_$(FIP)".E%XO(;$$^?L#N%I67 MW;S.93@H&ZF%*9*:9M$J M20(*`3Q*;N%A&`AN+YGR`#*YL:A#N]:, MZ*>:]4\HI&_F,6Y'MYM,M3T5(97K+J+7)]Q$K>$Z=CLY361[*T:!&WQ*7H80J%N MNDG=H+Y8N55H8RCN(^V"45#@AX0)VLEG,$:&C!LT#+1"FP[_@H7J2RMWG]2! M9-]R>O/]E+B(HP>^A!FT=74R&QJWM&K5#H"12WQU6MN4>?8!#DY?OV:TAO=5 M_((S.KDL_#Q\D9K6G!N0;2<(/30NW>&PDK!U([1&T4^T'41W0TU3J&W+D7WO MB$]8OM"U7'4SE$36E-$"LIU61#Z;KF:@6])>&B0`BW1S_60G#2IZH):1BJFV M3O_Y.(='"UU=KL.8[,=69RD.0JU]>L1`C2.646T9QD/_47(!,$LG\=)DX`S( M@9I&)J7:.-T\;X>#1K*L7H:Q%_N]9?6LC"W2`\@ZMCC&NS!L$9"-=Z3(2"^D M:;[CA1R@]@MM9-?=MN*%@#A)7VG`.4JR(A6_Y&I"#\C<1F+R^X6*";5AS=^;0E M;Z5QZ.E-`D+&KC01QJS+=GMEA3/N'D%39?ABM<)^WFY#LRKAD'ZQ4X(8SBQR MA_WD*:9OU5\%1--P%;(S.W;4NO#):I?B@"R;W63^+"O6.*`[K6H]??$BNODV MG'%V^$5`&+2DJ-E,UGX9=3]=G:"C^N/,H^G>MJB^?U!NHVM_IY+A!\!LLZF< M&ZK-AWY0A/+Z60)F\^$?`(W5;=>2LI_Q5.=,R/."G`CR@Z)YO/ZVIN%2,%3? M[Q^DM'6R7YSF1LUF"VF*X[Q?_#W`7)U2:0G/+A,R=]FSU=&"%]F9KP>?^T'A M*M/2$E:;S_]P>A%*YSI+4,X';$^`&FZ;;J M5.>WZR1^>L#I6I;/9E6`'W3J-M?;TB3>"M2?QZE,;W(BE,N4OME[WHIS(O_R M[PGD3EP4&;I_4"^ENM9S%9.!F^6"/:8K&7X?_HI:=;M.BU"6WPGBY3<^84CT M.QX-DHX`,#;ZDOT(#@^>WXO'/ZR?CNU[XMB5F]W+Z5:G='_&,?E7Q+*WUV$< MTC?E:1Z6HK#-[EH'A+49E%+GN>O3W`]0]24&L?ZW')?6&=%;YWB38C]D_Z9= MMD[(?/S/WMLD$\&E:'D_@66BT/:@ZGZE1%;G.Y`*L3UXWRN4GY)QL`IS6N"N M6XAL6-?2BR2(VDG;L#"U6Y5,Z[61;Z"?JJ_\"57?*2L`]DNY557<6$6W3BDW M:+=TR*`15T96N)C.D`;06)&*QFV#:N^X+#_N.2MO-RP6AFD#U8X MS.GI")F$PR00V=+BYP'!Q(76W"-K]`-O'ND74%<*U!F'JTE6B(";+0?TR M6T>H<#LE*4+P6158*(Q90Y MY#9X9FP`@#)%6OZ4Q81]_Z<1>N[T?1,V10)+5/Z*PZ=GXF\N7G#J/>&+[SCU MPPPSY6>><,8+]".LJ#OM!UN3&#MY;&5L)[4#5,N)*D%1+2EBHD(=-YG&/K46 M\PV4G4JP3R-C'L6G#(7,="PT(OT.D-_WZ*W#WOSS/Q+F)V@]*^"'NRAH:&>. MW^B"B'U7C_=[MVT0BD>\,ST4I2(G->P")?<$P#@[+R5=%GF6$V\FC)].\5,8 MQ_0?98%L#@VFC%"L/EI>;@8Q;,#ERO8XG&0K!!;YP!?XX#LV2C:RLF, MILYEO1GTCLZ&U5\H8JM)3S7I'DJ7.D?R0%O[7'>#Z6+8!L,;R5!!14-,MFH! M9/F6';>O7.(0D[#Y*\M<:A9,6,LCE[G(DA'*C29[)5:9F#DD!@0VO8SRY$O& M4F]E&9.[*M>=U^!%C[\T%P1N:=8_\21["RR]7TV8R.=(XT]U.H_(I/-\"1`> M9E90X/^0SZ&?Z`?_5*;4"U_6Z5[QJ+[+%=/N?[K)R@+SUFK,MS"B=X/)HDMT"IO;Z48&5O!#-K&)V$9&KAMBUFV; MPN76+P9'I!`ZG>) M9,H[%Y023%BB*B/560'-PA$\'R"SC!+7,/Q0M=`M>P3B`F?GX?*K^NUS'/SB M1051^^*[C[.,GAN&L1]N),5"MF@/D-%WHH;VMF>GW0-TM7KCUTTCUC9%2MDZ M?;^O:1_(9<2C,7<0&V(`-C:7T>#&X9&CBX;EJ7+]CO1R19_+NXR2;UDEE]0X M!CQ0;#1&5-Y7U/*ZL1AQ89^3*,!I5EZ:J(1ZIS"8C@6.O8PE%;KV2E90UAIO MK+VQU713*2S5_=,U^1?Y<_TG\A\T%8#\Y?\#4$L#!!0````(`/&("D&UL550)``.6$LE5EA+) M575X"P`!!"4.```$.0$``.V]>7/D.+(G^/^:[7>(K9FUZ6?:\WK'0 ME4]OE`JMI*S:^:N-(A$A=C'(*!Y*J3_]`CPB>`%PD`3AC(RVMDJE$@["_><` M'(`?__X_7]?>[(6$D1OX?__E^*_O?ID1WPXS*)9[SM]E%8!]=^\O@?\QNK37Y MV^PK\4EHQ4'X/V:_65["?A-N.1F-!_R#[\M]G[OWZR9D='@&Y_ M([X3A-_OK[?=/L?QYF^__OKCQX^_^L&+]2,(_XC^:@>P[AZ")+3)MJ_`]E;_ M]\G%R;OC#VOK[?3X'\?O_K3^^KJD3%Q8,6W`_H4V>/>9_N?XW>/QQ[^=TO^? M`C\66W$2;3_V[O5=_K^,_-\]U__C;^P_3U9$9A09/_K;:^3^_9<2BS]._QJ$ MJU]/WKT[_O7_^W;S8#^3M77D^@PAF_Q24+%>VNB.OWSY\FOZKT731LO7I]`K MOG'Z:S&<;<_T7UU!^])((O=O43J\F\"VXE3!I)^9<5NPOQT5S8[8KXZ.3XY. MC__Z&CF_%,)/)1@&'KDGRQG[DRK*]JNV^P<3]J?\K^]=?*4+)FOCQ MW'4@[>XY),N__\(TXXBA_^Y#]LW_`J&-WS9TQD0N4_A? M9K]V'>:9Y3&9/CP3$D>R<;4VUC&0.RND[#^3V+4M3VE4K90##9%-,L)PB1;+ MQ88M010/J=#$5!J&=FY%SU=>\$-I9`VB@0:V"%>6[_XK99JJ\P6)[-#=L+_1 M;]+5VO+?9,-4Z&(H:2;KM16^+98/[LIWEU25Z%RT[2"AD]%?W06>:[M$+EZE M7@8:^M>`]GT>T/D02I>9MK8##6-N_YFXD0N:(&UM!QK&A1O9`1-W0ASXC!53 M#32T:_^%SKP@E*I_H^%``[@+`\I;_,8V&0K`ABT$LK&(:`8:U@VAF[`4HFJK MP>9.X/QP/>^.+HMT4:1,+NA.$E[[U.Q8N4\>F4<18)=4[&9H?;IR?;H=TID] M7X6$0%`%D`XTR-L@)G2+?K.>6#?B4;6U'6RW#.P_G@//H8<$IL>Q=!+R*08: MTCWQJ+HXU'R)WQY#RX\L&[16R>B&LLZ2R/5)%#V056HP2&TR3ON!AO.?=.>* MZ7DM3D+Y6M':>##88C=,9\H=-4+E8+6U'FP!L(,U>;1>Y1)I:3J8/&Q2L7)" M^H--0#H#H1W:7.YB+>LSEB\I??"6GOR*!5@Z+!'-0,.B1O;:C=?Y9G:>FD8K MXD-L8`#I8#;[4T3^3.B7+E\@Q10M.1`O;Q1[9/#\1(M2\-1Q+8 M8/D46H\GL,%!:#6>%&"#E%,.>FJ`#:JMK7XC'#8V<`<:#'+8"/D4VHQSX-(B MH=-D"<,&)Z8:W@*$:AN'0*.9!0531CG4$MQRFWA!8LOUY"NPG'34'?BH;;7- M!_0]3HR8I5!(&M8^=*,"48\RU.-^8SW69:^K8B\EU'CT M4AVK2A^#'L>`ZMG:6,=`P!(34XW[VJ2^UO?J5O]!^*CY*ZBF].MUL-M0.HHP M9J(LGX6!+,"H1QFJ="T&DH\RV*VB]AQULQ\--RE'Y5JL9RRM&4H_M81YQR1^FOV(.D';I/V[N5'DH"[7$T'$[ZXW"B'X?? MV;=\=9N[0U?C,]%A*LC[TL?&"6V2_OK:9VXA5OSB$N8UTWE_@O9HC*4N`$&[ MU,G4\>EB[;M/"?BZ5:433:]V1^6@`07$_E+:IC=\,SHWXC+B75Z%4`WT+E MM",,4RF^3;DCC=ZHJEJATH=^;U75T7?H2I,W*_@E6T@F&MR&[J^I!4DWJ!OZ MBPH)>8V)[Y"M9<#&V#?XE?Z:=?(N^]_Q[&A64)5_M'QGEG4Q*_>1#[T8O!?8 ME?%Z+"PX"*67F>K(?G:]K0XMPV"M*LI< M;(&$D;)TZ1!&A^"<,A):WC6=,J__B[R),&@T!8)PC`\%#M*3=MDN_ MV@(H]!-,0F_CT:2L[TCH!I0#AZ6S$`N]UA0H_5.,TF_EV@0,*O-0&*_3TFL;=R:4+[()0G:BS9)'":U4#@40E,_X0!'+P!PVJ8Z@D MT='*LC9,H3[\2KPX*GZ3/E>4-"O_]3]*3X)YW`-=AG+O`L&;14X.H^X]509@ M[[&<_$O`2-Y.-FD:FCCLS%$2;W7RU188%3[]JL+1QLGLB-CE1J$%.HOE=F/M/I2/\1M9/K3?!!?M#6L-],;KH@A&'R-A+2C>,A*SCP"AS.I3;D_5VIOQ(!%MX*Q#M_&&2 M?7Y+#86@T=R8,XE8PFTP<%C%@0;SNV0>@/0/%K'P8GF$^03&YU88OKG^*BV[ M(=CS8>3&O%!`0`1=6,($8I[2A[ERIH&V+-\L'3B+$R>BJ24F,VT:J(`&D@`. ML,JI'MSHF3@LKX7@I,-K;\S)I0,\8IYQX$*MEHWE.I>O&^)'I,@N4N&2#Q*( MV+0=IX*8@C0PPJ<(F"I$P[O&](8()2C`V=-MG@SO$--EXY',B$UQ%KK)N.:. M,!U>',26E[8T/)>RO%HLWC8N)]<2FA-B*F,.-9UFEIQ_'!/L@FS8_7NU[DH3 MFEHS8RXU';!HY1"'\(N$9'RY[UJ8EJI*!<=T*XT: M?)Z`,$$`&B,#*!UA*(4Z-*3>^LFS&]-NYM:$_T57_Q7(]QM%5$#Z&ED/NDM!^+I=( M;=OFNO4'A5S;'84RY/TDAP/]XNDFUURZ&M'?A`FUK!O2D#]E@3J!XJSM_D,9 MYPXRP@$N/;42*MT8NK_RVH,?D-%`)N8CI>^2Q:8P.7G>%S8E*Z" M"@[+YU70-5@[(10Q?;*4U9,<@:*\K-X<"I>]&I0M00MXGO^OM MF`/!"0=1WQU)3Q#W!;HNKW<#O->=C'$ITL50FW]H8[)>M[V55 M$1L!SSA`*64CD04\-%I"X=!VZ:$,!X];'%CLRD#=6:YS[9];&S>V!$Y67`(H M,MJN/)21D?".`Z![EGK;)\ZE%?JNOXKFMIVLD_0*[8(L7=L5[$`06BAL&CU' M%&P0'@HWD2WD]K32MB<`2E-%!D=-VV=%G*11(`@=JWUP_"-.,-=G+`A^G M9DLH,MJN-921X7&+`XLF.RI6-QP/;9<6`]C7^W*2DAT\0"=C#B449VUW'GW\ MZ(32&!1UL_FRVDO-5))GG<*39\W^4NGOWP[)M`[)M-IGYB&9%CDDT]*'PB&9 MUB&9EDXL#LFT#LFT#LFT#LFTV$O1 MJ'4SF7R07:2#!-CR6QJ5K^VFTJ4_>R05L^_,UZS2T;_2WW-3MP@P'^P+II-2 MPO5A8*'B4!667"XF-^X+<>K9,DH,EQGC*T67ODQGN03#WUU0.("N;F3??2L; M*55F-TH7-:C5VTIJ^A0/AA$L!ARH54^R=U:X"%-6G=0)Z8Z$Z0L\'SHHO>G$ MF&#\U`2"$<3,9V*>Q,]!R!0/"EZ3SO2U3$?0>`+`"U9:,541J(+&=';,7B!5 M&<<+D+@RH(#!+J4!-?H=](!*VQNB*6Q0%7_F)^*<)?2( MZ*K.)PZ]\22>W;$32J0%Q=%]$[>L18OE8D-"J^J+7O%+?%_S2]S1SH+EK$1M M,@60':S)=F!ROT,N@=&8EQ?B)Z(HV5T+TT=9B<`;L2M5SK"L8U&\6.9C$RU7 ME6:F#SUJDF_E$8?XOX9!%-V%P5(4RU5I9-H65A-]"W\X!)^OV/Z**0=SP,^K M>P!JU0%(C5M<:BB!A8$#NZ_$I^/UV-N9LV9UCF(V^A>2CUHPD62$QJTM.!*! M&F>8\+NG0J5C8,7?+NBB[`7I$Z<4/0F9\3SH7;$#B0,'@E4$!D M/!MZ5]0`HL"!V9;!@C'`SK9K:CS5=E=\N&Q//8IRRUBVQ]]0`PN`:+FQ\?3+ MO3%MLCYY5+/2,XPM-6-40F<\GV]GK$$"P;'$SNT_$S<+*$RYY,/5;&D\E2]0 MT'6_MG:.<>!1I#)(+:HGN67):V\\E6\G;,32``["OENM';,,ET<*G)Y8X3.PX">FZOEB*R^O(*8VG[NT$'50BZI;)E\PR M\-_.DCB;,L8=5ITMKDC"R#D&0-*7.**M7E M`\;3B&I6!X#N=<<%L;(5(LI92H5$CS;#*UV?#QG/A&I>^?KCA$8)T[%_#8.$ MQ<0+F=V)3JALW3HTGDQR;*7J(W<.R- MD#87WSP.T3M4K?3EI1A3K89$!(>.528*9<]+F%]ZJU"5'FG[]@N-P]7VA&1N MN>J,`@Z-NB=1XE7=S[.AUC9JL3\TO`^HINR'J:XN71Q:L1U8?AP^(SX1.@AS M":!X:[MC-[#C<.6&`US*RVXUVI8.?PQ*X3-Y&O`S*W)M/NC*'4&583^LVHYR MQJ$D17V3(L!7?D'(IX#"OA]6ITQR./%-59#Y:[A>$HO"!J6$X)@H76A+`1#C MQ9$$#MBZWOT5NDN9K/$GR62@[8-0-=%V9%!4$\V2[_RH^$+"IR`BYI\5=:TH M_SB!*XNV4\.P:PIC:5]@_YVXJV>60HZ.R%J1VX0E#%TL4[9+L?-@;>C:'U1% MM'E[**I(/[EA"UX_MZ+G*R_XP8E=_R",76?$LXP:02V-$C-*A7-:J,P>\MB` M[L+@Q:68GKU]CU@&R.U]U-R.W9>L]).4R2Y]H5[K*#(*OIFLHSHC]F$Q`.IE,#B';Z^B5_ MBBMNQ"O1",5?,_+2=?GE*Q4Y50'7M\*W-"=0]?&N((RH*/L\JNHG\?X-I M.`9P<6S!N[O$Z#&X)W3,MNN1RJY"-Y.A[#(]7S.>3F\PO=2)!@Y],Y<-09L[ MKE;0)II`8?<6\6!Y9+%,79;AP4\M1,93E8P(,T!Z.&`NK@J)0\\;;(N43&1> M>^,9348$5RPS'+B6%Y8L,K.HVG`7DK6;K`5;O)P4BK8V#XL1T09+LB_P@>VM M4CC??6$J:EH+X7/1`["5/VA0=5"1E4#[3YU1C!;K+AU$;3W@UO%+PA;2/*E%L)4^H("/ M[48/`2SHS#5&Q*^"D([8)L1)XP#.DLCU"2M.0(>^\_6?+Y?42*:G*<%*W[U' MXPGN!M>&KE+5Y`)3*KNS6,[7KN7_![&\^+EXA>4XOLC)P#&$>)&#,8IQZFZ7 MG)U&L=KIKN-:H9NJFLJT5>O->.Y`?0NX@C1QZ`-<%$-8;0BR`0Z&O;KD^I9H M><1138+#^)7K6[X]C,$O[,MX@D'=*@20)([%HVRF[#RVQ*6Y1#109,<.`8<` M$H"YQ(J@)':AA;-.L0GZ&` M]9YL#/D\Y^Z<`- MN_6AZQ1E0I2'6T!B/.&F%O1;Y;)?T&=A4+%+US?X[&\00>'7%AJ@!7Z.;*:O M`'!I#>)W`>X7JD9CYWI35Z-A)#SU8J!,!'/?87^PYZ47RV,3*TN!7G_*%'MJ MP'LQGJIU,!WJ(CTA"O+S_.QL"35)+)#=Y,] M?K)\/):_*Z!620C]<78T8WYK7A`E(:%_*?1=XK@W+TB>@,3B["T>"DIPI@BRM+36K[TI*\DB5XLP37B!VZ0LXZ[4% M*DN1K,WM[O)"D:L]6:^M\&VQ?'!7OKMT;>91U!!!^US]5)^K>6=L6I:ZF^WZ MFVT[/$S5(?+"B3`#3$\H_=2FI)I<,$S#KP$=(3U.VB3TVR?;Y_ID2TEF!8TY M)2QOT'0T$16S4^S[Y>5OL/X4 M)'$9<,A,5>C#\&P=5!_J$UM9E!@F=\GUC[.3?JE/[@J)>5N0&MA/%*QT./(I M*Z9"8-J6I,L\\5;9U=T]8>FE[#@)V=$NCP7.'Y'.@RB&[*C#?<'P+(8@SS&$ MAY(NAJDK":$J3^+C=_5)7":>E:B15?.(TBI2IF3Q6Q_7KJ^+@^QW?M30;KYV/8C0R2/$Y` M9#3S0&-<@)DHIC(\RP#X-/()R(4P<`J!T6=:$<36&K]6F70G]4E7D*;WP3MB MHSZ6[0%Y\GD((#7K/-H^.J79J=:+X=D*QK+I/ZHL*@P[W@U[@^:8M*?UF90V0#DTZK>SN`M:D!E@"&^?`U")P?KN?= MT9,INY'*CZKT*&OY*^9/5DLW5YDP[YNWM%EO_WV6]Y?N66F/LUV7L[Q/@_4' M\G%FP<,53E6L2L5N3!9<@(P4,$55^S$\7SOA7*^TT$ET&.;VUJ[>N7"L0D+X MIN<'[GEOMNUBMNO#;,T!E8G*:V^X;$+J)+-QF0=DNF?LA@BY?87W8/K>18A6 M2^D#%;E@F&BML3>5F=5P]$E)9@6-T=0';`1I-#[+WV=Y`'-32&2RPE@CPVDS M)Z'2=M>Y0].G.CFJ]9)B_42'81:6ZY*SXVC,N=5L.O*4"/_;+"=5`<&U%RRG+",!,+[X('LDH] MA=IG8,.1IB";;>D,[@G9$.[)AA4KI6=/Z83C4YCHP)+4_QV"?N`=&13X2@ MX)P'D1"&><G56^S"JKSS.%&]F5+HQ M.T'E(X5-4Z5^S$]6=9R;,[>#Z##,7Y8+@/R9T/XN7_A[9DN.FH)LEM.9S0Q1 M9@%BI_(H#">X*`\*F,^"0V+<^A1CTI*10L@[CJD"2?(D3/9TTO!M@2=[FOVE M^.G?#D^'`UZWE"\GZ.+=-QM4OUZG]H`XA`R19&PMWUEECYP@6T=$!4136TIX M93@A0L`!U_>(+):74>RNQ47SZNV`D&A+TZX,23NC.$"H^^QD&@.>/$!R:-%1 M-)`IB04'DO>$VET)N2=V0)=NI2400`HN/HH%0;`X<*#'R9,.WL1@Y.#Z-EA0 M5!(+#B39XRT=*(NQ49B`?!IP\F\LF,D%@`.H<@RL&ST3AX7S`EP+151`L+25 M].O@/B@7`@ZXN&E%P+,,W@,01FU%&91A5!4.#D@O2&RY'CU\7J\WEAMF+_`W M@;^Z<5^(DP72_P?Q',H0*SAP]I;^"A3_W+-CH`)HJP.HK``#B1*'7M23*;"U M*28I)P#/;QDI^$B/!ERP/'#`]\WU@]"-WPK7=*6G)Q`Q%$(\US(*,L$!XMQ) MR\9%:4KI2.$H(B6$@H?G`@6YT>,L,!^O;4G&X'5T'(_$48PRS2+@Q6H;6&7R0`^H!" MC.<22%U".)"M)J0"IMKJ9:/BN0N2\(X#H'MB>U84I6_3E0PDK;>J]:904/#< M['#YQ0%'$!@HIO^>H]0:'%$JR!<6]?^ MDOW!?G4;^"%3Q+1^I_//),JB!J%+_Z`?V8OBJ'UEW'>/"&QOE:K$NP^Y0BS. M;[[VTX83J3JP;PS["=.V@8HV#,\]7ETXUJ\+C4^8WO%'U06.@#%L]>VU7T6; M?B//):=Z,H;]_Z*=M\46>69_DV>7@FA#GLSATG57K59$9& M!F.Z:-`@Q9H-PEA:F/:F8JUH20/6K<6PHOU\!6S[!$[@61,&+U:[=Y,VJY!6U5^C!VKN-+OW4NJW"M(FL4E=3 M63(8#M;EPIJBN=;(%5HIKXEA;NU5G6PGS!]::V`[O#,XWSC M9DJ;,1"EEY6J\[>=UO2-=-]I+)((-@1YI0W5UV-H3Z8S//5!5TU:9A?N\EAU MK=S0;YC.":5GZ5:3,+:9#RG6K;X*=.G5=*ZI/BM"=RFB6!W85J5Y<9!]PG36 M*JUK`TR^&$[)S5KCHK-R([%_F?R_S;(.,!R9V^NLMP0GU=H9?7_)[S=3F8(> M73@$4ZAQ+^%6TRI9_>J%;,7C-S=]*!7+6#QVG';)SG67A4,Z=/6\)Y;C>F_? MK/`/$BM;)&K]F3Y[@N9,/V&A`YSIY=G;.0M>5D.VG=#T`5,50A'[V+!BM4\" M/PM63N(HMGSF_W(?>!ZU>7Y888>P%N4N31\F%?'M*#)\R&\OM7*=54190&[Z M`*B,J%042-!C<2W10_+T3V+'C\$WJGKL4V_WQ"'K-(>.DB="Q^Y,'_!@Z/81 M%1*T=UM*:]:D;`G:9"Z0=NR^%&<\M4VW<]^F,QZK[LL]A8A#*;9YTJ[]#=U] MLJR@_V]B^?0\;[%(N9+//%09^O1I.E\R2`GZ"PT'^$K*[&<'Q/F&0F*[65U* M=_5,V6=&BM8%H]NG36=>'GX]Z0/!-#1N'H8LN#_UAW_;-.>`OB-1#%A M&=0O7S?4GB3.8\!^53K_I?]&0MN-0,\N92O5X+B,9].&V_+&T'.>M&T[P$H1<,@^ M#N[!\$0%X-:H[JPF'"0&7_FZ?A/X;+LKL<`,`3\B9\0G2[>#KWJ'3DT_+'=` MOK\,L2G#Y7))[.S")^?BGIYC6*5(GX6\=,SEUZ57T^_2?=2ANQ2QZ<-%;D)0 M%K)+07H0Z.4NJ=BAZ:?M/EK02788#E';#`YT8;.BYRLO^"$TQIH968L.6$Y6 MUL4L[0.#7?:0;#9>.C;+*YB[S'X!""V#4:.8N<7PRD,N)]Y0W]+5.C1]X%+` MF;^M=Y$AAAE\02([=-/+G&2*;LB31?$#IG7]!7MBQH'[(#/GW@`4E-3#"SYUND%E@F&B01+ M5W[4EO4GE\;WR&F?+_SKH-(7)0BP*R7P>]A,F M]^'"`DKW",'V6FLGF]*-F3'\S-8!U-0P> M1[AB!$K#+U>;P9B-Z^SMD7Y[_NH*8`$13P@G$#^EFS&,N+&!7@1KR_4[X%8F MQH&;@GZ"$ZJ5F-P9;0:QS/+&DW`[PF]D_41"/GY<`M.WN@I:64-+(@,<-W5@ M@+H"HR_G1&=@4`-2:,U#L(Q_4#G4ZM-#YY&$W/2U:/]9!9(/#DBODM!W6>0S M9?3*?64_13(<132FPWFZ@R>7A+;H5C!]=\D] MAU3#7)5E8A`=Z[4O.ML>3)L4P\%3$\J$+KR^!H'SP_4\X:5R([>UT@U7\0D] M=\XP/FML#G)[Q>T3P\W'OEY728`\W$\AN_=`?#]U39?3)=U88W+COA"G9L!& M9V_?K'\&81K=+KZK4NYH0O@I\X;C#DLR[-V@;ZVU]$ZK4V^7KS8A3G1NA>$;Q3K]W6(I$"TC M!U.;OF^'W5HH"@.']O].6,PX<>8O)+16:5$5=OQC/M=W=)NC///G!836],X/ MGC%P04SHJNF6Q#=!Q*I6YXFE6"3KT5.U0KKP'JI1O$GI'HI^?\8&,*,CF&5# MF*5CF!VE9=I3#ZQ\&";OJEKE=-8JID'NL3I]S^C9CKGRLR%GE='3\H64GUW] M0M%13DYK;('7#!GG:`<5YL`!J2:<>,LU,,4E,+=EOG;RX2M5WWZ-;4LF%&X8 M$*:OC%2B.[;F+U1R:1!"4$JZF">E3L7,US[ECHR=MDVH6TM0$`[:1P?T9NPG2"GW*'Q-EFQ`%GFDR0F/I-$VH$5", MG?4EIDO6'FO+/TX,IMU$J"],'IBVIE:#K7J8:&U"!;98/EJOE,T:ARG70B-; MSP>-Y?4T9'WKA.VP^W'G[ZG!M)\8U[-333HSK=O/5!KN"]E5PQ!>@#:*:@]U M`3HK!C+;C03='2A76/JN00&?-+H)UT<'J%HNH#$9ASZ&7C0V0YGX<-A:I4*[ MU9)(6>K_ZRBB6_7W3>#ORCOP\>_4F>FG9@!2]>B4SB+#@3FUR<(BZ\E.TZ-Y M'(?N4Q(7EUC%X+/RO3OQ"%]`^G5L^OU;61<&$N7T;=OYFJVFE+^&!&NYW.\) M%:B;)CY+_X5YRPA4JF^_II_EE35J&$%J9V MI.>6YQ'G["UO%^4-(UYD3_]N37OYP6$>AE],V\F<6E%.@__+5_;\1ISLZ9?% M,$*,$SWIOT-U1>"(<6*P97G:T#'1_="FX1^;D3?,LUF#+8? M23_4CZ1I%[.\C^T97I3P:&RRL)%HFN[K([@*@@7U&![)E;;75_+D"L$QLY) M`V+0(@$,*]/V\@J`2QTQ%89(QVG% MHX+$VFH1'").34C:H6)QEZZUC87,.7:JI0GHOR5K MXK#TYWGFFA?+HZ2`+4?7=TW/3'`,UC@`3/]585`Y)2&#,&M)>R%47.5R%9K5 ME?MUTTN<&:65@+%_Z^2U_T+;!^';./I6^ISI)S`C"M80]V$QY,Z_NY!L+-?) M2Y'1]HOXF839OQE8'<7#,?W29WZYA,!UT/:R^+AI%L?1;L'G3;]*&M%F*1S[ MM_M7)G`Z7PTLK/EWC85*H5E!*P`67DH&82R^RZQ6@J#9/YV\ MHAWXMFMY8^I@XZ/@Z_2]4CJ.[+L'TP>QY>V7D9@;T^5_R**IHCOK3>R,,_(P MH"J\E[?K[L^3 M*`[6)+P@FR!JCYABHQA[$%#E-'@=;T(LYI44W^IZ&_AV0W0W@;]Z).&:A46. ML\X"A@%5ZOVZE0?CFL!VK^ATEZ@4+"*.8? MTO3OE9R10#75X,V_,=D<='8GC7OB,6;NK)"3B<(02O5Q0?79X"L"$DF9UVZ$ M-@49RQ@F<'/W9+^N>4LR'O1JUVCP*BRL_I,P<%5S5'WY6W/'27^P/,7X>M5. M#*X+=V&0%LEA"1ON0O+B!DDYFH0_SZ6$)F/RNZ%8F\Y`T>!ZWBMS?I>$]K,5 MD;O0M9A"X`3+15Z!^[491$+[=!C&Y"L('RR.+99I;B[,- MB4F,EE[I!X:<.4SSJ,4LS`W`D(K`7^VJ#ZV(SS)]9KF1=J:CDK&MVK71DBB# M+L&]Y8M#7=C](%UE%B$[@^9_*6\:V6^V;B"+D/FGQV_7/A52PHXIE-?(=?+L MY45RMBSM9UN2I?R[FC]KM([*(&HV"BXX5+#(6DXXFQ-M&3L5\\9,DM$)38J*T1$[E39+65T3.[&B"-';S)+9)E+WN*H&>:)35DTUE] M19CG3OIF(5CN)'1&#]R]L())!`=ZS/MD9^;=D=`-'-?.=V&ZR5)[<&,)(HB@ M]$9/[+W05),0_LWJN'VW^J*\6\V.1]ROCGMM6,0[T^E M;UN1#[FX-3LU'CHY@FKQ1(EF_VL.N2BN,W?^F41QFETXH-9Q$&86\U?+]5D) MN(5?B.&,+(,TC6>P)H_6JU!;='S.>/QB#SW2)WX<&I:ZE&=C4S.3)73&8ZJZ M8@X3"`[P5-:Y'5O#[!;E_HR':`!!Z[Y+-*6'1@,FOT$H5++7YVK>58/TB&./ M;-JF@"B/N7S/Z%ERZ<:9ZV3PXK(;W*L@;(I(42,[?0&J@MJRTPRG@CTDO!5T=_]:+9;+ MW'QH(\J"QXZ6M'DL2)D]3.]0_=*68J.3?@TI6<0F67/!9<5Q6QK>$FHZJ-M@ M'?J'ZHNV!`'#[7>=I8OA#7&;Y!T4]_3A7?WU<$L_6-#34&MFP==VM/)K!2$1 MAO)PDRS3!X#B4*5O/#BF7J6/GB2.E9P6^0>'AEHRKLJ%8+TZ;(2]5JG84,!:)V^Y\ M5\Q5X9DX+!6T8+'BM3<5IBS8##C'*1&_&,S=HFY&N60&S/(]KEN^155_11]#8779`(2HYZI76"K32ZI M-'"L><70RIS*0..3&(W\'`(TF30T16*S"*R$75]RUH#2OQN->NPCXAH?F";! MN;5Q8\MC@;O%"!^"9?R#RD,R%^241OU_!Y@24-G@0/*&6!%Y#CSG>KT)@Y?4 M#))M0B(:HT%]`Z`GEP<.W+Y95`X^"=\4]B$1C3$_UX%PD\L#!V[U_1GC[2X7W_H) M*+DL"K-)BJF@:J(G%EGGRK,WZ1]3FT88X__AI'[[D]'HB>BOC$=RF<-IBR'Z M,1O:5<(.P-]?)8ZWNF"E[_Y5?_DL0+5TNFP!?9]?8$M>O_O ML[S_U'\H_<)L]XE9]@UDZW`Q=BJ2AC04W.P5NS'JS.*[,;FA8G=RM*2N+!P" MPZMM)^0:OBQ"8>!88$N#K#-:>N^`Y4CJTI?II7A@H!5E./WXW3)7BV6=?<&[ MHH3.V-7E@'H!DPV&+;SLB,Q2W?NK^2HDJ;/*4?-7XJ>?#_R0MVU7LVU?]-]; M?MOWH6B@8Y3KD\7RG,Y)-[ZR;%;,[0UPJ!)2F73-:AF8)$!.0((C^@0"4=TC MB\\3DKBYMA'>R$/H)&1X`1.%&!$3!./)V>H9D\=QUOB=>%YT986KX/@3-]*.M6QK:#K6#JI%99=[/L.: M8AE^^_KM].1$*-MJ$V,O33VDVL:D)GF6`/P,U=C/BK+5EF.ZI\9^'D]C3^4: M>ZHH56W)OSIK[.DH\KRXN?EX_.7DO5"B]4;F'"]["+6=4XUB_?3E^)UJG[^QG#31XUKD:?)"O!A\4Y:HO66/GU>##>/;`Q_=BC:TW,IZAL+,] MT.`4QU-;F1_8=8/YY[%6#"193=KXQ($`WZ4B]X51]202](#RJD*"G*I\,#Q= MG0?^"PEC]JY6K@4I?*+Z6'^B*G4R2WN9Y=V@>(=BE?94_$5X[=&44Y2\.K4V MQG')*H9"6"$1UQM3=6R-A4$&R@VV=R6!@@E1N4'WEE0=G_@5J:WMM/'`]&94 M'=FMM2:RMR(^!494!*]#?$909&KD;/JRS(T2,M/&MDS?ZHF!($+0EB^K]=LG M](@M/&0"Z$P;SE`4@.P8@D'\4@6@,_TH.`P,X[Q?<;]_*GZ&!="9?C\-L.%6=#=HN;H>!P?1L$%]``NB,OU$.@\,XU^C<[[\7.]X`Z(P_:0Z" M0UT.)KWQ53'\T-'.^J!J9^E[0AT$P[H8.PP.X_AZ.Z]$EU7=+W_CL( M#G4YC(Z#V*L)0&>\\MLP.(SC]\3_OM@5"D`'Q0'W/EV7P^@X=#R*?U(]BI_@ MWJ?KY]NBZ'L7'XTO$<]T7YOASW/EV7P^@X=+RI_:)Z M4WN*>Y^NRV%T'#K:2U]4[:53W/MT70ZCX]#Q'/=%.58/]SY=E\/(.)QV?$\] M57Y/?8]ZGV[(870AV_Y0HH/B@'J?;LAA=!RZG:=+ M=%`<4._3#3F,C8,DT!M`!\4!]3X]>"RX5C^U%K#$/EW&\^%)W(5AGFGCS1$V MW)O`7SV2<"V?&=76N+P`N:(6\C"FG/.Z&\]:F\[PUEW.=8[QA\'LAEJ) M@_FD'@.X3&26UQ609@][ M$DW&$\W>QI4-7Q%N?^+*=LK0%9#V'L`[.6)L1+(9!R75:+,N468C71$K(2", M+M,J;[7(L"X18AWQ8F+!>VA\OZ(4][CY#)N?E2M%H'8)?(0YWYI)N)0-?*V0\3M*<[]TDRDK6HD M6Y<(-IS[I>G(M=$B:D\Q[I]X(FH_*YT_V^B@.&#<5_ERV-O(YE.,^RV>R.;1 M(FK?8]R'?\*(6MR1:S]/1.U[C';23QA1^QZWO?3S1-2B]G#XB2)J4;LS_$01 MM;@C"'^:B-H/J.VEGR>B]@-J1\1I1=3F(7DMF(E#4K=T^Q!?6Q."IHDSCR)W MY1-G&Z;U&,S]('XFX34=553JIC9S((2XW*>Y.$#9P31SJJQ=^S&ALHWOK9@\ M4/E2/DAH,U&OP%%1XCXF$M_;@3-LJ&;+043EFB\,Q-FQPE@0`PH@Q^59#\$2 M+!,\,.[&5UK?=WS0=<8F;5'VK3(2=@&^X$0#IY)LD$-Z1GRR=&W7\G8,7!$K M3D+PR@OM#5@`1)#@GE"'H,%LP'NB9=N&Q;E@$2Y93;WG=O`MV6VJEHO M0(Q'>KR38MQ!0CBP+;*KP!+YM+?&%7\CPTK$L:;#1:H>\^72]5RJ')+4,KS& MN()JA(<(,;^:A$QMV8=GRLAN,64&T6)YF2?#2/'FR!Q("X1@I!M!(01*TAA3 M[4]4U/X$7<"2NMZ?M$@92R&FKY;KWP11M/`?+(]JQP.AFY3+=JY;PEV@9$10 MQ#!<=\`$@&.KEAX`TPD?74=10AS)D4JE'V0!:[W/R:UBF@C$\W60M)L.4.ZW M/4!AG=K,^",`Q^N/[JW-K0?XG?!",%5336IT@<46"P7&PB*Q8##%B[O>GU>857[,>Q!R-\BVVX@E.6#`UND/FS:IBD8U%[N M:Z._L>Q=905M%_H=%0!\N)TH](6"7[YNB!^EVQ(?Z=;&ICT:P<`*6$6R)N/U M>=)VYP^?EOWR, MN.ZU#A50#A50,.)QN/#Z*2^\RIMVN@WG/T?Y]BN\]8(2FSY3JUQ]J0E$EW-H M$(M3W)4;F#[7J$BWR9@^"8J#NLL-<,7,2"4X3O8(^B%QFKER`UQ1#E()CI,W M[J;D@S"?BR=]YK2%RAC;GM?D=Q09@^V*75^1Y&Q@EUQ MJFI7X*BE(.1W%!DKV!6GROGY\>UY=7['D/$'\:4;I^VD75^1Y&Q@GW\0=4^QI$S7\CO&#+^*'YHXK2=5#Y\(;^CR%C\T,1I.ZE< M]T)^1Y#QZ3OX&:34%BIC='M>@]\19/S^5/SPSVD+E3&Z/:_!+XZHD$800`L< M>=N6IKA\!&\D01Y<7JN>F,W=DPXX]QB^M<*0?N)EMT94HJ&.9=E[LNBH(AYJMNWN$!EUB(PZ M1$8=(J,.D5&'R"@H'H?(**,Q."BNG28=@X/B4FG2,3@HKHSV,`8'Q361D-W) MQ^",5+[EIP[!&:E4R$\=@C/2G==/'8(S4O+_GSH$9Z0D[C]S",XQBCUOST-P M$.YY>Q:"@V+'V^\0'!0;WIZ'X*#8\/8[!.<$Q8:WYR$X*#:\/0_!P;;E[6,( M#K8];Q]#7L7@G.*;\_;OQ`_H7@X-OS]B\$!]^>MW\A./CVO+T+ MP7F/;\_;OQ`_H7@H-OS]C`$!]V>AS0$I\K.8KDDH>NO+JR8'+<`TRJ# M&A$0(1QA`@#V,>+TW4\BXC3J3<_700(O9R7I!)>#HAJ0(/E@!/;<"L,W.F(U M).M4TPJD@DA@^D%R2E%8>Q"`I19[90"0NS"P"7&B*\HG>T$71"BT-`7?(:$` M@\LK#BCXA2DOZ8YLL]"U?D4[6[O!Y?VLMDH"933]9;/*-N70#1S75BSRV5=)AAAO/;M MD%@1F=MVF!!'%48N.;*`#E6+1R@41#A&44+7"R)9)UN:0O'!=.72QNSTK4YV M1DK/3%%$U_TK(CATM#1%%M0CPY'++)XY=1[X5#S^BS@LC0F[)[P+R=I- MUK=$X?9;V`FRH#&UO1(D(#S([A1T$;HK:FU[[+?9!3!X%K>20E%$=,<#$@8. M[!8__.B92N&&^`Z[L6TT MKY*)[`24B:R9B&QVW"T5&:`D=3V%VJD@U5CQ1@^@17`'*1DM3C_$* MDA7>OM1Y'OAH,?I,>X@#^X_GP*-2CR[_3-SX+9=,^_PZK<^O,OTLZV";YV_0 M*<4=J&0Z`>@,3J4'"B,!).^KMS.<^`HHV-:95&<%2>J^[;`:NZD`C1ML"?O: M]8F'P`VZ-'W;H9U[5A0MEJF2B;/U"4BFB$F3"QQI^\KCDB7L:VN+#`N>?M5@ M:>.D9ZZ^@28*"5T2S>\*FR,=(==_M>!>1&3:O8ZO8/6I(F<=QW$T/5V=61%Q MSH/UAOA1+LOM\>OL;=_9O3J_F<@,78^W6W21UZJN6%L M_O&HLV1O`S\3;F;?[VZ?!9V,N M/1-EWA-ME_#IF73X[YAV."9'_J,,4$'S/M MXCV-]4X.%PY]U&7)_>/$O"/#Y;N740S1W' M93]8WNZ"7W2YWA?JO@,R[3(_C=5P&-AQK)CI>LZ8L#PJA77@9W-]'L>A^Y3$ M[';U,2BY*RRK*P-?AWMW;-KSW[1Z!,.*$Y/2Z1-M?OS:&8^NX4@ZXT7O!'R0,(7UR;1(Q5A1`7O;A>(S28,7HA# M!5.X<4.F1.]/F(XFP:KP`V&W3^H\-$!?4U]GDQM`?03&8W*PSH9QH)_^9,%J MI2OW1-I M,R]A9_I40@4VTEN4D3YO/!`,E_Z/"CJ.XVQY-I?N2[>/-X+P%@"I\6"T<1$- M5.6#21/ZWE^67H\UVJ^BCQD/B3.I;1KAF_YNWEZ-M'XJCOL\(Q7F)SR>CBHBFAR#*Q>*-P3AZS3P:=CN,O] M>'C>?E!BJ!;AN^#7@F2@+D'S6^D>K+I(5UL$-691S@\,8_N)9EXDD6,A%]U3 M;>!Q0.<6OA<'#'-+BU(<)E/MJ&QH)JD,PGB1[KV>1NKJ@/!6!63+\JY6H,10 M/40;#F3V*"&ZA,&3^F:;%&@[VDH.G/B;I;M' MVRRH/_<_2.+G(&3)`F$G?T`O)M-.J6/%GU=@@8UR7U,?S9T5+L(T7-_YS?(2 MQ0L-Q[1SS6LR7FKDWYZT+Q#=X4X[;&O<4UI%^>21():%KSJE^]35@"H<4R M^^T#L9.0JFZ1')6:S>=6]`P#!=J5T5U,)G,N/&J"&A6[U"=0."XE_"#=&=V_ M>F,(%Y@1N^,VH/90:@=U,S@J],82>2@BI2P2'`X-1=[^N>_$Z0'E(7F*[-#-[@9YBZQ:%\;R,BBNLUT$@V,&?Z>K2I2% MZ!#GT@I]NL8`8DPD9,9R&/0\0,"XTSK'>L91\>9=_VY-A_+#0`F&9!GM^U3. M#QOFCH$S*W(%ZZZ`PG30NC*T`/YQWHSE*Q&GXLA'I=>@8RB*@*@H`EJWTT-1A$-1A'W,5S^2,+7>&O;,A3.!H@@3ST1_*(JP/T41]B/5 MO4:X<.@C@J((^Y$P_E`48;RL=E[$OFQ,L:X$L",[&\UH>R!M,J:_#S97(_ MU#70O@E,MZX!OD0L$UO_\:7AW.^Z!H>L[MK+CTU48P\U#\_:DXS'^V=_]A4.]IH&^Y627I,PS2LSWIH&^Y4$ M_E#3X">O::#M(6+*Z^&AID%.?,C9?JAI@3K:'O*NXUV%?Z*9]Y/7-,#W MWH!A;AUJ&AQJ&BA-(WP/%U.81H>:!D/7-$`;S7.H::!0TX"3QN93MZ(&8R6T MV7[PI'<6YY-#DAO=N=H:(!W2W6!-K7*#+MW-=M'][KMLE[^UUD2<[89/,2%$ M^$S@R'53'5^:F$26\D9`@@,8F:H)(:KP@R+_S2[)K%H*'!F=Z5PG4M6KX023 M`XXWL]O`MZWH>1'>66&<_V5NTUTU2CV_J%)2IO],R`79IJ,5+X:=.\0Q)4%K M96<>2^E:\&+.5B'9TJK0!0Y<>^JYF@*4V4>Q,AO+3*8MF%U9A\=/6":.K^6F M_]X54^,=,14Z,+UURM.$J7)D%)NB]D5'9';DQO-Z#8)+71PX3!I^HF>1'S:? MQGA&*VBJ/3GC.`"J*M$-W79=)W/K2?^!"`-40<3&\T-!(5,0!4;L?@MBEBDC M+3@#A:Q*8SQ]4C>DVA@WM"=EY;(Z[D@%L6ES;IC]J"H*'!.F-+"+)*1*DST) MI?MF^0`BNNJ%]F`\^PXX*:RB4'`^;1UE/M%9I9XGR@JH<.EGR$M7_MO9KO/Q M"YA*N%-^"`/WA\-VS!R2*W680/9C*QVR@M&*T/+M3(&0]L`EJ'V5*@=!9+$1 MI0UI5\92>4$']XNL9G4_91I&R#@WB,:[=/N.\*6C[\/)P?>AT[R^LMSLWH*J M%(LTR;QU%LM[-_KCFBI9%*<.7OP)#.X`=TULF9N$HIQPV-O7ZPT=-G&N7-_R M;79((S9Q7]AKSN]N_'Q//(MY8GE>\(,%'M%_92`X.W[XL`_0-3([0%4C!A.N MIK/R-]O'O]%AT&66O1OX5!"\0*AN M72';FL'X=N<8\_Y[5%1%!IW,/KV#GHA8UU6QE"L>)YYOU"I)WM9G1; M>5'$?&=?A.DK(*A(B)S2U(6!LJL!4`8X$!/>,9:SAQ216:+T5!WZPN^%U8,Y M5$#O=XXR@^Y@FACO^504TW,6AH>BGE(I+9QFDIV`!S`97[B1(<&Q_&TO[.=T M"5\7*_6&V'3TOP4>%8'GQF_W5(2`MPU`'Y-QLU,7#%Y`V>O+54A(<4VK#F=[ M#Y/QQ%,5"EXH"Q6\<%]&#"F%B M+T/MZ2D^'0.>AH0O0Z,GJCCM[:QQBN,UJ*LA=YNPJZ,BL:@PJJJOS7")['.NX^+:CE?>N]T*QU;\XA*V3N>" M:S^HG8A5J?<9ZWY[>!OGP/:^ZSGM/8[CV3XYZ_$@.3CG(7,40^R< MMQU:[B*1)3`1.NL)2*:(29,+'!D$R^.2Y;=J:XL,"YY^M7OJ5#CIZ28HVN** MW90:-&PSY3JE;1=@#H'IAV:^LE02$DA9QFQ"@P[%9V_-8[%D.=/Q,6233[@0 MZN`?1^;`'JPU&9.MP5H^AD2/],W'X921+T04;N;92&5>S]56QOWL],V?&NYM MTL&Q%V4CNZ8\OA+G,4B?#XH#6/9?\?8"I4)?,BO]#E7/>ST'O*./.7 M2BROOIM4L:N$O0P-K#*P3YE> M0_0HCXJ8<6C1@,[SF2>0OM?>ED\9-_(-Q"A4Q8Q(BQJ>&$WVGL2%*)G=?.W' MH>M'KIUZG"J[S@SS3=-7DFIZI57PNE+=]APX/VCGGC#KC_[^//#3ISVZ+C,O MY;9S9GJQ:V(D^,-IC(D&W;K68]DN32\ST7[@`4PF)&AD2##KH3:_*//10LH> MQ1/P8N+$FYP.Y\:D/?)$QJ&R@Q.\0PQ^'OO@^*0*X<$A"MD+PL$A"C$F!X>H M@T/46`Y1VNY&]\PA2A"YUCS;\@V8\ON1>G?3N:GL(RXDB/\,=]H:[Q[[*,#X MU]YJ,3";C)G8"N/IA]XASV&F\?82CXI*TYPAW?H0)4/4>*DXH)X,D2_Q$"(\ M:E"P\HJE\>(3SXHE0..0G=&/$PPIH?"H::N`!K'^+GT'90ST\>EB[;M/ M220,>WX/?2\X/IWE_8T_U6QG#<9QR"(P[!$8?@B)\T.&+T,]I9 M$E'VH^B!K!@ST=&9Y;$Q/CP3$CNB(]J'^A&MZ&I6],5^E_4V2[O3@8\I+6331&;=DXT%9_D?E58D%)* MA4SN(IVJN@I)^-)S1+LC813XU/"@3#U0>\.UB?B\)B(PG+\;I$YEF$X2REY,9SE:MC`!4$'IQN`L#)['C8KP0##@D MAE,I=Y6_4``X3JOG0;@)0LJ@+!E'HZ'A1,=*F/!XP(3$/(I(')TG(>-=[@S* M:6[>VP!X?A>RBP.1G[B%W[ M+U080?AVY?IN]$R2C>6RN@_$CPC5P$7\ M3,+*JL]'"$0,/A89QTM!%AC!4X1+&2#SCPE"?G%``IPY'>>(^70RLMF@Z!0: MQ)9G?F>B!\`-">,W%J`6LRHXU&[:,&D(S0\Q%112\R8^A/OI6Q\79!-$;ISI MK^BMMM(,BJ)YL[^5/QQK(C-[?KB>QY?ZK@54X.:M]CI7.&2=FBS75&#^RJ4' MB$P=A,L8GP**A7E+6\;U])Z?_'NT" M:2K^(!]!_B"-WVV=0F9_^?YP,?NO>IU#N#RI^H@`.L+P(+X'KB)@R`X>(UB] M$DK#/WB,(,/FX#%R\!@Y>(P@&8_@M\[F/` MA*1F:DOHP%>0V!0&)A`G]HB[G$AE`_NGGCT M].?<66'\)H>IE0B*E;[34!^L!'+``I@=$BLB%R3[\]I/@U?NK#>V'Y3&[8IL M-;5>H)#J.R1U@U1=4M/?+[]:KL^LB85_X4:I;RH%:;&4.;))R*`:H._`U44# M0+)0A_Q+!KE/5DR#S$.>RH;:@4%A44CW63X%%&AM3R&=@)9)P.2TYKSI/K+S M7XE9/F:L.;`EY,8_58#>5"6VV6%;.<)33,[(,0I+]_&B]BM\F MX7U`=4#;FTZG.:LNI8$U8W1WY?\,7#_^C7;',OS7LSUOF:PX*'^J.RBG?FIC7#OW!7;K4N"1A6H5M)=B*1QV$ MJ=RG"OK0NE880`K':8_=&US[5#8)&_.599/YFB4M$+V;\"B,NCWV05\F!(Q0 MU0^?5T&8E>P0!H6I]&'4AW(X."&"PI!TMF2/''WW;1)2GGWZU[O\6"FN#?*Y MOH]GWIB]NQ,3/9T^Q&],)Y@$0UB9I)SEAFZ?;G\^(3Y9N+)RB M7R13=/?76=[=878.S4R>X&([O/PHF=O7Y!Y,$%LLG.XMS!MOV MIBU7T5Z=3F^]'4"&N)3ABCC,MU!Y*D/IC85+#`A8NPK`)(<+[=1IF)H&-_13 MW3&']6(Z6$,?\BI2Q(5_9\C[HJS-8U`?RI,`=CO(>V('ONUZF<_J^3,K(7/M M%[RP8T+ZFLHNW#)L/"_X(2[,,T3?IH.'AE>/X22.3(.@2T+?I4";:Z=&K*5+ MP`2S\I1/X&Q'2U@NUIUVTRU.=`[__$YR#M]V63Z1LUX/Q_&AF;E<+HG-;G0K MZ%77IWFPE"[82OR?^C7J[&W$:UJ(9/B=/0A M=1C9_LI?I6&F^1ML/YT0]SR]>Z&AI(E9-]H,*%4M:._#]"714'B+)(3MT:5Q M4+EQK2>JE\Q70VCX'4L,OZ+CU.#+NI[]I=3YOQT,P,'?8X+U)O#9L]]BV<"5 M[40[Z926YEK3%Q0!J+8M16F,:2SZ5W#])`9T@V<_G!._^[&E<'G.1R+O,T*N`/[ M,WT],P#T2I)#BCY??0>9ZN8O5;1.<>3@FK+-$3U\3=>_;=H>DMJN3M150(L' MY"0S16QS<"^6YU;T?$79*VSTXW;;_+1NFV^[F`7+&>MDEO:R,]./!\T4(1BQ M)$\$B!)#V:WIU:53`.50B&X$3#C"%2-P@ZX0W6-H^1'5'2JT1_HM6+B8(F?\56RV/ MA36W((2F3UE_;`9(Z4P_Q/:4OVG]/^TH_U-%^6M[..TI M_U/#\G_?4?[O%>6O[9VRI_S?&Y;_AX[R_Z`H?VWI2GO*_X-A^7_L*/^/BO(_ MUE;ZHB<`'PT#\*DC`)]4`=#VG-H3@$^&`?C<$8#/J@!H>]3L"\VXB=,3L;^(CF(3&>($6D.1!C(\J=/&Y2T)C MO(1*#Z&/<^"ZT"%6MN2SOC54`4!3JVAHJW MOY9V4(&:O7/A,JA=H.(S?4L[XW5/%`5J^M#^I:/)_$55X%AO3;X8!N#X7==K M\W>J$)@VF:$B&!^#SD\7ZN]W6#$P_7IQW/7YXEC5.CG%>GU2%\'X&'1]PCA6 M-6A.L=Z@U$4P/@9=GS&.56V@4]/.!%`1C(]!UZ>,8]6WC%/3W@10$8R/0=?G MC&/5]XQ3M`X%IA\TCKN^:!RK/FF<8G4JJ(M@?`RZ/FHDX^Q7I.KHL`1[Q36DKQS(J(4WX;F(1()0;#U?,QW&S(]?J'O_:Q0V M#G5Z)/:S'WC!ZNV!A"^N32(V1E$@`8_`=(`R&%0)RSAP8=49=TM3]E/,LG"Y=6L+X33(Q6YJ:=K$'`\ME$\=D M_$IM!Q;+OO#OR28)[6>ZW+/<-N4"JGQ@8-2FO?'!6*D(`P=\=%4(8_=?69+N MY97K6[[M^JM4T>:^P^)UV;(AF%OP'DP[]8-A5!4*#BBIBB4A"S%G'F'45'=9 MD1??N2*B(@9"(M-1`&#``*SCP&AG$;,LJFR,MX%/UALO>".D,+E*9[-S:^/& MEN?^B]G*L,-(QXY-1QQT.'?T$B$.?6`;1L1V#$+WC,M7EA@F<:/G+"">[1OB MK5-":CJ*06G?!(D!!VJ=C[XLN7;\MK,%LARZC\^6O]BP+J+?2)0:[5E]^4>6 M@^_*(Q':>B_K!@$,1Q:6S5#\Q,BR]V=E7:S7>926QP@KX@5 M)Z$PQU.7WHR'E2B=I[M*:_IGZ_+-;QI:D-T>7$=10AS!Q8J,SGA4"QA_F`1P MS.PB/R!=VY[H826[3?4CU\D+\:364*:&`NS4>H$B:?YFK(MT<.!Z%P8V(4YT M17E/]QVQ1T'`HQ`Y@6S6O? M#@DUXR](]N=U5GQP;F=W=M2X%R?)@](;=[-6N!U3D4@+BJB22]ZELGDFL6M; MWG;0E4R3[SMDFIS]I=+Q(?/D(?/D(?,DUHR'A\R3.'`X9)[4B@'*S).F<^ZA M#9DR[94Z4LX]K.%2XT2L9=X=73/O@:E-NYV!L%"4A2%$Q$%L8&K3_F*#(#). M-)ML%.*0-C"U::^P01`9)[;M=RL,Z4G_*@B[)&L"4YMV\`(AHB@+0XB(=W,P MM6D/KD$0&6=GEXU"O+.#J4W[60V"R#@[NVP4XIT=3&W:2VH01,:*4]_F&J0C MR5(',2=+<-&!=BKC?D2JB19%S(\L>G"Q@78JXPXYO40_5I:2]J^#,XRV4QGW MA>DE^K&2D[1_79:91$)EW'FEE^A'7^N-U9C1YY-R*#(#QL!T3A+#569R;V!Z MBI_GT06P:0"@@R)@]L`,%L#H`(CG`(`."H#9\S%8`(;N\R0Y"^'D4#C,'HY5 MQ6$*%?'L@)-/(PV^JCA,H=+O@4@YN^&)V3.SJCAPN!`R1\<'8B>A&[^)'3B: M+7%X#H"\-YJ#+SWQ&A3_-^N?0<@<'J(L^"\?HTLBF2>'G!('/#P%JP$D9Z>G MD\>`'K=,V=(K26:MLU"Z:!['H?N4Q$P#'X-SR_/RD+FY[[#K3$N85J!7IZ9= M&=1<<_N)#L>2F1W0TN"H"ZJC_BJ+A\S82=V-^5!#:$T[1,`C3<&"&#B@970G M[O[&$T M/,4NS2\1I\,3>&[G)'P*@Q.U/BB)XS:G.8YM5`9);6IR>$'BOET?76.AD8-S M@\V96ZAL$G1N\+EVLT5LL;SV'??%=1++DSAWMS>?'C(<1I#X>=<'][L;/Z"H`\(M.G@0$!%,M%TRWE MW%\1^L%O)+3?Z!%47#6RO:UQ/[9^$`@XPS1UBMP5I7!WL='!)<"Q6ZF8'5Q6 M<-Q2M@V/_4B/KS)3`T"*`RZ)^@$`J[&%PJ#8WN44`WX@J^S\*)Q:$C(RX^*C0 M#A"3F'/A!4FQ*7B(!'#8`.4$X*5'UP?BT4^MOA*?A/34YSMS9^WZ+KL!8^>! MRU?F&T[27$HEJFAK)N4]\M<[W=\%JHPN`U)ZWR;(PZX/!APJ]V!Y5NB2Z'=K M1=B;4WXVBC* M5H4.*6-(X5=^EO<=YK!.K63BV\QY#>0D\K'N)%+J<6;YSJS2)S)G$1'W6Y[D M'B2*W6"X4YM6(L!N-+>WGA`2[0S@/JID6-^2SW+R+='4I,'T3I/\C,GG\+D MK*L.2G;(;&V-PV"3`5*?3:VL8#E;5@<'.6%R*5"B(SQMG,U7W$/$[A`U;H-_%B2^+;WFQF/"6UJFQ;V=25D;&2PTN%7-Z'9&!\ZD8P#` M""8<-52R-=^3*AHXWLK)N4W#SYP4'K3[O>*"*J) M!0>4C*?%\IPN&6Y\9=FLA/A;-D[7SATN^3B"B)'=5_"L[(G>6"IZ=*CZ9#!'I-6'71X5"`\L9Q9OE_,*Y@F^:N-;)[ M+I6]LL[R],VAK]0"7(19\N`'B^7YR`L`,"FYCFN%@KA5$#&R^S89W`H"P3"!A8$#NZ)F+VN-`?%$:-[8)3!K:*3*:O`56[O'1U?KW,_T*:U1[A6H,ENND(60X?4U"DIA]M*M\F5:,D)\])B$&Y(T% M$^@KFZB(]2&H8*"@`BS758/%%F##^);\2/^I*[8E>BBF6*XVU.2"!,N2PE&; MP29TS.GO!/#Q2:"(8;G,D'*O%,R3_PO[SQ.UZ^EO_G]02P,$%`````@`\8@* M1RM%0>^@&@``VEX!`!$`'`!O8VQG+3(P,34P-3,Q+GAS9%54"0`#EA+)5982 MR55U>`L``00E#@``!#D!``#L7>MSXSAR_YQ4Y7]@7$EEKQ*-+W3+UMNO+KQ MX,]_?5GZSA,,*"+XW=[PS<&>`[%+/(07[_8^WPVF=^=75WO.7__R+__LL']^ M_M?!P+E$T/?>.A?$'5SA.?FS\PDLX5OG`\0P`"$)_NS\"OR(IY!+Y,/`.2?+ ME0]#R#+BFMXZAV].@#,8&+#]%6*/!)]OKS*VCV&X>KN___S\_`:3)_!,@J_T MC4O,V-V1*'!AQHNX_N+?1Q>C@^'1$JS'P[\/#WX';U[F3(@+$#("GL,(#D[9 M?X8']\/CMV/V[]BPLA"$$O7+"_K?KR_TRVH]!_B_OZT73S??GN;>VGV\_/)M=`KH M+*[R9^H^PB5PF-DQ?;=74.7S^`T)%ONC@X/A_F\?K^\$W5Y,^/;%1_BKC'PX MF4SV16Y*6J-\>0C\E/5XGV<_``HSSBP7:>@1IB'`;HG>"[,"1>*C_3BS1(JD MI,+(10$!\<<5+HPR7$X24)EA=P#B*?V>[W"/AHCJ"W MYX0@6,"0-W>Z`BYL8I=V&H`Q87V+#25)"D];K1#K/"SAGW[FK>PMU^H]P^[P M'VP`43#GN?NLZT4=?ND-")A@CS!$#*Y$V>5\O>;'YIIW?BHQ_E,_+9$IB\[FLQ5? M,K'JDB:OR--;X+!B@9R)0^9.SF:G[G-`'R]]\BS1=IZE5_:15MF
I-=%(U4<*56Z/`U\D9.RGG?EKH`V$Z8!.H"X-DU5E*T6O[M*IM4=9)"O=3 MH5/W]PA15)AA2REZA4ZJ"BV6[:<^N3H([ZD18UM9NRCRM#H>'E1U7.32^[7+ M%7YBLI`@F33S/_5*'5:5FA7LIQIO`L(:4KCFKCOKP2N^7(LU*LW1*W=456[* M(W;G4R[]U/0U!#1=0B2_]=H<5[49E^JG]CX0XCTCW[]A+@5S*%BCG+%%:W#% MY,,+].##*:59=,246*__P_JB(6;[7T["6#1KP=K)>3LQ\WZ:*1M-+Q$&V&6+ MK.DB@#`?570$>G,<*4=N)^/E9,SZJ?Y/)(3T!JP!:X>QODLI>@77O$91UDD* M]U.A=R%QOSX2WX,!Y?-7N$[#([5TO7+K_EZ!PW\X,8]^ZO@6^CP@>@/80N$^ M`)@"M[!T5N;J]5WS^!(^CF#D%#GU4^MG$4484GH'%R)$EX2ZJZEZ+=?W=CM:^^^7*Y^LQ<&/ MU.U*5"W-T:NZYM[E/'*OKJ>*/B?+)0J722SC7,2`%Q#G6U(Z`KW::TY?@94( M;Y28]5/]=]$#A;]'3)[W3WD;KZ7J%2W9\$O+.S&#OBK79#=UDQU8LYW84YY_*B5Z9(2>L/5G,\VAHMKZ*G9BINU1>-(TK4F&-<< MU2*'GBM9ON=;5+>60J_XFB^KV!ONN0UD>YA%"VCR]?HWW.GLN?KC#A4KMC][KE+-_EE1S\UD>N77'%_M9EO/;5+<8RL:09*NUWK-!R[MP/5SS7/ MMAB?[[F*9<'@\GBBS-Z5RD/&/=>_[%;#!0P!\E/G2$.@MR=5K7KH,;F>83#*\)I3NU&S5O?=.I;^*_4=)P4D9-#ZGOK*5[)2S3Q"00\ M%OT$ZY?V:A1Z2]:B(Z5+?)GJG8Q?3XU0W(,9%/\H=<9&*KTQ:H&3TLY/=2.H MW[U"HMU*K]!2Z`U1"Z9(-=_[3B'VQZ+:9EO9Y=33Z.U0"[:4N)6VY/K=&_1: M'IJ88MA@BUH,IM$6SK"GULCV=>0#DSI;:X&C6@PFWS_:#4F:S6FY%8PH]0:I MA4\:(B*]MTZ\VUR:'\I)>GW70ACI[G6_!_^2"BNM7)&GU[/RE,"N';>Z.*WR MUC8KK+?9]UVLWIG6X"S(H)Y4'LLV+*LW;+LKVLY`EMK[(?*<,*4%(6_QQ0,D M)>LUT.BM)#GRGW&KGCC9F4*MYJ&)+1I?2DP(]::IA0.DIME- M()K3ON6M9&6VW@[U@P0%1MEQWWZ/5TK=5L8K`SJ],22WZ]7&Z/UH55?WU/-$ MG<`W-9"FA-Y4-<]>9JJ<^\YJC9UIV-")FF84[LC.!C:.:HWE](:K/P`@,5R2ZN2U[,8X\TXV,NUD MHP9;26Y7&'6RT=-K"9UXO))D4BM4 M(UY"W'G`;4VB[HB-!?7&-`I8F!ESUS.+5AF.9TN,'B+:W!EKI'J3&84UN,F& M8R=AW/<.5[U&/BA^GY>M]/8G>.+6(1_F9ZMV*7O*>P^`SOZW$U(+9 MGS=$=C/'F%IO'?WK#P,G8\U3G(QYWZ>BHO:SWV<0LZI#I9E4A'H+U8(9%0OE M?SH)WYUQG*MH4XEMQE*ALIX%TW&V>_LE1O@`LYA M$$"/_14?Y+U&X`'YJ'9-N&TAO>TD'WPKV2ZM0=@L/6%ZNH&G?04.AM(`DP*-XKVH41U$J6?#7>G%QO(--O$!0-M/N: M/%%\GT`^A!E1ZLUD]OV"W:!F\$T#N8W:%-";JMTW#W8F4WT'H1PY563J3='\ M581_Q.47_\\#H/`6SIT7D1*R_'=[%+$Q@S7W..TQ@/-W>\3U%SP&?71P-![^ MG8GVYF7IIR2<=6:QY^?G-R\/@?^&!(O]T<'!.+9:51M)Q2D+$+@U+L]CP6,X MF4SV!15C(FX+L^ZPGX)/&80HY,5O"M4XO![6+O9?0V0?/+05F16!_@^4]9KS M?U4A6>MK*V2EP?X@4<_S6EY58-9UV@I<[FT_2-Z+K)*BN([XY^=]L%HA/"=) M"OL;8Q(W^32)"4Z"T,%@">D*N#JA$*8AWV/8,Z/!P<#!D+)0II M&?YCD!2L-D'#.P]])3B"UP9X M2O;VPF"?,]K'!`]PM(0!V**)C5\1)_T0 MD&B54B)&\KT2LN&PK81YD'Q7!C^N/Z11(=% MB\CO-]PQ")#&+60:A8\D0-^@5^@C;8MUW;+TB&]`,`M$V,G[%?@1O(&!$,)0 M8%WQUH*S89SG"P9_D(4+;;>5B2OENK9Q?/+HBM*(KQ[9I/P`@]D\3LV?,.7Y MT+LD`8\L9N)N6':S_ON#)197+;70]5(;E>]8V5 MN^P5=N.O=@._\$`PG89A@!ZB4'QMAQ2G\[)LFP.9H<)W_2F@[S M98V.I&/\;*'(ID#6PW`(&@L]N!3KIAOFL63SY4C>6374=LVN"J"*,4A# MW;58\:!X47@)IC)\9FN[;/GD\A!![T!./MF1=RI"XZ\GJW`>4SN;)E;U9<,NC+ZDODSLP MY\#WH7>V3J_V)82%E>3W\^G:`[X$*)Z*WK^X$'H,:Q"LF7&1LN'B'P%/*5*:P52[4J$L-6\DI"'/HM^**MRMBQ#*Z%\L[@ M`F$>KTZNB%66BR;T78^#]X2UM^0E9^XPOW_A$?U,$G6VK:TQO0%6^/8)6_&R MGK0$5WC._\>3/A$<\'DJX$\;>_\7T?C(UTA\B/,>OH1G?F')_,H\VR\#".;3 M1)CRZ%I-PQ^@ICI/&]1TYSY"+^+^T67$XT?)?J9X63[9VJ(\TBM_8%:NIE?F MN45J2AYAY9*]FII,>=J@IO)4=U$369-O`_Q"OY[-ITL$\-\@\,-'-MT],><[ M6W,:T%GK]Z61@PL8__\R(,OXQIV+^.9`ZN!=0L`;9;')E383-F9AZ[Q:E>J* MK6.\R(U[7BQ09>W0JH2M8A=&X0OX$%;C-.KLC9VM']S`*XBO"5[P(Q8*@0K9 MM@HTI10M,/1NV(+"12O@WY,I)O&2]0G2D`39N&1"::N8%<,4GTC_"'GD16%! M*>&FLXE'^`&=UP@7:D6P&#<)1Q6LQ93.\=VAEYLXF,2GE8L(SMR0,&RC@^%) M&;<19>?R%"='X88FO],[)669C*D[E^L>+=-%K%C0,OW_`G#$A@I^B+DLE2%M M]S(]0_\)%AI5HOU?(G\]'O(WCBIRF=-W+EMQ-*I_&J$LER%MYS*]IR&$2Y=O M+6"W+((\JW/$4[R`_FS^D369=0VS*K-SU&R&(#ZYA12"P'T\)\&*Q!76)I(& MLLXEJ:AXI#6`1;-B)90R5"Z8RKFVX1YI<5ND[VN$X6Q^+A;$TVE%W:K,SE%? M(#_B5WKCL'VE<\KS.L;\S@(/;)>E,*#K7);RZ=;B$2'I<*DGM%@:Z2"J)^Q<&GZ*=8;5 M4"L+:W-RZR4[;">91=Y0$]2C=I(=V2,9/\X3[[WD=P.*-\$JXX4YN?62C=I) M9M$(T@1UW$XRBT:0)JB'[22S:`0IW-=@<"\1]F!P"2&MS<=-9-9*4IN+F\BL ME61L)HE%_48%\=!,$CO[2;J/D]X?5G<5-:7-\J@[C)JR/&E1V3'04G>.O1H-&AR?H MFUR/XW:>RO'V2#9I)]ED>R0[;2?9J3V2%>:T_`-[RFE/0F*!!*7./LX=#>V@ M(*/K7)8DY8?K1#FET4T73N0Q-C7]XT*ZS#"V:>=*#L#,\3<+CBJ6O M":'%THQ,I;%HW=O8CJH;8^;T]LLV:BG;-MFM9;C=IG,L26_)7Z&NV$F3WSEV M?K#@$>#PFE0],VE.YWCYS41Z"8(%J;88:8Y->(^4>"W:A[@^GQX.CZN3=R6Q MCRBA62>L<8T%SITJ=6N6#5<,5%4]9 M1V`?^F/]@:\20>?H+TA8F2U**9WCRX^&WD+^5"_"B\\855S")J+.I1`CQ%@R M:EBD:8'G4(+1HKV7B^OKX^&DBK*6:@7.D\GP0`*TG&P%TN'QX42BT6)JYSCK M@^A1TRAKT=JQ#JYIM^38HC5/'5S3_'QL<\LYJ>TYJPDL1-^TNCBQ:'51`W?: MA/[43O3\BJ`:>CG7-MSJ<_SE7-MPJS<3U""EJU$]H<72G)I*8U4,3'FV3GW8 M4TW9N3Q&9_6M/Z%O="[?^M/X\3%:>@FK=ZMD&1:A':G06JG;L0JM1;TR!W6H M0FO16H)'H4XGX\I46TOM'&>^JW(PK$1&Y%F=(Q9QWL?#9`26BR-J6W&6V$;?=162FBO-`WW#:2$]DK3 MT&)I3-<")]NP%FC8AY,2VBO-Q'3VG&S#[#DQ74-/MF$-/3$=TR;;,*9-3&?/ MR1;,GF-33WJ\#9[TN'H)Q(308FD,^\W8IC=9U2`-UP)CF\ZF:X(7AIH3'6J+^F(9V*D.M9U] MD0%3=\92IEVHQP<:U&.+O/$R,/484LJT#+5N#+'IG$D9F&X,&=LZAAP=:5`? M6;3B*P/3Z?K(6EWKQNLC6\?KX[$&];%%_E<9V*$.M47^5Q'8^$`SRQ0SK4)] M6#UCI,KL'/4YP33R^=?[:J&F:GKG6,L'X\MX%7F=8ZZ^'E19?:BSK4/>\"R2 M76W:['7+K7C7TOR5ONUXG\_\];?M>/?-_,6W[7CKS?R5M^UXWTV#TOCRHGW[ MEU*4QM<7;7JS3(/2^`*C?3NR4I3&5QAM>DU,@]+X$J-]]P*D*(V7!S;=DU&C M'!FO#T;6K0\DQRZJ3]J9$'8NS05Q(YXRQ=Y[S#BLK_"L\QT*I(\CSK1+AS'Z$7^7`VOXS"*(`? M$4;+:"G0IP\K7Y)`]1EC(=\]?`G/?.)^S3RD5V:Z:5L.4QZOT9PA?UM^%8HQ MA%\E!GB=?$F\UII-2.UK"=%R"8+U;'Z'%AC-D0M8?W1=$F'^8M\-\9&+F(D" MPC"%:]Y3?X_0BO-(9/M,O:HF7I?GEJKL`R'>,X.J:"W?R61+E?()AORI[!L8 M)"\F\&_IG@&*7-8*Q`=VH?=="MNH@G\D969?*89N%*"0D;V^/@WJL$ZE'PCC MPU90+@QP@O83"'B53["J&C-:ZT0\BRC"D%)FJ0>$14VWT"7,NM^@=^4Q6F9F M<>"%4AC2J@`^8*9\M^>*4XYEY;,FS0PQSF(2N-FP,#:0 M349LG9#BJ<1'XO,'SO@@&*JB:@:$]@F7!!W8JJWP^."4F04O!.G9.B=)(J/3 M9Q!XL8#)8,.7=C<"=-9-?P3C397%ZZ$_LB4HY\\V)>QK&XW@:Y-/JR+6"1PC MOF)>#)\04J!9DU9F6R=(LQEJ,T^K(EL@<.5[N^T[JC&#+5#&%XX:A[2]%II+ M_O\&G?>#0#6,"WB2&.8O%"'*'4SUY9P$\QY&8XHD+8,NBG"ZWH1H?YH,*>\9 M&1@80(_<3@8J32PIRTP-`'8[<'7B*#%A"`0'>EHE/MJQ:1ET'H8-ID+O%B]V M@O0P@S-24TM2L/<=2-(RZ#P<#$R/D$8]FC=0BV&"R@9?T8P1+^@NQ[FR@!R= M@RYBO?(S\TK"@$*E1:D$6P]$*AYTGH0G2_\TY\3B#+><_'*<,]'$*!UT'@3= MO^.9!S0.O(3-+375,1`L``00E#@``!#D!``!02P$"'@,4```` M"`#QB`I',!`'TPT8``!42`$`%0`8```````!````I(%/AP$`;V-L9RTR,#$U M,#4S,5]C86PN>&UL550%``.6$LE5=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`\8@*1QXKQ(\^0@``)\<$`!4`&````````0```*2!JY\!`&]C;&`Q0` M```(`/&("D?3=BOWI*$``,+""0`5`!@```````$```"D@3CB`0!O8VQG+3(P M,34P-3,Q7VQA8BYX;6Q55`4``Y82R55U>`L``00E#@``!#D!``!02P$"'@,4 M````"`#QB`I'*R.)7-IB``!$'P<`%0`8```````!````I($KA`(`;V-L9RTR M,#$U,#4S,5]P&UL550%``.6$LE5=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`\8@*1RM%0>^@&@``VEX!`!$`&````````0```*2!5.<"`&]C;&'-D550%``.6$LE5=7@+``$$)0X```0Y`0``4$L%!@`````& -``8`&@(``#\"`P`````` ` end XML 53 R45.htm IDEA: XBRL DOCUMENT v3.2.0.727
Acquisitions (Details Narrative) - USD ($)
Sep. 25, 2014
Dec. 10, 2013
Acquisitions Details Narrative    
Purchase price $ 400,000 $ 100,000
Down payment received 100,000 75,000
Promissory note for sale of stock   $ 25,000
Payoff operating leases $ 173,433  

XML 54 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727
Organization and Description of the Company
 9 Months Ended
May. 31, 2015
Accounting Policies [Abstract]  
Organization and Description of the Company

NOTE 1 - ORGANIZATION AND DESCRIPTION OF THE COMPANY

 

Oncologix Tech, Inc. is a diversified medical holding company with operating segments in medical device, healthcare services and medical products and technologies. We operate and manufacture Class II medical device products, deliver Personal Healthcare Services and provide Home Medical Equipment (HME) and Durable Medical Equipment (DME) sales in licensed markets. For its clients, Oncologix provides FDA approved medical devices, State licensed healthcare services and medical product sales. For its shareholders, Oncologix operates profitable business divisions that build, maintain and nourish shareholder value. The Company’s corporate mission is to be the best small cap medical device and healthcare services holding company in North America.

 

We were originally formed in 1995 and in 2000 we changed our name to "BestNet Communications Corp." At that time we provided worldwide long distance telephone communication and teleconferencing services to commercial and residential consumers through the internet, which we disposed of in 2007 due to lack of profitability. In July 2006 we changed our business model to medical device products.  In July 2006 we acquired JDA Medical Technologies, Inc. ("JDA") and merged this business into Oncologix Corporation, our wholly owned subsidiary.  On January 22, 2007, we changed our name to Oncologix Tech, Inc., to reflect this new business model. Our business at this time was the development of a medical device for brachytherapy (radiation therapy), called the “Oncosphere” (or “Oncosphere System”), for the advanced medical treatment of soft tissue cancers. Due to a lack of funding, we suspended these development activities on December 31, 2007. On November 1, 2013, due to the development of the brachytherapy device being several years away, indication that the product could not be marketed and no guarantee of FDA approvals, it was determined that continued financial support of this product by Oncologix Corporation would cost the Company substantial capital beyond its means and the Company’s management and Board of Directors disposed of Oncologix Corporation and its Brachytherapy medical device subsidiary. Furthermore, as part of the disposal, the Company was relieved of over $90,000 in debt.   

 

On March 22, 2013, we acquired all the outstanding stock of Dotolo Research Corporation (“Dotolo”), a FDA Registered, Class II, medical device manufacturer with 25 years of product sales in the hydro-colonic irrigation, bowel preparation market. Dotolo Research Corporation began operations in 1989 and sells hardware and disposable products to a customer base of over 900+ customers both domestically and internationally.  The Company currently operates in a limited, but competitive environment in hydro-colonic irrigation, of which there are only four (4) companies approved by the FDA to manufacture a Class II medical device for colonic-hydro therapy.  Since the acquisition, we have not had significant revenues from sales of our products, including sales to medical facilities due to a lack of operating capital needed to procure raw material inventory to currently fill customers’ orders. We are currently in the final phase of new product hardware redesign which we believe will allow Dotolo Research the ability to successfully enter into the medical markets to become the dominate market leader.

 

On August 1, 2013, we acquired the outstanding stock of Angels of Mercy, Inc. (“AOM”). Angels provides non-medical, Personal Care Attendant (PCA) services, Supervised Independent Living (SIL), Long-Term Senior Care, and other approved health service programs performed by a trained caregiver that will meet the health service needs of beneficiaries whose disabilities preclude the performance of certain independent living skills related to the activities of daily living (ADL). We changed the name to Amian Angels Inc. (“Amian”) in August 2014.

 

On December 10, 2013, Angels of Mercy, Inc. acquired the assets of Amian Health Services LLC and Amian Health Services of Alex LLC, herein after referred to as “Amian”.  Amian delivers health-care care-services who provide routine health and personal care support with Activities of Daily Living (ADL) to clients with physical impairments or disabilities in private homes, nursing care facilities, hospice care settings, and other residential settings. Amian holds both PCA-Medicaid Waiver Provider and Residential Rehabilitation/Supervised Independent Living (SIL), and personal care services for Veterans with licenses issued by the Division of Licensing and Certification of the Department of Social Services, Veterans Administration Social Services and the Louisiana Department of Health and Hospitals.  All administrative personnel of Amian have been merged to gain operating synergies.

 

On July 21, 2014 we formed Advanced Medical Products and Technologies Inc.. (“AMPT”) to enter into the Durable Medical and Home Medical Equipment markets. We anticipate acquiring active companies in this area to develop our Medical Products and Technologies Segment.

 

 

On September 25, 2014, we acquired the outstanding stock of Esteemcare, Inc. and its wholly owned subsidiary Affordable Medical Equipment Solutions, Inc. Esteemcare, Inc is a Durable and Home Medical equipment and supply distributor for respiratory therapy and is accredited by the “Joint Commission on Healthcare Organizations”. Esteemcare targets patients with sleep obstructive disorders or related chronic illnesses who are insured by Medicare, Medicaid, third-party insurers, or have the ability to pay for our products from their own private resources. Sleep apnea is a serious sleep disorder that occurs when a person's breathing is interrupted during sleep. People with untreated sleep apnea stop breathing repeatedly during their sleep, sometimes hundreds of times. This means the brain -- and the rest of the body -- may not get enough oxygen.
XML 55 R59.htm IDEA: XBRL DOCUMENT v3.2.0.727
Notes Payable - Other (Details Narrative) - May. 31, 2015 - USD ($)
Total
Dot 1 [Member]  
Debt Instrument [Line Items]  
Date Apr. 30, 2012
Notes Payable $ 150,000
Note payable - current 1,500
Monthly installments $ 1,500
Number of installments 10
Total Payments $ 45,000
Dot 2[Member]  
Debt Instrument [Line Items]  
Date Feb. 27, 2013
Notes Payable $ 30,000
Interest rate of note 18.00%
Interest payments $ 1,350
Accrued Interest 1,965
Dot 3 [Member]  
Debt Instrument [Line Items]  
Notes Payable 20,000
Proceeds of Loan $ 45,000
Interest rate of note 18.00%
Interest payments $ 900
Accrued Interest 1,090
Line of credit AA1 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 50,000
Notes Payable 43,265
Line of credit AA2 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 80,000
Notes Payable 37,467
Proceeds of Loan $ 80,000
Interest rate of note 15.00%
Total Payments $ 42,533
Merchant Loan AA3 [Member]  
Debt Instrument [Line Items]  
Date Mar. 11, 2014
Financing Agreement $ 120,000
Proceeds of Loan 119,301
Monthly installments $ 800
Number of installments 189
Total Payments $ 151,200
Merchant Loan AA4 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 150,000
Proceeds of Loan 146,750
Monthly installments $ 940
Number of installments 209
Total Payments $ 196,500
Merchant Loan AA5 [Member]  
Debt Instrument [Line Items]  
Date May 22, 2015
Financing Agreement $ 50,000
Proceeds of Loan 68,409
Monthly installments $ 530
Number of installments 132
Total Payments $ 70,000
Merchant Loan AA6 [Member]  
Debt Instrument [Line Items]  
Date May 07, 2015
Financing Agreement $ 35,000
Proceeds of Loan 42,080
Monthly installments $ 599
Number of installments 85
Total Payments $ 51,065
Merchant Loan AA7 [Member]  
Debt Instrument [Line Items]  
Date Dec. 15, 2014
Financing Agreement $ 300,000
Notes Payable 228,215
Proceeds of Loan 163,713
Monthly installments $ 1,607
Number of installments 252
Total Payments $ 405,000
Merchant Loan AA8 [Member]  
Debt Instrument [Line Items]  
Date Apr. 30, 2015
Financing Agreement $ 60,000
Notes Payable 67,400
Monthly installments $ 999
Number of installments 87
Total Payments $ 87,450
Note Payable AA9 [Member]  
Debt Instrument [Line Items]  
Notes Payable $ 25,000
Interest rate of note 6.00%
Monthly installments $ 2,152
Note Payable EST1 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 75,000
Note payable - current 68,920
Monthly installments 4,524
Accrued Interest 2,688
Note Payable 2226 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 65,000
Monthly installments 5,417
Note Payable 2227 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 20,000
Monthly installments $ 150
Warrant issued for debt 3,000,000
Debt Discount $ 14,805
Note Payable 2228 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 10,000
Monthly installments 150
Note Payable 2229 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 145,523
Monthly installments 4,257
Total Payments 50,000
Note Payable 2230 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 75,000
Note payable - current $ 68,510
Interest rate of note 18.00%
Monthly installments $ 1,375
Warrant issued for debt 3,500,000
Debt Discount $ 5,992
Shares issued for debt 1,000,000
Note Payable 2231 [Member]  
Debt Instrument [Line Items]  
Financing Agreement $ 12,000
Interest rate of note 10.00%
Accrued Interest $ 1,437
Warrant issued for debt 3,000,000
Debt Discount $ 7,746
Note Payable 2236 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 4,000,000
Note payable - current 1,533,584
Proceeds of Loan $ 500,000
Interest rate of note 14.50%
Note Payable 2237 [Member]  
Debt Instrument [Line Items]  
Financing Agreement $ 15,000
Interest rate of note 6.00%
Loan fees $ 9,000
Warrant issued for debt 1,500,000
Debt Discount $ 5,151
Converted debt, amount $ 10,000
Shares issued for debt 1,000,000
Note Payable 2255 [Member]  
Debt Instrument [Line Items]  
Financing Agreement $ 25,000
Accrued Interest $ 1,993
Warrant issued for debt 4,000,000
Debt Discount $ 10,177
Note Payable 2257 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 75,000
Note payable - current 68,920
Note Payable 2258 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 25,000
Note payable - current 22,973
Note Payable 2263 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 60,000
Note payable - current $ 56,217
Interest rate of note 12.00%
Monthly installments $ 1,334
Note Payable 2264 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 48,000
Note payable - current 11,500
Monthly installments 8,500
Note Payable 2300 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 550,000
Note payable - current $ 416,466
Interest rate of note 6.00%
Monthly installments $ 9,115
Total Payments 205,705
Note Payable 2432 [Member]  
Debt Instrument [Line Items]  
Financing Agreement 100,000
Note payable - current $ 25,499
Interest rate of note 18.00%
Monthly installments $ 6,200
Interest payments $ 1,200
XML 56 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders' Equity (Tables)
 9 Months Ended
May. 31, 2015
Equity [Abstract]  
Series A Convertible Preferred Stock
     Preferred    Number of          Weighted Avg. 
     Shares    Common Shares    Proceeds if    Per Common Sh. 
     Outstanding    Convertible    Converted    Exercise Price 
Outstanding, August 31, 2013    129,062    64,531   $25,812   $0.40 
                      
Expired/Retired    —      —      —     $—   
Converted    —      —      —     $0.40 
Issued    —      —      —     $—   
Outstanding, August 31, 2014    129,062    64,531   $25,812   $0.40 
                      
Expired/Retired    —      —      —     $0.40 
Converted    —      —      —     $—   
Issued    —      —      —     $—   
Outstanding, May 31, 2015    129,062    64,531   $25,812   $0.40 
Series D Convertible Preferred Stock
     Preferred    Number of          Weighted Avg. 
     Shares    Common Shares    Proceeds if    Per Common Sh. 
     Outstanding    Convertible    Converted    Exercise Price 
Outstanding, August 31, 2013    58,564    58,564,000   $—     $80.25 
                      
Expired/Retired    —      —      —     $—   
Converted    —      —      —     $—   
Issued    20,000    20,000,000    —     $80.25 
Outstanding, August 31, 2014    78,564    78,564,000   $—     $—   
                      
Expired/Retired    —      —      —     $—   
Converted    —      —      —     $—   
Issued    —      —      —     $—   
Outstanding, May 31, 2015    78,564    78,564,000   $—     $80.25 
Registered Securities
  Number of Securities       Number of Securities
  To Be Issued Upon   Weighted Average   Remaining Available
  Exercise of Outstanding   Exercise Price of   For Future
  Options   Outstanding Options   Issuance Under Plans
           
Equity compensation plans          
approved by stockholders                                           -      $0.00                                7,000,000
           
Equity compensation plans          
not approved by stockholders                                           -      $0.00                                             -   
           
TOTAL                                           -      $0.00                                7,000,000
Subscribed Stock issuable
For the period Ended May 31, 2015
              Shares   Amount  
Shares issuable upon conversion of convertible notes payable            4,500,000    $             20,572  
                     
Total subscribed stock              4,500,000    $             20,572  
                     
For the period Ended August 31, 2014
              Shares   Amount  
Shares issuable upon conversion of convertible notes payable            1,058,201    $               5,000  
                     
Total subscribed stock              1,058,201    $               5,000  
Warrant Activity
        Weighted Avg.
    Number Exercise Price
Outstanding, August 31, 2013              7,000,000                       0.012
Expired/Retired                          -                               -    
Exercised                          -                               -    
Issued            23,583,333                       0.011
Outstanding, August 31, 2014            30,583,333                            -    
         
Expired/Retired                          -                               -    
Exercised                          -                               -    
Issued                          -                               -    
Outstanding, May 31, 2015            30,583,333                       0.011
Fair-Value of Warrants
        For the Six Months Ended May 31,
        2015   2014
Volatility                                     -       124% - 384% 
Risk free rate     0.00%   0.25%
Expected dividends      None     None 
Expected term (in years)                                   -    2 to 3 years 
Exercisable outstanding warrants
        Weighted          
        Average          
Date of   Number   Exercise    Remaining    Expiration  
Grant   of Shares   Price    Exercise Life    Date  
                   
Outstanding, August 31, 2013              7,000,000              
                   
First quarter of fiscal 2014              4,500,000    $     0.012    3 years    November 2017  
Second quarter of fiscal 2014              5,500,000    $     0.017    2 to 3 years    Dec 2015 to Dec 2016
Third quarter of fiscal 2014              9,583,333    $     0.012    5 years    May 2019  
Fourth quarter of fiscal 2014              4,000,000    $     0.007    2 years    August 2016  
                   
Outstanding, August 31, 2014            30,583,333              
                   
First quarter of fiscal 2015                          -       $          -                              -         
Second quarter of fiscal 2015                          -                 
                   
                   
Outstanding, May 31, 2015            30,583,333              
Stock Options
               Weighted Average 
     Number of    Option Price    Exercise Price 
     Options Granted    Per Share    Per Share 
                 
Outstanding, August 31, 2013    217,085   $0.12 - 2.00   $1.120 
Granted    6,120,000   $ 0.015 - 0.016    $0.020 
Exercised    —      —     $—   
Cancelled    (163,335)  $1.04 - 2.00   $1.380 
Outstanding, August 31, 2014    6,173,750   $0.12 - 2.00   $0.016 
Granted    —     $—     $—   
Exercised    —      —     $—   
Cancelled    —     $0.00   $—   
Outstanding, May 31, 2015    6,173,750   $0.12 - 2.00   $0.016 
Average Intrinsic Value of Options

 

   Options  Options 
   Outstanding  Exercisable
Number of options   6,173,750     6,173,750
Aggregate intrinsic value of options  $—     $ -
Weighted average remaining contractual term (years)   8.74     8.74
Weighted average exercise price  $0.016   $ 0.016
XML 57 R65.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity (Details Narrative 1) - $ / shares
 15 Months Ended
May. 31, 2018
May. 31, 2017
May. 31, 2016
May. 31, 2015
May. 31, 2014
Mar. 22, 2013
Series D Preferred Stock [Member]            
Series D Convertible Preferred Stock, authorized           60,000
Series D Convertible Preferred Stock, par value           $ 0.001
Series D Convertible Preferred Stock, liquidation value           $ 80.25
Series D Convertible Preferred Stock, issued           58,564
New Series D Convertible Preferred Stock [Member]            
Votes per share 2000 1600 1200 800 400  
XML 58 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727
Recent Accounting Prouncements
 9 Months Ended
May. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Recent Accounting Prouncements

NOTE 17 - RECENT ACCOUNTING PRONOUNCEMENTS

 

 

We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact on our financial condition or results of operations.

 

NEW ACCOUNTING STANDARD

 

In July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2012-02 “Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment” (“ASU 2012-02”). ASU 2012-02 permits entities to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. Under the amendments in ASU 2012-02, an entity is not required to calculate the fair value of an indefinite-lived intangible asset unless it determines that it is more likely than not that the fair value of the asset is less than its carrying amount. An entity also will have the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. ASU 2012-02 is effective for interim and annual indefinite-lived intangible asset impairment tests performed for fiscal years beginning on or after September 15, 2012, with early adoption permitted. The Company’s adoption of ASU 2012-02 is not expected to have an impact on its consolidated financial statements.

 
XML 59 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727
Business Segments (Tables)
 9 Months Ended
May. 31, 2015
Segment Reporting [Abstract]  
Business Segments

Below are the segment assets as of May 31, 2015.

 

As of May 31, 2015
   Personal Care  Medical Device  Med. Products  Corporate   
   Segment  Segment  Segment  Overhead  Totals
   (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited)   
ASSETS                 
Current Assets:                         
Cash and cash equivalents  $76,633   $120   $21,008   $22,724   $120,485 
Accounts receivable (net)   233,710    —     $803,299    —      1,037,009 
Inventory   —      31,271   $106,165    —      137,436 
Prepaid expenses and other current assets   —      —     $2,946    12,965    15,911 
Prepaid commissions and finders' fees   —      —      85    3,889    3,974 
                          
Total current assets   310,343    31,391    933,503    39,578    1,314,815 
                          
Property and equipment (net)   16,211    15,217    3,283    535    35,246 
Deposits and other assets   2,307    32,303    9,866    33,202    77,678 
Goodwill   564,075    1,217,704    622,610    —      2,404,389 
Patents, registrations (net of amortization)   —      19,903    —      —      19,903 
                          
Total assets  $892,936   $1,316,518   $1,569,262   $73,315   $3,852,031 

 

Below are the segment assets as of August 31, 2014.

 

As of August 31, 2014
   Personal Care  Medical Device  Med. Products  Corporate   
   Segment  Segment  Segment  Overhead  Totals
                
ASSETS                 
Current Assets:                         
Cash and cash equivalents  $9,336   $(110)  $1,000   $7,278   $17,504 
Accounts receivable (net)   213,399    —      —      —      213,399 
Inventory   —      31,271    —      —      31,271 
Prepaid expenses and other current assets   —      —      —      9,307    9,307 
Prepaid commissions   —      —      —      3,152    3,152 
                          
Total current assets   222,735    31,161    1,000    19,737    274,633 
                          
Property and equipment (net)   21,287    17,893    —      787    39,967 
Deposits and other assets   2,082    12,500    —      —      14,582 
Goodwill   564,075    1,217,704    —      —      1,781,779 
Patents, registrations (net of amortization)   —      24,497    —      —      24,497 
                          
Total assets  $810,179   $1,303,755   $1,000   $20,524   $2,135,458 

 

Below are the statements of operations for the reporting periods presented.

 

   For the Three Months Ended May 31, 2015
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $812,626   $—     $423,030   $—     $1,235,656 
                          
Cost of revenues   698,215    —      187,381    —      885,596 
                          
Gross profit   114,411    —      235,649    —      350,060 
                          
Operating expenses:                         
General and administrative   81,451    14,739    159,793    187,906    443,889 
Research and development Expense   —      —      —      —      —   
Depreciation and amortization   2,262    2,423    253    84    5,022 
                          
Total operating expenses   83,713    17,162    160,046    187,990    448,911 
                          
Loss from operations   30,698    (17,162)   75,603    (187,990)   (98,851)
                          
Other income (expense):                         
Interest and finance charges   (81,952)   (1,500)   (3,076)   (351,380)   (437,908)
Interest and finance charges - related parties   —      —      —      —      —   
Other income (expenses)   11,307    14    —      —      11,321 
                          
Total other income (expense)   (70,645)   (1,486)   (3,076)   (351,380)   (426,587)
                          
Loss from continuing operations  $(39,947)  $(18,648)  $72,527   $(539,370)  $(525,438)

 

   For the Three Months Ended May 31, 2014
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $988,385   $—     $—     $—     $988,385 
                          
Cost of revenues   776,406    12,351    —      —      788,757 
                          
Gross profit   211,979    (12,351)   —      —      199,628 
                          
Operating expenses:                         
General and administrative   166,867    4,979    —      105,104    276,950 
Depreciation and amortization   3,157    2,423    —      84    5,664 
                          
Total operating expenses   170,024    7,402    —      105,188    282,614 
                          
Loss from operations   41,955    (19,753)   —      (105,188)   (82,986)
                          
Other income (expense):                         
Interest and finance charges   (80,786)   (2,250)   —      (84,438)   (167,474)
Interest and finance charges - related parties   —      (791)   —      —      (791)
Loss on conversion of notes payable - related parties   —      —      —      (62,151)   (62,151)
Loss on disposal of assets   —      —      —      —      —   
Other income (expenses)   74,667    (217)   —      —      74,450 
                          
Total other income (expense)   (6,119)   (3,258)   —      (146,589)   (155,966)
                          
Loss from continuing operations  $35,836   $(23,011)  $—     $(251,777)  $(238,952)

 

 

Below are the statements of operations for the reporting periods presented.

 

   For the Nine Months Ended May 31, 2015
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $2,573,547   $—     $1,051,860   $—     $3,625,407 
                          
Cost of revenues   2,129,572    —      499,225    —      2,628,797 
                          
Gross profit   443,975    —      552,635    —      996,610 
                          
Operating expenses:                         
General and administrative   317,165    58,489    424,693    579,422    1,379,769 
Research and development expense   —      10,000    —      —      10,000 
Depreciation and amortization   6,289    7,269    546    252    14,356 
                          
Total operating expenses   323,454    75,758    425,239    579,674    1,404,125 
                          
Loss from operations   120,521    (75,758)   127,396    (579,674)   (407,515)
                          
Other income (expense):                         
Interest and finance charges   (244,613)   (5,500)   (3,848)   (836,052)   (1,090,013)
Interest and finance charges - related parties   —      (1,051)   —      —      (1,051)
Other income (expenses)   8,541    (3,854)   —      (204)   4,483 
                          
Total other income (expense)   (236,072)   (10,405)   (3,848)   (836,256)   (1,086,581)
                          
Loss from operations  $(115,551)  $(86,163)  $123,548   $(1,415,930)  $(1,494,096)

 

   For the Nine Months Ended May 31, 2014
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $2,696,776   $—     $—     $—     $2,696,776 
                          
Cost of revenues   2,030,450    36,350    —      —      2,066,800 
                          
Gross profit   666,326    (36,350)   —      —      629,976 
                          
Operating expenses:                         
General and administrative   506,387    28,222    —      465,301    999,910 
Depreciation and amortization   9,636    7,268    —      252    17,156 
                          
Total operating expenses   516,023    35,490    —      465,553    1,017,066 
                          
Loss from operations   150,303    (71,840)   —      (465,553)   (387,090)
                          
Other income (expense):                         
Interest and finance charges   (171,837)   (8,560)   —      (454,436)   (634,833)
Interest and finance charges - related parties   —      (2,348)   —      (15,708)   (18,056)
Loss on conversion of notes payable - related parties   —      —      —      (155,728)   (155,728)
Loss on disposal of assets   (28,748)   —      —      —      (28,748)
Other income (expenses)   72,775    (713)   —      —      72,062 
                          
Total other income (expense)   (127,810)   (11,621)   —      (625,872)   (765,303)
                          
Loss from operations  $22,493   $(83,461)  $—     $(1,091,425)  $(1,152,393)

 

 
XML 60 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727
Employment Agreements
 9 Months Ended
May. 31, 2015
Compensation Related Costs [Abstract]  
Employment Agreements

NOTE 19 - EMPLOYMENT AGREEMENTS

 

On March 22, 2013, Wayne Erwin, the Company’s Chief Executive Officer, signed a three year employment agreement. The agreement provides for an annual salary of $120,000 along with a monthly auto allowance and health insurance allowance totaling $1,250. The annual salary was increased to $150,000 per year beginning March 2015. Annual increases are to be approved by the Company’s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $97,500 and $101,250 was expensed as salary, respectively.

 

On October 1, 2013, Michael Kramarz, the Company’s Chief Financial Officer, signed a three year employment agreement. The agreement provides for an annual salary of $80,000 along with a monthly auto allowance and health insurance allowance totaling $500. The annual salary was increased to $120,000 beginning on March 1, 2015.Annual increases are to be approved by the Company’s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $76,333 and 62,669 was expensed as salary, respectively.

 

On August 1, 2013, Vickie Hart, the President of Amian Angels Inc., signed a three year employment agreement. The agreement provides for an annual salary of $52,000 along with a monthly health insurance allowance totaling $400. The annual salary was increased to $85,000 beginning on March 1, 2015. Annual increases are to be approved by the Company’s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $49,900 and $46,214 was expensed as salary, respectively.

 

On July 16, 2014, Harold Halman, the President of our Medical Products Segment, signed a three year employment agreement. The agreement provides for an annual salary of $85,000, along with a monthly auto allowance and health insurance allowance totaling $1,300 plus bonus allowances. Annual increases are to be approved by the Company’s Board of Directors or Compensation Committee. During the nine months ended May 31, 2015 and 2014, $63,750 and $0 was expensed as salary, respectively.
XML 61 R68.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity - Warrants (Details Narrative) - $ / shares
 9 Months Ended 12 Months Ended
May. 31, 2015
May. 31, 2014
Aug. 31, 2014
Aug. 31, 2013
Outstanding Warrants 21,000,000 17,000,000 30,583,333 7,000,000
Warrants Exercised (9,583,333)      
Warrants issued     23,583,333  
Weighted Average Exercise Price $ 0.012 $ 0.014 $ 0.011 $ 0.012
Minimum [Member]        
Votality   124.00%    
Risk free rate 0.00% 0.25%    
Expected dividends        
Exepected Term   2 years    
Maximum [Member]        
Votality   702.00%    
Risk free rate 0.00%      
Exepected Term   5 years    
XML 62 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 63 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727
Summary of Significant Accounting Policies
 9 Months Ended
May. 31, 2015
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

BASIS OF PRESENTATION

 

In the opinion of management, the accompanying balance sheets and related interim statements of income, cash flows, and stockholders' equity include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management's estimates and assumptions. Interim results are not necessarily indicative of results for a full year.

 

PRINCIPLES OF CONSOLIDATION

 

The unaudited consolidated financial statements for the three and nine months ended May 31, 2015 and 2014 include the accounts of Oncologix Tech, Inc. and its wholly owned subsidiaries, Dotolo Research Corporation (“Dotolo”), Amian Angels, Inc. (“Amian”), Advanced Medical Products & Technologies Inc. (“AMPT”), Esteemcare Inc. and Affordable Medical Equipment Solutions Inc. (collectively “Esteemcare”) Dotolo and Amian are Louisiana Corporations. AMPT is a Nevada corporation. Esteem & Affordable are South Carolina corporations. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

USE OF ESTIMATES

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reportable amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

SEGMENT INFORMATION

 

ASC 280-10 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the Company’s Chief Executive Officer and Chief Financial Officer in deciding how to allocate resources and in assessing performance. The Company currently has three business segments; medical device manufacturing (Dotolo), personal care services (Amian) and medical products and technologies (AMPT and Esteem & Affordable.

 

REVENUE RECOGNITION

 

Revenue is recognized by the Company in accordance with Accounting Standards Codification Topic (“ASC”) 605. Accordingly, revenue is recognized when all the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the seller’s price to the buyer is fixed and determinable; and collectability is reasonably assured. Currently, the primary revenue for the Company is derived from its sales in its Personal Care Services and Medical Products and Technologies Segments’.

  

Amian is reimbursed for each approved “Unit of Service” provided, as determined by the Health Care Financing Administration (HCFA), the Department of Health & Hospitals and the Department of Social Services and based upon a detailed Case Management, Plan of Care for each beneficiary. A unit of service for PCA services will be one-half hour. At least fifteen (15) minutes of service must be provided to the individual in order for Amian Angels to bill for a unit of service. A maximum of 1,825 hours (3,650 half-hour units) per beneficiary, per year can be billed under the Medicaid waiver program. Our primary payer sources is the State of Louisiana, the Department of Veterans Administration and Private Pay individuals who reimburse us for the services we provide. We currently experience a two percent claims rejection rate. With the acquisition of Amian, Amian Angels now has private pay clients as well as Veterans Administration Social Services clients.

 

Esteemcare recognizes revenue related to product sales upon delivery to customers provided that we have received and verified any written documentation required to bill Medicare, other government agencies, third-party payers, and patients. For product shipments for which we have not yet received the required written documentation, revenue recognition is delayed until the period in which those documents are collected and verified. We record revenue at the amounts expected to be collected from government agencies, other third-party payers, and from patients directly. Government and insurance payers’ generally require patient compliance with product usage. Accordingly, most pay for the product purchases over a multi-month plan, generally 10 to 13 months. We record these revenues as received since the transfer of ownership is not guaranteed until the full purchase price is paid to us. We record, if necessary, contractual adjustments equal to the difference between the reimbursement amounts defined in the fee schedule and the revenue recorded per the billing system. These adjustments are recorded as a reduction of both gross revenues and accounts receivable. We analyze various factors in determining revenue recognition, including a review of specific transactions, current Medicare regulations and reimbursement rates, historical experience and the credit-worthiness of patients. Medicare reimburses at 80% of the government-determined prices for reimbursable supplies, and we bill the remaining balance to either third-party payers or directly to patients.

 

CASH AND CASH EQUIVALENTS

 

The Company considers all highly liquid instruments, with an initial maturity of three (3) months or less to be cash equivalents.

 

ACCOUNTS RECEIVABLE

 

The Company’s receivables in its medical device segment are subject to credit risk, and the Company typically does not require collateral on its accounts receivable. Receivables are generally due within 30 days. The Company maintains an allowance for uncollectable receivables that reduces the receivables to amounts that are expected to be collected. .

 

The lead time for account receivables in our Personal Care service divisions ranges from 14 to 90 days. The majority of the Company’s receivables, approximately 90%, are collected within 14 days. We bill the State of Louisiana on a weekly basis and are reimbursed two weeks later via electronic funds transfer. We are able to resubmit any rejected claims an additional two times to Molina Healthcare, the EDI payment provider for payments within the next twelve months. Currently we maintain an allowance for uncollectible receivables at a rejection rate of 2% of outstanding receivables. We analyze our claim rejection rate on a quarterly basis and make quality improvements to reduce the number of rejected claims. Private pay customers are billed semi-monthly. Generally collections occur within 30 days. Veterans Administration (VA) customers are billed monthly. Generally collections occur within 45 to 60 days. Due to the recent governmental shutdown, the current lead time for payments is approximately 90 days. Upon final rejection of any resubmitted claims, the claims are resubmitted and after twelve months the receivables are written off to bad debt expense.

 

Our medical products and technologies accounts receivable are generally due from Medicare, Medicaid, private insurance companies, and our private patients. Accounts receivable are reported net of allowances for contractual adjustments and uncollectible accounts. The collection process is time consuming, complex and typically involves the submission of claims to multiple layers of payers whose payment of claims may be contingent upon the payment of another payer. As a result, our collection efforts may be active for up to 18 to 24 months from the initial billing date. In accordance with regulatory requirements, we make reasonable and appropriate efforts to collect our accounts receivable, including deductible and co-payment amounts, in a manner consistent for all classes of payers.

 

 

INVENTORY

 

Inventories are stated at cost and are held on a first-in, first-out basis. Our inventory in our medical device segment consists primarily of miscellaneous hardware parts. Our inventory in our medical products and technologies segment consists of masks, CPAP machines, BiPAP machines and other necessary breathing equipment and supplies.

 

PROPERTY AND EQUIPMENT

 

Property and equipment is recorded at cost. Depreciation is provided for on the straight-line method over the estimated useful lives of the related assets as follows:

 

Furniture and fixtures 5 to 10 years
Computer equipment 5 years
Equipment 5 to 10 years
Software 3 to 5 years

 

The cost of maintenance and repairs is charged to expense in the period incurred. Expenditures that increase the useful lives of assets are capitalized and depreciated over the remaining useful lives of the assets. When items are retired or disposed of, the cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.

 

LONG-LIVED ASSETS

     ASC 360 – Property, Plant and Equipment addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment or whether the remaining balance of property and equipment, or other long-lived assets, should be evaluated for possible impairment. Instances that may lead to an impairment include: (i) a significant decrease in the market price of a long-lived asset group; (ii) a significant adverse change in the extent or manner in which a long-lived asset or asset group is being used or in its physical condition; (iii) a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset or asset group, including an adverse action or assessment by a regulatory agency; (iv) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset or asset group; (v) a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset or asset group; or (vi) a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

An estimate of the related undiscounted cash flows, excluding interest, over the remaining life of the property and equipment and long-lived assets is used in assessing recoverability. Impairment loss is measured by the amount which the carrying amount of the asset(s) exceeds the fair value of the asset(s). The Company primarily employs two methodologies for determining the fair value of a long-lived asset: (i) the amount at which the asset could be bought or sold in a current transaction between willing parties or (ii) the present value of estimated expected future cash flows grouped at the lowest level for which there are identifiable independent cash flows.

 

GOODWILL AND OTHER INTANGIBLE ASSETS

 

The Company adopted Accounting Standards Update 2011-08 “Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment (“ASU 2011-08”) in the fourth quarter of fiscal 2014 due to its recent acquisition of Dotolo Research Corporation and Angels of Mercy, Inc. ASU 2011-08 permits an entity to first assess qualitative factors to determine whether it is more likely that not that the fair value of a reporting unit is less than its carrying amount. Goodwill represents the excess of the cost of a business combination over the fair value of the net assets acquired and these costs are subject to annual impairment tests.

 We accounted for the acquisition of Dotolo, Amian and Esteemcare using the acquisition method of accounting under ASC 805 and ASC 810-10-65. The purchase price was allocated first to identifiable current then fixed assets as well as liabilities assumed. We then earmarked identifiable intangibles, with the remainder to goodwill. We identified patents as our identifiable asset for Dotolo Research Corporation. Amounts allocated to Goodwill for the acquisition of Dotolo are based on expanding our product into the medical market and the potential upside of the sale with a FDA medical device product with a reimbursement code. Dotolo is one of four companies worldwide with an FDA approved, Class II medical device product. Amounts allocated to goodwill for Amian and Esteemcare are based on increased clients and future revenues.

The Company evaluates the recoverability of its indefinite lived intangible assets, which consist of Dotolo, Amian and Esteemcare, based on estimates of future royalty payments that are avoided through its ownership of the intangibles and patents, discounted to their present value. In determining the estimated fair value of the intangibles and patents, management considers current and projected future levels of revenue based on its plans for Dotolo, business trends, prospects and market and economic conditions. See Note 4 – Acquisitions for further information on the acquisition of Dotolo.

We follow the two step process in ASC 350-20-35 for impairment testing. In the first step we compare the fair value of the reporting unit as a whole to its carrying value, including goodwill. For both reporting units, we have determined that the reporting units’ fair value exceeds its carrying value. We also compare the carrying value of goodwill by itself for both reporting units.

The following explains the results of our impairment testing. We have allocated $564,075 of goodwill to the Amian Angels, Inc. reporting unit. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 39%. We have allocated $1,217,704 of goodwill to the reporting unit Dotolo Research Corporation. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 18%. We have allocated $622,610 of goodwill the Esteemcare reporting unit. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 47%. In calculating the valuation, we used a discounted cash flow method based on the future 5 years cash flows of each reporting unit. We used a discount rate of 8% which is currently higher that the current long term interest rate. An increase in the overall national interest rate could have a negative impact on our valuation. An additional risk is the possibility of cash flow projections falling short of our 5 year estimate amount.

 

 

ADVERTISING COSTS

 

Advertising costs included with selling, general and administrative expenses in the accompanying consolidated statements of operations were minimal for the three and nine months ended May 31, 2015 and 2014. Such costs are expensed as incurred.

 

INCOME TAXES

 

The Company adopted the provisions of FASB ASC 740 - Income Taxes provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Income taxes are determined using the asset and liability method. This method gives consideration to the future tax consequences associated with temporary differences between the carrying amounts of assets and liabilities for financial statement purposes and the amounts used for income tax purposes.

 

FAIR VALUE OF FINANCIAL INSTRUMENTS

 

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable, accrued expenses, and notes payable approximate fair value.

  

 

STOCK-BASED COMPENSATION

 

The Company has a stock-based compensation plan, which is described more fully in Note 12. The Company accounts for stock-based compensation in accordance with ASC 718. Under the fair value recognition provisions of this statement, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation model. The fair value of all awards is amortized on a straight-line basis over the vesting periods. The expected term of awards granted represent the period of time they are expected to be outstanding. The Company determines the expected term based on historical experience with similar awards, giving consideration to the contractual terms and vesting schedules. The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of its common stock. The risk-free interest rate is based on the U.S. treasury security rate estimated for the expected life of the options at the date of grant. If actual results differ significantly from estimates, stock-based compensation could be impacted.

 

INVENTORY FINANCING AGREEMENTS

 

Our inventory finance agreements consist of qualified for-sale equipment purchases. Qualifying inventory purchases are grouped into a 12 month finance agreements allowing the company to spread the payments for this inventory over a twelve month period. All inventory finance agreements are interest free and consist of only minor fees for setup.

 

CONVERTIBLE DEBT

 

Interest on convertible debt is calculated using the simple interest method. The company recognizes a beneficial conversion feature to the extent the conversion price is less than the closing stock price on the issuance of the convertible notes. The Company also follows ASC 470-50 and ASC 470-20 regarding changes in the terms of the convertible notes and the induced conversion of its convertible debt.

 

RECLASSIFICATIONS

 

Certain prior year amounts have been reclassified to conform to the current year presentation.

 

STOCK INCENTIVE PLANS

 

Share based payment compensation costs for equity-based awards are measured on the grant date based on the fair value of the award on that date and is recognized over the required service period. The fair-value of stock option awards is estimated using the Black-Scholes model. Fair value of restricted stock awards is based upon the quoted market price of the common stock on the date of grant.

  

NET LOSS PER COMMON SHARE

 

Basic earnings (loss) per share is calculated under the provisions of ASC 260 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is calculated by dividing income (loss) available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is calculated based on the weighted average number of common shares outstanding during the period plus the dilutive effect of common stock purchase warrants and stock options using the treasury stock method and the dilutive effects of convertible notes payable and convertible preferred stock using the if-converted method. On Basic and diluted earnings per share for the three and nine months ended May 31, 2015 and 2014 are as follows:

 

   For the Three Months Ended  For the Nine Months Ended
   May 31,  May 31,  May 31,  May 31,
   2015  2014  2015  2014
             
             
Net gain (loss) attributable to common shareholders                    
Continuing operations  $(525,438)  $(238,952)  $(1,494,096)  $(1,152,393)
Discontinued operations   —      —      —      95,528 
                     
                     
   $(525,438)  $(238,952)  $(1,494,096)  $(1,056,865)
                     
Weighted average shares outstanding   242,589,170    112,247,396    187,353,653    93,925,094 
                     
Loss per common shares, basis and diluted                    
Continuing operations  $(0.00)  $(0.00)  $(0.01)  $(0.01)
Discontinued operations   —      —      —      0.00 
                     
                     
   $(0.00)  $(0.00)  $(0.01)  $(0.01)

 

 

 

Due to the net losses during the three and nine months ended May 31, 2015 and 2014, basic and diluted loss per share was the same, as the effect of potentially dilutive securities would have been anti-dilutive. Shares attributable to convertible notes, stock options, preferred stock and warrants not included the diluted loss per share calculation. Below lists all dilutive securities as of May 31, 2015 and 2014:

  

   As of
   May 31,  May 31,
   2015  2014
     Underlying      Underlying  
Description    Common Shares      Common Shares  
Convertible preferred stock   78,564,000    22,500,000 
Convertible notes payable   123,452,480    6,433,965 
Options   6,173,750    6,186,250 
Warrants   30,583,333    17,000,000 
           
Total potentially dilutive securities   238,773,563    52,120,215 

 

 

 

SEGMENT INFORMATION

 

ASC 280-10 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the Company’s Chief Executive Officer and Chief Financial Officer in deciding how to allocate resources and in assessing performance. The Company currently has three business segments; medical device manufacturing, personal care services and medical products and technologies.

 
RECENT ACCOUNTING PRONOUNCEMENTS

 

We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact.

 

New Accounting Standard

 

In July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2012-02 “Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment” (“ASU 2012-02”). ASU 2012-02 permits entities to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. Under the amendments in ASU 2012-02, an entity is not required to calculate the fair value of an indefinite-lived intangible asset unless it determines that it is more likely than not that the fair value of the asset is less than its carrying amount. An entity also will have the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. ASU 2012-02 is effective for interim and annual indefinite-lived intangible asset impairment tests performed for fiscal years beginning on or after September 15, 2012, with early adoption permitted. The Company’s adoption of ASU 2012-02 is not expected to have an impact on its consolidated financial statements.
XML 64 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727
Consolidated Balance Sheets (Parenthetical) - USD ($)
May. 31, 2015
Aug. 31, 2014
Allowance for doubtful accounts receivable $ 71,000 $ 9,000
Property and equipment, accumulated depreciation 38,026 28,264
Patents and registrations,net of, amortization $ 102,576 $ 97,983
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 750,000,000 750,000,000
Common stock, shares issued 276,746,130 134,600,152
Common stock, shares outstanding 276,746,130 134,600,152
Common stock suscribed 0 1,058,201
Convertible Notes Payable [Member]    
Notes payable, discount $ 405,429 $ 99,491
Notes Payable [Member]    
Notes payable, discount $ 2,091 $ 18,596
Series A Preferred Stock [Member]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 129,062 129,062
Preferred stock, shares outstanding 129,062 129,062
Series D Preferred Stock [Member]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 78,564 78,564
Preferred stock, shares outstanding 78,564 78,564
XML 65 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders' Equity
 9 Months Ended
May. 31, 2015
Equity [Abstract]  
Stockholders' Equity

NOTE 12 — STOCKHOLDERS EQUITY

PREFERRED STOCK:

 

Series A Convertible Preferred Stock.

 

The Company is authorized to issue up to 10,000,000 shares of preferred stock, in one or more series, and to determine the price, rights, preferences and privileges of the shares of each such series without any further vote or action by the stockholders. The rights of the holders of common stock will be subject to, and may be adversely affected by, the rights of the holders of any shares of preferred stock that may be issued in the future.  

 

In January 2003, our Board of Directors authorized up to 4,500,000 shares of Series A Convertible Preferred Stock.  Each share of Series A Convertible Preferred stock has a par value of $0.001 and is convertible into one-half share of common stock in upon a cash payment by the holder to the Company of $0.40 per common share.  The Series A Convertible Preferred Stock is entitled to receive, in preference to the common stock, of noncumulative dividends, if declared by the Board of Directors, and a claim on the Company's assets upon any liquidation of the Company senior to the common stock.  These preferred shares are not entitled to voting rights. There are presently outstanding 129,062 shares of Series A Preferred Stock.

 

On March 30, 2003, the Company completed the private placement of Units pursuant to the terms of a Unit Purchase Agreement (the “Units”) with accredited investors. Each Unit consists of the following underlying securities: (i) three shares of the Company’s common stock; (ii) one share of Series A Convertible Preferred Stock, par value $.001 per share; and (iii) one three-year warrant to purchase one share of common stock at a per share price of $0.30. The warrants expired on March 31, 2006. Each share of Series A Convertible Preferred Stock is convertible into one half share of the Company’s common stock in exchange for $0.40 per common share ($.20 for each Series A Convertible Preferred share converted). The securities underlying the Units are not to be separately tradable or transferable apart from the Units until such time as determined by the Company’s Board of Directors. A total of 4,032,743 Units were issued. As of August 31, 2014 and August 31, 2013, there were 129,062 and 129,062 Units outstanding that had not been separated, respectively. These units are presented as their underlying securities on our balance sheet and consist of 64,531 shares of Series A Preferred Stock and 96,797 shares of common stock which is included in the issued and outstanding shares.

   

Below is a table detailing the outstanding Series A Convertible Preferred Stock shares outstanding during the last two fiscal years:

 

 

      Preferred    Number of          Weighted Avg. 
      Shares    Common Shares    Proceeds if    Per Common Sh. 
      Outstanding    Convertible    Converted    Exercise Price 
 Outstanding, August 31, 2013    129,062    64,531   $25,812   $0.40 
                       
 Expired/Retired    —      —      —     $—   
 Converted    —      —      —     $0.40 
 Issued    —      —      —     $—   
 Outstanding, August 31, 2014    129,062    64,531   $25,812   $0.40 
                       
 Expired/Retired    —      —      —     $0.40 
 Converted    —      —      —     $—   
 Issued    —      —      —     $—   
 Outstanding, May 31, 2015    129,062    64,531   $25,812   $0.40 

 

Series D Convertible Preferred Stock

 

In March 2013, our Board of Directors authorized up to 60,000 shares of Series D Convertible Preferred Stock. Each share of Series D Convertible stock has a par value of $0.001 and is convertible into 1,000 shares of common stock beginning after March 1, 2014. Each share of Series D Convertible Preferred Stock has a stated liquidation value of $80.25. Each shares of Series D Convertible Preferred Stock shall have voting rights as stated below:

 

March 1, 2013 to May 31, 2014, 400 votes per share;

March 1, 2014 to May 31, 2015, 800 votes per share;

March 1, 2015 to May 31, 2016, 1,200 votes per share;

March 1, 2016 to May 31, 2017, 1,600 votes per share;

March 1, 2017 and after, 2,000 votes per share;

 

On March 22, 2013, the Company issued 58,564 shares of Series D Convertible Preferred Stock to acquire 100% of the outstanding common stock of Dotolo. On March 22, 2013 the issued shares had a fair market value of $585,640 based on the fair market value of the underlying common stock shares.

 

On January 3, 2014, as payment for $150,000 of banking fees associated with our $4 million line of credit, we issued 20,000 shares of Series D Convertible Preferred Stock.

 

  

Below is a table detailing the outstanding Series D Convertible Preferred Stock shares outstanding during the last two fiscal years:

 

      Preferred    Number of          Weighted Avg. 
      Shares    Common Shares    Proceeds if    Per Common Sh. 
      Outstanding    Convertible    Converted    Exercise Price 
 Outstanding, August 31, 2013    58,564    58,564,000   $—     $80.25 
                       
 Expired/Retired    —      —      —     $—   
 Converted    —      —      —     $—   
 Issued    20,000    20,000,000    —     $80.25 
 Outstanding, August 31, 2014    78,564    78,564,000   $—     $—   
                       
 Expired/Retired    —      —      —     $—   
 Converted    —      —      —     $—   
 Issued    —      —      —     $—   
 Outstanding, May 31, 2015    78,564    78,564,000   $—     $80.25 

 

SUBSCRIBED COMMON STOCK:

 

Below is a table detailing the Common Stock Subscribed during the last two fiscal years:

 

For the period Ended May 31, 2015
              Shares   Amount  
Shares issuable upon conversion of convertible notes payable                        -       $                    -     
                     
Total subscribed stock                          -       $                    -     
                     
For the period Ended August 31, 2014
              Shares   Amount  
Shares issuable upon conversion of convertible notes payable            1,058,201    $               5,000  
                     
Total subscribed stock              1,058,201    $               5,000  

 

COMMON STOCK:

 

On March 7, 2014, the Company increased its authorized shares of common stock to 750,000,000. The increase was approved by a majority of the Company’s shareholders on January 27, 2014. As of May 31, 2015, the Company has 276,746,130 shares outstanding. Please see Part II, Item II – Sale of Unregistered Securities for information on recent sales of unregistered securities.

 

NON-CONTROLLING INTEREST

 

On February 27, 2009, in connection with the Technology Agreement we entered into with Institut für Umwelttechnologien GmbH, a German Company (“IUT”) whereunder the parties have agreed that the Company’s marketing rights have been transferred to its subsidiary, Oncologix Corporation and have issued IUTM 10% of the equity ownership of that subsidiary. As of February 27, 2009, the value of the non-controlling interest was $212. It was determined at August 31, 2010 the value of the investment in IUTM was impaired. Accordingly, we recorded an impairment loss in the amount of $3,186 for the year ended August 31, 2010. As of May 31, 2015, as a result of the disposition of Oncologix Corporation, we do not have to recognize a non-controlling interest.

 

 

 

WARRANTS:

 

The following table summarizes warrant activity in fiscal 2015 and 2014:

 

        Weighted Avg.
    Number Exercise Price
Outstanding, August 31, 2013              7,000,000                       0.012
Expired/Retired                          -                               -    
Exercised                          -                               -    
Issued            23,583,333                       0.011
Outstanding, August 31, 2014            30,583,333                            -    
         
Expired/Retired                          -                               -    
Exercised            (9,583,333)                       0.009
Issued                          -                               -    
Outstanding, May 31, 2015            21,000,000                       0.012

 

The fair value of warrants granted is estimated using the Black-Scholes option pricing model. This model utilizes the following factors to calculate the fair value of options granted: (i) annual dividend yield, (ii) weighted-average expected life, (iii) risk-free interest rate and (iv) expected volatility. The warrants were expensed and accounted for under ASC 718.

 

The fair value for these warrants was estimated as of the date of grant using a Black-Scholes option-pricing model with the following assumptions:

 

        For the Nine Months Ended May 31,
        2015   2014
Volatility                                     -       124% - 702% 
Risk free rate     0.00%   0.25%
Expected dividends      None     None 
Expected term (in years)                                   -    2 to 5 years 

 

 

Details relative to the 21,000,000 immediately exercisable outstanding warrants at May 31, 2015 are as follows:

 

        Weighted          
        Average          
Date of   Number   Exercise    Remaining    Expiration  
Grant   of Shares   Price    Exercise Life    Date  
                   
Outstanding, August 31, 2013              7,000,000              
                   
First quarter of fiscal 2014              4,500,000    $     0.012    3 years    November 2017  
Second quarter of fiscal 2014              5,500,000    $     0.017    2 to 3 years    Dec 2015 to Dec 2016
Third quarter of fiscal 2014              9,583,333    $     0.012    5 years    May 2019  
Fourth quarter of fiscal 2014              4,000,000    $     0.007    2 years    August 2016  
                   
Outstanding, August 31, 2014            30,583,333              
                   
First quarter of fiscal 2015                          -       $         -                              -         
Second quarter of fiscal 2015                          -                 
Third quarter of fiscal 2015            (9,583,333)    $     0.009          
                   
                   
Outstanding, May 31, 2015            21,000,000              

 

On August 1, 2013, the company issued 1,000,000 four-year cashless warrants as additional consideration for the acquisition of Amian Angels. These warrants expire four years after the date of issuance and have an exercise price of $.015.

 

On August 5, 2013, the company issued 6,000,000 three-year cashless warrants, to a related party, as finder’s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.012.

 

On September 11, 2013, the company issued 1,500,000 three-year cashless warrants, to a related party, as finder’s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.015.

 

On November 8, 2013, the company issued 3,000,000 three-year cashless warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.01.

 

On December 3, 2014, the company issued 1,000,000 three-year cashless warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire three years after the date of issuance and have an exercise price of $.025.

 

On December 20, 2014, the company issued 3,000,000 two-year cashless warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire two years after the date of issuance and have an exercise price of $.016.

 

On February 7, 2014, the company issued 1,000,000 two-year cashless warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire two years after the date of issuance and have an exercise price of $.015.

 

On May 21, 2014, the company issued 9,583,333 five-year cashless warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire five years after the date of issuance and have an exercise price of $.009.

  

On August 15, 2014, the company issued 4,000,000 two-year warrants, to an unrelated party, as finder’s fees related to a working capital investment. These warrants expire two years after the date of issuance and have an exercise price of $.0065.

During the third quarter of fiscal 2015, 9,583,333 warrants were exercised in a cashless transaction. 33,382,960 shares of Common stock were issued for the warrants’ exercise.

 

The remaining contractual life of warrants outstanding as of May 31, 2015 was 1.17 years. Warrants for the purchase of 21,000,000 and 26,586,333 shares were immediately exercisable on May 31, 2015 and 2014, respectively with a weighted-average price of $0.012 and $0.011 per share, respectively.

 

STOCK OPTIONS:

 

ASC 718 requires the estimation of forfeitures when recognizing compensation expense and that this estimate of forfeitures be adjusted over the requisite service period should actual forfeitures differ from such estimates. Changes in estimated forfeitures are recognized through a cumulative adjustment, which is recognized in the period of change and which impacts the amount of unamortized compensation expense to be recognized in future periods.

 

ASC 718 requires that modification of the terms or conditions of an equity award is to be treated as an exchange of the original award for a new award. This event is accounted for as if the entity repurchases the original instrument by issuing a new instrument of equal or greater value, incurring additional compensation cost for any incremental value.

 

2000 Stock Incentive Plan

 

The Company is authorized to issue up to 7,500,000 shares of common stock under its 2000 Stock Incentive Plan. Shares may be issued as incentive stock options, non-statutory stock options, deferred shares or restricted shares. Options are granted at the fair market value of the common stock on the date of the grant and have terms of up to ten years. The 2000 Stock Incentive Plan also provides for an annual grant of options to members of our Board of Directors. For fiscal years ended August 31, 2008 through 2012, our Board of Directors elected to waive the grant of these annual options.

 

On December 13, 2013, the Board of directors authorized the granting of 6,100,000 options to its three officers; 2,400,000 options to Wayne Erwin, our CEO; 2,100,000 options to Michael Kramarz, our CFO; and 1,600,000 options to Vickie Hart, President of Amian Angels. These options vest immediately and have an exercise price $.015, the closing stock price on December 13, 2013.

 

On December 20, 2014, the Company issued 20,000 options as part of its annual grant program to its two directors. These options vest in 1 year and have an exercise price of $.016, the closing stock price on December 20, 2013.

 

We have 473,253 shares of common stock available for future issuance under our 2000 Stock Incentive Plan as of May 31, 2015. This plan has been approved by our shareholders.

 

During the three and nine months years ended May 31, 2015 and 2014, we granted 6,120,000 and nil options from the stock incentive plan described above, respectively. During the three and nine months ended May 31, 2015 and 2014, nil and nil options were exercised, respectively. During the three months ended May 31, 2015 and 2014, nil and nil options expired, respectively. During the nine months ended May 31, 2015 and 2014, nil and 150,835 options expired, respectively. During the three and nine months ended May 31, 2015 and 2014, $0 and $91,163 was expensed as stock based compensation, respectively.

  

 

                Weighted Average 
      Number of    Option Price    Exercise Price 
      Options Granted    Per Share    Per Share 
 Outstanding, August 31, 2013    217,085    $0.12 - $2.00   $1.120 
 Granted    6,120,000     $0.015 - $0.016    $0.020 
 Exercised    —      —     $—   
 Cancelled    (163,335)   $1.04 - $2.00   $1.380 
 Outstanding, August 31, 2014    6,173,750    $0.12 - $2.00   $0.016 
 Granted    —     $—     $—   
 Exercised    —      —     $—   
 Cancelled    —     $0.00   $—   
 Outstanding, May 31, 2015    6,173,750    $0.12 - $2.00   $0.016 

 

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between our closing stock price on the last trading day of the third quarter of fiscal 2015 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on May 31, 2015.

 

Expected volatility is based primarily on historical volatility. Historical volatility is computed using weekly average pricing observations for an applicable historic period. We believe this method produces an estimate that is representative of our expectations of the future volatility over the expected term of our options. We currently have no reason to believe future volatility over the expected life of these options is likely to differ materially from historical volatility. The weighted-average expected life is based upon share option exercises, pre and post vesting terminations and share option term expirations. The risk-free interest rate is based on the U.S. treasury security rate estimated for the expected life of the options at the date of grant.

 

The remaining contractual life of options outstanding as of May 31, 2015 was 8.49 years. Options for the purchase of 6,173,750 exercisable on May 31, 2015 with a weighted-average price of $0.016 and $0.016 per share, respectively.

 

          Options   Options
          Outstanding   Exercisable
Number of options                      6,173,750                  6,173,750
Aggregate intrinsic value of options    $                           -    $                           -
Weighted average remaining contractual term (years)                         8.74                           8.74
Weighted average exercise price      $                   0.016   $                   0.016

 

2013 Omnibus Incentive Plan

 

The Company is authorized to issue up to 10,000,000 shares of common stock under its 2013 Omnibus Incentive Plan to employees, officers, directors and consultants. The issuance adoption of this plan has been approved by the Company’s Board of Directors on May 20, 2013 and was approved by our shareholders on January 27, 2014. Any options are granted at the fair market value of the common stock on the date of the grant and have terms of up to ten years. Under the 2013 Omnibus Incentive Plan the price of the granted common stock options are equal to the fair market value of such shares on the date of grant.

 

On September 11, 2013, we issued 1,000,000 S-8 shares to a consultant in payment for investor relations work for the Company. On January 3, 2014, we issued 1,000,000 S-8 shares to a consultant in payment for services to be provided for the Company. On November 15, 2014 we issued 1,000,000 S-8 shares to a consultant in payment for investor relations work for the Company. We have 7,000,000 shares of common stock available for future issuance under our 2013 Omnibus Incentive Plan as of May 31, 2015.

 

 

   Number of Securities     Number of Securities
   To Be Issued Upon  Weighted Average  Remaining Available
   Exercise of Outstanding  Exercise Price of  For Future
   Options  Outstanding Options  Issuance Under Plans
                
Equity compensation plans               
approved by stockholders   —     $0.00    7,000,000 
                
Equity compensation plans               
not approved by stockholders   —     $0.00    —   
                
TOTAL   —     $0.00    7,000,000 

 
XML 66 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727
Document and Entity Information - shares
 9 Months Ended
May. 31, 2015
Jul. 03, 2015
Underlying Series A preferred stock    
Entity Registrant Name Oncologix Tech Inc.  
Entity Central Index Key 0000799694  
Document Type 10-Q  
Document Period End Date May 31, 2015  
Amendment Flag true  
Current Fiscal Year End Date --08-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   340,126,946
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2015  
Amendment

The reclassification of a $100,000 convertible note from accounts payable and accrued expenses.

  
XML 67 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727
Related Party Transactions
 9 Months Ended
May. 31, 2015
Related Party Transactions [Abstract]  
Related Party Transactions

NOTE 13 - RELATED PARTY TRANSACTIONS AND CONTINGENCIES:

 

FINANCING WITH RELATED PARTIES:

 

During the three and six months ended May 31, 2015 and 2014, the Company entered into financing agreements with related parties of the Company. Please see Note 11 – Notes Payable for further descriptions of these transactions.
XML 68 R80.htm IDEA: XBRL DOCUMENT v3.2.0.727
Subsequent Events (Details) - 9 months ended May. 31, 2015 - USD ($)
Total
Consultant[Member]  
Subsequent Event [Line Items]  
Share issued 2,500,000
Promissory Note[Member]  
Subsequent Event [Line Items]  
Loan obtained $ 50,000
Interest rate 8.00%
Investor[Member]  
Subsequent Event [Line Items]  
Loan obtained $ 45,000
Interest rate 8.00%
XML 69 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727
Statements of Operations - USD ($)
 3 Months Ended 9 Months Ended
May. 31, 2015
May. 31, 2014
May. 31, 2015
May. 31, 2014
Income Statement [Abstract]        
Revenues $ 1,235,656 $ 988,385 $ 3,625,407 $ 2,696,776
Cost of revenues 885,596 788,757 2,628,797 2,066,800
Gross profit 350,060 199,628 996,610 629,976
Operating expenses:        
General and administrative $ 443,889 276,950 1,379,769 999,910
Research and development expense     10,000  
Depreciation and amortization $ 5,022 5,664 14,356 17,156
Total operating expenses 448,911 282,614 1,404,125 1,017,066
Loss from operations (98,851) (82,986) $ (407,515) $ (387,090)
Other income (expense):        
Acquisition costs        
Interest and finance charges $ (437,908) (167,474) $ (1,090,013) $ (634,833)
Interest and finance charges - related parties   (791) $ (1,051) (18,056)
Loss on conversion of notes payable - related parties   $ (62,151)   (155,728)
Loss on disposal of assets       (28,748)
Other income (expenses) $ 11,321 $ 74,450 $ 4,483 72,062
Total other income (expense) (426,587) (155,966) (1,086,581) (765,303)
Loss from continuing operations $ (525,438) $ (238,952) $ (1,494,096) (1,152,393)
Discontinued operations        
Operating loss from discontinued operations       (36)
Gain on disposal of discontinued operations       95,564
Gain from discontinued operations       $ 95,528
Less loss attributable to noncontrolling interest        
Net gain from discontinued operations       $ 95,528
Net loss before income taxes $ (525,438) $ (238,952) $ (1,494,096) $ (1,152,393)
Income taxes        
Net loss attributable to common shareholders $ (525,438) $ (238,952) $ (1,494,096) $ (1,056,865)
Gain (loss) per common share, basic and diluted:        
Continuing operations $ 0.00 $ 0.00 $ (0.01) $ (0.01)
Discontinued operations       0.00
Common share, basic and diluted $ 0.00 $ 0.00 $ (0.01) $ (0.01)
Weighted average number of shares outstanding - basic and diluted 242,589,170 112,247,396 187,353,653 93,925,094
XML 70 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727
Property and Equipment
 9 Months Ended
May. 31, 2015
Property, Plant and Equipment [Abstract]  
Property and Equipment

NOTE 7 - PROPERTY AND EQUIPMENT

 

Property and equipment is composed of the following at May 31, 2015 and August 31, 2014

 

   May 31,  August 31,
   2015  2014
Furniture  $14,118   $12,688 
Office Equipment   13,625    12,962 
Computers   24,409    22,321 
Software   3,497    3,497 
Leasehold improvements   —      —   
Equipment   17,623    16,763 
           
Total property and equipment at cost   73,272    68,231 
           
Less: accumulated depreciation and amortization   (38,026)   (28,264)
           
   $35,246   $39,967 
XML 71 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727
Inventory
 9 Months Ended
May. 31, 2015
Inventory Disclosure [Abstract]  
Inventory

NOTE 6 – INVENTORY

 

We have inventory, on hand in the amounts of $137,436 and $31,271 as of May 31, 2015 and 2014, respectively. Our inventory as of May 31, 2015 relates to our medical device manufacturing segment. Inventories at May 31, 2015 also included $106,165 related to our medical products and technologies division. Our inventory in our medical device segment consists primarily of miscellaneous parts. Our inventory in our medical products and technologies segment consists primarily of disposable products such as masks, oxygen tubing, and other breathing equipment supplies. We also hold minor amounts of CPAP machines and BiPAP machines. Our machine purchases are generally set up on a Just-in-time order system. We do not maintain any inventory for our personal service care segment or our medical products division. We are currently in the redesign and final bench testing phase of our Toxygen hardware system and disposable products. The new hardware design will position Dotolo Research with a unique technological advantage in the medical markets.. Currently, inventory on hand is made up of miscellaneous Toxygen hardware parts, custom tooling and molds.
XML 72 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727
Statement of Cash Flows
 9 Months Ended
May. 31, 2015
Supplemental Cash Flow Elements [Abstract]  
Statement of Cash Flows

NOTE 18 – STATEMENT OF CASH FLOWS

 

For the nine months ended May 31, 2015, these supplemental non-cash investing and financing activities are summarized as follows:

Amount

On November 15, 2014, the Company issued 1,000,000 S-8 shares of common stock in payment for a investor relations consulting contract.   

 

4,000

   
On November 15, 2014, the Company issued 5,000,000 shares of common stock in payment for  investor relations consulting contract.   

 

20,000

   
On November 17, 2014, the Company issued a $25,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $10,545 related to that transaction.

 

 

10,545

   
On November 17, 2014, the Company issued a $25,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $10,545 related to that transaction.

 

 

10,545

   
On January 22, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $35,000 related to that transaction.

 

 

35,000

   
On January 30, 2015, the Company issued 5,000,000 shares of common stock in payment for  investor relations consulting contract.   

 

38,500

   
On January 30, 2015, the Company issued a $50,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $50,000 related to that transaction.

 

 

50,000

   
On February 5 2015, the Company issued a $50,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $50,000 related to that transaction.

 

 

50,000

   
On February 4, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $35,000 related to that transaction.

 

 

35,000

   
On February 12, 2015, the Company issued a $75,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $75,000 related to that transaction.

 

 

75,000

   
On February 25, 2015, the Company issued a $30,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $30,000 related to that transaction.

 

 

30,000

   
       On March 5, 2015, the Company issued a $36,750 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $25,698 related to that transaction.

 

 

25,698

   
       On March 11, 2015, the Company issued a $88,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $49,539 related to that transaction.

 

 

49,539

   

 

 For the nine months ended May 31, 2015, these supplemental non-cash investing and financing activities are summarized as follows:

Amount

       On March 11, 2015, the Company issued a $30,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $20,100 related to that transaction.

 

 

20,100

   
On March 25, 2015, the Company issued a $50,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $29,404 related to that transaction.

 

 

29,404

   
On March 30, 2015, the Company issued a $32,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $15,790 related to that transaction.

 

 

15,790

   
On April 7, 2015, the Company issued a $27,500 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $10,372 related to that transaction.

 

 

10,372

   
On April 8, 2015, the Company issued a $58,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $39,146 related to that transaction.

 

 

39,146

   
On May 7, 2015, the Company issued a $35,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $21,452 related to that transaction.

 

 

21,452

   
On May 8, 2015, the Company issued a $45,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $29,715 related to that transaction.

 

 

29,715

   
On May 22, 2015, the Company issued a $50,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $30,645 related to that transaction.

 

 

30,645

   
On May 22, 2015, the Company issued a $75,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $45,968 related to that transaction.

 

 

45,968

   
Total non-cash transactions from investing and financing activities.  $      676,419

 

  

For the nine months ended May 31, 2014, these supplemental non-cash investing and financing activities are summarized as follows:

 

On September 11, 2013, the Company issued 1,500,000 warrants to an affiliated party for additional compensation related to an operating capital investment.  The value of these warrants was expensed as interest and finance charges.

 

 

$ 15,656

   
On September 11, 2013, the Company issued 1,000,000 S-8 shares of common stock in payment for a investor relations consulting contract.   

 

11,500

   
On October 2, 2013, the Company issued a $25,000 convertible promissory note to a non-related party.  We recorded a beneficial conversion feature the in amount of $25,000 related to that transaction.

 

 

25,000

   
On October 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $15,620.

 

15,620

   
On November 5, 2013 and November 8, 2013, the Company issued a total of 3,000,000 warrants to a non-related party as additional compensation for an operating capital investment.

 

 

14,805

   
On December 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $12,069.

 

12,069

   
On December 3, 2013, the Company recorded a loss on conversion of a convertible promissory note in the amount of $9,720.

 

9,720

   
On December 3, 2013, the Company issued a total of 1,000,000 warrants as additional compensation.

 

5,992

   
On December 20, 2013, the Company issued a total of 3,000,000 warrants as additional compensation.

 

7,746

   
On January 3, 2014, the Company issued 2,000,000 shares of common stock in payment for a services contract.

 

22,000

   
On January 13, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $26,154.

 

26,154

   
On January 14, 2014, the Company issued 1,000,000 shares of common stock as partial compensation for a investor relations contract.

 

19,000

   
On January 21, 2014, the Company issued 3,500,000 shares of common stock as additional compensation for finder’s fees.

 

45,500

   
On January 21, 2014, the Company issued 1,500,000 shares of common stock as additional compensation for finder’s fees.

 

30,000

   
On January 31, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $16,667.

 

16,667

   
On February 7, 2014, the Company issued 1,000,000 shares of common stock as additional compensation for finder’s fees.

 

9,000

 

 

For the nine months ended May 31, 2014, these supplemental non-cash investing and financing activities are summarized as follows (continued):

 

On February 7, 2014, the Company issued 3,000,000 shares of common stock as additional compensation for finder’s fees.

 

5,151

   
On February 24, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $2,308.

 

2,308

   
On March 19, 2014, the Company recorded a beneficial conversion feature on the issuance of a convertible note.

 

26,500

   
On March 31, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $30,000.

 

30,000

   
On April 6, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $1,468.

 

1,468

   
On April 6, 2014, the Company recorded a loss on conversion of a convertible promissory note in the amount of $30,683

 

30,683

   
On April 8, 2014, the Company recorded a beneficial conversion feature on the issuance of a convertible note.

 

50,000

   
On April 25, 2014, the Company recorded a beneficial conversion feature on the issuance of a convertible note.

 

25,000

   
On May 21, the Company recorded a discount for the issuance of 9,583,333 warrants in connection with the issuance of a convertible note.

 

38,322

   
       Total non-cash transactions from investing and financing activities.  $      495,861

 

 
XML 73 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727
Business Segments
 9 Months Ended
May. 31, 2015
Segment Reporting [Abstract]  
Business Segments

NOTE 14 – BUSINESS SEGMENTS

 

We identify our reportable segments based on our management structure, financial data and market. We have identified three business segments: Personal Care Services and Medical Device Products and Medical Products & Technologies

 

Our Personal Care Service segment consists of the services of Angels of Mercy, Inc. This segment provides non-medical, Personal Care Attendant (PCA) services, Supervised Independent Living (SIL), Long-Term Senior Care, and other approved programs performed by a trained caregiver that will meet the health service needs of beneficiaries whose disabilities preclude the performance of certain independent living skills related to the activities of daily living (ADL).

 

Our Medical Device Manufacturing segment consists of the products of Dotolo Research Corporation. This segment designs, develops, manufactures and distributes the Toxygen hardware system with disposable speculums and medical grade tubing.

 

Our Medical Products and Technologies segment will consist of Advanced Medical Products and Technologies, Esteemcare Inc. and Affordable Medical Inventory Solutions Inc. and future acquisitions.

 

The accounting policies of the segments are the same as those described, or referred to, in Note 2 - Summary of Significant Accounting Policies. Assets and related depreciation expense in the column labeled “Corporate Overhead” pertain to capital assets maintained at the corporate level. Segment loss from operations in the “Corporate Overhead” column contains corporate related expenses not allocable to the operating segments. Intercompany transactions between operating segments were immaterial in all periods presented.

 

 Below are the segment assets as of May 31, 2015.

 

As of May 31, 2015
   Personal Care  Medical Device  Med. Products  Corporate   
   Segment  Segment  Segment  Overhead  Totals
   (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited)   
ASSETS                 
Current Assets:                         
Cash and cash equivalents  $76,633   $120   $21,008   $22,724   $120,485 
Accounts receivable (net)   233,710    —     $803,299    —      1,037,009 
Inventory   —      31,271   $106,165    —      137,436 
Prepaid expenses and other current assets   —      —     $2,946    12,965    15,911 
Prepaid commissions and finders' fees   —      —      85    3,889    3,974 
                          
Total current assets   310,343    31,391    933,503    39,578    1,314,815 
                          
Property and equipment (net)   16,211    15,217    3,283    535    35,246 
Deposits and other assets   2,307    32,303    9,866    33,202    77,678 
Goodwill   564,075    1,217,704    622,610    —      2,404,389 
Patents, registrations (net of amortization)   —      19,903    —      —      19,903 
                          
Total assets  $892,936   $1,316,518   $1,569,262   $73,315   $3,852,031 

 

Below are the segment assets as of August 31, 2014.

 

As of August 31, 2014
   Personal Care  Medical Device  Med. Products  Corporate   
   Segment  Segment  Segment  Overhead  Totals
                
ASSETS                 
Current Assets:                         
Cash and cash equivalents  $9,336   $(110)  $1,000   $7,278   $17,504 
Accounts receivable (net)   213,399    —      —      —      213,399 
Inventory   —      31,271    —      —      31,271 
Prepaid expenses and other current assets   —      —      —      9,307    9,307 
Prepaid commissions   —      —      —      3,152    3,152 
                          
Total current assets   222,735    31,161    1,000    19,737    274,633 
                          
Property and equipment (net)   21,287    17,893    —      787    39,967 
Deposits and other assets   2,082    12,500    —      —      14,582 
Goodwill   564,075    1,217,704    —      —      1,781,779 
Patents, registrations (net of amortization)   —      24,497    —      —      24,497 
                          
Total assets  $810,179   $1,303,755   $1,000   $20,524   $2,135,458 

 

 

 

Below are the statements of operations for the reporting periods presented.

 

   For the Three Months Ended May 31, 2015
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $812,626   $—     $423,030   $—     $1,235,656 
                          
Cost of revenues   698,215    —      187,381    —      885,596 
                          
Gross profit   114,411    —      235,649    —      350,060 
                          
Operating expenses:                         
General and administrative   81,451    14,739    159,793    187,906    443,889 
Research and development Expense   —      —      —      —      —   
Depreciation and amortization   2,262    2,423    253    84    5,022 
                          
Total operating expenses   83,713    17,162    160,046    187,990    448,911 
                          
Loss from operations   30,698    (17,162)   75,603    (187,990)   (98,851)
                          
Other income (expense):                         
Interest and finance charges   (81,952)   (1,500)   (3,076)   (351,380)   (437,908)
Interest and finance charges - related parties   —      —      —      —      —   
Other income (expenses)   11,307    14    —      —      11,321 
                          
Total other income (expense)   (70,645)   (1,486)   (3,076)   (351,380)   (426,587)
                          
Loss from continuing operations  $(39,947)  $(18,648)  $72,527   $(539,370)  $(525,438)

 

   For the Three Months Ended May 31, 2014
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $988,385   $—     $—     $—     $988,385 
                          
Cost of revenues   776,406    12,351    —      —      788,757 
                          
Gross profit   211,979    (12,351)   —      —      199,628 
                          
Operating expenses:                         
General and administrative   166,867    4,979    —      105,104    276,950 
Depreciation and amortization   3,157    2,423    —      84    5,664 
                          
Total operating expenses   170,024    7,402    —      105,188    282,614 
                          
Loss from operations   41,955    (19,753)   —      (105,188)   (82,986)
                          
Other income (expense):                         
Interest and finance charges   (80,786)   (2,250)   —      (84,438)   (167,474)
Interest and finance charges - related parties   —      (791)   —      —      (791)
Loss on conversion of notes payable - related parties   —      —      —      (62,151)   (62,151)
Loss on disposal of assets   —      —      —      —      —   
Other income (expenses)   74,667    (217)   —      —      74,450 
                          
Total other income (expense)   (6,119)   (3,258)   —      (146,589)   (155,966)
                          
Loss from continuing operations  $35,836   $(23,011)  $—     $(251,777)  $(238,952)

 

 

Below are the statements of operations for the reporting periods presented.

 

   For the Nine Months Ended May 31, 2015
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $2,573,547   $—     $1,051,860   $—     $3,625,407 
                          
Cost of revenues   2,129,572    —      499,225    —      2,628,797 
                          
Gross profit   443,975    —      552,635    —      996,610 
                          
Operating expenses:                         
General and administrative   317,165    58,489    424,693    579,422    1,379,769 
Research and development expense   —      10,000    —      —      10,000 
Depreciation and amortization   6,289    7,269    546    252    14,356 
                          
Total operating expenses   323,454    75,758    425,239    579,674    1,404,125 
                          
Loss from operations   120,521    (75,758)   127,396    (579,674)   (407,515)
                          
Other income (expense):                         
Interest and finance charges   (244,613)   (5,500)   (3,848)   (836,052)   (1,090,013)
Interest and finance charges - related parties   —      (1,051)   —      —      (1,051)
Other income (expenses)   8,541    (3,854)   —      (204)   4,483 
                          
Total other income (expense)   (236,072)   (10,405)   (3,848)   (836,256)   (1,086,581)
                          
Loss from operations  $(115,551)  $(86,163)  $123,548   $(1,415,930)  $(1,494,096)

 

   For the Nine Months Ended May 31, 2014
    Personal Care    Medical Device    Medical Products    Corporate      
    Segment    Segment    Segment    Overhead    Totals 
                          
Revenues  $2,696,776   $—     $—     $—     $2,696,776 
                          
Cost of revenues   2,030,450    36,350    —      —      2,066,800 
                          
Gross profit   666,326    (36,350)   —      —      629,976 
                          
Operating expenses:                         
General and administrative   506,387    28,222    —      465,301    999,910 
Depreciation and amortization   9,636    7,268    —      252    17,156 
                          
Total operating expenses   516,023    35,490    —      465,553    1,017,066 
                          
Loss from operations   150,303    (71,840)   —      (465,553)   (387,090)
                          
Other income (expense):                         
Interest and finance charges   (171,837)   (8,560)   —      (454,436)   (634,833)
Interest and finance charges - related parties   —      (2,348)   —      (15,708)   (18,056)
Loss on conversion of notes payable - related parties   —      —      —      (155,728)   (155,728)
Loss on disposal of assets   (28,748)   —      —      —      (28,748)
Other income (expenses)   72,775    (713)   —      —      72,062 
                          
Total other income (expense)   (127,810)   (11,621)   —      (625,872)   (765,303)
                          
Loss from operations  $22,493   $(83,461)  $—     $(1,091,425)  $(1,152,393)

 
XML 74 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727
Inventory Financing Agreement
 9 Months Ended
May. 31, 2015
Debt Disclosure [Abstract]  
Inventory Financing Agreement

NOTE 10 – INVENTORY FINANCE AGREEMENTS

 

Our inventory finance agreements consist of qualified for-sale inventory purchases. These finance agreements are held solely by Esteemcare. Qualifying inventory purchases are grouped into a 12 month finance agreements allowing the company to spread the payments for this inventory over a twelve month period. This allows the company to collect payments for the purchases of that inventory over that time period as most insurance plans spread the purchase payments over a multi-month period, generally 10 to 13 months. All inventory finance agreements are interest free and consist of only minor fees for setup. Below is a listing of our outstanding inventory finance agreements as of May 31, 2015 and 2014 as well as the monthly payment on each agreement.

 

   As of May 31,   
   2015  2014  Monthly Payment
Wells Fargo (017)  $8,331   $—     $4,165 
VGM (322)   23,787    —      5,947 
Wells Fargo (018)   24,694    —      6,174 
VGM (323)   32,106    —      5,351 
DLL (61942)   90,781    —      11,348 
DLL (67910)   31,389    —      3,488 
VGM (324)   32,512    —      3,612 
DLL (68936)   11,263    —      1,126 
Wells Fargo (019)   76,459    —      6,951 
VGM (325)   85,680    —      7,140 
DLL (61649)   —           1,126 
                
                
Outstanding leases  $417,001   $—     $56,428 

 

 
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.2.0.727
Notes Payable - Other(Details Narrative 1) - USD ($)
 12 Months Ended
Aug. 31, 2019
Aug. 31, 2018
Aug. 31, 2017
Aug. 31, 2016
Aug. 31, 2015
NotesPayableDetailsNarrative3Abstract          
Future minimum payments $ 17,599 $ 14,580 $ 326,226 $ 97,813 $ 2,394,130
XML 76 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727
Leases
 9 Months Ended
May. 31, 2015
Leases [Abstract]  
Leases

NOTE 8 – OFFICE LEASES

 

The Company leases office space in Alexandria and Lafayette Louisiana and in West Columbia and Charleston SC. Alexandria is on a three year lease; Lafayette a five year lease; West Columbia has one year remaining on its lease; and Charleston is on a three year lease. On March 28, 2014, Dotolo Research moved from its current manufacturing location in Phoenix AZ into E&R Engineer manufacturing facilities located in Tempe, AZ. Rent expense for the three months ended May 31, 2015 and 2014 were $36,527 and $19,178, respectively. Rent expense for the nine months ended May 31, 2015 and 2014 were $112,055 and $64,680, respectively. Following are the minimum lease payments:

   
2015  $             33,495
2016               126,424
2017               114,808
2018                 42,448
   
   
Totals  $           317,175
XML 77 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727
Goodwill, Patents and Other Intangible Assets
 9 Months Ended
May. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill, Patents and Other Intangible Assets

NOTE 9 – GOODWILL, PATENTS AND OTHER INTANGIBLE ASSETS

 

We currently carry our patents and registrations net of amortization. As of May 31, 2015 and 2014, the Company has a capitalized cost of patents and registrations in the amount of $122,479 and accumulated amortization of 101,045. Our patents and registrations are amortized over a 20 year period. Amortization for each of the next 4 fiscal years, assuming no impairment, will be $6,124 per year.
XML 78 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727
Notes Payable
 9 Months Ended
May. 31, 2015
Payables and Accruals [Abstract]  
Notes Payable

NOTE 11 — NOTES PAYABLE

 

CONVERTIBLE NOTES PAYABLE:

 

Convertible notes payable consist of the following as of May 31, 2015 and 2014:

 

The following is a summary of future minimum payments on convertible notes payable as of May 31, 2015:

 

Ref.     May 31,  May 31,
Numb.  Description  2015  2014
 2210   Conv. Note Payable (net of discount)  $64,025   $235,025 
 2218   Conv. Note Payable (net of discount)  $—     $100,000 
 2232   Conv. Note Payable (net of discount)  $—     $(567)
 2238   Conv. Note Payable (net of discount)  $—     $5,300 
 2239   Conv. Note Payable (net of discount)  $—     $7,260 
 2247   Conv. Note Payable (net of discount)  $—     $4,918 
 2250   Conv. Note Payable (net of discount)  $—     $68,429 
 2261   Conv. Note Payable (net of discount)  $8,100   $—   
 2265   Conv. Note Payable (net of discount)  $12,370   $—   
 2267   Conv. Note Payable (net of discount)  $24,897   $—   
 2271   Conv. Note Payable (net of discount)  $16,911   $—   
 2274   Conv. Note Payable (net of discount)  $11,123   $—   
 2276   Conv. Note Payable (net of discount)  $17,161   $—   
 2278   Conv. Note Payable (net of discount)  $56,910   $—   
 2281   Conv. Note Payable (net of discount)  $13,095   $—   
 2290   Conv. Note Payable (net of discount)  $31,918   $—   
 2292   Conv. Note Payable (net of discount)  $18,885   $—   
 2294   Conv. Note Payable (net of discount)  $15,579   $—   
 2297   Conv. Note Payable (net of discount)  $17,680   $—   
 2310   Conv. Note Payable (net of discount)  $15,650   $—   
 2312   Conv. Note Payable (net of discount)  $1,813   $—   
 2314   Conv. Note Payable (net of discount)  $20,592   $—   
 2316   Conv. Note Payable (net of discount)  $30,887   $—   
 2322   Conv. Note Payable (net of discount)  $100,000   $—   
                
                
     Subtotal   477,596    420,365 
                
 Less:  Long-Term portion    —    (235,025 )
                
 Current portion $477,596 $ 185,340  

 

 

 

The following is a summary of future minimum payments on convertible notes payable as of May 31, 2015:

 

      Convertible 
 Fiscal Year Ending August 31,    Notes Payable 
 2015   $0 
 2016   $477,596 

 

 

  

2210 - On April 1, 2009, we issued to Ms. Lindstrom, our former Chief Executive Officer, a convertible promissory note in lieu of payment of $235,025 in accrued salary owed to Ms. Lindstrom. This note accrues interest at a rate of 6% per annum and was originally due on March 31, 2012. On March 16, 2012, Ms. Lindstrom agreed to extend the due date of the note to September 30, 2013. There was no beneficial conversion feature recognized upon the issuance of this note. An outside party has entered into an assignment and settlement agreement with Ms. Lindstrom to purchase the note. The note assignment is currently in default. During fiscal 2014, the Assignee has converted $46,000 of principal into 8,788,171 shares of stock reducing the current balance of the note to $189,025. During fiscal 2015, the Holder assigned $125,000 of principal to another accredited investor. As of May 31, 2015, the Company has an outstanding principal balance of $64,025 and an accrued interest in the amount of $82,833.

 

2218 - During May and June 2007, we issued nine Convertible Promissory Notes in an aggregate principal amount of $700,000. Eight of these notes we-+re converted into common stock in fiscal 2009. The remaining Convertible Promissory Note, in the principal amount of $125,000, was extended on January 28, 2010 initially to March 31, 2012, where the conversion rate was reduced to $.60, and then extended to September 30, 2013. In October 2013 and November 2014, the investor sold two $25,000 positions of principal in the note to another accredited investor. In May 2015, the investor sold the remaining $75,000 of principal in the note to another accredited investor. The note has been extended to December 31, 2015 and we are negotiating the final payment of accrued interest. As of May 31, 2015, the Company has accrued interest in the amount of $65,469.

 

2232 - On October 2, 2013 we issued a convertible promissory note in the principal amount of $25,000. This promissory note bore interest at a rate of 8% per annum and is due on October 2, 2013. The note was convertible at a 45% discount of the average of the three lowest closing bid prices in the twenty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $25,000. On April 6, 2014 the holder elected to convert $17,074 in principal plus $690 in accrued interest into 5,383,007 shares of common stock at a conversion price of $.0033. In August 1, 2014 the remaining principal of $7,926 plus accrued interest of $530 was converted into 3,416,764 shares of common stock at a conversion rate of $.002475.

 

2238 - On March 19, 2014 we issued a convertible promissory note in the principal amount of $26,500 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on March 19, 2015. The note was convertible at a 38% discount of the lowest closing bid prices in the thirty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $26,500. During fiscal 2015, the investor converted $26,500 of principal plus accrued interest of $1,384 into 16,801,705 shares of common stock.

 

2239 - On April 8, 2014 we issued a convertible promissory note in the principal amount of $50,000 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on April 8, 2015. The note is convertible at a 35% discount of the average 4 lowest closing bid prices in the twenty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $50,000. This note was paid in full on October 2, 2014.

 

2247 - On April 25, 2014 we issued a convertible promissory note in the principal amount of $25,000 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on October 25, 2015. The note is convertible at a 35% discount of the average 4 lowest closing bid prices in the thirty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $25,000. During October and November 2014, the entire principal amount of $25,000 was converted into 8,284,469 shares of common stock.

 

 

2250 -On May 21, 2014 we issued a convertible promissory note in the principal amount of $115,000 to an unrelated accredited investor. This promissory note bore interest at a rate of 10% per annum. This principal includes a 10% OID in the amount of $10,000, which is being amortized over the term of the note. The note is due in 4 equal installments beginning on the 180th day after the execution of the note. The company may make the payments in common stock. The note is convertible at a $.009 per share. As additional consideration, the Company issued 9,583,333 5 year warrants with an exercise price of $.009. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $38,322 related to the issuance of the warrants. This note was paid in full on February 23, 2015.

 

2253 - On July 16, 2014 we issued a convertible promissory note in the principal amount of $26,500 to an unrelated accredited investor. This promissory note bore interest at a rate of 12% per annum and is due on July 26, 2015. The note is convertible at a 38% discount of the lowest closing bid prices in the thirty days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $26,500. During the second quarter of fiscal 2015, the company converted $26,500 in principal plus $1,134 of accrued interest into 18,571,550 shares of common stock.

 

2259 -On November 17, 2014, the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $25,000 of the current convertible note holder note. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 30% discount into shares of the Company’s common stock using a five-day average of the lowest closing stock prices immediately preceding the conversion date. The Company recorded a beneficial conversion feature of $10,545. During fiscal 2015, the investor converted the $25,000 in principal plus $85 in accrued interest into 9,641,872 shares of common stock.

 

2261 -On November 17, 2014 we issued a convertible promissory note in the principal amount of $25,000. This promissory note bears interest at a rate of 8% per annum and is due on October 2, 2013. The note is convertible at a 30% discount of the average of the five closing stock prices immediately preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $10,545. During fiscal 2015 the investor converted $11,989 of principal and $1,011 of interest into 6,211,180 shares of common stock. As of May 31, 2015 the company has accrued interest of $7.

 

2265 -On January 22, 2015 we issued a convertible promissory note in the principal amount of $35,000. This promissory note bears interest at a rate of 8% per annum and is due on January 22, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $35,000. As of May 31, 2015 the company has accrued interest of $1,003.

 

2267 - On January 30, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 12% per annum and is due on September 30, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $50,000. As of May 31, 2015 the company has accrued interest of $1,989.

 

2269 - On February 5, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $50,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. The Company recorded a beneficial conversion feature of $50,000. During the second and third quarters of fiscal 2015, the investor converted the $50,198 in principal and interest into 16,669,092 shares of common stock.

 

 

2274 - On February 4, 2015 we issued a convertible promissory note in the principal amount of $35,000. This promissory note bears interest at a rate of 8% per annum and is due on February 4, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $35,000. As of May 31, 2015 the company has accrued interest of $1,128.

 

2271 - On February 12, 2015 we issued a convertible promissory note in the principal amount of $75,000. This promissory note bears interest at a rate of 10% per annum and is due on February 12, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $75,000. As of May 31, 2015 the company has accrued interest of $2,250.

 

2281 - On February 25, 2015 we issued a convertible promissory note in the principal amount of $30,000. This promissory note bears interest at a rate of 12% per annum and is due on October 25, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $30,000. As of May 31, 2015 the company has accrued interest of $937.

.

2276 - On March 5, 2015 we issued a convertible promissory note in the principal amount of $36,750. This promissory note bears interest at a rate of 8% per annum and is due on March 5, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $711.

 

2283 - On March 9, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $30,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. During the third quarter of fiscal 2015, the investor converted $30,096 of principal and interest into 9,180,298 shares of common stock.

 

2278 - On March 11, 2015 we issued a convertible promissory note in the principal amount of $88,000. This promissory note bears interest at a rate of 12% per annum and is due on September 11, 2015. The note is convertible at a 38% discount of the lowest closing price immediately during the 20 days preceding the date of conversion. The Company also paid an OID in the amount of $6,000. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $2,376.

 

2290 - On March 25, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 10% per annum and is due on September 25, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $931.

 

2292 - On March 30, 2015 we issued a convertible promissory note in the principal amount of $32,000. This promissory note bears interest at a rate of 8% per annum and is due on March 30, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 15 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $441.

 

 

2294 - On April 7, 2015 we issued a convertible promissory note in the principal amount of $27,500. This promissory note bears interest at a rate of 12% per annum and is due on April 7, 2017. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. The Company also paid an OID in the amount of $6,000. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $330.

 

2297 - On April 8, 2015 we issued a convertible promissory note in the principal amount of $58,000. The company received net proceeds of $50,000 with the balance of the note going for finders fees and processing fees. This promissory note bears interest at a rate of 8% per annum and is due on April 8, 2016. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. As of May 31, 2015 the company has accrued interest of $683.

 

2310 - On May 7, 2015 we issued a convertible promissory note in the principal amount of $35,000. This promissory note bears interest at a rate of 12% per annum and is due on October 25, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $21,452. As of May 31, 2015 the company has accrued interest of $280.

 

2312 - On May 8, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $45,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $29,715. During the third quarter of fiscal 2015, the investor converted $16,261 of principal into 9,400,000 shares of common stock.

 

2314 - On May 22, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 8% per annum and is due on December 31, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $30,645. As of May 31, 2015 the company has accrued interest of $100.

 

2316 - On May 22, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $75,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares. We recorded a beneficial conversion feature of $45,968.

 

2322 - On January 2, 2015, The Company issued a $100,000 convertible promissory note in full payment of an outstanding invoice of an accredited investor. The Company issued to the accredited investor a convertible promissory note bearing interest at 4% and convertible at a 35% discount of the average of the last en closing stock prices immediately preceding the date of the conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares.

 

  

CONVERTIBLE RELATED PARTY NOTES PAYABLE:

 

As of May 31, 2015, there are currently no related party convertible notes payable outstanding. The note related to our former CEO is now classified as non-related convertible debt for all comparable periods.

 

 

RELATED PARTY NOTES PAYABLE:

 

   May 31,  May 31,
   2015  2014
6.0% line of credit (2)  $—     $51,600 
         —   
           
Outstanding unsecured related party notes payable  $—     $51,600 
           
(1)  Note payable to current CEO.          

 

During the last two years, Wayne Erwin, our President and CEO, has advanced a total of $51,600 directly to Dotolo in an open advance account. Interest is being accrued at a rate of 6% per annum. As of May 31, 2015 the Company has repaid $51,600 of principal and $7,393 of accrued interest.

 

OTHER NOTES PAYABLE:

Ref.     May 31,  May 31,
Numb.  Description  2015  2014
 Dot 1   Note Payable (net of discount)  $1,500   $60,600 
 Dot 2   Note Payable (net of discount)   30,000    30,000 
 Dot 3   Note Payable (net of discount)   20,000    20,000 
 AA 1   Line of Credit   43,149    44,469 
 AA 2   Line of Credit   37,467    —   
 AA 3   Merchant Loan   —      130,400 
 AA 4   Merchant Loan   —      142,109 
 AA 5   Merchant Loan   68,409    —   
 AA 6   Merchant Loan   42,080    —   
 AA 7   Merchant Loan   228,215    —   
 AA 8   Merchant Loan   67,400    —   
 AA 9   Note Payable (net of discount)   —      14,765 
 EST 1   Note Payable (net of discount)   73,552    —   
 2226   Note Payable (net of discount)   —      10,833 
 2227   Note Payable (net of discount)   —      6,689 
 2228   Note Payable (net of discount)   —      6,844 
 2229   Note Payable (net of discount)   —      21,076 
 2230   Note Payable (net of discount)   68,510    70,659 
 2231   Note Payable (net of discount)   12,000    7,692 
 2236   Note Payable (net of discount)   1,533,584    275,155 
 2237   Note Payable (net of discount)   —      11,444 
 2255   Note Payable (net of discount)   22,909    —   
 2257   Note Payable (net of discount)   68,920    —   
 2258   Note Payable (net of discount)   22,973    —   
 2263   Note Payable (net of discount)   56,215    —   
 2264   Note Payable (net of discount)   11,500    —   
 2300   Note Payable (net of discount)   416,466    498,179 
 2432   Note Payable (net of discount)   25,499    78,915 
                
     Subtotal   2,850,348    1,429,829 
                
 Less:  Long-Term portion (376,037 )  (416,466 )
                
 Current portion $2,474,311 $ 1,013,363  

 

 

Notes held by Dotolo

 

DOT 1 - During April 2012, our subsidiary Dotolo, entered into a financing agreement to provide up to $150,000 in funding for the subsidiary. The financing agreement was due in January 2013. We entered into a settlement agreement whereby we paid $45,000 from amounts held in reserve by our senior lender and are required to make 10 monthly payments of $1,500. As of May 31, 2015, the current balance is $1,500.

 

DOT 2 - On February 27, 2013 our subsidiary Dotolo, entered into a note payable agreement to provide funding to its subsidiary in the principal amount of $30,000. The note bears interest at 18% payable monthly on the 15th and is due in full in January 2016. For the three months ended May 31, 2015, we made interest payments in the amount of $1,350. As of May 31, 2015, we have accrued interest of $1,965.

 

DOT 3 - On March 17, 2013 our subsidiary Dotolo, entered into a note payable agreement to provide funding to its subsidiary in the principal amount of $20,000. The note bears interest at 18% payable monthly on the 15th and is due in full in January 2016. For the year ended May 31, 2015, we made interest payments in the amount of $900. As of May 31, 2015, we have accrued interest of $1,090.

 

Notes held by Amian Angels

 

AA 1 – During fiscal 2014 we borrowed $45,000 from our $50,000 line of open line of credit with our bank. As of May 31, 2015 the outstanding balance of the line of credit loan was $43,149.

 

AA 2 – During fiscal 2015 we borrowed $80,000 from our line of open line of credit with another lender. During the third quarter of fiscal 2015 we have repaid $42,533 of principal plus additional interest. As of May 31, 2015 the outstanding balance of the line of credit loan was $37,467.

 

AA 3 – On April 18, 2014, the Company obtained a merchant loan for additional working capital in the amount of $120,000. This loan requires 189 daily payments in the amount of $800 for a total repayment amount of $151,200. We netted gross proceeds of $119,301 after paying loan fees. This note was paid in full in December 2014.

 

AA 4 – On March 11, 2014, the Company obtained a merchant loan for additional working capital in the amount of $150,000. This loan requires 209 daily payments in the amount of $940 for a total repayment amount of $196,500. We netted gross proceeds of $146,750 after paying loan fees. This note was paid in full in December 2014.

 

AA 5 – On May 22, 2015, the Company obtained a merchant loan for additional working capital in the amount of $50,000. This loan requires 132 daily payments in the amount of $530 for a total repayment amount of $70,000. The balance of this loan on May 31, 2015 was $68,409.

 

AA 6 – On May 7, 2015, the Company obtained a merchant loan for additional working capital in the amount of $35,000. This loan requires 85 daily payments in the amount of $599 for a total repayment amount of $51,065. The balance of this loan on May 31, 2015 was $42,080.

 

AA 7 – On December 15, 2014, the Company obtained a merchant loan for additional working capital in the amount of $300,000. This loan requires 252 daily payments in the amount of $1,607 for a total repayment amount of $405,000. We netted gross proceeds of $163,713 after paying loan fees and paying off our other 4 merchant loans. The balance of this loan on May 31, 2015 was $228,215.

 

AA 8 – On April 30, 2015, the Company obtained a merchant loan for additional working capital in the amount of $60,000. This loan requires 87 daily payments in the amount of $999 for a total repayment amount of $87,450. The balance of this loan on May 31, 2015 was $67,400.

 

AA 9 – In connection with the acquisition of Amian Health Services, the Company entered into a twelve month promissory note in the total principal amount of $25,000. The note bears interest at $6% and requires monthly payments of $2,152. This note was paid in full in December 2014.

 

Notes held by Esteemcare

 

EST 1 - On September 25, 2014, as part of the terms and conditions of the acquisition of Esteemcare Inc. and Affordable Medical Inventory Solutions Inc., the company issued an 18 month note to Imad Siddiqui in the principal amount of $75,000. This note was executed on May 1, 2015 and requires monthly payments of $4,524. As a result of the delay in execution of the note, the Company accrued $2,688 of interested and added it to the balance of the note.

 

Notes held by Oncologix Tech

 

2216 - On August 1, 2013, in connection with our acquisition of Angels of Mercy, Inc. we entered into a promissory note to pay $65,000 of broker’s fees incurred in the acquisition. Monthly payments of $5,417 are due and payable beginning on August 15, 2013. This note bears no interest. This was paid in full in July 2014.

 

2227 & 2228 - On November 5, 2013 and November 8, 2013, the Company entered into two, one-year promissory notes with accredited investors to borrow a total principal amount of $20,000. Each promissory note is $10,000 in principal balance, bore interest at 18% and requires monthly interest payments of $150 each. The company also issued 3,000,000 in cashless warrants as finder’s fees for these funds. The Company recorded a discount of $14,805 for the issuance of the warrants. These notes were paid in full in November 2014.

 

2229 - On November 1, 2013, the Company entered into a Settlement Agreement with its former legal counsel. The current balance owed to prior counsel is $145,523. Pursuant to the settlement agreement, the Company agreed to pay $50,000 in the form of a one year promissory note and transfer its 90% ownership interest and all marketing rights of Oncologix Corporation, one of its subsidiaries as full settlement of the current balance owed. The promissory note bears interest of 4% and requires monthly payment of $4,257 beginning on December 1, 2013. This note was paid in full during November 2014.

 

2230 - On December 3, 2013, The Company entered into a twelve month promissory note with an accredited investor to borrow a total principal amount of $75,000. The note bears interest of 18% per annum and calls for monthly payments of principal and interest of $1,375 beginning on January 15, 2014 with a balloon payment due December 15, 2014. The Company also issued as additional finders’ fees to the investor, 3,500,000 shares of common stock and 1,000,000 cashless warrants with an exercise price of $.025. As of May 31, 2015, the balance was $68,510. The Company recorded a discount of $5,992 for the issuance of the warrants.

 

2231 - On December 20, 2013, the Company issued a 1-year promissory note to a non-related accredited investor in the principal amount of $12,000. This note bears interest at 10% per annum and matures in December 2014. This note was extended to June 2015. As additional consideration for the operating capital loan, the company issued 3,000,000 cashless two-year warrants with an exercise price of $0.02. The Company recorded a discount of $7,746 for the issuance of the warrants. As of May 31, 2015 the Company has accrued interest of $1,437.

 

2236 - On January 3, 2014, the Company closed on a 4 million dollar line of credit facility, with an initial draw of $500,000. The Company must meet specific monthly reporting and collateral requirements to further draw on the revolving credit facility. The $500,000 initial draw is secured by a 14.5% promissory note, which is convertible ONLY upon default by the Company. In July 2014, we borrowed an additional $75,000 from the principal we repaid. This note is due in nine months with an automatic option to renew after nine months. On September 25, 2014, the Company took down a second draw from its $4 million dollar line of credit facility in the amount of $1,200,000. The Company must meet specific monthly reporting and collateral requirements to further draw on the revolving credit facility. The outstanding balance at the time of the draw was $1,533,584 which is secured by twelve month 14.5% promissory note, which is convertible ONLY upon default by the Company. This note is automatically renewable for an additional twelve months. The company is required to pay interest and fees only for the initial 3 months. The balance of this note on May 31, 2015 is $1,533,584.

 

2237 - On February 7, 2014, the Company issued a 1-year promissory note in the principal amount of $15,000 to a non-related accredited investor. This note bears interest at 6% per annum and matures in February 2015. As additional consideration for the operating capital loan, the company issued 1,500,000 two-year warrants with an exercise price of $0.15 and 1,000,000 shares of common stock. The Company recorded an expense of $9,000 for the issuance of the common stock. The Company recorded a discount of $5,151 for the issuance of the warrants. On August 1, 2014 this investor used $10,000 to purchase 1,200,000 shares of common stock. This note was paid in February 2015.

 

2255 - On August 15, 2014 the Company issued a 1-year promissory note to a non-related accredited investor in the principal amount of $25,000. This note bears interest at 10% per annum and matures in August 2015. As additional consideration for the operating capital loan, the company issued 4,000,000 cashless two-year warrants with an exercise price of $0.065. The Company recorded a discount of $10,177 for the issuance of the warrants. As of May 31, 2015 the Company has accrued interest of $1,993.

 

2257 & 2258 - On September 25, 2014, the Company issued a $75,000 and $25,000 1-year promissory notes bearing interest at 6% in connection with the acquisition of Esteemcare Inc. and Affordable Medical Inventory Solutions Inc. As of May 31, 2015, the outstanding balances of these notes were $68,920 and $22,973, respectively.

 

2263 - On November 16, 2014, the Company borrowed $60,000 in principal from an unrelated investor. This note bears interest at a rate of 12% and calls for 60 monthly payments of $1,334.67 beginning on January 19, 2015. The note matures on January 19, 2019. As of May 31, 2015, the outstanding balance of this note was 56,217.

 

2264 - On December 16, 2014, the Company borrowed $48,000 in principal from an unrelated investor. This note bears calls for two interest payments, each in the amount of $8,500 in January and February 2015. The note matures on March 16, 2015. As of May 31, 2015, the outstanding balance of this note was 11,500.

 

2300 - On August 1, 2013, in connection with our acquisition of Angels of Mercy, Inc. we entered into a promissory note to pay $550,000 for the purchase of Angels of Mercy, Inc. Monthly payments of $9,115 are due and payable beginning on November 1, 2013 with a final balloon payment of $205,705 due on October 1, 2017. This note bears interest at a rate of 6%. As of May 31, 2015, the outstanding balance of the note is $416,466.

 

2432 - On July 26, 2013 the Company issued an 18 month promissory note in the principal amount of $100,000. These funds were used for the cash down payment for the Angels acquisition. The note bears interest at 18% and requires monthly interest payments of $1,200 beginning on September 26, 2013. In December 2013, we modified the loan agreement to make monthly payments of $6,200. As of May 31, 2015 the outstanding balance was $25,499.

 

The following is a summary of future minimum payments on r notes payable as of May 31, 2015:

    Related Conv.
Fiscal Year Ending August 31,   Notes Payable
2015      2,394,130
2016           97,813
2017         326,226
2018           14,580
2019           17,599

 

 
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity (Details 1) - $ / shares
 9 Months Ended 12 Months Ended
May. 31, 2015
Aug. 31, 2014
Proceeds if Shares Converted    
Shares Issued   23,583,333
Series D Preferred Stock [Member]    
Number of Preferred Shares    
Shares Outstanding, beginning balance 78,564 58,564
Shares Issued   20,000
Shares Outstanding, ending balance 78,564 78,564
Number of Common Shares Convertible    
Shares Outstanding, beginning balance 78,564,000 58,564,000
Shares Issued   20,000,000
Shares Outstanding, ending balance 78,564,000 78,564,000
Proceeds if Shares Converted    
Amount converted, ending balance    
Weighted Average Exercise Price Per Common Stock    
Shares Outstanding, beginning balance   $ 80.25
Shares Expired/Retired   80.25
Sharess Outstanding, ending balance $ 80.25 $ 80.25
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity - Stock Subscribed (Details Narrative) - Aug. 31, 2014 - USD ($)
Total
Stockholders Equity - Stock Subscribed Details Narrative  
Common stock subscribed $ 5,000
Shares issued conversion of notes payable 1,058,201
XML 81 R63.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity Additional (Details Narrative) - $ / shares
May. 31, 2015
Aug. 31, 2014
Aug. 31, 2013
Private Placement of Units      
Common stock unit     3
Series A preferred stock unit     1
Par value of Series A preferred stock     $ 0.001
Total convertible units issued 4,032,743    
Units Outstanding      
Underlying Series A preferred stock   129,062 64,531
Underlying common stock   129,062 96,797
XML 82 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727
Notes Payable (Tables)
 9 Months Ended
May. 31, 2015
Payables and Accruals [Abstract]  
Convertible Notes Payable

 

Ref.     May 31,  May 31,
Numb.  Description  2015  2014
 2210   Conv. Note Payable (net of discount)  $64,025   $235,025 
 2218   Conv. Note Payable (net of discount)  $—     $100,000 
 2232   Conv. Note Payable (net of discount)  $—     $(567)
 2238   Conv. Note Payable (net of discount)  $—     $5,300 
 2239   Conv. Note Payable (net of discount)  $—     $7,260 
 2247   Conv. Note Payable (net of discount)  $—     $4,918 
 2250   Conv. Note Payable (net of discount)  $—     $68,429 
 2261   Conv. Note Payable (net of discount)  $8,100   $—   
 2265   Conv. Note Payable (net of discount)  $12,370   $—   
 2267   Conv. Note Payable (net of discount)  $24,897   $—   
 2271   Conv. Note Payable (net of discount)  $16,911   $—   
 2274   Conv. Note Payable (net of discount)  $11,123   $—   
 2276   Conv. Note Payable (net of discount)  $17,161   $—   
 2278   Conv. Note Payable (net of discount)  $56,910   $—   
 2281   Conv. Note Payable (net of discount)  $13,095   $—   
 2290   Conv. Note Payable (net of discount)  $31,918   $—   
 2292   Conv. Note Payable (net of discount)  $18,885   $—   
 2294   Conv. Note Payable (net of discount)  $15,579   $—   
 2297   Conv. Note Payable (net of discount)  $17,680   $—   
 2310   Conv. Note Payable (net of discount)  $15,650   $—   
 2312   Conv. Note Payable (net of discount)  $1,813   $—   
 2314   Conv. Note Payable (net of discount)  $20,592   $—   
 2316   Conv. Note Payable (net of discount)  $30,887   $—   
 2322   Conv. Note Payable (net of discount)  $100,000   $—   
                
                
     Subtotal   477,596    420,365 
                
 Less:  Long-Term portion    —    (235,025 )
                
 Current portion $477,596 $ 185,340  
Future minimum payments of Convertible Notes Payable

 

      Convertible 
 Fiscal Year Ending August 31,    Notes Payable 
 2015   $0 
 2016   $477,596 
Related Party Notes Payable

 

   May 31,  May 31,
   2015  2014
6.0% line of credit (2)  $—     $51,600 
         —   
           
Outstanding unsecured related party notes payable  $—     $51,600 
           
(1)  Note payable to current CEO.          
Other Notes Payable

 

Ref.     May 31,  May 31,
Numb.  Description  2015  2014
 Dot 1   Note Payable (net of discount)  $1,500   $60,600 
 Dot 2   Note Payable (net of discount)   30,000    30,000 
 Dot 3   Note Payable (net of discount)   20,000    20,000 
 AA 1   Line of Credit   43,149    44,469 
 AA 2   Line of Credit   37,467    —   
 AA 3   Merchant Loan   —      130,400 
 AA 4   Merchant Loan   —      142,109 
 AA 5   Merchant Loan   68,409    —   
 AA 6   Merchant Loan   42,080    —   
 AA 7   Merchant Loan   228,215    —   
 AA 8   Merchant Loan   67,400    —   
 AA 9   Note Payable (net of discount)   —      14,765 
 EST 1   Note Payable (net of discount)   73,552    —   
 2226   Note Payable (net of discount)   —      10,833 
 2227   Note Payable (net of discount)   —      6,689 
 2228   Note Payable (net of discount)   —      6,844 
 2229   Note Payable (net of discount)   —      21,076 
 2230   Note Payable (net of discount)   68,510    70,659 
 2231   Note Payable (net of discount)   12,000    7,692 
 2236   Note Payable (net of discount)   1,533,584    275,155 
 2237   Note Payable (net of discount)   —      11,444 
 2255   Note Payable (net of discount)   22,909    —   
 2257   Note Payable (net of discount)   68,920    —   
 2258   Note Payable (net of discount)   22,973    —   
 2263   Note Payable (net of discount)   56,215    —   
 2264   Note Payable (net of discount)   11,500    —   
 2300   Note Payable (net of discount)   416,466    498,179 
 2432   Note Payable (net of discount)   25,499    78,915 
                
     Subtotal   2,850,348    1,429,829 
                
 Less:  Long-Term portion (376,037 )  (416,466 )
                
 Current portion $2,474,311 $ 1,013,363  
Future Minimum payments related conv. notes payable

 

    Related Conv.
Fiscal Year Ending August 31,   Notes Payable
2015      2,394,130
2016           97,813
2017         326,226
2018           14,580
2019           17,599
XML 83 R51.htm IDEA: XBRL DOCUMENT v3.2.0.727
Leases (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
May. 31, 2015
May. 31, 2014
May. 31, 2015
May. 31, 2014
Leases [Abstract]        
Rent Expense $ 36,527 $ 19,178 $ 112,055 $ 64,680
XML 84 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727
Retirement Plan
 9 Months Ended
May. 31, 2015
Compensation and Retirement Disclosure [Abstract]  
Retirement Plan

NOTE 16 - RETIREMENT PLAN

 

Currently, the Company does not have a retirement plan in place.
XML 85 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727
Subsequent Events
 9 Months Ended
May. 31, 2015
Subsequent Events [Abstract]  
Subsequent Events

NOTE 21 - SUBSEQUENT EVENTS

 

On June 3 2015, the Company entered into a 1 year consulting agreement. The Company agrees to pay consultant 4% of any monies raised by the efforts of the consultant. In addition, the Company issued 2,500,000 shares of its Common Stock as additional compensation.

 

On June 15, 2015 we issued a convertible promissory note in the principal amount of $50,000. This promissory note bears interest at a rate of 8% per annum and is due on December 31, 2015. The note is convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares.

 

On June 5, 2015 the Company entered into a securities transfer agreement with an accredited investor as well as a current convertible note holder. The agreement called for the accredited investor to purchase $45,000 of the current convertible note holder note to repay our former CEO. The Company issued to the accredited investor a convertible promissory note bearing interest at 8% and convertible at a 38% discount of the average of the three lowest closing bid prices immediately during the 20 days preceding the date of conversion. At no time may the holder of the note convert the note into shares exceeding 4.99% of the Company’s then outstanding common stock shares.
XML 86 R49.htm IDEA: XBRL DOCUMENT v3.2.0.727
Property and Equipment (Details Narrative) - USD ($)
May. 31, 2015
Aug. 31, 2014
Property And Equipment Details Narrative    
Furniture $ 14,118 $ 12,688
Office Equipment 13,625 12,962
Computers 24,409 22,321
Software $ 3,497 $ 3,497
Leasehold improvements    
Equipment $ 17,623 $ 16,763
Total property and equipment at cost 73,272 68,231
Less: accumulated depreciation and amortization (38,026) (28,264)
Property and equipment (net of accumulated depreciation of $28,264 and $11,820) $ 35,246 $ 39,967
XML 87 R41.htm IDEA: XBRL DOCUMENT v3.2.0.727
Summary of Significant Accounting Policies - Net Loss Per Common Share -Basic and Diluted (Details) - USD ($)
 3 Months Ended 9 Months Ended
May. 31, 2015
May. 31, 2014
May. 31, 2015
May. 31, 2014
Summary Of Significant Accounting Policies - Net Loss Per Common Share -basic And Diluted Details        
Continuing operations $ (525,438) $ (238,952) $ (1,494,096) $ (1,152,393)
Discontinued operations       95,528
Net loss attributable to common shareholders $ (525,438) $ (238,952) $ (1,494,096) $ (1,056,865)
Weighted average shares outstanding 242,589,170 112,247,396 187,353,653 93,925,094
Loss per common share, basic and diluted: $ 0.00 $ 0.00 $ (0.01) $ (0.01)
Continuing operations $ 0.00 $ 0.00 $ (0.01) (0.01)
Discontinued operations       0.00
Common share, basic and diluted $ 0.00 $ 0.00 $ (0.01) $ (0.01)
XML 88 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727
Statements of Cash Flows - USD ($)
 9 Months Ended
May. 31, 2015
May. 31, 2014
Operating activities:    
Net loss $ (1,494,096) $ (1,056,865)
Net gain from discontinued operations   (95,528)
Net loss from continuing operations $ (1,494,097) (1,152,393)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization $ 14,356 17,156
Loss on disposal of property and equipment   28,748
Stock based compensation   91,163
Amortization of discount on notes payable and warrants $ 334,437 18,021
Beneficial conversion feature notes payable   139,823
Loss on conversion of notes payable - related parties   $ 155,729
Induced conversion expense notes payable $ 66,520  
Non-cash interest charges 218,415  
Issuance of stock and warrants for fees 78,100 $ 302,658
Changes in operating assets and liabilities:    
Accounts receivable (250,480) (125,813)
Prepaid expenses and other current assets (5,829) $ (2,686)
Prepaid commissions and finders' fees (737)  
Deposits and other assets (52,545) $ (43,700)
Accounts payable and other accrued expenses 626,654 6,691
Accrued interest payable - related parties (6,342) (60,192)
Accrued interest payable 80,578 83,424
Net operating cash flows - continuing operations $ (390,970) (546,190)
Net operating cash flows - discontinued operations   95,528
Net cash used in operating activities $ (390,970) (450,662)
Investing activities:    
Purchase of property and equipment $ (2,033) (878)
Cash acquired from Amian Health Services   8,646
Acquisition of Amian Health Services   $ (75,000)
Acquisition of Esteemcare and Affordable $ (560,984)  
Net cash used in investing activities (563,017) $ (67,232)
Financing activities:    
Proceeds from issuance of convertible notes 596,250 719,933
Proceeds from issuance of notes payable $ 1,933,000 655,128
Proceeds from the issuance of common stock   10,000
Repayment of notes payable $ (918,975) (490,798)
Repayment of notes payable - related parties (51,600) $ (4,600)
Repayment of inventory financing agreements (335,608)  
Repayment of convertible notes payable (166,099) $ (224,845)
Net cash provided by financing activities 1,056,968 664,818
Net increase (decrease) in cash and cash equivalents 102,981 146,924
Cash and cash equivalents, beginning of period 17,504 39,456
Cash and cash equivalents, end of period $ 120,485 $ 186,380
XML 89 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727
Discontinued Operations
 9 Months Ended
May. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations

NOTE 5 – DISCONTINUED OPERATIONS

 

During October 2013 the Company’s management and Board of Directors determined to dispose of Oncologix Corporation its Brachytherapy medical device subsidiary. On November 1, 2013, the company entered into a settlement agreement with Firetag, Stoss & Dowdell, PC., our former attorneys. Per the terms of the settlement agreement, we exchanged our 90% ownership and executed a $50,000 promissory note payable to Firetag in exchange for the forgiveness by Firetag of $145,522 in prior legal billings. The promissory note bears interest at 4% and requires 12 monthly payments of $4,257.49 beginning on December 1, 2013. Detailed below are the income and expenses related to these discontinued operations:

 

   For the Three Months Ended  For the Six Months Ended
   May 31,  May 31,  May 31,  May 31,
   2015  2014  2015  2014
Operating expenses:                    
General and administrative  $—     $—     $—     $36 
Depreciation and amortization   —      —      —      —   
                     
Total operating expenses   —      —      —      36 
                     
Loss from operations   —      —      —      (36)
                     
Other income (expense):                    
                     
Total other income (expense)   —      —      —      —   
                     
Loss from discontinued operations   —      —      —      (36)
Gain on disposal of discontinued operations   —      —      —      95,564 
                     
Loss from discontinued operations   —      —      —      95,528 
                     
Less loss attributable to noncontrolling interest   —      —      —      —   
                     
Net loss from discontinued operations  $—     $—     $—     $95,528 

 
XML 90 R58.htm IDEA: XBRL DOCUMENT v3.2.0.727
Other Notes Payable (Details) - USD ($)
May. 31, 2015
May. 31, 2014
Note payable [Member]    
Debt Instrument [Line Items]    
Other Notes Payable $ 2,850,348 $ 1,429,829
Less: Long-term Portion (376,037) (416,466)
Current Portion 2,474,311 1,013,363
Dot 1 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 1,500 60,600
Dot 2[Member]    
Debt Instrument [Line Items]    
Other Notes Payable 30,000 30,000
Dot 3 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 20,000 20,000
Line of credit AA1 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 43,149 $ 44,469
Line of credit AA2 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable $ 37,467  
Merchant Loan AA3 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable   $ 130,400
Merchant Loan AA4 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable   142,109
Merchant Loan AA5 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable $ 68,409  
Merchant Loan AA6 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 42,080  
Merchant Loan AA7 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 228,215  
Merchant Loan AA8 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 67,400  
Note Payable AA9 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable   14,765
Note Payable EST1 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 73,552  
Note Payable 2226 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable   10,833
Note Payable 2227 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable   6,689
Note Payable 2228 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable   6,844
Note Payable 2229 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable   21,076
Note Payable 2230 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 68,510 70,659
Note Payable 2231 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 12,000 7,692
Note Payable 2236 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable $ 1,533,584 275,155
Note Payable 2237 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable   $ 11,444
Note Payable 2255 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable $ 22,909  
Note Payable 2257 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 68,920  
Note Payable 2258 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 22,973  
Note Payable 2263 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 56,215  
Note Payable 2264 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 11,500  
Note Payable 2300 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable 416,466 $ 498,179
Note Payable 2432 [Member]    
Debt Instrument [Line Items]    
Other Notes Payable $ 25,499 $ 78,915
XML 91 R69.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stockholders Equity- Warrants (Details Narrative 1) - USD ($)
 9 Months Ended
May. 31, 2015
May. 31, 2014
May. 30, 2015
Aug. 31, 2014
Aug. 30, 2014
May. 30, 2014
Feb. 27, 2014
Aug. 31, 2013
Stockholders Equity- Warrants Details Narrative 1                
Shares authorized under stock option plans 21,000,000 4,500,000 (9,583,333) 30,583,333 4,000,000 9,583,333 5,500,000 7,000,000
Weighted Average Exercise Price   $ 0.012 $ 0.009 $ 0.012 $ .007 $ 0.012 $ 0.017 $ 0.012
Share compensation expense   $ 91,163            
XML 92 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
May. 31, 2015
Accounting Policies [Abstract]  
BASIS OF PRESENTATION

BASIS OF PRESENTATION

 

In the opinion of management, the accompanying balance sheets and related interim statements of income, cash flows, and stockholders' equity include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management's estimates and assumptions. Interim results are not necessarily indicative of results for a full year.
PRINCIPLES OF CONSOLIDATION

PRINCIPLES OF CONSOLIDATION

 

The unaudited consolidated financial statements for the three and nine months ended May 31, 2015 and 2014 include the accounts of Oncologix Tech, Inc. and its wholly owned subsidiaries, Dotolo Research Corporation (“Dotolo”), Amian Angels, Inc. (“Amian”), Advanced Medical Products & Technologies Inc. (“AMPT”), Esteemcare Inc. and Affordable Medical Equipment Solutions Inc. (collectively “Esteemcare”) Dotolo and Amian are Louisiana Corporations. AMPT is a Nevada corporation. Esteem & Affordable are South Carolina corporations. All significant intercompany accounts and transactions have been eliminated in consolidation.
USE OF ESTIMATES

USE OF ESTIMATES

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reportable amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
SEGMENT INFORMATION

SEGMENT INFORMATION

 

ASC 280-10 defines operating segments as components of a company about which separate financial information is available that is evaluated regularly by the Company’s Chief Executive Officer and Chief Financial Officer in deciding how to allocate resources and in assessing performance. The Company currently has three business segments; medical device manufacturing (Dotolo), personal care services (Amian) and medical products and technologies (AMPT and Esteem & Affordable.
REVENUE RECOGNITION

REVENUE RECOGNITION

 

Revenue is recognized by the Company in accordance with Accounting Standards Codification Topic (“ASC”) 605. Accordingly, revenue is recognized when all the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the seller’s price to the buyer is fixed and determinable; and collectability is reasonably assured. Currently, the primary revenue for the Company is derived from its sales in its Personal Care Services and Medical Products and Technologies Segments’.

  

Amian is reimbursed for each approved “Unit of Service” provided, as determined by the Health Care Financing Administration (HCFA), the Department of Health & Hospitals and the Department of Social Services and based upon a detailed Case Management, Plan of Care for each beneficiary. A unit of service for PCA services will be one-half hour. At least fifteen (15) minutes of service must be provided to the individual in order for Amian Angels to bill for a unit of service. A maximum of 1,825 hours (3,650 half-hour units) per beneficiary, per year can be billed under the Medicaid waiver program. Our primary payer sources is the State of Louisiana, the Department of Veterans Administration and Private Pay individuals who reimburse us for the services we provide. We currently experience a two percent claims rejection rate. With the acquisition of Amian, Amian Angels now has private pay clients as well as Veterans Administration Social Services clients.

 

Esteemcare recognizes revenue related to product sales upon delivery to customers provided that we have received and verified any written documentation required to bill Medicare, other government agencies, third-party payers, and patients. For product shipments for which we have not yet received the required written documentation, revenue recognition is delayed until the period in which those documents are collected and verified. We record revenue at the amounts expected to be collected from government agencies, other third-party payers, and from patients directly. Government and insurance payers’ generally require patient compliance with product usage. Accordingly, most pay for the product purchases over a multi-month plan, generally 10 to 13 months. We record these revenues as received since the transfer of ownership is not guaranteed until the full purchase price is paid to us. We record, if necessary, contractual adjustments equal to the difference between the reimbursement amounts defined in the fee schedule and the revenue recorded per the billing system. These adjustments are recorded as a reduction of both gross revenues and accounts receivable. We analyze various factors in determining revenue recognition, including a review of specific transactions, current Medicare regulations and reimbursement rates, historical experience and the credit-worthiness of patients. Medicare reimburses at 80% of the government-determined prices for reimbursable supplies, and we bill the remaining balance to either third-party payers or directly to patients.
CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS

 

The Company considers all highly liquid instruments, with an initial maturity of three (3) months or less to be cash equivalents.
ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE

 

The Company’s receivables in its medical device segment are subject to credit risk, and the Company typically does not require collateral on its accounts receivable. Receivables are generally due within 30 days. The Company maintains an allowance for uncollectable receivables that reduces the receivables to amounts that are expected to be collected. .

 

The lead time for account receivables in our Personal Care service divisions ranges from 14 to 90 days. The majority of the Company’s receivables, approximately 90%, are collected within 14 days. We bill the State of Louisiana on a weekly basis and are reimbursed two weeks later via electronic funds transfer. We are able to resubmit any rejected claims an additional two times to Molina Healthcare, the EDI payment provider for payments within the next twelve months. Currently we maintain an allowance for uncollectible receivables at a rejection rate of 2% of outstanding receivables. We analyze our claim rejection rate on a quarterly basis and make quality improvements to reduce the number of rejected claims. Private pay customers are billed semi-monthly. Generally collections occur within 30 days. Veterans Administration (VA) customers are billed monthly. Generally collections occur within 45 to 60 days. Due to the recent governmental shutdown, the current lead time for payments is approximately 90 days. Upon final rejection of any resubmitted claims, the claims are resubmitted and after twelve months the receivables are written off to bad debt expense.

 

Our medical products and technologies accounts receivable are generally due from Medicare, Medicaid, private insurance companies, and our private patients. Accounts receivable are reported net of allowances for contractual adjustments and uncollectible accounts. The collection process is time consuming, complex and typically involves the submission of claims to multiple layers of payers whose payment of claims may be contingent upon the payment of another payer. As a result, our collection efforts may be active for up to 18 to 24 months from the initial billing date. In accordance with regulatory requirements, we make reasonable and appropriate efforts to collect our accounts receivable, including deductible and co-payment amounts, in a manner consistent for all classes of payers.
INVENTORY

INVENTORY

 

Inventories are stated at cost and are held on a first-in, first-out basis. Our inventory in our medical device segment consists primarily of miscellaneous hardware parts. Our inventory in our medical products and technologies segment consists of masks, CPAP machines, BiPAP machines and other necessary breathing equipment and supplies.
PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT

 

Property and equipment is recorded at cost. Depreciation is provided for on the straight-line method over the estimated useful lives of the related assets as follows:

 

Furniture and fixtures 5 to 10 years
Computer equipment 5 years
Equipment 5 to 10 years
Software 3 to 5 years

 

The cost of maintenance and repairs is charged to expense in the period incurred. Expenditures that increase the useful lives of assets are capitalized and depreciated over the remaining useful lives of the assets. When items are retired or disposed of, the cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income.
LONG-LIVED ASSETS

LONG-LIVED ASSETS

     ASC 360 – Property, Plant and Equipment addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Company periodically evaluates whether events and circumstances have occurred that may warrant revision of the estimated useful life of property and equipment or whether the remaining balance of property and equipment, or other long-lived assets, should be evaluated for possible impairment. Instances that may lead to an impairment include: (i) a significant decrease in the market price of a long-lived asset group; (ii) a significant adverse change in the extent or manner in which a long-lived asset or asset group is being used or in its physical condition; (iii) a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset or asset group, including an adverse action or assessment by a regulatory agency; (iv) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset or asset group; (v) a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset or asset group; or (vi) a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

An estimate of the related undiscounted cash flows, excluding interest, over the remaining life of the property and equipment and long-lived assets is used in assessing recoverability. Impairment loss is measured by the amount which the carrying amount of the asset(s) exceeds the fair value of the asset(s). The Company primarily employs two methodologies for determining the fair value of a long-lived asset: (i) the amount at which the asset could be bought or sold in a current transaction between willing parties or (ii) the present value of estimated expected future cash flows grouped at the lowest level for which there are identifiable independent cash flows.
GOODWILL AND OTHER INTANGIBLE ASSETS

GOODWILL AND OTHER INTANGIBLE ASSETS

 

The Company adopted Accounting Standards Update 2011-08 “Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment (“ASU 2011-08”) in the fourth quarter of fiscal 2014 due to its recent acquisition of Dotolo Research Corporation and Angels of Mercy, Inc. ASU 2011-08 permits an entity to first assess qualitative factors to determine whether it is more likely that not that the fair value of a reporting unit is less than its carrying amount. Goodwill represents the excess of the cost of a business combination over the fair value of the net assets acquired and these costs are subject to annual impairment tests.

 We accounted for the acquisition of Dotolo, Amian and Esteemcare using the acquisition method of accounting under ASC 805 and ASC 810-10-65. The purchase price was allocated first to identifiable current then fixed assets as well as liabilities assumed. We then earmarked identifiable intangibles, with the remainder to goodwill. We identified patents as our identifiable asset for Dotolo Research Corporation. Amounts allocated to Goodwill for the acquisition of Dotolo are based on expanding our product into the medical market and the potential upside of the sale with a FDA medical device product with a reimbursement code. Dotolo is one of four companies worldwide with an FDA approved, Class II medical device product. Amounts allocated to goodwill for Amian and Esteemcare are based on increased clients and future revenues.

The Company evaluates the recoverability of its indefinite lived intangible assets, which consist of Dotolo, Amian and Esteemcare, based on estimates of future royalty payments that are avoided through its ownership of the intangibles and patents, discounted to their present value. In determining the estimated fair value of the intangibles and patents, management considers current and projected future levels of revenue based on its plans for Dotolo, business trends, prospects and market and economic conditions. See Note 4 – Acquisitions for further information on the acquisition of Dotolo.

We follow the two step process in ASC 350-20-35 for impairment testing. In the first step we compare the fair value of the reporting unit as a whole to its carrying value, including goodwill. For both reporting units, we have determined that the reporting units’ fair value exceeds its carrying value. We also compare the carrying value of goodwill by itself for both reporting units.

The following explains the results of our impairment testing. We have allocated $564,075 of goodwill to the Amian Angels, Inc. reporting unit. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 39%. We have allocated $1,217,704 of goodwill to the reporting unit Dotolo Research Corporation. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 18%. We have allocated $622,610 of goodwill the Esteemcare reporting unit. As of May 31, 2015 the fair value exceeds the carrying value of goodwill by 47%. In calculating the valuation, we used a discounted cash flow method based on the future 5 years cash flows of each reporting unit. We used a discount rate of 8% which is currently higher that the current long term interest rate. An increase in the overall national interest rate could have a negative impact on our valuation. An additional risk is the possibility of cash flow projections falling short of our 5 year estimate amount.

 
ADVERTISING COSTS

ADVERTISING COSTS

 

Advertising costs included with selling, general and administrative expenses in the accompanying consolidated statements of operations were minimal for the three and nine months ended May 31, 2015 and 2014. Such costs are expensed as incurred.
INCOME TAXES

INCOME TAXES

 

The Company adopted the provisions of FASB ASC 740 - Income Taxes provides detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the financial statements. Income taxes are determined using the asset and liability method. This method gives consideration to the future tax consequences associated with temporary differences between the carrying amounts of assets and liabilities for financial statement purposes and the amounts used for income tax purposes.
FAIR VALUE OF FINANCIAL INSTRUMENTS

FAIR VALUE OF FINANCIAL INSTRUMENTS

 

The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable, accrued expenses, and notes payable approximate fair value.
STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION

 

The Company has a stock-based compensation plan, which is described more fully in Note 12. The Company accounts for stock-based compensation in accordance with ASC 718. Under the fair value recognition provisions of this statement, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the vesting period. The Company estimates the fair value of stock options granted using the Black-Scholes option valuation model. The fair value of all awards is amortized on a straight-line basis over the vesting periods. The expected term of awards granted represent the period of time they are expected to be outstanding. The Company determines the expected term based on historical experience with similar awards, giving consideration to the contractual terms and vesting schedules. The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of its common stock. The risk-free interest rate is based on the U.S. treasury security rate estimated for the expected life of the options at the date of grant. If actual results differ significantly from estimates, stock-based compensation could be impacted.
INVENTORY FINANCING AGREEMENTS

INVENTORY FINANCING AGREEMENTS

 

Our inventory finance agreements consist of qualified for-sale equipment purchases. Qualifying inventory purchases are grouped into a 12 month finance agreements allowing the company to spread the payments for this inventory over a twelve month period. All inventory finance agreements are interest free and consist of only minor fees for setup.

 
CONVERTIBLE DEBT

CONVERTIBLE DEBT

 

Interest on convertible debt is calculated using the simple interest method. The company recognizes a beneficial conversion feature to the extent the conversion price is less than the closing stock price on the issuance of the convertible notes. The Company also follows ASC 470-50 and ASC 470-20 regarding changes in the terms of the convertible notes and the induced conversion of its convertible debt.
RECLASSIFICATIONS

RECLASSIFICATIONS

 

Certain prior year amounts have been reclassified to conform to the current year presentation.
STOCK INCENTIVE PLANS

STOCK INCENTIVE PLANS

 

Share based payment compensation costs for equity-based awards are measured on the grant date based on the fair value of the award on that date and is recognized over the required service period. The fair-value of stock option awards is estimated using the Black-Scholes model. Fair value of restricted stock awards is based upon the quoted market price of the common stock on the date of grant.
NET LOSS PER COMMON SHARE

NET LOSS PER COMMON SHARE

 

Basic earnings (loss) per share is calculated under the provisions of ASC 260 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is calculated by dividing income (loss) available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is calculated based on the weighted average number of common shares outstanding during the period plus the dilutive effect of common stock purchase warrants and stock options using the treasury stock method and the dilutive effects of convertible notes payable and convertible preferred stock using the if-converted method. On Basic and diluted earnings per share for the three and nine months ended May 31, 2015 and 2014 are as follows:

 

   For the Three Months Ended  For the Nine Months Ended
   May 31,  May 31,  May 31,  May 31,
   2015  2014  2015  2014
             
             
Net gain (loss) attributable to common shareholders                    
Continuing operations  $(525,438)  $(238,952)  $(1,494,096)  $(1,152,393)
Discontinued operations   —      —      —      95,528 
                     
                     
   $(525,438)  $(238,952)  $(1,494,096)  $(1,056,865)
                     
Weighted average shares outstanding   242,589,170    112,247,396    187,353,653    93,925,094 
                     
Loss per common shares, basis and diluted                    
Continuing operations  $(0.00)  $(0.00)  $(0.01)  $(0.01)
Discontinued operations   —      —      —      0.00 
                     
                     
   $(0.00)  $(0.00)  $(0.01)  $(0.01)

 

 

 

Due to the net losses during the three and nine months ended May 31, 2015 and 2014, basic and diluted loss per share was the same, as the effect of potentially dilutive securities would have been anti-dilutive. Shares attributable to convertible notes, stock options, preferred stock and warrants not included the diluted loss per share calculation. Below lists all dilutive securities as of May 31, 2015 and 2014:

 

            As of
            May 31,   May 31,
            2015 2014
           Underlying     Underlying 
Description  Common Shares     Common Shares 
Convertible preferred stock            78,564,000              22,500,000
Convertible notes payable          210,272,886              81,383,460
Options              6,173,750                6,186,250
Warrants            21,000,000              26,583,333
                 
Total potentially dilutive securities          316,010,636            136,653,043

 

 

 
RECENT ACCOUNTING PRONOUNCEMENTS

RECENT ACCOUNTING PRONOUNCEMENTS

 

We have evaluated all Accounting Standards Updates through the date the financial statements were issued and do not believe any will have a material impact.

 
NEW ACCOUNTING STANDARD

New Accounting Standard

 

In July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2012-02 “Intangibles – Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment” (“ASU 2012-02”). ASU 2012-02 permits entities to first assess qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is impaired as a basis for determining whether it is necessary to perform the quantitative impairment test. Under the amendments in ASU 2012-02, an entity is not required to calculate the fair value of an indefinite-lived intangible asset unless it determines that it is more likely than not that the fair value of the asset is less than its carrying amount. An entity also will have the option to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to performing the quantitative impairment test. ASU 2012-02 is effective for interim and annual indefinite-lived intangible asset impairment tests performed for fiscal years beginning on or after September 15, 2012, with early adoption permitted. The Company’s adoption of ASU 2012-02 is not expected to have an impact on its consolidated financial statements.
XML 93 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 328 345 1 true 145 0 false 6 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://cik0000799694/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://cik0000799694/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://cik0000799694/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://cik0000799694/role/StatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statements of Cash Flows Sheet http://cik0000799694/role/StatementsOfCashFlows Statements of Cash Flows Statements 5 false false R6.htm 00000006 - Disclosure - Organization and Description of the Company Sheet http://cik0000799694/role/OrganizationAndDescriptionOfCompany Organization and Description of the Company Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://cik0000799694/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://cik0000799694/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Acquisitions Sheet http://cik0000799694/role/Acquisitions Acquisitions Notes 9 false false R10.htm 00000010 - Disclosure - Discontinued Operations Sheet http://cik0000799694/role/DiscontinuedOperations Discontinued Operations Notes 10 false false R11.htm 00000011 - Disclosure - Inventory Sheet http://cik0000799694/role/Inventory Inventory Notes 11 false false R12.htm 00000012 - Disclosure - Property and Equipment Sheet http://cik0000799694/role/PropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 00000013 - Disclosure - Leases Sheet http://cik0000799694/role/Leases Leases Notes 13 false false R14.htm 00000014 - Disclosure - Goodwill, Patents and Other Intangible Assets Sheet http://cik0000799694/role/GoodwillPatentsAndOtherIntangibleAssets Goodwill, Patents and Other Intangible Assets Notes 14 false false R15.htm 00000015 - Disclosure - Inventory Financing Agreement Sheet http://cik0000799694/role/InventoryFinancingAgreement Inventory Financing Agreement Notes 15 false false R16.htm 00000016 - Disclosure - Notes Payable Notes http://cik0000799694/role/NotesPayable Notes Payable Notes 16 false false R17.htm 00000017 - Disclosure - Stockholders' Equity Sheet http://cik0000799694/role/StockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 00000018 - Disclosure - Related Party Transactions Sheet http://cik0000799694/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 00000019 - Disclosure - Business Segments Sheet http://cik0000799694/role/BusinessSegments Business Segments Notes 19 false false R20.htm 00000020 - Disclosure - Joint Ventures Sheet http://cik0000799694/role/JointVentures Joint Ventures Notes 20 false false R21.htm 00000021 - Disclosure - Retirement Plan Sheet http://cik0000799694/role/RetirementPlan Retirement Plan Notes 21 false false R22.htm 00000023 - Disclosure - Recent Accounting Prouncements Sheet http://cik0000799694/role/RecentAccountingProuncements Recent Accounting Prouncements Notes 22 false false R23.htm 00000024 - Disclosure - Statement of Cash Flows Sheet http://cik0000799694/role/StatementOfCashFlows Statement of Cash Flows Notes 23 false false R24.htm 00000025 - Disclosure - Employment Agreements Sheet http://cik0000799694/role/EmploymentAgreements Employment Agreements Notes 24 false false R25.htm 00000026 - Disclosure - Commitments and Contingencies Sheet http://cik0000799694/role/CommitmentsAndContingencies Commitments and Contingencies Notes 25 false false R26.htm 00000027 - Disclosure - Subsequent Events Sheet http://cik0000799694/role/SubsequentEvents Subsequent Events Notes 26 false false R27.htm 00000028 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://cik0000799694/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://cik0000799694/role/SummaryOfSignificantAccountingPolicies 27 false false R28.htm 00000029 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://cik0000799694/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://cik0000799694/role/SummaryOfSignificantAccountingPolicies 28 false false R29.htm 00000030 - Disclosure - Acquisitions (Tables) Sheet http://cik0000799694/role/AcquisitionsTables Acquisitions (Tables) Tables http://cik0000799694/role/Acquisitions 29 false false R30.htm 00000031 - Disclosure - Discontinued Operations (Tables) Sheet http://cik0000799694/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://cik0000799694/role/DiscontinuedOperations 30 false false R31.htm 00000032 - Disclosure - Property and Equipment (Tables) Sheet http://cik0000799694/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://cik0000799694/role/PropertyAndEquipment 31 false false R32.htm 00000033 - Disclosure - Leases (Tables) Sheet http://cik0000799694/role/LeasesTables Leases (Tables) Tables http://cik0000799694/role/Leases 32 false false R33.htm 00000034 - Disclosure - Inventory Financing Agreement (Tables) Sheet http://cik0000799694/role/InventoryFinancingAgreementTables Inventory Financing Agreement (Tables) Tables http://cik0000799694/role/InventoryFinancingAgreement 33 false false R34.htm 00000035 - Disclosure - Notes Payable (Tables) Notes http://cik0000799694/role/NotesPayableTables Notes Payable (Tables) Tables http://cik0000799694/role/NotesPayable 34 false false R35.htm 00000036 - Disclosure - Stockholders' Equity (Tables) Sheet http://cik0000799694/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://cik0000799694/role/StockholdersEquity 35 false false R36.htm 00000037 - Disclosure - Business Segments (Tables) Sheet http://cik0000799694/role/BusinessSegmentsTables Business Segments (Tables) Tables http://cik0000799694/role/BusinessSegments 36 false false R37.htm 00000039 - Disclosure - Statement of Cash Flows (Tables) Sheet http://cik0000799694/role/StatementOfCashFlowsTables Statement of Cash Flows (Tables) Tables http://cik0000799694/role/StatementOfCashFlows 37 false false R38.htm 00000040 - Disclosure - Description of Company (Details) Sheet http://cik0000799694/role/DescriptionOfCompanyDetails Description of Company (Details) Details 38 false false R39.htm 00000041 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) (USD$) Sheet http://cik0000799694/role/SummaryOfSignificantAccountingPolicies-PropertyAndEquipmentDetailsUsd Summary of Significant Accounting Policies - Property and Equipment (Details) (USD$) Details 39 false false R40.htm 00000042 - Disclosure - Summary of Significant Accounting Policies - Goodwill (Details) Sheet http://cik0000799694/role/SummaryOfSignificantAccountingPolicies-GoodwillDetails Summary of Significant Accounting Policies - Goodwill (Details) Details 40 false false R41.htm 00000043 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share -Basic and Diluted (Details) Sheet http://cik0000799694/role/SummaryOfSignificantAccountingPolicies-NetLossPerCommonShare-basicAndDilutedDetails Summary of Significant Accounting Policies - Net Loss Per Common Share -Basic and Diluted (Details) Details 41 false false R42.htm 00000044 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share - Dilutive Securities (Details) Sheet http://cik0000799694/role/SummaryOfSignificantAccountingPolicies-NetLossPerCommonShare-DilutiveSecuritiesDetails Summary of Significant Accounting Policies - Net Loss Per Common Share - Dilutive Securities (Details) Details 42 false false R43.htm 00000045 - Disclosure - Going Concern (Details Narrative) Sheet http://cik0000799694/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://cik0000799694/role/GoingConcern 43 false false R44.htm 00000046 - Disclosure - Acquisitions - Acquisitions (Details) Sheet http://cik0000799694/role/Acquisitions-AcquisitionsDetails Acquisitions - Acquisitions (Details) Details 44 false false R45.htm 00000047 - Disclosure - Acquisitions (Details Narrative) Sheet http://cik0000799694/role/AcquisitionsDetailsNarrative Acquisitions (Details Narrative) Details http://cik0000799694/role/AcquisitionsTables 45 false false R46.htm 00000048 - Disclosure - Discountinued Operations (Details) Sheet http://cik0000799694/role/DiscountinuedOperationsDetails Discountinued Operations (Details) Details 46 false false R47.htm 00000049 - Disclosure - Discountinued Operations (Details 1) Sheet http://cik0000799694/role/DiscountinuedOperationsDetails1 Discountinued Operations (Details 1) Details 47 false false R48.htm 00000050 - Disclosure - Inventory (Details Narrative) Sheet http://cik0000799694/role/InventoryDetailsNarrative Inventory (Details Narrative) Details http://cik0000799694/role/InventoryFinancingAgreementTables 48 false false R49.htm 00000051 - Disclosure - Property and Equipment (Details Narrative) Sheet http://cik0000799694/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://cik0000799694/role/PropertyAndEquipmentTables 49 false false R50.htm 00000052 - Disclosure - Leases (Details) Sheet http://cik0000799694/role/LeasesDetails Leases (Details) Details http://cik0000799694/role/LeasesTables 50 false false R51.htm 00000053 - Disclosure - Leases (Details Narrative) Sheet http://cik0000799694/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://cik0000799694/role/LeasesTables 51 false false R52.htm 00000054 - Disclosure - Goodwill, Patents and Other Intangible Assets (Details Narrative) Sheet http://cik0000799694/role/GoodwillPatentsAndOtherIntangibleAssetsDetailsNarrative Goodwill, Patents and Other Intangible Assets (Details Narrative) Details http://cik0000799694/role/GoodwillPatentsAndOtherIntangibleAssets 52 false false R53.htm 00000055 - Disclosure - Inventory Financing Agreement - Financing Agreements (Details) Sheet http://cik0000799694/role/InventoryFinancingAgreement-FinancingAgreementsDetails Inventory Financing Agreement - Financing Agreements (Details) Details 53 false false R54.htm 00000056 - Disclosure - Convertible Notes Payable (Details) Notes http://cik0000799694/role/ConvertibleNotesPayableDetails Convertible Notes Payable (Details) Details 54 false false R55.htm 00000057 - Disclosure - Convertible Notes Payable (Details 1) Notes http://cik0000799694/role/ConvertibleNotesPayableDetails1 Convertible Notes Payable (Details 1) Details 55 false false R56.htm 00000058 - Disclosure - Convertible Notes Payable (Details Narrative 1) Notes http://cik0000799694/role/ConvertibleNotesPayableDetailsNarrative1 Convertible Notes Payable (Details Narrative 1) Details 56 false false R57.htm 00000059 - Disclosure - Notes Payable - Related Party (Details) Notes http://cik0000799694/role/NotesPayable-RelatedPartyDetails Notes Payable - Related Party (Details) Details 57 false false R58.htm 00000060 - Disclosure - Other Notes Payable (Details) Notes http://cik0000799694/role/OtherNotesPayableDetails Other Notes Payable (Details) Details 58 false false R59.htm 00000061 - Disclosure - Notes Payable - Other (Details Narrative) Notes http://cik0000799694/role/NotesPayable-OtherDetailsNarrative Notes Payable - Other (Details Narrative) Details 59 false false R60.htm 00000062 - Disclosure - Notes Payable - Other(Details Narrative 1) Notes http://cik0000799694/role/NotesPayable-OtherdetailsNarrative1 Notes Payable - Other(Details Narrative 1) Details 60 false false R61.htm 00000063 - Disclosure - Stockholders Equity (Details) Sheet http://cik0000799694/role/StockholdersEquityDetails Stockholders Equity (Details) Details 61 false false R62.htm 00000064 - Disclosure - Stockholders Equity (Details Narrative) Sheet http://cik0000799694/role/StockholdersEquityDetailsNarrative Stockholders Equity (Details Narrative) Details 62 false false R63.htm 00000065 - Disclosure - Stockholders Equity Additional (Details Narrative) Sheet http://cik0000799694/role/StockholdersEquityAdditionalDetailsNarrative Stockholders Equity Additional (Details Narrative) Details 63 false false R64.htm 00000066 - Disclosure - Stockholders Equity (Details 1) Sheet http://cik0000799694/role/StockholdersEquityDetails1 Stockholders Equity (Details 1) Details 64 false false R65.htm 00000067 - Disclosure - Stockholders Equity (Details Narrative 1) Sheet http://cik0000799694/role/StockholdersEquityDetailsNarrative1 Stockholders Equity (Details Narrative 1) Details 65 false false R66.htm 00000068 - Disclosure - Stockholders Equity - Stock Subscribed (Details Narrative) Sheet http://cik0000799694/role/StockholdersEquity-StockSubscribedDetailsNarrative Stockholders Equity - Stock Subscribed (Details Narrative) Details 66 false false R67.htm 00000069 - Disclosure - Stockholders Equity (Details Narrative 2) Sheet http://cik0000799694/role/StockholdersEquityDetailsNarrative2 Stockholders Equity (Details Narrative 2) Details 67 false false R68.htm 00000070 - Disclosure - Stockholders Equity - Warrants (Details Narrative) Sheet http://cik0000799694/role/StockholdersEquity-WarrantsDetailsNarrative Stockholders Equity - Warrants (Details Narrative) Details 68 false false R69.htm 00000071 - Disclosure - Stockholders Equity- Warrants (Details Narrative 1) Sheet http://cik0000799694/role/StockholdersEquity-WarrantsDetailsNarrative1 Stockholders Equity- Warrants (Details Narrative 1) Details 69 false false R70.htm 00000072 - Disclosure - Stockholders Equity - 2000 Stock Incentatvie Plan (Details) Sheet http://cik0000799694/role/StockholdersEquity-2000StockIncentatviePlanDetails Stockholders Equity - 2000 Stock Incentatvie Plan (Details) Details 70 false false R71.htm 00000073 - Disclosure - Stockholders Equity - 2000 Stock Incentatvie Plan (Details 1) Sheet http://cik0000799694/role/StockholdersEquity-2000StockIncentatviePlanDetails1 Stockholders Equity - 2000 Stock Incentatvie Plan (Details 1) Details 71 false false R72.htm 00000074 - Disclosure - Stockholders Equity - 2013 Omnibus (Details) Sheet http://cik0000799694/role/StockholdersEquity-2013OmnibusDetails Stockholders Equity - 2013 Omnibus (Details) Details 72 false false R73.htm 00000075 - Disclosure - Business Segments - Balance Sheet(Details) Sheet http://cik0000799694/role/BusinessSegments-BalanceSheetdetails Business Segments - Balance Sheet(Details) Details 73 false false R74.htm 00000076 - Disclosure - Business Segments - Business Segments (Details) (USD $) Sheet http://cik0000799694/role/BusinessSegments-BusinessSegmentsDetailsUsd Business Segments - Business Segments (Details) (USD $) Details 74 false false R75.htm 00000079 - Disclosure - Income Taxes - Income Tax Benefit (Details) Sheet http://cik0000799694/role/IncomeTaxes-IncomeTaxBenefitDetails Income Taxes - Income Tax Benefit (Details) Details 75 false false R76.htm 00000083 - Disclosure - Statement of Cash Flows (Details 1) Sheet http://cik0000799694/role/StatementOfCashFlowsDetails1 Statement of Cash Flows (Details 1) Details http://cik0000799694/role/StatementOfCashFlowsTables 76 false false R77.htm 00000084 - Disclosure - Statement of Cash Flows (Details 1) (Parenthetical) Sheet http://cik0000799694/role/StatementOfCashFlowsDetails1Parenthetical Statement of Cash Flows (Details 1) (Parenthetical) Details http://cik0000799694/role/StatementOfCashFlowsTables 77 false false R78.htm 00000085 - Disclosure - Employment Agreements (Details Narrative) Sheet http://cik0000799694/role/EmploymentAgreementsDetailsNarrative Employment Agreements (Details Narrative) Details http://cik0000799694/role/EmploymentAgreements 78 false false R79.htm 00000086 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://cik0000799694/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://cik0000799694/role/CommitmentsAndContingencies 79 false false R80.htm 00000087 - Disclosure - Subsequent Events (Details) Sheet http://cik0000799694/role/SubsequentEventsDetails Subsequent Events (Details) Details http://cik0000799694/role/SubsequentEvents 80 false false All Reports Book All Reports In ''Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Consolidated Balance Sheets (Parenthetical)'', column(s) 7 are contained in other reports, so were removed by flow through suppression. In ''Statements of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. oclg-20150531.xml oclg-20150531_cal.xml oclg-20150531_def.xml oclg-20150531_lab.xml oclg-20150531_pre.xml oclg-20150531.xsd true true XML 94 R74.htm IDEA: XBRL DOCUMENT v3.2.0.727
Business Segments - Business Segments (Details) (USD $) - USD ($)
 3 Months Ended 9 Months Ended
May. 31, 2015
May. 31, 2014
May. 31, 2015
May. 31, 2014
Revenues $ 1,235,656 $ 988,385 $ 3,625,407 $ 2,696,776
Cost of revenues 885,596 788,757 2,628,797 2,066,800
Gross profit 350,060 199,628 996,610 629,976
Operating expenses:        
General and administrative $ 443,889 276,950 1,379,769 999,910
Research and development expense     10,000  
Depreciation and amortization $ 5,022 5,664 14,356 17,156
Total operating expenses 448,911 282,614 1,404,125 1,017,066
Loss from operations (98,851) (82,986) (407,515) (387,090)
Other income (expense):        
Interest and finance charges $ (437,908) (167,474) (1,090,013) (634,833)
Interest and finance charges - related parties   (791) (1,051) (18,056)
Loss on conversion of notes payable - related parties $ 11,321 $ (62,151)   (155,728)
Loss on disposal of assets       (28,748)
Other income (expenses) $ (426,587) $ 74,450 4,483 72,062
Total other income (expense)   (155,966) (1,086,581) (765,303)
Loss from continuing operations (525,438) (238,952) (1,494,096) (1,152,393)
Personal Care Segment [Member]        
Revenues 812,626   2,573,547 2,696,776
Cost of revenues 698,215 776,406 2,129,572 2,030,450
Gross profit 114,411 211,979 443,975 666,326
Operating expenses:        
General and administrative $ 81,451 166,867 $ 317,165 506,387
Research and development expense        
Depreciation and amortization $ 2,262 3,157 $ 6,289 9,636
Total operating expenses 83,713 170,024 323,454 516,023
Loss from operations 30,698 41,955 120,521 150,303
Other income (expense):        
Interest and finance charges $ (81,952) $ (80,786) $ (244,613) $ (171,837)
Interest and finance charges - related parties        
Loss on conversion of notes payable - related parties $ 11,307      
Loss on disposal of assets       $ (28,748)
Other income (expenses) (70,645) $ 74,667 $ 8,541 72,775
Total other income (expense)   (6,119) (236,072) (127,810)
Loss from continuing operations $ (39,947) 35,836 $ (115,551) $ 22,493
Medical Device Segment [Member]        
Revenues        
Cost of revenues   12,351   $ 36,350
Gross profit   (12,351)   (36,350)
Operating expenses:        
General and administrative $ 14,739 4,979 $ 58,489 28,222
Research and development expense     10,000  
Depreciation and amortization $ 2,423 2,423 7,269 7,268
Total operating expenses 17,162 7,402 75,758 35,490
Loss from operations (17,162) (19,753) (75,758) (71,840)
Other income (expense):        
Interest and finance charges $ (1,500) (2,250) (5,500) (8,560)
Interest and finance charges - related parties   $ (791) (1,051) $ (2,348)
Loss on conversion of notes payable - related parties $ 14      
Loss on disposal of assets        
Other income (expenses) (1,486) $ (217) (3,854) $ (713)
Total other income (expense)   (3,258) (10,405) (11,621)
Loss from continuing operations (18,648) $ (23,011) (86,163) $ (83,461)
Medical Products Segment [Member]        
Revenues 423,030   1,051,860  
Cost of revenues 187,381   499,225  
Gross profit 235,649   552,635  
Operating expenses:        
General and administrative $ 159,793   $ 424,693  
Research and development expense        
Depreciation and amortization $ 253   $ 546  
Total operating expenses 160,046   425,239  
Loss from operations 75,603   127,396  
Other income (expense):        
Interest and finance charges $ (3,076)   $ (3,848)  
Interest and finance charges - related parties        
Loss on conversion of notes payable - related parties        
Loss on disposal of assets        
Other income (expenses) $ (3,076)      
Total other income (expense)     $ (3,848)  
Loss from continuing operations $ 72,527   $ 123,548  
Corporate Overhead [Member]        
Revenues        
Cost of revenues        
Gross profit        
Operating expenses:        
General and administrative $ 187,906 $ 105,104 $ 579,422 $ 465,301
Research and development expense        
Depreciation and amortization $ 84 84 $ 252 252
Total operating expenses 187,990 105,188 579,674 465,553
Loss from operations (187,990) (105,188) (579,674) (465,553)
Other income (expense):        
Interest and finance charges $ (351,380) $ (84,438) $ (836,052) (454,436)
Interest and finance charges - related parties       (15,708)
Loss on conversion of notes payable - related parties   $ (62,151)   $ (155,728)
Loss on disposal of assets        
Other income (expenses) $ (351,380)   $ (204)  
Total other income (expense)   $ (146,589) (836,256) $ (625,872)
Loss from continuing operations $ (539,370) $ (251,777) $ (1,415,930) $ (1,091,425)
XML 95 R38.htm IDEA: XBRL DOCUMENT v3.2.0.727
Description of Company (Details)
 9 Months Ended
May. 31, 2014
USD ($)
Description Of Company Details  
Debt relief $ 90,000
XML 96 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727
Joint Ventures
 9 Months Ended
May. 31, 2015
Accounting Policies [Abstract]  
Joint Ventures

NOTE 15 - JOINT VENTURE

 

Institut für Umwelttechnologien GmbH (IUT)

 

In February 2009, we entered into a Technology Agreement with Institut für Umwelttechnologien GmbH, a German Company (“IUT”). On September 23, 2010, the Company signed a Memorandum of Understanding with Institut für Umwelttechnologien GmbH and IUT Medical GMBH confirming certain understandings among the parties with respect to their future relationships and business activities as originally contemplated in their Technology Agreement of February 27, 2009, which was reaffirmed. On November 1, 2013, with the disposal of the Company’s subsidiary Oncologix Corporation, the company also ended its relationship with IUT and IUTM.